aspirin has been researched along with Stroke in 2542 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Warfarin and aspirin are used to prevent stroke in patients with atrial fibrillation (AF)." | 10.27 | Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. ( Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M, 2013) |
| "We sought to derive and internally validate a simple and easily applied clinical prediction rule to identify patients with nonvalvular atrial fibrillation (AF) whose stroke risk while taking aspirin is, irrespective of age, low enough that oral anticoagulation therapy is unnecessary." | 10.20 | A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. ( Gullov, AL; Hart, RG; Hellemons, BS; Koefed, BG; Koudstaal, PJ; Laupacis, A; Petersen, P; van Walraven, C; Wells, GA, 2003) |
| "We compared the risk of recurrent ischemic stroke, vascular events, and major bleeding between DAPT with cilostazol plus aspirin or clopidogrel and aspirin or clopidogrel alone in patients with ischemic stroke between 8 and 180 days before starting trial treatment and ECAS or without arterial stenosis." | 9.69 | Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial. ( Hoshino, H; Kimura, K; Kitagawa, K; Minematsu, K; Okamura, S; Omae, K; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2023) |
| "This trial investigates the efficacy and safety of tirofiban compared with aspirin for acute ischemic stroke within 24 h after symptom onset." | 9.69 | RESCUE BT 2, a multicenter, randomized, double-blind, double-dummy trial of intravenous tirofiban in acute ischemic stroke: Study rationale and design. ( Hu, J; Huang, J; Kong, W; Li, F; Li, L; Liu, S; Luo, W; Nogueira, RG; Qiu, Z; Sang, H; Saver, JL; Song, J; Tian, Y; Yang, J; Yang, Q; Zi, W, 2023) |
| "THEMIS is a double-blind, randomized trial of 19,220 patients with diabetes mellitus and stable coronary artery disease (CAD) comparing ticagrelor to placebo, in addition to aspirin." | 9.69 | External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Hea ( Abtan, J; Bhatt, DL; Bueno, H; Ducrocq, G; Eagle, KA; Elbez, Y; Fox, K; Goto, S; Harrington, RA; Leiter, LA; Lev, E; Mehta, SR; Ohman, EM; Pais, P; Petrov, I; Simon, T; Sinnaeve, PR; Smith, SC; Steg, PG; Wilson, P, 2023) |
| " Its efficacy may exceed aspirin in improving clinical outcomes in patients with acute ischemic stroke who are ineligible for rt-PA." | 9.69 | A randomized pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke. ( Aref, HM; El-Khawas, H; Elbassiouny, A; Roushdy, TM; Shokri, HM; Zeinhom, MG, 2023) |
| "In patients with lacunar stroke, DAPT using cilostazol had significant benefits in reducing recurrent ischemic stroke incidence compared with SAPT without increasing the risk of severe or life-threatening bleeding." | 9.69 | Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial. ( Hoshino, H; Houkin, K; Kimura, K; Matsumoto, M; Minematsu, K; Naritomi, H; Nishiyama, Y; Okada, Y; Origasa, H; Otsuka, T; Sakai, N; Terayama, Y; Tomimoto, H; Tominaga, T; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T; Yasuda, S, 2023) |
| "Aspirin is recommended for secondary stroke prevention in patients with moderate-to-severe ischaemic stroke but can lead to gastrointestinal intolerance and bleeding." | 9.69 | Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial. ( Bath, PM; Dong, Q; Feng, Y; Huang, X; Jiang, Y; Jin, A; Jing, J; Johnston, SC; Li, H; Li, X; Li, Z; Lin, J; Liu, B; Liu, L; Liu, Q; Meng, X; Pan, Y; Suo, Y; Wang, Y; Xie, X; Xiong, Y; Xu, A; Yang, H; Yuan, B; Zhao, J; Zhao, X; Zhou, Y; Zhu, H, 2023) |
| "The Clopidogrel With Aspirin in High-Risk Patients With Acute Nondisabling Cerebrovascular Events II (CHANCE-2) trial showed that ticagrelor-aspirin combination therapy reduced the risk of stroke compared with a clopidogrel-aspirin combination among carriers of CYP2C19 loss-of-function (LOF) alleles after a transient ischemic attack (TIA) or minor ischemic stroke." | 9.69 | Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial. ( Bath, PM; Jiang, Y; Jing, J; Johnston, SC; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, Y; Xie, X; Xu, A; Xu, Q; Zhao, X, 2023) |
| "In this secondary analysis of a randomized controlled trial involving patients with minor ischemic stroke or TIA, compared with clopidogrel-ASA, patients with obesity received more clinical benefit from ticagrelor-ASA therapy than those without obesity." | 9.69 | Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack. ( Jiang, Y; Jing, J; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Tian, X; Wang, A; Wang, Y; Xie, X; Zhang, J; Zhao, X, 2023) |
| "To establish the risks of ischemic stroke and intracranial bleeding among healthy older people receiving daily low-dose aspirin." | 9.69 | Low-Dose Aspirin and the Risk of Stroke and Intracerebral Bleeding in Healthy Older People: Secondary Analysis of a Randomized Clinical Trial. ( Cloud, GC; Donnan, GA; Eaton, CB; Fitzgerald, SM; Lockery, J; McNeil, JJ; Murray, AM; Nelson, MR; Newman, AB; Reid, CM; Shah, RC; Thao, LTP; Tran, C; Williamson, JD; Wolfe, R; Woods, RL, 2023) |
| "The aim of this study is to investigate the effect of gradual dipyridamole titration and the incidence of dipyridamole-induced headache in patients with ischemic stroke or transient ischemic attack (TIA)." | 9.51 | Effects of Dose Titration on Dipyridamole-Induced Headache: A Randomized, Double-Blind Clinical Trial. ( Cha, JK; Chang, DI; Chang, JY; Chung, JW; Hong, KS; Jung, KH; Kang, MK; Kim, BK; Kim, HY; Lee, KY; Lee, SJ; Park, JM; Park, MS; Rha, JH; Shin, DI; Yoon, BW, 2022) |
| "In the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trial, acute treatment with clopidogrel-aspirin was associated with significantly reduced risk of recurrent stroke." | 9.51 | Infarct on Brain Imaging, Subsequent Ischemic Stroke, and Clopidogrel-Aspirin Efficacy: A Post Hoc Analysis of a Randomized Clinical Trial. ( de Havenon, A; Easton, JD; Henninger, N; Johnston, SC; Kim, AS; Kvernland, A; Liberman, AL; Mac Grory, B; Rostanski, SK; Yaghi, S, 2022) |
| "In this prospective cohort study, we randomly assigned patients with PFO who had a cryptogenic stroke, in a 1:1 ratio, to dabigatran or aspirin group." | 9.51 | Dabigatran versus aspirin for stroke prevention after cryptogenic stroke with patent foramen ovale: A prospective study. ( Cai, D; Chen, S; He, J; Huang, P; Lai, Y; Sun, H; Wu, Q; Zhou, L, 2022) |
| "Aspirin and unfractionated heparin are often used during endovascular stroke treatment to improve reperfusion and outcomes." | 9.51 | Safety and efficacy of aspirin, unfractionated heparin, both, or neither during endovascular stroke treatment (MR CLEAN-MED): an open-label, multicentre, randomised controlled trial. ( Beenen, LFM; Berkhemer, O; Boiten, J; Bokkers, RPH; Boukrab, I; Chalos, V; Coutinho, JM; de Laat, KF; de Ridder, I; den Hertog, HM; Dippel, DWJ; Elgersma, O; Emmer, BJ; Gerrits, D; Gons, RAR; Hammer, S; Hofmeijer, J; Jenniskens, SFM; Kerkhoff, H; Koudstaal, PJ; Krietemeijer, M; Lingsma, HF; Lycklama, G; Majoie, CBLM; Manschot, S; Martens, J; Meijer, FJA; Nieboer, D; Postma, AA; Remmers, M; Roos, YBWEM; Roosendaal, SD; Roozenbeek, B; Rozeman, A; Schonewille, W; Staals, J; Tolhuisen, M; Truijman, MTB; Tuladhar, AM; Uyttenboogaart, M; van de Graaf, RA; van den Berg, R; van den Wijngaard, I; van der Hoorn, A; van der Lugt, A; van der Schaaf, I; van der Sluijs, PM; van der Steen, W; van der Worp, HB; van Dijk, LC; van Doormaal, PJ; van Es, ACGM; van Hasselt, B; van Oostenbrugge, RJ; van Tuijl, J; van Voorst, H; van Zwam, W; Vos, D; Vos, JA; Wolff, L; Yo, LSF; Yoo, AJ; Zinkstok, S, 2022) |
| "Irrespective of the presence of DM, CKD, and their combination, ticagrelor monotherapy reduced the risk of bleeding without a significant increase in ischaemic events compared with ticagrelor plus aspirin." | 9.51 | Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. ( Angiolillo, DJ; Baber, U; Briguori, C; Cao, D; Cohen, DJ; Collier, T; Dangas, G; Dehghani, P; Dudek, D; Escaned, J; Gibson, M; Gil, R; Huber, K; Kaul, U; Kornowski, R; Krucoff, MW; Kunadian, V; Mehran, R; Mehta, S; Moliterno, DJ; Nicolas, J; Ohman, EM; Pivato, CA; Pocock, S; Sardella, G; Sartori, S; Sharma, SK; Shlofmitz, R; Weisz, G; Witzenbichler, B; Zhang, Z, 2022) |
| "To test whether indobufen is non-inferior to aspirin in reducing the risk of new stroke at 3 months in patients with moderate to severe ischaemic stroke." | 9.51 | Indobufen versus aspirin in acute ischaemic stroke (INSURE): rationale and design of a multicentre randomised trial. ( Bath, PM; Chen, W; Dong, Q; Jiang, Y; Jing, J; Johnston, SC; Li, H; Lin, J; Meng, X; Pan, Y; Wang, Y; Xu, AD, 2022) |
| " Aspirin increased major or CRNM bleeding, particularly in patients without prior stroke/TIA/TE." | 9.51 | Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial. ( Alexander, JH; Aronson, R; Bahit, MC; Berwanger, O; Dombrowski, KE; Goodman, SG; Granger, CB; Halvorsen, S; Jordan, JD; Kolls, BJ; Li, Z; Lopes, RD; Mehran, R; Thomas, L; Vinereanu, D; Vora, AN; Windecker, S; Wojdyla, DM, 2022) |
| "Ticagrelor-aspirin was associated with reduced risk of new stroke in patients without hypertension (32 [4." | 9.51 | Effect of Hypertension on Efficacy and Safety of Ticagrelor-Aspirin Versus Clopidogrel-Aspirin in Minor Stroke or Transient Ischemic Attack. ( Bath, PM; Chen, G; Huang, P; Jiang, Y; Jing, J; Johnston, SC; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Tian, X; Wang, A; Wang, F; Wang, Y; Xie, X; Zhao, X; Zuo, Y, 2022) |
| "Dual antiplatelet therapy (DAPT) with ticagrelor and aspirin has been found to be effective for secondary prevention after minor ischemic stroke or transient ischemic attack (TIA) in individuals who carry CYP2C19 loss-of-function (LOF) alleles; however, uncertainties remain about the time course of benefit and risk with ticagrelor and aspirin in these patients." | 9.51 | Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial. ( Bath, PM; Cheng, J; Jiang, Y; Jin, A; Jing, J; Johnston, SC; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Pan, Y; Wang, Y; Wang, Z; Xie, X; Yang, H; Zhao, X, 2022) |
| "Whether aspirin platelet reactivity affects platelet function and clinical outcomes with different antiplatelet therapies in patients with mild stroke or transient ischemic attack (TIA) remains unclear." | 9.51 | Aspirin platelet reactivity on platelet function and clinical outcome in minor stroke or transient ischemic attack. ( Chen, W; Guo, L; Jiang, L; Liu, L; Pan, Y; Wang, Y; Xu, Y; Yao, D; Zhao, X, 2022) |
| "Aspirin, as an typical antiplatelet therapy for secondary stroke prevention, have been proved that can significantly reduce incidence and recurrence of cerebrovascular ischemic events." | 9.51 | To study the mechanism of panax notoginseng in the treatment of aspirin resistance in the secondary prevention of stroke based on TLR4/MyD88/NF-κB signaling pathway: A study protocol. ( Chen, J; Wang, H; Wang, Y; Yuan, J, 2022) |
| "In this open-label, assessor-masked, multicentre, non-inferiority, randomised trial (TALOS-AMI), patients at 32 institutes in South Korea with acute myocardial infarction receiving aspirin and ticagrelor without major ischaemic or bleeding events during the first month after index percutaneous coronary intervention (PCI) were randomly assigned in a 1:1 ratio to a de-escalation (clopidogrel plus aspirin) or active control (ticagrelor plus aspirin) group." | 9.41 | Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. ( Ahn, Y; Chang, K; Choi, YS; Choo, EH; Hwang, BH; Jeon, DS; Jeong, MH; Jeong, YH; Kim, CJ; Kim, HY; Kim, MC; Lee, KY; Park, MW; Seung, KB; Shin, ES; Yim, HW; Yoo, KD, 2021) |
| "Ticagrelor is slightly better than clopidogrel and aspirin in preventing stroke, especially ischemic stroke, with significant safety risks." | 9.41 | Efficacy and Safety of Ticagrelor versus Aspirin and Clopidogrel for Stroke Prevention in Patients with Vascular Disease: A Systematic Review and Meta-Analysis. ( Chen, Y; Li, D; Liu, S; Ma, X; Zhong, P, 2023) |
| " The incidence of all bleeding events with ticagrelor was higher than that with clopidogrel (RR, 1." | 9.41 | Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials. ( He, X; Li, J; Ma, S; Qiu, M; Qu, X; Wang, Q; Wang, X; Wu, C; Zhang, L, 2023) |
| "The study aimed to evaluate the clinical efficacy of the Huo Xue Hua Yu method combined with aspirin in the treatment of patients with acute cerebral infarction (ACI)." | 9.41 | Clinical Efficacy of the Huo Xue Hua Yu Method Combined with Aspirin in the Treatment of Acute Cerebral Infarction: A Systematic Evaluation and Meta-analysis. ( Chen, C; Liu, X; Ma, F; Tang, Q; Wen, X; Wu, Y, 2023) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel was recommended as the secondary prevention of minor ischemic stroke or transient ischaemic attack (TIA)." | 9.41 | Ticagrelor plus aspirin in patients with minor ischemic stroke and transient ischemic attack: a network meta-analysis. ( Ge, F; Li, M; Lin, H; Shi, J; Yang, Q; Zhang, X, 2023) |
| "The efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valves and atrial fibrillation or flutter remain uncertain." | 9.41 | A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial. ( Almeida, AP; Ardito, RV; Atik, FA; Barreto, DO; Berwanger, O; Campos, VB; Cavalcante, MA; Cavalcanti, AB; D'Oliveira Vieira, R; Damiani, L; de Barros E Silva, PGM; de Lima, CEB; de Souza Neto, JD; Dos Santos, JRY; Farias, FR; Ferreira, JFM; Figueira, FAMS; Fonseca, FH; Guimarães, HP; Hoffmann-Filho, CR; Junior, RA; Kalil, PSA; Kojima, F; Lamprea, D; Laranjeira, L; Leiria, TLL; Liporace, IL; Lopes, RD; Magalhães, CC; Maldonado, JGA; Mesas, CE; Moisés, VA; Nakagawa, RH; Paiva, MSMO; Paixão, M; Patriota, R; Pavanello, R; Pinto, IM; Precoma, DB; Sampaio, BS; Sampaio, RO; Saraiva, JFK; Silveira, FS; Tarasoutchi, F; Zilli, AC, 2021) |
| "In the AFIRE trial, rivaroxaban monotherapy was noninferior to combination therapy with rivaroxaban and an antiplatelet agent for thromboembolic events or death, and superior for major bleeding in patients with atrial fibrillation (AF) and stable coronary artery disease." | 9.41 | Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis. ( Akao, M; Ako, J; Hagiwara, N; Hirayama, A; Kaikita, K; Kimura, K; Matoba, T; Matsui, K; Miyauchi, K; Nakamura, M; Ogawa, H; Yasuda, S, 2021) |
| "It is the common clinical practice to prescribe indefinite aspirin for patients with non-valvular atrial fibrillation (NVAF) post left atrial appendage occlusion (LAAO)." | 9.41 | Double-blind, placebo-controlled randomised clinical trial to evaluate the effect of ASPIRIN discontinuation after left atrial appendage occlusion in atrial fibrillation: protocol of the ASPIRIN LAAO trial. ( Chen, M; Chen, TZ; Li, W; Li, YG; Mo, BF; Sun, J; Tang, X; Wang, Q; Zhang, PP, 2021) |
| "Clopidogrel and aspirin are key intervention for acute ischemic stroke (AIS) and transient ischemic attack (TIA)." | 9.41 | Personalized antiplatelet therapy based on clopidogrel/aspirin resistance tests in acute ischemic stroke and transient ischemic attack: Study protocol of a multi-center, single-blinded and randomized controlled trial. ( Chen, J; Gao, P; Han, M; Jia, W; Kuang, J; Peng, C; Starcevich, K; Tu, J; Wang, J; Wu, Y; Yi, Y; Yin, S; Zhang, X, 2021) |
| "To analyze the association between low-dose rivaroxaban with or without aspirin and different ischemic stroke subtypes." | 9.34 | Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial. ( Bosch, J; Catanese, L; Connolly, SJ; Dyal, L; Eikelboom, JW; Hart, RG; Nayar, S; Ng, KKH; Perera, KS; Sharma, M; Yusuf, S, 2020) |
| " Approach and Results: The CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) randomized patients with acute minor ischemic stroke or high-risk transient ischemic attack to clopidogrel plus aspirin or aspirin alone from October 1, 2009, to July 30, 2012, in China." | 9.34 | Homocysteine Level Predicts Response to Dual Antiplatelet in Women With Minor Stroke or Transient Ischemic Attack: Subanalysis of the CHANCE Trial. ( Li, H; Li, J; Lin, J; Liu, L; Wang, A; Wang, Y; Zhao, X; Zuo, Z, 2020) |
| " Patients with newly diagnosed ischemic stroke who are just about to start Aspirin were assessed for eligibility and inclusion in our trial." | 9.34 | An investigation into the impact of enteric coated of aspirin in patients with newly diagnosed ischemic stroke (ECASIS). ( Abdallah, IM; Ahmed, MS; Ali, M; AlSaud, AE; Danjuma, MI; Elshafei, MN; Imam, Y; Mohamed, MFH; Obeidat, K; Parray, AS; Saeid, R, 2020) |
| "Trials have evaluated the use of clopidogrel and aspirin to prevent stroke after an ischemic stroke or transient ischemic attack (TIA)." | 9.34 | Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. ( Amarenco, P; Denison, H; Evans, SR; Himmelmann, A; James, S; Johnston, SC; Knutsson, M; Ladenvall, P; Molina, CA; Wang, Y, 2020) |
| "The OPT-BIRISK trial is a multicenter, double-blinded, placebo-controlled randomized study designed to test the superiority of extended antiplatelet therapy with clopidogrel monotherapy compared with aspirin and clopidogrel for reduction of bleeding events in ACS patients with both high bleeding and high ischemic risks ("bi-risk")." | 9.34 | Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the O ( Angiolillo, DJ; Chen, S; Han, Y; Jing, Q; Li, J; Li, Y; Qiao, S; Wang, B; Wang, X, 2020) |
| "Adding rivaroxaban to aspirin in patients with stable atherosclerotic disease reduces the recurrence of cardiovascular disease (CVD) but increases the risk of major bleeding." | 9.30 | Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. ( Alings, M; Berkowitz, SD; Bosch, J; de Vries, TI; Dorresteijn, JAN; Dyal, L; Eikelboom, JW; Fox, KAA; van der Graaf, Y; Visseren, FLJ; Westerink, J, 2019) |
| "The benefits of both dabigatran 110 mg and 150 mg dual therapy compared with warfarin triple therapy in reducing bleeding risks were consistent across subgroups of patients with or without ACS, and patients treated with ticagrelor or clopidogrel." | 9.30 | Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. ( Bhatt, DL; Brueckmann, M; Cannon, CP; Hohnloser, SH; Kimura, T; Kleine, E; Lip, GYH; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2019) |
| "The NAVIGATE ESUS randomized clinical trial found that 15 mg of rivaroxaban per day does not reduce stroke compared with aspirin in patients with embolic stroke of undetermined source (ESUS); however, it substantially reduces stroke risk in patients with atrial fibrillation (AF)." | 9.30 | Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial. ( Arauz, A; Berkowitz, SD; Connolly, SJ; Coutts, SB; Czlonkowska, A; Eckstein, J; Endres, M; Epstein, AE; Gladstone, DJ; Haeusler, KG; Hankey, GJ; Hart, RG; Healey, JS; Karlinski, M; Kasner, SE; Lutsep, H; Mikulik, R; Molina, CA; Mundl, H; Ntaios, G; Pagola, J; Perera, K; Santo, G; Shuaib, A; Swaminathan, B; Toni, D; Uchiyama, S; Yang, X, 2019) |
| " The COMMANDER HF randomized clinical trial evaluated the effects of adding low-dose rivaroxaban to antiplatelet therapy in patients with recent worsening of chronic HF with reduced ejection fraction, coronary artery disease (CAD), and sinus rhythm." | 9.30 | Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. ( Anker, SD; Byra, WM; Cleland, JGF; Deng, H; Fu, M; Greenberg, B; La Police, DA; Lam, CSP; Mehra, MR; Neaton, JD; Nessel, CC; Spiro, TE; van Veldhuisen, DJ; Vanden Boom, CM; Zannad, F, 2019) |
| "Results show the short-term risk of hemorrhage in treating patients with acute transient ischemic attack (TIA) or minor acute ischemic stroke (AIS) with clopidogrel plus aspirin or aspirin alone." | 9.30 | Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial. ( Barsan, W; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY; Tillman, H, 2019) |
| " This study investigated the effect of warfarin versus aspirin on WBV in patients presenting with non-valvular atrial fibrillation (NVAF) and acute cardioembolic stroke." | 9.30 | Effect of warfarin versus aspirin on blood viscosity in cardioembolic stroke with atrial fibrillation: a prospective clinical trial. ( Cho, DJ; Jeong, SK; Jung, KH; Lee, CH, 2019) |
| "We conducted a multicenter, randomized, double-blind trial of dabigatran at a dose of 150 mg or 110 mg twice daily as compared with aspirin at a dose of 100 mg once daily in patients who had had an embolic stroke of undetermined source." | 9.30 | Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. ( Bernstein, RA; Brueckmann, M; Chernyatina, M; Cotton, D; Cronin, L; Diener, HC; Donnan, G; Easton, JD; Ferro, JM; Granger, CB; Grauer, C; Grond, M; Kallmünzer, B; Kreuzer, J; Krupinski, J; Lee, BC; Lemmens, R; Masjuan, J; Odinak, M; Sacco, RL; Saver, JL; Schellinger, PD; Toni, D; Toyoda, K; Uchiyama, S, 2019) |
| "While the addition of low dose chlorpromazine and promethazine to standard of care for acute ischemic stroke did not have any significant improvement in functional outcomes, there were no serious adverse effects." | 9.30 | Low dose concomitant treatment with chlorpromazine and promethazine is safe in acute ischemic stroke. ( Chandra, A; Cheng, Z; Ding, Y; Du, H; Geng, X; Tong, Y; Zhu, H, 2019) |
| "Although dual antiplatelet therapy with aspirin and clopidogrel reduces early recurrence of ischaemic stroke, with long-term use this type of therapy is no longer effective and the risk of bleeding increases." | 9.30 | Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. ( Easton, JD; Hoshino, H; Houkin, K; Isobe, M; Kimura, K; Minematsu, K; Naritomi, H; Okada, Y; Origasa, H; Sakai, N; Tanaka, K; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T, 2019) |
| "Exploratory analyses of 7213 participants in the NAVIGATE ESUS international trial who were randomized to aspirin 100 mg/day or rivaroxaban 15 mg/day and followed for a median of 11 months, during which time there were 309 first recurrent ischemic strokes (4." | 9.30 | Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. ( Ameriso, SF; Bangdiwala, SI; Berkowitz, SD; Connolly, SJ; Coutts, SB; Czlonkowska, A; Gagliardi, RJ; Hankey, GJ; Hart, RG; Kasner, SE; Lindgren, A; Mundl, H; Ntaios, G; Perera, KS; Peters, G; Sharma, M; Sheridan, P; Shoamanesh, A; Shuaib, A; Toni, D; Veltkamp, RC, 2019) |
| "Dual antiplatelet therapy (DAT) with clopidogrel plus aspirin has been suggested by American Heart Association/American Stroke Association guidelines for minor stroke (MS) and transient ischemic attack (TIA) patients." | 9.30 | Efficacy of clopidogrel for stroke depends on CYP2C19 genotype and risk profile. ( Chen, W; Chen, Z; Dai, L; Li, H; Meng, X; Mo, J; Wang, A; Wang, Y; Wangqin, R; Xian, Y; Xu, J; Zhao, X, 2019) |
| "In patients with acute minor ischemic stroke or high-risk transient ischemic attack enrolled in the POINT trial (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke [POINT] Trial), the combination of clopidogrel and aspirin for 90 days reduced major ischemic events but increased major hemorrhage in comparison to aspirin alone." | 9.30 | Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient Ischemic Attack and Minor Ischemic Stroke. ( Albers, GW; Barsan, WG; Cucchiara, BL; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Kleindorfer, DO; Lindblad, AS; Lutsep, HL; Palesch, YY; Pearson, C; Sethi, P; Vora, N; Zurita, KG, 2019) |
| "Background The aim of the present study was to investigate the efficacy and safety of antiplatelet (aspirin plus cilostazol) dual therapy for patients with noncardioembolic stroke within 48 hours of symptom onset." | 9.30 | Acute Aspirin Plus Cilostazol Dual Therapy for Noncardioembolic Stroke Patients Within 48 Hours of Symptom Onset. ( Abe, K; Aoki, J; Fujimoto, S; Idomari, K; Iguchi, Y; Inoue, T; Iwanaga, T; Kaneko, N; Kimura, K; Matsuoka, H; Nomura, K; Okada, Y; Tanaka, R; Terasaki, T; Todo, K; Tsujino, A; Uno, M; Urabe, T; Yagita, Y; Yamagami, H; Yamagata, S; Yamamoto, N; Yamamoto, Y; Yonehara, T, 2019) |
| "In patients with stable coronary artery disease, addition of rivaroxaban to aspirin lowered major vascular events, but increased major bleeding." | 9.27 | Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. ( Anand, SS; Avezum, AA; Berkowitz, SD; Bhatt, DL; Bosch, J; Branch, KRH; Connolly, SJ; Cook Bruns, N; Dagenais, G; Dans, AL; Dyal, L; Eikelboom, JW; Felix, C; Fox, KAA; Guzik, TJ; Ha, JW; Hori, M; Keltai, K; Lanas, F; Lisheng, L; Lonn, E; Maggioni, AP; Metsarinne, K; O'Donnell, M; Parkhomenko, AN; Torp-Pedersen, C; Varigos, JD; Widimsky, P; Yusoff, K; Yusuf, S, 2018) |
| "Ticagrelor plus low-dose aspirin for up to 1 year was associated with a low rate of major bleeding events and a low incidence of major CV events (CV death, myocardial infarction, stroke) in Chinese patients with ACS." | 9.27 | Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study. ( Gao, R; Han, Y; Leonsson-Zachrisson, M; Liu, H; Liu, L; Shen, L; Su, G; Wang, Y; Wang, Z; Wu, Y; Yuan, Z; Zhang, A; Zhang, H; Zheng, Y, 2018) |
| " The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days." | 9.27 | Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018) |
| "Rivaroxaban was not superior to aspirin with regard to the prevention of recurrent stroke after an initial embolic stroke of undetermined source and was associated with a higher risk of bleeding." | 9.27 | Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. ( Amarenco, P; Ameriso, SF; Arauz, A; Bangdiwala, SI; Benavente, OR; Bereczki, D; Berkowitz, SD; Bornstein, N; Brouns, R; Connolly, SJ; Cunha, L; Czlonkowska, A; Davalos, A; De Vries Basson, MM; Eckstein, J; Endres, M; Gagliardi, RJ; Hankey, GJ; Hart, RG; Joyner, C; Kasner, SE; Kirsch, B; Lang, W; Lavados, P; Lindgren, A; Mikulik, R; Muir, KW; Mundl, H; Ntaios, G; O'Donnell, MJ; Ozturk, S; Pare, G; Pater, C; Peacock, WF; Peters, G; Shamalov, N; Sharma, M; Sheridan, P; Shoamanesh, A; Swaminathan, B; Tatlisumak, T; Themeles, E; Toni, D; Uchiyama, S; Veltkamp, R; Wang, Y; Weitz, JI; Yoon, BW, 2018) |
| "The PRISMS trial was designed as a 948-patient, phase 3b, double-blind, double-placebo, multicenter randomized clinical trial of alteplase compared with aspirin for emergent stroke at 75 stroke hospital networks in the United States." | 9.27 | Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial. ( Broderick, J; Chatterjee, A; Devenport, J; Devlin, T; Jauch, EC; Khatri, P; Kleindorfer, DO; Levine, SR; Mejilla, J; Pavlov, A; Purdon, B; Romano, JG; Saver, JL; Sawyer, RN; Starr, M; Vagal, A; Yeatts, SD, 2018) |
| "NAVIGATE ESUS was a double-blinded, randomised, phase 3 trial done at 459 centres in 31 countries that assessed the efficacy and safety of rivaroxaban versus aspirin for secondary stroke prevention in patients with ESUS." | 9.27 | Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. ( Ameriso, SF; Bangdiwala, S; Berkowitz, SD; Connolly, SJ; Endres, M; Hart, RG; Kasner, SE; Lavados, P; Lindgren, A; Lutsep, H; Messé, SR; Muir, K; Mundl, H; Nedeltechev, K; Olavarria, V; Perera, K; Santo, G; Sharma, M; Shoamanesh, A; Spence, JD; Swaminathan, B; Veltkamp, R, 2018) |
| "To investigate the short-term time course risks and benefits of clopidogrel with aspirin in minor ischemic stroke or TIA." | 9.24 | Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: Time course analysis of CHANCE. ( Chen, W; Jing, J; Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, D; Wang, Y; Zhao, X, 2017) |
| "Objective Some previous studies have found clinical benefit of dual antiplatelet therapy with aspirin and cilostazol for prevention of secondary stroke, but the physiological mechanism involved remains unknown." | 9.24 | Dual Therapy with Aspirin and Cilostazol May Improve Platelet Aggregation in Noncardioembolic Stroke Patients: A Pilot Study. ( Kohara, S; Ohnuki, Y; Shimizu, M; Takizawa, S, 2017) |
| "To elucidate the efficacy and safety between aspirin and clopidogrel, a multicenter randomized controlled trial was designed in AF patients with low stroke risk." | 9.24 | Rationale and Design for a Randomized Comparison of Efficacy and Safety between Aspirin and Clopidogrel in Atrial Fibrillation Patients with Low Stroke Risk: CESAC-AF trial. ( Bang, CS; Hong, KS; Hong, MK; Jeong, H; Jung, MH; Kim, CY; Park, SM, 2017) |
| "Ticagrelor is an effective antiplatelet therapy among patients with atherosclerotic disease and, therefore, could be more effective than aspirin in preventing recurrent stroke and cardiovascular events among patients with embolic stroke of unknown source (ESUS), which includes patients with ipsilateral stenosis <50% and aortic arch atherosclerosis." | 9.24 | Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017) |
| "In the SOCRATES trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes), ticagrelor was not superior to aspirin." | 9.24 | Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes). ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wang, Y; Wong, KS, 2017) |
| "Ticagrelor is an effective antiplatelet therapy for patients with coronary atherosclerotic disease and might be more effective than aspirin in preventing recurrent stroke and cardiovascular events in patients with acute cerebral ischaemia of atherosclerotic origin." | 9.24 | Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017) |
| "This systematic review aimed to compare early use of P2Y12 inhibitors (clopidogrel/ticagrelor) plus aspirin to aspirin alone for acute treatment and secondary prevention in acute non-cardioembolic minor ischemic stroke or TIA." | 9.22 | P2Y12 inhibitors plus aspirin for acute treatment and secondary prevention in minor stroke and high-risk transient ischemic attack: A systematic review and meta-analysis. ( Bellesini, M; Galli, E; Maroni, L; Pomero, F; Squizzato, A, 2022) |
| "Our aim was to establish (1) if there is an association between aspirin and subarachnoid hemorrhage, (2) how this differs between the general population and those with intracranial aneurysms." | 9.22 | A meta-analysis of aspirin and subarachnoid hemorrhage in patients with intracranial aneurysms yields different results to the general population. ( Birks, J; Bulters, D; Ewbank, F, 2022) |
| "P2Y12 receptor inhibitor plus aspirin vs aspirin given within 24 h after acute noncardioembolic ischemic stroke or TIA reduces the risk of subsequent stroke." | 9.22 | P2Y12 receptor inhibitor plus aspirin versus aspirin treated within 24 hours of acute noncardioembolic ischemic stroke or TIA: Meta-analysis. ( Huang, WY; Lee, M; Ovbiagele, B, 2022) |
| "The aim of this study was to analyze the benefits and safety associated with the combination therapy of clopidogrel and aspirin among minor stroke or transient ischemic attack patients treated within 12 hours." | 9.22 | Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. ( Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Yang, X; Zhang, C; Zhao, X, 2016) |
| "Medically managed patients with ACS in the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial were randomised to clopidogrel versus prasugrel (plus aspirin), stratified by prior clopidogrel use." | 9.22 | Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. ( Armstrong, PW; Boden, WE; Chin, CT; Corbalán, R; Dalby, AJ; Fox, KA; Gottlieb, S; Leiva-Pons, JL; Neely, B; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Schiele, F; White, HD; Winters, KJ, 2016) |
| "PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) randomized 21,162 patients with prior MI (1 to 3 years) to ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, or placebo, all on a background of low-dose aspirin." | 9.22 | Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. ( Abola, MTB; Aylward, P; Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Corbalán, R; Dalby, A; Dellborg, M; Goodrich, E; Held, P; Jensen, EC; Kuder, J; López-Sendón, J; Nicolau, JC; Parkhomenko, A; Sabatine, MS; Špinar, J; Steg, PG; Storey, RF, 2016) |
| "Ticagrelor may be a more effective antiplatelet therapy than aspirin for the prevention of recurrent stroke and cardiovascular events in patients with acute cerebral ischemia." | 9.22 | Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wang, Y; Wong, KS, 2016) |
| "A total of 14 464 patients (age, 60-85 years) with hypertension, dyslipidemia, and diabetes mellitus participated and were randomized into 2 treatment groups: 100 mg of aspirin or no aspirin." | 9.22 | Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project. ( Ando, K; Ikeda, Y; Ishizuka, N; Matsumoto, M; Minematsu, K; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Yamazaki, T; Yokoyama, K, 2016) |
| "The objective of this study was to evaluate the efficacy and safety of intravenous vinpocetine administration as part of a comprehensive treatment for acute cerebral infarction in a Chinese population." | 9.22 | Efficacy and Safety of Vinpocetine as Part of Treatment for Acute Cerebral Infarction: A Randomized, Open-Label, Controlled, Multicenter CAVIN (Chinese Assessment for Vinpocetine in Neurology) Trial. ( Hu, H; Huang, Y; Kong, Y; Li, C; Li, Y; Nao, J; Song, Y; Tan, L; Zhang, J; Zhang, W, 2016) |
| "Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding." | 9.22 | Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016) |
| "Patients with acute minor ischemic stroke or transient ischemic attack in the trial were randomized to treatment with clopidogrel combined with aspirin or to aspirin alone." | 9.22 | Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. ( Johnston, SC; Li, H; Lin, J; Lin, Y; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Xu, J; Zhao, X, 2016) |
| "In patients with acute ischemic stroke caused by large artery atherosclerosis, clopidogrel plus aspirin versus aspirin alone might be more effective to prevent recurrent cerebral ischemia." | 9.22 | Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone. ( Bae, HJ; Cha, JK; Chang, DI; Cho, KH; Cho, YJ; Choi, JC; Hong, KS; Kang, DW; Kim, DE; Kim, EG; Kim, GM; Kim, HY; Kwon, SU; Lee, J; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Park, KY; Rha, JH; Sohn, CH; Sohn, SI; Yoon, BW; Yu, KH, 2016) |
| "In the PEGASUS-TIMI 54 trial (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54), ticagrelor reduced the risk of major adverse cardiovascular events when added to low-dose aspirin in stable patients with prior myocardial infarction, resulting in the approval of ticagrelor 60 mg twice daily for long-term secondary prevention." | 9.22 | Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm ( Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Dalby, AJ; Goodrich, E; Goto, S; Held, P; Hu, D; Jensen, E; Mauri, L; Morrow, DA; Ophuis, TO; Ruda, M; Sabatine, MS; Seung, KB; Špinar, J; Steg, PG; Storey, RF, 2016) |
| "Dual clopidogrel-aspirin therapy was associated with a marked reduction in new strokes compared with the therapy of aspirin alone in patients with normal renal function (hazard ratio, 0." | 9.22 | Effect of Estimated Glomerular Filtration Rate Decline on the Efficacy and Safety of Clopidogrel With Aspirin in Minor Stroke or Transient Ischemic Attack: CHANCE Substudy (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). ( Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Wu, Y; Zhao, X; Zhou, Y, 2016) |
| "The Elderly-ACS 2 study is a multicenter, randomized, parallel-group, open-label trial designed to demonstrate the superiority of a strategy of dual antiplatelet treatment using a reduced 5-mg daily dose of prasugrel over a standard strategy with a daily clopidogrel dose of 75mg in patients older than 74years with ACS (either ST- or non-ST-elevation myocardial infarction) undergoing early percutaneous revascularization." | 9.22 | A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. ( Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A, 2016) |
| " This study was aimed at determining the efficacy of minocycline adjunct to aspirin in improving neurological outcomes of ischemic stroke during 3-month follow-up." | 9.20 | An open-label evaluator-blinded clinical study of minocycline neuroprotection in ischemic stroke: gender-dependent effect. ( Amiri-Nikpour, MR; Hamdi-Holasou, M; Nazarbaghi, S; Rezaei, Y, 2015) |
| "We analysed the rates of stroke and systemic embolism in 6563 aspirin-treated patients with AF from the ACTIVE-A/AVERROES databases." | 9.20 | Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. ( Alings, M; Avezum, A; Connolly, SJ; Díaz, R; Eikelboom, JW; Hart, RG; Healey, JS; Hohnloser, SH; Lauw, MN; Lewis, BS; Shestakovska, O; Vanassche, T; Wang, J, 2015) |
| "To evaluate the effects of treatments with clopidogrel plus aspirin (dual therapy) on early neurological deterioration (END) and outcomes at 6 months in patients with acute large artery atherosclerosis (LAA) stroke." | 9.20 | Clopidogrel plus aspirin prevents early neurologic deterioration and improves 6-month outcome in patients with acute large artery atherosclerosis stroke. ( Chi, L; Liao, D; Lin, J; Wang, C; Yi, X; Zhang, B, 2015) |
| "This study aims to evaluate whether cilostazol plus aspirin is more efficacious than aspirin alone for preventing progression of atherosclerosis in patients with ischemic stroke or transient ischemic attack (TIA) who also have peripheral arterial disease." | 9.20 | The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double-blind, placebo-controlled multicenter trial. ( Chen, CH; Chen, ST; Chern, CM; Chiou, HY; Chiu, HC; Hsu, CY; Hu, HH; Jeng, JS; Lee, JT; Lien, LM; Lin, HJ; Lin, RT; Liu, CH; Ma, H; Po, HL; Sun, MC; Sun, MH; Sun, Y, 2015) |
| "Aspirin is a primary antiplatelet agent for the secondary prevention of ischemic stroke." | 9.20 | Aspirin resistance in the acute stages of acute ischemic stroke is associated with the development of new ischemic lesions. ( Cho, KH; Choi, KH; Choi, MJ; Heo, SH; Kim, BC; Kim, JT; Kim, MK; Lee, JS; Lee, SH; Nam, TS; Park, MS, 2015) |
| "We used data from the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial to assess the relationship of TTR with the WARCEF primary outcome (ischemic stroke, intracerebral hemorrhage, or death), with death alone, ischemic stroke alone, major hemorrhage alone, and net clinical benefit (primary outcome and major hemorrhage combined)." | 9.20 | Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy. ( Anker, SD; Buchsbaum, R; Di Tullio, MR; Estol, CJ; Freudenberger, RS; Graham, S; Homma, S; Labovitz, AJ; Levin, B; Lip, GY; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Teerlink, JR; Thompson, JL; Ye, S, 2015) |
| "The Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial showed that the combined treatment of clopidogrel and aspirin decreases the 90-day risk of stroke without increasing hemorrhage in comparison with aspirin alone, but provided insufficient data to establish whether the benefit persisted over a longer period of time beyond the trial termination." | 9.20 | Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes. ( Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, C; Wang, D; Wang, Y; Zhao, X, 2015) |
| "We sought to assess the performance of existing bleeding risk scores, such as the Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly (HAS-BLED) score or the Outpatient Bleeding Risk Index (OBRI), in patients with heart failure with reduced ejection fraction (HFrEF) in sinus rhythm (SR) treated with warfarin or aspirin." | 9.20 | Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin. ( Anker, SD; Buchsbaum, R; Cheng, B; Di Tullio, MR; Estol, CJ; Freudenberger, RS; Graham, S; Homma, S; Labovitz, AJ; Levin, B; Lip, GY; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Teerlink, JR; Thompson, JL; Ye, S, 2015) |
| "We compared the effect of clopidogrel plus aspirin vs aspirin alone on functional outcome and quality of life in the Clopidogrel in High-risk Patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial of aspirin-clopidogrel vs aspirin alone after acute minor stroke or TIA." | 9.20 | Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: CHANCE substudy. ( Fang, J; Hu, B; Johnston, SC; Li, H; Liu, L; Meng, X; Wang, A; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Zhao, X, 2015) |
| "Apixaban was associated with fewer strokes and systemic embolism versus aspirin across all subgroups; however, it caused more major bleeding events." | 9.20 | Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients. ( Dorian, P; Kongnakorn, T; Lanitis, T; Lip, GY; Mardekian, J; Phatak, H, 2015) |
| "To study whether Clopidogrel-Aspirin combined treatment for high risk transient ischaemic attack (TIA) or minor stroke results in increased number of lesions associated with anti-thrombotic cerebral haemorrhage or cerebral micro-bleeds (CMB) than aspirin alone treatment." | 9.20 | Combined clopidogrel-aspirin treatment for high risk TIA or minor stroke does not increase cerebral microbleeds. ( Wang, P; Wang, Y; Wang, Z; Xin, H; Xu, C, 2015) |
| "The Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs." | 9.20 | Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT E ( Brueckmann, M; Cotton, D; Cronin, L; Diener, HC; Duffy, C; Easton, JD; Granger, CB; Sacco, RL, 2015) |
| "The goal of this study was to analyze the impact of dabigatran plasma concentrations, patient demographics, and aspirin (ASA) use on frequencies of ischemic strokes/systemic emboli and major bleeds in atrial fibrillation patients." | 9.19 | The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). ( Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Haertter, S; Lehr, T; Nehmiz, G; Reilly, PA; Wallentin, L; Wang, S; Yusuf, S, 2014) |
| "Apixaban had similar beneficial effects on stroke or systemic embolism and major bleeding compared with warfarin, irrespective of concomitant aspirin use." | 9.19 | Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. ( Alexander, JH; Alings, M; Atar, D; Aylward, P; Goto, S; Granger, CB; Hanna, M; Huber, K; Husted, S; Lewis, BS; Lopes, RD; McMurray, JJ; Pais, P; Pouleur, H; Steg, PG; Thomas, L; Verheugt, FW; Wallentin, L; Wojdyla, DM, 2014) |
| "We randomised 238 patients with non-valvular atrial fibrillation and a moderate stroke risk to aspirin or adjusted vitamin K antagonist therapy after TEE had ruled out thrombogenic features in the atria and aorta." | 9.19 | Aspirin versus vitamin K antagonist treatment guided by transoesophageal echocardiography in patients with atrial fibrillation: a pilot study. ( Baur, LH; Cheriex, EC; Crijns, HJ; Dinh, T; Heesen, WF; Kamp, O; Lindeboom, JE; Pisters, R; Prins, MH; Smeets, JL; Tieleman, RG; Verheugt, FW, 2014) |
| "This prospective randomized controlled, open-labeled trial, with blinded end point evaluation (PROBE design) tested superiority of aspirin 75 to 150 mg/d plus clopidogrel 75 mg/d (A+C) over warfarin therapy (international normalized ratio 2-3) in patients with ischemic stroke, transient ischemic attack, or peripheral embolism with plaque in the thoracic aorta>4 mm and no other identified embolic source." | 9.19 | Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. ( Amarenco, P; Cohen, AA; Davis, S; Donnan, GA; Heiss, WD; Jones, EF; Kaste, M; Laouénan, C; Macleod, M; Young, D, 2014) |
| "To compare the therapeutic warfarin and aspirin efficacies for treatments of atrial fibrillation (AF) complicated with stable coronary heart disease particularly in older Chinese patients." | 9.19 | Warfarin compared with aspirin for older Chinese patients with stable coronary heart diseases and atrial fibrillation complications. ( Cao, G; Feng, L; Huang, H; Li, Y; Liu, X; Xu, Q; Yu, J; Zhang, S; Zhou, M, 2014) |
| "We showed that slower than standard dose escalation of dipyridamole in combination therapy with acetylsalicylic acid does not reduce headaches as a side effect." | 9.19 | The effect of a slower than standard dose escalation scheme for dipyridamole on headaches in secondary prevention therapy of strokes: a randomized, open-label trial (DOSE). ( de Vogel, EM; de Vos-Koppelaar, NC; Dieleman, HG; Kerkhoff, H; Zock, E, 2014) |
| "Ancillary analysis of the Apixaban Versus Acetylsalicylic Acid [ASA] to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trial, comparing aspirin and apixaban, focused on sex differences." | 9.19 | Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study. ( Connolly, S; Eikelboom, J; Hart, RG; Lip, GY; Shestakovska, O; Yusuf, S, 2014) |
| "Aspirin early after intravenous thrombolysis in acute ischemic stroke increases the risk of symptomatic intracranial hemorrhage (SICH), without influencing functional outcome at 3 months." | 9.19 | Early deterioration after thrombolysis plus aspirin in acute stroke: a post hoc analysis of the Antiplatelet Therapy in Combination with Recombinant t-PA Thrombolysis in Ischemic Stroke trial. ( Beenen, LF; de Haan, RJ; Majoie, CB; Marquering, HA; Roos, YB; Zinkstok, SM, 2014) |
| "Among patients with TIA or minor stroke who can be treated within 24 hours after the onset of symptoms, the combination of clopidogrel and aspirin is superior to aspirin alone for reducing the risk of stroke in the first 90 days and does not increase the risk of hemorrhage." | 9.17 | Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. ( Cui, L; Dong, Q; Jia, J; Johnston, SC; Li, H; Li, Y; Liu, L; Meng, X; Wang, C; Wang, D; Wang, Y; Wang, Z; Xia, H; Xu, A; Zeng, J; Zhao, X, 2013) |
| "To investigate the prevalent of aspirin resistance (AR) in Chinese stroke patients and its association with recurrent stroke and other vascular events, including cardiovascular disease and death." | 9.17 | Aspirin resistance in Chinese stroke patients increased the rate of recurrent stroke and other vascular events. ( Chi, L; Lin, J; Yi, X; Zhou, Q, 2013) |
| "The impact of apixaban versus aspirin on ischemic stroke and major bleeding in relation to the CHADS(2) and CHA(2)DS(2)-VASc stroke risk scores in atrial fibrillation has not been investigated." | 9.17 | Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study. ( Connolly, S; Eikelboom, J; Flaker, G; Hart, R; Lanas, F; Lip, GY; Shestakovska, O; Xavier, D; Yusuf, S, 2013) |
| "Recent randomized trials have shown that cilostazol is superior to aspirin for secondary stroke prevention." | 9.16 | Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study. ( Nakamura, T; Tsuruta, S; Uchiyama, S, 2012) |
| "The Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study showed no superiority of low-molecular-weight heparin (LMWH) over aspirin for the primary end point (Barthel Index) in acute ischemic stroke due to large artery occlusive disease." | 9.16 | Low-molecular-weight heparin versus aspirin for acute ischemic stroke with large artery occlusive disease: subgroup analyses from the Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study. ( Chen, C; Chen, XY; Han, JH; Leung, TW; Mok, V; Soo, Y; Wang, QS; Wong, KS, 2012) |
| "In AVERROES, 5599 patients (mean age 70 years) with atrial fibrillation who were at increased risk of stroke and unsuitable for vitamin K antagonist therapy were randomly assigned to receive apixaban (5 mg twice daily) or aspirin (81-324 mg per day)." | 9.16 | Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. ( Connolly, SJ; Diener, HC; Eikelboom, J; Hankey, GJ; Hart, RG; Hohnloser, SH; Joyner, CD; Lip, GY; O'Donnell, M; Shestakovska, O; Yusuf, S, 2012) |
| "Dizziness was significantly improved in the cilostazol group versus the aspirin group (P<0." | 9.16 | Cilostazol versus aspirin therapy in patients with chronic dizziness after ischemic stroke. ( Johkura, K; Kudo, Y; Kuroiwa, Y; Momoo, T; Nakae, Y; Yoshida, TN, 2012) |
| "It is unknown whether warfarin or aspirin therapy is superior for patients with heart failure who are in sinus rhythm." | 9.16 | Warfarin and aspirin in patients with heart failure and sinus rhythm. ( Ammon, SE; Anker, SD; Buchsbaum, R; del Valle, ML; Di Tullio, MR; Estol, CJ; Freudenberger, RS; Gabriel, AP; Graham, S; Homma, S; Labovitz, AJ; Levin, B; Lip, GY; Lok, DJ; Mann, DL; Massie, BM; Mejia, V; Mohr, JP; Ponikowski, P; Pullicino, PM; Sacco, RL; Sanford, AR; Teerlink, JR; Thompson, JL, 2012) |
| " We investigated whether telmisartan prevents WML progression in the imaging substudy of the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial." | 9.16 | Telmisartan on top of antihypertensive treatment does not prevent progression of cerebral white matter lesions in the prevention regimen for effectively avoiding second strokes (PRoFESS) MRI substudy. ( Blatchford, J; Demchuk, AM; Diehl, A; Diener, HC; Forsting, M; Gizewski, ER; Hermansson, K; Möller-Hartmann, C; Sacco, RL; Saver, JL; Wanke, I; Warach, S; Weber, R; Weimar, C, 2012) |
| "In this multicentre, randomised, open-label trial with blind-endpoint assessment, patients with acute ischaemic stroke treated with alteplase were randomly assigned to 300 mg intravenous aspirin within 90 min after start of alteplase treatment or to no additional treatment." | 9.16 | Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. ( Roos, YB; Zinkstok, SM, 2012) |
| "Apixaban is superior to aspirin for the prevention of stroke in patients with atrial fibrillation." | 9.16 | Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. ( Connolly, SJ; De Caterina, R; Eikelboom, JW; Gao, P; Hart, RG; Husted, S; O'Donnell, M; Paolasso, E; Yusuf, S, 2012) |
| "Previous studies have suggested that pre-stroke treatment with low-dose aspirin (A) could reduce the severity of acute ischaemic stroke, but less is known on the effect of pre-stroke treatment with a combination of aspirin and dipyridamole (A + D) and post-stroke effects of these drugs." | 9.16 | Comparative evaluation of treatment with low-dose aspirin plus dipyridamole versus aspirin only in patients with acute ischaemic stroke. ( Andersson, B; Arnarsdottir, L; Bokemark, L; Hjalmarsson, C, 2012) |
| "Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed." | 9.16 | Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ, 2012) |
| "Among patients with recent lacunar strokes, the addition of clopidogrel to aspirin did not significantly reduce the risk of recurrent stroke and did significantly increase the risk of bleeding and death." | 9.16 | Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. ( Benavente, OR; Coffey, CS; Hart, RG; McClure, LA; Pearce, LA; Szychowski, JM, 2012) |
| "Apixaban reduces stroke with comparable bleeding risks when compared with aspirin in patients with atrial fibrillation who are unsuitable for vitamin k antagonist therapy." | 9.16 | Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K ( Budaj, A; Connolly, SJ; Eikelboom, JW; Flaker, GC; Hart, RG; Husted, S; Kaatz, S; Lip, GY; Shestakovska, O; Yusuf, S, 2012) |
| " We defined the time course and magnitude of changes of plasma eNOS and oxLDL after Aggrenox or aspirin in post-stroke patients." | 9.15 | Effects of Aggrenox and aspirin on plasma endothelial nitric oxide synthase and oxidised low-density lipoproteins in patients after ischaemic stroke. The AGgrenox versus aspirin therapy evaluation (AGATE) biomarker substudy. ( Eisert, C; Fong, A; Hanley, D; Sani, Y; Schevchuck, A; Serebruany, V, 2011) |
| " Platelet surface marker expression, leucocyte-platelet complex formation and inhibition of platelet function at high shear stress as detected by the PFA-100® Collagen-Adenosine-diphosphate (C-ADP) and Collagen-Epinephrine cartridges was assessed in 52 patients within 4 weeks of transient ischaemic attack (TIA) or ischaemic stroke on aspirin, and then 14 d (14 d) and >90 d (90 d) after adding dipyridamole." | 9.15 | Enhanced ex vivo inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: first results from the TRinity AntiPlatelet responsiveness (TrAP) study. ( Collins, DR; Coughlan, T; Egan, B; Feeley, TM; Kinsella, JA; McCabe, DJ; Murphy, RP; O'Neill, D; Tierney, S; Tobin, WO, 2011) |
| "In a double-blind study, we randomly assigned 5599 patients with atrial fibrillation who were at increased risk for stroke and for whom vitamin K antagonist therapy was unsuitable to receive apixaban (at a dose of 5 mg twice daily) or aspirin (81 to 324 mg per day), to determine whether apixaban was superior." | 9.15 | Apixaban in patients with atrial fibrillation. ( Afzal, R; Avezum, A; Budaj, A; Commerford, P; Connolly, SJ; Dans, AL; Diaz, R; Diener, HC; Eikelboom, J; Flaker, G; Golitsyn, S; Gonzalez-Hermosillo, A; Hart, R; Hohnloser, SH; Jansky, P; Joyner, C; Kim, JH; Lanas-Zanetti, F; Lawrence, J; Lewis, BS; Lewis, G; Lip, GY; Munawar, M; O'Donnell, M; Pais, P; Parkhomenko, A; Sim, KH; Talajic, M; Tan, RS; Van Mieghem, W; Yusuf, S; Zhu, J, 2011) |
| "Oral anticoagulants are effective at reducing stroke compared with aspirin in atrial fibrillation patients older than 75 years." | 9.15 | Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation. ( Bryan, S; Fitzmaurice, D; Fletcher, K; Hobbs, FD; Jowett, S; Lip, GY; Mant, J; Roalfe, A, 2011) |
| "Aspirin is a proven antiplatelet agent in acute ischemic stroke, and there are no current guidelines for other antiplatelet treatments." | 9.15 | Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial. ( Bae, HJ; Cho, YJ; Han, MG; Hong, KS; Jung, SW; Kang, DW; Kim, DE; Kim, JS; Koo, J; Kwon, SU; Lee, BC; Lee, JH; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Rha, JH; Yu, K, 2011) |
| "The trial was terminated prematurely after recruitment of 7392 patients because of an increase in major bleeding events with apixaban in the absence of a counterbalancing reduction in recurrent ischemic events." | 9.15 | Apixaban with antiplatelet therapy after acute coronary syndrome. ( Alexander, JH; Atar, D; Bhatt, DL; Cools, F; Cornel, JH; Darius, H; De Caterina, R; Diaz, R; Flather, M; Geraldes, M; Goodman, S; Harrington, RA; He, Y; Huber, K; Husted, SE; James, S; Jansky, P; Keltai, M; Kilaru, R; Lawrence, J; Leiva-Pons, JL; Liaw, D; Lopes, RD; Lopez-Sendon, J; Mohan, P; Ogawa, H; Pais, P; Parkhomenko, A; Ruda, M; Ruzyllo, W; Verheugt, FW; Vinereanu, D; Wallentin, L; White, H, 2011) |
| "Using five-colour flow cytometry the platelet surface expression of CD62P and CD40L and subpopulations of leukocyte-platelet aggregates were assessed in 63 acute stroke patients and 40 healthy volunteers at baseline and after a 10-day period of aspirin intake at a daily dose of 150 mg." | 9.15 | Aspirin treatment influences platelet-related inflammatory biomarkers in healthy individuals but not in acute stroke patients. ( Dworacki, G; Golanski, J; Kozubski, W; Kufel-Grabowska, J; Lukasik, M; Michalak, S; Watala, C, 2011) |
| "001) by adjusted-dose warfarin compared with aspirin/low-dose warfarin; there was no difference in major hemorrhage (5 patients versus 6 patients, respectively)." | 9.15 | Warfarin in atrial fibrillation patients with moderate chronic kidney disease. ( Asinger, RW; Hart, RG; Herzog, CA; Pearce, LA, 2011) |
| "Adding clopidogrel to aspirin therapy reduces stroke in patients with atrial fibrillation (AF) but increases hemorrhage." | 9.15 | Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. ( Connolly, SJ; de Caterina, R; Eikelboom, JW; Hart, RG; Hirsh, J; Hohnloser, S; Ng, J; Pogue, J; Yusuf, S, 2011) |
| "In this large observational analysis of patients undergoing PCI, low-dose aspirin appeared to be as effective as higher doses in preventing ischaemic events but was also associated with a lower rate of major bleeding and an improved net efficacy to safety balance." | 9.14 | Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. ( Avezum, A; Fox, KA; Gersh, BJ; Haladyn, K; Jolly, SS; Mehta, SR; Peters, RJ; Pogue, J; Rupprecht, HJ; Yusuf, S, 2009) |
| "Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead." | 9.14 | Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009) |
| "The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study is an international double-blind, randomized controlled trial designed to investigate the superiority of the specific TP receptor antagonist terutroban (30 mg/day) over aspirin (100 mg/day), in reducing cerebrovascular and cardiovascular events in patients with a recent history of ischemic stroke or transient ischemic attack." | 9.14 | The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population. ( Amarenco, P; Bousser, MG; Chamorro, A; Fisher, M; Ford, I; Fox, K; Hennerici, M; Mattle, HP; Rothwell, PM, 2009) |
| "Secondary pharmacological prevention of ischemic stroke or transient ischemic attack (TIA) is often provided with acetylsalicylic acid (ASA), dipyridamole (DP) or a combination of the two." | 9.14 | Dipyridamole-associated headache in stroke patients--interindividual differences? ( Lökk, J, 2009) |
| "In this double-blind, dose-escalation, phase II study, undertaken at 297 sites in 27 countries, 3491 patients stabilised after an acute coronary syndrome were stratified on the basis of investigator decision to use aspirin only (stratum 1, n=761) or aspirin plus a thienopyridine (stratum 2, n=2730)." | 9.14 | Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. ( Barnathan, ES; Bordes, P; Braunwald, E; Burton, P; Gibson, CM; Hricak, V; Markov, V; Mega, JL; Misselwitz, F; Mohanavelu, S; Oppenheimer, L; Poulter, R; Witkowski, A, 2009) |
| "To explore whether triflusal may modulate those pathways in human stroke, evolution of several inflammation markers (pro-inflammatory, adhesion molecules, chemokines, metalloproteinases, apoptosis and angiogenesis-related biomarkers) and neurological outcome were evaluated at baseline, and at days 1, 3, 7 and 90 in a pilot study in which 30 patients with acute ischemic stroke were randomly allocated to receive triflusal or aspirin." | 9.14 | Triflusal and aspirin have different effects on inflammatory biomarkers measured in patients with acute ischemic stroke. ( Alvarez-Sabín, J; García-Bonilla, L; Krupinski, J; Montaner, J; Penalba, A; Quintana, M, 2009) |
| "Extended release dipyridamole (ERD) is widely used in patients after ischaemic stroke; however, the ability of this antithrombotic agent to be stored in different blood cells has never been explored in post-stroke patients." | 9.14 | Distribution of dipyridamole in blood components among post-stroke patients treated with extended release formulation. ( Atar, OD; Booze, C; Eisert, C; Hanley, D; Sabaeva, E; Serebruany, V, 2009) |
| "The antithrombotic, antiplatelet and endothelial activity of terutroban, a specific thromboxane prostaglandin receptor antagonist, was assessed in patients previously treated with aspirin for the prevention of ischemic stroke." | 9.14 | Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. ( Bal Dit Sollier, C; Bergmann, JF; Bousser, MG; Crassard, I; Drouet, L; Simoneau, G, 2009) |
| "Despite its widespread use, there are many concerns about the efficacy of aspirin in the secondary prevention of cardiovascular events after stroke, leading to the concept of aspirin non-response (ANR)." | 9.14 | Stroke and aspirin non-responder patients: relation with hypertension and platelet response to adenosine diphosphate. ( Chomel, JC; Godeneche, G; Macchi, L; Neau, JP; Ragot, S; Sorel, N, 2009) |
| "In this double-blind multicenter trial, 244 aspirin users with ischaemic stroke were randomly assigned to receive cilostazol 100 mg twice daily or to placebo." | 9.14 | Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial. ( Cha, JK; Ha, SW; Kwon, SU; Lee, JH; Lee, SJ, 2010) |
| "During the clinical follow-up, ischemic stroke recurred in 2 patients in cilostazol group, while in aspirin group, one case of ischemic stroke recurrence and one case of acute myocardial infarction were found." | 9.14 | Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. ( Guo, JJ; Lin, QY; Xie, HF; Xu, E; Zeng, GL, 2009) |
| "In spite of the fact that the null hypothesis was not supported by our data, we found results supporting the safety (and potential efficacy) of ASA and tirofiban when used in the first hours of acute ischemic stroke." | 9.14 | Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial. ( Boiti, C; Borutti, G; Cazzaniga, M; Falaschi, F; Maestroni, A; Mandelli, C; Manganaro, D; Monzani, V; Rossi, P; Torgano, G; Zecca, B; Zilioli, E, 2010) |
| "In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain." | 9.14 | Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010) |
| "The factorial PRoFESS secondary prevention trial assessed antiplatelet and blood pressure-lowering strategies in 20,332 patients, 1360 of whom were randomized within 72 hours of ischemic stroke to combined aspirin (Asp; 25 mg BID) and extended-release dipyridamole (ER-DP; 200 mg BID, n=672) or clopidogrel (75 mg/d, n=688)." | 9.14 | Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. ( Bath, PM; Cotton, D; Diener, HC; Estol, C; Martin, RH; Palesch, Y; Roberts, R; Sacco, R; Yusuf, S, 2010) |
| " However, the reported use of warfarin among patients with AF at elevated risk of stroke remains low." | 9.14 | Warfarin and aspirin use in atrial fibrillation among practicing cardiologist (from the AFFECTS Registry). ( Kowey, PR; Myerburg, R; Naccarelli, GV; Packer, DL; Pratt, CM; Reiffel, JA; Reiter, MJ; Waldo, AL, 2010) |
| "PERFORM is exploring the efficacy of terutroban versus aspirin for secondary prevention in patients with a history of ischemic stroke or transient ischemic attacks (TIAs)." | 9.14 | Rationale, design and population baseline characteristics of the PERFORM vascular project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke o ( Bots, ML; Ford, I; Hennerici, MG; Laurent, S; Touboul, PJ, 2010) |
| "8%) patients had a definite adjudicated stroke and a follow-up assessment of the mRS at 3 months poststroke, of whom 202 had been randomly assigned clopidogrel and 234 placebo (relative risk reduction 14%, 95% CI: -4% to 29%, P=0." | 9.14 | Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial. ( Bhatt, DL; Brennan, DM; Easton, JD; Fox, KA; Hacke, W; Hankey, GJ; Johnston, SC; Mas, JL; Topol, EJ, 2010) |
| "The 160 patients with acute ischemic stroke were divided into two groups randomly: treatment group 85 cases (Songling Xuemaikang + Shuxuetong + Aspirin enterie coated tablets), control group 75 cases (Shuxuetong + Aspirin enterie ccoated tablets)." | 9.14 | [Changes of plasma fibrinogen level among acute ischemic stroke subtypes according to TOAST criteria and effects of Songling Xuemaikang]. ( Chen, Y; Huang, J; Liu, G; Liu, X; Lu, N; Xu, Y; Yang, D, 2010) |
| "In patients with an acute coronary syndrome who were referred for an invasive strategy, there was no significant difference between a 7-day, double-dose clopidogrel regimen and the standard-dose regimen, or between higher-dose aspirin and lower-dose aspirin, with respect to the primary outcome of cardiovascular death, myocardial infarction, or stroke." | 9.14 | Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Diaz, R; Eikelboom, JW; Fox, KA; Granger, CB; Jolly, S; Joyner, CD; Mehta, SR; Pogue, J; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2010) |
| "Patients aged 20-79 years who had had a cerebral infarction within the previous 26 weeks were enrolled at 278 sites in Japan and allocated to receive 100 mg cilostazol twice daily or 81 mg aspirin once daily for 1-5 years." | 9.14 | Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. ( Genka, C; Hamada, C; Handa, S; Katayama, Y; Kitagawa, Y; Koretsune, Y; Kusuoka, H; Matsuoka, K; Nishimaru, K; Ohashi, Y; Sawada, T; Shinohara, Y; Tanahashi, N; Tsushima, M; Uchiyama, S; Yamaguchi, T; Yamamoto, H, 2010) |
| "The combination of low-dose aspirin and dipyridamole is more effective than aspirin alone in reducing the risk of recurrent stroke and other major cardiovascular events in patients with a recent transient ischemic attack or minor stroke." | 9.14 | Prevention with low-dose aspirin plus dipyridamole in patients with disabling stroke. ( Algra, A; Dippel, DW; Halkes, P; Kappelle, LJ; Koudstaal, PJ; Maasland, L, 2010) |
| "Although aspirin (ASA) remains the most popular and accepted agent for secondary stroke prevention, its efficacy does not exceed 25%." | 9.13 | Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke. ( Karepov, V; Kuliczkowski, W; Serebruany, V; Tolpina, G, 2008) |
| "The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel." | 9.13 | Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| "Patients who had had an ischaemic stroke were randomly assigned in a two by two factorial design to receive either 25 mg aspirin (ASA) and 200 mg extended-release dipyridamole (ER-DP) twice a day or 75 mg clopidogrel once a day, and either 80 mg telmisartan or placebo once per day." | 9.13 | Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFE ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; VanderMaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| "All patients with acute ischemic stroke or transient ischemic attack within a 10 month period were administered 600 mg clopidogrel bolus if they were already taking aspirin regularly, or had aspirin allergy or intolerance." | 9.13 | Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience. ( Abdelmoula, MM; Divani, AA; Hussein, HM; Qureshi, AI; Suri, MF, 2008) |
| "Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces major cardiovascular events in patients with ST and non-ST-segment-elevation acute coronary syndromes (ACS)." | 9.13 | Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. ( Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2008) |
| "To determine the prevalence of platelet nonresponsiveness to aspirin treatment for secondary stroke prophylaxis, the authors studied consecutive patients during a 29-month period." | 9.13 | Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. ( Bates, V; Forrest, A; Gengo, FM; Gengo, MF; Hourihane, M; Rainka, M; Robson, M, 2008) |
| "Aspirin offers modest reduction in stroke in patients with atrial fibrillation." | 9.13 | Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. ( Berger, PB; Bhatt, DL; Fox, KA; Hacke, W; Hankey, GJ; Hart, RG; Hu, T; Topol, EJ, 2008) |
| "In ACTIVE-W, oral anticoagulation (OAC) was more efficacious than combined clopidogrel plus aspirin (C+A) in preventing vascular events in patients with atrial fibrillation." | 9.13 | Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). ( Connolly, SJ; De Caterina, R; Flaker, G; Hart, RG; Healey, JS; Hohnloser, SH; Pfeffer, MA; Pogue, J; Yusuf, S, 2008) |
| "Aspirin inhibits platelet activation and reduces major vascular events in patients with stable coronary artery disease." | 9.13 | Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study. ( Allal, J; Christiaens, L; Macchi, L; Mergy, J; Ragot, S, 2008) |
| "To examine the impact of prognostic factors on the outcome of treatment with warfarin or aspirin after acute myocardial infarction." | 9.13 | Less benefit from warfarin in diabetics after myocardial infarction? ( Abdelnoor, M; Arnesen, H; Hurlen, M; Smith, PJ, 2008) |
| "Most patients who have had a stroke are given aspirin; however, aspirin-related cerebral haemorrhage is a complication that is currently of concern, particularly in China where there is a high incidence of cerebral haemorrhage in secondary prevention programmes and within the community." | 9.13 | Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. ( Cheng, Y; Ding, M; Fan, D; Gao, X; Hong, Z; Huang, Y; Li, Y; Li, Z; Lu, C; Wong, K; Wu, J; Xiao, J; Xu, E; Yao, C; Zeng, J; Zhang, W, 2008) |
| "Patients experiencing acute ischemic stroke or transient ischemic attack are commonly treated with clopidogrel and/or aspirin (mono- and dual-antiplatelet therapy) to minimize the risk for recurrent stroke." | 9.12 | Efficacy and safety of clopidogrel and/or aspirin for ischemic stroke/transient ischemic attack: An overview of systematic reviews and meta-analysis. ( Huang, Z; Yang, Y; Zhang, X, 2021) |
| "As compared to aspirin alone, short-term DAPT within 24 hours of high-risk transient ischemic attack or mild-moderate ischemic stroke reduces the risk of recurrent stroke at the expense of higher risk of major bleeding." | 9.12 | Dual Antiplatelet Therapy Versus Aspirin in Patients With Stroke or Transient Ischemic Attack: Meta-Analysis of Randomized Controlled Trials. ( Aggarwal, D; Arora, S; Bhatia, K; Hussain, Z; Jain, V; Qamar, A; Ricciardi, M; Tafur, A; Uberoi, G; Vaduganathan, M; Zhang, C, 2021) |
| "In patients with noncardioembolic mild stroke or high-risk transient ischemic attack, DAPT with aspirin and clopidogrel/ticagrelor is more effective than aspirin alone for recurrent stroke prevention with a small absolute increase in the risk of severe or moderate bleeding." | 9.12 | P2Y12 Inhibitors Plus Aspirin Versus Aspirin Alone in Patients With Minor Stroke or High-Risk Transient Ischemic Attack. ( Fisher, M; Gu, HQ; Johnston, SC; Li, ZX; Wang, YJ; Xian, Y; Xiong, Y, 2021) |
| "gov databases, main international conference proceedings were searched for randomized controlled trials comparing DAPT versus aspirin monotherapy in patients with acute ischemic stroke or TIA not eligible for thrombolysis or thrombectomy presenting in the first 24 hours after the acute event." | 9.12 | Clinical Effects of Dual Antiplatelet Therapy or Aspirin Monotherapy after Acute Minor Ischemic Stroke or Transient Ischemic Attack, a Meta-Analysis. ( Condello, F; Ferrante, G; Liccardo, G, 2021) |
| "We investigated the platelet function in stroke patients treated with aspirin [acetylsalicylic acid (ASA)] for secondary stroke prevention during a follow-up period of 1 year." | 9.12 | Aspirin resistance in secondary stroke prevention. ( Berrouschot, J; Fischer, C; Roessler, A; Schwetlick, B; Siegemund, A; Siegemund, T; Uhlemann, H; von Twickel, G, 2006) |
| "For prevention of stroke in patients with NVAF, aspirin at 150 to 200 mg per day does not seem to be either effective or safe." | 9.12 | Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. ( Doi, Y; Fukuyama, T; Hiramori, K; Hori, M; Ishikawa, K; Izumi, T; Kitabatake, A; Maruyama, Y; Matsumoto, M; Mochizuki, S; Ogawa, S; Origasa, H; Sato, H; Takekoshi, N; Uchiyama, S; Yamaguchi, T; Yokota, Y; Yoshida, K, 2006) |
| " Orbofiban, despite no significant excess risk of ICH, was not effective in preventing ischemic stroke or TIA." | 9.12 | Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. ( Cannon, CP; Feske, SK; Murphy, S; Schwamm, LH; Smith, EE, 2006) |
| "We performed a combination of prespecified and exploratory subgroup analyses to detect any treatment differences among various baseline subgroups in the Warfarin-Aspirin Recurrent Stroke Study (WARSS) cohort." | 9.12 | Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death: subgroup analyses from the Warfarin-Aspirin Recurrent Stroke Study. ( Levin, B; Mohr, JP; Murphy, A; Prabhakaran, S; Sacco, RL; Sciacca, RR; Thompson, JL, 2006) |
| "Oral anticoagulation therapy is superior to clopidogrel plus aspirin for prevention of vascular events in patients with atrial fibrillation at high risk of stroke, especially in those already taking oral anticoagulation therapy." | 9.12 | Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. ( Chrolavicius, S; Connolly, S; Hart, R; Hohnloser, S; Pfeffer, M; Pogue, J; Yusuf, S, 2006) |
| "Combination of low-dose aspirin and modified-release dipyridamole (ASA+MR-DP) provides a significantly increased benefit in stroke prevention over aspirin alone." | 9.12 | Dose titration to reduce dipyridamole-related headache. ( Chang, YJ; Lee, TH; Ryu, SJ, 2006) |
| "In the European Stroke Prevention Study (ESPS 2), oral administration of a fixed combination of 200 mg extended-release dipyridamole and 25 mg aspirin (twice daily) after ischemic stroke or transient ischemic attack, significantly reduced the risk of stroke compared to placebo as well as compared to aspirin or dipyridamole alone." | 9.12 | Dipyridamole/aspirin combination in secondary stroke prevention: effects on absolute myocardial blood flow and coronary vascular resistance. ( Buell, U; Koch, KC; Noth, J; Nowak, B; Schaefer, WM; Weiss, PH, 2006) |
| "Low-dose aspirin taken every other day helps prevent stroke in women aged 45 years and older, but does not prevent a first myocardial infarction (MI) or cardiovascular death among healthy women." | 9.12 | Aspirin prevents stroke but not MI in women; vitamin E has no effect on CV disease or cancer. ( Buring, JE, 2006) |
| "Aspirin resistance may increase the risk of major adverse cardiac events (MACE) more than threefold in patients with stable coronary artery disease (CAD)." | 9.12 | Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR). ( Mercanoglu, F; Meric, M; Nisanci, Y; Oflaz, H; Oncul, A; Onur, I; Ozcan, M; Pamukcu, B; Umman, B, 2007) |
| "A large number of patients experience ischemic stroke despite treatment with aspirin (acetylsalicylic acid, ASA)." | 9.12 | Variable platelet response to aspirin in patients with ischemic stroke. ( Boucher, M; Hohlfeld, T; Junghans, U; Schrör, K; Schumacher, M; Siebler, M; Weber, AA, 2007) |
| "2) with atrial fibrillation were recruited from primary care and randomly assigned to warfarin (target international normalised ratio 2-3) or aspirin (75 mg per day)." | 9.12 | Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. ( Fitzmaurice, D; Fletcher, K; Hobbs, FD; Lip, GY; Mant, J; Murray, E; Roalfe, A, 2007) |
| "Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention." | 9.12 | Prasugrel versus clopidogrel in patients with acute coronary syndromes. ( Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD, 2007) |
| "In the majority of patients with acute ischemic stroke, ASA and acetaminophen are insufficient for reducing an elevated BT to a state of normothermia." | 9.11 | Acetylsalicylic acid and acetaminophen to combat elevated body temperature in acute ischemic stroke. ( De Keyser, J; Elting, JW; Luijckx, GJ; Luyckx, GJ; Maurits, N; Sulter, G, 2004) |
| "To evaluate whether long-term treatment with a fixed low dose of warfarin in combination with aspirin improves the prognosis compared with aspirin treatment alone after an acute myocardial infarction (AMI)." | 9.11 | Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study. ( Erhardt, L; Haglid Evander, M; Herlitz, J; Holm, J; Karlson, BW; Peterson, M, 2004) |
| "The CAPRIE study showed the superiority of clopidogrel over acetylsalicylic acid (ASA) for reducing the combined risk of major atherothrombotic events in patients with recent myocardial infarction (MI), recent ischaemic stroke (IS) or established peripheral arterial disease." | 9.11 | Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. ( Bogousslavsky, J; Brass, LM; Cimminiello, C; Csiba, L; Diener, HC; Kaste, M; Leys, D; Matias-Guiu, J; Rupprecht, HJ, 2004) |
| "There is still worldwide disagreement about the optimal lowest dose of aspirin to be used in patients after a transient ischemic attack (TIA) or nondisabling stroke." | 9.11 | What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke? ( Dippel, DW; Koudstaal, PJ; Leebeek, FW; Li, SS; Mehicevic, A; Van Kooten, F; van Vliet, HH, 2004) |
| "This pilot trial has not found differences between triflusal and aspirin in the prevention of vascular complications after TIA or ischemic stroke, although given the wide CI, potentially important group differences could not be ruled out." | 9.11 | Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study. ( Abiusi, G; Bauso-Tosselli, L; Culebras, A; Domínguez, R; Famulari, A; Ferrari, J; Gori, H; Reich, E; Rey, R; Rotta-Escalante, R; Vila, J, 2004) |
| "The European Stroke Prevention Study showed greater stroke prevention for Aggrenox than either for aspirin or dipyridamole alone." | 9.11 | Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. ( Atar, D; Hennekens, CH; Jilma, B; Malinin, AI; Sane, DC; Serebruany, VL; Takserman, A, 2004) |
| " Aspirin (A), clopidogrel (C), and dipyridamole (D) were administered singly and in various combinations (A, C, D, AC, AD, CD, ACD), each for two weeks (without washout) to 11 healthy subjects and to 11 patients with previous ischaemic stroke in two randomised multiway crossover trials." | 9.11 | Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke. ( Bath, P; Fletcher, S; Fox, S; Heptinstal, S; Leonardi-Bee, J; May, J; Weaver, C; Willmot, M; Zhao, L, 2005) |
| "Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) is a randomized, double-blind study in subjects with recently symptomatic > or =50% carotid stenosis." | 9.11 | Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. ( Droste, DW; Kaps, M; Larrue, V; Lees, KR; Markus, HS; Ringelstein, EB; Siebler, M, 2005) |
| "Clopidogrel is widely used in patients after recent ischemic stroke; however, its ability to yield additional antiplatelet protection on top of aspirin has never been explored in a controlled study." | 9.11 | Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial. ( Alberts, MJ; Bhatt, DL; Hanley, DF; Malinin, AI; Pokov, AN; Serebruany, VL; Ziai, W, 2005) |
| "This pilot study enrolled ischemic stroke patients within 48 hours and randomized to aspirin 300 mg/d or combination (aspirin 300 mg/d+ standard release dipyridamole 75 mg thrice a day) and followed up for 6 months." | 9.11 | Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study. ( Chairangsarit, P; Nidhinandana, S; Niyasom, S; Sithinamsuwan, P; Suwantamee, J; Udommongkol, C, 2005) |
| "In a case-crossover study, 31 patients with previous atherothrombotic or lacunar stroke who were treated with aspirin (100 to 300 mg/d) received clopidogrel (75 mg/d) and both aspirin and clopidogrel for 4 weeks." | 9.10 | Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. ( Buggle, F; Grau, AJ; Lichy, C; Reiners, S; Ruf, A, 2003) |
| "We performed a randomized, double-blind, multicenter study to test the efficacy of triflusal (600 mg/d) versus aspirin (325 mg/d) for prevention of vascular events in patients with stroke or transient ischemic attack (Triflusal versus Aspirin in Cerebral Infarction Prevention [TACIP])." | 9.10 | Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. ( Alvarez-Sabín, J; Ferro, JM; Jiménez, MD; Lago, A; Matías-Guiu, J; Melo, T; Torres, F, 2003) |
| " In this study, we showed that the combination regimen of clopidogrel with aspirin could downregulate the P-selectin expression on platelets and the plasma concentration of C-reactive protein (CRP) in acute stage of atherosclerotic ischemic stroke." | 9.10 | Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. ( Bae, HR; Cha, JK; Cheon, SM; Jeong, MH; Lee, KM; Lim, YJ; Park, KW, 2002) |
| "To determine the efficacy and safety of aspirin and ticlopidine to prevent recurrent stroke in black patients." | 9.10 | Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. ( Gorelick, PB; Harris, Y; Hung, E; Kelly, M; Kittner, S; Leurgans, S; Richardson, D; Ruland, S, 2003) |
| "The Thrombosis Prevention Trial was a primary prevention factorial trial that reported a reduction in the risk of coronary heart disease (CHD) with warfarin and/or aspirin." | 9.10 | Thrombosis prevention trial: compliance with warfarin treatment and investigation of a retained effect. ( Ashby, D; Brennan, P; Meade, T; Rudnicka, AR, 2003) |
| "In this study, 591 patients with recent cerebral ischemia of arterial origin were randomly allocated to treatment with aspirin 30 to 325 mg/d or with the combination of aspirin and dipyridamole 400 mg/d in the European/Australian Stroke Prevention in Reversible Ischemia Trial." | 9.10 | Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure. ( De Schryver, EL, 2003) |
| "We studied the benefits and risks of adding clopidogrel to different doses of aspirin in the treatment of patients with acute coronary syndrome (ACS)." | 9.10 | Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. ( Commerford, PJ; Diaz, R; Fox, KA; Kopecky, SL; Lewis, BS; Mehta, SR; Peters, RJ; Valentin, V; Yusuf, S; Zhao, F, 2003) |
| "To compare the efficacy and safety of two antiplatelet regimens, ticlopidine alone (200 mg daily) and ticlopidine (100 mg daily) plus aspirin (81 mg daily), in patients with ischemic stroke from the Tokai district of Japan." | 9.10 | Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke. ( Ito, E; Kuzuhara, S; Nakajima, M; Takahashi, A; Uchiyama, S; Yamamoto, H, 2003) |
| "Aspirin treatment did not significantly reduce the frequency of stroke progression." | 9.10 | Aspirin in the prevention of progressing stroke: a randomized controlled study. ( Britton, M; Leijd, B; Malmkvist, K; Rödén-Jüllig, A, 2003) |
| "The aim of the study was to evaluate the relationship between daily aspirin use and urinary excretion of a stable thromboxane metabolite, 11-dehydrothromboxane B(2) (11-DTB2), in African American stroke patients." | 9.10 | Aspirin and urinary 11-dehydrothromboxane B(2) in African American stroke patients. ( Bang, NU; Bruno, A; Cohen, SN; Mansbach, HH; McConnell, JP; Tietjen, GE, 2002) |
| "The dose of aspirin for secondary stroke prevention and the clinical meaning of ex vivo platelet abnormalities are debated." | 9.09 | Ex vivo response to aspirin differs in stroke patients with single or recurrent events: a pilot study. ( Chamorro, A; Escolar, G; Obach, V; Ordinas, A; Reverter, JC; Revilla, M; Vila, N, 1999) |
| "A longitudinal cohort study was performed comparing 460 participants with intermittent AF with 1,552 with sustained AF treated with aspirin in the Stroke Prevention in Atrial Fibrillation studies and followed for a mean of two years." | 9.09 | Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. ( Asinger, RW; Halperin, JL; Hart, RG; McAnulty, JH; Pearce, LA; Rothbart, RM, 2000) |
| "30-day survivors of ischaemic stroke treated with low dose aspirin, modified-release dipyridamole; the coformulation of low dose aspirin plus modified-release dipyridamole, or no antiplatelet therapy." | 9.09 | Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole. ( Chambers, M; Gladman, J; Hutton, J, 1999) |
| "Heparin in Acute Embolic Stroke Trial (HAEST) was a multicentre, randomised, double-blind, and double-dummy trial on the effect of low-molecular-weight heparin (LMWH, dalteparin 100 IU/kg subcutaneously twice a day) or aspirin (160 mg every day) for the treatment of 449 patients with acute ischaemic stroke and atrial fibrillation." | 9.09 | Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. ( Abdelnoor, M; Berge, E; Nakstad, PH; Sandset, PM, 2000) |
| "The Coumadin Aspirin Reinfarction Study demonstrated that combination treatment with fixed dose warfarin (1 or 3 mg) + aspirin 80 mg was not superior to aspirin 160 mg alone after myocardial infarction for reducing nonfatal reinfarction, nonfatal stroke, and cardiovascular death." | 9.09 | Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS). ( Berkowitz, SD; Califf, RM; Daly, R; Fuster, V; Gattis, WA; Gheorghiade, M; Harrington, RA; Hellkamp, AS; Kopecky, SL; Langer, A; Larsen, RL; O'Connor, CM; O'Gara, PT, 2001) |
| "This randomised, double-blind, aspirin-controlled trial tested the safety and efficacy of treatment with high-dose tinzaparin (175 anti-Xa IU/kg daily; 487 patients), medium-dose tinzaparin (100 anti-Xa IU/kg daily; 508 patients), or aspirin (300 mg daily; 491 patients) started within 48 h of acute ischaemic stroke and given for up to 10 days." | 9.09 | Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. ( Bath, PM; Boysen, G; De Deyn, P; Friis, P; Leys, D; Lindenstrom, E; Marttila, R; O'Neill, D; Olsson, J; Orgogozo, J; Ringelstein, B; Turpie, AG; van der Sande, J, 2001) |
| "We sought to compare different antithrombotic secondary treatments (mainly medium-dose aspirin with low-dose low-molecular-weight heparin [LMWH]) in pediatric patients with a first ischemic stroke onset with regard to the risk of stroke recurrence." | 9.09 | Aspirin versus low-dose low-molecular-weight heparin: antithrombotic therapy in pediatric ischemic stroke patients: a prospective follow-up study. ( Heller, C; Kurnik, K; Luigs, P; Nowak-Göttl, U; Schobess, R; Sträter, R, 2001) |
| "Although the efficacy of aspirin in reducing stroke incidence is clear, its role in reducing stroke severity is disputed." | 9.09 | Effect of prior aspirin use on stroke severity in the trial of Org 10172 in acute stroke treatment (TOAST). ( Adams, HP; Bendixen, B; Clarke, WR; Hansen, MD; Wilterdink, JL; Woolson, RF, 2001) |
| "Over two years, we found no difference between aspirin and warfarin in the prevention of recurrent ischemic stroke or death or in the rate of major hemorrhage." | 9.09 | A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. ( Adams, HP; Albers, GW; Furie, KL; Jackson, CM; Kistler, JP; Lazar, RM; Levin, B; Mohr, JP; Pettigrew, LC; Pullicino, P; Sacco, RL; Thompson, JL, 2001) |
| "To evaluate the effectiveness and adverse effects of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) for the primary or secondary prevention of dementia." | 9.05 | Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. ( Devane, D; Jordan, F; Kelly, JP; McGuinness, B; Murphy, K; Passmore, P; Quinn, TJ; Tudur Smith, C, 2020) |
| "A considerable proportion of patients with atrial fibrillation (AF) are still treated with aspirin despite current guidelines due to presumed favorable safety." | 9.05 | Bleeding risk comparison between direct oral anticoagulants at doses approved for atrial fibrillation and aspirin: systematic review, meta-analysis and meta-regression. ( Georgiopoulos, G; Korompoki, E; Leventis, I; Lip, GYH; Makaritsis, K; Milionis, H; Ntaios, G; Sagris, D; Vemmos, K, 2020) |
| "The benefits of aspirin for primary prevention of stroke are uncertain." | 9.05 | Aspirin for primary prevention of stroke in individuals without cardiovascular disease-A meta-analysis. ( Costello, M; Ferguson, J; Gorey, S; Halloran, MO; Judge, C; Loughlin, E; Murphy, R; Nolan, A; O'Canavan, M; O'Donnell, MJ; Ruttledge, S, 2020) |
| "Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention." | 9.01 | Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. ( Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS, 2019) |
| "The analysis showed lower risks of major adverse cardiovascular or cerebrovascular events, recurrent stroke, and bleeding events for clopidogrel monotherapy compared to aspirin." | 9.01 | Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis. ( Del Aguila, M; Girotra, S; Hu, B; Ince, B; Jeng, JS; Kutluk, K; Liu, L; Lou, M; Min Han, J; Paciaroni, M; Paek, D; Parfenov, V; Wong, KSL; Zamani, B, 2019) |
| "Background and Purpose- The role of aspirin plus clopidogrel (A+C) therapy compared with aspirin monotherapy in patients presenting with acute ischemic stroke (IS) or transient ischemic attack remains uncertain." | 9.01 | Optimal Duration of Aspirin Plus Clopidogrel After Ischemic Stroke or Transient Ischemic Attack. ( Hammad, T; Kaluski, E; Khan, SU; Meyer, MA; Nasir, F; Rahman, H, 2019) |
| "Although aspirin (ASA) is the mainstay of treatment for the prevention of recurrent ischemic stroke, the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial showed ASA monotherapy to be inferior to clopidogrel in preventing recurrent adverse cardiovascular outcomes in patients with high cardiac risks." | 9.01 | Aspirin Versus Clopidogrel Monotherapy for the Treatment of Patients with Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis. ( Ding, J; Xu, GM; Yuan, J, 2019) |
| "A systematic electronic literature search was done in MEDLINE, EMBASE, and Cochrane CENTRAL Register of Controlled Trials for studies including published data of patients ≥18 years of age with nonvalvular atrial fibrillation, randomized to either VKAs or NOACs, or receiving aspirin therapy at any time during the study that report all-cause stroke or systemic embolism, vascular death, myocardial infarction, major bleeding, or intracranial hemorrhage as an outcome." | 8.98 | Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials. ( Bennaghmouch, N; Bode, K; Brueckmann, M; de Veer, AJWM; Dewilde, WJM; Kleine, E; Lip, GYH; Mahmoodi, BK; Ten Berg, JM, 2018) |
| "To assess the effectiveness and safety of dual agent antiplatelet therapy combining clopidogrel and aspirin to prevent recurrent thrombotic and bleeding events compared with aspirin alone in patients with acute minor ischaemic stroke or transient ischaemic attack (TIA)." | 8.98 | Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis. ( Foroutan, F; Guyatt, G; Hao, Q; O'Donnell, M; Siemieniuk, RA; Tampi, M, 2018) |
| "Optimal antiplatelet therapy after an ischemic stroke or transient ischemic attack while on aspirin is uncertain." | 8.95 | Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL, 2017) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel for 90 days was recommended as the secondary prevention of minor ischaemic strokes or transient ischaemic attacks (TIAs) in 2014." | 8.93 | Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis. ( Chang, T; Ge, F; Guo, R; Li, M; Lin, H; Liu, Y; Ruan, Z, 2016) |
| "To evaluate the risk for serious bleeding with regular aspirin use in cardiovascular disease (CVD) primary prevention." | 8.93 | Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force. ( Burda, BU; Evans, CV; Guirguis-Blake, JM; Whitlock, EP; Williams, SB, 2016) |
| "Aspirin is recommended for secondary prevention after transient ischaemic attack (TIA) or ischaemic stroke on the basis of trials showing a 13% reduction in long-term risk of recurrent stroke." | 8.93 | Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. ( Algra, A; Chen, Z; Diener, HC; Mehta, Z; Norrving, B; Rothwell, PM, 2016) |
| "Low-dose aspirin, alone or in combination, is recommended for the secondary prevention of acute non-cardioembolic ischemic stroke and transient ischemic attack, starting soon after the acute event." | 8.93 | Aspirin, stroke and drug-drug interactions. ( Petrucci, G; Rocca, B; Russo, NW, 2016) |
| "It remains controversial whether dual antiplatelet therapy reduces stroke more than aspirin alone." | 8.91 | Effect of addition of clopidogrel to aspirin on stroke incidence: Meta-analysis of randomized trials. ( Anderson, DC; Benavente, OR; Birnbaum, LA; Hart, RG; Palacio, S; Pearce, LA; Sharma, M, 2015) |
| "Compared with monotherapy, short-term aspirin in combination with clopidogrel is more effective as secondary prevention of stroke or TIA without increasing the risk of hemorrhagic stroke and major bleeding events." | 8.91 | Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. ( Li, J; Li, Y; Shang, X; Wang, C; Yan, C; Zhang, L; Zhang, Q; Zheng, M, 2015) |
| " We found no evidence that the net benefit of aspirin increased with increasing risk of thrombosis, haemorrhage or poor functional outcome in all three trials." | 8.91 | Targeting aspirin in acute disabling ischemic stroke: an individual patient data meta-analysis of three large randomized trials. ( Candelise, L; Chen, Z; Murray, GD; Sandercock, PA; Thompson, DD; Whiteley, WN, 2015) |
| " A pooled analysis showed that dual therapy with clopidogrel and aspirin had a lower stroke incidence than monotherapy in both the short term and long term (RR = 0." | 8.91 | Clopidogrel and Aspirin versus Aspirin Alone for Stroke Prevention: A Meta-Analysis. ( Chen, J; Ding, L; Hong, H; Huang, X; Ma, H; Tan, S; Xiao, X; Xu, R; Yang, S; Yu, S; Zhang, Z, 2015) |
| "Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel." | 8.91 | Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ( Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015) |
| "The safety and efficacy of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel in the setting of secondary stroke prevention are reviewed." | 8.91 | Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence. ( Davis, KA; Dietrich, E; Miyares, MA, 2015) |
| "Despite its lack of efficacy, aspirin is commonly used for stroke prevention in atrial fibrillation." | 8.91 | Aspirin Compared to Low Intensity Anticoagulation in Patients with Non-Valvular Atrial Fibrillation. A Systematic Review and Meta-Analysis. ( Gándara, E; Gonzalez, JP; Vazquez, FJ, 2015) |
| "To present the systematic assessment on the efficacy and bleeding adverse events of dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin-mono-antiplatelet therapy in patients with ischemic stroke or transient ischemic attack." | 8.91 | [Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack]. ( Gao, P; Hu, Y; Qian, J; Tang, X; Yang, C, 2015) |
| "Dual antiplatelet therapy with aspirin plus clopidogrel is not recommended for secondary stroke prevention because of lack of effectiveness and increased hemorrhagic risk." | 8.90 | Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence. ( Censori, B, 2014) |
| "Whether clopidogrel should be added to aspirin for stroke prevention remained controversial for the risk of hemorrhagic complications." | 8.90 | Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials. ( Chen, S; He, L; Li, H; Li, M; Li, Y; Peng, Y; Shen, Q; Tang, Y, 2014) |
| "While previous meta-analysis have investigated the efficacy of cilostazol in the secondary prevention of ischemic stroke, they were criticized for their methodology, which confused the acute and chronic phases of stroke." | 8.90 | The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population--an updated meta-analysis. ( Chen, S; Malaguit, J; Pu, J; Shi, L; Xu, L; Zhang, J, 2014) |
| "Aspirin is the most widely prescribed antiplatelet agent for the secondary prevention of stroke." | 8.89 | Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke. ( Bangalore, S; Dinicolantonio, JJ; Fares, H; Lavie, CJ; Menezes, AR; Messerli, FH; O'Keefe, JH, 2013) |
| "Given the high risk of stroke after TIA (transient ischemia attack) or stroke and the adverse reaction of bleeding of antiplatelets, we undertook a meta-analysis, reviewed randomized controlled trials (RCTs) comparing aspirin plus clopidogrel with aspirin alone to determine the efficacy and adverse reaction of bleeding of the two protocols in the prevention of stroke." | 8.89 | The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a systematic review. ( Hu, B; Huang, Y; Li, JY; Li, M; Mao, L; Xia, YP, 2013) |
| "We performed meta-analyses to assess the effectiveness and safety of combination therapy with aspirin and dipyridamole (A+D) versus aspirin (A) alone in secondary prevention after transient ischemic attack (TIA) or stroke of presumed arterial origin within one week and six months." | 8.89 | The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials. ( Li, X; Zhou, G; Zhou, S; Zhou, X, 2013) |
| " The effects of cilostazol and aspirin on ischemic stroke prevention and treatment were almost equal (combined odds ratio (OR) 0." | 8.89 | Systematic study of cilostazol on secondary stroke prevention: a meta-analysis. ( Bi, Q; Qian, Y, 2013) |
| "There is clinical equipoise between warfarin and aspirin for stroke prevention in patients with heart failure in sinus rhythm (SR)." | 8.89 | Warfarin versus aspirin for prevention of stroke in heart failure: a meta-analysis of randomized controlled clinical trials. ( Goyal, MK; Kumar, G, 2013) |
| "The risk-benefit profile of warfarin versus aspirin for patients with heart failure in normal sinus rhythm has not been definitively established." | 8.89 | Risk-benefit profile of warfarin versus aspirin in patients with heart failure and sinus rhythm: a meta-analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Saver, JL; Wu, HC, 2013) |
| "This review examines the role of platelets in ischemic stroke, platelet activation mechanisms, aspirin's rise as an antithrombotic agent, clopidogrel's appearance on the stage, a possible role for combination therapy, antiplatelet resistance, practical considerations, and future directions." | 8.89 | Aspirin and clopidogrel for prevention of ischemic stroke. ( Anderson, DC; Thomson, RM, 2013) |
| "Until recently, pharmaceutical options for stroke prevention in atrial fibrillation were restricted to aspirin or vitamin K antagonist therapy." | 8.88 | Apixaban for the prevention of stroke in atrial fibrillation. ( Flaker, G; Littrell, R, 2012) |
| "Although several new antithrombotic agents have been developed for stroke prevention in patients with nonvalvular atrial fibrillation (AF), many patients will continue to be treated with warfarin worldwide." | 8.88 | Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. ( Agarwal, S; Hachamovitch, R; Menon, V, 2012) |
| "To identify confounding factors that may explain the incoherence between direct and indirect evidence in a published analysis comparing extended-release dipyridamole (ERDP) plus aspirin to clopidogrel for the reduction of stroke." | 8.88 | Investigating incoherence gives insight: clopidogrel is equivalent to extended-release dipyridamole plus aspirin in secondary stroke prevention. ( Dewilde, S; Hawkins, N, 2012) |
| "Aspirin is widely used for secondary prevention after stroke." | 8.87 | Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. ( Husain, MR; Kamal, AK; Khealani, BA; Naqvi, I, 2011) |
| " For the composite of non-fatal stroke, non-fatal myocardial infarction and vascular death, aspirin was associated with a 13% reduction in risk (risk ratio, RR: 0." | 8.87 | Validity of composite outcomes in meta-analyses of stroke prevention trials: the case of aspirin. ( Dinneen, SF; Eikelboom, JW; McGrath, E; O'Conghaile, A; O'Donnell, MJ; Oczkowski, C, 2011) |
| "Aspirin is used to prevent ischemic stroke and other types of cardiovascular disease." | 8.87 | Gender differences in the primary prevention of stroke with aspirin. ( Adelman, EE; Brown, DL; Lisabeth, L, 2011) |
| "Clopidogrel prevents more vascular events, including stroke, in patients with a recent myocardial infarction, stroke or peripheral vascular disease than aspirin." | 8.87 | Clopidogrel hydrogen sulphate for atrial fibrillation. ( Flaker, G; Garg, N; Rajpurohit, N, 2011) |
| "This review aims to determine whether it is cost-effective to replace aspirin and warfarin with more effective, yet more costly, treatments for secondary stroke prevention." | 8.86 | Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs? ( Hankey, GJ, 2010) |
| "PubMed and MEDLINE searches (up to January 2010) were performed to identify primary literature, using search terms including aspirin, stroke prevention, acute ischemic stroke, acetylsalicylic acid, atrial fibrillation, myocardial infarction, and carotid endarterectomy." | 8.86 | Aspirin dosing for the prevention and treatment of ischemic stroke: an indication-specific review of the literature. ( Ansara, AJ; Arif, SA; Koehler, JM; Nisly, SA; Nordmeyer, ST, 2010) |
| "Oral antiplatelet drugs, including aspirin, clopidogrel and extended-release dipyridamole, are widely prescribed for the secondary prevention of vascular events, including stroke." | 8.86 | Aspirin and antiplatelet agent resistance: implications for prevention of secondary stroke. ( Greer, DM, 2010) |
| "We compared the efficacy and safety of cilostazol and aspirin in 2,672 Japanese patients with non-cardioembolic ischemic stroke." | 8.86 | [Results of the Cilostazol Stroke Prevention Study II (CSPS II): a randomized controlled trial for the comparison of cilostazol and aspirin in stroke patients]. ( Uchiyama, S, 2010) |
| "To determine the effectiveness and safety of thienopyridine derivatives (ticlopidine and clopidogrel) versus aspirin for preventing serious vascular events (stroke, myocardial infarction (MI) or vascular death) in patients at high risk, and specifically in patients with a previous TIA or ischaemic stroke." | 8.85 | Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. ( Hankey, GJ; Mason, G; Maurice, JB; Sudlow, CL; Wedderburn, CJ, 2009) |
| "To study the effect of combination therapy with aspirin and dipyridamole (A+D) over aspirin alone (ASA) in secondary prevention after transient ischaemic attack (TIA) or minor stroke of presumed arterial origin and to perform subgroup analyses to identify patients that might benefit most from secondary prevention with A+D." | 8.84 | Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk. ( Algra, A; Bath, PM; Diener, HC; Gray, LJ; Guiraud-Chaumeil, B; Halkes, PH; Yatsu, FM, 2008) |
| "The results obtained in the CAPRIE study in 1996 led to the introduction of the clopidogrel as a new antiplatelet drug in the secondary prevention of acute myocardial infarct (AMI), ischemic stroke (IS) and symptomatic peripheral artery disease (PAD)." | 8.84 | Clopidogrel in secondary ischemic stroke prevention. ( Belvís, R; Kulisevsky, J; Pagonabarraga, J; Santamaría, A, 2008) |
| "The purpose of this review was to discuss results from clinical trials that have compared the efficacy of ASA monotherapy versus ASA + extendedrelease dipyridamole in secondary stroke prevention." | 8.84 | Acetylsalicylic acid + extended-release dipyridamole combination therapy for secondary stroke prevention. ( Chaturvedi, S, 2008) |
| "We presented a patient suffered from stroke related to thalidomide therapy." | 8.84 | [Brief report: stroke in multiple myeloma patient treated with thalidomide]. ( Hashimoto, Y; Hirano, T; Ito, Y; Mori, A; Uchino, M; Yonemura, K, 2007) |
| "This meta-analysis systematically reviewed randomized controlled trials comparing aspirin plus dipyridamole with aspirin alone in patients with stroke and TIA to determine the efficacy of these agents in preventing recurrent cerebral and systemic vascular events." | 8.84 | Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. ( Gorelick, PB; Nguyen, D; Verro, P, 2008) |
| "To compare the effectiveness of aspirin, warfarin, and ximelagatran as thromboprophylaxis in patients with non-valvular atrial fibrillation (NVAF)." | 8.83 | Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. ( Edwards, SJ; Lip, GY, 2006) |
| "Despite hundreds of clinical trials, the appropriate dose of aspirin to prevent myocardial infarction (MI) and stroke is uncertain." | 8.83 | Aspirin to prevent heart attack and stroke: what's the right dose? ( Dalen, JE, 2006) |
| "A short-cut review was carried out to establish whether the administration of aspirin before computed tomography scanning improved outcome in patients with symptoms suggestive of stroke." | 8.83 | Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. Use of aspirin in acute stroke. ( Body, R; Ferguson, C, 2006) |
| "The increasing burden of cardiovascular diseases in developed, as well as developing countries, underscores the need for the more widespread and appropriate use of aspirin in secondary prevention of occlusive vascular events during acute evolving myocardial infarction (MI) and in primary prevention." | 8.82 | The role of aspirin in cardiovascular diseases--forgotten benefits? ( Hennekens, CH; Williams, A, 2004) |
| "Warfarin has been in routine clinical use for more than 50 years; however, it was not proven to be of benefit in both primary and secondary prevention of stroke for patients with non-valvular atrial fibrillation (AF) until about a decade ago." | 8.82 | Warfarin for atrial fibrillation: the end of an era? ( Chambers, BR; Dewey, HM; Donnan, GA, 2004) |
| "The study pooled individual data from 2580 participants with nonvalvular AF who were prescribed aspirin in a multicenter trial (Atrial Fibrillation, Aspirin, Anticoagulation I study [AFASAK-1], AFASAK-2, European Atrial Fibrillation Trial, Primary Prevention of Arterial Thromboembolism in patients with nonrheumatic Atrial Fibrillation in primary care study, and Stroke Prevention and Atrial Fibrillation [SPAF]-III high risk or SPAF-III low risk)." | 8.82 | Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. ( Boode, BS; Gage, BF; Hart, RG; Koudstaal, PJ; Pearce, L; Petersen, P; van Walraven, C, 2004) |
| "Results from randomized controlled trials of dipyridamole, given with or without aspirin, for secondary prevention after ischemic stroke or transient ischemic attack (TIA) have given conflicting results." | 8.82 | Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. ( Bath, PM; Bousser, MG; Davalos, A; Dewey, ME; Diener, HC; Guiraud-Chaumeil, B; Leonardi-Bee, J; Sivenius, J; Yatsu, F, 2005) |
| "In the secondary prevention of cardiovascular, cerebrovascular, and ischemic events, the evidence supports that the benefits of aspirin treatment significantly outweigh the risk of a major hemorrhage." | 8.82 | Risk of hemorrhagic stroke with aspirin use: an update. ( Gorelick, PB; Weisman, SM, 2005) |
| "According to meta-analysis and the results of the two studies with the highest power, aspirin is effective in primary prevention of coronary heart disease." | 8.82 | [Primary prevention of coronary heart disease with aspirin]. ( Darius, H; Kübler, W, 2005) |
| "To compare the risk of vascular and bleeding events in patients with nonvalvular AF treated with vitamin K -inhibiting oral anticoagulants or acetylsalicylic acid (aspirin)." | 8.81 | Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. ( Chang, Y; Connolly, S; Hart, RG; Hellemons, B; Koudstaal, PJ; Laupacis, A; Petersen, P; Singer, DE; van Walraven, C, 2002) |
| "To determine the cardiovascular and coronary risk thresholds at which aspirin for primary prevention of coronary heart disease is safe and worthwhile." | 8.81 | Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. ( Ghahramani, P; Jackson, PR; Ramsay, LE; Sanmuganathan, PS; Wallis, EJ, 2001) |
| "Aspirin therapy reduces stroke by about 25% for persons with atherosclerotic vascular disease, but the effect in those without clinically apparent vascular disease is distinctly different." | 8.80 | Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. ( Benavente, O; Halperin, JL; Hart, RG; Kronmal, RA; Man-Son-Hing, M; McBride, R, 2000) |
| "The most widely studied and prescribed antiplatelet agent for the prevention of stroke and other serious vascular events among high vascular risk patients is aspirin." | 8.80 | Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. ( Dunbabin, DW; Hankey, GJ; Sudlow, CL, 2000) |
| "Acute stroke treatment using aspirin and/or heparin was studied in the International Stroke Trial (IST) and Chinese Acute Stroke Trial (CAST) which randomised over 40,000 patients altogether." | 8.80 | Aspirin or heparin in acute stroke. ( Brown, MM; Pereira, AC, 2000) |
| "A retrospective analysis was performed on 75 patients with cancer and mild to moderate ischemic stroke, 34 of whom received tirofiban treatment and 41 aspirin treatment." | 8.31 | Tirofiban in the treatment of cancer-associated ischemic stroke. ( Lin, ZH; Zhang, ZM; Zhu, GL, 2023) |
| " We explored the outcomes of restarting aspirin use on secondary stroke and mortality in patients with chronic stroke 4 weeks after suffering from a TBI episode in Taiwan." | 8.31 | Risk of secondary stroke subsequent to restarting aspirin in chronic stroke patients suffering from traumatic brain injury in Taiwan. ( Chien, WC; Chou, CL; Chung, CH; Fann, LY; Hsu, YH; Sun, CA; Tang, SE; Wu, CC, 2023) |
| " Patients with diagnosis codes for ischemic stroke without cardiac disease were included and divided into two groups, those receiving cilostazol and those receiving clopidogrel." | 8.31 | Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke. ( Je, NK; Lee, YJ, 2023) |
| "Among patients with TIA or mild ischemic stroke, the combination of cinnamon and aspirin could be superior to aspirin alone for reducing the risk of 90-day recurrent stroke." | 8.12 | Cinnamon and Aspirin for Mild Ischemic Stroke or Transient Ischemic Attack: A Pilot Trial. ( Fan, Y; He, P; He, Z; Li, Z; Liang, J; Wu, Y; Zhang, L, 2022) |
| "The goal of this work was to investigate the short-term time-course benefit and risk of ticagrelor with aspirin in acute mild-moderate ischemic stroke or high-risk TIA in The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and ASA for Prevention of Stroke and Death (THALES) trial." | 8.12 | Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack. ( Amarenco, P; Denison, H; Evans, SR; Himmelmann, A; James, S; Johnston, SC; Knutsson, M; Ladenvall, P; Li, H; Molina, CA; Pan, Y; Wang, Y, 2022) |
| "Background The objective of the study was to assess the cost-effectiveness of cilostazol (a selective phosphodiesterase 3 inhibitor) added to aspirin or clopidogrel for secondary stroke prevention in patients with noncardioembolic stroke." | 8.12 | Cost-Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke. ( de Havenon, A; Kraler, L; Lansberg, MG; Zhou, LW, 2022) |
| "Among the 3456 patients included, a total of 10 patients in the Clopidogrel Discontinuation Group and 11 patients in the non-Clopidogrel Discontinuation Group presented ischemic stroke recurrence during the 90-180-day period." | 8.12 | No rebound effect after a course of clopidogrel in patients with acute TIA or minor stroke. ( Jing, J; Johnston, SC; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, D; Wang, Y; Zhang, X; Zhao, X, 2022) |
| "Bleeding is the most common adverse reaction to aspirin and can lead to drug discontinuation or even be life-threatening in the secondary prevention of stroke or transient ischemic attack." | 8.12 | Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients. ( Cheng, J; Deng, X; Li, H; Ma, Y; Shi, T; Wang, X; Wu, Y; Zhang, Z; Zhu, Q, 2022) |
| " Patients aged 80 years or older who received monotherapy with clopidogrel or aspirin following hospitalization for primary acute ischemic stroke between January 1, 2009, and December 31, 2018, were included." | 8.12 | Effectiveness and Safety of Clopidogrel vs Aspirin in Elderly Patients With Ischemic Stroke. ( Huang, HY; Katz, AJ; Lin, FJ; Lin, SY; Sheu, JJ; Wang, CC; Wu, CH, 2022) |
| "This prospective, observational study assessed TIA/ischaemic stroke patients before (baseline; N = 60), at 14 ±7 days (14d, N = 39) and ≥ 90 days (90d, N = 31) after adding dipyridamole to aspirin." | 8.12 | Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke. ( Collins, DR; Coughlan, T; Cox, D; Egan, B; Lim, ST; Lim, SY; McCabe, DJH; McCarthy, AJ; Murphy, SJX; Murphy, SM; O'Neill, D; Smith, DR; Tierney, S, 2022) |
| "Patients with diabetes and no obstructive coronary artery disease (CAD) as assessed by coronary angiography (CAG) are frequently treated with aspirin and statins." | 8.12 | Statin but not aspirin treatment is associated with reduced cardiovascular risk in patients with diabetes without obstructive coronary artery disease: a cohort study from the Western Denmark Heart Registry. ( Bøtker, HE; Heide-Jørgensen, U; Maeng, M; Olesen, KKW; Sørensen, HT; Thim, T; Thomsen, RW, 2022) |
| "We investigated (1) the associations of pre-stroke aspirin use with thrombus burden, infarct volume, hemorrhagic transformation, early neurological deterioration (END), and functional outcome, and (2) whether stroke subtypes modify these associations in first-ever ischemic stroke." | 8.02 | Relation of Pre-Stroke Aspirin Use With Cerebral Infarct Volume and Functional Outcomes. ( Bae, HJ; Cha, JK; Cho, YJ; Choi, KH; Han, MK; Hong, KS; Jeong, SW; Kang, K; Kim, BJ; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Lee, BC; Lee, J; Lee, KB; Lee, SJ; Nahrendorf, M; Oh, MS; Park, HK; Park, JM; Park, MS; Park, SS; Park, TH; Ryu, WS; Schellingerhout, D; Yu, KH, 2021) |
| "Fifty one acute stroke/transient ischemic attack (TIA) patients (ASG) with a history of regular aspirin intake for the previous 7 days or more were included to the study within 24 hours of symptoms onset." | 8.02 | Biochemical aspirin resistance in acute stroke patients and its association with clinical factors: a prospective pilot study. ( Fiszer, U; Kubiak-Balcerewicz, K; Morton, M; Sarnowska, A, 2021) |
| " The purpose of this study was to evaluate the incidence of major bleeding and thromboembolic events (TEs) in patients with atrial fibrillation (AF) receiving warfarin alone (monotherapy group) versus warfarin plus aspirin (combination therapy group)." | 8.02 | Risk Versus Benefit of Combined Aspirin and Warfarin Therapy in Patients With Atrial Fibrillation. ( Afzal, M; Davidson, E; Li, J; Nagaraj, TA; Snider, MJ; Weiss, R, 2021) |
| "Ticagrelor plus aspirin could reduce the risks of major adverse cardiac events in diabetic patients with stable coronary artery disease (SCD), and yet it also increases bleeding risk." | 8.02 | Cost-utility of ticagrelor plus aspirin in diabetic patients with stable coronary artery disease. ( Shi, L; Wu, B, 2021) |
| "Patients with ischemic stroke receiving aspirin (100 mg/day) for three months were recruited for a multicenter, prospective, cohort study." | 8.02 | Safety and efficacy of low-dose aspirin in ischemic stroke patients with different G6PD conditions. ( Chen, Y; Deng, W; Huang, W; Jiang, H; Li, J; Liang, Z; Liu, Q; Ou, Z; Ouyang, F; Wu, Z; Xing, S; Zeng, J; Zhang, Y, 2021) |
| "This study provides supporting evidence that aspirin use is associated with reduced ischaemic events after pneumonia in a primary care setting." | 8.02 | Aspirin reduces cardiovascular events in patients with pneumonia: a prior event rate ratio analysis in a large primary care database. ( Arnold, D; Hamilton, F; Henley, W; Payne, RA, 2021) |
| " Here we assessed the contribution of clopidogrel versus aspirin to the development of pneumonia during an acute ischemic stroke admission." | 8.02 | Clopidogrel increases risk of pneumonia compared with aspirin in acute ischemic minor stroke patients. ( Feng, Q; Fu, J; Jin, X; Shan, B; Shen, R; Yu, Z; Zhou, H; Zhu, H, 2021) |
| "We initiated a multicenter, prospective cohort study to test the hypothesis that aspirin is safe for patients with ischemic cerebrovascular disease (ICVD) harboring unruptured intracranial aneurysms (UIAs) <7 mm." | 8.02 | Safety of Aspirin Use in Patients With Stroke and Small Unruptured Aneurysms. ( Cao, Y; Du, X; Fu, WL; Huo, R; Jiao, YM; Li, H; Wang, J; Wang, S; Weng, JC; Xu, HY; Yan, ZH; Zhao, JZ, 2021) |
| "Clopidogrel is commonly used for secondary stroke prevention in patients with large vessel stenosis." | 8.02 | Clopidogrel underactivity is a common in patients with acute symptomatic severe carotid stenosis. ( Cohen, JE; Filioglo, A; Gomori, JM; Honig, A; Horev, A; Kalish, Y; Leker, RR; Sacagiu, T; Simaan, N, 2021) |
| " We conducted a network meta-analysis to compare ticagrelor with other receptor antagonists (P2Y12) inhibitors and aspirin in monotherapy or combination in the treatment of patients with high risk for cardiovascular or cerebrovascular disease, defined as coronary artery disease, acute coronary syndrome, stroke or transient ischemic attack, or peripheral artery disease." | 8.02 | Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events. ( Bálint, A; El Alaoui El Abdallaoui, O; Komócsi, A; Kupó, P; Tornyos, D, 2021) |
| "Aspirin is indispensable in secondary prevention of ischemic events in patients with coronary artery disease (CAD)." | 7.96 | Enhanced Platelet Reactivity under Aspirin Medication and Major Adverse Cardiac and Cerebrovascular Events in Patients with Coronary Artery Disease. ( Ayhan, A; Dannenberg, L; Helten, C; Hohlfeld, T; Kelm, M; Knoop, B; Konsek, D; Levkau, B; Metzen, D; Mourikis, P; Naguib, D; Petzold, T; Pöhl, M; Polzin, A; Trojovsky, K; Veulemans, V; Zako, S; Zeus, T, 2020) |
| "The RE-DUAL PCI trial reported that dabigatran dual therapy (110/150 mg twice daily, plus clopidogrel or ticagrelor) reduced bleeding events versus warfarin triple therapy (warfarin plus aspirin and clopidogrel or ticagrelor) in patients with atrial fibrillation who underwent percutaneous coronary intervention, with noninferiority in composite thromboembolic events." | 7.96 | Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percut ( Bhatt, DL; Cannon, CP; de Veer, A; Hohnloser, SH; Kimura, T; Lip, GYH; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2020) |
| " Despite the modified dose, bleeding events were higher among patients receiving low-dose prasugrel than among patients receiving clopidogrel, with no difference in ischemic events between the 2 groups." | 7.96 | Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment. ( Fukuda, K; Heidenreich, PA; Ikemura, N; Kohsaka, S; Numasawa, Y; Sandhu, AT; Sawano, M; Shiraishi, Y; Shoji, S; Suzuki, M; Ueno, K, 2020) |
| "Comparative gastrointestinal bleeding (GIB) risk between rivaroxaban and low-dose aspirin is unknown in patients with atrial fibrillation (AF)." | 7.96 | Gastrointestinal bleeding risk with rivaroxaban vs aspirin in atrial fibrillation: A multinational study. ( Bell, JS; Chan, EW; Darzins, P; Fanning, L; Ilomaki, J; Lau, WCY; Leung, WK; Li, X; Man, KKC; Mongkhon, P; Wei, L; Wong, ICK, 2020) |
| " In the overall trial rivaroxaban plus aspirin reduced ischemic stroke by 49% (0." | 7.96 | Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy. ( A A Fox, K; Avezum, A; Berkowitz, SD; Bhatt, DL; Bosch, J; Branch, KRH; Casanova, A; Connolly, SJ; Dagenais, GR; Diaz, R; Dyal, L; Eikelboom, JW; Ertl, G; Hart, RG; Keltai, K; Keltai, M; Kim, JH; Liang, Y; Liu, L; Lonn, EM; Lopez-Jaramillo, P; Maggioni, AP; O'Donnell, M; Piegas, LS; Pogosova, N; Probstfield, JL; Reeh, KW; Ryden, L; Sharma, M; Smith, EE; Störk, S; Tonkin, AM; Varigos, JD; Vinereanu, D; Yusuf, S; Zhu, J, 2020) |
| "Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial." | 7.96 | Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. ( Bikdeli, B; Cho, J; Gupta, A; Hripcsak, G; Kim, J; Krumholz, HM; Londhe, A; Madigan, D; Park, J; Park, RW; Reich, CG; Rho, Y; Ryan, PB; Schuemie, M; Siapos, A; Suchard, MA; Weaver, J; You, SC, 2020) |
| "Despite international treatment guidelines currently advocating oral anticoagulants (OACs) as the only appropriate stroke prevention therapy for patients with atrial fibrillation (AF) and evidence that OACs can greatly reduce the risk of stroke with similar risk of bleeding compared with aspirin, the underuse of OACs in patients with AF is common globally, especially in Asia." | 7.96 | Understanding the barriers to using oral anticoagulants among long-term aspirin users with atrial fibrillation - a qualitative study. ( Chiu, PKC; Jamieson, E; Kng, CPL; Lam, MPS; Ng, VWS; Siu, CW; Wong, ICK, 2020) |
| "Atorvastatin and aspirin have been used in treating different forms of epilepsy." | 7.96 | Effects of atorvastatin and aspirin on post-stroke epilepsy and usage of levetiracetam. ( Ding, Y; Feng, X; Lin, W; Zhao, T; Zhou, C, 2020) |
| "In real-world practice settings, there is insufficient evidence on the efficacy of antiplatelet drugs, including clopidogrel, aspirin, and ticlopidine, in stroke prevention." | 7.96 | Efficacy of aspirin, clopidogrel, and ticlopidine in stroke prevention: A population-based case-cohort study in Taiwan. ( Hsu, YH; Ong, CT; Tsai, CF; Wong, YS, 2020) |
| " We now investigate if initiation of treatment with SSRIs, statins, clopidogrel, aspirin or oral anticoagulants and smoking cessation impacts coated-platelet levels at 90 days after ischemic stroke." | 7.96 | Clopidogrel use and smoking cessation result in lower coated-platelet levels after stroke. ( Dale, GL; Kirkpatrick, AC; Prodan, CI; Vincent, AS, 2020) |
| "Several clinical trials reported that clopidogrel was superior to aspirin in secondary stroke prevention by reducing the risk of major adverse cardiovascular events (MACE)." | 7.91 | Aspirin better than clopidogrel on major adverse cardiovascular events reduction after ischemic stroke: A retrospective nationwide cohort study. ( Chan, L; Chen, YC; Hsu, CY; Hu, CJ; Lin, CL; Muo, CH; Vidyanti, AN; Wu, D, 2019) |
| "Background and Purpose- This study aimed to compare the effectiveness of dual antiplatelet therapy with clopidogrel plus aspirin (DAPT) with that of aspirin monotherapy (AM) in patients with acute, nonminor, and noncardioembolic stroke." | 7.91 | Comparative Effectiveness of Dual Antiplatelet Therapy With Aspirin and Clopidogrel Versus Aspirin Monotherapy in Acute, Nonminor Stroke: A Nationwide, Multicenter Registry-Based Study. ( Bae, HJ; Cha, JK; Cho, KH; Cho, YJ; Choi, JC; Choi, KH; Hong, JH; Hong, KS; Kang, K; Kim, BJ; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Kim, WJ; Kwon, JH; Lee, BC; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Oh, MS; Park, HK; Park, JM; Park, MS; Park, SS; Park, TH; Ryu, WS; Shin, DI; Sohn, SI; Yu, KH, 2019) |
| "Background As an alternative to vitamin K antagonist and low-dose aspirin (< 325 mg), non-vitamin K oral anticoagulants are available for the prevention of stroke in patients with atrial fibrillation." | 7.91 | Mortality risk in atrial fibrillation: the role of aspirin, vitamin K and non-vitamin K antagonists. ( Burden, A; de Boer, A; de Vries, F; Gieling, E; Kramers, C; Ten Cate, V; van Onzenoort, HAW; Williams, R, 2019) |
| "This study aimed to investigate the effectiveness of monotherapy acetylsalicylic acid (ASA) and warfarin for stroke prevention in low-risk atrial fibrillation (AF) by using a population- -based cohort study in Taiwan." | 7.91 | Monotherapy of acetylsalicylic acid or warfarin for prevention of ischemic stroke in low-risk atrial fibrillation: A Easter Asian population-based study. ( Chen, HC; Liu, CY, 2019) |
| "Despite its well-known antithrombotic properties, the effect of aspirin on blood pressure (BP) and hypertension pathology is unclear." | 7.91 | Effects of high- and low-dose aspirin on adaptive immunity and hypertension in the stroke-prone spontaneously hypertensive rat. ( Andrews, KL; Chin-Dusting, JPF; Dragoljevic, D; Gaspari, T; Jefferis, AM; Jennings, GL; Khan, SI; Lee, MKS; Moore, XL; Murphy, AJ; Shihata, WA; Vinh, A, 2019) |
| "To evaluate the effect of prestroke aspirin (PA) use on initial stroke severity, early neurologic deterioration (END), stroke recurrence, hemorrhagic transformation (HT), and functional outcome in patients with ischemic stroke (IS)." | 7.91 | Prestroke Aspirin Use is Associated with Clinical Outcomes in Ischemic Stroke Patients with Atherothrombosis, Small Artery Disease, and Cardioembolic Stroke. ( Han, Z; Lin, J; Luo, H; Yi, X; Zhou, J; Zhou, Q, 2019) |
| "To determine whether hypertensive disorders of pregnancy (HDP) increased long-term stroke risk in women in the California Teachers Study (CTS), a prospective cohort study, and whether aspirin or statin use modified this risk." | 7.91 | Aspirin reduces long-term stroke risk in women with prior hypertensive disorders of pregnancy. ( Bello, NA; Boehme, AK; Chung, NT; Elkind, MSV; Lacey, JV; Lakshminarayan, K; Miller, EC; Wang, SS; Wapner, R; Willey, JZ; Woo, D; Zhong, C, 2019) |
| " Clopidogrel plus aspirin treatment was associated with reduced risk of new stroke in patients with ABCB1 -154 TT and 3435 CC genotype (hazard ratio [HR], 0." | 7.91 | Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial. ( Chen, W; Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Simon, T; Wang, D; Wang, Y; Zhao, X, 2019) |
| "To understand the efficacy of aspirin use for preventing ischaemic stroke after central retinal artery occlusion (CRAO)." | 7.91 | Aspirin use in central retinal arterial occlusion to prevent ischaemic stroke: a retrospective cohort study in Taiwan. ( Chen, TH; Hung, MJ; Kang, EY; Kang, JH; Lin, YH; Luo, C; Sun, CC; Wang, NK; Wu, WC; Yeung, L, 2019) |
| "To investigate the association of aspirin resistance (AR) with mortality in a cohort of Chinese patients with acute ischemic stroke (AIS)." | 7.91 | Association of Aspirin Resistance with Increased Mortality in Ischemic Stroke. ( Jing, Y; Li, S; Yang, S; Yue, X, 2019) |
| "High plasma level of HbA1c is involved in enhanced platelet aggregability in acute atherothrombotic stroke patients, and prestroke administration of aspirin may be beneficial to clinical outcomes." | 7.91 | Collagen-Induced Platelet Aggregates, Diabetes, and Aspirin Therapy Predict Clinical Outcomes in Acute Ischemic Stroke. ( Hagii, J; Harima, K; Honda, S; Kitajima, M; Metoki, H; Mikami, K; Osanai, T; Tomisawa, T; Urushizaka, M; Yasujima, M, 2019) |
| "Most stroke patients are prescribed aspirin (ASA) to adjust blood coagulability." | 7.91 | Aspirin in stroke patients modifies the immunomodulatory interactions of marrow stromal cells and monocytes. ( Aronowski, J; Cai, C; Giridhar, K; Norris, DD; Olson, SD; Satani, N; Savitz, SI; Wewior, N, 2019) |
| "Our aims were to examine the prevalence and genetic predictors of aspirin and clopidogrel high on-treatment platelet reactivity (HoTPR), and associated adverse cardiovascular outcomes in patients with peripheral arterial disease (PAD)." | 7.88 | Aspirin and clopidogrel high on-treatment platelet reactivity and genetic predictors in peripheral arterial disease. ( Amsterdam, EA; Anderson, D; Armstrong, EJ; Chen, DC; Chiamvimonvat, N; Hua, A; Laird, JR; Li, CS; López, JE; Singapuri, A; Westin, GG; Yeo, KK, 2018) |
| "This study sought to assess safety and effectiveness of low-dose aspirin in heart failure (HF) not complicated by atrial fibrillation." | 7.88 | Low-Dose Aspirin in Heart Failure Not Complicated by Atrial Fibrillation: A Nationwide Propensity-Matched Study. ( Bjerre, J; D'Souza, M; Fosbøl, EL; Gislason, G; Gustafsson, F; Kober, L; Kristensen, SL; Madelaire, C; Schou, M; Torp-Pedersen, C, 2018) |
| "To investigate the associations between CYP2C19 genotypes and early neurological deterioration (END), and to carry out a stratified analysis of the effectiveness of clopidogrel alone and dual antiplatelet therapy with clopidogrel and aspirin for prevention of END according to CYP2C19 genotypes in ischemic stroke (IS) patients." | 7.88 | Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles. ( Chai, Z; Han, Z; Huang, R; Lin, J; Wang, C; Yi, X; Zhou, Q, 2018) |
| "The relationship of CYP2C19 genotype and clinical efficacy in stroke or transient ischemic attack (TIA) patients treated with clopidogrel monotherapy or clopidogrel plus aspirin remains unknown." | 7.88 | Efficacy and safety of CYP2C19 genotype in stroke or transient ischemic attack patients treated with clopidogrel monotherapy or clopidogrel plus aspirin: Protocol for a systemic review and meta-analysis. ( Cui, M; Gu, ZC; Li, WY; Pan, MM; Yao, JC, 2018) |
| "To investigate the prognostic value of aspirin reaction units (ARU) in a 3-month follow-up study in a cohort of Chinese patients with first-ever ischemic stroke." | 7.88 | Aspirin resistance predicts unfavorable functional outcome in acute ischemic stroke patients. ( Fan, YN; He, Y; Hua, QJ; Ji, SB; Liu, YX; Su, LL; Wang, CW; Xi, TT; Yuan, B, 2018) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel reduces the risk for recurrent cardiovascular events after acute coronary syndrome (ACS)." | 7.88 | Pharmacogenetic and clinical predictors of response to clopidogrel plus aspirin after acute coronary syndrome in Egyptians. ( Cavallari, LH; El Wakeel, LL; Fathy, S; Khalil, BM; Langaee, T; Sabry, NA; Saleh, A; Schaalan, MF; Shahin, MH, 2018) |
| "WHAT IS THE ROLE OF DUAL ANTIPLATELET THERAPY AFTER HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR STROKE? SPECIFICALLY, DOES DUAL ANTIPLATELET THERAPY WITH A COMBINATION OF ASPIRIN AND CLOPIDOGREL LEAD TO A GREATER REDUCTION IN RECURRENT STROKE AND DEATH OVER THE USE OF ASPIRIN ALONE WHEN GIVEN IN THE FIRST 24 HOURS AFTER A HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR ISCHAEMIC STROKE? AN EXPERT PANEL PRODUCED A STRONG RECOMMENDATION FOR INITIATING DUAL ANTIPLATELET THERAPY WITHIN 24 HOURS OF THE ONSET OF SYMPTOMS, AND FOR CONTINUING IT FOR 10-21 DAYS CURRENT PRACTICE IS TYPICALLY TO USE A SINGLE DRUG." | 7.88 | Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline. ( Agoritsas, T; Booth, B; Fisch, L; Fobuzi, AC; Fraiz, A; Gorthi, SP; Guyatt, G; Hao, Q; Heen, AF; Horton, E; Jusufovic, M; Katragunta, N; Lytvyn, L; Muller, J; O'Donnell, M; Prasad, K; Rochwerg, B; Siemieniuk, J; Siemieniuk, R; Vandvik, PO, 2018) |
| "Prostaglandin-Endoperoxide Synthase 1 (PTGS1) and smoking may play important roles in aspirin nonresponsiveness, but the effect of their interaction on stroke outcomes remains largely unknown." | 7.85 | Association between PTGS1 polymorphisms and functional outcomes in Chinese patients with stroke during aspirin therapy: Interaction with smoking. ( Cai, B; Cai, H; Cao, L; Davis, SM; Guo, H; Liu, X; Sun, L; Sun, W; Yan, B; Zhang, H; Zhang, Z; Zhou, S, 2017) |
| "Antiplatelet therapy with ticagrelor in patients with acute ischemic stroke or transient ischemic attack showed a bleeding profile similar to that of aspirin for major bleeds." | 7.85 | Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcome ( Albers, GW; Amarenco, P; Aunes, M; Bokelund-Singh, S; Denison, H; Easton, JD; Evans, SR; Held, P; Jahreskog, M; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017) |
| "Our findings indicate a favorable effect of clopidogrel at discharge compared with aspirin in preventing death, recurrent stroke, and CVD events in diabetic patients with a first-ever noncardioembolic AIS." | 7.85 | Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project. ( Elisaf, M; Manios, E; Milionis, H; Ntaios, G; Papavasileiou, V; Spengos, K; Vemmos, K, 2017) |
| "This study is the largest to investigate platelet aggregation in stable coronary artery disease patients receiving aspirin as single antithrombotic therapy." | 7.85 | Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S; Würtz, M, 2017) |
| "To investigate the prevalent of aspirin resistance (AR) in stroke and its association with recurrent stroke in 214 patients with ischemic stroke who were receiving aspirin before the stroke onset." | 7.85 | Aspirin resistance are associated with long-term recurrent stroke events after ischaemic stroke. ( Wang, Z; Zhang, N; Zhou, L, 2017) |
| "BACKGROUND To investigate the combination of beraprost sodium (BPS) and aspirin in the treatment of acute ischemic stroke (AIS)." | 7.85 | Beneficial Effect of Beraprost Sodium Plus Aspirin in the Treatment of Acute Ischemic Stroke. ( Chen, S; Chen, W; He, W; Li, S; Wei, D; Xie, S, 2017) |
| "Aspirin and statin are recommended for the treatment of acute ischemic stroke." | 7.85 | Statin and Aspirin Pretreatment Are Associated with Lower Neurological Deterioration and Platelet Activity in Patients with Acute Ischemic Stroke. ( Han, Z; Lin, J; Wang, C; Yi, X; Zhou, Q, 2017) |
| "Based on the present analysis, apixaban represents a cost-effective treatment option versus warfarin and aspirin for the prevention of stroke in patients with AF from a Greek healthcare payer perspective over a lifetime horizon." | 7.85 | Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective. ( Athanasakis, K; Bilitou, A; Boubouchairopoulou, N; Karampli, E; Kyriopoulos, J; Savvari, P; Tarantilis, F, 2017) |
| "Adjusted survival curves showed that the usage of aspirin was not associated with ischemic stroke, hospitalization for bleeding events, cardiovascular mortality or all-cause mortality, however, it was significantly associated with renal failure." | 7.85 | Different impact of aspirin on renal progression in patients with predialysis advanced chronic kidney disease with or without previous stroke. ( Chang, HR; Hsiao, KC; Huang, JY; Hung, TW; Lee, CT; Liaw, YP, 2017) |
| "Active smokers with myocardial infarction were shown to have enhanced benefit with clopidogrel compared with aspirin." | 7.85 | Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox? ( Cao, Q; Dong, K; Feng, W; Hou, C; Huang, X; Ji, X; Ovbiagele, B; Song, H; Wang, M; Wang, Y; Zhang, Q, 2017) |
| "Nonvitamin K antagonist oral anticoagulants (NOACs) are now available for the prevention of stroke in patients with atrial fibrillation (AF) as an alternative to vitamin K antagonists (VKA) and aspirin." | 7.85 | Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. ( Bos, J; Burden, AM; de Boer, A; de Vries, F; Gieling, EM; Kramers, C; van den Ham, HA; van Onzenoort, H, 2017) |
| "In this hypothesis generating pilot analysis, dipyrone medication in aspirin treated coronary artery disease patients is associated with an increased cumulative incidence of death, MI or stroke as well as all-cause mortality and ischemic events." | 7.85 | Analgesic medication with dipyrone in patients with coronary artery disease: Relation to MACCE. ( Achilles, A; Dannenberg, L; Hohlfeld, T; Kelm, M; Levkau, B; Mohring, A; Piayda, K; Polzin, A; Zeus, T, 2017) |
| "To evaluate long-term health benefits and risks of adding vorapaxar (VOR) to the standard care antiplatelet therapy (SC) of aspirin and/or clopidogrel, among a population with a recent myocardial infarction (MI) and/or peripheral artery disease (PAD)." | 7.85 | State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. ( Chase, M; Davies, G; Du, M; Oguz, M, 2017) |
| "This retrospective, cross-sectional study evaluated whether HIV-infected patients received aspirin and statins for the primary prevention of myocardial infarction and stroke." | 7.83 | Use of aspirin and statins for the primary prevention of myocardial infarction and stroke in patients with human immunodeficiency virus infection. ( Park, TE; Sharma, R; Yusuff, J, 2016) |
| "Admission National Institutes of Health Stroke Scale (NIHSS) score, ischemic lesion volumes on diffusion-weighted imaging (DWI), and in vitro aspirin resistance, in addition to other pertinent stroke features, were determined in a series of ischemic stroke patients." | 7.83 | The Interplay between Stroke Severity, Antiplatelet Use, and Aspirin Resistance in Ischemic Stroke. ( Agayeva, N; Arsava, EM; Topcuoglu, MA, 2016) |
| "We measured serum levels of proinflammatory/prothrombotic markers P-selectin, CD40L, matrix metalloproteinase 9 (MMP-9), intracellular adhesion molecule 1 (ICAM-1), and interleukin (IL)-6 in ischemic stroke patients, correlating their levels with the results of aspirin (ASA) and clopidogrel antiplatelet responses, using 3 "point of care" platelet function instruments, thromboelastograph (TEG), Accumetrics (ACU), and impedance aggregometer (IMP)." | 7.83 | Relationship between Inflammation and Aspirin and Clopidogrel Antiplatelet Responses in Acute Ischemic Stroke. ( Ambrus, JL; Chichelli, T; Ching, M; Janicke, D; Munschauer, F; Sawyer, R; Sternberg, D; Sternberg, Z; Yu, J, 2016) |
| "Selecting among different antiplatelet strategies when patients experience a new ischemic stroke while taking aspirin is a common clinical challenge, currently addressed by a paucity of data." | 7.83 | Different Antiplatelet Strategies in Patients With New Ischemic Stroke While Taking Aspirin. ( Bae, HJ; Cha, JK; Cho, KH; Cho, YJ; Choi, JC; Choi, KH; Han, MK; Hong, KS; Kang, K; Kim, BJ; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Kim, WJ; Ko, YC; Lee, BC; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Nah, HW; Oh, MS; Park, JM; Park, MS; Park, SS; Park, TH; Ryu, WS; Saver, JL; Shin, DI; Yeo, MJ; Yu, KH, 2016) |
| "The effect of prestroke aspirin use on initial severity, hemorrhagic transformation, and functional outcome of ischemic stroke is uncertain." | 7.83 | Comparative Effectiveness of Prestroke Aspirin on Stroke Severity and Outcome. ( Bae, HJ; Cha, JK; Cho, YJ; Choi, JC; Gorelick, PB; Han, MK; Hong, KS; Kang, K; Kim, DE; Kim, DH; Kim, JT; Ko, Y; Lee, BC; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Park, JM; Park, TH; Yu, KH, 2016) |
| " Among these 397 patients, 69 were receiving monotherapy with clopidogrel prior to stroke, 69 were receiving monotherapy with aspirin and 236 patients were not on any antiplatelet treatment." | 7.83 | Treatment with Clopidogrel Prior to Acute Non-Cardioembolic Ischemic Stroke Attenuates Stroke Severity. ( Angelopoulou, SM; Bouziana, SD; Giampatzis, V; Hatzitolios, AI; Kostaki, S; Papadopoulou, M; Savopoulos, C; Spanou, M; Tsopozidi, M; Tziomalos, K, 2016) |
| " Our results suggest that this strategy is not beneficial as compared to aspirin alone in terms of ischaemic or bleeding events." | 7.83 | Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study). ( Bauters, C; Caudmont, S; Ketelers, R; Lamblin, N; Lemaire, N; Lemesle, G; Meurice, T; Philias, A; Schurtz, G; Tricot, O, 2016) |
| "A cost-effectiveness model was constructed using data from three studies on stroke prevention in patients with contraindications: the ASAP study evaluating the Watchman device, the ACTIVE A trial of aspirin and clopidogrel, and the AVERROES trial evaluating apixaban." | 7.83 | Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin. ( Akehurst, RL; Amorosi, SL; Armstrong, SO; Brereton, N; Hertz, DS; Holmes, DR; Reddy, VY, 2016) |
| "Concomitant use of vitamin K antagonist (VKA) and aspirin (ASA) is becoming increasingly prevalent among atrial fibrillation (AF) patients." | 7.83 | Net clinical benefit of adding aspirin to warfarin in patients with atrial fibrillation: Insights from the J-RHYTHM Registry. ( Atarashi, H; Chishaki, A; Inoue, H; Kiyono, K; Kodama, I; Kodani, E; Lip, GY; Okumura, K; Okuyama, Y; Origasa, H; Watanabe, E; Yamamoto, M; Yamashita, T, 2016) |
| "To investigate whether aspirin resistance is associated with initial stroke severity and infarct volume, using diffusion-weighted imaging (DWI) in patients with acute ischemic stroke that occurred while taking aspirin." | 7.83 | Aspirin resistance is associated with increased stroke severity and infarct volume. ( Jang, MU; Jung, S; Kim, C; Lee, BC; Lee, J; Lee, JH; Oh, MS; Yu, KH, 2016) |
| "Evidence indicates that aspirin is effective for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC) but also increases the risk for gastrointestinal (GI) and cerebral hemorrhages." | 7.83 | Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force. ( Dehmer, SP; Flottemesch, TJ; LaFrance, AB; Maciosek, MV; Whitlock, EP, 2016) |
| "This model demonstrates that increased use of rivaroxaban in inadequately-managed NVAF patients could avoid 456 081 non-fatal ischemic strokes (IS) and 76 975 cardiovascular deaths over 10 years in Japan." | 7.83 | Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: The case study of Japan. ( Briere, JB; Evers, T; Hori, M; Ikeda, S; Koretsune, Y; Matsuda, S; Montouchet, C; Okumura, K; Rossi, B; Ruff, L; Watanabe-Fujinuma, E, 2016) |
| "The TRA 2°P-TIMI 50 trial showed the addition of vorapaxar to standard care (SC) antiplatelet therapy reduced the combined risk of death, myocardial infarction (MI), and stroke, while exhibiting an increase in moderate, but not other bleeding events." | 7.83 | A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction. ( Bash, LD; Davies, G; Du, M; Oguz, M; Ozer-Stillman, I; Whalen, JD, 2016) |
| "Dipyrone comedication in patients with stroke impairs pharmacodynamic response to aspirin." | 7.83 | Dipyrone comedication in aspirin treated stroke patients impairs outcome. ( Bönner, F; Dannenberg, L; Erschoff, V; Gliem, M; Hohlfeld, T; Jander, S; Kelm, M; Levkau, B; Polzin, A; Zeus, T, 2016) |
| "Oral anticoagulation (OAC), rather than aspirin, is recommended in patients with atrial fibrillation (AF) at moderate to high risk of stroke." | 7.83 | Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke. ( Gehi, AK; Hsu, JC; Katz, DF; Kennedy, K; Lubitz, SA; Maddox, TM; Marcus, GM; Marzec, LN; Turakhia, MP, 2016) |
| "A higher loading dose of aspirin (160-325 mg) can be beneficial in treating acute ischemic stroke, although there is an increased risk of minor bleeding." | 7.83 | To Load or Not to Load? Aspirin Loading in Acute Ischemic Stroke: A Study of Clinical Outcomes. ( Chan, YL; Lee, JD; Lee, M; Lee, TH; Lin, LC; Su, TH; Wen, YW, 2016) |
| "miR-145 is involved in the anti-proliferation and anti-inflammation effects of aspirin on VSMCs by inhibiting the expression of CD40." | 7.83 | miR-145 mediated the role of aspirin in resisting VSMCs proliferation and anti-inflammation through CD40. ( Chen, M; Guo, R; Guo, X; Peng, X; Wu, T; Yu, L; Zhang, B, 2016) |
| "To evaluate the efficacy and safety of well-managed warfarin therapy in patients with nonvalvular AF, the risk of complications, especially intracranial bleeding, in patients with concomitant use of aspirin, and the impact of international normalized ratio (INR) control." | 7.83 | Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. ( Björck, F; Lip, GY; Renlund, H; Själander, A; Svensson, PJ; Wester, P, 2016) |
| "Aspirin is known to reduce stroke risk; however, its role in reducing severity of ischemic syndrome is not clear." | 7.83 | Antecedent Aspirin Use Is Associated with Less Severe Symptoms on Admission for Ischemic Stroke. ( Cloonan, L; Fitzpatrick, KM; Furie, KL; Kanakis, AS; Nelson, S; Perilla, AS; Rost, NS; Shideler, KI, 2016) |
| "Aspirin use at baseline was associated with an increased risk for bleeding and all-cause death in ROCKET AF, a risk most pronounced in patients without known CAD." | 7.83 | Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. ( Becker, RC; Berkowitz, SD; Breithardt, G; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, A; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Shah, R; Singer, DE, 2016) |
| "Aspirin resistance has an incidence of 5%-65% in patients with ischemic stroke, who receive the standard dose of aspirin, but the platelet function is inadequately inhibited, thereby leading to thrombotic events." | 7.83 | Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy. ( Cai, YF; Chen, LY; Chen, XM; Huang, M; Jin, J; Li, JL; Peng, LL; Zhao, M; Zhao, YQ; Zhou, ZY, 2016) |
| "Fourteen hybrids (10a-g, 11a-g) of 3-n-butylphthalide (NBP) and edaravone (Eda) analogues have been designed and synthesized as potential anti-ischemic stroke agents." | 7.81 | Novel hybrids of 3-n-butylphthalide and edaravone: Design, synthesis and evaluations as potential anti-ischemic stroke agents. ( Hua, K; Huang, Z; Ji, H; Sheng, X; Wang, X; Xu, J; Yang, C; Zhang, Y, 2015) |
| " We investigated the risks of ischemic stroke and intracranial hemorrhage (ICH) in relation to warfarin at various TTRs in a real-world cohort of Chinese patients with atrial fibrillation receiving warfarin and compared with those on dabigatran, aspirin, and no therapy." | 7.81 | Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. ( Chan, KH; Chan, PH; Cheung, E; Hai, JJ; Ho, CW; Ho, MH; Lau, CP; Lau, KK; Leung, GK; Lip, GY; Siu, CW; Tse, HF; Yeung, CY, 2015) |
| "Aspirin is recommended in stable coronary artery disease based on myocardial infarction and stroke studies." | 7.81 | Impact of aspirin according to type of stable coronary artery disease: insights from a large international cohort. ( Bavry, AA; Cooper-DeHoff, RM; Gong, Y; Handberg, EM; Pepine, CJ, 2015) |
| "Aspirin use increased among Chinese patients newly diagnosed with AF, with no relationship to the patient's stroke or bleeding risk." | 7.81 | Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation. ( Guo, Y; Lip, GYH; Tian, Y; Wang, H; Wang, Y, 2015) |
| "A significant proportion of ischemic strokes occur while using aspirin and therefore can be considered as clinical aspirin resistance." | 7.81 | Pathophysiologic, rather than laboratory-defined resistance drives aspirin failure in ischemic stroke. ( Agayeva, N; Arsava, EM; Gungor, L; Topcuoglu, MA, 2015) |
| " We studied 39,400 patients discharged with incident nonvalvular atrial fibrillation with 0 or 1 CHA2DS2-VASc risk factor; 23,572 were not treated, 5,353 were initiated on aspirin, and 10,475 were initiated on warfarin." | 7.81 | Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. ( Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F, 2015) |
| "Randomised trials have shown the efficacy of antiplatelet therapy with cilostazol to prevent secondary ischaemic stroke." | 7.81 | Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. ( Hayashi, K; Horie, N; Izumo, T; Kaminogo, M; Nagata, I; Tsujino, A, 2015) |
| "We aimed to study differences in the prescribing of warfarin, aspirin and statins to patients with atrial fibrillation (AF) in socio-economically diverse neighborhoods." | 7.81 | Neighborhood deprivation and warfarin, aspirin and statin prescription - A cohort study of men and women treated for atrial fibrillation in Swedish primary care. ( Carlsson, AC; Gasevic, D; Sundquist, J; Sundquist, K; Wändell, P, 2015) |
| "Clopidogrel or aspirin are indicated for patients with recent ischemic stroke (IS) or established peripheral artery disease (PAD)." | 7.81 | Clopidogrel versus aspirin in patients with recent ischemic stroke and established peripheral artery disease: an economic evaluation in a Chinese setting. ( Ben, H; Li, T; Liu, M; Wu, B; Xu, Z; Zhong, H, 2015) |
| "Low-dose aspirin (ASA) is effective for secondary prevention of ischemic stroke but can increase the risks of hemorrhagic stroke, upper gastrointestinal bleeding (UGIB), and dyspepsia." | 7.81 | Cost-Effectiveness of Proton Pump Inhibitor Co-Therapy in Patients Taking Aspirin for Secondary Prevention of Ischemic Stroke. ( Kawakami, K; Murata, K; Takabayashi, N; Tanaka, S, 2015) |
| " Therefore, we sought to evaluate the time-dependent changes in platelet reactivity to aspirin during the acute stage after ischemic stroke and the clinical implications of variable patient responses to aspirin in acute ischemic stroke." | 7.81 | Clinical Implications of Changes in Individual Platelet Reactivity to Aspirin Over Time in Acute Ischemic Stroke. ( Cho, KH; Choi, KH; Choi, SM; Heo, SH; Kim, BC; Kim, JT; Kim, MK; Lee, SH; Nam, TS; Park, MS; Saver, JL, 2015) |
| " We aimed to evaluate the effect of DAPT duration with clopidogrel and aspirin on the recurrence of ischaemic events and bleeding in a large, unselected ACS population." | 7.80 | Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. ( Hasvold, P; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Sundström, A; Varenhorst, C, 2014) |
| "Some patients with a recent ischemic stroke who are being treated with aspirin as an antiaggregant suffer a new ischemic stroke." | 7.80 | Aspirin resistant patients with recent ischemic stroke. ( Castilla-Guerra, L; Fernández-Moreno, MC; Navas-Alcántara, MS, 2014) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 7.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| " Apixaban is an oral anticoagulant that has demonstrated better efficacy than warfarin and aspirin in the ARISTOTLE and AVERROES studies, respectively, and causes less bleeding than warfarin." | 7.80 | Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. ( Dorian, P; Hernandez, L; Iloeje, U; Kongnakorn, T; Kuznik, A; Lanitis, T; Lip, GY; Liu, LZ; Phatak, H; Rublee, DA, 2014) |
| "To conduct an economic evaluation of the currently prescribed treatments for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) including warfarin, aspirin, and novel oral anticoagulants (NOACs) from a French payer perspective." | 7.80 | Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin. ( Cotté, FE; Durand-Zaleski, I; Gaudin, AF; Kachaner, I; Kongnakorn, T; Lanitis, T, 2014) |
| "Treatment with the combination of clopidogrel and aspirin taken soon after a transient ischemic attack (TIA) or minor stroke was shown to reduce the 90-day risk of stroke in a large trial in China, but the cost-effectiveness is unknown." | 7.80 | Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke. ( Johnston, SC; Liu, G; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, C; Wang, Y; Zhao, K; Zhao, X, 2014) |
| "Apixaban was found to be a cost-effective alternative to warfarin and aspirin for stroke prevention in patients with AF in Sweden." | 7.80 | Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation. ( De Geer, A; Jacobson, L; Kongnakorn, T; Lanitis, T, 2014) |
| "Our objective was to investigate the association between recurrent stroke risk and headache induced by extended-release dipyridamole (ER-DP) when administered alone or with low-dose aspirin (ASA+ER-DP)." | 7.80 | Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis. ( Bath, PM; Cotton, D; Davidai, G; Diener, HC; Gorelick, P; Lipton, RB; Sacco, R, 2014) |
| "To analyze the potential impact of aspirin on outcome at hospital discharge after acute stroke in resource-limited settings without access to neuroimaging to distinguish ischemic stroke from intracerebral hemorrhage (ICH)." | 7.80 | Aspirin for acute stroke of unknown etiology in resource-limited settings: a decision analysis. ( Berkowitz, AL; Bianchi, MT; Chou, SH; Westover, MB, 2014) |
| "To analyze the potential impact of aspirin therapy for long-term secondary prevention after stroke of undetermined etiology in resource-limited settings without access to neuroimaging to distinguish ischemic stroke from intracerebral hemorrhage (ICH)." | 7.80 | Aspirin for secondary prevention after stroke of unknown etiology in resource-limited settings. ( Berkowitz, AL; Bianchi, MT; Chou, SH; Westover, MB, 2014) |
| "Evidence indicates that vitamin K antagonists (VKAs) and oral anticoagulant therapy are under-utilised for stroke prevention in patients with non-valvular atrial fibrillation (AF), and patients who decline or cannot tolerate such treatment are often prescribed aspirin instead." | 7.80 | Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in Belgium. ( Annemans, L; Kongnakorn, T; Lanitis, T; Lieven, A; Marbaix, S; Thijs, V, 2014) |
| " The risks of suffering ischemic stroke, bleeding, or death with warfarin, aspirin, or no antithrombotic treatment during 2010 were related to CHA2DS2VASc scores, age, and complicating co-morbidities." | 7.80 | Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region. ( Forslund, T; Hasselström, J; Hjemdahl, P; von Euler, M; Wändell, P; Wettermark, B, 2014) |
| "To project the long-term cost-effectiveness of treating non-valvular atrial fibrillation (AF) patients for stroke prevention with rivaroxaban compared to warfarin in Portugal." | 7.80 | Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting. ( Aguiar, C; Chatzitheofilou, I; Fonseca Santos, I; McLeod, E; Morais, J; Pereira, S, 2014) |
| "To examine whether preadmission use of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) influenced 30-day stroke mortality." | 7.80 | Preadmission use of nonaspirin nonsteroidal anti-inflammatory drugs and 30-day stroke mortality. ( Bøtker, HE; Christiansen, CF; Hováth-Puhó, E; Petersen, KL; Schmidt, M; Sørensen, HT, 2014) |
| "In search of novel anti-ischemic stroke agents with higher potency than a known drug 3-n-butylphthalide (NBP), a series of hybrids ((S)- and (R)-5a-f) from optically active ring-opened NBP derivative and isosorbide were synthesized for evaluating their anti-ischemic stroke activity." | 7.79 | Novel hybrids of optically active ring-opened 3-n-butylphthalide derivative and isosorbide as potential anti-ischemic stroke agents. ( Huang, Z; Ji, H; Lai, Y; Li, T; Tian, J; Wan, X; Wang, L; Wang, X; Xu, J; Zhang, Y, 2013) |
| "Clopidogrel, cilostazol, and aspirin were compared in terms of efficacy and safety for primary prevention of stroke in peripheral artery disease (PAD) patients." | 7.79 | Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan. ( Chu, CY; Hsu, PC; Lai, WT; Lee, WH; Lin, TH; Sheu, SH; Su, HM; Voon, WC, 2013) |
| "Studies have shown that aspirin used for secondary prevention significantly reduces cardiovascular and stroke risk." | 7.79 | Primary prophylactic aspirin use and incident stroke: reasons for geographic and racial differences in stroke study. ( Cushman, M; Glasser, SP; Hovater, MK; Howard, G; Howard, VJ; Lackland, DT, 2013) |
| "To describe the prevalence of aspirin resistance based on optical platelet aggregometry in stroke patients who attended the Neurological Institute and investigate the clinical risk factors associated with aspirin resistance." | 7.79 | Aspirin non-responder in Thai ischemic stroke patients. ( Jongjaroenprasert, W; Mahasirimongkol, S; Suanprasert, N; Tantirithisak, T; Yadee, T, 2013) |
| "We examined 157 aspirin-treated patients with acute stroke or TIA, 128 aspirin-free and 15 aspirin-treated healthy subjects (HS)." | 7.79 | TXA2 synthesis and COX1-independent platelet reactivity in aspirin-treated patients soon after acute cerebral stroke or transient ischaemic attack. ( Lago, A; Moscardo, A; Parkhutik, V; Santos, MT; Tembl, J; Valles, J, 2013) |
| "A prospective study included 35 patients admitted with ischemic stroke and commenced on 300 mg aspirin." | 7.79 | "Aspirin resistance" in ischemic stroke: insights using short thrombelastography. ( Curzen, N; Englyst, N; Radhakrishnan, A; Sambu, N; Weir, N, 2013) |
| "The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial found no difference between warfarin and aspirin in patients with low ejection fraction in sinus rhythm for the primary outcome: first to occur of 84 incident ischemic strokes (IIS), 7 intracerebral hemorrhages or 531 deaths." | 7.79 | Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial. ( Anker, SD; Di Tullio, MR; Diek, M; Freudenberger, RS; Graham, S; Haddad, H; Homma, S; Labovitz, AJ; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Sanford, AR; Teerlink, JR; Thompson, JL, 2013) |
| "Among patients with stroke, the phenomenon of resistance to treatment with low-dose aspirin acetylsalicylic acid (ASA) is quite common." | 7.79 | Factors influencing multiplate whole blood impedance platelet aggregometry measurements, during aspirin treatment in acute ischemic stroke: a pilot study. ( Chełstowski, K; Clark, J; Jastrzębska, M; Nowacki, P; Siennicka, A; Wódecka, A, 2013) |
| "The prognostic value of occurrence of ischemic stroke in a patient despite aspirin treatment (aspirin treatment failure) is not known." | 7.79 | Aspirin treatment failure and the risk of recurrent stroke and death among patients with ischemic stroke. ( Adams, HP; Cordina, SM; Georgiadis, AL; Lakshminarayan, K; Qureshi, AI; Suri, MF; Tariq, N; Vazquez, G, 2013) |
| "This study evaluated the antiplatelet effects of clopidogrel (CPG) in patients sustaining acute ischemic stroke who were already receiving chronic outpatient aspirin therapy (81-325 mg/day)." | 7.79 | Clopidogrel responsiveness in stroke patients on a chronic aspirin regimen. ( Chichelli, T; Ching, M; Farooq, O; Janicke, D; Li, F; Mehta, B; Munschauer, FE; Radovic, V; Sawyer, RN; Sternberg, Z, 2013) |
| "Aspirin resistance (AR) is common in Chinese stroke patients taking antiplatelet medications; however, few studies have documented the role of cyclooxygenase (COX)-1 C50T and COX-2 G765C polymorphisms in AR." | 7.79 | Platelet response to aspirin in Chinese stroke patients is independent of genetic polymorphisms of COX-1 C50T and COX-2 G765C. ( Chi, L; Han, Z; Lin, J; Yi, X; Zhou, Q, 2013) |
| "To investigate the relationship between aspirin resistance and clinical and neuroimaging measures of stroke severity in acute stroke patients." | 7.79 | Association of aspirin resistance with increased stroke severity and infarct size. ( Churilov, L; Colley, RE; Davis, SM; Goh, C; Yan, B; Zheng, AS, 2013) |
| "Randomized trials suggested superior stroke prevention with extended-release dipyridamole (ERD) in combination with low-dose aspirin than either with aspirin or dipyridamole alone." | 7.78 | Effects of extended-release dipyridamole in vitro on thrombin indices measured by calibrated automated thrombography in poststroke survivors. ( Fong, A; Hanley, D; Pokov, I; Sani, Y; Schevchuck, A; Serebruany, V; Thevathasan, L, 2012) |
| "The widespread use of aspirin-driven vascular prevention strategies does not impede the occurrence of first and recurrent ischemic strokes in numerous subjects." | 7.78 | Ischemic stroke in patients receiving aspirin. ( Ameriso, S; Ameriso, SF; Povedano, GP; Pujol Lereis, VA, 2012) |
| "Treatment with cilostazol for 7 days before ischemia significantly suppressed the risk and severity of cerebral hemorrhage after injection of tissue-type plasminogen activator, although treatment with aspirin had no such protective effect compared with nontreated mice." | 7.78 | Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model. ( Kasahara, Y; Matsuyama, T; Nakagomi, T; Stern, D; Taguchi, A, 2012) |
| "the primary prevention of ischaemic stroke in chronic non-valvular atrial fibrillation (AF) typically involves consideration of aspirin or warfarin." | 7.78 | Aspirin versus warfarin in atrial fibrillation: decision analysis may help patients' choice. ( O'Shea, D; Romero-Ortuno, R, 2012) |
| "Aspirin is the most commonly used antiplatelet drug for treatment of a serious vascular event, most notably myocardial infarction and stroke." | 7.78 | Association of C3435T multi drug resistance gene-1 polymorphism with aspirin resistance in ischemic stroke and its subtypes. ( Al-Hazzani, A; Dadheech, S; Jyothy, A; Kaul, S; Munshi, A; Prabha, TS; Rao, PP; Sharma, V, 2012) |
| "Guidelines for atrial fibrillation (AF) recommend clopidogrel plus aspirin as an alternative stroke prevention strategy in patients in whom warfarin is unsuitable." | 7.78 | Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable. ( Anglade, MW; Coleman, CI; Kluger, J; Sobieraj, DM; Straznitskas, AD, 2012) |
| "As the management of patients treated with anticoagulants and antiplatelet drugs entails balancing coagulation levels, we evaluated the net clinical benefit of warfarin and aspirin on stroke in a large cohort of patients with atrial fibrillation (AF)." | 7.78 | A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study. ( Azoulay, L; Dell'Aniello, S; Langleben, D; Renoux, C; Simon, TA; Suissa, S, 2012) |
| "Compared with aspirin, apixaban reduces stroke risk in atrial fibrillation (AF) patients unsuitable for warfarin by 63% but does not increase major bleeding." | 7.78 | Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin. ( Anglade, MW; Coleman, CI; Hagstrom, K; Kluger, J; Lee, S; Meng, J, 2012) |
| "To examine healthcare costs among patients hospitalized for transient ischemic attack or ischemic stroke (TIA/stroke) and prescribed aspirin plus extended-release dipyridamole (ASA-ERDP) or clopidogrel (CLOPID) within 30 days post-discharge using a retrospective claims database from a large US managed care organization." | 7.78 | One-year follow-up healthcare costs of patients hospitalized for transient ischemic attack or ischemic stroke and discharged with aspirin plus extended-release dipyridamole or clopidogrel. ( Burton, TM; Lacey, M; Lang, K; Liu, F; Monsalvo, ML; Sander, S; Yu, Y, 2012) |
| " In this study, the authors assess the incidence of stroke or transient ischemic attack (TIA) following discontinuation of a 6-week course of clopidogrel in patients with cerebral aneurysms treated with stent-assisted techniques." | 7.78 | Incidence of cerebral ischemic events after discontinuation of clopidogrel in patients with intracranial aneurysms treated with stent-assisted techniques. ( Abel, TJ; Chalouhi, N; Hasan, DM; Jabbour, PM; Kung, DK; Rossen, JD; Thomas, J; Wassef, SN, 2012) |
| "The relationship between biochemical aspirin resistance (AR) and functional outcome of acute ischemic stroke is uncertain." | 7.78 | Relationship between acute stroke outcome, aspirin resistance, and humoral factors. ( Chen, SY; Chiang, YY; Ho, YP; Hsu, HY; Lai, PT; Lee, YS, 2012) |
| "Aspirin is used in ischemic stroke therapy." | 7.77 | Aspirin resistance in patients with acute ischemic stroke. ( Ozben, B; Ozben, S; Ozben, T; Ozer, F; Tanrikulu, AM, 2011) |
| "To examine the effect of proton pump inhibitors on adverse cardiovascular events in aspirin treated patients with first time myocardial infarction." | 7.77 | Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Grove, EL; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Olesen, JB; Selmer, C; Torp-Pedersen, C, 2011) |
| "To test the hypothesis that HRPR after clopidogrel loading is an independent prognostic marker of risk of long-term thrombotic events in patients with acute coronary syndromes (ACS) undergoing an invasive procedure and antithrombotic treatment adjusted according to the results of platelet function tests." | 7.77 | High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. ( Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R, 2011) |
| "Aspirin plus clopidogrel (A+C) may be more effective than aspirin only (AO) acutely after TIA and minor stroke, but the risk of bleeding in the acute phase is uncertain." | 7.76 | Preliminary evidence of a high risk of bleeding on aspirin plus clopidogrel in aspirin-naïve patients in the acute phase after TIA or minor ischaemic stroke. ( Buchan, AM; Chandratheva, A; Geraghty, OC; Kennedy, J; Marquardt, L; Rothwell, PM, 2010) |
| "This study investigated the efficacy of terutroban, a specific thromboxane/prostaglandin endoperoxide receptor antagonist, on stroke incidence in spontaneously hypertensive stroke-prone rats (SHRSP)." | 7.76 | Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, increases survival in stroke-prone rats by preventing systemic inflammation and endothelial dysfunction: comparison with aspirin and rosuvastatin. ( Ballerio, R; Banfi, C; Blanc-Guillemaud, V; Brioschi, M; Castiglioni, L; Gelosa, P; Gianella, A; Guerrini, U; Lerond, L; Nobili, E; Pignieri, A; Sironi, L; Tremoli, E, 2010) |
| "The combination of aspirin and clopidogrel is indicated after acute coronary events and possibly for a short period after TIA or minor ischemic stroke." | 7.76 | Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke. ( Chandratheva, A; Geraghty, OC; Paul, NL; Rothwell, PM, 2010) |
| "The effect of biochemical aspirin resistance (BAR) on ischemic stroke has not been well established." | 7.76 | Biochemical aspirin resistance and recurrent lesions in patients with acute ischemic stroke. ( Jeon, SB; Kang, DW; Kim, BJ; Kim, HJ; Kim, JS; Kwon, SU; Song, HS, 2010) |
| "A rapid and sustained reduction in the frequency of aspirin+clopidogrel use in ischemic stroke and transient ischemic attack was observed after publication of the MATCH trial in the absence of MATCH-specific GWTG-Stroke initiatives and preceding an American Heart Association guideline update." | 7.76 | Rapid change in prescribing behavior in hospitals participating in get with the guidelines-stroke after release of the management of atherothrombosis with clopidogrel in high-risk patients (MATCH) clinical trial results. ( Ellrodt, G; Fonarow, GC; Frankel, MR; Hernandez, AF; Labresh, KA; Liang, L; Menon, BK; Schwamm, LH; Smith, EE, 2010) |
| "In patients with AF, all combinations of warfarin, aspirin, and clopidogrel are associated with increased risk of nonfatal and fatal bleeding." | 7.76 | Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. ( Abildstrøm, SZ; Andersen, SS; Clausen, MT; Fog-Petersen, ML; Folke, F; Gadsbøll, N; Gislason, GH; Hansen, ML; Køber, L; Poulsen, HE; Raunsø, J; Schramm, TK; Sørensen, R; Torp-Pedersen, C, 2010) |
| "The purpose of the study was to establish the frequency of aspirin resistance in patients treated in the Department of Neurology in Zabrze with diagnosed transient ischaemic attack (TIA) or ischaemic stroke who used aspirin in the dose of 150 mg daily." | 7.76 | [Resistance to aspirin in secondary stroke prevention. A pilot study]. ( Kumor, K; Pierzhała, PA; Trautsolt, W; Łabuz-Roszak, B, 2010) |
| "The acute ischemic and stable stroke patients who received aspirin at least 60 mg, at least 7 days and the last dose of aspirin at least 24 hours before blood test for platelet aggregation." | 7.76 | Prevalence of aspirin resistance in stroke patients in Phramongkutklao Hospital. ( Changchit, S; Nidhinandana, S, 2010) |
| "The present study was aimed to investigate the usage of aspirin for the secondary prevention of ischemic stroke, evaluate the correlated factors, and analyze the reasons for not taking and irregularly taking aspirin." | 7.75 | The utilization status of aspirin for the secondary prevention of ischemic stroke. ( Guo, ZL; Hai, H; Jiang, H; Ke, XJ; Peng, H; Xu, K; Yu, YF; Zhang, AH, 2009) |
| "To determine whether arterial cardiovascular events, use of statins and low-dose aspirin were associated with the risk of venous thromboembolism." | 7.75 | Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. ( Baron, JA; Christensen, S; Horvath-Puho, E; Johnsen, SP; Prandoni, P; Søgaard, KK; Sørensen, HT; Thomsen, RW, 2009) |
| "The objective of this study was to evaluate the rate of stroke associated with aspirin and warfarin in routine clinical practice." | 7.75 | How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database. ( Gallagher, AM; Plumb, JM; Rietbrock, S; van Staa, TP, 2009) |
| "A considerable proportion of patients discontinue dipyridamole therapy because of headache." | 7.75 | Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin. ( Algra, A; Halkes, PH; Kappelle, LJ; Koudstaal, PJ; van Gijn, J, 2009) |
| "There are very limited data on the influence of pretreatment with aspirin (ASA) on the etiology of subsequent first-ever ischemic stroke." | 7.75 | Pretreatment with aspirin and etiology of first-ever ischemic stroke in young and middle-aged patients. ( Kouperberg, E; Sprecher, E; Telman, G; Yarnitsky, D, 2009) |
| "We sought to determine whether cyclooxygenase-1 (PTGS1) genotype is associated with the ability of aspirin to inhibit platelet aggregation in patients at risk for stroke." | 7.75 | Influence of cyclooxygenase-1 genotype on ex vivo aspirin response in patients at risk for stroke. ( Brace, LD; Cavallari, LH; Grossi, E; Helgason, CM; Momary, KM; Nutescu, EA; Shapiro, NL; Shord, SS; Viana, MA, 2009) |
| "Previous cost-effectiveness analyses analyzed warfarin for stroke prevention in randomized trial settings." | 7.75 | Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. ( Dewilde, S; Goldhaber, SZ; Monz, BU; Plumb, JM; Singer, DE; Sorensen, SV, 2009) |
| "A subgaleal hematoma (SGH) occurred in a young patient with Sturge-Weber syndrome (SWS) who was treated with aspirin after a mild head trauma." | 7.74 | Subgaleal hematoma in a child with Sturge-Weber syndrome: to prevent stroke-like episodes, is treatment with aspirin advisable? ( Fiumara, A; Greco, F; Pavone, L; Sorge, G, 2008) |
| "Aspirin use may reduce the risk of stroke and coronary heart disease." | 7.74 | Does differential prophylactic aspirin use contribute to racial and geographic disparities in stroke and coronary heart disease (CHD)? ( Cushman, M; Glasser, SP; Howard, G; Howard, VJ; Kleindorfer, D; Prince, V; Prineas, R; You, Z, 2008) |
| "The authors prospectively included acute ischemic stroke/TIA patients who were treated at Thammasat Hospital from August, 2006 to July, 2007 and had already been on aspirin." | 7.74 | Aspirin non-responders in Thai ischemic stroke/TIA patients. ( Dharmasaroja, P, 2008) |
| "Aspirin is an important therapeutic regimen to prevent the recurrent ischemic events or death after acute ischemic stroke." | 7.74 | ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy. ( Cha, JK; Jeon, HW; Kang, MJ, 2008) |
| "Patients from SPORTIF III (n=3407) and SPORTIF V (n=3922) trials were categorized by prior stroke/TIA (21%) versus no prior stroke/TIA (79%) and by treatment group (ximelagatran vs warfarin)." | 7.74 | Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials. ( Akins, PT; Albers, GW; Diener, HC; Feldman, HA; Newman, D; Spitzer, SG; Zoble, RG, 2007) |
| "The present study was carried out to investigate the effect of the combination of an endothelin antagonist TAK-044 and an antiinflammatory agent aspirin in middle cerebral artery (MCA) occlusion model of acute ischemic stroke in rats." | 7.74 | Effect of combination of endothelin receptor antagonist (TAK-044) and aspirin in middle cerebral artery occlusion model of acute ischemic stroke in rats. ( Briyal, S; Gulati, A; Gupta, YK, 2007) |
| "The contribution of genetic factors to aspirin treatment failure (ATF) for secondary prevention is not settled in patients with ischemic stroke." | 7.74 | The BC genotype of the VNTR polymorphism of platelet glycoprotein Ibalpha is overrepresented in patients with recurrent stroke regardless of aspirin therapy. ( Amaro, S; Cervera, A; Chamorro, A; Obach, V; Reverter, JC; Tàssies, D, 2007) |
| "A goal of the Women's Health Study was to evaluate the balance of benefits and risks of low-dose aspirin in the primary prevention of stroke in healthy women." | 7.74 | CON: Should aspirin be used in all women older than 65 years to prevent stroke? ( Buring, JE, 2007) |
| "In clinical practice, early therapy with clopidogrel, in addition, to aspirin in patients with NSTEMI is associated with a significant reduction of the combined endpoint of death, non-fatal reinfarction and non-fatal stroke after one year." | 7.74 | Clopidogrel in addition to aspirin reduces one-year major adverse cardiac and cerebrovascular events in unselected patients with non-ST segment elevation myocardial infarction. ( Bauer, T; Gitt, AK; Gottwik, M; Heer, T; Jünger, C; Köth, O; Senges, J; Wienbergen, H; Zahn, R; Zeymer, U, 2008) |
| "A total of 88 patients taking aspirin daily for the secondary prevention of stroke were included." | 7.74 | Can aspirin resistance be clinically predicted in stroke patients? ( Bang, OY; Choi, YJ; Huh, K; Joo, IS; Lee, PH; Seok, JI; Yoon, JH, 2008) |
| "The relationship between nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and hemorrhagic stroke (HS) remains unclear." | 7.74 | Nonaspirin nonsteroidal anti-inflammatory drugs and hemorrhagic stroke risk: the Acute Brain Bleeding Analysis study. ( Choi, NK; Jeong, SW; Park, BJ; Yoon, BW; Yu, KH, 2008) |
| "The aim of this study was to investigate the relationship between aspirin resistance, ischaemic stroke subtype, stroke severity, and inflammatory cytokines." | 7.74 | Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity. ( Byrne, CD; Englyst, NA; Horsfield, G; Kwan, J, 2008) |
| "Aspirin has been used for secondary prevention of myocardial infarction (MI) in individuals with coronary disease." | 7.74 | Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers. ( Eskola, M; Karhunen, PJ; Mikkelsson, J; Niemela, K; Nikus, K, 2008) |
| "To compare quality-adjusted survival and cost among 3 alternative therapies for patients with chronic atrial fibrillation: ximelagatran, warfarin, and aspirin." | 7.73 | Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. ( Gage, BF; O'Brien, CL, 2005) |
| "To assess the efficacy of aspirin plus extended-release dipyridamole compared with aspirin alone for the prevention of recurrent stroke among high-risk groups." | 7.73 | Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations. ( Diener, HC; Sacco, RL; Sivenius, J, 2005) |
| "The proportional benefit gained from the use of low dose aspirin by the prevention of myocardial infarctions (-389 in men, -321 in women) and ischaemic stroke (-19 in men and -35 in women) is offset by excess gastrointestinal (499 in men, 572 in women) and intracranial (76 in men, 54 in women) bleeding." | 7.73 | Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70. ( Bertram, M; Liew, D; Nelson, MR; Vos, T, 2005) |
| "We aimed to study the timing of aspirin prescription in ischaemic stroke comparing patients admitted to an acute stroke unit (ASU) directly or via a general medical ward." | 7.73 | Timing of aspirin and secondary preventative therapies in acute stroke: support for use of stroke units. ( MacLeod, MJ; Reid, J; Williams, D, 2005) |
| "Vascular events commonly recur in stroke patients on aspirin, and may reflect incomplete inhibition of platelet function with aspirin therapy." | 7.73 | Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. ( Brown, MM; Harrison, P; Lawrie, AS; Machin, SJ; Mackie, IJ; McCabe, DJ; Purdy, G; Sidhu, PS, 2005) |
| "To study the discontinuation of aspirin therapy as a risk factor for ischemic stroke (IS)." | 7.73 | Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. ( Bezerra, DC; Bogousslavsky, J; Maulaz, AB; Michel, P, 2005) |
| "Eligibility for tissue plasminogen activator (tPA), aspirin, stroke unit management and neuroprotection were assessed among incident stroke cases within the community-based North East Melbourne Stroke Incidence Study." | 7.73 | Stroke units, tissue plasminogen activator, aspirin and neuroprotection: which stroke intervention could provide the greatest community benefit? ( Dewey, HM; Donnan, GA; Gilligan, AK; Macdonell, RA; Sturm, JW; Thrift, AG, 2005) |
| "To determine the effect of access to ambulatory anticoagulation management services (AMS) on the rate of warfarin use in patients with atrial fibrillation." | 7.73 | Effect of access to anticoagulation management services on warfarin use in patients with atrial fibrillation. ( Burkiewicz, JS, 2005) |
| "Regular aspirin use was associated with increasing age, male gender, lower educational attainment, hypertension, diabetes, overweight, and histories of myocardial infarction, coronary heart disease, and stroke." | 7.73 | Racial differences in the use of aspirin: an important tool for preventing heart disease and stroke. ( Brown, DW; Croft, JB; Giles, WH; Greenlund, KJ; Shepard, D, 2005) |
| " This phenomenon may explain the clinical advantages of Aggrenox, known to reduce ischemic events in post stroke patients as proven in clinical trials, though an additional antithrombotic benefit beyond the platelet inhibition by aspirin alone." | 7.73 | Dipyridamole decreases protease-activated receptor and annexin-v binding on platelets of post stroke patients with aspirin nonresponsiveness. ( Atar, D; Hanley, D; Jilma, B; Malinin, A; Pokov, A; Serebruany, V; Ziai, W, 2006) |
| "We studied outpatients of 5 neurological ambulatory centers in an urban city, Valencia, all with a history of ischemic stroke who had received aspirin for at least 6 months." | 7.73 | Adherence to aspirin in secondary prevention of ischemic stroke. ( Ferrer, JM; Lago, A; Pareja, A; Ponz, A; Santos, MT; Tembl, JI; Vallés, J, 2006) |
| "Aspirin and statins are both effective for primary prevention of coronary heart disease (CHD), but their combined use has not been well studied." | 7.73 | Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. ( Earnshaw, S; Pignone, M; Pletcher, MJ; Tice, JA, 2006) |
| "The purpose of this study was to determine safety and tolerability of clopidogrel in children with arterial ischemic stroke (AIS)." | 7.73 | The risks and safety of clopidogrel in pediatric arterial ischemic stroke. ( Allen, A; deVeber, G; Hune, S; MacGregor, D; Rafay, MF; Soman, T, 2006) |
| "There is substantial interpatient variability in response to aspirin after an ischemic stroke or transient ischemic attack (TIA), as assessed by ex vivo effects of aspirin on platelet aggregation." | 7.73 | Sex difference in the antiplatelet effect of aspirin in patients with stroke. ( Brace, LD; Cavallari, LH; Helgason, CM; Nutescu, EA; Viana, MA, 2006) |
| "Warfarin can be more effective than aspirin for stroke prevention in elderly patients with atrial fibrillation, but in clinical practice, the usage rate of warfarin still remains low with insufficient monitoring." | 7.73 | [Comparative study of warfarin and aspirin for stroke prevention in elderly patients with atrial fibrillation]. ( Han, W; Shen, DT; Wang, YM, 2006) |
| "Millions of people around the world regularly consume aspirin, but its value in determining stroke severity is still not clear." | 7.73 | Does prior aspirin use reduce stroke mortality? ( Demirkaya, M; Karlikaya, G; Orken, C; Tireli, H; Varlbas, F, 2006) |
| "Our study demonstrates an increased risk of major bleeding in unselected patients receiving combination therapy with ASA and clopidogrel after UAP or NSTEMI." | 7.73 | [Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome]. ( Kjaer, J; Larsen, CH; Mickley, H; Møller, JE; Poulsen, TS, 2006) |
| "Aspirin is used in combination with anticoagulant therapy in patients with atrial fibrillation (AF), but evidence of additional efficacy is not available." | 7.73 | Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. ( Chaparro, S; Connolly, SJ; Flaker, GC; Goldman, S; Gruber, M; Halinen, MO; Halperin, JL; Horrow, J; Vahanian, A, 2006) |
| "The authors describe course and outcome of eight patients with ischemic stroke as the first thrombotic manifestation of antiphospholipid syndrome who received low-dose aspirin as prophylactic treatment." | 7.72 | Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome. ( de Groot, PG; Derksen, RH; Kappelle, LJ, 2003) |
| "Two groups of patients were included: 1) patients that have suffered 1 stroke event and were thereafter under continuous treatment with aspirin 75-160 mg once daily (n=17); 2) patients that have suffered at least 2 stroke events, and aspirin 75-160 mg was prescribed after the 1(st) event (n=17)." | 7.72 | Increased sensitivity to ADP-aggregation in aspirin treated patients with recurrent ischemic stroke? ( Hillarp, A; Lethagen, S; Mattiasson, I, 2003) |
| "Aspirin is a common antiplatelet drug used in the prevention of ischemic stroke due to its inhibitory effect on platelet cyclooxygenase-1 (Cox-1)." | 7.72 | Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke. ( Hillarp, A; Lethagen, S; Mattiasson, I; Palmqvist, B; Villoutreix, BO, 2003) |
| "In part III of a series of papers on epidemiology and drug prevention of stroke and other thromboembolic complications of atrial fibrillation the authors present data on clinical pharmacology of aspirin as well as discussion of results of randomized trials in which cerebroprotective efficacy and safety of the use of aspirin for primary and secondary prevention of thromboembolism was studied in comparison with placebo and warfarin." | 7.72 | [Stroke and Other Thromboembolic Complications of Atrial Fibrillation. Part III. Prevention With Aspirin]. ( Batyraliev, TA; Kiktev, VG; Pershukov, IV; Preobrazhenskiĭ, DV; Sidorenko, BA, 2004) |
| "To assess the cost effectiveness of aspirin 25 mg plus dipyridamole 200 mg twice daily in the secondary prevention of ischaemic stroke, according to the French social security perspective, using efficacy data from the second European Stroke Prevention Study (ESPS-2)." | 7.72 | Economic assessment of the secondary prevention of ischaemic stroke with dipyridamole plus aspirin (Aggrenox/Asasantin) in France. ( Marissal, JP; Selke, B, 2004) |
| "Aspirin is widely used as an antiplatelet drug in patients with coronary heart disease." | 7.72 | Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. ( Abdelnoor, M; Arnesen, H; Pettersen, AA; Seljeflot, I, 2004) |
| "Aspirin has been shown to reduce the risk of myocardial infarction and stroke." | 7.71 | Effect of increasing doses of aspirin on platelet aggregation among stroke patients. ( Bitanga, ES; Florento, L; Gan, R; Teleg, RA, 2002) |
| "Epistaxis is a risk factor for ICH in middle-aged and elderly people, both independently and combined with the use of aspirin." | 7.71 | Use of aspirin, epistaxis, and untreated hypertension as risk factors for primary intracerebral hemorrhage in middle-aged and elderly people. ( Hillbom, M; Juvela, S; Saloheimo, P, 2001) |
| "The objective of the study was to assess the association between aspirin use and the risk of stroke in a population-based study in the elderly." | 7.71 | Aspirin use and risk of stroke in the elderly: the Rotterdam Study. ( Bots, ML; Breteler, MM; Hofman, A; Koudstaal, PJ; Vokó, Z, 2001) |
| " Using a nested case-control design, we measured urinary 11-dehydro thromboxane B2 levels, a marker of in vivo thromboxane generation, in 488 cases treated with aspirin who had myocardial infarction, stroke, or cardiovascular death during 5 years of follow-up and in 488 sex- and age-matched control subjects also receiving aspirin who did not have an event." | 7.71 | Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. ( Eikelboom, JW; Hirsh, J; Johnston, M; Weitz, JI; Yi, Q; Yusuf, S, 2002) |
| "Large intervention studies suggest that aspirin may reduce mortality when given to patients who present with strokes or transient ischemic attacks." | 7.70 | Does prior use of aspirin affect outcome in ischemic stroke? ( Kalra, L; Perez, I; Smithard, DG; Sulch, D, 2000) |
| "The value of warfarin in preventing stroke in patients with chronic atrial fibrillation is well established." | 7.70 | Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. ( Almoznino-Sarafian, D; Alon, I; Chachashvily, S; Cohen, N; Gorelik, O; Koopfer, M; Litvinjuk, V; Modai, D; Shteinshnaider, M, 2000) |
| "The goal of this health economic analysis was to asses the cost-effectiveness of a fixed combination of aspirin plus extended-release dipyridamole (ASA/ER-DP) or clopidogrel compared with ASA monotherapy for prevention of recurrent ischemic stroke." | 7.70 | Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis. ( Gondek, K; Shah, H, 2000) |
| "The recommended treatment of ischaemic stroke patients with atrial fibrillation (AF) is anticoagulation therapy with warfarin sodium and if this is contraindicated then aspirin should be used." | 7.70 | Which acute stroke patients with atrial fibrillation are prescribed warfarin therapy? Results from one-year's experience in Dundee. ( Craig, J; Goudie, BM; MacWalter, RS, 2000) |
| "Covert brain infarcts are associated with important neurological morbidity." | 7.11 | Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy. ( Ameriso, SF; Bereczki, D; Berkowitz, SD; Damgaard, D; Engelter, ST; Fiebach, JB; Gagliardi, RJ; Hart, RG; Kasner, SE; Mikulik, R; Muir, KW; Mundl, H; O'Donnell, MJ; Pearce, LA; Perera, KS; Puig, J; Saad, F; Shamalov, N; Sharma, M; Shoamanesh, A; Smith, EE; Toni, DS; Veltkamp, RC; Yoon, BW, 2022) |
| "Methods- Carotid atherosclerosis was analyzed either as the presence of mild (ie, 20%-49%) atherosclerotic stenosis or, separately, as the presence of carotid plaque." | 6.90 | Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis. ( Amarenco, P; Berkowitz, SD; Bornstein, N; Camps-Renom, P; Connolly, SJ; Cucchiara, B; Gagliardi, RJ; Hart, RG; Korompoki, E; Lang, W; Lavados, P; Makaritsis, K; Marti-Fabregas, J; Meseguer, E; Milionis, H; Mundl, H; Ntaios, G; Papavasileiou, V; Siegler, JE; Swaminathan, B; Vemmos, K, 2019) |
| "The risk of bleeding is a major concern when oral anticoagulation is required to prevent stroke, and concomitant therapy with antiplatelet agents is required to minimize recurrent ischemic events." | 6.87 | An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rat ( Alexander, JH; Darius, H; Goodman, SG; Granger, CB; Liaw, D; Lopes, RD; Mehran, R; Vora, AN; Windecker, S, 2018) |
| "Patients with API (lacunar infarcts or branch atheromatous disease) admitted within 48 hours after onset were enrolled." | 6.82 | [Argatroban, Aspirin, and Clopidogrel Combination Therapy for Acute Penetrating Artery Infarction: A Pilot Study]. ( Kobayashi, Y; Mano, T; Matsuo, K; Nishi, R, 2016) |
| "The primary outcome is IS recurrence." | 6.80 | Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. ( Hoshino, H; Kimura, K; Minematsu, K; Naritomi, H; Origasa, H; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2015) |
| "Despite improvements in treatment, stroke still carries a high death toll and disability in Asia." | 6.76 | The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial. ( Horie, Y; Ikeda, Y; Uchiyama, S; Urano, Y; Yamaguchi, T, 2011) |
| "Fatal bleeding was low and did not differ between groups." | 6.76 | Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bassand, JP; Becker, RC; Budaj, A; Cornel, JH; French, J; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Lassila, R; Lopez-Sendon, J; Mahaffey, KW; Storey, RF; Wallentin, L; Wojdyla, DM, 2011) |
| " These results suggest that administration of aspirin and cilostazol is safe for acute ischemic stroke." | 6.76 | Pilot study of the safety of starting administration of low-dose aspirin and cilostazol in acute ischemic stroke. ( Fujita, K; Higuchi, O; Kamezaki, T; Komatsu, Y; Kujiraoka, Y; Matsumura, A; Sato, N; Suzuki, K, 2011) |
| "Terutroban is a specific TP receptor antagonist with antithrombotic, antivasoconstrictive, and antiatherosclerotic properties, which may be of interest for the secondary prevention of ischemic stroke." | 6.74 | Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with ( Amarenco, P; Bousser, MG; Chamorro, A; Fisher, M; Ford, I; Fox, K; Hennerici, MG; Mattle, HP; Rothwell, PM, 2009) |
| " The number of patients with adverse events and bleeding complications, and their severity, were significantly greater in the triple therapy group (p<0." | 6.73 | A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. ( Bath, PM; England, T; Gray, LJ; Sare, GM; Sprigg, N; Willmot, MR; Zhao, L, 2008) |
| "Aspirin resistance has been shown to be a significant risk factor for recurrent cardiovascular ischaemic events." | 6.73 | A pilot study of resistance to aspirin in stroke patients. ( Bennett, D; Davis, SM; Eccleston, D; Macgregor, L; Yan, B, 2008) |
| " Ten normal volunteer subjects underwent 3 randomized treatment sessions: aspirin 325 mg alone, ibuprofen 400 mg alone, and ibuprofen 400 mg, followed by dosing with aspirin 325 mg 2 hours thereafter." | 6.73 | Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis. ( Bates, V; Gengo, FM; Gengo, MF; Mager, DE; Rainka, M; Robson, M; Rubin, L, 2008) |
| "Bleedings were documented in 19 versus four patients (W/A 5." | 6.71 | Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation. ( Edvardsson, N; Juul-Möller, S; Omblus, R; Pehrsson, K, 2003) |
| "Piracetam was significantly superior to ASA in the secondary endpoint (P=0." | 6.69 | Piracetam versus acetylsalicylic acid in secondary stroke prophylaxis. A double-blind, randomized, parallel group, 2 year follow-up study. ( Evers, S; Fischer, M; Grotemeyer, KH; Husstedt, IW, 2000) |
| "Main outcomes were stroke recurrence and major bleeding." | 6.66 | Aspirin or anticoagulation after cryptogenic stroke with patent foramen ovale: systematic review and meta-analysis of randomized controlled trials. ( Calabresi, P; Cupini, LM; Eusebi, P; Giannandrea, D; Ricci, S; Romoli, M, 2020) |
| "Recurrent stroke is common immediately following a transient ischemic attack (TIA) or ischemic stroke." | 6.61 | Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials. ( Abdalla, A; Ahmed, S; Al Qasmi, M; Bachuwa, G; Bhatt, DL; Chahine, A; Hassan, M; Haykal, T; Kheiri, B; Osman, M; Swaid, B, 2019) |
| "Aspirin has a complex matrix of benefits and risks, and its use in primary prevention requires individualized decision-making." | 6.58 | Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach. ( Ames, JM; Dugani, S; Manson, JE; Mora, S, 2018) |
| "Stroke is one of the leading causes of death." | 6.55 | Genetic Signatures in Ischemic Stroke: Focus on Aspirin Resistance. ( Chaurasia, P; Munshi, A; Singh, S; Vasudeva, K, 2017) |
| "0) combined with ASA (mean dose ≥100 mg/day) and ASA." | 6.55 | Efficacy and safety of aspirin combined with warfarin after acute coronary syndrome : A meta-analysis. ( Huang, X; Li, J; Li, L; Shen, C; Wu, C; Zhang, P; Zhang, W, 2017) |
| "5, and aspirin was administered at a dosage of 75 to 325 mg/d." | 6.52 | Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis. ( Chen, KP; Zhang, JT; Zhang, S, 2015) |
| " Although administration of antiplatelet agents has been confirmed to be one of the major approaches for secondary prevention of noncardioembolic stroke, the short-term or long-term use of aspirin plus clopidogrel for secondary stroke prevention remains to be controversial." | 6.52 | Dual antiplatelet therapy with clopidogrel and aspirin for secondary stroke prevention. ( Chen, W; Wang, Y, 2015) |
| "Aspirin is a well-established medication in the treatment of atherothrombotic vascular disease." | 6.43 | Aspirin resistance in stroke: 2004. ( Sas, K; Sztriha, LK; Vecsei, L, 2005) |
| "Warfarin and aspirin are used to prevent stroke in patients with atrial fibrillation (AF)." | 6.27 | Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. ( Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M, 2013) |
| "We sought to derive and internally validate a simple and easily applied clinical prediction rule to identify patients with nonvalvular atrial fibrillation (AF) whose stroke risk while taking aspirin is, irrespective of age, low enough that oral anticoagulation therapy is unnecessary." | 6.20 | A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. ( Gullov, AL; Hart, RG; Hellemons, BS; Koefed, BG; Koudstaal, PJ; Laupacis, A; Petersen, P; van Walraven, C; Wells, GA, 2003) |
| "The mainstay of treatment for unstable coronary artery disease (UCAD) currently consists of antithrombotic therapy with aspirin plus unfractionated heparin (UFH), together with anti-ischemic treatment with beta blockers and nitrates." | 6.19 | Long-term management--the way forward? ( Wallentin, L, 2000) |
| "A previous randomized study showed that dual antiplatelet therapy (DAPT) with aspirin and cilostazol is not superior to aspirin monotherapy for patients with acute non-cardioembolic stroke; however, the reason for this remains uncertain." | 5.69 | Tachycardia Changes Increase Neurological Deterioration in Patients with Acute Non-Cardioembolic Stroke: An ADS Post-Hoc Analysis. ( Aoki, J; Fujimoto, S; Kimura, K; Matsuzono, K; Ozawa, T, 2023) |
| "We compared the risk of recurrent ischemic stroke, vascular events, and major bleeding between DAPT with cilostazol plus aspirin or clopidogrel and aspirin or clopidogrel alone in patients with ischemic stroke between 8 and 180 days before starting trial treatment and ECAS or without arterial stenosis." | 5.69 | Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial. ( Hoshino, H; Kimura, K; Kitagawa, K; Minematsu, K; Okamura, S; Omae, K; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2023) |
| "This trial investigates the efficacy and safety of tirofiban compared with aspirin for acute ischemic stroke within 24 h after symptom onset." | 5.69 | RESCUE BT 2, a multicenter, randomized, double-blind, double-dummy trial of intravenous tirofiban in acute ischemic stroke: Study rationale and design. ( Hu, J; Huang, J; Kong, W; Li, F; Li, L; Liu, S; Luo, W; Nogueira, RG; Qiu, Z; Sang, H; Saver, JL; Song, J; Tian, Y; Yang, J; Yang, Q; Zi, W, 2023) |
| "THEMIS is a double-blind, randomized trial of 19,220 patients with diabetes mellitus and stable coronary artery disease (CAD) comparing ticagrelor to placebo, in addition to aspirin." | 5.69 | External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Hea ( Abtan, J; Bhatt, DL; Bueno, H; Ducrocq, G; Eagle, KA; Elbez, Y; Fox, K; Goto, S; Harrington, RA; Leiter, LA; Lev, E; Mehta, SR; Ohman, EM; Pais, P; Petrov, I; Simon, T; Sinnaeve, PR; Smith, SC; Steg, PG; Wilson, P, 2023) |
| " Its efficacy may exceed aspirin in improving clinical outcomes in patients with acute ischemic stroke who are ineligible for rt-PA." | 5.69 | A randomized pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke. ( Aref, HM; El-Khawas, H; Elbassiouny, A; Roushdy, TM; Shokri, HM; Zeinhom, MG, 2023) |
| "This study was performed to investigate whether ticagrelor/aspirin versus clopidogrel/aspirin can further reduce the residual risk of stroke recurrence in patients with positive diffusion-weighted imaging (DWI) in the High-Risk Patients with Acute Nondisabling Cerebrovascular Events II (CHANCE-2) trial." | 5.69 | Genotype-Guided Dual Antiplatelet Use for Transient Ischemic Attack and Minor Stroke by Imaging Status: Subgroup Analysis of the CHANCE-2 Trial. ( Bath, PM; Jiang, Y; Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Wang, A; Wang, Y; Xie, X; Xu, Q; Zhao, X, 2023) |
| "In patients with lacunar stroke, DAPT using cilostazol had significant benefits in reducing recurrent ischemic stroke incidence compared with SAPT without increasing the risk of severe or life-threatening bleeding." | 5.69 | Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial. ( Hoshino, H; Houkin, K; Kimura, K; Matsumoto, M; Minematsu, K; Naritomi, H; Nishiyama, Y; Okada, Y; Origasa, H; Otsuka, T; Sakai, N; Terayama, Y; Tomimoto, H; Tominaga, T; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T; Yasuda, S, 2023) |
| "In this prospective, open-label, multi-centre, 2 × 2 factorial, randomized, controlled study, 1,800 patients with diabetes mellitus and multi-vessel disease (inclusion criteria similar to FREEDOM trial) with indication for coronary revascularization will be randomly assigned to Supraflex Cruz or Xience stents and also to ticagrelor- or prasugrel- based antiplatelet strategies." | 5.69 | Rationale and design of the TUXEDO-2 India study: Ultra-Thin strUt Supraflex Cruz versus XiencE in a Diabetic pOpulation with multi-vessel disease-2. ( Abhaichand, R; Agrawal, DK; Arambam, P; Bangalore, S; Banker, D; Chandra, S; Garg, R; Kaul, U; Khan, A; Koduganti, SC; Mody, R; Moorthy, N; Parida, AK; Reddy, KMK; Sarma, PR; Sharma, R; Sinha, SK, 2023) |
| "The optimal duration of dual antiplatelet therapy (DAPT) with clopidogrel-aspirin for the large artery atherosclerotic (LAA) stroke subtype has been debated." | 5.69 | Dual antiplatelet Use for extended period taRgeted to AcuTe ischemic stroke with presumed atherosclerotic OrigiN (DURATION) trial: Rationale and design. ( Bae, HJ; Cha, JK; Cho, KH; Cho, YJ; Choi, JC; Choi, JK; Choi, KH; Gorelick, PB; Gwak, DS; Han, MK; Hong, JH; Hong, KS; Jeong, HB; Kang, CH; Kang, J; Kang, K; Kim, BJ; Kim, C; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Kim, JY; Kim, WJ; Kim, YS; Kwon, DH; Kwon, JH; Lee, BC; Lee, J; Lee, K; Lee, M; Lee, SH; Lee, SJ; Norrving, B; Oh, MS; Park, H; Park, HK; Park, JM; Park, KY; Park, MS; Park, SS; Park, TH; Shin, DI; Sohn, SI; Yu, KH; Yum, KS, 2023) |
| "The aim of this study was to determine the effect of smoking status on subsequent stroke risk in patients with minor ischemic stroke or TIA and to determine whether smoking modifies the effect of clopidogrel-based DAPT on subsequent stroke risk." | 5.69 | Subsequent ischemic stroke and tobacco smoking: A secondary analysis of the POINT trial. ( de Havenon, A; Easton, JD; Furie, KL; Henninger, N; Johnston, SC; Kim, A; Lang, AE; Mac Grory, B; Shu, L; Yaghi, S, 2023) |
| "COMPASS trial patients with IAD <15 mmHg and IAD >15 mmHg were compared with respect to thirty-month incidence risk of: 1) composite of stroke, myocardial infarction, or cardiovascular death (MACE), 2) composite of acute limb-ischemia or vascular amputation (MALE), 3) composite of MACE or MALE, and 4) effects of treatment with the combination versus aspirin alone on these outcomes." | 5.69 | The predictive value of interarm systolic blood pressure differences in patients with vascular disease: Sub-analysis of the COMPASS trial. ( Aboyans, V; Anand, S; Bosch, J; Connolly, S; Eikelboom, J; Muehlhofer, E; Qadura, M; Syed, MH; Yusuf, S, 2023) |
| "Aspirin is recommended for secondary stroke prevention in patients with moderate-to-severe ischaemic stroke but can lead to gastrointestinal intolerance and bleeding." | 5.69 | Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial. ( Bath, PM; Dong, Q; Feng, Y; Huang, X; Jiang, Y; Jin, A; Jing, J; Johnston, SC; Li, H; Li, X; Li, Z; Lin, J; Liu, B; Liu, L; Liu, Q; Meng, X; Pan, Y; Suo, Y; Wang, Y; Xie, X; Xiong, Y; Xu, A; Yang, H; Yuan, B; Zhao, J; Zhao, X; Zhou, Y; Zhu, H, 2023) |
| "The Clopidogrel With Aspirin in High-Risk Patients With Acute Nondisabling Cerebrovascular Events II (CHANCE-2) trial showed that ticagrelor-aspirin combination therapy reduced the risk of stroke compared with a clopidogrel-aspirin combination among carriers of CYP2C19 loss-of-function (LOF) alleles after a transient ischemic attack (TIA) or minor ischemic stroke." | 5.69 | Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial. ( Bath, PM; Jiang, Y; Jing, J; Johnston, SC; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, Y; Xie, X; Xu, A; Xu, Q; Zhao, X, 2023) |
| "In this secondary analysis of a randomized controlled trial involving patients with minor ischemic stroke or TIA, compared with clopidogrel-ASA, patients with obesity received more clinical benefit from ticagrelor-ASA therapy than those without obesity." | 5.69 | Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack. ( Jiang, Y; Jing, J; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Tian, X; Wang, A; Wang, Y; Xie, X; Zhang, J; Zhao, X, 2023) |
| "To establish the risks of ischemic stroke and intracranial bleeding among healthy older people receiving daily low-dose aspirin." | 5.69 | Low-Dose Aspirin and the Risk of Stroke and Intracerebral Bleeding in Healthy Older People: Secondary Analysis of a Randomized Clinical Trial. ( Cloud, GC; Donnan, GA; Eaton, CB; Fitzgerald, SM; Lockery, J; McNeil, JJ; Murray, AM; Nelson, MR; Newman, AB; Reid, CM; Shah, RC; Thao, LTP; Tran, C; Williamson, JD; Wolfe, R; Woods, RL, 2023) |
| "In this post hoc secondary analysis of the ADAPTABLE randomized clinical trial, enteric-coated aspirin was not associated with significantly higher risk of myocardial infarction, stroke, or death or with lower bleeding risk compared with uncoated aspirin, regardless of dose, although a reduction in bleeding with enteric-coated aspirin cannot be excluded." | 5.69 | Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial. ( Benziger, CP; Effron, MB; Farrehi, PM; Girotra, S; Gupta, K; Harrington, RA; Hernandez, AF; Jain, SK; Jones, WS; Knowlton, KU; Marquis-Gravel, G; Muñoz, D; Pepine, CJ; Polonsky, TS; Re, RN; Roe, MT; Rothman, RL; Sleem, A; Stebbins, A; Whittle, J; Wruck, LM, 2023) |
| "The beneficial effect of clopidogrel over aspirin monotherapy was consistent regardless of clinical risk or relative ischemic and bleeding risks compared with aspirin monotherapy." | 5.69 | Comparison of Antiplatelet Monotherapies After Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks. ( Ahn, HS; Cha, KS; Choi, HH; Han, JK; Hur, SH; Hwang, D; Jo, SH; Kang, J; Kim, HS; Koo, BK; Lee, NH; Park, KW; Ryu, JK; Shin, ES; Suh, IW; Woo, SI; Yang, HM; Yang, S, 2023) |
| "In the NAVIGATE ESUS trial (New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial Versus ASA to Prevent Embolism in Embolic Stroke of Undetermined Source), an MRI substudy was carried out at 87 sites in 15 countries." | 5.51 | Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial. ( Ameriso, SF; Barlinn, J; Berkowitz, SD; Connolly, SJ; Coutts, SB; Damgaard, D; Hart, RG; Lambeck, J; Messé, SR; Modrau, B; Mundl, H; Pearce, LA; Perera, KS; Rha, JH; Romano, M; Saad, F; Sharma, M; Shoamanesh, A; Smith, EE; Yoon, BW, 2022) |
| "The aim of this study is to investigate the effect of gradual dipyridamole titration and the incidence of dipyridamole-induced headache in patients with ischemic stroke or transient ischemic attack (TIA)." | 5.51 | Effects of Dose Titration on Dipyridamole-Induced Headache: A Randomized, Double-Blind Clinical Trial. ( Cha, JK; Chang, DI; Chang, JY; Chung, JW; Hong, KS; Jung, KH; Kang, MK; Kim, BK; Kim, HY; Lee, KY; Lee, SJ; Park, JM; Park, MS; Rha, JH; Shin, DI; Yoon, BW, 2022) |
| "In the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trial, acute treatment with clopidogrel-aspirin was associated with significantly reduced risk of recurrent stroke." | 5.51 | Infarct on Brain Imaging, Subsequent Ischemic Stroke, and Clopidogrel-Aspirin Efficacy: A Post Hoc Analysis of a Randomized Clinical Trial. ( de Havenon, A; Easton, JD; Henninger, N; Johnston, SC; Kim, AS; Kvernland, A; Liberman, AL; Mac Grory, B; Rostanski, SK; Yaghi, S, 2022) |
| "The NAVIGATE-ESUS trial evaluated rivaroxaban compared to aspirin in preventing recurrent stroke in 7213 participants." | 5.51 | Functional Abilities of an International Post-Stroke Population: Standard Assessment of Global Everyday Activities (SAGEA) Scale. ( Bosch, J; Canavan, M; Hart, RG; Mikulík, R; O'Donnell, MJ; Pearce, LA; Sharma, M; Whiteley, WN, 2022) |
| "In this prospective cohort study, we randomly assigned patients with PFO who had a cryptogenic stroke, in a 1:1 ratio, to dabigatran or aspirin group." | 5.51 | Dabigatran versus aspirin for stroke prevention after cryptogenic stroke with patent foramen ovale: A prospective study. ( Cai, D; Chen, S; He, J; Huang, P; Lai, Y; Sun, H; Wu, Q; Zhou, L, 2022) |
| "Aspirin and unfractionated heparin are often used during endovascular stroke treatment to improve reperfusion and outcomes." | 5.51 | Safety and efficacy of aspirin, unfractionated heparin, both, or neither during endovascular stroke treatment (MR CLEAN-MED): an open-label, multicentre, randomised controlled trial. ( Beenen, LFM; Berkhemer, O; Boiten, J; Bokkers, RPH; Boukrab, I; Chalos, V; Coutinho, JM; de Laat, KF; de Ridder, I; den Hertog, HM; Dippel, DWJ; Elgersma, O; Emmer, BJ; Gerrits, D; Gons, RAR; Hammer, S; Hofmeijer, J; Jenniskens, SFM; Kerkhoff, H; Koudstaal, PJ; Krietemeijer, M; Lingsma, HF; Lycklama, G; Majoie, CBLM; Manschot, S; Martens, J; Meijer, FJA; Nieboer, D; Postma, AA; Remmers, M; Roos, YBWEM; Roosendaal, SD; Roozenbeek, B; Rozeman, A; Schonewille, W; Staals, J; Tolhuisen, M; Truijman, MTB; Tuladhar, AM; Uyttenboogaart, M; van de Graaf, RA; van den Berg, R; van den Wijngaard, I; van der Hoorn, A; van der Lugt, A; van der Schaaf, I; van der Sluijs, PM; van der Steen, W; van der Worp, HB; van Dijk, LC; van Doormaal, PJ; van Es, ACGM; van Hasselt, B; van Oostenbrugge, RJ; van Tuijl, J; van Voorst, H; van Zwam, W; Vos, D; Vos, JA; Wolff, L; Yo, LSF; Yoo, AJ; Zinkstok, S, 2022) |
| "Irrespective of the presence of DM, CKD, and their combination, ticagrelor monotherapy reduced the risk of bleeding without a significant increase in ischaemic events compared with ticagrelor plus aspirin." | 5.51 | Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. ( Angiolillo, DJ; Baber, U; Briguori, C; Cao, D; Cohen, DJ; Collier, T; Dangas, G; Dehghani, P; Dudek, D; Escaned, J; Gibson, M; Gil, R; Huber, K; Kaul, U; Kornowski, R; Krucoff, MW; Kunadian, V; Mehran, R; Mehta, S; Moliterno, DJ; Nicolas, J; Ohman, EM; Pivato, CA; Pocock, S; Sardella, G; Sartori, S; Sharma, SK; Shlofmitz, R; Weisz, G; Witzenbichler, B; Zhang, Z, 2022) |
| "To test whether indobufen is non-inferior to aspirin in reducing the risk of new stroke at 3 months in patients with moderate to severe ischaemic stroke." | 5.51 | Indobufen versus aspirin in acute ischaemic stroke (INSURE): rationale and design of a multicentre randomised trial. ( Bath, PM; Chen, W; Dong, Q; Jiang, Y; Jing, J; Johnston, SC; Li, H; Lin, J; Meng, X; Pan, Y; Wang, Y; Xu, AD, 2022) |
| " Low-dose aspirin is of proven benefit in the secondary prevention of myocardial infarction (MI) and stroke in people with pre-existing CVD." | 5.51 | Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiov ( Dumbleton, J; Fitzmaurice, D; Fraser, SD; Fuat, A; Gallagher, H; Griffith, KE; Hawkey, CJ; Henderson, RA; Lord, J; Lown, M; Maishman, T; Moore, MV; Roderick, PJ; Stevens, P; Stevenson, D; Taal, MW; Whitehead, A, 2022) |
| " Aspirin increased major or CRNM bleeding, particularly in patients without prior stroke/TIA/TE." | 5.51 | Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial. ( Alexander, JH; Aronson, R; Bahit, MC; Berwanger, O; Dombrowski, KE; Goodman, SG; Granger, CB; Halvorsen, S; Jordan, JD; Kolls, BJ; Li, Z; Lopes, RD; Mehran, R; Thomas, L; Vinereanu, D; Vora, AN; Windecker, S; Wojdyla, DM, 2022) |
| "Ticagrelor-aspirin was associated with reduced risk of new stroke in patients without hypertension (32 [4." | 5.51 | Effect of Hypertension on Efficacy and Safety of Ticagrelor-Aspirin Versus Clopidogrel-Aspirin in Minor Stroke or Transient Ischemic Attack. ( Bath, PM; Chen, G; Huang, P; Jiang, Y; Jing, J; Johnston, SC; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Tian, X; Wang, A; Wang, F; Wang, Y; Xie, X; Zhao, X; Zuo, Y, 2022) |
| "Dual antiplatelet therapy (DAPT) with ticagrelor and aspirin has been found to be effective for secondary prevention after minor ischemic stroke or transient ischemic attack (TIA) in individuals who carry CYP2C19 loss-of-function (LOF) alleles; however, uncertainties remain about the time course of benefit and risk with ticagrelor and aspirin in these patients." | 5.51 | Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial. ( Bath, PM; Cheng, J; Jiang, Y; Jin, A; Jing, J; Johnston, SC; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Pan, Y; Wang, Y; Wang, Z; Xie, X; Yang, H; Zhao, X, 2022) |
| "Whether aspirin platelet reactivity affects platelet function and clinical outcomes with different antiplatelet therapies in patients with mild stroke or transient ischemic attack (TIA) remains unclear." | 5.51 | Aspirin platelet reactivity on platelet function and clinical outcome in minor stroke or transient ischemic attack. ( Chen, W; Guo, L; Jiang, L; Liu, L; Pan, Y; Wang, Y; Xu, Y; Yao, D; Zhao, X, 2022) |
| "In high-risk patients with prior CABG, ticagrelor monotherapy reduced bleeding without compromising ischaemic outcomes compared with ticagrelor plus aspirin." | 5.51 | Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study. ( Angiolillo, DJ; Baber, U; Beerkens, FJ; Briguori, C; Cao, D; Claessen, B; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Escaned, J; Gibson, CM; Gil, R; Huber, K; Kastrati, A; Kornowski, R; Krucoff, MW; Kunadian, V; Marx, S; Mehran, R; Mehta, S; Moliterno, DJ; Nicolas, J; Ohman, EM; Pocock, S; Sardella, G; Sartori, S; Sharma, S; Shlofmitz, R; Steg, PG; Weisz, G; Zhang, Z, 2022) |
| "Aspirin, as an typical antiplatelet therapy for secondary stroke prevention, have been proved that can significantly reduce incidence and recurrence of cerebrovascular ischemic events." | 5.51 | To study the mechanism of panax notoginseng in the treatment of aspirin resistance in the secondary prevention of stroke based on TLR4/MyD88/NF-κB signaling pathway: A study protocol. ( Chen, J; Wang, H; Wang, Y; Yuan, J, 2022) |
| "To identify the ischemic stroke and transient ischemic attack (TIA) prevalence related to length of time of discontinuation of antiplatelet or vitamin K antagonist therapy, in a group of inpatients from a specialized neurological hospital in Brazil." | 5.51 | Stroke and transient ischemic attacks related to antiplatelet or warfarin interruption. ( Kowacs, PA; Macuco, ALB; Nascimento, MTMS; Rizelio, V; Sato, HK; Souza, RKM, 2019) |
| "Stroke recurrence and mortality rates in patients receiving aspirin (N=34 679) were compared with those receiving clopidogrel (N=7611) during a 12-month follow-up period." | 5.48 | Comparison Between Aspirin and Clopidogrel in Secondary Stroke Prevention Based on Real-World Data. ( Chang, WL; Chen, CH; Chi, NF; Hsu, CY; Hu, CJ; Jeng, JS; Li, JY; Lien, LM; Lin, CH; Liu, CH; Sun, Y; Wen, CP, 2018) |
| "Aspirin resistance was measured by the PFA-100 system (collagen/epinephrine cartridge) and glycoprotein IIIa P1A1/A2 polymorphism was determined by PCR." | 5.43 | Aspirin resistance in cerebrovascular disease and the role of glycoprotein IIIa polymorphism in Turkish stroke patients. ( Ataç, BF; Bayraktar, N; Can, U; Çelikkol, C; Derle, E; Kibaroğlu, S; Öcal, R; Verdi, H, 2016) |
| "The major result events, included: (1) recurrence of ischemic stroke; (2) hemorrhagic transformation of ischemic stroke; (3) myocardial infarction; (4) the digestive hemorrhage." | 5.43 | [Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy]. ( Gao, P; Hu, YH; Tang, X; Wei, CL; Yang, C; Zhang, YQ, 2016) |
| "Minor stroke and transient ischemic attack are common disorders with high rate of subsequent disabling stroke." | 5.43 | High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome: Subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial. ( Li, J; Lin, J; Liu, L; Meng, X; Wang, A; Wang, C; Wang, Y; Zhao, X, 2016) |
| "In warfarin-treated patients, each 5% LVEF decrement significantly increased the stroke risk (adjusted hazard ratio, 1." | 5.43 | Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial. ( Anker, SD; Buchsbaum, R; Di Tullio, MR; Estol, CJ; Freudenberger, RS; Graham, S; Homma, S; Labovitz, AJ; Levin, B; Lip, GY; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Teerlink, JR; Thompson, JL, 2016) |
| "When aspirin was compared to no treatment, NCB was neutral or negative for both risk strata." | 5.42 | Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. ( Larsen, TB; Lip, GY; Nielsen, PB; Skjøth, F, 2015) |
| "In this open-label, assessor-masked, multicentre, non-inferiority, randomised trial (TALOS-AMI), patients at 32 institutes in South Korea with acute myocardial infarction receiving aspirin and ticagrelor without major ischaemic or bleeding events during the first month after index percutaneous coronary intervention (PCI) were randomly assigned in a 1:1 ratio to a de-escalation (clopidogrel plus aspirin) or active control (ticagrelor plus aspirin) group." | 5.41 | Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. ( Ahn, Y; Chang, K; Choi, YS; Choo, EH; Hwang, BH; Jeon, DS; Jeong, MH; Jeong, YH; Kim, CJ; Kim, HY; Kim, MC; Lee, KY; Park, MW; Seung, KB; Shin, ES; Yim, HW; Yoo, KD, 2021) |
| "Anticoagulation with apixaban after minimally invasive robotic MVRep is safe and has similar rates of bleeding and thromboembolism compared to patients treated with warfarin." | 5.41 | Apixaban for Anticoagulation After Robotic Mitral Valve Repair. ( Arghami, A; Crestanello, JA; Daly, RC; Dearani, JA; King, KS; Macielak, SA; Mazur, PK; Nei, SD; Schaff, HV; Viehman, JK, 2023) |
| "Evidence regarding using acetylsalicylic acid (aspirin) for the prevention of cardiovascular (CV) events in patients with diabetes mellitus (DM) is inconsistent." | 5.41 | Acetylsalicylic Acid (Aspirin) for Primary Prevention of Cardiovascular Events in Patients with Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ( Cheema, AN; Eckstein, J; Lam, A; Liu, S, 2023) |
| " Furthermore, the current evidence seems to support that single-drug antiplatelet can be used as the basic treatment, and new antithrombotic strategies, such as ticagrelor only or aspirin combined with low-dose rivaroxaban are expected to further reduce the incidence of stroke for ICVD patients with PAD." | 5.41 | Early identification and treatment for peripheral arterial disease in patients with ischemic cerebrovascular disease. ( Li, LG; Ma, X, 2023) |
| "Considering MACEs, myocardial infarction, all kinds of stroke, ischemic stroke, and major bleeding, low-dose aspirin plus rivaroxaban 2." | 5.41 | Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis. ( Chen, X; Jiang, L; Liu, C; Su, J; Zheng, N; Zhong, J, 2023) |
| "Single antiplatelet therapy (SAPT) with aspirin or clopidogrel reduces the risk of recurrent ischemic stroke in patients with non-cardioembolic ischemic stroke or TIA." | 5.41 | Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines. ( Alsbrook, DL; Bhatia, K; Carr, KH; Di Napoli, M; Divani, AA; Hinduja, A; Hosseini Farahabadi, M; Jafarli, A; Ladd, LM; McCullough, LD; Ortiz Garcia, JG; Sabbagh, SY; Saver, JL, 2023) |
| "Ticagrelor is slightly better than clopidogrel and aspirin in preventing stroke, especially ischemic stroke, with significant safety risks." | 5.41 | Efficacy and Safety of Ticagrelor versus Aspirin and Clopidogrel for Stroke Prevention in Patients with Vascular Disease: A Systematic Review and Meta-Analysis. ( Chen, Y; Li, D; Liu, S; Ma, X; Zhong, P, 2023) |
| " The incidence of all bleeding events with ticagrelor was higher than that with clopidogrel (RR, 1." | 5.41 | Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials. ( He, X; Li, J; Ma, S; Qiu, M; Qu, X; Wang, Q; Wang, X; Wu, C; Zhang, L, 2023) |
| "The study aimed to evaluate the clinical efficacy of the Huo Xue Hua Yu method combined with aspirin in the treatment of patients with acute cerebral infarction (ACI)." | 5.41 | Clinical Efficacy of the Huo Xue Hua Yu Method Combined with Aspirin in the Treatment of Acute Cerebral Infarction: A Systematic Evaluation and Meta-analysis. ( Chen, C; Liu, X; Ma, F; Tang, Q; Wen, X; Wu, Y, 2023) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel was recommended as the secondary prevention of minor ischemic stroke or transient ischaemic attack (TIA)." | 5.41 | Ticagrelor plus aspirin in patients with minor ischemic stroke and transient ischemic attack: a network meta-analysis. ( Ge, F; Li, M; Lin, H; Shi, J; Yang, Q; Zhang, X, 2023) |
| "5 mg twice daily and aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events (MACE) in patients with chronic coronary artery disease or peripheral artery disease by 24% during a mean follow-up of 23 months." | 5.41 | Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. ( Anand, SS; Berkowitz, SD; Bosch, J; Connolly, SJ; Dagenais, GR; Eikelboom, JW; Fox, KA; Guzik, TJ; Keller, L; Liang, Y; Liu, L; Muehlhofer, E; O'Donnell, M; Shestakovska, O; Yusuf, S; Zhu, J, 2021) |
| "The efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valves and atrial fibrillation or flutter remain uncertain." | 5.41 | A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial. ( Almeida, AP; Ardito, RV; Atik, FA; Barreto, DO; Berwanger, O; Campos, VB; Cavalcante, MA; Cavalcanti, AB; D'Oliveira Vieira, R; Damiani, L; de Barros E Silva, PGM; de Lima, CEB; de Souza Neto, JD; Dos Santos, JRY; Farias, FR; Ferreira, JFM; Figueira, FAMS; Fonseca, FH; Guimarães, HP; Hoffmann-Filho, CR; Junior, RA; Kalil, PSA; Kojima, F; Lamprea, D; Laranjeira, L; Leiria, TLL; Liporace, IL; Lopes, RD; Magalhães, CC; Maldonado, JGA; Mesas, CE; Moisés, VA; Nakagawa, RH; Paiva, MSMO; Paixão, M; Patriota, R; Pavanello, R; Pinto, IM; Precoma, DB; Sampaio, BS; Sampaio, RO; Saraiva, JFK; Silveira, FS; Tarasoutchi, F; Zilli, AC, 2021) |
| "In the AFIRE trial, rivaroxaban monotherapy was noninferior to combination therapy with rivaroxaban and an antiplatelet agent for thromboembolic events or death, and superior for major bleeding in patients with atrial fibrillation (AF) and stable coronary artery disease." | 5.41 | Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis. ( Akao, M; Ako, J; Hagiwara, N; Hirayama, A; Kaikita, K; Kimura, K; Matoba, T; Matsui, K; Miyauchi, K; Nakamura, M; Ogawa, H; Yasuda, S, 2021) |
| "It is the common clinical practice to prescribe indefinite aspirin for patients with non-valvular atrial fibrillation (NVAF) post left atrial appendage occlusion (LAAO)." | 5.41 | Double-blind, placebo-controlled randomised clinical trial to evaluate the effect of ASPIRIN discontinuation after left atrial appendage occlusion in atrial fibrillation: protocol of the ASPIRIN LAAO trial. ( Chen, M; Chen, TZ; Li, W; Li, YG; Mo, BF; Sun, J; Tang, X; Wang, Q; Zhang, PP, 2021) |
| " We sought to determine whether the presence of carotid stenosis was associated with increased risk of ischemic stroke and whether the addition of clopidogrel to aspirin was associated with more benefit in patients with versus without carotid stenosis." | 5.41 | Carotid Stenosis and Recurrent Ischemic Stroke: A Post-Hoc Analysis of the POINT Trial. ( de Havenon, A; Easton, JD; Furie, KL; Henninger, N; Johnston, SC; Kim, AS; Kvernland, A; Mac Grory, B; Rostanski, S; Yaghi, S, 2021) |
| "In patients with a minor ischaemic stroke or transient ischaemic attack (TIA), separate trials have shown that dual antiplatelet therapy with clopidogrel plus aspirin (clopidogrel-aspirin) or ticagrelor plus aspirin (ticagrelor-aspirin) are more effective than aspirin alone in stroke secondary prevention." | 5.41 | Clopidogrel with aspirin in High-risk patients with Acute Non-disabling Cerebrovascular Events II (CHANCE-2): rationale and design of a multicentre randomised trial. ( Bath, PM; Dong, Q; Jing, J; Johnston, C; Li, H; Li, Z; Meng, X; Pan, Y; Wang, A; Wang, Y; Xie, X; Xu, A; Zhao, X, 2021) |
| "The appropriate dose of aspirin to lower the risk of death, myocardial infarction, and stroke and to minimize major bleeding in patients with established atherosclerotic cardiovascular disease is a subject of controversy." | 5.41 | Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. ( Ahmad, FS; Alikhaani, JD; Anderson, RD; Antman, EM; Bell, DS; Benziger, CP; Berdan, LG; Bradley, SM; Brown, LS; Campbell, JR; Carton, TW; Crenshaw, DL; Curtis, LH; Davidson, DR; DeWalt, DA; Edgley, K; Effron, MB; Farrehi, P; Fintel, DJ; Fonarow, GC; Ford, DE; Girotra, S; Goldberg, YH; Gregoire, KC; Gupta, K; Hammill, BG; Handberg, EM; Harrington, RA; Harris, DF; Haynes, K; Hernandez, AF; Hess, R; Jain, SK; Jones, WS; Kaushal, R; Kho, AN; Knowlton, KU; Kraschnewski, JL; Kripalani, S; Manning, BR; Marcus, GM; Marquis-Gravel, G; Masoudi, FA; McClay, JC; McCormick, TE; McTigue, KM; Merritt, JG; Modrow, MF; Mulder, H; Muñoz, D; Nauman, E; Paranjape, A; Pencina, MJ; Pepine, CJ; Polonsky, TS; Qualls, LG; Re, RN; Riley, D; Robertson, HR; Roe, MT; Roger, VL; Rothman, RL; Sharlow, AG; Shenkman, EA; VanWormer, JJ; Waitman, LR; Whittle, J; Wruck, LM; Zemon, DN; Zhou, L, 2021) |
| "Clopidogrel and aspirin are key intervention for acute ischemic stroke (AIS) and transient ischemic attack (TIA)." | 5.41 | Personalized antiplatelet therapy based on clopidogrel/aspirin resistance tests in acute ischemic stroke and transient ischemic attack: Study protocol of a multi-center, single-blinded and randomized controlled trial. ( Chen, J; Gao, P; Han, M; Jia, W; Kuang, J; Peng, C; Starcevich, K; Tu, J; Wang, J; Wu, Y; Yi, Y; Yin, S; Zhang, X, 2021) |
| "Stroke is the major cause of death and decrease in the activities of daily living." | 5.40 | Neurovascular protection of cilostazol in stroke-prone spontaneous hypertensive rats associated with angiogenesis and pericyte proliferation. ( Abe, K; Deguchi, K; Ikeda, Y; Kono, S; Kurata, T; Liu, N; Liu, W; Omote, Y; Yamashita, T, 2014) |
| "Stroke is the second leading cause of death." | 5.39 | Neuroprotective effect of a new synthetic aspirin-decursinol adduct in experimental animal models of ischemic stroke. ( Ahn, JH; Cho, JH; Choi, JH; Her, S; Hwang, IK; Hyun, BH; Jun, JG; Kim, CK; Kim, IH; Kim, JS; Kim, YM; Kwon, SH; Kwon, YG; Lee, CH; Lee, JC; Lee, YL; Park, JH; Shin, BN; Suh, HW; Won, MH; Yan, BC; Yoo, KY, 2013) |
| "Aspirin resistance was more common in patients with MES (50% compared to 17." | 5.38 | Microembolic signals and aspirin resistance in patients with carotid stenosis. ( Dawson, J; Lees, KR; Quinn, T; Walters, MR, 2012) |
| "Despite aspirin's established role in the treatment of atherosclerotic vascular disease, considerable controversy exists regarding its most effective dosing strategy." | 5.35 | Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial). ( Amarenco, P; Aronow, HD; Califf, RM; Davis, S; Diener, HC; Easton, JD; Ferguson, J; Fitzgerald, DJ; Graffagnino, C; Harrington, RA; Koudstaal, PJ; Shuaib, A; Theroux, P; Topol, EJ; Vallee, M; Van de Werf, F, 2008) |
| "Although intracerebral hemorrhage (ICH) has been described in patients with CADASIL, the cause of such ICH is still unknown." | 5.35 | Aspirin-associated intracerebral hemorrhage in a patient with CADASIL. ( Choi, JC; Kang, JH; Kang, SY; Lee, JS; Oh, JH, 2008) |
| "To analyze the association between low-dose rivaroxaban with or without aspirin and different ischemic stroke subtypes." | 5.34 | Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial. ( Bosch, J; Catanese, L; Connolly, SJ; Dyal, L; Eikelboom, JW; Hart, RG; Nayar, S; Ng, KKH; Perera, KS; Sharma, M; Yusuf, S, 2020) |
| "Of the 1534 ischemic stroke patients who randomly assigned to aspirin or cilostazol treatment with best medical therapy by the PICASSO (PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage) trial, 1240 with baseline mini-mental state examination (MMSE) scores were analysed retrospectively." | 5.34 | Post-stroke cognitive impairment as an independent predictor of ischemic stroke recurrence: PICASSO sub-study. ( Hong, KS; Kang, DW; Kwon, HS; Kwon, SU; Lee, D; Lee, EJ; Lee, JS; Lee, MH; Lim, JS; Oh, MS; Yu, KH; Yu, S, 2020) |
| " Approach and Results: The CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) randomized patients with acute minor ischemic stroke or high-risk transient ischemic attack to clopidogrel plus aspirin or aspirin alone from October 1, 2009, to July 30, 2012, in China." | 5.34 | Homocysteine Level Predicts Response to Dual Antiplatelet in Women With Minor Stroke or Transient Ischemic Attack: Subanalysis of the CHANCE Trial. ( Li, H; Li, J; Lin, J; Liu, L; Wang, A; Wang, Y; Zhao, X; Zuo, Z, 2020) |
| " Patients with newly diagnosed ischemic stroke who are just about to start Aspirin were assessed for eligibility and inclusion in our trial." | 5.34 | An investigation into the impact of enteric coated of aspirin in patients with newly diagnosed ischemic stroke (ECASIS). ( Abdallah, IM; Ahmed, MS; Ali, M; AlSaud, AE; Danjuma, MI; Elshafei, MN; Imam, Y; Mohamed, MFH; Obeidat, K; Parray, AS; Saeid, R, 2020) |
| " In this study, we compared three major platelet function tests to assess their performance and found better methods for platelet function evaluation after aspirin or clopidogrel treatment in ischemic stroke patients by comparative study." | 5.34 | A comparison of three platelet function tests in ischemic stroke patients with antiplatelet therapy. ( Cheng, Y; Ge, W; Han, Z; Huang, L; Jin, J; Luo, C; Shao, T; Wang, Z; Xu, Y; Yang, D, 2020) |
| "Data were obtained from the biomarker substudy of the NAVIGATE ESUS trial, a randomized controlled trial testing the efficacy of rivaroxaban versus aspirin for secondary stroke prevention in ESUS." | 5.34 | High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source. ( Berkowitz, SD; Czlonkowska, A; Endres, M; Krahn, T; Mundl, H; Nolte, CH; Pare, G; Peacock, WF; Pearce, LA; Scheitz, JF; Sharma, M; Shoamanesh, A, 2020) |
| "Trials have evaluated the use of clopidogrel and aspirin to prevent stroke after an ischemic stroke or transient ischemic attack (TIA)." | 5.34 | Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. ( Amarenco, P; Denison, H; Evans, SR; Himmelmann, A; James, S; Johnston, SC; Knutsson, M; Ladenvall, P; Molina, CA; Wang, Y, 2020) |
| " There were no statistically significant differences between rivaroxaban and aspirin prophylaxis for recurrent ischemic stroke in patients with non-stenotic intracranial atherosclerosis and/or systemic atherosclerosis." | 5.34 | Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy. ( Amarenco, P; Ameriso, SF; Bereczki, D; Berkowitz, SD; Connolly, SJ; Ferrari, J; Firstenfeld, A; Hart, RG; Kasner, SE; Lang, W; Lavados, P; Mikulik, R; Mundl, H; Ntaios, G; Pearce, LA; Perera, KS; Povedano, GP; Uchiyama, S; Yoon, BW, 2020) |
| "The present results are similar to those observed in clinical trials where administration of low-dose aspirin plus prasugrel was associated with a low rate of major bleeding and CV events." | 5.34 | Incidence of Cardiovascular Events and Safety Profile of Prasugrel in Korean Patients With Acute Coronary Syndrome. ( Choi, JH; Chon, MK; Chun, KJ; Hwang, KW; Jung, SM; Kim, JH; Kim, JS; Lee, SH; Lee, SY; Park, YH, 2020) |
| "The OPT-BIRISK trial is a multicenter, double-blinded, placebo-controlled randomized study designed to test the superiority of extended antiplatelet therapy with clopidogrel monotherapy compared with aspirin and clopidogrel for reduction of bleeding events in ACS patients with both high bleeding and high ischemic risks ("bi-risk")." | 5.34 | Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the O ( Angiolillo, DJ; Chen, S; Han, Y; Jing, Q; Li, J; Li, Y; Qiao, S; Wang, B; Wang, X, 2020) |
| "The stroke rate was numerically lower in the group on clopidogrel vs off clopidogrel among both the AMM alone arm (6." | 5.34 | Dual Antiplatelet Therapy Beyond 90 days in Symptomatic Intracranial Stenosis in the SAMMPRIS Trial. ( Abdul Rahman, L; Almallouhi, E; Chimowitz, MI; Cotsonis, G; Holmstedt, CA; Turan, TN, 2020) |
| "We performed an exploratory analysis of the interaction of the treatment effects of aspirin plus clopidogrel versus aspirin monotherapy, stratified by presence of ipsilateral nonstenotic carotid disease in patients with minor ischemic stroke in the POINT trial." | 5.34 | Ipsilateral Nonstenotic Carotid Disease in Minor Ischemic Stroke: an Exploratory Analysis of The POINT Randomized Clinical Trial. ( Brorson, JR; Bulwa, Z; Pinto, CB; Saleh Velez, FG, 2020) |
| "A temporary middle cerebral artery occlusion (tMCAO) model was used in 80 Wistar rats to evaluate whether a high dose of Aspirin (40 mg/kg) applied with different initiation time points after stroke onset (30 min, 3 h, 6 h, 12 h, 20 rats for each time group) and followed by repeated administration (1, 2 and 3 days) is neuroprotective." | 5.34 | Neuroprotection by early and delayed treatment of acute stroke with high dose aspirin. ( Berger, C; Grau, A; Schwab, S; Zheng, Z, 2007) |
| "The risk of stroke is reduced with primary PTCA (OR = 0." | 5.33 | Primary angioplasty in acute myocardial infarction: Hypothetical estimate of superiority over aspirin or untreated controls. ( Massel, D, 2005) |
| "(2) Aspirin has been tested in several placebo-controlled trials and has a positive risk-benefit balance, preventing about 5 deaths per 1000 patients with ischaemic stroke." | 5.33 | Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparin. ( , 2005) |
| "In patients with stable coronary artery disease and diabetes without a history of myocardial infarction or stroke, those who received ticagrelor plus aspirin had a lower incidence of ischemic cardiovascular events but a higher incidence of major bleeding than those who received placebo plus aspirin." | 5.30 | Ticagrelor in Patients with Stable Coronary Disease and Diabetes. ( Andersson, M; Bhatt, DL; Corbalán, R; Cornel, JH; Fox, K; Ge, J; Harrington, RA; Held, C; Himmelmann, A; Leiter, LA; Leonsson-Zachrisson, M; Liu, Y; Mehta, SR; Nicolau, JC; Opolski, G; Ridderstråle, W; Simon, T; Steg, PG; Widimský, P; Zateyshchikov, D, 2019) |
| "Adding rivaroxaban to aspirin in patients with stable atherosclerotic disease reduces the recurrence of cardiovascular disease (CVD) but increases the risk of major bleeding." | 5.30 | Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. ( Alings, M; Berkowitz, SD; Bosch, J; de Vries, TI; Dorresteijn, JAN; Dyal, L; Eikelboom, JW; Fox, KAA; van der Graaf, Y; Visseren, FLJ; Westerink, J, 2019) |
| "In a double-blind trial, we examined the effect of ticagrelor alone as compared with ticagrelor plus aspirin with regard to clinically relevant bleeding among patients who were at high risk for bleeding or an ischemic event and had undergone PCI." | 5.30 | Ticagrelor with or without Aspirin in High-Risk Patients after PCI. ( Angiolillo, DJ; Baber, U; Briguori, C; Cha, JY; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Džavík, V; Escaned, J; Gibson, CM; Gil, R; Gurbel, P; Hamm, CW; Han, YL; Henry, T; Huber, K; Kastrati, A; Kaul, U; Kornowski, R; Krucoff, M; Kunadian, V; Marx, SO; Mehran, R; Mehta, SR; Moliterno, D; Ohman, EM; Oldroyd, K; Pocock, S; Sardella, G; Sartori, S; Sharma, SK; Shlofmitz, R; Steg, PG; Weisz, G; Witzenbichler, B, 2019) |
| "Long-term ticagrelor monotherapy following 1-month DAPT can favorably balance ischemic and bleeding risks in patients with multivessel PCI." | 5.30 | Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI. ( Carrie, D; Chang, CC; Chichareon, P; Chowdhary, S; de Winter, RJ; Eitel, I; Garg, S; Hamm, C; Kogame, N; Magro, M; Modolo, R; Ong, P; Onuma, Y; Ottesen, MM; Serruys, PW; Steg, PG; Stoll, HP; Takahashi, K; Tijssen, JGP; Tomaniak, M; Valgimigli, M; Vranckx, P; Windecker, S; Wykrzykowska, JJ; Zweiker, R, 2019) |
| "Triflusal has demonstrated an efficacy similar to aspirin in the prevention of vascular events in patients with acute myocardial infarction (ΜΙ) and ischaemic stroke but with less bleeding events." | 5.30 | Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial. ( Adamopoulos, D; Asimakopoulos, C; Bourdakis, A; Chantzichristos, VG; Darmanis, P; Dimitriadou, A; Gkiokas, S; Goudevenos, JA; Ipeirotis, K; Kalantzi, KI; Kitikidou, K; Klonaris, I; Kostaki, A; Logothetis, D; Mainas, K; Mais, T; Maragiannis, A; Martiadou, K; Mavronasos, K; Michelongonas, I; Mitropoulos, D; Ntalas, IV; Panagiotakos, DB; Papadimitriou, G; Papadopoulos, A; Papaioakeim, M; Sofillas, K; Stabola, S; Stefanakis, E; Stergiou, D; Thoma, M; Tselepis, AD; Tsoumani, ME; Zenetos, A; Zisekas, S, 2019) |
| "Strokes were significantly reduced by the combination of rivaroxaban plus aspirin in comparison with aspirin in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies)." | 5.30 | Stroke Outcomes in the COMPASS Trial. ( Aboyans, V; Alings, M; Berkowitz, SD; Bhatt, DL; Bosch, J; Bruns, NC; Catanese, L; Connolly, SJ; Eikelboom, JW; Fox, K; Ha, JW; Hart, RG; Keltai, K; Maggioni, A; Ng, KKH; O'Donnell, M; Sharma, M; Shestakovska, O; Tonkin, A; Varigos, J; Yusuf, S, 2019) |
| " In patients with prior coronary artery disease or peripheral arterial disease the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial revealed that compared with acetylsalicylic acid alone, dual pathway inhibition with low-dose rivaroxaban (2." | 5.30 | Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. ( Coppens, M; Eikelboom, JWA; Weitz, JI, 2019) |
| "In patients with acute cerebral ischemia, the rate of stroke, myocardial infarction, or death during 90 days was reported to be non-significantly lower with ticagrelor compared with aspirin, with no increase in major hemorrhage." | 5.30 | The Acute S ( Amarenco, P; Denison, H; Evans, SR; Himmelmann, A; James, S; Johnston, SC; Knutsson, M; Ladenvall, P; Molina, CA; Wang, Y, 2019) |
| "In the setting of prior myocardial infarction, the oral antiplatelet ticagrelor added to aspirin reduced the risk of recurrent ischemic events, especially, in those with diabetes mellitus." | 5.30 | Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. ( Andersson, M; Bhatt, DL; Fox, K; Harrington, RA; Held, C; Himmelmann, A; Leiter, LA; Mehta, SR; Ridderstråle, W; Simon, T; Steg, PG, 2019) |
| "The benefits of both dabigatran 110 mg and 150 mg dual therapy compared with warfarin triple therapy in reducing bleeding risks were consistent across subgroups of patients with or without ACS, and patients treated with ticagrelor or clopidogrel." | 5.30 | Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. ( Bhatt, DL; Brueckmann, M; Cannon, CP; Hohnloser, SH; Kimura, T; Kleine, E; Lip, GYH; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2019) |
| "5%), an independent adjudication process of reported and unreported potential endpoints, using standardised CEC procedures, in order to assess whether 23-month ticagrelor monotherapy (90 mg twice daily) after 1-month DAPT is non-inferior to a standard regimen of DAPT for 12 months followed by aspirin monotherapy for the primary efficacy endpoint of death, non-fatal myocardial infarction, non-fatal stroke or urgent target vessel revascularisation and superior for the primary safety endpoint of type 3 or 5 bleeding according to the Bleeding Academic Research Consortium criteria." | 5.30 | Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY). ( Aminian, A; Benit, E; Bolognese, L; Bryniarski, K; Buszman, P; Dominici, M; Ferrario, M; Franzone, A; Garg, S; Hamm, C; Heg, D; Huber, K; Janssens, L; Juni, P; Leonardi, S; Liebetrau, C; McFadden, E; Naber, C; Petrov, I; Piccolo, R; Prokopczuk, J; Serruys, P; Slagboom, T; Steg, G; Tumscitz, C; Valgimigli, M; van Geuns, RJ; Vranckx, P; Vrolix, M; Windecker, S; Zurakowski, A, 2019) |
| "The NAVIGATE ESUS randomized clinical trial found that 15 mg of rivaroxaban per day does not reduce stroke compared with aspirin in patients with embolic stroke of undetermined source (ESUS); however, it substantially reduces stroke risk in patients with atrial fibrillation (AF)." | 5.30 | Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial. ( Arauz, A; Berkowitz, SD; Connolly, SJ; Coutts, SB; Czlonkowska, A; Eckstein, J; Endres, M; Epstein, AE; Gladstone, DJ; Haeusler, KG; Hankey, GJ; Hart, RG; Healey, JS; Karlinski, M; Kasner, SE; Lutsep, H; Mikulik, R; Molina, CA; Mundl, H; Ntaios, G; Pagola, J; Perera, K; Santo, G; Shuaib, A; Swaminathan, B; Toni, D; Uchiyama, S; Yang, X, 2019) |
| " The aim was to assess whether the effect of clopidogrel plus aspirin versus aspirin alone on recurrent stroke would be affected by admission activated partial thromboplastin time (aPTT)." | 5.30 | Effect of dual versus mono antiplatelet therapy on recurrent stroke modulated by activated partial thromboplastin time. ( Laskowitz, DT; Li, H; Liu, L; Meng, X; Miao, Z; Wang, X; Wang, Y; Xie, X; Zhao, X, 2019) |
| " The COMMANDER HF randomized clinical trial evaluated the effects of adding low-dose rivaroxaban to antiplatelet therapy in patients with recent worsening of chronic HF with reduced ejection fraction, coronary artery disease (CAD), and sinus rhythm." | 5.30 | Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. ( Anker, SD; Byra, WM; Cleland, JGF; Deng, H; Fu, M; Greenberg, B; La Police, DA; Lam, CSP; Mehra, MR; Neaton, JD; Nessel, CC; Spiro, TE; van Veldhuisen, DJ; Vanden Boom, CM; Zannad, F, 2019) |
| "Results show the short-term risk of hemorrhage in treating patients with acute transient ischemic attack (TIA) or minor acute ischemic stroke (AIS) with clopidogrel plus aspirin or aspirin alone." | 5.30 | Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial. ( Barsan, W; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY; Tillman, H, 2019) |
| " This study investigated the effect of warfarin versus aspirin on WBV in patients presenting with non-valvular atrial fibrillation (NVAF) and acute cardioembolic stroke." | 5.30 | Effect of warfarin versus aspirin on blood viscosity in cardioembolic stroke with atrial fibrillation: a prospective clinical trial. ( Cho, DJ; Jeong, SK; Jung, KH; Lee, CH, 2019) |
| "We conducted a multicenter, randomized, double-blind trial of dabigatran at a dose of 150 mg or 110 mg twice daily as compared with aspirin at a dose of 100 mg once daily in patients who had had an embolic stroke of undetermined source." | 5.30 | Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. ( Bernstein, RA; Brueckmann, M; Chernyatina, M; Cotton, D; Cronin, L; Diener, HC; Donnan, G; Easton, JD; Ferro, JM; Granger, CB; Grauer, C; Grond, M; Kallmünzer, B; Kreuzer, J; Krupinski, J; Lee, BC; Lemmens, R; Masjuan, J; Odinak, M; Sacco, RL; Saver, JL; Schellinger, PD; Toni, D; Toyoda, K; Uchiyama, S, 2019) |
| "SOCRATES compared ticagrelor and aspirin in 13,199 patients with acute minor stroke or high-risk transient ischemic attack." | 5.30 | Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Johnston, SC; Knutsson, M; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KL, 2019) |
| "While the addition of low dose chlorpromazine and promethazine to standard of care for acute ischemic stroke did not have any significant improvement in functional outcomes, there were no serious adverse effects." | 5.30 | Low dose concomitant treatment with chlorpromazine and promethazine is safe in acute ischemic stroke. ( Chandra, A; Cheng, Z; Ding, Y; Du, H; Geng, X; Tong, Y; Zhu, H, 2019) |
| "Although dual antiplatelet therapy with aspirin and clopidogrel reduces early recurrence of ischaemic stroke, with long-term use this type of therapy is no longer effective and the risk of bleeding increases." | 5.30 | Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. ( Easton, JD; Hoshino, H; Houkin, K; Isobe, M; Kimura, K; Minematsu, K; Naritomi, H; Okada, Y; Origasa, H; Sakai, N; Tanaka, K; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T, 2019) |
| "Antiplatelet therapy combining aspirin and clopidogrel is considered to be a key intervention for acute ischaemic minor stroke (AIMS) and transient ischaemic attack (TIA)." | 5.30 | Personalised antiplatelet therapy based on pharmacogenomics in acute ischaemic minor stroke and transient ischaemic attack: study protocol for a randomised controlled trial. ( Hu, L; Jiang, HY; Li, ZZ; Xue, J; Yue, YH; Zhang, XG; Zhu, XQ, 2019) |
| "Exploratory analyses of 7213 participants in the NAVIGATE ESUS international trial who were randomized to aspirin 100 mg/day or rivaroxaban 15 mg/day and followed for a median of 11 months, during which time there were 309 first recurrent ischemic strokes (4." | 5.30 | Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. ( Ameriso, SF; Bangdiwala, SI; Berkowitz, SD; Connolly, SJ; Coutts, SB; Czlonkowska, A; Gagliardi, RJ; Hankey, GJ; Hart, RG; Kasner, SE; Lindgren, A; Mundl, H; Ntaios, G; Perera, KS; Peters, G; Sharma, M; Sheridan, P; Shoamanesh, A; Shuaib, A; Toni, D; Veltkamp, RC, 2019) |
| "Dual antiplatelet therapy (DAT) with clopidogrel plus aspirin has been suggested by American Heart Association/American Stroke Association guidelines for minor stroke (MS) and transient ischemic attack (TIA) patients." | 5.30 | Efficacy of clopidogrel for stroke depends on CYP2C19 genotype and risk profile. ( Chen, W; Chen, Z; Dai, L; Li, H; Meng, X; Mo, J; Wang, A; Wang, Y; Wangqin, R; Xian, Y; Xu, J; Zhao, X, 2019) |
| "In patients with acute minor ischemic stroke or high-risk transient ischemic attack enrolled in the POINT trial (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke [POINT] Trial), the combination of clopidogrel and aspirin for 90 days reduced major ischemic events but increased major hemorrhage in comparison to aspirin alone." | 5.30 | Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient Ischemic Attack and Minor Ischemic Stroke. ( Albers, GW; Barsan, WG; Cucchiara, BL; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Kleindorfer, DO; Lindblad, AS; Lutsep, HL; Palesch, YY; Pearson, C; Sethi, P; Vora, N; Zurita, KG, 2019) |
| "Background The aim of the present study was to investigate the efficacy and safety of antiplatelet (aspirin plus cilostazol) dual therapy for patients with noncardioembolic stroke within 48 hours of symptom onset." | 5.30 | Acute Aspirin Plus Cilostazol Dual Therapy for Noncardioembolic Stroke Patients Within 48 Hours of Symptom Onset. ( Abe, K; Aoki, J; Fujimoto, S; Idomari, K; Iguchi, Y; Inoue, T; Iwanaga, T; Kaneko, N; Kimura, K; Matsuoka, H; Nomura, K; Okada, Y; Tanaka, R; Terasaki, T; Todo, K; Tsujino, A; Uno, M; Urabe, T; Yagita, Y; Yamagami, H; Yamagata, S; Yamamoto, N; Yamamoto, Y; Yonehara, T, 2019) |
| "In patients with stable coronary artery disease, addition of rivaroxaban to aspirin lowered major vascular events, but increased major bleeding." | 5.27 | Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. ( Anand, SS; Avezum, AA; Berkowitz, SD; Bhatt, DL; Bosch, J; Branch, KRH; Connolly, SJ; Cook Bruns, N; Dagenais, G; Dans, AL; Dyal, L; Eikelboom, JW; Felix, C; Fox, KAA; Guzik, TJ; Ha, JW; Hori, M; Keltai, K; Lanas, F; Lisheng, L; Lonn, E; Maggioni, AP; Metsarinne, K; O'Donnell, M; Parkhomenko, AN; Torp-Pedersen, C; Varigos, JD; Widimsky, P; Yusoff, K; Yusuf, S, 2018) |
| " The combination of rivaroxaban plus aspirin compared with aspirin alone reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke (126 [5%] of 2492 vs 174 [7%] of 2504; hazard ratio [HR] 0·72, 95% CI 0·57-0·90, p=0·0047), and major adverse limb events including major amputation (32 [1%] vs 60 [2%]; HR 0·54 95% CI 0·35-0·82, p=0·0037)." | 5.27 | Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. ( Aboyans, V; Alings, M; Anand, SS; Avezum, AA; Bangdiwala, SI; Bhatt, DL; Bosch, J; Branch, K; Chen, E; Commerford, PJ; Connolly, SJ; Diaz, R; Eikelboom, JW; Fox, KAA; Hart, RG; Kakkar, AK; Keltai, K; Leong, DP; Lewis, BS; Lopez-Jaramillo, P; Maggioni, AP; Misselwitz, F; O'Donnell, M; Pogosova, N; Ryden, L; Störk, S; Vanassche, T; Varigos, JD; Vinereanu, D; Widimsky, P; Yusuf, S; Zhu, J, 2018) |
| "The objective was to assess whether rivaroxaban is superior to acetylsalicylic acid (ASA) in reducing the risk of clinically overt stroke, systemic embolism, or covert stroke among patients without apparent recurrent atrial arrhythmias for at least 1 year after their most recent AF ablation procedure." | 5.27 | The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial. ( Birnie, DH; Champagne, J; Essebag, V; Gupta, D; Ha, ACT; Healey, JS; Heidbuchel, H; Hill, MD; Hindricks, G; Kirchhof, P; Sanders, P; Sharma, M; Verma, A; Wells, G; Wyse, DG, 2018) |
| "Ticagrelor plus low-dose aspirin for up to 1 year was associated with a low rate of major bleeding events and a low incidence of major CV events (CV death, myocardial infarction, stroke) in Chinese patients with ACS." | 5.27 | Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study. ( Gao, R; Han, Y; Leonsson-Zachrisson, M; Liu, H; Liu, L; Shen, L; Su, G; Wang, Y; Wang, Z; Wu, Y; Yuan, Z; Zhang, A; Zhang, H; Zheng, Y, 2018) |
| " ASA to Prevent Embolism in Embolic Stroke of Undetermined Source (NAVIGATE-ESUS) trial is a randomized phase-III trial comparing rivaroxaban versus aspirin in patients with recent ESUS." | 5.27 | Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. ( Amarenco, P; Ameriso, SF; Arauz, A; Bereczki, D; Berkowitz, SD; Bornstein, N; Brouns, R; Connolly, SJ; Cunha, L; Czlonkowska, A; Dávalos, A; DeVries Basson, MM; Eckstein, J; Endres, M; Gagliardi, R; Hankey, GJ; Hart, RG; Kasner, SE; Kirsch, B; Lang, W; Lavados, P; Lindgren, A; Mikulik, R; Muir, K; Mundl, H; Ntaios, G; O'Donnell, M; Ozturk, S; Pare, G; Pater, C; Peacock, WF; Peters, G; Shamalov, N; Sharma, M; Shoamanesh, A; Swaminathan, B; Tatlisumak, T; Themeles, E; Toni, DS; Uchiyama, S; Veltkamp, R; Wang, Y; Weitz, J; Yoon, BW, 2018) |
| " The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days." | 5.27 | Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018) |
| "Rivaroxaban was not superior to aspirin with regard to the prevention of recurrent stroke after an initial embolic stroke of undetermined source and was associated with a higher risk of bleeding." | 5.27 | Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. ( Amarenco, P; Ameriso, SF; Arauz, A; Bangdiwala, SI; Benavente, OR; Bereczki, D; Berkowitz, SD; Bornstein, N; Brouns, R; Connolly, SJ; Cunha, L; Czlonkowska, A; Davalos, A; De Vries Basson, MM; Eckstein, J; Endres, M; Gagliardi, RJ; Hankey, GJ; Hart, RG; Joyner, C; Kasner, SE; Kirsch, B; Lang, W; Lavados, P; Lindgren, A; Mikulik, R; Muir, KW; Mundl, H; Ntaios, G; O'Donnell, MJ; Ozturk, S; Pare, G; Pater, C; Peacock, WF; Peters, G; Shamalov, N; Sharma, M; Sheridan, P; Shoamanesh, A; Swaminathan, B; Tatlisumak, T; Themeles, E; Toni, D; Uchiyama, S; Veltkamp, R; Wang, Y; Weitz, JI; Yoon, BW, 2018) |
| "In patients with ischaemic stroke at high risk of cerebral haemorrhage, cilostazol was non-inferior to aspirin for the prevention of cardiovascular events, but did not reduce the risk of haemorrhagic stroke." | 5.27 | Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial. ( Ahn, SH; Heo, SH; Hong, KS; Hwang, YH; Jung, JM; Kang, DW; Kim, BJ; Kim, YJ; Kwon, JH; Kwon, SU; Lee, EJ; Lee, J; Lee, JH; Lee, JS; Navarro, JC; Park, JH; Park, JM; Rha, JH; Seo, WK; Sohn, SI; Wong, LKS; Yu, S, 2018) |
| "The PRISMS trial was designed as a 948-patient, phase 3b, double-blind, double-placebo, multicenter randomized clinical trial of alteplase compared with aspirin for emergent stroke at 75 stroke hospital networks in the United States." | 5.27 | Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial. ( Broderick, J; Chatterjee, A; Devenport, J; Devlin, T; Jauch, EC; Khatri, P; Kleindorfer, DO; Levine, SR; Mejilla, J; Pavlov, A; Purdon, B; Romano, JG; Saver, JL; Sawyer, RN; Starr, M; Vagal, A; Yeatts, SD, 2018) |
| "NAVIGATE ESUS was a double-blinded, randomised, phase 3 trial done at 459 centres in 31 countries that assessed the efficacy and safety of rivaroxaban versus aspirin for secondary stroke prevention in patients with ESUS." | 5.27 | Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. ( Ameriso, SF; Bangdiwala, S; Berkowitz, SD; Connolly, SJ; Endres, M; Hart, RG; Kasner, SE; Lavados, P; Lindgren, A; Lutsep, H; Messé, SR; Muir, K; Mundl, H; Nedeltechev, K; Olavarria, V; Perera, K; Santo, G; Sharma, M; Shoamanesh, A; Spence, JD; Swaminathan, B; Veltkamp, R, 2018) |
| "Clinical studies results show that policosanol (20 mg/day) + aspirin therapy had benefits versus placebo + aspirin to patients with recent non-cardioembolic ischemic stroke." | 5.27 | Effects of policosanol in the functional recovery of non-cardioembolic ischemic stroke hypertensive patients. ( Fernandez-Dorta, L; Fernandez-Travieso, JC; Illnait-Ferrer, J; Mas-Ferreiro, R; Mendoza-Castano, S; Mesa-Angarica, M; Reyes-Suarez, P; Sanchez-Lopez, J, 2018) |
| "To investigate the short-term time course risks and benefits of clopidogrel with aspirin in minor ischemic stroke or TIA." | 5.24 | Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: Time course analysis of CHANCE. ( Chen, W; Jing, J; Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, D; Wang, Y; Zhao, X, 2017) |
| "The DAPT (Dual Antiplatelet Therapy) study randomized 11,648 patients free from ischemic and bleeding events 12 months after coronary stenting to continued thienopyridine plus aspirin therapy for an additional 18 months versus aspirin therapy alone." | 5.24 | Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. ( Apruzzese, PK; Cutlip, DE; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW, 2017) |
| "The aim of this study was to compare aspirin plus clopidogrel with aspirin alone as antithrombotic treatment following transcatheter aortic valve replacement (TAVR) for the prevention of ischemic events, bleeding events, and death." | 5.24 | Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi ( Al-Qoofi, F; Chamandi, C; Côté, M; Dumont, E; Garcia Del Blanco, B; Généreux, P; Maluenda, G; Masson, JB; Paradis, JM; Pelletier, M; Rodés-Cabau, J; Serra, V; Thoenes, M; Webb, JG; Welsh, RC, 2017) |
| "Objective Some previous studies have found clinical benefit of dual antiplatelet therapy with aspirin and cilostazol for prevention of secondary stroke, but the physiological mechanism involved remains unknown." | 5.24 | Dual Therapy with Aspirin and Cilostazol May Improve Platelet Aggregation in Noncardioembolic Stroke Patients: A Pilot Study. ( Kohara, S; Ohnuki, Y; Shimizu, M; Takizawa, S, 2017) |
| "To elucidate the efficacy and safety between aspirin and clopidogrel, a multicenter randomized controlled trial was designed in AF patients with low stroke risk." | 5.24 | Rationale and Design for a Randomized Comparison of Efficacy and Safety between Aspirin and Clopidogrel in Atrial Fibrillation Patients with Low Stroke Risk: CESAC-AF trial. ( Bang, CS; Hong, KS; Hong, MK; Jeong, H; Jung, MH; Kim, CY; Park, SM, 2017) |
| "Ticagrelor is an effective antiplatelet therapy among patients with atherosclerotic disease and, therefore, could be more effective than aspirin in preventing recurrent stroke and cardiovascular events among patients with embolic stroke of unknown source (ESUS), which includes patients with ipsilateral stenosis <50% and aortic arch atherosclerosis." | 5.24 | Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017) |
| "The Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6 ) trial tests whether oral anticoagulation with edoxaban is superior to prevent the primary efficacy outcome of stroke or cardiovascular death compared with aspirin or no antithrombotic therapy based on evidence-based indications." | 5.24 | Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. ( Blank, BF; Calvert, M; Camm, AJ; Chlouverakis, G; Diener, HC; Goette, A; Huening, A; Kirchhof, P; Lip, GYH; Simantirakis, E; Vardas, P, 2017) |
| "In the SOCRATES trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes), ticagrelor was not superior to aspirin." | 5.24 | Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes). ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wang, Y; Wong, KS, 2017) |
| "Accordingly, 50 mg clopidogrel plus aspirin, and 75 mg clopidogrel plus aspirin were all superior to aspirin alone as stroke prevention in patients with cerebral infarction or transient ischemic attack combined with intracranial and extracranial arteriostenosis." | 5.24 | The effectiveness and safety of dual antiplatelet therapy in ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis in Chinese patients: A randomized and controlled trail. ( Dong, AQ; Liu, H; Liu, JQ; Su, N; Wu, HJ; Zuo, FT, 2017) |
| "Ticagrelor is an effective antiplatelet therapy for patients with coronary atherosclerotic disease and might be more effective than aspirin in preventing recurrent stroke and cardiovascular events in patients with acute cerebral ischaemia of atherosclerotic origin." | 5.24 | Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017) |
| "Antiplatelet therapy with aspirin 160 mg to 300 mg daily, given orally (or by nasogastric tube or per rectum in people who cannot swallow) and started within 48 hours of onset of presumed ischaemic stroke, significantly decreased death and dependency, and reduced the risk of early recurrent ischaemic stroke without a major risk of early haemorrhagic complications; long-term outcomes were improved." | 5.22 | Oral antiplatelet therapy for acute ischaemic stroke. ( Barnes, SC; Beishon, LC; Chithiramohan, T; Clough, RH; Kadicheeni, M; Minhas, JS; Robinson, T; Wang, X, 2022) |
| " Search terms included ischemic stroke, aspirin, clopidogrel, dipyridamole, ticagrelor, cilostazol, prasugrel, glycoprotein IIb/IIIa inhibitors." | 5.22 | Antiplatelet Use in Ischemic Stroke. ( Ali, A; Baig, S; Bell, SM; Kamarova, M; Majid, A; Monks, K; Patel, H; Redgrave, J; Wasay, M, 2022) |
| "This systematic review aimed to compare early use of P2Y12 inhibitors (clopidogrel/ticagrelor) plus aspirin to aspirin alone for acute treatment and secondary prevention in acute non-cardioembolic minor ischemic stroke or TIA." | 5.22 | P2Y12 inhibitors plus aspirin for acute treatment and secondary prevention in minor stroke and high-risk transient ischemic attack: A systematic review and meta-analysis. ( Bellesini, M; Galli, E; Maroni, L; Pomero, F; Squizzato, A, 2022) |
| "To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review on the effectiveness of aspirin to reduce the risk of CVD events (myocardial infarction and stroke), cardiovascular mortality, and all-cause mortality in persons without a history of CVD." | 5.22 | Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. ( Barry, MJ; Cabana, M; Chelmow, D; Coker, TR; Davidson, KW; Davis, EM; Donahue, KE; Jaén, CR; Krist, AH; Kubik, M; Li, L; Mangione, CM; Ogedegbe, G; Pbert, L; Ruiz, JM; Stevermer, J; Tseng, CW; Wong, JB, 2022) |
| " In patients with established cardiovascular disease, clopidogrel was associated with a 17% relative-risk reduction for nonfatal MI, borderline decreased risk for MACE, and similar risk for all-cause mortality, stroke, and major bleeding compared with aspirin." | 5.22 | Clopidogrel Monotherapy versus Aspirin Monotherapy in Patients with Established Cardiovascular Disease: Systematic Review and Meta-Analysis. ( Diener, HC; Kyriakoulis, IG; Ntaios, G; Sagris, D; Tasoudis, PT, 2022) |
| "It was found that the effectiveness of dual antiplatelet therapy in patients with minor ischaemic stroke or high risk transient ischaemic attack does not significantly differ in patients with prior aspirin exposure; therefore there should be no influence on the decision to use dual antiplatelet therapy." | 5.22 | Does prior use of antiplatelet therapy modify the effect of dual antiplatelet therapy in transient ischaemic attack/minor ischaemic stroke: A systematic review and meta-analysis. ( Clarke, A; Murphy, R; O'Donnell, MJ; Reddin, C, 2022) |
| "Long-term therapy with aspirin, clopidogrel, or aspirin plus extended-release dipyridamole is recommended for secondary stroke prevention in patients with noncardioembolic ischemic stroke." | 5.22 | Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies. ( Moustafa, B; Testai, FD, 2022) |
| "Our systematic review and meta-analysis suggested that aspirin alone could decrease the risk of bleeding and was not associated with higher risk of mortality, stroke or myocardial infarction compared with DAPT." | 5.22 | Aspirin Alone Versus Dual Antiplatelet Therapy after Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis. ( Guan, Y; Huang, J; Lin, X; Wang, L; Wang, S, 2022) |
| "Our aim was to establish (1) if there is an association between aspirin and subarachnoid hemorrhage, (2) how this differs between the general population and those with intracranial aneurysms." | 5.22 | A meta-analysis of aspirin and subarachnoid hemorrhage in patients with intracranial aneurysms yields different results to the general population. ( Birks, J; Bulters, D; Ewbank, F, 2022) |
| "P2Y12 receptor inhibitor plus aspirin vs aspirin given within 24 h after acute noncardioembolic ischemic stroke or TIA reduces the risk of subsequent stroke." | 5.22 | P2Y12 receptor inhibitor plus aspirin versus aspirin treated within 24 hours of acute noncardioembolic ischemic stroke or TIA: Meta-analysis. ( Huang, WY; Lee, M; Ovbiagele, B, 2022) |
| "compared with aspirin, apixaban was more efficacious for preventing strokes and systemic embolism in patients ≥85 years (absolute rate [AR] 1%/year on apixaban versus 7." | 5.22 | Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. ( Avezum, A; Connolly, SJ; Diaz, R; Eikelboom, JW; Hart, RG; Lanas, F; Ng, KH; Shestakovska, O; Yusuf, S, 2016) |
| "The objective of the present substudy was to examine whether aspirin poor/high responsiveness (APR/AHR) is associated with increased rates of major adverse cardiovascular events (MACE) and serious bleeding after primary percutaneous coronary intervention (PPCI)." | 5.22 | Clinical Significance of Laboratory-determined Aspirin Poor Responsiveness After Primary Percutaneous Coronary Intervention. ( Asanin, M; Čolić, M; Krljanac, G; Kruzliak, P; Lasica, R; Marinkovic, J; Mrdovic, I; Savic, L; Stanković, S, 2016) |
| "The aim of this study was to analyze the benefits and safety associated with the combination therapy of clopidogrel and aspirin among minor stroke or transient ischemic attack patients treated within 12 hours." | 5.22 | Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. ( Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Yang, X; Zhang, C; Zhao, X, 2016) |
| "Medically managed patients with ACS in the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial were randomised to clopidogrel versus prasugrel (plus aspirin), stratified by prior clopidogrel use." | 5.22 | Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. ( Armstrong, PW; Boden, WE; Chin, CT; Corbalán, R; Dalby, AJ; Fox, KA; Gottlieb, S; Leiva-Pons, JL; Neely, B; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Schiele, F; White, HD; Winters, KJ, 2016) |
| "PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) randomized 21,162 patients with prior MI (1 to 3 years) to ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, or placebo, all on a background of low-dose aspirin." | 5.22 | Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. ( Abola, MTB; Aylward, P; Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Corbalán, R; Dalby, A; Dellborg, M; Goodrich, E; Held, P; Jensen, EC; Kuder, J; López-Sendón, J; Nicolau, JC; Parkhomenko, A; Sabatine, MS; Špinar, J; Steg, PG; Storey, RF, 2016) |
| "Ticagrelor may be a more effective antiplatelet therapy than aspirin for the prevention of recurrent stroke and cardiovascular events in patients with acute cerebral ischemia." | 5.22 | Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wang, Y; Wong, KS, 2016) |
| "A total of 14 464 patients (age, 60-85 years) with hypertension, dyslipidemia, and diabetes mellitus participated and were randomized into 2 treatment groups: 100 mg of aspirin or no aspirin." | 5.22 | Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project. ( Ando, K; Ikeda, Y; Ishizuka, N; Matsumoto, M; Minematsu, K; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Yamazaki, T; Yokoyama, K, 2016) |
| "Compared with 12-month DAPT, 6-month DAPT did not increase the composite events of cardiac death, myocardial infarction, stroke, or TIMI major bleeding at 1 year in patients who underwent everolimus-eluting stent implantation." | 5.22 | 6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial. ( Choi, D; Her, AY; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Shin, DH, 2016) |
| "The objective of this study was to evaluate the efficacy and safety of intravenous vinpocetine administration as part of a comprehensive treatment for acute cerebral infarction in a Chinese population." | 5.22 | Efficacy and Safety of Vinpocetine as Part of Treatment for Acute Cerebral Infarction: A Randomized, Open-Label, Controlled, Multicenter CAVIN (Chinese Assessment for Vinpocetine in Neurology) Trial. ( Hu, H; Huang, Y; Kong, Y; Li, C; Li, Y; Nao, J; Song, Y; Tan, L; Zhang, J; Zhang, W, 2016) |
| "Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding." | 5.22 | Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016) |
| "Patients with acute minor ischemic stroke or transient ischemic attack in the trial were randomized to treatment with clopidogrel combined with aspirin or to aspirin alone." | 5.22 | Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. ( Johnston, SC; Li, H; Lin, J; Lin, Y; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Xu, J; Zhao, X, 2016) |
| "In patients with acute ischemic stroke caused by large artery atherosclerosis, clopidogrel plus aspirin versus aspirin alone might be more effective to prevent recurrent cerebral ischemia." | 5.22 | Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone. ( Bae, HJ; Cha, JK; Chang, DI; Cho, KH; Cho, YJ; Choi, JC; Hong, KS; Kang, DW; Kim, DE; Kim, EG; Kim, GM; Kim, HY; Kwon, SU; Lee, J; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Park, KY; Rha, JH; Sohn, CH; Sohn, SI; Yoon, BW; Yu, KH, 2016) |
| " In a previous study, we found that the number of MESs is associated with stroke recurrence and that clopidogrel plus aspirin more effectively reduce the number of MESs than does aspirin alone." | 5.22 | The curative effect comparison of two kinds of therapeutic regimens on decreasing the relative intensity of microembolic signal in CLAIR trial. ( Chen, C; Deng, QQ; Fu, JH; Huang, YN; Markus, H; Ratanakorn, D; Tang, J; Wong, KS; Zhao, H, 2016) |
| "In the PEGASUS-TIMI 54 trial (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54), ticagrelor reduced the risk of major adverse cardiovascular events when added to low-dose aspirin in stable patients with prior myocardial infarction, resulting in the approval of ticagrelor 60 mg twice daily for long-term secondary prevention." | 5.22 | Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm ( Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Dalby, AJ; Goodrich, E; Goto, S; Held, P; Hu, D; Jensen, E; Mauri, L; Morrow, DA; Ophuis, TO; Ruda, M; Sabatine, MS; Seung, KB; Špinar, J; Steg, PG; Storey, RF, 2016) |
| "Dual clopidogrel-aspirin therapy was associated with a marked reduction in new strokes compared with the therapy of aspirin alone in patients with normal renal function (hazard ratio, 0." | 5.22 | Effect of Estimated Glomerular Filtration Rate Decline on the Efficacy and Safety of Clopidogrel With Aspirin in Minor Stroke or Transient Ischemic Attack: CHANCE Substudy (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). ( Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Wu, Y; Zhao, X; Zhou, Y, 2016) |
| "The Elderly-ACS 2 study is a multicenter, randomized, parallel-group, open-label trial designed to demonstrate the superiority of a strategy of dual antiplatelet treatment using a reduced 5-mg daily dose of prasugrel over a standard strategy with a daily clopidogrel dose of 75mg in patients older than 74years with ACS (either ST- or non-ST-elevation myocardial infarction) undergoing early percutaneous revascularization." | 5.22 | A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. ( Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A, 2016) |
| "Carotid endarterectomy and medical therapy (aspirin) were shown superior to medical therapy alone for asymptomatic (≥ 60%) carotid stenosis." | 5.20 | Optimal medical treatment versus carotid endarterectomy: the rationale and design of the Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis (AMTEC) study. ( Boytsov, S; Deev, A; Dupik, N; Kolos, I; Loukianov, M, 2015) |
| " This study was aimed at determining the efficacy of minocycline adjunct to aspirin in improving neurological outcomes of ischemic stroke during 3-month follow-up." | 5.20 | An open-label evaluator-blinded clinical study of minocycline neuroprotection in ischemic stroke: gender-dependent effect. ( Amiri-Nikpour, MR; Hamdi-Holasou, M; Nazarbaghi, S; Rezaei, Y, 2015) |
| "We analysed the rates of stroke and systemic embolism in 6563 aspirin-treated patients with AF from the ACTIVE-A/AVERROES databases." | 5.20 | Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. ( Alings, M; Avezum, A; Connolly, SJ; Díaz, R; Eikelboom, JW; Hart, RG; Healey, JS; Hohnloser, SH; Lauw, MN; Lewis, BS; Shestakovska, O; Vanassche, T; Wang, J, 2015) |
| "To evaluate the effects of treatments with clopidogrel plus aspirin (dual therapy) on early neurological deterioration (END) and outcomes at 6 months in patients with acute large artery atherosclerosis (LAA) stroke." | 5.20 | Clopidogrel plus aspirin prevents early neurologic deterioration and improves 6-month outcome in patients with acute large artery atherosclerosis stroke. ( Chi, L; Liao, D; Lin, J; Wang, C; Yi, X; Zhang, B, 2015) |
| "This study aims to evaluate whether cilostazol plus aspirin is more efficacious than aspirin alone for preventing progression of atherosclerosis in patients with ischemic stroke or transient ischemic attack (TIA) who also have peripheral arterial disease." | 5.20 | The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double-blind, placebo-controlled multicenter trial. ( Chen, CH; Chen, ST; Chern, CM; Chiou, HY; Chiu, HC; Hsu, CY; Hu, HH; Jeng, JS; Lee, JT; Lien, LM; Lin, HJ; Lin, RT; Liu, CH; Ma, H; Po, HL; Sun, MC; Sun, MH; Sun, Y, 2015) |
| "Participants in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE) trials with HF, but not randomized to oral anticoagulation, were categorized as having preserved versus reduced ejection fraction." | 5.20 | Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure. ( Connolly, SJ; Hart, RG; Healey, JS; Hohnloser, SH; McAlister, FA; Pfeffer, MA; Sandhu, RK; Yuan, F; Yusuf, S, 2015) |
| "Antiplatelet agents such as aspirin, clopidogrel and dipyridamole are effective in reducing the risk of recurrence after a stroke." | 5.20 | Statistical analysis plan for the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial. ( Bath, PM; Dineen, R; Pocock, S; Robson, K; Sprigg, N; Woodhouse, LJ, 2015) |
| "The Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events trial randomized minor ischemic stroke or TIA patients to antiplatelet therapy of clopidogrel plus aspirin or aspirin alone." | 5.20 | Glycated albumin predicts the effect of dual and single antiplatelet therapy on recurrent stroke. ( Li, J; Lin, J; Liu, L; Wang, A; Wang, C; Wang, D; Wang, Y; Zhao, X, 2015) |
| "Aspirin is a primary antiplatelet agent for the secondary prevention of ischemic stroke." | 5.20 | Aspirin resistance in the acute stages of acute ischemic stroke is associated with the development of new ischemic lesions. ( Cho, KH; Choi, KH; Choi, MJ; Heo, SH; Kim, BC; Kim, JT; Kim, MK; Lee, JS; Lee, SH; Nam, TS; Park, MS, 2015) |
| "We used data from the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial to assess the relationship of TTR with the WARCEF primary outcome (ischemic stroke, intracerebral hemorrhage, or death), with death alone, ischemic stroke alone, major hemorrhage alone, and net clinical benefit (primary outcome and major hemorrhage combined)." | 5.20 | Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy. ( Anker, SD; Buchsbaum, R; Di Tullio, MR; Estol, CJ; Freudenberger, RS; Graham, S; Homma, S; Labovitz, AJ; Levin, B; Lip, GY; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Teerlink, JR; Thompson, JL; Ye, S, 2015) |
| "The Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial showed that the combined treatment of clopidogrel and aspirin decreases the 90-day risk of stroke without increasing hemorrhage in comparison with aspirin alone, but provided insufficient data to establish whether the benefit persisted over a longer period of time beyond the trial termination." | 5.20 | Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes. ( Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, C; Wang, D; Wang, Y; Zhao, X, 2015) |
| "PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage was designed to compare cilostazol and aspirin and to assess the effect of adding probucol, a lipid-lowering and anti-oxidative agent, in patients at high risk of haemorrhagic stroke." | 5.20 | Rationale and design of the PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage (PICASSO) study: A randomized controlled trial. ( Hong, KS; Kim, BJ; Kwon, SU; Lee, JY, 2015) |
| "We sought to assess the performance of existing bleeding risk scores, such as the Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly (HAS-BLED) score or the Outpatient Bleeding Risk Index (OBRI), in patients with heart failure with reduced ejection fraction (HFrEF) in sinus rhythm (SR) treated with warfarin or aspirin." | 5.20 | Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin. ( Anker, SD; Buchsbaum, R; Cheng, B; Di Tullio, MR; Estol, CJ; Freudenberger, RS; Graham, S; Homma, S; Labovitz, AJ; Levin, B; Lip, GY; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Teerlink, JR; Thompson, JL; Ye, S, 2015) |
| "We compared the effect of clopidogrel plus aspirin vs aspirin alone on functional outcome and quality of life in the Clopidogrel in High-risk Patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial of aspirin-clopidogrel vs aspirin alone after acute minor stroke or TIA." | 5.20 | Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: CHANCE substudy. ( Fang, J; Hu, B; Johnston, SC; Li, H; Liu, L; Meng, X; Wang, A; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Zhao, X, 2015) |
| "Apixaban was associated with fewer strokes and systemic embolism versus aspirin across all subgroups; however, it caused more major bleeding events." | 5.20 | Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients. ( Dorian, P; Kongnakorn, T; Lanitis, T; Lip, GY; Mardekian, J; Phatak, H, 2015) |
| "To study whether Clopidogrel-Aspirin combined treatment for high risk transient ischaemic attack (TIA) or minor stroke results in increased number of lesions associated with anti-thrombotic cerebral haemorrhage or cerebral micro-bleeds (CMB) than aspirin alone treatment." | 5.20 | Combined clopidogrel-aspirin treatment for high risk TIA or minor stroke does not increase cerebral microbleeds. ( Wang, P; Wang, Y; Wang, Z; Xin, H; Xu, C, 2015) |
| "The Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs." | 5.20 | Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT E ( Brueckmann, M; Cotton, D; Cronin, L; Diener, HC; Duffy, C; Easton, JD; Granger, CB; Sacco, RL, 2015) |
| " Treatment with rivaroxaban may prevent more cerebrovascular events with an acceptable risk profile after TIA or minor stroke, compared with aspirin, thus helping to improve the outcome of the disease." | 5.20 | Treatment of Rivaroxaban versus Aspirin for Non-disabling Cerebrovascular Events (TRACE): study protocol for a randomized controlled trial. ( Bai, Y; Han, J; Jiang, W; Liu, X; Yang, F; Zhang, G; Zhao, G, 2015) |
| "We examined the efficacy and safety of dual antiplatelets in patients with transient ischemic attack or minor stroke, defined as National Institute of Health Stroke Scale scores 0-3, in a subgroup analysis of Clopidogrel plus aspirin versus Aspirin alone for Reducing embolization in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR) study." | 5.19 | Dual antiplatelets reduce microembolic signals in patients with transient ischemic attack and minor stroke: subgroup analysis of CLAIR study. ( Chen, C; Fu, J; Han, Z; Huang, Y; Lau, AY; Leung, TW; Markus, HS; Ratanakorn, D; Suwanwela, NC; Tan, KS; Wong, KS; Zhao, Y, 2014) |
| "The goal of this study was to analyze the impact of dabigatran plasma concentrations, patient demographics, and aspirin (ASA) use on frequencies of ischemic strokes/systemic emboli and major bleeds in atrial fibrillation patients." | 5.19 | The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). ( Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Haertter, S; Lehr, T; Nehmiz, G; Reilly, PA; Wallentin, L; Wang, S; Yusuf, S, 2014) |
| "Apixaban had similar beneficial effects on stroke or systemic embolism and major bleeding compared with warfarin, irrespective of concomitant aspirin use." | 5.19 | Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. ( Alexander, JH; Alings, M; Atar, D; Aylward, P; Goto, S; Granger, CB; Hanna, M; Huber, K; Husted, S; Lewis, BS; Lopes, RD; McMurray, JJ; Pais, P; Pouleur, H; Steg, PG; Thomas, L; Verheugt, FW; Wallentin, L; Wojdyla, DM, 2014) |
| "In this study, patients taking 100 mg aspirin daily (orally) were examined after admittance to the stroke unit due to a stroke or stroke recurrence." | 5.19 | [Acetylsalicylic acid non-responders after ischemic insult in geriatric patients]. ( Kolb, GF; Nosul, M, 2014) |
| "We performed a secondary analysis from the Cilostazol in Acute Ischemic Stroke Treatment (CAIST) trial, which was a double-blinded, randomized, multicenter trial, assessing the noninferiority of cilostazol over aspirin within 48 hours of an acute ischemic stroke." | 5.19 | Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke. ( Bae, HJ; Kang, DW; Kwon, HM; Lee, YS, 2014) |
| "We randomised 238 patients with non-valvular atrial fibrillation and a moderate stroke risk to aspirin or adjusted vitamin K antagonist therapy after TEE had ruled out thrombogenic features in the atria and aorta." | 5.19 | Aspirin versus vitamin K antagonist treatment guided by transoesophageal echocardiography in patients with atrial fibrillation: a pilot study. ( Baur, LH; Cheriex, EC; Crijns, HJ; Dinh, T; Heesen, WF; Kamp, O; Lindeboom, JE; Pisters, R; Prins, MH; Smeets, JL; Tieleman, RG; Verheugt, FW, 2014) |
| "The AVERROES double-blinded, randomized trial demonstrated that apixaban reduces the risk of stroke or systemic embolism (SSE) by 55% compared with aspirin without an increase in major bleeding in patients with atrial fibrillation either who previously tried but failed vitamin K antagonists (VKA) therapy or who were expected to be unsuitable for VKA therapy." | 5.19 | Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial. ( Connolly, SJ; Coppens, M; Eikelboom, JW; Shestakovska, O; Synhorst, D; Yusuf, S, 2014) |
| "We evaluated the efficacy of low-molecular-weight heparin (LMWH) relative to aspirin in preventing early neurologic deterioration (END), venous thromboembolism (VTE), and outcomes at 6 months." | 5.19 | Low-molecular-weight heparin is more effective than aspirin in preventing early neurologic deterioration and improving six-month outcome. ( Chi, W; Lin, J; Wang, C; Yi, X; Zhang, B, 2014) |
| "This prospective randomized controlled, open-labeled trial, with blinded end point evaluation (PROBE design) tested superiority of aspirin 75 to 150 mg/d plus clopidogrel 75 mg/d (A+C) over warfarin therapy (international normalized ratio 2-3) in patients with ischemic stroke, transient ischemic attack, or peripheral embolism with plaque in the thoracic aorta>4 mm and no other identified embolic source." | 5.19 | Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. ( Amarenco, P; Cohen, AA; Davis, S; Donnan, GA; Heiss, WD; Jones, EF; Kaste, M; Laouénan, C; Macleod, M; Young, D, 2014) |
| "Altogether 574 patients with acute (≤2 days) large-artery atherosclerosis stroke were randomly assigned to receive either combined clopidogrel and aspirin or aspirin alone." | 5.19 | A comparative study of dual versus monoantiplatelet therapy in patients with acute large-artery atherosclerosis stroke. ( Chi, W; Lin, J; Wang, C; Yi, X; Zhang, B, 2014) |
| "To compare the therapeutic warfarin and aspirin efficacies for treatments of atrial fibrillation (AF) complicated with stable coronary heart disease particularly in older Chinese patients." | 5.19 | Warfarin compared with aspirin for older Chinese patients with stable coronary heart diseases and atrial fibrillation complications. ( Cao, G; Feng, L; Huang, H; Li, Y; Liu, X; Xu, Q; Yu, J; Zhang, S; Zhou, M, 2014) |
| "We showed that slower than standard dose escalation of dipyridamole in combination therapy with acetylsalicylic acid does not reduce headaches as a side effect." | 5.19 | The effect of a slower than standard dose escalation scheme for dipyridamole on headaches in secondary prevention therapy of strokes: a randomized, open-label trial (DOSE). ( de Vogel, EM; de Vos-Koppelaar, NC; Dieleman, HG; Kerkhoff, H; Zock, E, 2014) |
| "Ancillary analysis of the Apixaban Versus Acetylsalicylic Acid [ASA] to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trial, comparing aspirin and apixaban, focused on sex differences." | 5.19 | Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study. ( Connolly, S; Eikelboom, J; Hart, RG; Lip, GY; Shestakovska, O; Yusuf, S, 2014) |
| "In TRITON-TIMI 38, patients with acute coronary syndromes were treated with prasugrel or clopidogrel, with aspirin, for a median of 14." | 5.19 | An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. ( Costigan, T; Iqbal, K; Lopez-Sendon, J; Ramos, Y; Widimsky, P; Wilcox, R, 2014) |
| "Aspirin early after intravenous thrombolysis in acute ischemic stroke increases the risk of symptomatic intracranial hemorrhage (SICH), without influencing functional outcome at 3 months." | 5.19 | Early deterioration after thrombolysis plus aspirin in acute stroke: a post hoc analysis of the Antiplatelet Therapy in Combination with Recombinant t-PA Thrombolysis in Ischemic Stroke trial. ( Beenen, LF; de Haan, RJ; Majoie, CB; Marquering, HA; Roos, YB; Zinkstok, SM, 2014) |
| " Then, patients with no MACCE or major bleeding will be randomized to receive either 36 additional months of clopidogrel plus aspirin or aspirin only." | 5.17 | Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial. ( Carrie, D; Cattan, S; Cayla, G; Eltchaninoff, H; Furber, A; Georges, JL; Helft, G; Le Feuvre, C; Leclercq, F; Metzger, JP; Prunier, F; Sebagh, L; Vicaut, E, 2013) |
| "Among patients with TIA or minor stroke who can be treated within 24 hours after the onset of symptoms, the combination of clopidogrel and aspirin is superior to aspirin alone for reducing the risk of stroke in the first 90 days and does not increase the risk of hemorrhage." | 5.17 | Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. ( Cui, L; Dong, Q; Jia, J; Johnston, SC; Li, H; Li, Y; Liu, L; Meng, X; Wang, C; Wang, D; Wang, Y; Wang, Z; Xia, H; Xu, A; Zeng, J; Zhao, X, 2013) |
| "The recurrent stroke and cardiovascular event rates following discontinuation of aspirin plus extended-release dipyridamole (ASA + ERDP) or clopidogrel were compared to the event rates in the on-treatment populations (patients who had discontinued their antiplatelet medication due to an outcome event were kept in the on-treatment population in order not to underestimate the on-treatment stroke rate)." | 5.17 | Discontinuation of antiplatelet study medication and risk of recurrent stroke and cardiovascular events: results from the PRoFESS study. ( Bath, PM; Cotton, D; Diener, HC; Sacco, RL; Sha, N; Weber, R; Weimar, C, 2013) |
| "The aim of POINT is to determine whether clopidogrel plus aspirin taken <12 h after transient ischemic attack or minor ischemic stroke symptom onset is more effective in preventing major ischemic vascular events at 90 days in the high-risk, and acceptably safe, compared with aspirin alone." | 5.17 | Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. ( Barsan, W; Battenhouse, H; Conwit, R; Dillon, C; Easton, JD; Elm, J; Farrant, M; Johnston, SC; Lindblad, A; Morgenstern, L; Palesch, Y; Poisson, SN, 2013) |
| " Its aim was to investigate the potential effects of terutroban in patients with atherothrombotic disorders, in comparison to aspirin, on the evolution of magnetic resonance imaging (MRI) lesions after a recent ischemic stroke or transient ischemic attack (TIA)." | 5.17 | Results of the PERFORM magnetic resonance imaging study. ( Bracoud, L; Chabriat, H; Gass, A; Hennerici, M; Maeder, P; Michel, P, 2013) |
| " Eligible patients were those with stable coronary artery disease or history of low-risk acute coronary syndrome (ACS) undergoing PCI with zotarolimus-eluting stents." | 5.17 | Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. ( Abizaid, A; Abizaid, AS; Bhatt, DL; Botelho, RV; Castello, HJ; Costa, JR; Costa, RA; de Castro, JP; de Paula, JE; Devito, FS; Feres, F; Gusmão, M; King, SB; Labrunie, A; Leon, MB; Liu, M; Mangione, JA; Marin-Neto, JA; Meireles, GX; Negoita, M; Nicolela, EL; Perin, MA; Salvadori, D; Staico, R, 2013) |
| "Aspirin is the most commonly used antiplatelet drug for treatment of a serious vascular event, most notably stroke and myocardial infarction." | 5.17 | Association of COX-2 rs20417 with aspirin resistance. ( Al-Hazzani, A; Alshatwi, AA; Jyothy, A; Kaul, S; Munshi, A; Sharma, V, 2013) |
| " Patients were assessed at baseline [≤ 4 weeks of transient ischaemic attack (TIA) or ischaemic stroke], and at 14 days and ≥ 90 days after changing treatment from (i) no medication to aspirin monotherapy (N = 26) or (ii) aspirin to clopidogrel monotherapy (N = 22)." | 5.17 | High on-treatment platelet reactivity on commonly prescribed antiplatelet agents following transient ischaemic attack or ischaemic stroke: results from the Trinity Antiplatelet Responsiveness (TRAP) study. ( Collins, DR; Coughlan, T; Egan, B; Feeley, TM; Kinsella, JA; McCabe, DJ; Murphy, RP; O'Neill, D; Tierney, S; Tobin, WO, 2013) |
| "We selected all patients with a CHADS(2) score of 1 from the AVERROES and ACTIVE trials who were treated with acetylsalicylic acid with or without clopidogrel and calculated the incidences of ischaemic or unspecified stroke or systemic embolus (SSE) according to their CHA(2)DS(2)-VASc score." | 5.17 | The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. ( Connolly, SJ; Coppens, M; Dorian, P; Eikelboom, JW; Hart, RG; Lip, GY; Shestakovska, O; Yusuf, S, 2013) |
| "Low dose aspirin reduces the secondary incidence of myocardial infarction and stroke." | 5.17 | Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. ( FitzGerald, GA; Fries, S; Grant, GR; Grosser, T; Kapoor, SC; Lawson, JA, 2013) |
| "To investigate the prevalent of aspirin resistance (AR) in Chinese stroke patients and its association with recurrent stroke and other vascular events, including cardiovascular disease and death." | 5.17 | Aspirin resistance in Chinese stroke patients increased the rate of recurrent stroke and other vascular events. ( Chi, L; Lin, J; Yi, X; Zhou, Q, 2013) |
| "The multicenter PROTECT AF study (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) was conducted to determine whether percutaneous left atrial appendage closure with a filter device (Watchman) was noninferior to warfarin for stroke prevention in atrial fibrillation." | 5.17 | Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. ( Buchbinder, M; Doshi, SK; Halperin, JL; Holmes, D; Huber, K; Neuzil, P; Reddy, VY; Sievert, H, 2013) |
| "Because of its association with atrial fibrillation and heart failure, we hypothesized that amino terminal pro-B-type natriuretic peptide (NT-proBNP) would identify a subgroup of patients from the Warfarin-Aspirin Recurrent Stroke Study, diagnosed with inferred noncardioembolic ischemic strokes, where anticoagulation would be more effective than antiplatelet agents in reducing risk of subsequent events." | 5.17 | Amino terminal pro-B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy. ( Brey, RL; Buchsbaum, R; Christenson, RH; deFilippi, CR; Elkind, MS; Gross, R; Kronmal, RA; Levine, SR; Longstreth, WT; Mohr, JP; Seliger, SL; Thompson, JL; Tirschwell, DL, 2013) |
| "The impact of apixaban versus aspirin on ischemic stroke and major bleeding in relation to the CHADS(2) and CHA(2)DS(2)-VASc stroke risk scores in atrial fibrillation has not been investigated." | 5.17 | Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study. ( Connolly, S; Eikelboom, J; Flaker, G; Hart, R; Lanas, F; Lip, GY; Shestakovska, O; Xavier, D; Yusuf, S, 2013) |
| "Recent randomized trials have shown that cilostazol is superior to aspirin for secondary stroke prevention." | 5.16 | Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study. ( Nakamura, T; Tsuruta, S; Uchiyama, S, 2012) |
| "The Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study showed no superiority of low-molecular-weight heparin (LMWH) over aspirin for the primary end point (Barthel Index) in acute ischemic stroke due to large artery occlusive disease." | 5.16 | Low-molecular-weight heparin versus aspirin for acute ischemic stroke with large artery occlusive disease: subgroup analyses from the Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study. ( Chen, C; Chen, XY; Han, JH; Leung, TW; Mok, V; Soo, Y; Wang, QS; Wong, KS, 2012) |
| "In AVERROES, 5599 patients (mean age 70 years) with atrial fibrillation who were at increased risk of stroke and unsuitable for vitamin K antagonist therapy were randomly assigned to receive apixaban (5 mg twice daily) or aspirin (81-324 mg per day)." | 5.16 | Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. ( Connolly, SJ; Diener, HC; Eikelboom, J; Hankey, GJ; Hart, RG; Hohnloser, SH; Joyner, CD; Lip, GY; O'Donnell, M; Shestakovska, O; Yusuf, S, 2012) |
| "Dizziness was significantly improved in the cilostazol group versus the aspirin group (P<0." | 5.16 | Cilostazol versus aspirin therapy in patients with chronic dizziness after ischemic stroke. ( Johkura, K; Kudo, Y; Kuroiwa, Y; Momoo, T; Nakae, Y; Yoshida, TN, 2012) |
| "A regimen of 24 months of clopidogrel therapy in patients who had received a balanced mixture of drug-eluting or bare-metal stents was not significantly more effective than a 6-month clopidogrel regimen in reducing the composite of death due to any cause, myocardial infarction, or cerebrovascular accident." | 5.16 | Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. ( Borghesi, M; Campo, G; Cangiano, E; Castriota, F; Cavazza, C; Colombo, F; Ferrari, R; Frangione, A; Fucà, G; Kubbajeh, M; Marchesini, J; Minarelli, M; Monti, M; Parrinello, G; Percoco, G; Scalone, A; Tebaldi, M; Tumscitz, C; Valgimigli, M; Vranckx, P, 2012) |
| "We identified 9 independent risk factors for SICH: baseline National Institutes of Health Stroke Scale, serum glucose, systolic blood pressure, age, body weight, stroke onset to treatment time, aspirin or combined aspirin and clopidogrel, and history of hypertension." | 5.16 | Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. ( Ahmed, N; Egido, JA; Ford, GA; Lees, KR; Mazya, M; Mikulik, R; Toni, D; Wahlgren, N, 2012) |
| "We analyzed MRI of 133 patients admitted consecutively for intra- and extracranial stenting for symptomatic large artery atherosclerosis who received aspirin and clopidogrel." | 5.16 | Risk of intracerebral hemorrhage in patients with cerebral microbleeds undergoing endovascular intervention. ( Abrigo, J; Ahuja, AT; Leung, TW; Ng, N; Siu, DY; Soo, YO; Wong, LK; Yu, S, 2012) |
| "It is unknown whether warfarin or aspirin therapy is superior for patients with heart failure who are in sinus rhythm." | 5.16 | Warfarin and aspirin in patients with heart failure and sinus rhythm. ( Ammon, SE; Anker, SD; Buchsbaum, R; del Valle, ML; Di Tullio, MR; Estol, CJ; Freudenberger, RS; Gabriel, AP; Graham, S; Homma, S; Labovitz, AJ; Levin, B; Lip, GY; Lok, DJ; Mann, DL; Massie, BM; Mejia, V; Mohr, JP; Ponikowski, P; Pullicino, PM; Sacco, RL; Sanford, AR; Teerlink, JR; Thompson, JL, 2012) |
| " We investigated whether telmisartan prevents WML progression in the imaging substudy of the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial." | 5.16 | Telmisartan on top of antihypertensive treatment does not prevent progression of cerebral white matter lesions in the prevention regimen for effectively avoiding second strokes (PRoFESS) MRI substudy. ( Blatchford, J; Demchuk, AM; Diehl, A; Diener, HC; Forsting, M; Gizewski, ER; Hermansson, K; Möller-Hartmann, C; Sacco, RL; Saver, JL; Wanke, I; Warach, S; Weber, R; Weimar, C, 2012) |
| "In this multicentre, randomised, open-label trial with blind-endpoint assessment, patients with acute ischaemic stroke treated with alteplase were randomly assigned to 300 mg intravenous aspirin within 90 min after start of alteplase treatment or to no additional treatment." | 5.16 | Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. ( Roos, YB; Zinkstok, SM, 2012) |
| "Apixaban is superior to aspirin for the prevention of stroke in patients with atrial fibrillation." | 5.16 | Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. ( Connolly, SJ; De Caterina, R; Eikelboom, JW; Gao, P; Hart, RG; Husted, S; O'Donnell, M; Paolasso, E; Yusuf, S, 2012) |
| "Previous studies have suggested that pre-stroke treatment with low-dose aspirin (A) could reduce the severity of acute ischaemic stroke, but less is known on the effect of pre-stroke treatment with a combination of aspirin and dipyridamole (A + D) and post-stroke effects of these drugs." | 5.16 | Comparative evaluation of treatment with low-dose aspirin plus dipyridamole versus aspirin only in patients with acute ischaemic stroke. ( Andersson, B; Arnarsdottir, L; Bokemark, L; Hjalmarsson, C, 2012) |
| "Among 603 patients recruited, 353 patients(180 treated with LMWH, 173 with aspirin) had acute ischemic stroke and LAOD." | 5.16 | Low-molecular-weight heparin and early neurologic deterioration in acute stroke caused by large artery occlusive disease. ( Chen, C; Chen, XY; Han, JH; Leung, TW; Mok, V; Soo, Y; Wang, Q; Wong, KS, 2012) |
| "Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed." | 5.16 | Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ, 2012) |
| "Among patients with recent lacunar strokes, the addition of clopidogrel to aspirin did not significantly reduce the risk of recurrent stroke and did significantly increase the risk of bleeding and death." | 5.16 | Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. ( Benavente, OR; Coffey, CS; Hart, RG; McClure, LA; Pearce, LA; Szychowski, JM, 2012) |
| "Apixaban reduces stroke with comparable bleeding risks when compared with aspirin in patients with atrial fibrillation who are unsuitable for vitamin k antagonist therapy." | 5.16 | Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K ( Budaj, A; Connolly, SJ; Eikelboom, JW; Flaker, GC; Hart, RG; Husted, S; Kaatz, S; Lip, GY; Shestakovska, O; Yusuf, S, 2012) |
| "Patients with medically managed unstable angina or non-ST-segment elevation myocardial infarction were enrolled in the TRILOGY ACS trial (2008 to 2011) comparing clopidogrel vs prasugrel." | 5.16 | Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. ( Armstrong, PW; Brown, E; Chan, MY; Cornel, JH; Erlinge, D; Fox, KA; Goodman, SG; Gurbel, PA; Huber, K; Jakubowski, JA; Neely, B; Neely, M; Ohman, EM; Prabhakaran, D; Roe, MT; Tantry, US; White, HD; Zhou, C, 2012) |
| " We defined the time course and magnitude of changes of plasma eNOS and oxLDL after Aggrenox or aspirin in post-stroke patients." | 5.15 | Effects of Aggrenox and aspirin on plasma endothelial nitric oxide synthase and oxidised low-density lipoproteins in patients after ischaemic stroke. The AGgrenox versus aspirin therapy evaluation (AGATE) biomarker substudy. ( Eisert, C; Fong, A; Hanley, D; Sani, Y; Schevchuck, A; Serebruany, V, 2011) |
| " Platelet surface marker expression, leucocyte-platelet complex formation and inhibition of platelet function at high shear stress as detected by the PFA-100® Collagen-Adenosine-diphosphate (C-ADP) and Collagen-Epinephrine cartridges was assessed in 52 patients within 4 weeks of transient ischaemic attack (TIA) or ischaemic stroke on aspirin, and then 14 d (14 d) and >90 d (90 d) after adding dipyridamole." | 5.15 | Enhanced ex vivo inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: first results from the TRinity AntiPlatelet responsiveness (TrAP) study. ( Collins, DR; Coughlan, T; Egan, B; Feeley, TM; Kinsella, JA; McCabe, DJ; Murphy, RP; O'Neill, D; Tierney, S; Tobin, WO, 2011) |
| "The Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) trial was a prospective, randomized, open-label trial conducted throughout Japan that enrolled 2,539 type 2 diabetic patients without a history of atherosclerotic diseases." | 5.15 | Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. ( Akai, Y; Doi, N; Jinnouchi, H; Morimoto, T; Nakayama, M; Ogawa, H; Okada, S; Saito, Y; Soejima, H; Sugiyama, S; Uemura, S; Waki, M, 2011) |
| "Any bleeding and TIMI major bleeding complications increase in patients aged ≥75 years treated with clopidogrel in addition to aspirin." | 5.15 | Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study. ( Aydogdu, S; Balbay, Y; Cagirci, G; Cay, S; Demir, AD; Erbay, AR; Maden, O; Sen, N, 2011) |
| "In a double-blind study, we randomly assigned 5599 patients with atrial fibrillation who were at increased risk for stroke and for whom vitamin K antagonist therapy was unsuitable to receive apixaban (at a dose of 5 mg twice daily) or aspirin (81 to 324 mg per day), to determine whether apixaban was superior." | 5.15 | Apixaban in patients with atrial fibrillation. ( Afzal, R; Avezum, A; Budaj, A; Commerford, P; Connolly, SJ; Dans, AL; Diaz, R; Diener, HC; Eikelboom, J; Flaker, G; Golitsyn, S; Gonzalez-Hermosillo, A; Hart, R; Hohnloser, SH; Jansky, P; Joyner, C; Kim, JH; Lanas-Zanetti, F; Lawrence, J; Lewis, BS; Lewis, G; Lip, GY; Munawar, M; O'Donnell, M; Pais, P; Parkhomenko, A; Sim, KH; Talajic, M; Tan, RS; Van Mieghem, W; Yusuf, S; Zhu, J, 2011) |
| "Oral anticoagulants are effective at reducing stroke compared with aspirin in atrial fibrillation patients older than 75 years." | 5.15 | Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation. ( Bryan, S; Fitzmaurice, D; Fletcher, K; Hobbs, FD; Jowett, S; Lip, GY; Mant, J; Roalfe, A, 2011) |
| "Aspirin is a proven antiplatelet agent in acute ischemic stroke, and there are no current guidelines for other antiplatelet treatments." | 5.15 | Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial. ( Bae, HJ; Cho, YJ; Han, MG; Hong, KS; Jung, SW; Kang, DW; Kim, DE; Kim, JS; Koo, J; Kwon, SU; Lee, BC; Lee, JH; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Rha, JH; Yu, K, 2011) |
| " Patients who had an ischaemic stroke in the previous 3 months or a TIA in the previous 8 days were randomly allocated with a central interactive response system to 30 mg per day terutroban or 100 mg per day aspirin." | 5.15 | Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. ( Amarenco, P; Bousser, MG; Chamorro, A; de Cordoüe, A; Fisher, M; Ford, I; Fox, KM; Fratacci, MD; Hennerici, MG; Mattle, HP; Rothwell, PM, 2011) |
| " The lowest risk of cardiovascular death, myocardial infarction, or stroke with ticagrelor compared with clopidogrel is associated with a low maintenance dose of concomitant aspirin." | 5.15 | Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. ( Angiolillo, DJ; Becker, RC; Cannon, CP; Carroll, K; Harrington, RA; Held, C; Horrow, J; James, S; Mahaffey, KW; Pieper, KS; Storey, RF; Wallentin, L; Wojdyla, DM, 2011) |
| "The trial was terminated prematurely after recruitment of 7392 patients because of an increase in major bleeding events with apixaban in the absence of a counterbalancing reduction in recurrent ischemic events." | 5.15 | Apixaban with antiplatelet therapy after acute coronary syndrome. ( Alexander, JH; Atar, D; Bhatt, DL; Cools, F; Cornel, JH; Darius, H; De Caterina, R; Diaz, R; Flather, M; Geraldes, M; Goodman, S; Harrington, RA; He, Y; Huber, K; Husted, SE; James, S; Jansky, P; Keltai, M; Kilaru, R; Lawrence, J; Leiva-Pons, JL; Liaw, D; Lopes, RD; Lopez-Sendon, J; Mohan, P; Ogawa, H; Pais, P; Parkhomenko, A; Ruda, M; Ruzyllo, W; Verheugt, FW; Vinereanu, D; Wallentin, L; White, H, 2011) |
| "Using five-colour flow cytometry the platelet surface expression of CD62P and CD40L and subpopulations of leukocyte-platelet aggregates were assessed in 63 acute stroke patients and 40 healthy volunteers at baseline and after a 10-day period of aspirin intake at a daily dose of 150 mg." | 5.15 | Aspirin treatment influences platelet-related inflammatory biomarkers in healthy individuals but not in acute stroke patients. ( Dworacki, G; Golanski, J; Kozubski, W; Kufel-Grabowska, J; Lukasik, M; Michalak, S; Watala, C, 2011) |
| "001) by adjusted-dose warfarin compared with aspirin/low-dose warfarin; there was no difference in major hemorrhage (5 patients versus 6 patients, respectively)." | 5.15 | Warfarin in atrial fibrillation patients with moderate chronic kidney disease. ( Asinger, RW; Hart, RG; Herzog, CA; Pearce, LA, 2011) |
| "Adding clopidogrel to aspirin therapy reduces stroke in patients with atrial fibrillation (AF) but increases hemorrhage." | 5.15 | Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. ( Connolly, SJ; de Caterina, R; Eikelboom, JW; Hart, RG; Hirsh, J; Hohnloser, S; Ng, J; Pogue, J; Yusuf, S, 2011) |
| "In this large observational analysis of patients undergoing PCI, low-dose aspirin appeared to be as effective as higher doses in preventing ischaemic events but was also associated with a lower rate of major bleeding and an improved net efficacy to safety balance." | 5.14 | Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. ( Avezum, A; Fox, KA; Gersh, BJ; Haladyn, K; Jolly, SS; Mehta, SR; Peters, RJ; Pogue, J; Rupprecht, HJ; Yusuf, S, 2009) |
| "TAIST was a randomized controlled trial assessing 10 days of treatment with tinzaparin versus aspirin in 1489 patients with acute ischemic stroke (<48 hr) with admission BP of | 5.14 | The relationship between baseline blood pressure and computed tomography findings in acute stroke: data from the tinzaparin in acute ischaemic stroke trial (TAIST). ( Bath, PM; Christensen, H; De Deyn, PP; England, T; Geeganage, C; Gray, LJ; Leys, D; Moulin, T; O'Neill, D; Ringelstein, EB; Sare, GM; Woimant, F, 2009) |
| "We compared baseline features and the rates of stroke or vascular death and stroke in the territory of the symptomatic artery between patients ON (n=299) versus OFF (n=269) antithrombotics at the time of their qualifying event for the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) trial." | 5.14 | Failure of antithrombotic therapy and risk of stroke in patients with symptomatic intracranial stenosis. ( Chimowitz, MI; Cotsonis, G; Levine, SR; Lynn, MJ; Maidan, L; Romano, JG; Turan, TN, 2009) |
| "Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead." | 5.14 | Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009) |
| "The relationship between arch plaques and recurrent events was studied in 516 patients with ischemic stroke who were double-blindly randomized to treatment with warfarin or aspirin as part of the Patent Foramen Ovale in Cryptogenic Stroke Study (PICSS), based on the Warfarin-Aspirin Recurrent Stroke Study (WARSS)." | 5.14 | Aortic arch plaques and risk of recurrent stroke and death. ( Di Tullio, MR; Homma, S; Jin, Z; Mohr, JP; Russo, C; Sacco, RL, 2009) |
| "We evaluated the location, type (lacunar vs nonlacunar), cause, and severity of stroke in patients who had an ischemic stroke endpoint in the Warfarin Aspirin Symptomatic Intracranial Disease (WASID) trial." | 5.14 | Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis. ( Chimowitz, MI; Famakin, BM; George, MG; Lynn, MJ; Stern, BJ, 2009) |
| "The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study is an international double-blind, randomized controlled trial designed to investigate the superiority of the specific TP receptor antagonist terutroban (30 mg/day) over aspirin (100 mg/day), in reducing cerebrovascular and cardiovascular events in patients with a recent history of ischemic stroke or transient ischemic attack." | 5.14 | The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population. ( Amarenco, P; Bousser, MG; Chamorro, A; Fisher, M; Ford, I; Fox, K; Hennerici, M; Mattle, HP; Rothwell, PM, 2009) |
| "Secondary pharmacological prevention of ischemic stroke or transient ischemic attack (TIA) is often provided with acetylsalicylic acid (ASA), dipyridamole (DP) or a combination of the two." | 5.14 | Dipyridamole-associated headache in stroke patients--interindividual differences? ( Lökk, J, 2009) |
| "In this double-blind, dose-escalation, phase II study, undertaken at 297 sites in 27 countries, 3491 patients stabilised after an acute coronary syndrome were stratified on the basis of investigator decision to use aspirin only (stratum 1, n=761) or aspirin plus a thienopyridine (stratum 2, n=2730)." | 5.14 | Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. ( Barnathan, ES; Bordes, P; Braunwald, E; Burton, P; Gibson, CM; Hricak, V; Markov, V; Mega, JL; Misselwitz, F; Mohanavelu, S; Oppenheimer, L; Poulter, R; Witkowski, A, 2009) |
| "We quantified visit-to-visit variability in BP and explored potential confounding factors by analysing repeat measurements obtained every few months during follow-up in two large trials in patients with a transient ischaemic attack (TIA) or minor ischaemic stroke: the UK-TIA Aspirin Trial (effect of aspirin, effect of season and day of the week of measurement) and the European Carotid Surgery Trial (ECST - effect of carotid endarterectomy)." | 5.14 | Reproducibility of measures of visit-to-visit variability in blood pressure after transient ischaemic attack or minor stroke. ( Howard, SC; Rothwell, PM, 2009) |
| "To explore whether triflusal may modulate those pathways in human stroke, evolution of several inflammation markers (pro-inflammatory, adhesion molecules, chemokines, metalloproteinases, apoptosis and angiogenesis-related biomarkers) and neurological outcome were evaluated at baseline, and at days 1, 3, 7 and 90 in a pilot study in which 30 patients with acute ischemic stroke were randomly allocated to receive triflusal or aspirin." | 5.14 | Triflusal and aspirin have different effects on inflammatory biomarkers measured in patients with acute ischemic stroke. ( Alvarez-Sabín, J; García-Bonilla, L; Krupinski, J; Montaner, J; Penalba, A; Quintana, M, 2009) |
| "Extended release dipyridamole (ERD) is widely used in patients after ischaemic stroke; however, the ability of this antithrombotic agent to be stored in different blood cells has never been explored in post-stroke patients." | 5.14 | Distribution of dipyridamole in blood components among post-stroke patients treated with extended release formulation. ( Atar, OD; Booze, C; Eisert, C; Hanley, D; Sabaeva, E; Serebruany, V, 2009) |
| "The antithrombotic, antiplatelet and endothelial activity of terutroban, a specific thromboxane prostaglandin receptor antagonist, was assessed in patients previously treated with aspirin for the prevention of ischemic stroke." | 5.14 | Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. ( Bal Dit Sollier, C; Bergmann, JF; Bousser, MG; Crassard, I; Drouet, L; Simoneau, G, 2009) |
| "Despite its widespread use, there are many concerns about the efficacy of aspirin in the secondary prevention of cardiovascular events after stroke, leading to the concept of aspirin non-response (ANR)." | 5.14 | Stroke and aspirin non-responder patients: relation with hypertension and platelet response to adenosine diphosphate. ( Chomel, JC; Godeneche, G; Macchi, L; Neau, JP; Ragot, S; Sorel, N, 2009) |
| "We present the protocol of a multicenter randomized clinical trial (n = 800) investigating the effects of immediate addition of aspirin to rt-PA on poor outcome (modified Rankin score >2) in ischemic stroke patients." | 5.14 | Antiplatelet therapy in combination with rt-PA thrombolysis in ischemic stroke (ARTIS): rationale and design of a randomized controlled trial. ( de Haan, RJ; Roos, YB; Stam, J; Vermeulen, M; Zinkstok, SM, 2010) |
| "In this double-blind multicenter trial, 244 aspirin users with ischaemic stroke were randomly assigned to receive cilostazol 100 mg twice daily or to placebo." | 5.14 | Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial. ( Cha, JK; Ha, SW; Kwon, SU; Lee, JH; Lee, SJ, 2010) |
| "During the clinical follow-up, ischemic stroke recurred in 2 patients in cilostazol group, while in aspirin group, one case of ischemic stroke recurrence and one case of acute myocardial infarction were found." | 5.14 | Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. ( Guo, JJ; Lin, QY; Xie, HF; Xu, E; Zeng, GL, 2009) |
| "In spite of the fact that the null hypothesis was not supported by our data, we found results supporting the safety (and potential efficacy) of ASA and tirofiban when used in the first hours of acute ischemic stroke." | 5.14 | Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial. ( Boiti, C; Borutti, G; Cazzaniga, M; Falaschi, F; Maestroni, A; Mandelli, C; Manganaro, D; Monzani, V; Rossi, P; Torgano, G; Zecca, B; Zilioli, E, 2010) |
| "In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain." | 5.14 | Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010) |
| "The factorial PRoFESS secondary prevention trial assessed antiplatelet and blood pressure-lowering strategies in 20,332 patients, 1360 of whom were randomized within 72 hours of ischemic stroke to combined aspirin (Asp; 25 mg BID) and extended-release dipyridamole (ER-DP; 200 mg BID, n=672) or clopidogrel (75 mg/d, n=688)." | 5.14 | Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. ( Bath, PM; Cotton, D; Diener, HC; Estol, C; Martin, RH; Palesch, Y; Roberts, R; Sacco, R; Yusuf, S, 2010) |
| "The Aspirin for Asymptomatic Atherosclerosis trial was an intention-to-treat double-blind randomized controlled trial conducted from April 1998 to October 2008, involving 28,980 men and women aged 50 to 75 years living in central Scotland, free of clinical cardiovascular disease, recruited from a community health registry, and had an ABI screening test." | 5.14 | Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. ( Butcher, I; Fowkes, FG; Fox, KA; Leng, GC; Lowe, GD; Murray, GD; Pell, AC; Price, JF; Sandercock, PA; Stewart, MC, 2010) |
| "The use of dual antiplatelet therapy for a period longer than 12 months in patients who had received drug-eluting stents was not significantly more effective than aspirin monotherapy in reducing the rate of myocardial infarction or death from cardiac causes." | 5.14 | Duration of dual antiplatelet therapy after implantation of drug-eluting stents. ( Chae, JK; Cheong, SS; Choi, YJ; Chung, WS; Han, KH; Hur, SH; Jang, JS; Jeon, DS; Jeong, MH; Kang, SJ; Kim, KS; Kim, YH; Lee, BK; Lee, CW; Lee, K; Lee, NH; Lee, SG; Lee, SW; Lim, DS; Nah, DY; Park, DW; Park, HS; Park, SJ; Park, SW; Rha, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2010) |
| "The clopidogrel plus aspirin for infarction reduction in acute stroke or transient ischaemic attack patients with large artery stenosis and microembolic signals (CLAIR) trial was a randomised, open-label, blinded-endpoint trial." | 5.14 | Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. ( Chang, HM; Chen, C; Chollate, P; Fu, J; Han, Z; Hao, Q; Huang, YN; Koh, A; Markus, HS; Ratanakorn, D; Suwanwela, NC; Tan, KS; Wong, KS; Zhao, Y, 2010) |
| " However, the reported use of warfarin among patients with AF at elevated risk of stroke remains low." | 5.14 | Warfarin and aspirin use in atrial fibrillation among practicing cardiologist (from the AFFECTS Registry). ( Kowey, PR; Myerburg, R; Naccarelli, GV; Packer, DL; Pratt, CM; Reiffel, JA; Reiter, MJ; Waldo, AL, 2010) |
| "To evaluate the efficacy and safety of aspirin in preventing stroke and mortality in tuberculous meningitis (TBM)." | 5.14 | Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial. ( Kalita, J; Misra, UK; Nair, PP, 2010) |
| " Our objective is to investigate whether immediate addition of aspirin to rt-PA thrombolysis improves functional outcome in ischemic stroke." | 5.14 | A randomised controlled trial of antiplatelet therapy in combination with Rt-PA thrombolysis in ischemic stroke: rationale and design of the ARTIS-Trial. ( de Haan, RJ; Roos, YB; Stam, J; Vermeulen, M; Zinkstok, SM, 2010) |
| "PERFORM is exploring the efficacy of terutroban versus aspirin for secondary prevention in patients with a history of ischemic stroke or transient ischemic attacks (TIAs)." | 5.14 | Rationale, design and population baseline characteristics of the PERFORM vascular project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke o ( Bots, ML; Ford, I; Hennerici, MG; Laurent, S; Touboul, PJ, 2010) |
| "8%) patients had a definite adjudicated stroke and a follow-up assessment of the mRS at 3 months poststroke, of whom 202 had been randomly assigned clopidogrel and 234 placebo (relative risk reduction 14%, 95% CI: -4% to 29%, P=0." | 5.14 | Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial. ( Bhatt, DL; Brennan, DM; Easton, JD; Fox, KA; Hacke, W; Hankey, GJ; Johnston, SC; Mas, JL; Topol, EJ, 2010) |
| " In the 3371 patients randomized to vitamin K antagonists and the 3335 patients randomized to clopidogrel plus aspirin in ACTIVE-W, the hazard ratio (HR) and 95% confidence intervals (95% CIs) for subsequent death associated with the occurrence of non-fatal stroke was 5." | 5.14 | Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. ( Budaj, A; Chrolavicius, S; Connolly, SJ; De Caterina, R; Morais, J; Pogue, J; Renda, G; Yusuf, S, 2010) |
| "The 160 patients with acute ischemic stroke were divided into two groups randomly: treatment group 85 cases (Songling Xuemaikang + Shuxuetong + Aspirin enterie coated tablets), control group 75 cases (Shuxuetong + Aspirin enterie ccoated tablets)." | 5.14 | [Changes of plasma fibrinogen level among acute ischemic stroke subtypes according to TOAST criteria and effects of Songling Xuemaikang]. ( Chen, Y; Huang, J; Liu, G; Liu, X; Lu, N; Xu, Y; Yang, D, 2010) |
| "In patients with an acute coronary syndrome who were referred for an invasive strategy, there was no significant difference between a 7-day, double-dose clopidogrel regimen and the standard-dose regimen, or between higher-dose aspirin and lower-dose aspirin, with respect to the primary outcome of cardiovascular death, myocardial infarction, or stroke." | 5.14 | Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Diaz, R; Eikelboom, JW; Fox, KA; Granger, CB; Jolly, S; Joyner, CD; Mehta, SR; Pogue, J; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2010) |
| "The study will randomize 5,100 Chinese patients with acute TIA or minor stroke to receive a 3-month regimen of clopidogrel initiated with a loading dose of 300 mg followed by 75 mg/d, combined with aspirin 75 mg/d during the first 21 days, or a 3-month regimen of aspirin 75 mg/d alone." | 5.14 | Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event. ( Johnston, SC; Wang, Y, 2010) |
| "Patients aged 20-79 years who had had a cerebral infarction within the previous 26 weeks were enrolled at 278 sites in Japan and allocated to receive 100 mg cilostazol twice daily or 81 mg aspirin once daily for 1-5 years." | 5.14 | Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. ( Genka, C; Hamada, C; Handa, S; Katayama, Y; Kitagawa, Y; Koretsune, Y; Kusuoka, H; Matsuoka, K; Nishimaru, K; Ohashi, Y; Sawada, T; Shinohara, Y; Tanahashi, N; Tsushima, M; Uchiyama, S; Yamaguchi, T; Yamamoto, H, 2010) |
| "The combination of low-dose aspirin and dipyridamole is more effective than aspirin alone in reducing the risk of recurrent stroke and other major cardiovascular events in patients with a recent transient ischemic attack or minor stroke." | 5.14 | Prevention with low-dose aspirin plus dipyridamole in patients with disabling stroke. ( Algra, A; Dippel, DW; Halkes, P; Kappelle, LJ; Koudstaal, PJ; Maasland, L, 2010) |
| "The analyses used data from the Tinzapararin in Acute Ischaemic Stroke Trial, a randomized controlled trial assessing tinzaparin (low molecular weight heparin) versus aspirin in 1484 patients with acute ischemic stroke." | 5.14 | Asymptomatic hemorrhagic transformation of infarction and its relationship with functional outcome and stroke subtype: assessment from the Tinzaparin in Acute Ischaemic Stroke Trial. ( Bath, PM; Christensen, H; De Deyn, P; England, TJ; Geeganage, C; Leys, D; Moulin, T; O'Neill, D; Ringelstein, EB; Sare, GM; Woimant, F, 2010) |
| "Although aspirin (ASA) remains the most popular and accepted agent for secondary stroke prevention, its efficacy does not exceed 25%." | 5.13 | Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke. ( Karepov, V; Kuliczkowski, W; Serebruany, V; Tolpina, G, 2008) |
| "The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel." | 5.13 | Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| "Patients who had had an ischaemic stroke were randomly assigned in a two by two factorial design to receive either 25 mg aspirin (ASA) and 200 mg extended-release dipyridamole (ER-DP) twice a day or 75 mg clopidogrel once a day, and either 80 mg telmisartan or placebo once per day." | 5.13 | Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFE ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; VanderMaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| "All patients with acute ischemic stroke or transient ischemic attack within a 10 month period were administered 600 mg clopidogrel bolus if they were already taking aspirin regularly, or had aspirin allergy or intolerance." | 5.13 | Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience. ( Abdelmoula, MM; Divani, AA; Hussein, HM; Qureshi, AI; Suri, MF, 2008) |
| "Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces major cardiovascular events in patients with ST and non-ST-segment-elevation acute coronary syndromes (ACS)." | 5.13 | Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. ( Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2008) |
| "To determine the prevalence of platelet nonresponsiveness to aspirin treatment for secondary stroke prophylaxis, the authors studied consecutive patients during a 29-month period." | 5.13 | Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. ( Bates, V; Forrest, A; Gengo, FM; Gengo, MF; Hourihane, M; Rainka, M; Robson, M, 2008) |
| "Aspirin offers modest reduction in stroke in patients with atrial fibrillation." | 5.13 | Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. ( Berger, PB; Bhatt, DL; Fox, KA; Hacke, W; Hankey, GJ; Hart, RG; Hu, T; Topol, EJ, 2008) |
| "In ACTIVE-W, oral anticoagulation (OAC) was more efficacious than combined clopidogrel plus aspirin (C+A) in preventing vascular events in patients with atrial fibrillation." | 5.13 | Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). ( Connolly, SJ; De Caterina, R; Flaker, G; Hart, RG; Healey, JS; Hohnloser, SH; Pfeffer, MA; Pogue, J; Yusuf, S, 2008) |
| "Thirty chronic ischemic stroke patients taking aspirin alone followed by aspirin-clopidogrel combined therapy had platelet reactivity tests performed over 3 months: ex vivo platelet aggregation, platelet recruitment and urinary 11-dehydro-thromboxane B(2) (11-dhTxB(2))excretion." | 5.13 | Platelet aggregation and recruitment with aspirin-clopidogrel therapy. ( Brace, LD; Cursio, J; Grossi, E; Helgason, CM; Pandey, D; Valika, A, 2008) |
| "Aspirin inhibits platelet activation and reduces major vascular events in patients with stable coronary artery disease." | 5.13 | Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study. ( Allal, J; Christiaens, L; Macchi, L; Mergy, J; Ragot, S, 2008) |
| "To examine the impact of prognostic factors on the outcome of treatment with warfarin or aspirin after acute myocardial infarction." | 5.13 | Less benefit from warfarin in diabetics after myocardial infarction? ( Abdelnoor, M; Arnesen, H; Hurlen, M; Smith, PJ, 2008) |
| "Most patients who have had a stroke are given aspirin; however, aspirin-related cerebral haemorrhage is a complication that is currently of concern, particularly in China where there is a high incidence of cerebral haemorrhage in secondary prevention programmes and within the community." | 5.13 | Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. ( Cheng, Y; Ding, M; Fan, D; Gao, X; Hong, Z; Huang, Y; Li, Y; Li, Z; Lu, C; Wong, K; Wu, J; Xiao, J; Xu, E; Yao, C; Zeng, J; Zhang, W, 2008) |
| "Patients experiencing acute ischemic stroke or transient ischemic attack are commonly treated with clopidogrel and/or aspirin (mono- and dual-antiplatelet therapy) to minimize the risk for recurrent stroke." | 5.12 | Efficacy and safety of clopidogrel and/or aspirin for ischemic stroke/transient ischemic attack: An overview of systematic reviews and meta-analysis. ( Huang, Z; Yang, Y; Zhang, X, 2021) |
| "As compared to aspirin alone, short-term DAPT within 24 hours of high-risk transient ischemic attack or mild-moderate ischemic stroke reduces the risk of recurrent stroke at the expense of higher risk of major bleeding." | 5.12 | Dual Antiplatelet Therapy Versus Aspirin in Patients With Stroke or Transient Ischemic Attack: Meta-Analysis of Randomized Controlled Trials. ( Aggarwal, D; Arora, S; Bhatia, K; Hussain, Z; Jain, V; Qamar, A; Ricciardi, M; Tafur, A; Uberoi, G; Vaduganathan, M; Zhang, C, 2021) |
| " The evidence is uncertain if warfarin has any effect on all-cause death compared to placebo or no treatment, but it may increase the risk of major bleeding events." | 5.12 | Anticoagulation versus placebo for heart failure in sinus rhythm. ( Kozieł, M; Lip, GY; Shantsila, E, 2021) |
| "In patients with noncardioembolic mild stroke or high-risk transient ischemic attack, DAPT with aspirin and clopidogrel/ticagrelor is more effective than aspirin alone for recurrent stroke prevention with a small absolute increase in the risk of severe or moderate bleeding." | 5.12 | P2Y12 Inhibitors Plus Aspirin Versus Aspirin Alone in Patients With Minor Stroke or High-Risk Transient Ischemic Attack. ( Fisher, M; Gu, HQ; Johnston, SC; Li, ZX; Wang, YJ; Xian, Y; Xiong, Y, 2021) |
| "gov databases, main international conference proceedings were searched for randomized controlled trials comparing DAPT versus aspirin monotherapy in patients with acute ischemic stroke or TIA not eligible for thrombolysis or thrombectomy presenting in the first 24 hours after the acute event." | 5.12 | Clinical Effects of Dual Antiplatelet Therapy or Aspirin Monotherapy after Acute Minor Ischemic Stroke or Transient Ischemic Attack, a Meta-Analysis. ( Condello, F; Ferrante, G; Liccardo, G, 2021) |
| "We investigated the platelet function in stroke patients treated with aspirin [acetylsalicylic acid (ASA)] for secondary stroke prevention during a follow-up period of 1 year." | 5.12 | Aspirin resistance in secondary stroke prevention. ( Berrouschot, J; Fischer, C; Roessler, A; Schwetlick, B; Siegemund, A; Siegemund, T; Uhlemann, H; von Twickel, G, 2006) |
| "For prevention of stroke in patients with NVAF, aspirin at 150 to 200 mg per day does not seem to be either effective or safe." | 5.12 | Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. ( Doi, Y; Fukuyama, T; Hiramori, K; Hori, M; Ishikawa, K; Izumi, T; Kitabatake, A; Maruyama, Y; Matsumoto, M; Mochizuki, S; Ogawa, S; Origasa, H; Sato, H; Takekoshi, N; Uchiyama, S; Yamaguchi, T; Yokota, Y; Yoshida, K, 2006) |
| " Orbofiban, despite no significant excess risk of ICH, was not effective in preventing ischemic stroke or TIA." | 5.12 | Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. ( Cannon, CP; Feske, SK; Murphy, S; Schwamm, LH; Smith, EE, 2006) |
| " Overall, clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing the rate of myocardial infarction, stroke, or death from cardiovascular causes." | 5.12 | Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. ( Berger, PB; Bhatt, DL; Black, HR; Boden, WE; Booth, J; Brennan, DM; Cacoub, P; Cohen, EA; Creager, MA; Easton, JD; Fabry-Ribaudo, L; Flather, MD; Fox, KA; Hacke, W; Haffner, SM; Hamm, CW; Hankey, GJ; Johnston, SC; Mak, KH; Mas, JL; Montalescot, G; Pearson, TA; Steg, PG; Steinhubl, SR; Topol, EJ; Weber, MA, 2006) |
| "We performed a combination of prespecified and exploratory subgroup analyses to detect any treatment differences among various baseline subgroups in the Warfarin-Aspirin Recurrent Stroke Study (WARSS) cohort." | 5.12 | Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death: subgroup analyses from the Warfarin-Aspirin Recurrent Stroke Study. ( Levin, B; Mohr, JP; Murphy, A; Prabhakaran, S; Sacco, RL; Sciacca, RR; Thompson, JL, 2006) |
| "Results of trials of aspirin and dipyridamole combined versus aspirin alone for the secondary prevention of vascular events after ischaemic stroke of presumed arterial origin are inconsistent." | 5.12 | Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. ( Algra, A; Halkes, PH; Kappelle, LJ; Koudstaal, PJ; van Gijn, J, 2006) |
| "Oral anticoagulation therapy is superior to clopidogrel plus aspirin for prevention of vascular events in patients with atrial fibrillation at high risk of stroke, especially in those already taking oral anticoagulation therapy." | 5.12 | Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. ( Chrolavicius, S; Connolly, S; Hart, R; Hohnloser, S; Pfeffer, M; Pogue, J; Yusuf, S, 2006) |
| "Combination of low-dose aspirin and modified-release dipyridamole (ASA+MR-DP) provides a significantly increased benefit in stroke prevention over aspirin alone." | 5.12 | Dose titration to reduce dipyridamole-related headache. ( Chang, YJ; Lee, TH; Ryu, SJ, 2006) |
| "In the European Stroke Prevention Study (ESPS 2), oral administration of a fixed combination of 200 mg extended-release dipyridamole and 25 mg aspirin (twice daily) after ischemic stroke or transient ischemic attack, significantly reduced the risk of stroke compared to placebo as well as compared to aspirin or dipyridamole alone." | 5.12 | Dipyridamole/aspirin combination in secondary stroke prevention: effects on absolute myocardial blood flow and coronary vascular resistance. ( Buell, U; Koch, KC; Noth, J; Nowak, B; Schaefer, WM; Weiss, PH, 2006) |
| "Low-dose aspirin taken every other day helps prevent stroke in women aged 45 years and older, but does not prevent a first myocardial infarction (MI) or cardiovascular death among healthy women." | 5.12 | Aspirin prevents stroke but not MI in women; vitamin E has no effect on CV disease or cancer. ( Buring, JE, 2006) |
| "Oral anticoagulants are better than aspirin for secondary prevention after myocardial infarction and after cerebral ischaemia in combination with non-rheumatic atrial fibrillation." | 5.12 | Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. ( Algra, A; Halkes, PH; Kappelle, LJ; Koudstaal, PJ; van Gijn, J, 2007) |
| "Aspirin resistance may increase the risk of major adverse cardiac events (MACE) more than threefold in patients with stable coronary artery disease (CAD)." | 5.12 | Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR). ( Mercanoglu, F; Meric, M; Nisanci, Y; Oflaz, H; Oncul, A; Onur, I; Ozcan, M; Pamukcu, B; Umman, B, 2007) |
| " The recently published European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT), an open-label randomised controlled study, compared long-term treatment of patients randomised to aspirin 30-325 mg daily with (n = 1363) or without (n = 1376) dipyridamole 200 mg twice daily." | 5.12 | ESPRIT study design and outcomes--a critical appraisal. ( Einhäupl, K, 2007) |
| "PRoFESS is the largest secondary stroke prevention trial to date and will directly compare two antiplatelet regimens as well as the benefit of telmisartan versus placebo." | 5.12 | Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with ( Diener, HC; Sacco, R; Yusuf, S, 2007) |
| " The rate of cardiovascular death, MI, or stroke was significantly lower in the clopidogrel plus aspirin arm than in the placebo plus aspirin arm: 7." | 5.12 | Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. ( Berger, PB; Bhatt, DL; Black, HR; Boden, WE; Cacoub, P; Cohen, EA; Creager, MA; Easton, JD; Fabry-Ribaudo, L; Flather, MD; Fox, KA; Hacke, W; Hamm, CW; Hankey, GJ; Hu, T; Johnston, SC; Mak, KH; Mas, JL; Montalescot, G; Pearson, TA; Steg, PG; Steinhubl, SR; Topol, EJ; Weber, MA, 2007) |
| "A large number of patients experience ischemic stroke despite treatment with aspirin (acetylsalicylic acid, ASA)." | 5.12 | Variable platelet response to aspirin in patients with ischemic stroke. ( Boucher, M; Hohlfeld, T; Junghans, U; Schrör, K; Schumacher, M; Siebler, M; Weber, AA, 2007) |
| "2) with atrial fibrillation were recruited from primary care and randomly assigned to warfarin (target international normalised ratio 2-3) or aspirin (75 mg per day)." | 5.12 | Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. ( Fitzmaurice, D; Fletcher, K; Hobbs, FD; Lip, GY; Mant, J; Murray, E; Roalfe, A, 2007) |
| "We examined the outcomes of 627 noncardioembolic stroke patients who were double-blindly assigned to either warfarin or aspirin therapy and assessed VaT using transesophageal echocardiography." | 5.12 | Impact of valvular thickness on stroke recurrence in medically treated patients with stroke. ( Abe, Y; Di Tullio, MR; Homma, S; Jin, Z; Mohr, JP; Okajima, K; Sacco, RL; Salameh, MJ; Suzuki, K, 2007) |
| "TAIST was a randomized, controlled trial assessing the safety and efficacy of tinzaparin versus aspirin in 1484 patients with acute ischemic stroke." | 5.12 | Sex differences in quality of life in stroke survivors: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST). ( Bath, PM; Boysen, G; De Deyn, PP; Gray, LJ; Leys, D; O'Neill, D; Ringelstein, EB; Sprigg, N, 2007) |
| "Immediately after TIA or minor stroke, patients are at high risk of stroke, which might be reduced by using clopidogrel in addition to aspirin." | 5.12 | Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. ( Buchan, AM; Demchuk, AM; Eliasziw, M; Hill, MD; Kennedy, J; Ryckborst, KJ, 2007) |
| "Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention." | 5.12 | Prasugrel versus clopidogrel in patients with acute coronary syndromes. ( Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD, 2007) |
| "The ACTIVE W (Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events) was a trial comparing OAC to combined antiplatelet therapy with aspirin and clopidogrel for prevention of vascular events in 6,706 AF patients." | 5.12 | Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. ( Connolly, SJ; Healey, JS; Hohnloser, SH; Pajitnev, D; Pfeffer, MA; Pogue, J; Yusuf, S, 2007) |
| "Aspirin is used commonly to prevent ischemic strokes and other vascular events." | 5.11 | Antiplatelet effect of aspirin in patients with cerebrovascular disease. ( Alberts, MJ; Bergman, DL; Jovanovic, BD; Molner, E; Teruya, J; Ushiwata, I, 2004) |
| "In the majority of patients with acute ischemic stroke, ASA and acetaminophen are insufficient for reducing an elevated BT to a state of normothermia." | 5.11 | Acetylsalicylic acid and acetaminophen to combat elevated body temperature in acute ischemic stroke. ( De Keyser, J; Elting, JW; Luijckx, GJ; Luyckx, GJ; Maurits, N; Sulter, G, 2004) |
| "The Antiphospholipid Antibodies and Stroke Study (APASS), a prospective cohort study within the Warfarin vs Aspirin Recurrent Stroke Study (WARSS), a randomized double-blind trial (N = 2206) conducted at multiple US clinical sites from June 1993 through June 2000 and comparing adjusted-dose warfarin (target international normalized ratio, 1." | 5.11 | Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. ( Brey, RL; Costigan, TM; Levin, B; Levine, SR; Lu, Y; Mohr, JP; Murphy, A; Rhine, C; Sacco, RL; Sciacca, RR; Thompson, JL; Tilley, BC; Triplett, DA, 2004) |
| "To evaluate whether long-term treatment with a fixed low dose of warfarin in combination with aspirin improves the prognosis compared with aspirin treatment alone after an acute myocardial infarction (AMI)." | 5.11 | Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study. ( Erhardt, L; Haglid Evander, M; Herlitz, J; Holm, J; Karlson, BW; Peterson, M, 2004) |
| "The CAPRIE study showed the superiority of clopidogrel over acetylsalicylic acid (ASA) for reducing the combined risk of major atherothrombotic events in patients with recent myocardial infarction (MI), recent ischaemic stroke (IS) or established peripheral arterial disease." | 5.11 | Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. ( Bogousslavsky, J; Brass, LM; Cimminiello, C; Csiba, L; Diener, HC; Kaste, M; Leys, D; Matias-Guiu, J; Rupprecht, HJ, 2004) |
| "Atrial fibrillation patients with TIA have a lower long-term risk of subsequent stroke than those with prior stroke, but their stroke risk during aspirin therapy is still high." | 5.11 | Transient ischemic attacks in patients with atrial fibrillation: implications for secondary prevention: the European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III trial. ( Hart, RG; Koudstaal, PJ; Pearce, LA, 2004) |
| "We studied 18 558 patients with ischemic stroke, myocardial infarction, or peripheral arterial disease who participated in the trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE), a study that compared the occurrence of ischemic stroke, myocardial infarction, or vascular death under randomized treatment with aspirin or clopidogrel." | 5.11 | Leukocyte count as an independent predictor of recurrent ischemic events. ( Boddy, AW; Brandt, T; Buggle, F; Dukovic, DA; Grau, AJ; Hacke, W; Lichy, C, 2004) |
| "There is still worldwide disagreement about the optimal lowest dose of aspirin to be used in patients after a transient ischemic attack (TIA) or nondisabling stroke." | 5.11 | What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke? ( Dippel, DW; Koudstaal, PJ; Leebeek, FW; Li, SS; Mehicevic, A; Van Kooten, F; van Vliet, HH, 2004) |
| " At the first a summary of the relevant evidence was provided and at the second detailed audit information was provided about fall rates, psychotropic drug prescribing and stroke risk reduction practices (BP monitoring, aspirin and warfarin use) for the facility relevant to the physician." | 5.11 | An outreach intervention to implement evidence based practice in residential care: a randomized controlled trial [ISRCTN67855475]. ( Crotty, M; Esterman, A; Finucane, P; Halbert, J; Rowett, D; Weller, D; Whitehead, C, 2004) |
| "This pilot trial has not found differences between triflusal and aspirin in the prevention of vascular complications after TIA or ischemic stroke, although given the wide CI, potentially important group differences could not be ruled out." | 5.11 | Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study. ( Abiusi, G; Bauso-Tosselli, L; Culebras, A; Domínguez, R; Famulari, A; Ferrari, J; Gori, H; Reich, E; Rey, R; Rotta-Escalante, R; Vila, J, 2004) |
| "In the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial, 12 562 patients were randomized to clopidogrel or placebo in addition to aspirin, and the primary outcome was cardiovascular (CV) death, myocardial infarction (MI), or stroke." | 5.11 | Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. ( Fox, KA; Gersh, BJ; Lakkis, N; Mehta, SR; Peters, R; Yusuf, S; Zhao, F, 2004) |
| "The European Stroke Prevention Study showed greater stroke prevention for Aggrenox than either for aspirin or dipyridamole alone." | 5.11 | Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. ( Atar, D; Hennekens, CH; Jilma, B; Malinin, AI; Sane, DC; Serebruany, VL; Takserman, A, 2004) |
| "We evaluated stroke incidence, subtypes, and outcomes, in addition to demographics and clinical risk characteristics associated with stroke among patients enrolled in the Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes (SYMPHONY) and 2nd SYMPHONY trials." | 5.11 | Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome. ( Bhapkar, MV; Califf, RM; Graffagnino, C; Kassem-Moussa, H; Mahaffey, KW; Newby, LK; Sila, CA; Simes, RJ; Tasissa, G; White, HD, 2004) |
| " Aspirin (A), clopidogrel (C), and dipyridamole (D) were administered singly and in various combinations (A, C, D, AC, AD, CD, ACD), each for two weeks (without washout) to 11 healthy subjects and to 11 patients with previous ischaemic stroke in two randomised multiway crossover trials." | 5.11 | Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke. ( Bath, P; Fletcher, S; Fox, S; Heptinstal, S; Leonardi-Bee, J; May, J; Weaver, C; Willmot, M; Zhao, L, 2005) |
| "Randomized trials have shown that low-dose aspirin decreases the risk of a first myocardial infarction in men, with little effect on the risk of ischemic stroke." | 5.11 | A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. ( Buring, JE; Cook, NR; Gaziano, JM; Gordon, D; Hennekens, CH; Lee, IM; Manson, JE; Ridker, PM, 2005) |
| "We randomly assigned patients with transient ischemic attack or stroke caused by angiographically verified 50 to 99 percent stenosis of a major intracranial artery to receive warfarin (target international normalized ratio, 2." | 5.11 | Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. ( Benesch, CG; Chaturvedi, S; Chimowitz, MI; Frankel, MR; Hertzberg, VS; Howlett-Smith, H; Jovin, TG; Kasner, SE; Levine, SR; Lynn, MJ; Romano, JG; Sila, CA; Stern, BJ, 2005) |
| "Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) is a randomized, double-blind study in subjects with recently symptomatic > or =50% carotid stenosis." | 5.11 | Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. ( Droste, DW; Kaps, M; Larrue, V; Lees, KR; Markus, HS; Ringelstein, EB; Siebler, M, 2005) |
| "The Clopidogrel for the Reduction of Events During Observation (CREDO) trial, a randomized trial of 2,116 patients, showed the effectiveness of antiplatelet therapy with clopidogrel 300 mg before PCI and 75 mg daily for one year afterward compared with placebo load and placebo days 29 to 365 in reducing the combined risk of death, myocardial infarction, and stroke." | 5.11 | Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) tria ( Beinart, SC; Bouin, O; Caro, J; Chen, R; Gabriel, S; Jackson, J; Kolm, P; Mahoney, EM; Steinhubl, S; Topol, E; Veledar, E; Weintraub, WS; Zhang, Z, 2005) |
| "Clopidogrel is widely used in patients after recent ischemic stroke; however, its ability to yield additional antiplatelet protection on top of aspirin has never been explored in a controlled study." | 5.11 | Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial. ( Alberts, MJ; Bhatt, DL; Hanley, DF; Malinin, AI; Pokov, AN; Serebruany, VL; Ziai, W, 2005) |
| "This pilot study enrolled ischemic stroke patients within 48 hours and randomized to aspirin 300 mg/d or combination (aspirin 300 mg/d+ standard release dipyridamole 75 mg thrice a day) and followed up for 6 months." | 5.11 | Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study. ( Chairangsarit, P; Nidhinandana, S; Niyasom, S; Sithinamsuwan, P; Suwantamee, J; Udommongkol, C, 2005) |
| "Antiplatelet treatment with aspirin and oral anticoagulants reduces recurrence of ischaemic events after myocardial infarction." | 5.10 | Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. ( Deckers, JW; Grobbee, DE; Jonker, JJ; van Es, RF; Verheugt, FW, 2002) |
| "In a case-crossover study, 31 patients with previous atherothrombotic or lacunar stroke who were treated with aspirin (100 to 300 mg/d) received clopidogrel (75 mg/d) and both aspirin and clopidogrel for 4 weeks." | 5.10 | Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. ( Buggle, F; Grau, AJ; Lichy, C; Reiners, S; Ruf, A, 2003) |
| "We performed a randomized, double-blind, multicenter study to test the efficacy of triflusal (600 mg/d) versus aspirin (325 mg/d) for prevention of vascular events in patients with stroke or transient ischemic attack (Triflusal versus Aspirin in Cerebral Infarction Prevention [TACIP])." | 5.10 | Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. ( Alvarez-Sabín, J; Ferro, JM; Jiménez, MD; Lago, A; Matías-Guiu, J; Melo, T; Torres, F, 2003) |
| " In this study, we showed that the combination regimen of clopidogrel with aspirin could downregulate the P-selectin expression on platelets and the plasma concentration of C-reactive protein (CRP) in acute stage of atherosclerotic ischemic stroke." | 5.10 | Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. ( Bae, HR; Cha, JK; Cheon, SM; Jeong, MH; Lee, KM; Lim, YJ; Park, KW, 2002) |
| "We measured vWf and sP-sel levels by ELISA in 994 participants receiving aspirin in the Stroke Prevention in Atrial Fibrillation III trial, at study entry or after 3 months, and related these indices to the subsequent incidence of stroke and vascular events." | 5.10 | Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. ( Chin, BS; Conway, DS; Hart, RG; Lip, GY; Pearce, LA, 2003) |
| "To determine the efficacy and safety of aspirin and ticlopidine to prevent recurrent stroke in black patients." | 5.10 | Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. ( Gorelick, PB; Harris, Y; Hung, E; Kelly, M; Kittner, S; Leurgans, S; Richardson, D; Ruland, S, 2003) |
| "The Thrombosis Prevention Trial was a primary prevention factorial trial that reported a reduction in the risk of coronary heart disease (CHD) with warfarin and/or aspirin." | 5.10 | Thrombosis prevention trial: compliance with warfarin treatment and investigation of a retained effect. ( Ashby, D; Brennan, P; Meade, T; Rudnicka, AR, 2003) |
| "In this study, 591 patients with recent cerebral ischemia of arterial origin were randomly allocated to treatment with aspirin 30 to 325 mg/d or with the combination of aspirin and dipyridamole 400 mg/d in the European/Australian Stroke Prevention in Reversible Ischemia Trial." | 5.10 | Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure. ( De Schryver, EL, 2003) |
| "We studied the benefits and risks of adding clopidogrel to different doses of aspirin in the treatment of patients with acute coronary syndrome (ACS)." | 5.10 | Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. ( Commerford, PJ; Diaz, R; Fox, KA; Kopecky, SL; Lewis, BS; Mehta, SR; Peters, RJ; Valentin, V; Yusuf, S; Zhao, F, 2003) |
| "To compare the efficacy and safety of two antiplatelet regimens, ticlopidine alone (200 mg daily) and ticlopidine (100 mg daily) plus aspirin (81 mg daily), in patients with ischemic stroke from the Tokai district of Japan." | 5.10 | Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke. ( Ito, E; Kuzuhara, S; Nakajima, M; Takahashi, A; Uchiyama, S; Yamamoto, H, 2003) |
| "Aspirin treatment did not significantly reduce the frequency of stroke progression." | 5.10 | Aspirin in the prevention of progressing stroke: a randomized controlled study. ( Britton, M; Leijd, B; Malmkvist, K; Rödén-Jüllig, A, 2003) |
| "The aim of the study was to evaluate the relationship between daily aspirin use and urinary excretion of a stable thromboxane metabolite, 11-dehydrothromboxane B(2) (11-DTB2), in African American stroke patients." | 5.10 | Aspirin and urinary 11-dehydrothromboxane B(2) in African American stroke patients. ( Bang, NU; Bruno, A; Cohen, SN; Mansbach, HH; McConnell, JP; Tietjen, GE, 2002) |
| "The PFO in Cryptogenic Stroke Study was a 42-center study that evaluated transesophageal echocardiographic findings in patients randomly assigned to warfarin or aspirin in the Warfarin-Aspirin Recurrent Stroke Study." | 5.10 | Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. ( Di Tullio, MR; Homma, S; Mohr, JP; Sacco, RL; Sciacca, RR, 2002) |
| "Compared with aspirin, clopidogrel reduced the combined risk of ischaemic stroke, myocardial infarction or vascular death by 8." | 5.09 | Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. ( Boissel, JP; Gent, M; Harker, LA; Pilgrim, AJ, 1999) |
| "The dose of aspirin for secondary stroke prevention and the clinical meaning of ex vivo platelet abnormalities are debated." | 5.09 | Ex vivo response to aspirin differs in stroke patients with single or recurrent events: a pilot study. ( Chamorro, A; Escolar, G; Obach, V; Ordinas, A; Reverter, JC; Revilla, M; Vila, N, 1999) |
| "A longitudinal cohort study was performed comparing 460 participants with intermittent AF with 1,552 with sustained AF treated with aspirin in the Stroke Prevention in Atrial Fibrillation studies and followed for a mean of two years." | 5.09 | Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. ( Asinger, RW; Halperin, JL; Hart, RG; McAnulty, JH; Pearce, LA; Rothbart, RM, 2000) |
| "30-day survivors of ischaemic stroke treated with low dose aspirin, modified-release dipyridamole; the coformulation of low dose aspirin plus modified-release dipyridamole, or no antiplatelet therapy." | 5.09 | Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole. ( Chambers, M; Gladman, J; Hutton, J, 1999) |
| "These associations between self-selected aspirin use and CVD risk factors increase the likelihood of residual confounding and emphasize the need for large-scale randomized trials, such as the ongoing Women's Health Study, to detect reliably the most plausible small to moderate effects of aspirin in the primary prevention of stroke and CVD-related death." | 5.09 | Self-selected posttrial aspirin use and subsequent cardiovascular disease and mortality in the physicians' health study. ( Buring, JE; Cook, NR; Hebert, PR; Hennekens, CH; Manson, JE, 2000) |
| "Heparin in Acute Embolic Stroke Trial (HAEST) was a multicentre, randomised, double-blind, and double-dummy trial on the effect of low-molecular-weight heparin (LMWH, dalteparin 100 IU/kg subcutaneously twice a day) or aspirin (160 mg every day) for the treatment of 449 patients with acute ischaemic stroke and atrial fibrillation." | 5.09 | Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. ( Abdelnoor, M; Berge, E; Nakstad, PH; Sandset, PM, 2000) |
| "The second European Stroke Prevention Study investigated the prevention of stroke and/or death in 6602 patients with transient ischaemic attack or stroke with aspirin (25 mg b." | 5.09 | Cardiac safety in the European Stroke Prevention Study 2 (ESPS2). ( Bertrand-Hardy, JM; Darius, H; Diener, HC; Humphreys, M, 2001) |
| "The Coumadin Aspirin Reinfarction Study demonstrated that combination treatment with fixed dose warfarin (1 or 3 mg) + aspirin 80 mg was not superior to aspirin 160 mg alone after myocardial infarction for reducing nonfatal reinfarction, nonfatal stroke, and cardiovascular death." | 5.09 | Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS). ( Berkowitz, SD; Califf, RM; Daly, R; Fuster, V; Gattis, WA; Gheorghiade, M; Harrington, RA; Hellkamp, AS; Kopecky, SL; Langer, A; Larsen, RL; O'Connor, CM; O'Gara, PT, 2001) |
| "This randomised, double-blind, aspirin-controlled trial tested the safety and efficacy of treatment with high-dose tinzaparin (175 anti-Xa IU/kg daily; 487 patients), medium-dose tinzaparin (100 anti-Xa IU/kg daily; 508 patients), or aspirin (300 mg daily; 491 patients) started within 48 h of acute ischaemic stroke and given for up to 10 days." | 5.09 | Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. ( Bath, PM; Boysen, G; De Deyn, P; Friis, P; Leys, D; Lindenstrom, E; Marttila, R; O'Neill, D; Olsson, J; Orgogozo, J; Ringelstein, B; Turpie, AG; van der Sande, J, 2001) |
| "We sought to compare different antithrombotic secondary treatments (mainly medium-dose aspirin with low-dose low-molecular-weight heparin [LMWH]) in pediatric patients with a first ischemic stroke onset with regard to the risk of stroke recurrence." | 5.09 | Aspirin versus low-dose low-molecular-weight heparin: antithrombotic therapy in pediatric ischemic stroke patients: a prospective follow-up study. ( Heller, C; Kurnik, K; Luigs, P; Nowak-Göttl, U; Schobess, R; Sträter, R, 2001) |
| "In this cohort of stroke patients with atrial fibrillation, anticoagulation was superior to aspirin in preventing cardioembolic but not lacunar recurrence." | 5.09 | Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation? ( Evans, A; Kalra, L; Perez, I; Yu, G, 2001) |
| "Although the efficacy of aspirin in reducing stroke incidence is clear, its role in reducing stroke severity is disputed." | 5.09 | Effect of prior aspirin use on stroke severity in the trial of Org 10172 in acute stroke treatment (TOAST). ( Adams, HP; Bendixen, B; Clarke, WR; Hansen, MD; Wilterdink, JL; Woolson, RF, 2001) |
| "Over two years, we found no difference between aspirin and warfarin in the prevention of recurrent ischemic stroke or death or in the rate of major hemorrhage." | 5.09 | A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. ( Adams, HP; Albers, GW; Furie, KL; Jackson, CM; Kistler, JP; Lazar, RM; Levin, B; Mohr, JP; Pettigrew, LC; Pullicino, P; Sacco, RL; Thompson, JL, 2001) |
| "Per 1200 persons taking aspirin for primary prevention for 5 years, there will be 4 fewer MACEs, 3 fewer ischaemic strokes, 3 more intracranial haemorrhages and 8 more major bleeding events." | 5.05 | A comparison of contemporary versus older studies of aspirin for primary prevention. ( Ebell, MH; Moriarty, F, 2020) |
| "To evaluate the effectiveness and adverse effects of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) for the primary or secondary prevention of dementia." | 5.05 | Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. ( Devane, D; Jordan, F; Kelly, JP; McGuinness, B; Murphy, K; Passmore, P; Quinn, TJ; Tudur Smith, C, 2020) |
| "A considerable proportion of patients with atrial fibrillation (AF) are still treated with aspirin despite current guidelines due to presumed favorable safety." | 5.05 | Bleeding risk comparison between direct oral anticoagulants at doses approved for atrial fibrillation and aspirin: systematic review, meta-analysis and meta-regression. ( Georgiopoulos, G; Korompoki, E; Leventis, I; Lip, GYH; Makaritsis, K; Milionis, H; Ntaios, G; Sagris, D; Vemmos, K, 2020) |
| " An updated meta analysis was done to determine the effect of the various dual antiplatelets vs aspirin alone on recurrence rate of ischemic stroke, cardiovascular morbidity and mortality, and its safety profile as reported through major bleeding." | 5.05 | Dual versus mono antiplatelet therapy for acute non- cardio embolic ischemic stroke or transient ischemic attack, an efficacy and safety analysis - updated meta-analysis. ( Albay, CEQ; Cheng, FC; Leyson, FGD, 2020) |
| "The benefits of aspirin for primary prevention of stroke are uncertain." | 5.05 | Aspirin for primary prevention of stroke in individuals without cardiovascular disease-A meta-analysis. ( Costello, M; Ferguson, J; Gorey, S; Halloran, MO; Judge, C; Loughlin, E; Murphy, R; Nolan, A; O'Canavan, M; O'Donnell, MJ; Ruttledge, S, 2020) |
| "Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention." | 5.01 | Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. ( Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS, 2019) |
| "The analysis showed lower risks of major adverse cardiovascular or cerebrovascular events, recurrent stroke, and bleeding events for clopidogrel monotherapy compared to aspirin." | 5.01 | Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis. ( Del Aguila, M; Girotra, S; Hu, B; Ince, B; Jeng, JS; Kutluk, K; Liu, L; Lou, M; Min Han, J; Paciaroni, M; Paek, D; Parfenov, V; Wong, KSL; Zamani, B, 2019) |
| " The objective of this study was to evaluate how treatment with DOACs affects stroke and bleeding outcomes compared with warfarin or aspirin." | 5.01 | A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation. ( Battistella, M; Cameron, K; Farrell, A; Feldberg, J; Ma, J; Patel, P; Sivarajahkumar, S, 2019) |
| " Data from one randomised controlled trial showed no significant difference in benefit with aspirin versus placebo in asymptomatic carotid stenosis, but it is still reasonable to recommend aspirin (81-325 mg daily) for prevention of vascular events in these patients." | 5.01 | Optimal Antiplatelet Therapy in Moderate to Severe Asymptomatic and Symptomatic Carotid Stenosis: A Comprehensive Review of the Literature. ( de Borst, GJ; Halliday, A; Hamilton, G; Kakkos, S; McCabe, DJH; Murphy, SJX; Naylor, AR; Ricco, JB; Sillesen, H; Vega de Ceniga, M, 2019) |
| " Similarly, in patients with stable coronary artery disease, two-thirds of whom had a history of myocardial infarction, dual antithrombotic therapy with very-low-dose rivaroxaban and aspirin also resulted in improved ischaemic outcomes." | 5.01 | Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease? ( Geisler, T; Kristensen, SD; Storey, RF; Sumaya, W, 2019) |
| "Background and Purpose- The role of aspirin plus clopidogrel (A+C) therapy compared with aspirin monotherapy in patients presenting with acute ischemic stroke (IS) or transient ischemic attack remains uncertain." | 5.01 | Optimal Duration of Aspirin Plus Clopidogrel After Ischemic Stroke or Transient Ischemic Attack. ( Hammad, T; Kaluski, E; Khan, SU; Meyer, MA; Nasir, F; Rahman, H, 2019) |
| " Data from RCTs show that aspirin is an effective antithrombotic at doses below 75 mg daily, and that direct oral anticoagulants reduce the risk of stroke in patients with coronary disease at doses 1/4 of those recommended in atrial fibrillation." | 5.01 | Antithrombotic dose: Some observations from published clinical trials. ( Dimmitt, SB; Ferner, RE; Floyd, CN, 2019) |
| "The result of Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events and the secondary analysis of Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) have shown that treatment with clopidogrel and aspirin for 21 days reduced the risk of recurrent stroke with no significant increase in bleeding risk." | 5.01 | Early Secondary Prevention in Transient Ischemic Attack (TIA) and Minor Stroke. ( Coutts, SB; Hill, MD; Tse, D, 2019) |
| "Although aspirin (ASA) is the mainstay of treatment for the prevention of recurrent ischemic stroke, the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial showed ASA monotherapy to be inferior to clopidogrel in preventing recurrent adverse cardiovascular outcomes in patients with high cardiac risks." | 5.01 | Aspirin Versus Clopidogrel Monotherapy for the Treatment of Patients with Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis. ( Ding, J; Xu, GM; Yuan, J, 2019) |
| "A systematic electronic literature search was done in MEDLINE, EMBASE, and Cochrane CENTRAL Register of Controlled Trials for studies including published data of patients ≥18 years of age with nonvalvular atrial fibrillation, randomized to either VKAs or NOACs, or receiving aspirin therapy at any time during the study that report all-cause stroke or systemic embolism, vascular death, myocardial infarction, major bleeding, or intracranial hemorrhage as an outcome." | 4.98 | Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials. ( Bennaghmouch, N; Bode, K; Brueckmann, M; de Veer, AJWM; Dewilde, WJM; Kleine, E; Lip, GYH; Mahmoodi, BK; Ten Berg, JM, 2018) |
| "Across trials of cardiovascular and cerebrovascular disease, extended-duration clopidogrel on a background of aspirin has no overall effect on mortality or cancer but does reduce rates of myocardial infarction and stroke and increase rates of bleeding." | 4.98 | Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis. ( Benavente, OR; Bhatt, DL; Connolly, SJ; Doros, G; Elmariah, S; Hsieh, WH; Liu, Y; Mauri, L; Steinhubl, SR; Yeh, RW; Yusuf, S, 2018) |
| "For stroke prevention in elderly patients with IS or TIA, DAPT is superior to aspirin monotherapy but appears to be equivalent to clopidogrel monotherapy, and is accompanied by an increased risk of bleeding." | 4.98 | Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a systematic review and meta-analysis. ( Ding, L; Peng, B, 2018) |
| "To assess the effectiveness and safety of dual agent antiplatelet therapy combining clopidogrel and aspirin to prevent recurrent thrombotic and bleeding events compared with aspirin alone in patients with acute minor ischaemic stroke or transient ischaemic attack (TIA)." | 4.98 | Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis. ( Foroutan, F; Guyatt, G; Hao, Q; O'Donnell, M; Siemieniuk, RA; Tampi, M, 2018) |
| "Aspirin use in PVD might not be associated with improved cardiovascular outcomes or worse bleeding outcomes." | 4.95 | Efficacy and safety of aspirin in patients with peripheral vascular disease: An updated systematic review and meta-analysis of randomized controlled trials. ( Bavry, AA; Elgendy, AY; Elgendy, IY; Mahmoud, AN; Mahtta, D; Rambarat, C, 2017) |
| "Aspirin reduces the risk of nonfatal myocardial infarction and stroke, and the risk of colorectal cancer." | 4.95 | Aspirin for Primary Prevention. ( Owens, DK; Richman, IB, 2017) |
| "Optimal antiplatelet therapy after an ischemic stroke or transient ischemic attack while on aspirin is uncertain." | 4.95 | Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL, 2017) |
| "The Dual Antiplatelet Therapy (DAPT) study demonstrated that DAPT beyond 1-year after drug-eluting stent (DES) implantation, as compared with aspirin therapy alone, significantly reduced the risk of major cardiovascular and cerebrovascular events, which was mainly driven by the large risk reduction for myocardial infarction (MI)." | 4.95 | Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: A comparison between the DAPT study and 9 other trials evaluating DAPT duration. ( Kimura, T; Morimoto, T; Natsuaki, M; Shiomi, H; Toyota, T, 2017) |
| "Cilostazol was significantly more effective than aspirin and clopidogrel alone in the long-term prevention of serious vascular events in patients with prior non-cardioembolic ischaemic stroke or transient ischaemic attack." | 4.93 | Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. ( Guo, ZN; Jin, H; Niu, PP; Xing, YQ; Yang, Y, 2016) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel for 90 days was recommended as the secondary prevention of minor ischaemic strokes or transient ischaemic attacks (TIAs) in 2014." | 4.93 | Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis. ( Chang, T; Ge, F; Guo, R; Li, M; Lin, H; Liu, Y; Ruan, Z, 2016) |
| "To evaluate the risk for serious bleeding with regular aspirin use in cardiovascular disease (CVD) primary prevention." | 4.93 | Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force. ( Burda, BU; Evans, CV; Guirguis-Blake, JM; Whitlock, EP; Williams, SB, 2016) |
| "Aspirin is recommended for secondary prevention after transient ischaemic attack (TIA) or ischaemic stroke on the basis of trials showing a 13% reduction in long-term risk of recurrent stroke." | 4.93 | Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. ( Algra, A; Chen, Z; Diener, HC; Mehta, Z; Norrving, B; Rothwell, PM, 2016) |
| "We searched articles describing the use aspirin for secondary prevention of stroke and cardiovascular events in PubMed published until May 2016." | 4.93 | Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events. ( Bliden, KP; Byun, S; Chaudhary, R; Gurbel, PA; Tantry, US, 2016) |
| "The net clinical benefit of aspirin in primary prevention is uncertain as the reduction in occlusive events needs to be balanced against the increase in gastro-intestinal and cerebral bleedings." | 4.93 | Aspirin use for primary prevention in elderly patients. ( Terrosu, P, 2016) |
| "Low-dose aspirin, alone or in combination, is recommended for the secondary prevention of acute non-cardioembolic ischemic stroke and transient ischemic attack, starting soon after the acute event." | 4.93 | Aspirin, stroke and drug-drug interactions. ( Petrucci, G; Rocca, B; Russo, NW, 2016) |
| "It remains controversial whether dual antiplatelet therapy reduces stroke more than aspirin alone." | 4.91 | Effect of addition of clopidogrel to aspirin on stroke incidence: Meta-analysis of randomized trials. ( Anderson, DC; Benavente, OR; Birnbaum, LA; Hart, RG; Palacio, S; Pearce, LA; Sharma, M, 2015) |
| "Compared with monotherapy, short-term aspirin in combination with clopidogrel is more effective as secondary prevention of stroke or TIA without increasing the risk of hemorrhagic stroke and major bleeding events." | 4.91 | Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. ( Li, J; Li, Y; Shang, X; Wang, C; Yan, C; Zhang, L; Zhang, Q; Zheng, M, 2015) |
| " We found no evidence that the net benefit of aspirin increased with increasing risk of thrombosis, haemorrhage or poor functional outcome in all three trials." | 4.91 | Targeting aspirin in acute disabling ischemic stroke: an individual patient data meta-analysis of three large randomized trials. ( Candelise, L; Chen, Z; Murray, GD; Sandercock, PA; Thompson, DD; Whiteley, WN, 2015) |
| " A pooled analysis showed that dual therapy with clopidogrel and aspirin had a lower stroke incidence than monotherapy in both the short term and long term (RR = 0." | 4.91 | Clopidogrel and Aspirin versus Aspirin Alone for Stroke Prevention: A Meta-Analysis. ( Chen, J; Ding, L; Hong, H; Huang, X; Ma, H; Tan, S; Xiao, X; Xu, R; Yang, S; Yu, S; Zhang, Z, 2015) |
| "Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel." | 4.91 | Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ( Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015) |
| "The safety and efficacy of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel in the setting of secondary stroke prevention are reviewed." | 4.91 | Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence. ( Davis, KA; Dietrich, E; Miyares, MA, 2015) |
| "Despite its lack of efficacy, aspirin is commonly used for stroke prevention in atrial fibrillation." | 4.91 | Aspirin Compared to Low Intensity Anticoagulation in Patients with Non-Valvular Atrial Fibrillation. A Systematic Review and Meta-Analysis. ( Gándara, E; Gonzalez, JP; Vazquez, FJ, 2015) |
| "To present the systematic assessment on the efficacy and bleeding adverse events of dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin-mono-antiplatelet therapy in patients with ischemic stroke or transient ischemic attack." | 4.91 | [Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack]. ( Gao, P; Hu, Y; Qian, J; Tang, X; Yang, C, 2015) |
| "In the overall population, dual antiplatelet therapy (DAPT) with aspirin and clopidogrel in comparison to aspirin monotherapy reduced the relative risk of total stroke by 20% (risk ratio [RR], 0." | 4.90 | Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. ( Arrich, J; Gouya, G; Gurbel, PA; Huber, K; Pirker-Kees, A; Siller-Matula, JM; Verheugt, FW; Wolzt, M, 2014) |
| "Antiplatelet therapy with aspirin 160 mg to 300 mg daily, given orally (or by nasogastric tube or per rectum in people who cannot swallow) and started within 48 hours of onset of presumed ischaemic stroke, reduced the risk of early recurrent ischaemic stroke without a major risk of early haemorrhagic complications; long-term outcomes were improved." | 4.90 | Oral antiplatelet therapy for acute ischaemic stroke. ( Cecconi, E; Counsell, C; Sandercock, PA; Tseng, MC, 2014) |
| "Dual antiplatelet therapy with aspirin plus clopidogrel is not recommended for secondary stroke prevention because of lack of effectiveness and increased hemorrhagic risk." | 4.90 | Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence. ( Censori, B, 2014) |
| "Whether clopidogrel should be added to aspirin for stroke prevention remained controversial for the risk of hemorrhagic complications." | 4.90 | Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials. ( Chen, S; He, L; Li, H; Li, M; Li, Y; Peng, Y; Shen, Q; Tang, Y, 2014) |
| " In patients on triple antithrombotic therapy with vitamin K antagonists, aspirin, and clopidogrel, a single clinical trial indicates that withdrawal of aspirin may reduce bleeding risk without increasing the risk of coronary thrombosis." | 4.90 | Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease. ( Thompson, PL; Verheugt, FW, 2014) |
| "While previous meta-analysis have investigated the efficacy of cilostazol in the secondary prevention of ischemic stroke, they were criticized for their methodology, which confused the acute and chronic phases of stroke." | 4.90 | The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population--an updated meta-analysis. ( Chen, S; Malaguit, J; Pu, J; Shi, L; Xu, L; Zhang, J, 2014) |
| "The role of aspirin in the early management of stroke is well established." | 4.89 | Pharmacokinetic considerations for antithrombotic therapies in stroke. ( Apostolakis, S; Lip, GY; Shantsila, E, 2013) |
| " Three preventive strategies were identified: (i) intra-operative transcranial Doppler (TCD) ultrasound and completion angioscopy which virtually abolished intra-operative stroke, primarily through the removal of residual luminal thrombus prior to restoration of flow; (ii) dual antiplatelet therapy with a single 75-mg dose of clopidogrel the night before surgery in addition to regular 75 mg aspirin which virtually abolished post-operative thromboembolic stroke and may also have contributed towards a decline in stroke/death following major cardiac events; and (iii) the provision of written guidance for managing post-CEA hypertension which was associated with virtual abolition of intracranial haemorrhage and stroke as a result of hyperperfusion syndrome." | 4.89 | Closing the loop: a 21-year audit of strategies for preventing stroke and death following carotid endarterectomy. ( Bell, PR; Bown, MJ; Dennis, MJ; London, NJ; McCarthy, MJ; Nasim, A; Naylor, AR; Sayers, RD, 2013) |
| "Aspirin is the most widely prescribed antiplatelet agent for the secondary prevention of stroke." | 4.89 | Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke. ( Bangalore, S; Dinicolantonio, JJ; Fares, H; Lavie, CJ; Menezes, AR; Messerli, FH; O'Keefe, JH, 2013) |
| "Given the high risk of stroke after TIA (transient ischemia attack) or stroke and the adverse reaction of bleeding of antiplatelets, we undertook a meta-analysis, reviewed randomized controlled trials (RCTs) comparing aspirin plus clopidogrel with aspirin alone to determine the efficacy and adverse reaction of bleeding of the two protocols in the prevention of stroke." | 4.89 | The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a systematic review. ( Hu, B; Huang, Y; Li, JY; Li, M; Mao, L; Xia, YP, 2013) |
| "We performed meta-analyses to assess the effectiveness and safety of combination therapy with aspirin and dipyridamole (A+D) versus aspirin (A) alone in secondary prevention after transient ischemic attack (TIA) or stroke of presumed arterial origin within one week and six months." | 4.89 | The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials. ( Li, X; Zhou, G; Zhou, S; Zhou, X, 2013) |
| " With others a number of observations showed that aspirin will reduce stroke." | 4.89 | Unique experiences with intercontinental trials in stroke - part II. ( Barnett, HJ; Laidlaw, JJ, 2013) |
| " As part of a planned re-evaluation within 2 years, we conducted an extensive literature search encompassing all topics included in the 2010 CCS Guidelines, and concluded that there were sufficient new data to merit revisiting the guidance on antiplatelet therapy for secondary prevention in the first year after acute coronary syndrome (ACS), percutaneous coronary intervention, or coronary artery bypass grafting, and the interaction between clopidogrel and proton pump inhibitors." | 4.89 | Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. ( Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G, 2013) |
| "Recurrent stroke risk did not differ between patients receiving dual-antiplatelet therapy and those receiving aspirin monotherapy (relative risk [RR], 0." | 4.89 | Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL, 2013) |
| " The combination of acetylsalicylic acid (ASA) plus dipyridamole (DP) was more protective against recurrent stroke than ASA alone (RR = 0." | 4.89 | Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis. ( Donovan, JL; Kanaan, AO; Malloy, RJ; Silva, MA, 2013) |
| "Drugs that prevent platelets from sticking together-ie, aspirin, dipyridamole, and clopidogrel-are an important part of therapy to prevent recurrence of ischemic stroke of atherosclerotic origin." | 4.89 | Antiplatelet therapy to prevent recurrent stroke: Three good options. ( Mansoor, AH; Mujtaba, MT; Silver, B, 2013) |
| " The effects of cilostazol and aspirin on ischemic stroke prevention and treatment were almost equal (combined odds ratio (OR) 0." | 4.89 | Systematic study of cilostazol on secondary stroke prevention: a meta-analysis. ( Bi, Q; Qian, Y, 2013) |
| "There is clinical equipoise between warfarin and aspirin for stroke prevention in patients with heart failure in sinus rhythm (SR)." | 4.89 | Warfarin versus aspirin for prevention of stroke in heart failure: a meta-analysis of randomized controlled clinical trials. ( Goyal, MK; Kumar, G, 2013) |
| "The risk-benefit profile of warfarin versus aspirin for patients with heart failure in normal sinus rhythm has not been definitively established." | 4.89 | Risk-benefit profile of warfarin versus aspirin in patients with heart failure and sinus rhythm: a meta-analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Saver, JL; Wu, HC, 2013) |
| "This review examines the role of platelets in ischemic stroke, platelet activation mechanisms, aspirin's rise as an antithrombotic agent, clopidogrel's appearance on the stage, a possible role for combination therapy, antiplatelet resistance, practical considerations, and future directions." | 4.89 | Aspirin and clopidogrel for prevention of ischemic stroke. ( Anderson, DC; Thomson, RM, 2013) |
| " In comparison with mono antiplatelet therapy, dual therapy (aspirin+dipyridamole and aspirin+clopidogrel) significantly reduced stroke recurrence, dual 58 (3." | 4.88 | Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. ( Algra, A; Bath, MW; Bath, PM; Chen, C; Dengler, R; Diener, HC; Geeganage, CM; Markus, HS; Topol, EJ, 2012) |
| "Until recently, pharmaceutical options for stroke prevention in atrial fibrillation were restricted to aspirin or vitamin K antagonist therapy." | 4.88 | Apixaban for the prevention of stroke in atrial fibrillation. ( Flaker, G; Littrell, R, 2012) |
| "Although the addition of aspirin to clopidogrel resulted in small relative reductions in major cardiovascular events, myocardial infarction, and stroke, it also resulted in a relative increase in major bleeding events." | 4.88 | Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis. ( He, J; Lu, J; Qin, YY; Wei, X; Wu, MJ; Xu, JF; Ye, XF; Zhou, YH, 2012) |
| "Although several new antithrombotic agents have been developed for stroke prevention in patients with nonvalvular atrial fibrillation (AF), many patients will continue to be treated with warfarin worldwide." | 4.88 | Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. ( Agarwal, S; Hachamovitch, R; Menon, V, 2012) |
| "To evaluate the efficacy and safety of the polypill for prevention of cardiovascular disease (CVD) and stroke and to present literature related to the polypill components (statin, aspirin, antihypertensive) for primary prevention of CVD and stroke." | 4.88 | A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke. ( Carey, KM; Comee, MR; Donovan, JL; Kanaan, AO, 2012) |
| "To identify confounding factors that may explain the incoherence between direct and indirect evidence in a published analysis comparing extended-release dipyridamole (ERDP) plus aspirin to clopidogrel for the reduction of stroke." | 4.88 | Investigating incoherence gives insight: clopidogrel is equivalent to extended-release dipyridamole plus aspirin in secondary stroke prevention. ( Dewilde, S; Hawkins, N, 2012) |
| "In those who have already survived myocardial infarction (MI) or stroke, or have had a transient ischaemic episode (TIA), daily low dose aspirin (ASA) reduces the risk of recurrences by an amount that greatly exceeds the risk of serious bleeding (secondary prevention)." | 4.88 | Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents. ( Meade, T, 2012) |
| "Aspirin is widely used for secondary prevention after stroke." | 4.87 | Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. ( Husain, MR; Kamal, AK; Khealani, BA; Naqvi, I, 2011) |
| "Although the exact prevalence of antiplatelet resistance in ischemic stroke is not known, estimates about the two most widely used antiplatelet agents - aspirin and clopidogrel - suggest that the resistance rate is high, irrespective of the definition used and parameters measured." | 4.87 | Antiplatelet resistance in stroke. ( Arsava, EM; Ay, H; Topçuoglu, MA, 2011) |
| " For the composite of non-fatal stroke, non-fatal myocardial infarction and vascular death, aspirin was associated with a 13% reduction in risk (risk ratio, RR: 0." | 4.87 | Validity of composite outcomes in meta-analyses of stroke prevention trials: the case of aspirin. ( Dinneen, SF; Eikelboom, JW; McGrath, E; O'Conghaile, A; O'Donnell, MJ; Oczkowski, C, 2011) |
| "Aspirin prevents deaths, myocardial infarction, and ischemic stroke, and increases hemorrhagic stroke and major bleeding when used in the primary prevention of cardiovascular disease." | 4.87 | Effect of aspirin on mortality in the primary prevention of cardiovascular disease. ( Eikelboom, J; Hirsh, J; O'Donnell, M; Raju, N; Sobieraj-Teague, M, 2011) |
| "Aspirin is used to prevent ischemic stroke and other types of cardiovascular disease." | 4.87 | Gender differences in the primary prevention of stroke with aspirin. ( Adelman, EE; Brown, DL; Lisabeth, L, 2011) |
| "Clopidogrel prevents more vascular events, including stroke, in patients with a recent myocardial infarction, stroke or peripheral vascular disease than aspirin." | 4.87 | Clopidogrel hydrogen sulphate for atrial fibrillation. ( Flaker, G; Garg, N; Rajpurohit, N, 2011) |
| "This review aims to determine whether it is cost-effective to replace aspirin and warfarin with more effective, yet more costly, treatments for secondary stroke prevention." | 4.86 | Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs? ( Hankey, GJ, 2010) |
| "The role of aspirin for the primary prevention of stroke in patients with non valvular atrial fibrillation is critically reviewed." | 4.86 | Antithrombotic treatment for the primary prevention of stroke in patients with non valvular atrial fibrillation: a reappraisal of the evidence and network meta analysis. ( Owen, A, 2010) |
| " One higher quality study (4415 participants) compared Nao-an capsule with aspirin for primary prevention in high-risk stroke populations." | 4.86 | Chuanxiong preparations for preventing stroke. ( Wu, T; Yang, X; Zeng, X, 2010) |
| "PubMed and MEDLINE searches (up to January 2010) were performed to identify primary literature, using search terms including aspirin, stroke prevention, acute ischemic stroke, acetylsalicylic acid, atrial fibrillation, myocardial infarction, and carotid endarterectomy." | 4.86 | Aspirin dosing for the prevention and treatment of ischemic stroke: an indication-specific review of the literature. ( Ansara, AJ; Arif, SA; Koehler, JM; Nisly, SA; Nordmeyer, ST, 2010) |
| "The safety of fixed-dose combination aspirin-extended-release (ER) dipyridamole for stroke prevention in patients with ischemic heart disease is reviewed." | 4.86 | Safety of fixed-dose aspirin-extended-release dipyridamole in patients with ischemic heart disease. ( Crown, N; Mysak, T, 2010) |
| " We give an overview of several new antiplatelet agents that are currently investigated in secondary stroke prevention: adenosine 5'-diphosphonate receptor antagonists, cilostazol, sarpogrelate, terutroban and SCH 530348." | 4.86 | Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention. ( Diener, HC; Weber, R, 2010) |
| "Oral antiplatelet drugs, including aspirin, clopidogrel and extended-release dipyridamole, are widely prescribed for the secondary prevention of vascular events, including stroke." | 4.86 | Aspirin and antiplatelet agent resistance: implications for prevention of secondary stroke. ( Greer, DM, 2010) |
| "Aspirin (ASA) use for secondary prevention in patients with cardiovascular (CV) disease is well established through its beneficial effects on the reduction of myocardial infarction, ischemic stroke and CV mortality." | 4.86 | Aspirin for the prevention of cardiovascular morbidity. ( Haider, B; Kaluski, E; Klapholz, M; Maher, J; Sanchez-Ross, M; Waller, AH, 2010) |
| "We compared the efficacy and safety of cilostazol and aspirin in 2,672 Japanese patients with non-cardioembolic ischemic stroke." | 4.86 | [Results of the Cilostazol Stroke Prevention Study II (CSPS II): a randomized controlled trial for the comparison of cilostazol and aspirin in stroke patients]. ( Uchiyama, S, 2010) |
| "To determine the benefits and harms of taking aspirin for the primary prevention of myocardial infarctions, strokes, and death." | 4.85 | Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. ( Ko, S; Miller, T; Wolff, T, 2009) |
| "In primary prevention trials conducted in low-risk subjects, aspirin is associated with a small reduction in ischemic strokes in women." | 4.85 | Antiplatelet drugs for ischemic stroke prevention. ( Balucani, C; Cordonnier, C; Leys, D, 2009) |
| " Currently, aspirin is generally prescribed for the primary prevention of stroke despite a number of trial results on effectiveness proving inconclusive." | 4.85 | Antithrombotic therapies in cerebrovascular disease: what should we use as secondary prevention in patients with carotid artery disease? ( Beckman, JA, 2009) |
| "We performed a systematic review to identify all published randomized controlled trials of patients with stroke or transient ischemic attack of presumed arterial origin that included an aspirin arm." | 4.85 | Is there a decline in the vascular event rate after transient ischemic attack or stroke in antiplatelet trials? ( Chen, F; Fieuws, S; Lemmens, R; Ni, Y; Thijs, V, 2009) |
| " The ratios of RRs comparing the benefit of aspirin among patients with diabetes compared with patients without diabetes for mortality, myocardial infarction, and ischemic stroke were 1." | 4.85 | Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. ( Aggarwal, NR; Albuquerque, FN; Calvin, AD; Elamin, MB; Erwin, PJ; Fernandez-Balsells, MM; Geske, JB; Lampropulos, JF; Montori, VM; Murad, MH; Shi, Q; Smith, SA, 2009) |
| "To determine the effectiveness and safety of thienopyridine derivatives (ticlopidine and clopidogrel) versus aspirin for preventing serious vascular events (stroke, myocardial infarction (MI) or vascular death) in patients at high risk, and specifically in patients with a previous TIA or ischaemic stroke." | 4.85 | Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. ( Hankey, GJ; Mason, G; Maurice, JB; Sudlow, CL; Wedderburn, CJ, 2009) |
| "Theoretical models suggest that a polypill containing low-dose aspirin, three blood pressure-lowering drugs at half dose and a potent statin, administered to a large proportion of the population at risk for cardiovascular events, could reduce ischemic heart disease and strokes by over 80%." | 4.85 | Polypill: the evidence and the promise. ( Lonn, E; Yusuf, S, 2009) |
| "To study the effect of combination therapy with aspirin and dipyridamole (A+D) over aspirin alone (ASA) in secondary prevention after transient ischaemic attack (TIA) or minor stroke of presumed arterial origin and to perform subgroup analyses to identify patients that might benefit most from secondary prevention with A+D." | 4.84 | Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk. ( Algra, A; Bath, PM; Diener, HC; Gray, LJ; Guiraud-Chaumeil, B; Halkes, PH; Yatsu, FM, 2008) |
| "The results obtained in the CAPRIE study in 1996 led to the introduction of the clopidogrel as a new antiplatelet drug in the secondary prevention of acute myocardial infarct (AMI), ischemic stroke (IS) and symptomatic peripheral artery disease (PAD)." | 4.84 | Clopidogrel in secondary ischemic stroke prevention. ( Belvís, R; Kulisevsky, J; Pagonabarraga, J; Santamaría, A, 2008) |
| "The purpose of this review was to discuss results from clinical trials that have compared the efficacy of ASA monotherapy versus ASA + extendedrelease dipyridamole in secondary stroke prevention." | 4.84 | Acetylsalicylic acid + extended-release dipyridamole combination therapy for secondary stroke prevention. ( Chaturvedi, S, 2008) |
| " The clinical benefits of combined pravastatin-acetylsalicylic acid in the management of coronary patients have been demonstrated by a meta-analysis of five randomized clinical trials for secondary prevention; compared with pravastatin alone, the pravastatin-acetylsalicylic acid combination reduced the risk of fatal or non fatal myocardial infarction by 26%, the risk of ischemic stroke by 31%, and the risk of cardiovascular events at 5 years by 13%." | 4.84 | [Pravastatin and acetylsalycilic acid fixed-combination: a strategy to improve cardiovascular outcomes]. ( Hennekens, C, 2007) |
| " The CHADS2 risk-stratification scheme, based on a clinical history of heart failure, hypertension, age >75, diabetes, or prior stroke, is a useful clinical tool to identify patients likely to benefit from warfarin, distinguishing these patients from patients at lower risk for whom aspirin is sufficient." | 4.84 | Confronting atrial fibrillation in the elderly: stroke risk stratification and emerging antithrombotic therapies. ( Halperin, JL; Strong, SH, 2007) |
| "Aspirin should be used to treat patients with acute myocardial infarction (MI) and continued indefinitely to reduce vascular death, nonfatal MI, and nonfatal stroke." | 4.84 | Antiplatelet therapy in the treatment of atherothrombotic disease: considering the evidence. ( Aronow, WS, 2007) |
| "Meta-analyses of randomised clinical trials in patients with TIA and ischaemic stroke of arterial origin indicate that, compared with control, the relative risk reduction (RRR) for recurrent stroke and other serious vascular events is 13% (95% confidence interval [CI] 6% to 19%) with aspirin, 13% (4% to 21%; p = 0." | 4.84 | Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines. ( Hankey, GJ, 2007) |
| "To quantify the impact of clopidogrel plus aspirin on the individual outcomes of death, myocardial infarction, or stroke in patients with established cardiovascular disease, or in patients with multiple risk factors for vascular disease." | 4.84 | Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials. ( Bavry, AA; Bhatt, DL; Duggal, S; Helton, TJ; Kumbhani, DJ; Roukoz, H, 2007) |
| "Low dose aspirin is effective in secondary stroke prevention." | 4.84 | Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected]. ( Kirshner, HS, 2007) |
| "In this paper, an overview is given of trials with oral anticoagulants and dipyridamole in the secondary prevention after transient ischaemic attack or minor stroke." | 4.84 | Anticoagulants, aspirin and dipyridamole in the secondary prevention of cerebral ischaemia: which is the best for which patient? ( Algra, A; Halkes, PH, 2007) |
| "In secondary prevention among male and female survivors of prior myocardial infarction (MI), occlusive stroke, transient ischemic attack, and other high-risk conditions, long-term use of aspirin confers very similar statistically significant and clinically important reductions in MI, stroke, and cardiovascular death." | 4.84 | Aspirin in the treatment and prevention of cardiovascular disease: current perspectives and future directions. ( Hennekens, CH, 2007) |
| "We presented a patient suffered from stroke related to thalidomide therapy." | 4.84 | [Brief report: stroke in multiple myeloma patient treated with thalidomide]. ( Hashimoto, Y; Hirano, T; Ito, Y; Mori, A; Uchino, M; Yonemura, K, 2007) |
| "Recent trials of antiplatelet therapy for stroke prevention indicate that the combination of clopidogrel (75 mg/d) plus low-dose aspirin (75-162 mg/d) was not more effective than low-dose aspirin alone in the long-term prevention of major vascular events among patients at high risk of atherothrombotic events, nor was it more effective than oral anticoagulation in patients with atrial fibrillation." | 4.84 | Antiplatelet therapy for stroke prevention. ( Hankey, GJ, 2007) |
| "This meta-analysis systematically reviewed randomized controlled trials comparing aspirin plus dipyridamole with aspirin alone in patients with stroke and TIA to determine the efficacy of these agents in preventing recurrent cerebral and systemic vascular events." | 4.84 | Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. ( Gorelick, PB; Nguyen, D; Verro, P, 2008) |
| "Primary literature was identified through PubMed MEDLINE (1966-December 2007) and EMBASE (1980-December 2007) using the search terms anticoagulation, warfarin, aspirin, elderly, falls, older persons, atrial fibrillation, bleeding, education, stroke, and use." | 4.84 | Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls. ( Corbett, TL; Garwood, CL, 2008) |
| "To compare the effectiveness of aspirin, warfarin, and ximelagatran as thromboprophylaxis in patients with non-valvular atrial fibrillation (NVAF)." | 4.83 | Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. ( Edwards, SJ; Lip, GY, 2006) |
| " Eligible studies were prospective, randomized controlled trials of aspirin therapy in participants without cardiovascular disease that reported data on myocardial infarction (MI), stroke, and cardiovascular mortality." | 4.83 | Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. ( Avanzini, F; Berger, JS; Brown, DL; Pangrazzi, I; Roncaglioni, MC; Tognoni, G, 2006) |
| "Despite hundreds of clinical trials, the appropriate dose of aspirin to prevent myocardial infarction (MI) and stroke is uncertain." | 4.83 | Aspirin to prevent heart attack and stroke: what's the right dose? ( Dalen, JE, 2006) |
| "Aspirin is not effective in the primary prevention of stroke." | 4.83 | Primary and secondary stroke prevention with antiplatelet drugs. ( Diener, HC, 2006) |
| "The long-awaited results of the Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attack (MATCH) study, a large-scale trial undertaken to evaluate the safety and efficacy of clopidogrel + aspirin for secondary prevention of stroke, have been published." | 4.83 | MATCH results: implications for the internist. ( Lutsep, HL, 2006) |
| "A lower rate of ischemic stroke and a higher rate of major bleeding episodes were found to be associated with oral anticoagulants compared with aspirin, and both anticoagulants and aspirin were found to be associated with a reduction in the rate of stroke compared with placebo." | 4.83 | Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. ( Cooper, NJ; Khunti, K; Lu, G; Sutton, AJ, 2006) |
| "Alternative antiplatelet therapy for stroke prevention is indicated for patients who experience transient ischemic attacks (TIAs) while on aspirin therapy (strength of recommendation [SOR]: A, based on 1 meta-analysis and 1 randomized controlled trial)." | 4.83 | Clinical inquiries. What is the best management for patients who have a TIA while on aspirin therapy? ( Ahmed, N; Coffey, JB; Oh, R, 2006) |
| " Increased leptin, dysregulation of adipocyte proteins, increased insulin resistance and C-reactive protein may be factors involved in the increased incidence of cardiovascular morbidity and mortality directly related to obesity." | 4.83 | Stroke prevention in diabetes and obesity. ( Govindarajan, G; Kurukulasuriya, LR; Sowers, J, 2006) |
| "A short-cut review was carried out to establish whether the administration of aspirin before computed tomography scanning improved outcome in patients with symptoms suggestive of stroke." | 4.83 | Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. Use of aspirin in acute stroke. ( Body, R; Ferguson, C, 2006) |
| " Pooled data from trials comparing antithrombotic treatment with placebo have shown that warfarin reduces the risk of stroke by 62%, and that aspirin alone reduces the risk by 22%." | 4.83 | Optimising stroke prevention in non-valvular atrial fibrillation. ( Cohen, A; Ederhy, S, 2006) |
| " In moderate- to high-risk subjects, oral anticoagulation with warfarin reduces stroke by two-thirds, while aspirin reduces stroke by 22%." | 4.83 | Atrial fibrillation and stroke prevention. ( Kakar, P; Lip, GY, 2006) |
| "The current evidence suggests that aspirin is treatment of choice when compared to anticoagulants for patients with non-cardioembolic stroke." | 4.83 | Antithrombotic agents in cerebral ischaemia. ( Bhat, P; Bhattacharjee, M; Dalal, PM; Mishra, NK, 2006) |
| "Among the 55 580 randomized participants (11 466 women), aspirin was associated with a statistically significant 32% reduction in the risk of a first MI and a significant 15% reduction in the risk of all important vascular events, but had no significant effects on nonfatal stroke or vascular death." | 4.82 | An update on aspirin in the primary prevention of cardiovascular disease. ( Eidelman, RS; Hebert, PR; Hennekens, CH; Weisman, SM, 2003) |
| "The increasing burden of cardiovascular diseases in developed, as well as developing countries, underscores the need for the more widespread and appropriate use of aspirin in secondary prevention of occlusive vascular events during acute evolving myocardial infarction (MI) and in primary prevention." | 4.82 | The role of aspirin in cardiovascular diseases--forgotten benefits? ( Hennekens, CH; Williams, A, 2004) |
| " The CURE study evaluated the efficacy and safety of clopidogrel on top of acetylsalicylic acid (ASA) versus standard therapy (including ASA) in over 12,000 patients with unstable angina or non-ST-segment elevation myocardial infarction (MI)." | 4.82 | Recent clinical trial results with antiplatelet therapy: implications in stroke prevention. ( Teal, PA, 2004) |
| " Increasing independent survival by even a small proportion through early use of aspirin in the majority with ischaemic stroke, avoiding aspirin in those with haemorrhagic stroke, and appropriate early management of those who have not had a stroke, reduced costs and increased QALYs." | 4.82 | What is the best imaging strategy for acute stroke? ( Cairns, J; Dennis, MS; Keir, SL; Lewis, S; Sandercock, PA; Seymour, J; Wardlaw, JM, 2004) |
| "Based on the established fact that anticoagulation with warfarin is superior to antiplatelet agents in the prevention of thromboembolic events in atrial fibrillation (AF), we propose that, in contrast to atherothrombotic disorders, the risk of developing a stroke or thromboembolic event in AF is more likely to be affected by the coagulation pathway than by platelet activity." | 4.82 | Atrial fibrillation: should we target platelets or the coagulation pathway? ( Lip, GY; Tan, KT, 2003) |
| "Warfarin has been in routine clinical use for more than 50 years; however, it was not proven to be of benefit in both primary and secondary prevention of stroke for patients with non-valvular atrial fibrillation (AF) until about a decade ago." | 4.82 | Warfarin for atrial fibrillation: the end of an era? ( Chambers, BR; Dewey, HM; Donnan, GA, 2004) |
| "The study pooled individual data from 2580 participants with nonvalvular AF who were prescribed aspirin in a multicenter trial (Atrial Fibrillation, Aspirin, Anticoagulation I study [AFASAK-1], AFASAK-2, European Atrial Fibrillation Trial, Primary Prevention of Arterial Thromboembolism in patients with nonrheumatic Atrial Fibrillation in primary care study, and Stroke Prevention and Atrial Fibrillation [SPAF]-III high risk or SPAF-III low risk)." | 4.82 | Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. ( Boode, BS; Gage, BF; Hart, RG; Koudstaal, PJ; Pearce, L; Petersen, P; van Walraven, C, 2004) |
| "Using the key terms acute coronary syndrome, atherothrombosis, ischemic stroke, myocardial infarction, MI, peripheral arterial disease, TIA, transient ischemic attack, unstable angina,aspirin,ticlopidine,dipyridamole, and clopidogrel, we searched the MEDLINE database as well as the trial register of the Cochrane Groups to identify studies published from 1960 to August 2004." | 4.82 | Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. ( Anand, SS; Tran, H, 2004) |
| "Results from randomized controlled trials of dipyridamole, given with or without aspirin, for secondary prevention after ischemic stroke or transient ischemic attack (TIA) have given conflicting results." | 4.82 | Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. ( Bath, PM; Bousser, MG; Davalos, A; Dewey, ME; Diener, HC; Guiraud-Chaumeil, B; Leonardi-Bee, J; Sivenius, J; Yatsu, F, 2005) |
| "Warfarin therapy achieving an International Normalized Ratio between 2 and 3 has been shown to be effective in preventing stroke." | 4.82 | New possibilities in anticoagulant management of atrial fibrillation. ( Waldo, AL, 2004) |
| "In the secondary prevention of cardiovascular, cerebrovascular, and ischemic events, the evidence supports that the benefits of aspirin treatment significantly outweigh the risk of a major hemorrhage." | 4.82 | Risk of hemorrhagic stroke with aspirin use: an update. ( Gorelick, PB; Weisman, SM, 2005) |
| "Aspirin is the standard treatment for secondary prevention of stroke and other vascular events." | 4.82 | Triflusal for preventing serious vascular events in people at high risk. ( Alvarez-Sabin, J; Costa, J; Ferro, JM; Matias-Guiu, J; Torres, F, 2005) |
| "Three trials tested aspirin in dosages ranging from 75 mg to 325 mg per day and 125 mg every other day to placebo (in two trials) or control (in one trial) in 1965 AF patients without prior stroke or TIA." | 4.82 | Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. ( Aguilar, M; Hart, R, 2005) |
| "According to meta-analysis and the results of the two studies with the highest power, aspirin is effective in primary prevention of coronary heart disease." | 4.82 | [Primary prevention of coronary heart disease with aspirin]. ( Darius, H; Kübler, W, 2005) |
| " Pooled data from trials comparing antithrombotic treatment with placebo show that warfarin reduces the risk of stroke by 62% and that aspirin alone reduces the risk by 22%." | 4.82 | [Preventing cerebrovascular accidents during atrial fibrillation]. ( Boccara, F; Cohen, A; Ederhy, S; Hammoudi, N; Janower, S; Meuleman, C, 2005) |
| " Low-dose aspirin as adjuvant therapy should be considered in patients with giant cell arteritis." | 4.82 | [Temporal arteritis and cerebrovascular complications]. ( Kerty, E; Øverlie, H, 2005) |
| "The use of low doses of aspirin on a daily basis has increased greatly in the past 20 years, based on observations that it can significantly reduce the risk of heart attacks and strokes." | 4.81 | Potential cardioprotective actions of no-releasing aspirin. ( Fiorucci, S; Ignarro, LJ; Wallace, JL, 2002) |
| "Results from a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) study suggest that angiotensin-converting-enzyme (ACE) inhibitors may be less effective in patients receiving aspirin." | 4.81 | Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. ( Collins, R; Hall, A; Kober, L; Latini, R; Pfeffer, M; Pogue, J; Teo, KK; Torp-Pedersen, C; Yusuf, S, 2002) |
| "We present a critical review of 3 randomized clinical trials testing aspirin, heparin/heparinoid, or both involving 5029 patients with AF and acute stroke." | 4.81 | Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials. ( Hart, RG; Palacio, S; Pearce, LA, 2002) |
| "To compare the risk of vascular and bleeding events in patients with nonvalvular AF treated with vitamin K -inhibiting oral anticoagulants or acetylsalicylic acid (aspirin)." | 4.81 | Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. ( Chang, Y; Connolly, S; Hart, RG; Hellemons, B; Koudstaal, PJ; Laupacis, A; Petersen, P; Singer, DE; van Walraven, C, 2002) |
| "Antiplatelet therapy, most notably aspirin, has been well documented to reduce risks of subsequent cardiovascular disease (CVD) in secondary prevention, acute myocardial infarction (MI), acute occlusive stroke, as well as in primary prevention." | 4.81 | Update on aspirin in the treatment and prevention of cardiovascular disease. ( Hennekens, CH, 2002) |
| "To determine the cardiovascular and coronary risk thresholds at which aspirin for primary prevention of coronary heart disease is safe and worthwhile." | 4.81 | Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. ( Ghahramani, P; Jackson, PR; Ramsay, LE; Sanmuganathan, PS; Wallis, EJ, 2001) |
| "Abciximab in addition to aspirin and heparin does not increase the risk of stroke in patients undergoing PCI." | 4.81 | Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention. ( Akkerhuis, KM; Anderson, K; Balog, C; Boersma, E; Califf, RM; Deckers, JW; Lincoff, AM; Simoons, ML; Tcheng, JE; Topol, EJ, 2001) |
| "Aspirin is a relatively inexpensive and effective agent for secondary stroke prevention, and lower doses of aspirin appear as effective as higher doses." | 4.81 | Antiplatelet agents for secondary prevention of ischemic stroke. ( Delanty, N; Kantor, J; Majid, A, 2001) |
| "Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardial infarction, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation." | 4.81 | Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. ( , 2002) |
| "1) Randomized trials at least 1 year in duration that examined aspirin chemoprevention in patients without previously known cardiovascular disease and 2) systematic reviews, recent trials, and observational studies that examined rates of hemorrhagic strokes and gastrointestinal bleeding secondary to aspirin use." | 4.81 | Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. ( Hayden, M; Mulrow, C; Phillips, C; Pignone, M, 2002) |
| " In the CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events) Trial, clopidogrel (clopidogrel bisulphate) was superior to acetylsalicylic acid (ASA) in reducing the combined risk of ischaemic stroke (IS), myocardial infarction (MI) or vascular death in patients with symptomatic atherosclerosis." | 4.81 | From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. ( Hacke, W, 2002) |
| " New data obtained from the Aspirin and Carotid Endarterectomy (ACE) Trial suggest that low-dose aspirin is superior to high-dose aspirin therapy in reducing rates of perioperative stroke and death." | 4.80 | Antiplatelet agents, carotid endarterectomy, and perioperative complications. ( Johnston, KC; Worrall, BB, 2000) |
| " Aspirin modestly reduces the risk for subsequent ischemic stroke after a transient ischemic attack or initial stroke." | 4.80 | Antithrombotic and thrombolytic therapy for ischemic stroke. ( Fisher, M, 1999) |
| "Aspirin therapy reduces stroke by about 25% for persons with atherosclerotic vascular disease, but the effect in those without clinically apparent vascular disease is distinctly different." | 4.80 | Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. ( Benavente, O; Halperin, JL; Hart, RG; Kronmal, RA; Man-Son-Hing, M; McBride, R, 2000) |
| "At the acute phase of cerebral infarction, two recent large studies found that the use of aspirin reduces both mortality and the risk of the recurrence of stroke." | 4.80 | [Aspirin and cerebral ischemic accidents]. ( Bousser, MG; Crassard, I; Niclot, P, 2000) |
| "The most widely studied and prescribed antiplatelet agent for the prevention of stroke and other serious vascular events among high vascular risk patients is aspirin." | 4.80 | Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. ( Dunbabin, DW; Hankey, GJ; Sudlow, CL, 2000) |
| "Acute stroke treatment using aspirin and/or heparin was studied in the International Stroke Trial (IST) and Chinese Acute Stroke Trial (CAST) which randomised over 40,000 patients altogether." | 4.80 | Aspirin or heparin in acute stroke. ( Brown, MM; Pereira, AC, 2000) |
| "Aspirin is the treatment of first choice for long-term secondary prevention of vascular events in patients with confirmed non-cardioembolic ischaemic stroke or TIA." | 4.80 | Prevention of ischaemic stroke--antiplatelets. ( Brown, MM; McCabe, DJ, 2000) |
| " Classic antiplatelet therapy with aspirin to prevent occlusive stroke offers significant clinical benefit (20-25% risk reduction), yet is less effective than in prevention of coronary artery occlusion (up to 50% risk reduction of myocardial infarction in unstable angina)." | 4.80 | Antiplatelet agents in stroke prevention. combination therapy: present and future. ( Weksler, BB, 2000) |
| "To describe the pharmacology, pharmacokinetics, efficacy, and safety of a fixed-dose combination of aspirin and extended-release (ER) dipyridamole indicated for the secondary prevention of stroke." | 4.80 | Aggrenox: a fixed-dose combination of aspirin and dipyridamole. ( Hilleman, DE; Lenz, TL, 2000) |
| "Randomized trials of aspirin have been conducted in three main populations: patients with evolving acute myocardial infarction (MI), patients with a history of cardiovascular disease and apparently healthy subjects." | 4.80 | Aspirin in the treatment and prevention of cardiovascular disease. ( Buring, JE; Gaziano, JM; Skerrett, PJ, 2000) |
| "The CHANCE-2 study compared 3 weeks of aspirin-ticagrelor to aspirin-clopidogrel in CYP2C19 loss-of-function (LOF) allele carriers following a transient ischemic attack (TIA)/minor stroke and demonstrated a modestly lower risk of stroke recurrence with aspirin-ticagrelor." | 4.31 | Cost-effectiveness of testing for CYP2C19 loss-of-function carriers following transient ischemic attack/minor stroke: A Canadian perspective. ( Demchuk, AM; Jahn, B; Menon, BK; Micieli, A; Siebert, U; Singh, N, 2023) |
| " We aim to compare rates of postoperative bleeding, stroke and major adverse events (stroke, death or MI) among patients on Aspirin alone (ASAA) versus DAPT (Clopidogrel and Aspirin)." | 4.31 | Dual Antiplatelet Therapy Is Associated with Increased Risk of Bleeding and Decreased Risk of Stroke Following Carotid Endarterectomy. ( Dakour, H; Elsayed, N; Malas, MB; Marmor, R; Patel, RJ; Ramachandran, M, 2023) |
| "Considering the 11 trials that reported > 10 ischemic strokes during follow-up (97,578 participants, 1195 ischemic strokes), 1 tested apixaban (57 strokes), 1 betrixaban (52 strokes), and 9 rivaroxaban (1086 strokes)." | 4.31 | Are Factor Xa Inhibitors Efficacious for Ischemic Stroke Prevention in Patients Without Atrial Fibrillation? Evidence From Randomized Clinical Trials. ( Eikelboom, JW; Hart, RG; Katsanos, AH; Perera, KS, 2023) |
| " Key consensus points include efforts to improve medical adherence through deprescribing and polypill use; adoption of universal risk definitions for bleeding, myocardial infarction, stroke and cause-specific death; multiple bleeding-avoidance strategies, ranging from gastroprotection with aspirin use to selection of antithrombotic-drug composition, dosing and duration tailored to multiple variables (setting, history, overall risk, age, weight, renal function, comedications, procedures) that need special consideration when managing older adults." | 4.31 | Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis ( Andreotti, F; Collet, JP; Geisler, T; Gigante, B; Gorog, DA; Halvorsen, S; Lip, GYH; Morais, J; Navarese, EP; Patrono, C; Rocca, B; Rubboli, A; Sibbing, D; Storey, RF; Verheugt, FWA; Vilahur, G, 2023) |
| " The system has been applied in: (1) the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial and (2) the New Approach riVaroxaban Inhibition of Factor Xa in a Global trial versus Aspirin to prevenT Embolism in Embolic Stroke of Undetermined Source (NAVIGATE ESUS) trial." | 4.31 | A hybrid automated event adjudication system for clinical trials. ( Bangdiwala, SI; Belanger, J; Bosch, J; Connolly, S; Dagenais, GR; Dyal, L; Eikelboom, J; Marsden, T; Renters, M; Swaminathan, B; Tang, C; Yuan, F, 2023) |
| "Within 12 months, ticagrelor 90 mg monotherapy was the only treatment associated with lower mortality, without bleeding risk trade-off compared with aspirin and clopidogrel." | 4.31 | Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneou ( Aboyans, V; Angiolillo, D; Atar, D; Capodanno, D; Fox, KAA; Halvorsen, S; James, S; Jüni, P; Kunadian, V; Landi, A; Leonardi, S; Mehran, R; Montalescot, G; Navarese, EP; Niebauer, J; Oliva, A; Piccolo, R; Price, S; Storey, RF; Valgimigli, M; Völler, H; Vranckx, P; Windecker, S, 2023) |
| "Our study aimed to explore the effectiveness and safety of intravenous t-PA compared with dual antiplatelet therapy (DAPT) and aspirin alone for minor stroke with National Institutes of Health Stroke Scale (NIHSS) score ≤5 and large vessel occlusion (LVO)." | 4.31 | Intravenous thrombolysis versus antiplatelet therapy in minor stroke patients with large vessel occlusion. ( Duan, C; Feng, X; Gu, H; Hao, M; Meng, X; Wang, S; Wang, Y; Xiong, Y; Yang, KX; Zhao, X, 2023) |
| "Aspirin is widely used as secondary prophylaxis for acute ischemic stroke." | 4.31 | In-Hospital Aspirin Dose as a Risk Factor for Hemorrhagic Transformation in Patients Not Treated With Thrombolysis. ( Clares de Andrade, JB; de Abreu, GQ; de Carvalho, JJF; Lima, FO; Maia Barros, LC; Mohr, JP; Pontes-Neto, OM; Silva, GS, 2023) |
| "A retrospective analysis was performed on 75 patients with cancer and mild to moderate ischemic stroke, 34 of whom received tirofiban treatment and 41 aspirin treatment." | 4.31 | Tirofiban in the treatment of cancer-associated ischemic stroke. ( Lin, ZH; Zhang, ZM; Zhu, GL, 2023) |
| " We explored the outcomes of restarting aspirin use on secondary stroke and mortality in patients with chronic stroke 4 weeks after suffering from a TBI episode in Taiwan." | 4.31 | Risk of secondary stroke subsequent to restarting aspirin in chronic stroke patients suffering from traumatic brain injury in Taiwan. ( Chien, WC; Chou, CL; Chung, CH; Fann, LY; Hsu, YH; Sun, CA; Tang, SE; Wu, CC, 2023) |
| " DOAC, vitamin K antagonist and aspirin treatment were assessed in the 6 months prior to the start of each year while strokes and bleeds were assessed during the year." | 4.31 | Heterogeneity after harmonisation: A retrospective cohort study of bleeding and stroke risk after the introduction of direct oral anticoagulants in four Western European countries. ( Bennie, M; Carragher, R; Forslund, T; Hjemdahl, P; Hunt, NB; Karlstad, Ø; Kjerpeseth, LJ; Klungel, OH; Komen, JJ; Mueller, T; Olesen, M; Pottegård, A; Wettermark, B, 2023) |
| "This study investigated the efficacy of antiplatelet therapy with ASA and clopidogrel using optical and impedance aggregometry in 42 consecutive patients with acute ischemic stroke." | 4.31 | Monitoring the Antiplatelet Therapy Efficacy in Patients with Acute Ischemic Stroke. ( Bultasova, L; Rohan, V; Slavik, L; Ulehlova, J, 2023) |
| " Patients with diagnosis codes for ischemic stroke without cardiac disease were included and divided into two groups, those receiving cilostazol and those receiving clopidogrel." | 4.31 | Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke. ( Je, NK; Lee, YJ, 2023) |
| "To evaluate the effects of aspirin in the primary prevention, we evaluated disability grades and mortality after ischemic/hemorrhagic stroke and myocardial infarction (MI)." | 4.31 | Pre-aspirin use has no benefit on the neurological disability and mortality after cardiovascular events: A nation-wide population-based cohort study. ( Kang, MJ; Kim, HS; Kim, JH; Lee, JH; Lim, HS; Park, D; Yoon, SY, 2023) |
| " In patients administered ticagrelor-aspirin and clopidogrel-aspirin, respectively, stroke recurred in 85 (9." | 4.31 | Dual Antiplatelet Therapies and Causes in Minor Stroke or Transient Ischemic Attack: A Prespecified Analysis in the CHANCE-2 Trial. ( Bath, PM; Claiborne Johnston, S; Jiang, Y; Jing, J; Li, H; Li, Z; Liu, L; Meng, X; Wang, A; Wang, Y; Xie, X; Xu, Q; Zhao, X, 2023) |
| "To compare the effectiveness of aspirin-clopidogrel dual antiplatelet therapy (DAPT) with aspirin or clopidogrel antiplatelet monotherapy (AM) in patients with ischemic stroke." | 4.31 | Comparative effectiveness of dual antiplatelet therapy versus monotherapy in patients with ischemic stroke. ( Algarni, RA; Alshargi, O; Alshehri, S; Alshibani, M; Althagafi, AA, 2023) |
| "Our study is based on the largest open-access all-payer inpatient database, revealing a noteworthy finding of aspirin's protective and adverse impact on different postoperative complications in the US population, such as acute cardiovascular disease, and stroke, etc." | 4.31 | The impact of long-term aspirin use on the patients undergoing shoulder arthroplasty. ( Cui, Y; Li, X; Liang, C; Liang, F; Mao, X; Shi, D; Xie, H; Yang, Q, 2023) |
| "Compared with aspirin/clopidogrel, aspirin/ticagrelor was associated with a potentially lower risk of stroke/death and bleeding complications after CAS in cases in which protamine was used but a higher risk of these outcomes in the absence of protamine." | 4.12 | Efficacy and safety of perioperative dual antiplatelet therapy with ticagrelor versus clopidogrel in carotid artery stenting. ( Jim, J; Liang, P; Marcaccio, CL; Patel, PB; Rastogi, V; Schermerhorn, ML; Schneider, PA; Stangenberg, L, 2022) |
| "Among Chinese minor stroke/transient ischemic attack population, the efficacy of clopidogrel-aspirin therapy was decreased in patients with higher ABCD-GENE score." | 4.12 | Application of Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping Score for Efficacy of Clopidogrel: Secondary Analysis of the CHANCE Trial. ( Chen, Z; Dai, L; Li, H; Meng, X; Pan, Y; Wang, Y; Xu, J; Yan, H, 2022) |
| "In this study based on high-intensity statin therapy, clopidogrel-aspirin reduced the risk of compound vascular events and did not increase the risk of hemorrhage during patients' hospitalization after mild-to-moderate ischemic stroke within 72 h." | 4.12 | Dual versus mono antiplatelet therapy in mild-to-moderate stroke during hospitalization. ( Fan, H; Li, J; Li, X; Li, Y; Liu, T; Niu, X; Ren, J; Wang, Y; Wu, X; Zhang, K, 2022) |
| "Clinicians should recommend aspirin 325 mg/d for long-term prevention of stroke and death and should recommend adding clopidogrel 75 mg/d to aspirin for up to 90 days to further reduce stroke risk in patients with severe (70%-99%) sICAS who have low risk of hemorrhagic transformation." | 4.12 | Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory: Report of the AAN Guideline Subcommittee. ( Chimowitz, MI; Culebras, A; Dolan O'Brien, M; Fletcher, JJ; Furlan, AJ; Goldstein, LB; Gonzalez, NR; Gronseth, GS; Latorre, JG; Messé, SR; Nguyen, TN; Rabinstein, AA; Sangha, RS; Schneck, MJ; Silsbee, H; Singhal, AB; Turan, TN; Wechsler, LR; Zaidat, OO, 2022) |
| "Among patients with TIA or mild ischemic stroke, the combination of cinnamon and aspirin could be superior to aspirin alone for reducing the risk of 90-day recurrent stroke." | 4.12 | Cinnamon and Aspirin for Mild Ischemic Stroke or Transient Ischemic Attack: A Pilot Trial. ( Fan, Y; He, P; He, Z; Li, Z; Liang, J; Wu, Y; Zhang, L, 2022) |
| "The goal of this work was to investigate the short-term time-course benefit and risk of ticagrelor with aspirin in acute mild-moderate ischemic stroke or high-risk TIA in The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and ASA for Prevention of Stroke and Death (THALES) trial." | 4.12 | Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack. ( Amarenco, P; Denison, H; Evans, SR; Himmelmann, A; James, S; Johnston, SC; Knutsson, M; Ladenvall, P; Li, H; Molina, CA; Pan, Y; Wang, Y, 2022) |
| "Background The objective of the study was to assess the cost-effectiveness of cilostazol (a selective phosphodiesterase 3 inhibitor) added to aspirin or clopidogrel for secondary stroke prevention in patients with noncardioembolic stroke." | 4.12 | Cost-Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke. ( de Havenon, A; Kraler, L; Lansberg, MG; Zhou, LW, 2022) |
| " OAC prescribing status was explored for patients at risk for stroke and classified into the following: OAC, aspirin only, or no treatment." | 4.12 | Incidence of nonvalvular atrial fibrillation and oral anticoagulant prescribing in England, 2009 to 2019: A cohort study. ( Ajabnoor, AM; Ashcroft, DM; Carr, MJ; Doran, T; Kontopantelis, E; Mamas, MA; Parisi, R; Rutter, MK; Zghebi, SS, 2022) |
| "Among the 3456 patients included, a total of 10 patients in the Clopidogrel Discontinuation Group and 11 patients in the non-Clopidogrel Discontinuation Group presented ischemic stroke recurrence during the 90-180-day period." | 4.12 | No rebound effect after a course of clopidogrel in patients with acute TIA or minor stroke. ( Jing, J; Johnston, SC; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, D; Wang, Y; Zhang, X; Zhao, X, 2022) |
| "Bleeding is the most common adverse reaction to aspirin and can lead to drug discontinuation or even be life-threatening in the secondary prevention of stroke or transient ischemic attack." | 4.12 | Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients. ( Cheng, J; Deng, X; Li, H; Ma, Y; Shi, T; Wang, X; Wu, Y; Zhang, Z; Zhu, Q, 2022) |
| "After the publication of the CHANCE (Clopidogrel in High Risk Patients With Acute Nondisabling Cerebrovascular Events) and POINT (Platelet-Oriented Inhibition in New Transient Ischemic Attack and Minor Ischemic Stroke) clinical trials, the American Heart Association/American Stroke Association (AHA/ASA) issued a new class 1, level of evidence A, recommendation for dual antiplatelet therapy (DAPT; aspirin plus clopidogrel) for secondary prevention in patients with minor ischemic stroke (National Institutes of Health Stroke Scale [NIHSS] score ≤3)." | 4.12 | Analysis of Prescriptions for Dual Antiplatelet Therapy After Acute Ischemic Stroke. ( Bhatt, DL; Feng, W; Fonarow, GC; Fosbøl, EL; Hannah, D; Johnson, M; Laskowitz, DT; Mac Grory, B; Maisch, L; Matsouaka, R; Peterson, ED; Schwamm, LH; Smith, EE; Xian, Y; Xu, H, 2022) |
| " Patients aged 80 years or older who received monotherapy with clopidogrel or aspirin following hospitalization for primary acute ischemic stroke between January 1, 2009, and December 31, 2018, were included." | 4.12 | Effectiveness and Safety of Clopidogrel vs Aspirin in Elderly Patients With Ischemic Stroke. ( Huang, HY; Katz, AJ; Lin, FJ; Lin, SY; Sheu, JJ; Wang, CC; Wu, CH, 2022) |
| "This prospective, observational study assessed TIA/ischaemic stroke patients before (baseline; N = 60), at 14 ±7 days (14d, N = 39) and ≥ 90 days (90d, N = 31) after adding dipyridamole to aspirin." | 4.12 | Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke. ( Collins, DR; Coughlan, T; Cox, D; Egan, B; Lim, ST; Lim, SY; McCabe, DJH; McCarthy, AJ; Murphy, SJX; Murphy, SM; O'Neill, D; Smith, DR; Tierney, S, 2022) |
| "Patients with diabetes and no obstructive coronary artery disease (CAD) as assessed by coronary angiography (CAG) are frequently treated with aspirin and statins." | 4.12 | Statin but not aspirin treatment is associated with reduced cardiovascular risk in patients with diabetes without obstructive coronary artery disease: a cohort study from the Western Denmark Heart Registry. ( Bøtker, HE; Heide-Jørgensen, U; Maeng, M; Olesen, KKW; Sørensen, HT; Thim, T; Thomsen, RW, 2022) |
| "We investigated (1) the associations of pre-stroke aspirin use with thrombus burden, infarct volume, hemorrhagic transformation, early neurological deterioration (END), and functional outcome, and (2) whether stroke subtypes modify these associations in first-ever ischemic stroke." | 4.02 | Relation of Pre-Stroke Aspirin Use With Cerebral Infarct Volume and Functional Outcomes. ( Bae, HJ; Cha, JK; Cho, YJ; Choi, KH; Han, MK; Hong, KS; Jeong, SW; Kang, K; Kim, BJ; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Lee, BC; Lee, J; Lee, KB; Lee, SJ; Nahrendorf, M; Oh, MS; Park, HK; Park, JM; Park, MS; Park, SS; Park, TH; Ryu, WS; Schellingerhout, D; Yu, KH, 2021) |
| "Fifty one acute stroke/transient ischemic attack (TIA) patients (ASG) with a history of regular aspirin intake for the previous 7 days or more were included to the study within 24 hours of symptoms onset." | 4.02 | Biochemical aspirin resistance in acute stroke patients and its association with clinical factors: a prospective pilot study. ( Fiszer, U; Kubiak-Balcerewicz, K; Morton, M; Sarnowska, A, 2021) |
| " The purpose of this study was to evaluate the incidence of major bleeding and thromboembolic events (TEs) in patients with atrial fibrillation (AF) receiving warfarin alone (monotherapy group) versus warfarin plus aspirin (combination therapy group)." | 4.02 | Risk Versus Benefit of Combined Aspirin and Warfarin Therapy in Patients With Atrial Fibrillation. ( Afzal, M; Davidson, E; Li, J; Nagaraj, TA; Snider, MJ; Weiss, R, 2021) |
| "Ticagrelor plus aspirin could reduce the risks of major adverse cardiac events in diabetic patients with stable coronary artery disease (SCD), and yet it also increases bleeding risk." | 4.02 | Cost-utility of ticagrelor plus aspirin in diabetic patients with stable coronary artery disease. ( Shi, L; Wu, B, 2021) |
| "Patients with ischemic stroke receiving aspirin (100 mg/day) for three months were recruited for a multicenter, prospective, cohort study." | 4.02 | Safety and efficacy of low-dose aspirin in ischemic stroke patients with different G6PD conditions. ( Chen, Y; Deng, W; Huang, W; Jiang, H; Li, J; Liang, Z; Liu, Q; Ou, Z; Ouyang, F; Wu, Z; Xing, S; Zeng, J; Zhang, Y, 2021) |
| "Warfarin is the most effective intervention for preventing thromboembolism within 6 months post-bioprosthetic MVR surgery in Chinese patients in sinus rhythm." | 4.02 | Comparison of Antithrombotic Strategies in Chinese Patients in Sinus Rhythm after Bioprosthetic Mitral Valve Replacement: Early Outcomes from a Multicenter Registry in China. ( Ao, X; Dong, L; Dong, Y; Fu, B; Zhang, H, 2021) |
| "This study provides supporting evidence that aspirin use is associated with reduced ischaemic events after pneumonia in a primary care setting." | 4.02 | Aspirin reduces cardiovascular events in patients with pneumonia: a prior event rate ratio analysis in a large primary care database. ( Arnold, D; Hamilton, F; Henley, W; Payne, RA, 2021) |
| " Here we assessed the contribution of clopidogrel versus aspirin to the development of pneumonia during an acute ischemic stroke admission." | 4.02 | Clopidogrel increases risk of pneumonia compared with aspirin in acute ischemic minor stroke patients. ( Feng, Q; Fu, J; Jin, X; Shan, B; Shen, R; Yu, Z; Zhou, H; Zhu, H, 2021) |
| "We initiated a multicenter, prospective cohort study to test the hypothesis that aspirin is safe for patients with ischemic cerebrovascular disease (ICVD) harboring unruptured intracranial aneurysms (UIAs) <7 mm." | 4.02 | Safety of Aspirin Use in Patients With Stroke and Small Unruptured Aneurysms. ( Cao, Y; Du, X; Fu, WL; Huo, R; Jiao, YM; Li, H; Wang, J; Wang, S; Weng, JC; Xu, HY; Yan, ZH; Zhao, JZ, 2021) |
| "To examine the association between CAC, bleeding, and ASCVD and explore the net estimated effect of aspirin at different CAC thresholds." | 4.02 | Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease. ( Ajufo, E; Ayers, CR; de Lemos, JA; Joshi, PH; Khera, A; Rohatgi, A; Vigen, R, 2021) |
| "Our previous trial acute dual study (ADS) reported that dual antiplatelet therapy (DAPT) using cilostazol and aspirin did not reduce the rate of short-term neurological worsening in non-cardioembolic stroke patients." | 4.02 | Cilostazol Addition to Aspirin could not Reduce the Neurological Deterioration in TOAST Subtypes: ADS Post-Hoc Analysis. ( Abe, K; Aoki, J; Fujimoto, S; Idomari, K; Iguchi, Y; Inoue, T; Iwanaga, T; Kaneko, N; Kimura, K; Matsuoka, H; Nomura, K; Okada, Y; Tanaka, R; Terasaki, T; Todo, K; Tsujino, A; Uno, M; Urabe, T; Yagita, Y; Yamagami, H; Yamagata, S; Yamamoto, N; Yamamoto, Y; Yonehara, T, 2021) |
| "COMBINE AF incorporates de-identified individual patient data from 77,282 patients with atrial fibrillation at risk for stroke randomized to NOAC, warfarin, or aspirin from 5 pivotal randomized controlled trials." | 4.02 | Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutio ( Alexander, JH; Carnicelli, AP; Connolly, SJ; Eikelboom, J; Giugliano, RP; Granger, CB; Hohnloser, SH; Hong, H; Hua, K; Lopes, RD; Morrow, DA; Oldgren, J; Patel, MR; Piccini, JP; Ruff, CT; Wallentin, L; Wojdyla, D, 2021) |
| "We selected newly diagnosed ischemic stroke patients aged ≥20years who were newly treated with aspirin or clopidogrel from 2003-2010 Korean National Health Insurance Service-National Sample Cohort, a random sample of 2." | 4.02 | Non-persistence with anti-platelet therapy and long-term mortality after ischemic stroke: A nationwide study. ( Cho, B; Choi, HC; Kim, SJ; Kwon, OD; Lee, EJ, 2021) |
| "Clopidogrel is commonly used for secondary stroke prevention in patients with large vessel stenosis." | 4.02 | Clopidogrel underactivity is a common in patients with acute symptomatic severe carotid stenosis. ( Cohen, JE; Filioglo, A; Gomori, JM; Honig, A; Horev, A; Kalish, Y; Leker, RR; Sacagiu, T; Simaan, N, 2021) |
| " We conducted a network meta-analysis to compare ticagrelor with other receptor antagonists (P2Y12) inhibitors and aspirin in monotherapy or combination in the treatment of patients with high risk for cardiovascular or cerebrovascular disease, defined as coronary artery disease, acute coronary syndrome, stroke or transient ischemic attack, or peripheral artery disease." | 4.02 | Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events. ( Bálint, A; El Alaoui El Abdallaoui, O; Komócsi, A; Kupó, P; Tornyos, D, 2021) |
| "We pooled individual patient data from 6 randomized clinical trials (CAPRIE [Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events], ESPS-2 [European Stroke Prevention Study-2], MATCH [Management of Atherothrombosis With Clopidogrel in High-Risk Patients], CHARISMA [Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance], ESPRIT [European/Australasian Stroke Prevention in Reversible Ischemia Trial], and PRoFESS [Prevention Regimen for Effectively Avoiding Second Strokes]) investigating antiplatelet therapy in the subacute or chronic phase after noncardioembolic transient ischemic attack or stroke." | 4.02 | Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke. ( Algra, A; Bath, PM; Csiba, L; Diener, HC; Greving, JP; Hacke, W; Hilkens, NA; Kappelle, LJ; Koudstaal, PJ; Leys, D; Mas, JL; Sacco, RL, 2021) |
| "Aspirin is indispensable in secondary prevention of ischemic events in patients with coronary artery disease (CAD)." | 3.96 | Enhanced Platelet Reactivity under Aspirin Medication and Major Adverse Cardiac and Cerebrovascular Events in Patients with Coronary Artery Disease. ( Ayhan, A; Dannenberg, L; Helten, C; Hohlfeld, T; Kelm, M; Knoop, B; Konsek, D; Levkau, B; Metzen, D; Mourikis, P; Naguib, D; Petzold, T; Pöhl, M; Polzin, A; Trojovsky, K; Veulemans, V; Zako, S; Zeus, T, 2020) |
| "In patients undergoing either MAG or SAG in the TiCAB trial, ticagrelor monotherapy compared with aspirin did not affect the rate of cardiovascular death, non-fatal MI, stroke or repeat revascularization, or the rate of bleeding, at 1 year after CABG." | 3.96 | Ticagrelor monotherapy versus aspirin in patients undergoing multiple arterial or single arterial coronary artery bypass grafting: insights from the TiCAB trial. ( Böning, A; Kastrati, A; Laufer, G; Misfeld, M; Nowak, B; Sandner, SE; Schunkert, H; Stritzke, J; Tebbe, U; von Scheidt, M; Wiedemann, D, 2020) |
| "The RE-DUAL PCI trial reported that dabigatran dual therapy (110/150 mg twice daily, plus clopidogrel or ticagrelor) reduced bleeding events versus warfarin triple therapy (warfarin plus aspirin and clopidogrel or ticagrelor) in patients with atrial fibrillation who underwent percutaneous coronary intervention, with noninferiority in composite thromboembolic events." | 3.96 | Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percut ( Bhatt, DL; Cannon, CP; de Veer, A; Hohnloser, SH; Kimura, T; Lip, GYH; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2020) |
| "In AUGUSTUS (Open-Label, 2×2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention), patients with atrial fibrillation and a recent acute coronary syndrome and those undergoing percutaneous coronary intervention had less bleeding with apixaban than vitamin K antagonist (VKA) and with placebo than aspirin." | 3.96 | Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. ( Alexander, JH; Aronson, R; Goodman, SG; Granger, CB; Lopes, RD; Mehran, R; Thomas, L; Vora, AN; Windecker, S; Wojdyla, D, 2020) |
| "Recent American College of Cardiology/American Heart Association Primary Prevention Guidelines recommended considering low-dose aspirin therapy only among adults 40 to 70 years of age who are at higher atherosclerotic cardiovascular disease (ASCVD) risk but not at high risk of bleeding." | 3.96 | Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The MESA Study (Multi-Ethnic Study of Atherosclerosis). ( Al Rifai, M; Blaha, MJ; Blumenthal, RS; Budoff, M; Cainzos-Achirica, M; Dardari, Z; Duprez, DA; Dzaye, O; Greenland, P; Hong, J; McEvoy, JW; Miedema, MD; Mortensen, MB; Nasir, K; Yeboah, J, 2020) |
| " Despite the modified dose, bleeding events were higher among patients receiving low-dose prasugrel than among patients receiving clopidogrel, with no difference in ischemic events between the 2 groups." | 3.96 | Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment. ( Fukuda, K; Heidenreich, PA; Ikemura, N; Kohsaka, S; Numasawa, Y; Sandhu, AT; Sawano, M; Shiraishi, Y; Shoji, S; Suzuki, M; Ueno, K, 2020) |
| "To investigate the long-term clinical benefit of dual antiplatelet therapy with potent P2Y12 inhibitors compared to clopidogrel in patients with acute coronary syndrome (ACS)." | 3.96 | Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients. ( Gager, GM; Hengstenberg, C; Jilma, B; Kolesnik, E; Lang, IM; Prüller, F; Siller-Matula, JM; Toma, A; von Lewinski, D; Wallner, M; Winter, MP, 2020) |
| "The prospective WATCH-AF registry (Warfarin Aspirin Ten-A Inhibitors and Cerebral Infarction and Hemorrhage and Atrial Fibrillation) enrolled consecutive patients admitted within 72 hours of an acute stroke associated with atrial fibrillation in 2 stroke centers." | 3.96 | Prevalence and Outcome of Potential Candidates for Left Atrial Appendage Closure After Stroke With Atrial Fibrillation: WATCH-AF Registry. ( Amarenco, P; Cabrejo, L; Charles, H; Guidoux, C; Hobeanu, C; Labreuche, J; Lavallée, PC; Martin-Bechet, A; Meseguer, E; Nighoghossian, N; Ong, E; Rigual, R, 2020) |
| " The methodologies are demonstrated using the acute stroke or transient ischemic attack treated with aspirin or ticagrelor and patient outcomes study (SOCRATES; NCT01994720), a randomized clinical trial." | 3.96 | Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial. ( Albers, GW; Amarenco, P; Bath, PM; Denison, H; Easton, JD; Evans, SR; Johnston, SC; Jonasson, J; Knutsson, M; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KL, 2020) |
| " In the GLOBAL LEADERS study, time-to-first-event analysis did not show superiority of ticagrelor monotherapy following one-month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention to conventional 12-month DAPT followed by aspirin monotherapy in the reduction of the primary composite end point of all-cause mortality or new Q-wave myocardial infarction." | 3.96 | Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events. ( Angioi, M; Barbato, E; Chichareon, P; Fontos, G; Gao, C; Hamm, C; Hara, H; Jüni, P; Kawashima, H; Kogame, N; Leandro, S; Modolo, R; Niethammer, M; Ono, M; Onuma, Y; Ribeiro, VG; Serruys, PW; Sharif, F; Steg, PG; Takahashi, K; Tijssen, JGP; Tomaniak, M; Valgimigli, M; van Klaveren, D; Verbeeck, J; Wang, R; Windecker, S, 2020) |
| "Aspirin and warfarin increased the risk for hemorrhagic stroke by 3." | 3.96 | Predictors of hemorrhagic stroke in older persons taking nonsteroidal anti-inflammatory drugs: Results from the Food and Drug Administration Adverse Event Reporting System. ( McDonald, DD; Srisopa, P, 2020) |
| "Comparative gastrointestinal bleeding (GIB) risk between rivaroxaban and low-dose aspirin is unknown in patients with atrial fibrillation (AF)." | 3.96 | Gastrointestinal bleeding risk with rivaroxaban vs aspirin in atrial fibrillation: A multinational study. ( Bell, JS; Chan, EW; Darzins, P; Fanning, L; Ilomaki, J; Lau, WCY; Leung, WK; Li, X; Man, KKC; Mongkhon, P; Wei, L; Wong, ICK, 2020) |
| " In the overall trial rivaroxaban plus aspirin reduced ischemic stroke by 49% (0." | 3.96 | Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy. ( A A Fox, K; Avezum, A; Berkowitz, SD; Bhatt, DL; Bosch, J; Branch, KRH; Casanova, A; Connolly, SJ; Dagenais, GR; Diaz, R; Dyal, L; Eikelboom, JW; Ertl, G; Hart, RG; Keltai, K; Keltai, M; Kim, JH; Liang, Y; Liu, L; Lonn, EM; Lopez-Jaramillo, P; Maggioni, AP; O'Donnell, M; Piegas, LS; Pogosova, N; Probstfield, JL; Reeh, KW; Ryden, L; Sharma, M; Smith, EE; Störk, S; Tonkin, AM; Varigos, JD; Vinereanu, D; Yusuf, S; Zhu, J, 2020) |
| "Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial." | 3.96 | Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. ( Bikdeli, B; Cho, J; Gupta, A; Hripcsak, G; Kim, J; Krumholz, HM; Londhe, A; Madigan, D; Park, J; Park, RW; Reich, CG; Rho, Y; Ryan, PB; Schuemie, M; Siapos, A; Suchard, MA; Weaver, J; You, SC, 2020) |
| "Despite international treatment guidelines currently advocating oral anticoagulants (OACs) as the only appropriate stroke prevention therapy for patients with atrial fibrillation (AF) and evidence that OACs can greatly reduce the risk of stroke with similar risk of bleeding compared with aspirin, the underuse of OACs in patients with AF is common globally, especially in Asia." | 3.96 | Understanding the barriers to using oral anticoagulants among long-term aspirin users with atrial fibrillation - a qualitative study. ( Chiu, PKC; Jamieson, E; Kng, CPL; Lam, MPS; Ng, VWS; Siu, CW; Wong, ICK, 2020) |
| "Atorvastatin and aspirin have been used in treating different forms of epilepsy." | 3.96 | Effects of atorvastatin and aspirin on post-stroke epilepsy and usage of levetiracetam. ( Ding, Y; Feng, X; Lin, W; Zhao, T; Zhou, C, 2020) |
| "In real-world practice settings, there is insufficient evidence on the efficacy of antiplatelet drugs, including clopidogrel, aspirin, and ticlopidine, in stroke prevention." | 3.96 | Efficacy of aspirin, clopidogrel, and ticlopidine in stroke prevention: A population-based case-cohort study in Taiwan. ( Hsu, YH; Ong, CT; Tsai, CF; Wong, YS, 2020) |
| " We now investigate if initiation of treatment with SSRIs, statins, clopidogrel, aspirin or oral anticoagulants and smoking cessation impacts coated-platelet levels at 90 days after ischemic stroke." | 3.96 | Clopidogrel use and smoking cessation result in lower coated-platelet levels after stroke. ( Dale, GL; Kirkpatrick, AC; Prodan, CI; Vincent, AS, 2020) |
| "Several clinical trials reported that clopidogrel was superior to aspirin in secondary stroke prevention by reducing the risk of major adverse cardiovascular events (MACE)." | 3.91 | Aspirin better than clopidogrel on major adverse cardiovascular events reduction after ischemic stroke: A retrospective nationwide cohort study. ( Chan, L; Chen, YC; Hsu, CY; Hu, CJ; Lin, CL; Muo, CH; Vidyanti, AN; Wu, D, 2019) |
| "Treatment of patients with stroke presenting with minor deficits remains controversial, and the recent Potential of rtPA for Ischemic Strokes with Mild Symptoms (PRISMS) trial, which randomized patients to thrombolysis vs aspirin, did not show benefit." | 3.91 | MRI-based thrombolytic therapy in patients with acute ischemic stroke presenting with a low NIHSS. ( Benson, RT; Hsia, AW; Kalaria, CP; Latour, LL; Leigh, R; Luby, M; Lynch, JK; Majidi, S; Nadareishvili, Z, 2019) |
| "Background and Purpose- This study aimed to compare the effectiveness of dual antiplatelet therapy with clopidogrel plus aspirin (DAPT) with that of aspirin monotherapy (AM) in patients with acute, nonminor, and noncardioembolic stroke." | 3.91 | Comparative Effectiveness of Dual Antiplatelet Therapy With Aspirin and Clopidogrel Versus Aspirin Monotherapy in Acute, Nonminor Stroke: A Nationwide, Multicenter Registry-Based Study. ( Bae, HJ; Cha, JK; Cho, KH; Cho, YJ; Choi, JC; Choi, KH; Hong, JH; Hong, KS; Kang, K; Kim, BJ; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Kim, WJ; Kwon, JH; Lee, BC; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Oh, MS; Park, HK; Park, JM; Park, MS; Park, SS; Park, TH; Ryu, WS; Shin, DI; Sohn, SI; Yu, KH, 2019) |
| "Background As an alternative to vitamin K antagonist and low-dose aspirin (< 325 mg), non-vitamin K oral anticoagulants are available for the prevention of stroke in patients with atrial fibrillation." | 3.91 | Mortality risk in atrial fibrillation: the role of aspirin, vitamin K and non-vitamin K antagonists. ( Burden, A; de Boer, A; de Vries, F; Gieling, E; Kramers, C; Ten Cate, V; van Onzenoort, HAW; Williams, R, 2019) |
| " This man was promptly treated with aspirin 300 mg one time per day, as per the stroke pathway." | 3.91 | Bilateral paramedian pontine infarcts: a rare cause of bilateral horizontal gaze palsy. ( Bhandari, M; Chernov, D; Hassan, F; Karavassilis, ME, 2019) |
| "This study aimed to investigate the effectiveness of monotherapy acetylsalicylic acid (ASA) and warfarin for stroke prevention in low-risk atrial fibrillation (AF) by using a population- -based cohort study in Taiwan." | 3.91 | Monotherapy of acetylsalicylic acid or warfarin for prevention of ischemic stroke in low-risk atrial fibrillation: A Easter Asian population-based study. ( Chen, HC; Liu, CY, 2019) |
| "Despite its well-known antithrombotic properties, the effect of aspirin on blood pressure (BP) and hypertension pathology is unclear." | 3.91 | Effects of high- and low-dose aspirin on adaptive immunity and hypertension in the stroke-prone spontaneously hypertensive rat. ( Andrews, KL; Chin-Dusting, JPF; Dragoljevic, D; Gaspari, T; Jefferis, AM; Jennings, GL; Khan, SI; Lee, MKS; Moore, XL; Murphy, AJ; Shihata, WA; Vinh, A, 2019) |
| "Of 149 subjects (mean age 57; 48% female; median NIH stroke scale (NIHSS) 19; 46% ischemic stroke; 54% hemorrhagic), implementation of treatments included: dysphagia screening (80%), deep venous thrombosis prophylaxis (0%), aspirin (83%), antihypertensives (89%) and statins (95%)." | 3.91 | Opportunities for intervention: stroke treatments, disability and mortality in urban Tanzania. ( Biseko, MR; Grundy, SJ; Kharal, GA; Klein, JP; Mateen, FJ; Mmbando, TN; Okeng'o, K; Parker, R; Regenhardt, RW; Saadi, A; Shayo, AF; Wibecan, L; Xu, A, 2019) |
| "A retrospective, single center, cohort study was carried out of 32 patients who underwent eCAS (18 received tirofiban, 14 received aspirin) at our comprehensive stroke center (2008-2016)." | 3.91 | Acute administration of tirofiban versus aspirin in emergent carotid artery stenting. ( Berberat, J; Diepers, M; Gruber, P; Hlavica, M; Kahles, T; Nedeltchev, K; Remonda, L; Victor Ineichen, B, 2019) |
| "To evaluate the effect of prestroke aspirin (PA) use on initial stroke severity, early neurologic deterioration (END), stroke recurrence, hemorrhagic transformation (HT), and functional outcome in patients with ischemic stroke (IS)." | 3.91 | Prestroke Aspirin Use is Associated with Clinical Outcomes in Ischemic Stroke Patients with Atherothrombosis, Small Artery Disease, and Cardioembolic Stroke. ( Han, Z; Lin, J; Luo, H; Yi, X; Zhou, J; Zhou, Q, 2019) |
| "To determine whether hypertensive disorders of pregnancy (HDP) increased long-term stroke risk in women in the California Teachers Study (CTS), a prospective cohort study, and whether aspirin or statin use modified this risk." | 3.91 | Aspirin reduces long-term stroke risk in women with prior hypertensive disorders of pregnancy. ( Bello, NA; Boehme, AK; Chung, NT; Elkind, MSV; Lacey, JV; Lakshminarayan, K; Miller, EC; Wang, SS; Wapner, R; Willey, JZ; Woo, D; Zhong, C, 2019) |
| "When warfarin was the mainstay of anticoagulation for the prevention of cardioembolic stroke, the paradigm was essentially "we mustn't anticoagulate anyone unless we prove that the stroke was cardioembolic." | 3.91 | Anticoagulation in patients with Embolic Stroke of Unknown Source. ( Spence, JD, 2019) |
| " Clopidogrel plus aspirin treatment was associated with reduced risk of new stroke in patients with ABCB1 -154 TT and 3435 CC genotype (hazard ratio [HR], 0." | 3.91 | Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial. ( Chen, W; Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Simon, T; Wang, D; Wang, Y; Zhao, X, 2019) |
| "To understand the efficacy of aspirin use for preventing ischaemic stroke after central retinal artery occlusion (CRAO)." | 3.91 | Aspirin use in central retinal arterial occlusion to prevent ischaemic stroke: a retrospective cohort study in Taiwan. ( Chen, TH; Hung, MJ; Kang, EY; Kang, JH; Lin, YH; Luo, C; Sun, CC; Wang, NK; Wu, WC; Yeung, L, 2019) |
| "To investigate the association of aspirin resistance (AR) with mortality in a cohort of Chinese patients with acute ischemic stroke (AIS)." | 3.91 | Association of Aspirin Resistance with Increased Mortality in Ischemic Stroke. ( Jing, Y; Li, S; Yang, S; Yue, X, 2019) |
| "Background and Purpose- Two large-scale randomized controlled trials of recurrent stroke prevention suggest that dual antiplatelet therapy with clopidogrel plus aspirin is beneficial for prevention of subsequent ischemic events." | 3.91 | Dual Versus Mono Antiplatelet Therapy in Large Atherosclerotic Stroke. ( Bae, HJ; Cha, JK; Cho, YJ; Choi, JC; Choi, KH; Gorelick, PB; Han, MK; Hong, JH; Hong, KS; Kang, K; Kim, BJ; Kim, D; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Kim, WJ; Kwon, JH; Lee, BC; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Nah, HW; Oh, MS; Park, JM; Park, TH; Ryu, WS; Shin, DI; Sohn, SI; Yu, KH, 2019) |
| "For patients with bifurcation lesions after PCI, ticagrelor treatment shows lower MACE and MI rates than the clopidogrel one, along with comparable major bleeding." | 3.91 | Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention. ( Azzalini, L; Li, L; Li, Y; Mao, Q; Tian, J; Tong, W; Xie, L; Zhao, X; Zheng, W; Zhou, D, 2019) |
| "We examined whether the efficacy of low-dose acetylsalicylic acid (aspirin) for primary prevention of cardiovascular events is influenced by blood pressure (BP) using data from patients aged 60-85 years with hypertension, dyslipidemia, and/or diabetes, but without cardiovascular disease of the Japanese Primary Prevention Project." | 3.91 | Influence of blood pressure on the effects of low-dose asprin in elderly patients with multiple atherosclerotic risks. ( Ando, K; Ikeda, Y; Ishizuka, N; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Uemura, Y; Yamazaki, T; Yokoyama, K, 2019) |
| "High plasma level of HbA1c is involved in enhanced platelet aggregability in acute atherothrombotic stroke patients, and prestroke administration of aspirin may be beneficial to clinical outcomes." | 3.91 | Collagen-Induced Platelet Aggregates, Diabetes, and Aspirin Therapy Predict Clinical Outcomes in Acute Ischemic Stroke. ( Hagii, J; Harima, K; Honda, S; Kitajima, M; Metoki, H; Mikami, K; Osanai, T; Tomisawa, T; Urushizaka, M; Yasujima, M, 2019) |
| "Most stroke patients are prescribed aspirin (ASA) to adjust blood coagulability." | 3.91 | Aspirin in stroke patients modifies the immunomodulatory interactions of marrow stromal cells and monocytes. ( Aronowski, J; Cai, C; Giridhar, K; Norris, DD; Olson, SD; Satani, N; Savitz, SI; Wewior, N, 2019) |
| "This study aimed to explore the association between GPIa, COX-2 gene polymorphisms and aspirin resistance in the ischemic stroke patients from the southern part of Jiangsu province." | 3.88 | Association of GPIa and COX-2 gene polymorphism with aspirin resistance. ( Cai, X; Dong, W; Fang, Q; Jiang, W; Sun, X; Wang, H; Zhang, Y; Zhou, Y, 2018) |
| " After multivariate logistic regression, 10 variables remained independent predictors of sICH to compose the STARTING-SICH (systolic blood pressure, age, onset-to-treatment time for thrombolysis, National Institutes of Health Stroke Scale score, glucose, aspirin alone, aspirin plus clopidogrel, anticoagulant with INR ≤1." | 3.88 | STARTING-SICH Nomogram to Predict Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis for Stroke. ( Bonetti, B; Bovi, P; Cappellari, M; Forlivesi, S; Toni, D; Turcato, G; Zivelonghi, C, 2018) |
| "8 years) with non-valvular atrial fibrillation (NVAF) underwent LAAC procedure using a Watchman device followed by DAPT (75 mg/d aspirin and 75 mg/d clopidogrel)." | 3.88 | Dual antiplatelet therapy is safe and efficient after left atrial appendage closure. ( Czub, P; Fojt, A; Grygier, M; Hendzel, P; Kapłon-Cieślicka, A; Karolczak, N; Kochman, J; Lodziński, P; Maksym, J; Marchel, M; Mazurek, T; Opolski, G; Piątkowski, R; Wilimski, R, 2018) |
| "Our aims were to examine the prevalence and genetic predictors of aspirin and clopidogrel high on-treatment platelet reactivity (HoTPR), and associated adverse cardiovascular outcomes in patients with peripheral arterial disease (PAD)." | 3.88 | Aspirin and clopidogrel high on-treatment platelet reactivity and genetic predictors in peripheral arterial disease. ( Amsterdam, EA; Anderson, D; Armstrong, EJ; Chen, DC; Chiamvimonvat, N; Hua, A; Laird, JR; Li, CS; López, JE; Singapuri, A; Westin, GG; Yeo, KK, 2018) |
| "This study sought to assess safety and effectiveness of low-dose aspirin in heart failure (HF) not complicated by atrial fibrillation." | 3.88 | Low-Dose Aspirin in Heart Failure Not Complicated by Atrial Fibrillation: A Nationwide Propensity-Matched Study. ( Bjerre, J; D'Souza, M; Fosbøl, EL; Gislason, G; Gustafsson, F; Kober, L; Kristensen, SL; Madelaire, C; Schou, M; Torp-Pedersen, C, 2018) |
| "We used nationwide population-based registries to identify all first-time hospitalizations for stroke and subsequent mortality in patients treated with aspirin and clopidogrel in Denmark during 2004-2012." | 3.88 | Pre-admission use of platelet inhibitors and short-term stroke mortality: a population-based cohort study. ( Christiansen, CF; Grove, EL; Henderson, VW; Horváth-Puhó, E; Schmidt, M; Sørensen, HT; Würtz, M, 2018) |
| "Using a combination of aspirin, anti-tuberculosis drugs and steroids may help to reduce the number of strokes and deaths in patients with tuberculous meningitis." | 3.88 | Can aspirin help? ( Kalantri, A; Kalantri, S, 2018) |
| "To investigate the associations between CYP2C19 genotypes and early neurological deterioration (END), and to carry out a stratified analysis of the effectiveness of clopidogrel alone and dual antiplatelet therapy with clopidogrel and aspirin for prevention of END according to CYP2C19 genotypes in ischemic stroke (IS) patients." | 3.88 | Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles. ( Chai, Z; Han, Z; Huang, R; Lin, J; Wang, C; Yi, X; Zhou, Q, 2018) |
| "The relationship of CYP2C19 genotype and clinical efficacy in stroke or transient ischemic attack (TIA) patients treated with clopidogrel monotherapy or clopidogrel plus aspirin remains unknown." | 3.88 | Efficacy and safety of CYP2C19 genotype in stroke or transient ischemic attack patients treated with clopidogrel monotherapy or clopidogrel plus aspirin: Protocol for a systemic review and meta-analysis. ( Cui, M; Gu, ZC; Li, WY; Pan, MM; Yao, JC, 2018) |
| "To investigate the prognostic value of aspirin reaction units (ARU) in a 3-month follow-up study in a cohort of Chinese patients with first-ever ischemic stroke." | 3.88 | Aspirin resistance predicts unfavorable functional outcome in acute ischemic stroke patients. ( Fan, YN; He, Y; Hua, QJ; Ji, SB; Liu, YX; Su, LL; Wang, CW; Xi, TT; Yuan, B, 2018) |
| "Clopidogrel plus aspirin is associated with a reduced risk for myocardial infarction and ischemic stroke and an increased risk for major bleeding compared with aspirin alone among patients at high risk for or with an established cardiovascular disease but without a coronary stent." | 3.88 | Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events. ( Bellesini, M; Donadini, MP; Squizzato, A, 2018) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel reduces the risk for recurrent cardiovascular events after acute coronary syndrome (ACS)." | 3.88 | Pharmacogenetic and clinical predictors of response to clopidogrel plus aspirin after acute coronary syndrome in Egyptians. ( Cavallari, LH; El Wakeel, LL; Fathy, S; Khalil, BM; Langaee, T; Sabry, NA; Saleh, A; Schaalan, MF; Shahin, MH, 2018) |
| "The authors investigated the risk of bleeding, ischemic stroke, MI, and all-cause mortality associated with direct oral anticoagulants (DOACs) compared with vitamin K antagonists (VKAs) in combination with aspirin, clopidogrel, or both in patients with AF following MI and/or PCI." | 3.88 | Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease. ( Berger, JS; Gislason, GH; Lamberts, M; Lock Hansen, M; Nissen Bonde, A; Olesen, JB; Pallisgaard, JL; Sindet-Pedersen, C; Staerk, L; Torp-Pedersen, C, 2018) |
| "WHAT IS THE ROLE OF DUAL ANTIPLATELET THERAPY AFTER HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR STROKE? SPECIFICALLY, DOES DUAL ANTIPLATELET THERAPY WITH A COMBINATION OF ASPIRIN AND CLOPIDOGREL LEAD TO A GREATER REDUCTION IN RECURRENT STROKE AND DEATH OVER THE USE OF ASPIRIN ALONE WHEN GIVEN IN THE FIRST 24 HOURS AFTER A HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR ISCHAEMIC STROKE? AN EXPERT PANEL PRODUCED A STRONG RECOMMENDATION FOR INITIATING DUAL ANTIPLATELET THERAPY WITHIN 24 HOURS OF THE ONSET OF SYMPTOMS, AND FOR CONTINUING IT FOR 10-21 DAYS CURRENT PRACTICE IS TYPICALLY TO USE A SINGLE DRUG." | 3.88 | Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline. ( Agoritsas, T; Booth, B; Fisch, L; Fobuzi, AC; Fraiz, A; Gorthi, SP; Guyatt, G; Hao, Q; Heen, AF; Horton, E; Jusufovic, M; Katragunta, N; Lytvyn, L; Muller, J; O'Donnell, M; Prasad, K; Rochwerg, B; Siemieniuk, J; Siemieniuk, R; Vandvik, PO, 2018) |
| "From January 2014 to September 2014, a single center continuously enrolled patients with minor ischemic stroke or high-risk TIA and gave them antiplatelet therapy consisting of aspirin with clopidogrel." | 3.85 | The association between high on-treatment platelet reactivity and early recurrence of ischemic events after minor stroke or TIA. ( Cao, Y; Dong, K; Liu, L; Rao, Z; Wang, A; Wang, F; Wang, Y; Zhao, X; Zheng, H, 2017) |
| "Prostaglandin-Endoperoxide Synthase 1 (PTGS1) and smoking may play important roles in aspirin nonresponsiveness, but the effect of their interaction on stroke outcomes remains largely unknown." | 3.85 | Association between PTGS1 polymorphisms and functional outcomes in Chinese patients with stroke during aspirin therapy: Interaction with smoking. ( Cai, B; Cai, H; Cao, L; Davis, SM; Guo, H; Liu, X; Sun, L; Sun, W; Yan, B; Zhang, H; Zhang, Z; Zhou, S, 2017) |
| " A substantial proportion of patients with stroke on ASA were "resistant", and the treatment with Clopidogrel was accompanied by even higher rates of unresponsiveness." | 3.85 | Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study. ( Bigliardi, G; Dell'Acqua, ML; Ferraro, D; Lelli, N; Mimmi, S; Nichelli, P; Pentore, R; Picchetto, L; Rosafio, F; Trenti, T; Vandelli, L; Zini, A, 2017) |
| "Antiplatelet therapy with ticagrelor in patients with acute ischemic stroke or transient ischemic attack showed a bleeding profile similar to that of aspirin for major bleeds." | 3.85 | Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcome ( Albers, GW; Amarenco, P; Aunes, M; Bokelund-Singh, S; Denison, H; Easton, JD; Evans, SR; Held, P; Jahreskog, M; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017) |
| "Our findings indicate a favorable effect of clopidogrel at discharge compared with aspirin in preventing death, recurrent stroke, and CVD events in diabetic patients with a first-ever noncardioembolic AIS." | 3.85 | Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project. ( Elisaf, M; Manios, E; Milionis, H; Ntaios, G; Papavasileiou, V; Spengos, K; Vemmos, K, 2017) |
| "This study is the largest to investigate platelet aggregation in stable coronary artery disease patients receiving aspirin as single antithrombotic therapy." | 3.85 | Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S; Würtz, M, 2017) |
| "To investigate the prevalent of aspirin resistance (AR) in stroke and its association with recurrent stroke in 214 patients with ischemic stroke who were receiving aspirin before the stroke onset." | 3.85 | Aspirin resistance are associated with long-term recurrent stroke events after ischaemic stroke. ( Wang, Z; Zhang, N; Zhou, L, 2017) |
| "BACKGROUND To investigate the combination of beraprost sodium (BPS) and aspirin in the treatment of acute ischemic stroke (AIS)." | 3.85 | Beneficial Effect of Beraprost Sodium Plus Aspirin in the Treatment of Acute Ischemic Stroke. ( Chen, S; Chen, W; He, W; Li, S; Wei, D; Xie, S, 2017) |
| "Clopidogrel is an antiplatelet drug widely used in patients with acute coronary syndromes or stroke." | 3.85 | The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry. ( Bălaşa, R; Bănescu, C; Dobreanu, M; Maier, S; Mărginean, A; Mărginean, M; Moldovan, V; Scridon, A; Ţăruşi, M, 2017) |
| "Aspirin and statin are recommended for the treatment of acute ischemic stroke." | 3.85 | Statin and Aspirin Pretreatment Are Associated with Lower Neurological Deterioration and Platelet Activity in Patients with Acute Ischemic Stroke. ( Han, Z; Lin, J; Wang, C; Yi, X; Zhou, Q, 2017) |
| "Scarce and conflicting evidence exists on whether clopidogrel is effective and whether dual antiplatelet treatment (DAPT) is safe in patients with acute coronary syndrome and chronic kidney disease (CKD)." | 3.85 | Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease. ( Carrero, JJ; Evans, M; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Spaak, J; Szummer, K; Varenhorst, C, 2017) |
| "Based on the present analysis, apixaban represents a cost-effective treatment option versus warfarin and aspirin for the prevention of stroke in patients with AF from a Greek healthcare payer perspective over a lifetime horizon." | 3.85 | Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective. ( Athanasakis, K; Bilitou, A; Boubouchairopoulou, N; Karampli, E; Kyriopoulos, J; Savvari, P; Tarantilis, F, 2017) |
| "Adjusted survival curves showed that the usage of aspirin was not associated with ischemic stroke, hospitalization for bleeding events, cardiovascular mortality or all-cause mortality, however, it was significantly associated with renal failure." | 3.85 | Different impact of aspirin on renal progression in patients with predialysis advanced chronic kidney disease with or without previous stroke. ( Chang, HR; Hsiao, KC; Huang, JY; Hung, TW; Lee, CT; Liaw, YP, 2017) |
| "Aspirin and clopidogrel are both acceptable antiplatelet options for the secondary prevention of noncardioembolic ischemic stroke." | 3.85 | Antiplatelet Strategies and Outcomes in Patients with Noncardioembolic Ischemic Stroke from a Real-World Study with a Five-Year Follow-Up. ( Dai, H; He, P; Li, W; Lin, H; Ping, Y; Xu, H, 2017) |
| "This study aimed to know how frontline physicians in France, Belgium, and Switzerland implement guidelines regarding the secondary prevention of childhood arterial ischemic stroke and to introduce physicians' point of view on a clinical trial assessing the efficacy of aspirin as a preventive strategy." | 3.85 | Secondary Prevention of Childhood Arterial Ischemic Stroke. ( Bertoletti, L; Chabrier, S; Darteyre, S; Fluss, J; Laporte, S; Renaud, C, 2017) |
| "Active smokers with myocardial infarction were shown to have enhanced benefit with clopidogrel compared with aspirin." | 3.85 | Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox? ( Cao, Q; Dong, K; Feng, W; Hou, C; Huang, X; Ji, X; Ovbiagele, B; Song, H; Wang, M; Wang, Y; Zhang, Q, 2017) |
| "Nonvitamin K antagonist oral anticoagulants (NOACs) are now available for the prevention of stroke in patients with atrial fibrillation (AF) as an alternative to vitamin K antagonists (VKA) and aspirin." | 3.85 | Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. ( Bos, J; Burden, AM; de Boer, A; de Vries, F; Gieling, EM; Kramers, C; van den Ham, HA; van Onzenoort, H, 2017) |
| "In this hypothesis generating pilot analysis, dipyrone medication in aspirin treated coronary artery disease patients is associated with an increased cumulative incidence of death, MI or stroke as well as all-cause mortality and ischemic events." | 3.85 | Analgesic medication with dipyrone in patients with coronary artery disease: Relation to MACCE. ( Achilles, A; Dannenberg, L; Hohlfeld, T; Kelm, M; Levkau, B; Mohring, A; Piayda, K; Polzin, A; Zeus, T, 2017) |
| "To evaluate long-term health benefits and risks of adding vorapaxar (VOR) to the standard care antiplatelet therapy (SC) of aspirin and/or clopidogrel, among a population with a recent myocardial infarction (MI) and/or peripheral artery disease (PAD)." | 3.85 | State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. ( Chase, M; Davies, G; Du, M; Oguz, M, 2017) |
| " Individuals who underwent coronary stenting and completed 12 months of thienopyridine plus aspirin therapy without ischemic or bleeding events remained on an aspirin regimen and were randomized to continued thienopyridine therapy vs placebo for 18 additional months." | 3.85 | Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. ( Apruzzese, PK; Cannon, CP; Cohen, DJ; Cutlip, DE; D'Agostino, RB; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW, 2017) |
| "This retrospective, cross-sectional study evaluated whether HIV-infected patients received aspirin and statins for the primary prevention of myocardial infarction and stroke." | 3.83 | Use of aspirin and statins for the primary prevention of myocardial infarction and stroke in patients with human immunodeficiency virus infection. ( Park, TE; Sharma, R; Yusuff, J, 2016) |
| "Little is known about the ischaemic stroke risk and benefit of warfarin therapy for stroke prevention in chronic kidney disease (CKD) patients on peritoneal dialysis (PD) with concomitant atrial fibrillation (AF)." | 3.83 | Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis. ( Chan, PH; Chan, TM; Hai, J; Huang, D; Lip, GY; Lo, WK; Siu, CW; Tse, HF; Yip, PS, 2016) |
| "Admission National Institutes of Health Stroke Scale (NIHSS) score, ischemic lesion volumes on diffusion-weighted imaging (DWI), and in vitro aspirin resistance, in addition to other pertinent stroke features, were determined in a series of ischemic stroke patients." | 3.83 | The Interplay between Stroke Severity, Antiplatelet Use, and Aspirin Resistance in Ischemic Stroke. ( Agayeva, N; Arsava, EM; Topcuoglu, MA, 2016) |
| "We measured serum levels of proinflammatory/prothrombotic markers P-selectin, CD40L, matrix metalloproteinase 9 (MMP-9), intracellular adhesion molecule 1 (ICAM-1), and interleukin (IL)-6 in ischemic stroke patients, correlating their levels with the results of aspirin (ASA) and clopidogrel antiplatelet responses, using 3 "point of care" platelet function instruments, thromboelastograph (TEG), Accumetrics (ACU), and impedance aggregometer (IMP)." | 3.83 | Relationship between Inflammation and Aspirin and Clopidogrel Antiplatelet Responses in Acute Ischemic Stroke. ( Ambrus, JL; Chichelli, T; Ching, M; Janicke, D; Munschauer, F; Sawyer, R; Sternberg, D; Sternberg, Z; Yu, J, 2016) |
| "Selecting among different antiplatelet strategies when patients experience a new ischemic stroke while taking aspirin is a common clinical challenge, currently addressed by a paucity of data." | 3.83 | Different Antiplatelet Strategies in Patients With New Ischemic Stroke While Taking Aspirin. ( Bae, HJ; Cha, JK; Cho, KH; Cho, YJ; Choi, JC; Choi, KH; Han, MK; Hong, KS; Kang, K; Kim, BJ; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Kim, WJ; Ko, YC; Lee, BC; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Nah, HW; Oh, MS; Park, JM; Park, MS; Park, SS; Park, TH; Ryu, WS; Saver, JL; Shin, DI; Yeo, MJ; Yu, KH, 2016) |
| "The effect of prestroke aspirin use on initial severity, hemorrhagic transformation, and functional outcome of ischemic stroke is uncertain." | 3.83 | Comparative Effectiveness of Prestroke Aspirin on Stroke Severity and Outcome. ( Bae, HJ; Cha, JK; Cho, YJ; Choi, JC; Gorelick, PB; Han, MK; Hong, KS; Kang, K; Kim, DE; Kim, DH; Kim, JT; Ko, Y; Lee, BC; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Park, JM; Park, TH; Yu, KH, 2016) |
| " Among these 397 patients, 69 were receiving monotherapy with clopidogrel prior to stroke, 69 were receiving monotherapy with aspirin and 236 patients were not on any antiplatelet treatment." | 3.83 | Treatment with Clopidogrel Prior to Acute Non-Cardioembolic Ischemic Stroke Attenuates Stroke Severity. ( Angelopoulou, SM; Bouziana, SD; Giampatzis, V; Hatzitolios, AI; Kostaki, S; Papadopoulou, M; Savopoulos, C; Spanou, M; Tsopozidi, M; Tziomalos, K, 2016) |
| " Our results suggest that this strategy is not beneficial as compared to aspirin alone in terms of ischaemic or bleeding events." | 3.83 | Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study). ( Bauters, C; Caudmont, S; Ketelers, R; Lamblin, N; Lemaire, N; Lemesle, G; Meurice, T; Philias, A; Schurtz, G; Tricot, O, 2016) |
| "Using the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (n = 10,135), we analyzed outcomes in patients with coronary artery disease (n = 1827) according to treatment with triple antithrombotic therapy (defined as concurrent therapy with an oral anticoagulant, a thienopyridine, and aspirin) or dual antithrombotic therapy (comprising either an oral anticoagulant and one antiplatelet agent [OAC plus AA] or 2 antiplatelet drugs and no anticoagulant [DAP])." | 3.83 | Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. ( Ansell, J; Chang, P; Fonarow, GC; Gersh, BJ; Go, AS; Hylek, EM; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Rao, M; Simon, DN; Singer, DE; Thomas, L, 2016) |
| "A cost-effectiveness model was constructed using data from three studies on stroke prevention in patients with contraindications: the ASAP study evaluating the Watchman device, the ACTIVE A trial of aspirin and clopidogrel, and the AVERROES trial evaluating apixaban." | 3.83 | Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin. ( Akehurst, RL; Amorosi, SL; Armstrong, SO; Brereton, N; Hertz, DS; Holmes, DR; Reddy, VY, 2016) |
| " Analysis of patient demographics and stroke risk identified trends in prescribing DOAC versus warfarin." | 3.83 | Adoption of direct oral anticoagulants for stroke prevention in atrial fibrillation. ( Baker, D; Narasimhan, S; Wilsmore, B, 2016) |
| "Concomitant use of vitamin K antagonist (VKA) and aspirin (ASA) is becoming increasingly prevalent among atrial fibrillation (AF) patients." | 3.83 | Net clinical benefit of adding aspirin to warfarin in patients with atrial fibrillation: Insights from the J-RHYTHM Registry. ( Atarashi, H; Chishaki, A; Inoue, H; Kiyono, K; Kodama, I; Kodani, E; Lip, GY; Okumura, K; Okuyama, Y; Origasa, H; Watanabe, E; Yamamoto, M; Yamashita, T, 2016) |
| "To investigate whether aspirin resistance is associated with initial stroke severity and infarct volume, using diffusion-weighted imaging (DWI) in patients with acute ischemic stroke that occurred while taking aspirin." | 3.83 | Aspirin resistance is associated with increased stroke severity and infarct volume. ( Jang, MU; Jung, S; Kim, C; Lee, BC; Lee, J; Lee, JH; Oh, MS; Yu, KH, 2016) |
| "Evidence indicates that aspirin is effective for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC) but also increases the risk for gastrointestinal (GI) and cerebral hemorrhages." | 3.83 | Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force. ( Dehmer, SP; Flottemesch, TJ; LaFrance, AB; Maciosek, MV; Whitlock, EP, 2016) |
| "This model demonstrates that increased use of rivaroxaban in inadequately-managed NVAF patients could avoid 456 081 non-fatal ischemic strokes (IS) and 76 975 cardiovascular deaths over 10 years in Japan." | 3.83 | Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: The case study of Japan. ( Briere, JB; Evers, T; Hori, M; Ikeda, S; Koretsune, Y; Matsuda, S; Montouchet, C; Okumura, K; Rossi, B; Ruff, L; Watanabe-Fujinuma, E, 2016) |
| "The TRA 2°P-TIMI 50 trial showed the addition of vorapaxar to standard care (SC) antiplatelet therapy reduced the combined risk of death, myocardial infarction (MI), and stroke, while exhibiting an increase in moderate, but not other bleeding events." | 3.83 | A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction. ( Bash, LD; Davies, G; Du, M; Oguz, M; Ozer-Stillman, I; Whalen, JD, 2016) |
| "Dipyrone comedication in patients with stroke impairs pharmacodynamic response to aspirin." | 3.83 | Dipyrone comedication in aspirin treated stroke patients impairs outcome. ( Bönner, F; Dannenberg, L; Erschoff, V; Gliem, M; Hohlfeld, T; Jander, S; Kelm, M; Levkau, B; Polzin, A; Zeus, T, 2016) |
| "Oral anticoagulation (OAC), rather than aspirin, is recommended in patients with atrial fibrillation (AF) at moderate to high risk of stroke." | 3.83 | Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke. ( Gehi, AK; Hsu, JC; Katz, DF; Kennedy, K; Lubitz, SA; Maddox, TM; Marcus, GM; Marzec, LN; Turakhia, MP, 2016) |
| "2% of dabigatran-treated patients had renal insufficiency requiring a dose reduction." | 3.83 | Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. ( Barra, ME; Connors, JM; Fanikos, J; Goldhaber, SZ; Piazza, G; Sylvester, KW, 2016) |
| "A higher loading dose of aspirin (160-325 mg) can be beneficial in treating acute ischemic stroke, although there is an increased risk of minor bleeding." | 3.83 | To Load or Not to Load? Aspirin Loading in Acute Ischemic Stroke: A Study of Clinical Outcomes. ( Chan, YL; Lee, JD; Lee, M; Lee, TH; Lin, LC; Su, TH; Wen, YW, 2016) |
| "miR-145 is involved in the anti-proliferation and anti-inflammation effects of aspirin on VSMCs by inhibiting the expression of CD40." | 3.83 | miR-145 mediated the role of aspirin in resisting VSMCs proliferation and anti-inflammation through CD40. ( Chen, M; Guo, R; Guo, X; Peng, X; Wu, T; Yu, L; Zhang, B, 2016) |
| "LAAC is a novel stroke preventative therapy for nonvalvular AF and is a cost-effective alternative to aspirin in patients with contraindications to OAC." | 3.83 | Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Patients With Contraindications to Anticoagulation. ( Bennell, MC; Saw, J; Singh, SM; Wijeysundera, HC, 2016) |
| "To evaluate the efficacy and safety of well-managed warfarin therapy in patients with nonvalvular AF, the risk of complications, especially intracranial bleeding, in patients with concomitant use of aspirin, and the impact of international normalized ratio (INR) control." | 3.83 | Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. ( Björck, F; Lip, GY; Renlund, H; Själander, A; Svensson, PJ; Wester, P, 2016) |
| "Aspirin is known to reduce stroke risk; however, its role in reducing severity of ischemic syndrome is not clear." | 3.83 | Antecedent Aspirin Use Is Associated with Less Severe Symptoms on Admission for Ischemic Stroke. ( Cloonan, L; Fitzpatrick, KM; Furie, KL; Kanakis, AS; Nelson, S; Perilla, AS; Rost, NS; Shideler, KI, 2016) |
| "Aspirin use at baseline was associated with an increased risk for bleeding and all-cause death in ROCKET AF, a risk most pronounced in patients without known CAD." | 3.83 | Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. ( Becker, RC; Berkowitz, SD; Breithardt, G; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, A; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Shah, R; Singer, DE, 2016) |
| "Aspirin resistance has an incidence of 5%-65% in patients with ischemic stroke, who receive the standard dose of aspirin, but the platelet function is inadequately inhibited, thereby leading to thrombotic events." | 3.83 | Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy. ( Cai, YF; Chen, LY; Chen, XM; Huang, M; Jin, J; Li, JL; Peng, LL; Zhao, M; Zhao, YQ; Zhou, ZY, 2016) |
| "This population-based time series study used administrative health data linked to 45 and Up Study participants with a high risk of cardiovascular disease (CVD) to assess the possible impact of the NPS MedicineWise program on first-time aspirin prescriptions and primary stroke-related hospitalizations." | 3.83 | Using Large-Scale Linkage Data to Evaluate the Effectiveness of a National Educational Program on Antithrombotic Prescribing and Associated Stroke Prevention in Primary Care. ( Bartlett, M; Khan, R; Liu, Z; Moorin, R; Tofler, G; Worthington, J; Zuo, Y, 2016) |
| "Plasma anticoagulation with warfarin during the early postoperative phase was shown statistically to be inferior to platelet aggregation inhibition by aspirin with regards to postoperative bleeding risk, cerebral ischemic events, and survival." | 3.83 | Anticoagulation After Biological Aortic Valve Replacement: Is There An Optimal Regimen? ( Breuer, M; Fuchs, J; Hüter, L; Kuntze, T; Lauer, B; Owais, T; Rouman, M, 2016) |
| "Fourteen hybrids (10a-g, 11a-g) of 3-n-butylphthalide (NBP) and edaravone (Eda) analogues have been designed and synthesized as potential anti-ischemic stroke agents." | 3.81 | Novel hybrids of 3-n-butylphthalide and edaravone: Design, synthesis and evaluations as potential anti-ischemic stroke agents. ( Hua, K; Huang, Z; Ji, H; Sheng, X; Wang, X; Xu, J; Yang, C; Zhang, Y, 2015) |
| " aspirin to achieve a reduction in three strokes in 100 patients over a 2-year period." | 3.81 | Values and preferences for oral antithrombotic therapy in patients with atrial fibrillation: physician and patient perspectives. ( Alonso-Coello, P; Coll-Vinent, B; Devereaux, PJ; Díaz, MG; Diez, AI; Gich, I; Guyatt, G; Mas, G; Montori, VM; Oliver, S; Roura, M; Ruiz, R; Schünemann, HJ; Solà, I; Souto, JC, 2015) |
| " We investigated the risks of ischemic stroke and intracranial hemorrhage (ICH) in relation to warfarin at various TTRs in a real-world cohort of Chinese patients with atrial fibrillation receiving warfarin and compared with those on dabigatran, aspirin, and no therapy." | 3.81 | Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. ( Chan, KH; Chan, PH; Cheung, E; Hai, JJ; Ho, CW; Ho, MH; Lau, CP; Lau, KK; Leung, GK; Lip, GY; Siu, CW; Tse, HF; Yeung, CY, 2015) |
| "Aspirin is recommended in stable coronary artery disease based on myocardial infarction and stroke studies." | 3.81 | Impact of aspirin according to type of stable coronary artery disease: insights from a large international cohort. ( Bavry, AA; Cooper-DeHoff, RM; Gong, Y; Handberg, EM; Pepine, CJ, 2015) |
| "Aspirin use increased among Chinese patients newly diagnosed with AF, with no relationship to the patient's stroke or bleeding risk." | 3.81 | Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation. ( Guo, Y; Lip, GYH; Tian, Y; Wang, H; Wang, Y, 2015) |
| "A significant proportion of ischemic strokes occur while using aspirin and therefore can be considered as clinical aspirin resistance." | 3.81 | Pathophysiologic, rather than laboratory-defined resistance drives aspirin failure in ischemic stroke. ( Agayeva, N; Arsava, EM; Gungor, L; Topcuoglu, MA, 2015) |
| "Preoperatively continued aspirin use was not associated with increased risk of intra- and post-operative blood loss, blood transfusion requirements and composite outcome of in-hospital death, stroke and reoperation for bleeding in off-pump CABG." | 3.81 | Effect of preoperatively continued aspirin use on early and mid-term outcomes in off-pump coronary bypass surgery: a propensity score-matched study of 1418 patients. ( Pan, S; Song, Y; Sun, H; Wu, H; Xiao, F; Xu, J, 2015) |
| " We studied 39,400 patients discharged with incident nonvalvular atrial fibrillation with 0 or 1 CHA2DS2-VASc risk factor; 23,572 were not treated, 5,353 were initiated on aspirin, and 10,475 were initiated on warfarin." | 3.81 | Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. ( Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F, 2015) |
| "Randomised trials have shown the efficacy of antiplatelet therapy with cilostazol to prevent secondary ischaemic stroke." | 3.81 | Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. ( Hayashi, K; Horie, N; Izumo, T; Kaminogo, M; Nagata, I; Tsujino, A, 2015) |
| "We aimed to study differences in the prescribing of warfarin, aspirin and statins to patients with atrial fibrillation (AF) in socio-economically diverse neighborhoods." | 3.81 | Neighborhood deprivation and warfarin, aspirin and statin prescription - A cohort study of men and women treated for atrial fibrillation in Swedish primary care. ( Carlsson, AC; Gasevic, D; Sundquist, J; Sundquist, K; Wändell, P, 2015) |
| "Clopidogrel or aspirin are indicated for patients with recent ischemic stroke (IS) or established peripheral artery disease (PAD)." | 3.81 | Clopidogrel versus aspirin in patients with recent ischemic stroke and established peripheral artery disease: an economic evaluation in a Chinese setting. ( Ben, H; Li, T; Liu, M; Wu, B; Xu, Z; Zhong, H, 2015) |
| "Low-dose aspirin (ASA) is effective for secondary prevention of ischemic stroke but can increase the risks of hemorrhagic stroke, upper gastrointestinal bleeding (UGIB), and dyspepsia." | 3.81 | Cost-Effectiveness of Proton Pump Inhibitor Co-Therapy in Patients Taking Aspirin for Secondary Prevention of Ischemic Stroke. ( Kawakami, K; Murata, K; Takabayashi, N; Tanaka, S, 2015) |
| " For subgroup analysis, all patients were stratified by the following factors: age (above 75), disease (presence of hypertension, diabetes, congestive heart failure, and a history of stroke or thromboembolism), rhythm control procedure, and concurrent aspirin therapy." | 3.81 | INR optimization based on stroke risk factors in patients with non-valvular atrial fibrillation. ( Choi, YR; Chung, JE; Gwak, HS; La, HO; Seong, JM, 2015) |
| " Therefore, we sought to evaluate the time-dependent changes in platelet reactivity to aspirin during the acute stage after ischemic stroke and the clinical implications of variable patient responses to aspirin in acute ischemic stroke." | 3.81 | Clinical Implications of Changes in Individual Platelet Reactivity to Aspirin Over Time in Acute Ischemic Stroke. ( Cho, KH; Choi, KH; Choi, SM; Heo, SH; Kim, BC; Kim, JT; Kim, MK; Lee, SH; Nam, TS; Park, MS; Saver, JL, 2015) |
| "Patients admitted for a suspected acute ischemic stroke, while under APD (aspirin and/or clopidogrel), were prospectively included." | 3.81 | Interest of Antiplatelet Drug Testing after an Acute Ischemic Stroke. ( Coignion, C; Debruxelles, S; Freyburger, G; Poli, M; Renou, P; Rouanet, F; Sagnier, S; Sibon, I, 2015) |
| "In patients with ischemic stroke of non-cardioembolic origin, acetylsalicylic acid, clopidogrel, or a combination of acetylsalicylic acid and dipyridamole are recommended for the prevention of a recurrent stroke." | 3.81 | Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study. ( Carlson, N; Christiansen, CB; Gerds, TA; Gislason, G; Jørgensen, ME; Kristensen, SL; Numé, AK; Olesen, JB; Pallisgaard, J; Torp-Pedersen, C, 2015) |
| "To compare the lifetime cost and effectiveness of five alternative chronic atrial fibrillation (AF) management strategies: rivaroxaban, warfarin, aspirin plus clopidogrel, aspirin and no prevention." | 3.80 | Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting. ( He, B; Kun, L; Liu, X; Wu, B, 2014) |
| " The odds of an adverse incidence of death/myocardial infarction/stroke 1 year after discharge was significantly reduced in patients receiving aspirin and clopidogrel for ≥9 months and was consequently higher in patients in whom dual antiplatelet therapy was discontinued or prescribed for <9 months." | 3.80 | Predictors of 1-year outcomes in the Taiwan Acute Coronary Syndrome Full Spectrum Registry. ( Chiang, FT; Hou, CJ; Hwang, JJ; Kuo, C; Kuo, CT; Lai, WT; Li, AH; Li, YH; Lin, SJ; Mar, GY; Shyu, KG; Wen, MS; Wu, CJ, 2014) |
| " We aimed to evaluate the effect of DAPT duration with clopidogrel and aspirin on the recurrence of ischaemic events and bleeding in a large, unselected ACS population." | 3.80 | Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. ( Hasvold, P; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Sundström, A; Varenhorst, C, 2014) |
| "Some patients with a recent ischemic stroke who are being treated with aspirin as an antiaggregant suffer a new ischemic stroke." | 3.80 | Aspirin resistant patients with recent ischemic stroke. ( Castilla-Guerra, L; Fernández-Moreno, MC; Navas-Alcántara, MS, 2014) |
| " However, in patients with atrial fibrillation (AF), there is a concern that combining warfarin with dual antiplatelet therapy may increase the risk of bleeding." | 3.80 | Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents. ( Araki, T; Enomoto, Y; Hara, H; Hori, M; Iijima, R; Itaya, H; Ito, N; Nagashima, Y; Nakamura, M; Shiba, M; Sugi, K; Tokue, M; Utsunomiya, M; Yamazaki, K, 2014) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 3.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| " Apixaban is an oral anticoagulant that has demonstrated better efficacy than warfarin and aspirin in the ARISTOTLE and AVERROES studies, respectively, and causes less bleeding than warfarin." | 3.80 | Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. ( Dorian, P; Hernandez, L; Iloeje, U; Kongnakorn, T; Kuznik, A; Lanitis, T; Lip, GY; Liu, LZ; Phatak, H; Rublee, DA, 2014) |
| "Anonymous surveys on treatment practices in patients with ICAS were sent to physicians at 3 time points: before publication of the NIH-funded Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) trial (pre-WASID survey, 2004), 1 year after WASID publication (post-WASID survey, 2006) and 1 year after the publication of the NIH-funded Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial (post-SAMMPRIS survey, 2012)." | 3.80 | Intracranial stenosis: impact of randomized trials on treatment preferences of US neurologists and neurointerventionists. ( Chimowitz, MI; Cotsonis, G; Derdeyn, CP; Fiorella, D; Lynn, MJ; Stern, BJ; Swanson, S; Turan, TN; Williams, JE; Wooley, RH, 2014) |
| "We estimated the effectiveness and safety of antiplatelet drugs (aspirin and clopidogrel) for the prevention of recurrent ischemic stroke in end-stage renal disease patients undergoing dialysis during long-term follow-up after first-time ischemic stroke." | 3.80 | Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis. ( Chen, CY; Huang, YB; Lai, WT; Lee, CT; Lee, KT, 2014) |
| "The majority of traumatic aneurysms can be managed with an antiplatelet regimen of 325 mg aspirin daily and serial imaging." | 3.80 | Extracranial traumatic aneurysms due to blunt cerebrovascular injury. ( Falola, M; Foreman, PM; Griessenauer, CJ; Harrigan, MR, 2014) |
| "Current guidelines recommend that patients with peripheral arterial disease (PAD) cease smoking and be treated with aspirin, statin medications, and angiotensin-converting enzyme (ACE) inhibitors." | 3.80 | Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. ( Amsterdam, EA; Anderson, D; Armstrong, EJ; Bang, H; Chen, DC; Laird, JR; McCoach, CE; Singh, S; Westin, GG; Yeo, KK, 2014) |
| "To conduct an economic evaluation of the currently prescribed treatments for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) including warfarin, aspirin, and novel oral anticoagulants (NOACs) from a French payer perspective." | 3.80 | Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin. ( Cotté, FE; Durand-Zaleski, I; Gaudin, AF; Kachaner, I; Kongnakorn, T; Lanitis, T, 2014) |
| "Treatment with the combination of clopidogrel and aspirin taken soon after a transient ischemic attack (TIA) or minor stroke was shown to reduce the 90-day risk of stroke in a large trial in China, but the cost-effectiveness is unknown." | 3.80 | Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke. ( Johnston, SC; Liu, G; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, C; Wang, Y; Zhao, K; Zhao, X, 2014) |
| "Apixaban was found to be a cost-effective alternative to warfarin and aspirin for stroke prevention in patients with AF in Sweden." | 3.80 | Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation. ( De Geer, A; Jacobson, L; Kongnakorn, T; Lanitis, T, 2014) |
| "Our objective was to investigate the association between recurrent stroke risk and headache induced by extended-release dipyridamole (ER-DP) when administered alone or with low-dose aspirin (ASA+ER-DP)." | 3.80 | Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis. ( Bath, PM; Cotton, D; Davidai, G; Diener, HC; Gorelick, P; Lipton, RB; Sacco, R, 2014) |
| "To analyze the potential impact of aspirin on outcome at hospital discharge after acute stroke in resource-limited settings without access to neuroimaging to distinguish ischemic stroke from intracerebral hemorrhage (ICH)." | 3.80 | Aspirin for acute stroke of unknown etiology in resource-limited settings: a decision analysis. ( Berkowitz, AL; Bianchi, MT; Chou, SH; Westover, MB, 2014) |
| "To analyze the potential impact of aspirin therapy for long-term secondary prevention after stroke of undetermined etiology in resource-limited settings without access to neuroimaging to distinguish ischemic stroke from intracerebral hemorrhage (ICH)." | 3.80 | Aspirin for secondary prevention after stroke of unknown etiology in resource-limited settings. ( Berkowitz, AL; Bianchi, MT; Chou, SH; Westover, MB, 2014) |
| " camphorata), a fungus commonly used in Chinese folk medicine for treatment of viral hepatitis and cancer, alone or in combination with aspirin was investigated in a rat embolic stroke model." | 3.80 | Extract of Antrodia camphorata exerts neuroprotection against embolic stroke in rats without causing the risk of hemorrhagic incidence. ( Chang, CY; Geraldine, P; Lan, CC; Lee, JJ; Lee, YM; Sheu, JR; Yen, TL, 2014) |
| "Evidence indicates that vitamin K antagonists (VKAs) and oral anticoagulant therapy are under-utilised for stroke prevention in patients with non-valvular atrial fibrillation (AF), and patients who decline or cannot tolerate such treatment are often prescribed aspirin instead." | 3.80 | Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in Belgium. ( Annemans, L; Kongnakorn, T; Lanitis, T; Lieven, A; Marbaix, S; Thijs, V, 2014) |
| " The risks of suffering ischemic stroke, bleeding, or death with warfarin, aspirin, or no antithrombotic treatment during 2010 were related to CHA2DS2VASc scores, age, and complicating co-morbidities." | 3.80 | Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region. ( Forslund, T; Hasselström, J; Hjemdahl, P; von Euler, M; Wändell, P; Wettermark, B, 2014) |
| "To project the long-term cost-effectiveness of treating non-valvular atrial fibrillation (AF) patients for stroke prevention with rivaroxaban compared to warfarin in Portugal." | 3.80 | Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting. ( Aguiar, C; Chatzitheofilou, I; Fonseca Santos, I; McLeod, E; Morais, J; Pereira, S, 2014) |
| "To examine whether preadmission use of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) influenced 30-day stroke mortality." | 3.80 | Preadmission use of nonaspirin nonsteroidal anti-inflammatory drugs and 30-day stroke mortality. ( Bøtker, HE; Christiansen, CF; Hováth-Puhó, E; Petersen, KL; Schmidt, M; Sørensen, HT, 2014) |
| " The net clinical benefit of warfarin was assessed using 4 endpoints: a composite endpoint of death/hospitalization from stroke/bleeding; a composite endpoint of fatal stroke/fatal bleeding; cardiovascular death; and all-cause death." | 3.80 | Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. ( Bonde, AN; Gislason, GH; Hansen, ML; Hansen, PR; Hommel, K; Kamper, AL; Lamberts, M; Lip, GY; Olesen, JB; Torp-Pedersen, C, 2014) |
| "In search of novel anti-ischemic stroke agents with higher potency than a known drug 3-n-butylphthalide (NBP), a series of hybrids ((S)- and (R)-5a-f) from optically active ring-opened NBP derivative and isosorbide were synthesized for evaluating their anti-ischemic stroke activity." | 3.79 | Novel hybrids of optically active ring-opened 3-n-butylphthalide derivative and isosorbide as potential anti-ischemic stroke agents. ( Huang, Z; Ji, H; Lai, Y; Li, T; Tian, J; Wan, X; Wang, L; Wang, X; Xu, J; Zhang, Y, 2013) |
| "A total of 2141 patients with coronary artery disease treated exclusively with Cypher sirolimus-eluting stents (SES) or Endeavor zotarolimus-eluting stents (ZES) were considered for retrospective analysis." | 3.79 | Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents. ( Chen, F; Gao, Y; He, J; Luo, Y; Lv, S; Ren, X; Wu, C; Yu, X; Zhang, X; Zhang, Y, 2013) |
| "Clopidogrel, cilostazol, and aspirin were compared in terms of efficacy and safety for primary prevention of stroke in peripheral artery disease (PAD) patients." | 3.79 | Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan. ( Chu, CY; Hsu, PC; Lai, WT; Lee, WH; Lin, TH; Sheu, SH; Su, HM; Voon, WC, 2013) |
| "Studies have shown that aspirin used for secondary prevention significantly reduces cardiovascular and stroke risk." | 3.79 | Primary prophylactic aspirin use and incident stroke: reasons for geographic and racial differences in stroke study. ( Cushman, M; Glasser, SP; Hovater, MK; Howard, G; Howard, VJ; Lackland, DT, 2013) |
| "To describe the prevalence of aspirin resistance based on optical platelet aggregometry in stroke patients who attended the Neurological Institute and investigate the clinical risk factors associated with aspirin resistance." | 3.79 | Aspirin non-responder in Thai ischemic stroke patients. ( Jongjaroenprasert, W; Mahasirimongkol, S; Suanprasert, N; Tantirithisak, T; Yadee, T, 2013) |
| "We examined 157 aspirin-treated patients with acute stroke or TIA, 128 aspirin-free and 15 aspirin-treated healthy subjects (HS)." | 3.79 | TXA2 synthesis and COX1-independent platelet reactivity in aspirin-treated patients soon after acute cerebral stroke or transient ischaemic attack. ( Lago, A; Moscardo, A; Parkhutik, V; Santos, MT; Tembl, J; Valles, J, 2013) |
| "A prospective study included 35 patients admitted with ischemic stroke and commenced on 300 mg aspirin." | 3.79 | "Aspirin resistance" in ischemic stroke: insights using short thrombelastography. ( Curzen, N; Englyst, N; Radhakrishnan, A; Sambu, N; Weir, N, 2013) |
| "To investigate the relationship between hemorrhagic stroke and use of antiplatelets and warfarin using data from The Health Improvement Network." | 3.79 | Antithrombotic drugs and risk of hemorrhagic stroke in the general population. ( Cookson, C; Gaist, D; García-Rodríguez, LA; González-Pérez, A; Morton, J, 2013) |
| "The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial found no difference between warfarin and aspirin in patients with low ejection fraction in sinus rhythm for the primary outcome: first to occur of 84 incident ischemic strokes (IIS), 7 intracerebral hemorrhages or 531 deaths." | 3.79 | Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial. ( Anker, SD; Di Tullio, MR; Diek, M; Freudenberger, RS; Graham, S; Haddad, H; Homma, S; Labovitz, AJ; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Sanford, AR; Teerlink, JR; Thompson, JL, 2013) |
| "Among patients with stroke, the phenomenon of resistance to treatment with low-dose aspirin acetylsalicylic acid (ASA) is quite common." | 3.79 | Factors influencing multiplate whole blood impedance platelet aggregometry measurements, during aspirin treatment in acute ischemic stroke: a pilot study. ( Chełstowski, K; Clark, J; Jastrzębska, M; Nowacki, P; Siennicka, A; Wódecka, A, 2013) |
| "The prognostic value of occurrence of ischemic stroke in a patient despite aspirin treatment (aspirin treatment failure) is not known." | 3.79 | Aspirin treatment failure and the risk of recurrent stroke and death among patients with ischemic stroke. ( Adams, HP; Cordina, SM; Georgiadis, AL; Lakshminarayan, K; Qureshi, AI; Suri, MF; Tariq, N; Vazquez, G, 2013) |
| "This study evaluated the antiplatelet effects of clopidogrel (CPG) in patients sustaining acute ischemic stroke who were already receiving chronic outpatient aspirin therapy (81-325 mg/day)." | 3.79 | Clopidogrel responsiveness in stroke patients on a chronic aspirin regimen. ( Chichelli, T; Ching, M; Farooq, O; Janicke, D; Li, F; Mehta, B; Munschauer, FE; Radovic, V; Sawyer, RN; Sternberg, Z, 2013) |
| " The patient was subsequently found to have incomplete inhibition of platelet activity despite being on clopidogrel 150 mg and aspirin 81 mg daily and having a normal CYP-2C19 genotype, suggesting that suboptimal antiplatelet inhibition, secondary to morbid obesity, contributed to his in-stent thrombosis." | 3.79 | Obesity and intracranial in-stent thrombosis. ( Koch, S; Reyes-Iglesias, Y; Rose, DZ; Yavagal, DR, 2013) |
| "Aspirin resistance (AR) is common in Chinese stroke patients taking antiplatelet medications; however, few studies have documented the role of cyclooxygenase (COX)-1 C50T and COX-2 G765C polymorphisms in AR." | 3.79 | Platelet response to aspirin in Chinese stroke patients is independent of genetic polymorphisms of COX-1 C50T and COX-2 G765C. ( Chi, L; Han, Z; Lin, J; Yi, X; Zhou, Q, 2013) |
| "To investigate the relationship between aspirin resistance and clinical and neuroimaging measures of stroke severity in acute stroke patients." | 3.79 | Association of aspirin resistance with increased stroke severity and infarct size. ( Churilov, L; Colley, RE; Davis, SM; Goh, C; Yan, B; Zheng, AS, 2013) |
| "Most ischemic strokes due to TCVI are embolic in nature and occur prior to screening CTA and initiation of treatment with aspirin." | 3.79 | Timing and mechanism of ischemic stroke due to extracranial blunt traumatic cerebrovascular injury. ( Alexandrov, AV; Barlinn, K; Cava, LP; Curé, JK; Fleming, JB; Griessenauer, CJ; Harrigan, MR; Richards, BF; Taylor, T; Younan, DS; Zhao, L, 2013) |
| "Randomized trials suggested superior stroke prevention with extended-release dipyridamole (ERD) in combination with low-dose aspirin than either with aspirin or dipyridamole alone." | 3.78 | Effects of extended-release dipyridamole in vitro on thrombin indices measured by calibrated automated thrombography in poststroke survivors. ( Fong, A; Hanley, D; Pokov, I; Sani, Y; Schevchuck, A; Serebruany, V; Thevathasan, L, 2012) |
| "The widespread use of aspirin-driven vascular prevention strategies does not impede the occurrence of first and recurrent ischemic strokes in numerous subjects." | 3.78 | Ischemic stroke in patients receiving aspirin. ( Ameriso, S; Ameriso, SF; Povedano, GP; Pujol Lereis, VA, 2012) |
| "Treatment with cilostazol for 7 days before ischemia significantly suppressed the risk and severity of cerebral hemorrhage after injection of tissue-type plasminogen activator, although treatment with aspirin had no such protective effect compared with nontreated mice." | 3.78 | Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model. ( Kasahara, Y; Matsuyama, T; Nakagomi, T; Stern, D; Taguchi, A, 2012) |
| "the primary prevention of ischaemic stroke in chronic non-valvular atrial fibrillation (AF) typically involves consideration of aspirin or warfarin." | 3.78 | Aspirin versus warfarin in atrial fibrillation: decision analysis may help patients' choice. ( O'Shea, D; Romero-Ortuno, R, 2012) |
| "Aspirin is the most commonly used antiplatelet drug for treatment of a serious vascular event, most notably myocardial infarction and stroke." | 3.78 | Association of C3435T multi drug resistance gene-1 polymorphism with aspirin resistance in ischemic stroke and its subtypes. ( Al-Hazzani, A; Dadheech, S; Jyothy, A; Kaul, S; Munshi, A; Prabha, TS; Rao, PP; Sharma, V, 2012) |
| "Evidence from pivotal clinical trials conducted more than a decade ago supports the use of antithrombotic therapy, particularly warfarin, for stroke prevention in atrial fibrillation (AF)." | 3.78 | Utilisation of antithrombotic therapy for stroke prevention in atrial fibrillation in a Sydney hospital: then and now. ( Bajorek, BV; Ren, S, 2012) |
| "Guidelines for atrial fibrillation (AF) recommend clopidogrel plus aspirin as an alternative stroke prevention strategy in patients in whom warfarin is unsuitable." | 3.78 | Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable. ( Anglade, MW; Coleman, CI; Kluger, J; Sobieraj, DM; Straznitskas, AD, 2012) |
| "These were post hoc analyses of datasets from the Aspirin Myocardial Infarction Study, a 1:1 randomized, double-blind clinical trial, conducted from 1975 to 1979, that examined mortality rates following daily aspirin administration over three years in individuals with documented MI." | 3.78 | Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction. ( Dabbous, O; Hariri, A; Krishnan, E; Lingala, B; Pandya, BJ, 2012) |
| "For patients with nonrheumatic AF, including those with paroxysmal AF, who are (1) at low risk of stroke (eg, CHADS(2) [congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack] score of 0), we suggest no therapy rather than antithrombotic therapy, and for patients choosing antithrombotic therapy, we suggest aspirin rather than oral anticoagulation or combination therapy with aspirin and clopidogrel; (2) at intermediate risk of stroke (eg, CHADS(2) score of 1), we recommend oral anticoagulation rather than no therapy, and we suggest oral anticoagulation rather than aspirin or combination therapy with aspirin and clopidogrel; and (3) at high risk of stroke (eg, CHADS(2) score of ≥ 2), we recommend oral anticoagulation rather than no therapy, aspirin, or combination therapy with aspirin and clopidogrel." | 3.78 | Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. ( Eckman, MH; Fang, MC; Go, AS; Halperin, JL; Howard, PA; Hughes, M; Hylek, EM; Lane, DA; Lip, GYH; Manning, WJ; Schulman, S; Singer, DE; Spencer, FA; You, JJ, 2012) |
| " In patients with patent foramen ovale (PFO) and stroke or transient ischemic attack, we recommend initial aspirin therapy (Grade 1B) and suggest substitution of VKA if recurrence (Grade 2C)." | 3.78 | Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. ( Fremes, SE; Rubens, FD; Sun, JC; Teoh, KH; Whitlock, RP, 2012) |
| "Using a single group, pretest/posttest design, 50 migraineurs without prior history of stroke or MI were prospectively treated for 14 to 21 consecutive days with 325 mg generic enteric-coated aspirin, after undergoing a 14-day aspirin washout." | 3.78 | Aspirin's effect on platelet inhibition in migraineurs. ( Fuller, CJ; Jesurum, JT; Lucas, SM; Murinova, N; Truva, CM, 2012) |
| " Aspirin has been increasingly recognised as an inferior choice for stroke prevention, and may not be any safer than warfarin in terms of major bleeding, especially in the elderly." | 3.78 | What is the most effective and safest delivery of thromboprophylaxis in atrial fibrillation? ( Lip, GY, 2012) |
| " The majority of patients had stable coronary artery disease (73%) and received sirolimus-eluting stents (93%), and approximately 90% of thienopyridine was ticlopidine." | 3.78 | Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2. ( Abe, M; Araki, M; Byrne, RA; Ehara, N; Eizawa, H; Fujiwara, H; Furukawa, Y; Inada, T; Iwabuchi, M; Kaburagi, S; Kadota, K; Kastrati, A; Kimura, T; Kita, T; Mitsudo, K; Mitsuoka, H; Mizoguchi, T; Morimoto, T; Nakagawa, Y; Nakano, A; Natsuaki, M; Nobuyoshi, M; Nohara, R; Shiomi, H; Shizuta, S; Suwa, S; Tada, T; Takizawa, A; Taniguchi, R; Tazaki, J, 2012) |
| "As the management of patients treated with anticoagulants and antiplatelet drugs entails balancing coagulation levels, we evaluated the net clinical benefit of warfarin and aspirin on stroke in a large cohort of patients with atrial fibrillation (AF)." | 3.78 | A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study. ( Azoulay, L; Dell'Aniello, S; Langleben, D; Renoux, C; Simon, TA; Suissa, S, 2012) |
| "Compared with aspirin, apixaban reduces stroke risk in atrial fibrillation (AF) patients unsuitable for warfarin by 63% but does not increase major bleeding." | 3.78 | Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin. ( Anglade, MW; Coleman, CI; Hagstrom, K; Kluger, J; Lee, S; Meng, J, 2012) |
| "Use of warfarin at discharge in patients with atrial fibrillation is greater among those with higher stroke and bleeding risks, but despite higher-risk profiles, less than half received warfarin at discharge." | 3.78 | Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. ( Alexander, KP; Foody, JM; Funk, M; Granger, CB; Li, L; Lopes, RD; Peterson, ED; Wang, TY, 2012) |
| "We compared efficacy and safety of warfarin, direct thrombin inhibitor dabigatran and clopidogrel in prevention of stroke in 210 patients with nonvalvular atrial fibrillation (AF) aged 65-80 years." | 3.78 | [Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation]. ( Kanorskiĭ, SG; Shevelev, VI, 2012) |
| "To examine healthcare costs among patients hospitalized for transient ischemic attack or ischemic stroke (TIA/stroke) and prescribed aspirin plus extended-release dipyridamole (ASA-ERDP) or clopidogrel (CLOPID) within 30 days post-discharge using a retrospective claims database from a large US managed care organization." | 3.78 | One-year follow-up healthcare costs of patients hospitalized for transient ischemic attack or ischemic stroke and discharged with aspirin plus extended-release dipyridamole or clopidogrel. ( Burton, TM; Lacey, M; Lang, K; Liu, F; Monsalvo, ML; Sander, S; Yu, Y, 2012) |
| " Fatal or nonfatal (requiring hospitalization) bleeding was determined according to antithrombotic treatment regimen: triple therapy (TT) with vitamin K antagonist (VKA)+aspirin+clopidogrel, VKA+antiplatelet, and dual antiplatelet therapy with aspirin+clopidogrel." | 3.78 | Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. ( Gislason, GH; Hansen, CM; Hansen, ML; Karasoy, D; Kristensen, SL; Køber, L; Lamberts, M; Olesen, JB; Ruwald, MH; Torp-Pedersen, C, 2012) |
| " In this study, the authors assess the incidence of stroke or transient ischemic attack (TIA) following discontinuation of a 6-week course of clopidogrel in patients with cerebral aneurysms treated with stent-assisted techniques." | 3.78 | Incidence of cerebral ischemic events after discontinuation of clopidogrel in patients with intracranial aneurysms treated with stent-assisted techniques. ( Abel, TJ; Chalouhi, N; Hasan, DM; Jabbour, PM; Kung, DK; Rossen, JD; Thomas, J; Wassef, SN, 2012) |
| "Despite changes in international guidelines, aspirin monotherapy should retain its position as the main antiplatelet agent for secondary prevention of non-cardioembolic ischaemic stroke." | 3.78 | Secondary stroke prevention: misguided by guidelines? ( Molenberghs, G; Vanstreels, L; Voigt, JU, 2012) |
| "The relationship between biochemical aspirin resistance (AR) and functional outcome of acute ischemic stroke is uncertain." | 3.78 | Relationship between acute stroke outcome, aspirin resistance, and humoral factors. ( Chen, SY; Chiang, YY; Ho, YP; Hsu, HY; Lai, PT; Lee, YS, 2012) |
| "We enrolled patients within 24 h of ischemic stroke and a group of controls taking aspirin who had never suffered a vascular event on therapy." | 3.77 | Aspirin resistance and compliance with therapy. ( Dawson, J; Higgins, P; Lees, KR; Quinn, T; Rafferty, M; Ray, G; Walters, MR, 2011) |
| "In this study, clopidogrel use during CEA resulted in a significant risk for developing a neck hematoma, particularly when using a Dacron-patch." | 3.77 | Outcomes related to antiplatelet or anticoagulation use in patients undergoing carotid endarterectomy. ( Alden, PB; Goldman, JA; Graber, JN; Rizvi, AZ; Rosenbaum, A; Sullivan, TM; Tretinyak, AS, 2011) |
| "A total of 85 patients with acute ischemic stroke on 160mg aspirin daily were prospectively included." | 3.77 | Aspirin non-responder status and early neurological deterioration: a prospective study. ( Bugnicourt, JM; Canaple, S; Garcia, PY; Godefroy, O; Lamy, C; Roussel, B, 2011) |
| "The accuracy of the NHIRD in recording ischemic stroke diagnoses and aspirin prescriptions was high, and the NHIRD appears to be a valid resource for population research in ischemic stroke." | 3.77 | Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. ( Cheng, CL; Kao, YH; Lai, ML; Lee, CH; Lin, SJ, 2011) |
| "Underuse and an inadequate range for the international normalized ratio (INR) for warfarin use are still problems in the management of the patients with atrial fibrillation (AF) in Japan." | 3.77 | Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM Registry. ( Atarashi, H; Inoue, H; Kumagai, N; Okumura, K; Origasa, H; Yamashita, T, 2011) |
| "Aspirin is used in ischemic stroke therapy." | 3.77 | Aspirin resistance in patients with acute ischemic stroke. ( Ozben, B; Ozben, S; Ozben, T; Ozer, F; Tanrikulu, AM, 2011) |
| "To examine the effect of proton pump inhibitors on adverse cardiovascular events in aspirin treated patients with first time myocardial infarction." | 3.77 | Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Grove, EL; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Olesen, JB; Selmer, C; Torp-Pedersen, C, 2011) |
| " The aim of the present study is to investigate the effects of cilostazol and aspirin on endothelial nitric oxide synthase (eNOS) phosphorylation in the cerebral cortex, endothelial function, and infarct size after brain ischemia in spontaneously hypertensive rats (SHR)." | 3.77 | Cilostazol, not aspirin, reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats. ( Kawamura, M; Kitagawa, K; Omura-Matsuoka, E; Oyama, N; Sasaki, T; Sugiyama, Y; Terasaki, Y; Yagita, Y, 2011) |
| "Current American Heart Association/American Stroke Association guidelines identify warfarin use as a class IA indication in patients with atrial fibrillation (AF) and ischemic stroke (IS) or transient ischemic attack (TIA)." | 3.77 | Antithrombotic therapy use at discharge and 1 year in patients with atrial fibrillation and acute stroke: results from the AVAIL Registry. ( Bushnell, CD; Lopes, RD; Olson, DM; Pan, W; Peterson, ED; Shah, BR; Zhao, X, 2011) |
| "To test the hypothesis that HRPR after clopidogrel loading is an independent prognostic marker of risk of long-term thrombotic events in patients with acute coronary syndromes (ACS) undergoing an invasive procedure and antithrombotic treatment adjusted according to the results of platelet function tests." | 3.77 | High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. ( Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R, 2011) |
| "The tool provides education incorporating patients ' illness perceptions to explain the relationship between NVAF and stroke, and then presents individualized risk estimates, derived using separate risk calculators for stroke and bleeding over a clinically meaningful time period (5 years) associated with no treatment, aspirin, and warfarin." | 3.77 | Development of a tool to improve the quality of decision making in atrial fibrillation. ( Fraenkel, L; Fried, TR; Street, RL, 2011) |
| "There was a clear impact of aspirin treatment on CMBs associated with intracerebral hemorrhage in Chinese patients." | 3.77 | Aspirin treatment increases the risk of cerebral microbleeds. ( Gao, Y; Ge, L; Guo, D; Han, X; Niu, G; Wu, H; Wu, Q; Zhang, Y, 2011) |
| "In AF patients with CHADS(2) score 1, warfarin was better to prevent ischemic stroke than aspirin without increasing the incidence of major bleeding complications." | 3.76 | The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1. ( Choi, DH; Hwang, ES; Kim, SK; Kim, YH; Kwak, JJ; Lee, BH; Pak, HN; Park, JH; Park, JS, 2010) |
| "Administrative claims from a large, geographically diverse US health plan were used to evaluate acetylsalicylic acid / extended-release dipyridamole (ASA/ERDP) treated and clopidogrel treated patients from November 1, 2002 - December 31, 2005 who had an ischemic stroke requiring hospitalization." | 3.76 | Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors. ( Burke, JP; Henk, H; Sander, S; Shah, H; Zarotsky, V, 2010) |
| "Aspirin plus clopidogrel (A+C) may be more effective than aspirin only (AO) acutely after TIA and minor stroke, but the risk of bleeding in the acute phase is uncertain." | 3.76 | Preliminary evidence of a high risk of bleeding on aspirin plus clopidogrel in aspirin-naïve patients in the acute phase after TIA or minor ischaemic stroke. ( Buchan, AM; Chandratheva, A; Geraghty, OC; Kennedy, J; Marquardt, L; Rothwell, PM, 2010) |
| "This study investigated the efficacy of terutroban, a specific thromboxane/prostaglandin endoperoxide receptor antagonist, on stroke incidence in spontaneously hypertensive stroke-prone rats (SHRSP)." | 3.76 | Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, increases survival in stroke-prone rats by preventing systemic inflammation and endothelial dysfunction: comparison with aspirin and rosuvastatin. ( Ballerio, R; Banfi, C; Blanc-Guillemaud, V; Brioschi, M; Castiglioni, L; Gelosa, P; Gianella, A; Guerrini, U; Lerond, L; Nobili, E; Pignieri, A; Sironi, L; Tremoli, E, 2010) |
| "In patients receiving the HeartMate II LVAD who were directly transitioned to warfarin and aspirin therapy without intravenous heparin there was no short-term increase in risk of thrombotic or thromboembolic events, and bleeding requiring transfusion was significantly reduced." | 3.76 | Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. ( Aaronson, KD; Boyle, A; Conte, JV; Farrar, DJ; John, R; Naka, Y; Pagani, FD; Russell, SD; Slaughter, MS; Sundareswaran, KS, 2010) |
| " The example developed concerns the probability of recurrent stroke and the risks and benefits of treatment with aspirin." | 3.76 | Determining patient characteristics for decision analysis support systems using anonymized electronic patient records. ( Bashford, J; Frisher, M; Short, D, 2010) |
| "The combination of aspirin and clopidogrel is indicated after acute coronary events and possibly for a short period after TIA or minor ischemic stroke." | 3.76 | Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke. ( Chandratheva, A; Geraghty, OC; Paul, NL; Rothwell, PM, 2010) |
| "The USPSTF recommends aspirin for the prevention of stroke and heart attack for those at risk, and screening for major depression and childhood obesity." | 3.76 | USPSTF recommendations you may have missed amid the breast cancer controversy. ( Campos-Outcalt, D, 2010) |
| "The effect of biochemical aspirin resistance (BAR) on ischemic stroke has not been well established." | 3.76 | Biochemical aspirin resistance and recurrent lesions in patients with acute ischemic stroke. ( Jeon, SB; Kang, DW; Kim, BJ; Kim, HJ; Kim, JS; Kwon, SU; Song, HS, 2010) |
| "A rapid and sustained reduction in the frequency of aspirin+clopidogrel use in ischemic stroke and transient ischemic attack was observed after publication of the MATCH trial in the absence of MATCH-specific GWTG-Stroke initiatives and preceding an American Heart Association guideline update." | 3.76 | Rapid change in prescribing behavior in hospitals participating in get with the guidelines-stroke after release of the management of atherothrombosis with clopidogrel in high-risk patients (MATCH) clinical trial results. ( Ellrodt, G; Fonarow, GC; Frankel, MR; Hernandez, AF; Labresh, KA; Liang, L; Menon, BK; Schwamm, LH; Smith, EE, 2010) |
| " Oklahoma Behavioral Risk Factor Surveillance System (BRFSS) data were used to determine past history of CHD, risk factors for CHD and stroke, and aspirin use among persons 45 years and older." | 3.76 | Increasing aspirin use among persons at risk for cardiovascular events in Oklahoma. ( Cline, TL; Daniels, CG; Mallonee, S; Mold, JW, 2010) |
| "In patients with AF, all combinations of warfarin, aspirin, and clopidogrel are associated with increased risk of nonfatal and fatal bleeding." | 3.76 | Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. ( Abildstrøm, SZ; Andersen, SS; Clausen, MT; Fog-Petersen, ML; Folke, F; Gadsbøll, N; Gislason, GH; Hansen, ML; Køber, L; Poulsen, HE; Raunsø, J; Schramm, TK; Sørensen, R; Torp-Pedersen, C, 2010) |
| " One hundred eighty patients were not on AP prior to their stroke, 76 were on aspirin, 15 were on clopidogrel, 2 were on aspirin-dipyridamole combination, 2 were on both aspirin and clopidogrel, and 9 patients on subtherapeutic coumadin." | 3.76 | Does current oral antiplatelet agent or subtherapeutic anticoagulation use have an effect on tissue-plasminogen-activator-mediated recanalization rate in patients with acute ischemic stroke? ( Al-Hussain, F; Alexandrov, AV; Demchuk, AM; Hussain, M; Ibrahim, MM; Khan, K; Molina, C; Saqqur, M; Sebastian, J; Uchino, K, 2010) |
| "Current guidelines for ischemic stroke prevention in atrial fibrillation or flutter (AFF) recommend Vitamin K antagonists (VKAs) for patients at high-intermediate risk and aspirin for those at intermediate-low risk." | 3.76 | Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. ( Corrao, S; Iorio, A; Mannucci, PM; Marcucci, M; Marengoni, A; Nobili, A; Pasina, L; Salerno, F; Tettamanti, M, 2010) |
| "The purpose of the study was to establish the frequency of aspirin resistance in patients treated in the Department of Neurology in Zabrze with diagnosed transient ischaemic attack (TIA) or ischaemic stroke who used aspirin in the dose of 150 mg daily." | 3.76 | [Resistance to aspirin in secondary stroke prevention. A pilot study]. ( Kumor, K; Pierzhała, PA; Trautsolt, W; Łabuz-Roszak, B, 2010) |
| "The acute ischemic and stable stroke patients who received aspirin at least 60 mg, at least 7 days and the last dose of aspirin at least 24 hours before blood test for platelet aggregation." | 3.76 | Prevalence of aspirin resistance in stroke patients in Phramongkutklao Hospital. ( Changchit, S; Nidhinandana, S, 2010) |
| " We replicated the observation of the Atherosclerosis Risk in Communities Study and observed an interaction of rs20417 with aspirin use on myocardial infarction risk (p for interaction=0." | 3.75 | Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke. ( Bis, JC; Heckbert, SR; Lemaitre, RN; Lumley, TS; Marciante, K; Psaty, BM; Rice, K; Smith, NL; Wiggins, KL, 2009) |
| "The present study was aimed to investigate the usage of aspirin for the secondary prevention of ischemic stroke, evaluate the correlated factors, and analyze the reasons for not taking and irregularly taking aspirin." | 3.75 | The utilization status of aspirin for the secondary prevention of ischemic stroke. ( Guo, ZL; Hai, H; Jiang, H; Ke, XJ; Peng, H; Xu, K; Yu, YF; Zhang, AH, 2009) |
| "To determine whether arterial cardiovascular events, use of statins and low-dose aspirin were associated with the risk of venous thromboembolism." | 3.75 | Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. ( Baron, JA; Christensen, S; Horvath-Puho, E; Johnsen, SP; Prandoni, P; Søgaard, KK; Sørensen, HT; Thomsen, RW, 2009) |
| "The objective of this study was to evaluate the rate of stroke associated with aspirin and warfarin in routine clinical practice." | 3.75 | How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database. ( Gallagher, AM; Plumb, JM; Rietbrock, S; van Staa, TP, 2009) |
| "A considerable proportion of patients discontinue dipyridamole therapy because of headache." | 3.75 | Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin. ( Algra, A; Halkes, PH; Kappelle, LJ; Koudstaal, PJ; van Gijn, J, 2009) |
| "There are very limited data on the influence of pretreatment with aspirin (ASA) on the etiology of subsequent first-ever ischemic stroke." | 3.75 | Pretreatment with aspirin and etiology of first-ever ischemic stroke in young and middle-aged patients. ( Kouperberg, E; Sprecher, E; Telman, G; Yarnitsky, D, 2009) |
| "We sought to determine whether cyclooxygenase-1 (PTGS1) genotype is associated with the ability of aspirin to inhibit platelet aggregation in patients at risk for stroke." | 3.75 | Influence of cyclooxygenase-1 genotype on ex vivo aspirin response in patients at risk for stroke. ( Brace, LD; Cavallari, LH; Grossi, E; Helgason, CM; Momary, KM; Nutescu, EA; Shapiro, NL; Shord, SS; Viana, MA, 2009) |
| "Previous cost-effectiveness analyses analyzed warfarin for stroke prevention in randomized trial settings." | 3.75 | Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. ( Dewilde, S; Goldhaber, SZ; Monz, BU; Plumb, JM; Singer, DE; Sorensen, SV, 2009) |
| "The aim of this study was to determine the prescribing patterns, risks, and benefits of anticoagulation with warfarin or acetylsalicylic acid (ASA) in elderly patients with AF at risk for stroke and hemorrhage, including those with falls and/or dementia." | 3.75 | Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study. ( Billett, HH; Dinglas, C; Freeman, K; Jacobs, LG; Jumaquio, L, 2009) |
| "Aspirin remains the most commonly used antithrombotic agent for the prevention of recurrent stroke among antithrombotic naive patients with a first-ever ischemic stroke in our institution." | 3.75 | The prescribing patterns of antithrombotic agents for prevention of recurrent ischemic stroke. ( Hseuh, IH; Lin, YJ; Po, HL, 2009) |
| "(1) For patients with acute coronary syndromes who have undergone percutaneous angioplasty and stenting, the best-assessed treatment for preventing relapses is a combination of aspirin and clopidogrel; (2) Prasugrel, an antiplatelet drug belonging the same chemical class as clopidogrel, is authorized in the EU for use in this indication; (3) Clinical evaluation is based on a randomized double-blind trial comparing prasugrel + aspirin versus clopidogrel + aspirin in 13 608 patients with acute coronary syndromes, half of whom were treated for at least 15 months." | 3.75 | Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. ( , 2009) |
| "In primary prevention, aspirin reduces the risk of stroke but not of myocardial infarction in women while in men only the risk of myocardial infarction but not stroke could be significantly reduced." | 3.75 | Antiplatelet agents in stroke prevention: acute and long-term treatment strategies. ( Diener, HC; Weber, R; Weimar, C, 2009) |
| "The P2Y12 receptor has proven to be a key target in the prevention of complications associated with atherosclerotic vascular disease especially in the context of acute coronary syndrome and percutaneous coronary intervention in addition to aspirin." | 3.75 | P2Y12 inhibitors: thienopyridines and direct oral inhibitors. ( Collet, JP; Montalescot, G, 2009) |
| " This is a case of a 79-year-old female with newly diagnosed atrial fibrillation who was inappropriately started on aspirin for anticoagulation despite her high risk for stroke." | 3.75 | Prevention and treatment of cardioembolic stroke: a case study. ( Brophy, GM; Glick, JA, 2009) |
| "A subgaleal hematoma (SGH) occurred in a young patient with Sturge-Weber syndrome (SWS) who was treated with aspirin after a mild head trauma." | 3.74 | Subgaleal hematoma in a child with Sturge-Weber syndrome: to prevent stroke-like episodes, is treatment with aspirin advisable? ( Fiumara, A; Greco, F; Pavone, L; Sorge, G, 2008) |
| "Aspirin use may reduce the risk of stroke and coronary heart disease." | 3.74 | Does differential prophylactic aspirin use contribute to racial and geographic disparities in stroke and coronary heart disease (CHD)? ( Cushman, M; Glasser, SP; Howard, G; Howard, VJ; Kleindorfer, D; Prince, V; Prineas, R; You, Z, 2008) |
| " Ischemic stroke was predicted by hypertension, myocardial infarction, low-dose aspirin, comorbidity score, Health Assessment Questionnaire score, and presence of total joint replacement, but not by diabetes, smoking, exercise, or body mass index." | 3.74 | Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. ( Hallenbeck, JM; Michaud, K; Nadareishvili, Z; Wolfe, F, 2008) |
| "Improved brain imaging provision was followed by a reduction in time to imaging and earlier prescription of aspirin for ischaemic stroke." | 3.74 | Use of statistical process control charts in stroke medicine to determine if clinical evidence and changes in service delivery were associated with improvements in the quality of care. ( Dennis, M; Henderson, GR; McDowall, MA; Mead, GE; Ramsay, S; van Dijke, ML, 2008) |
| "The authors prospectively included acute ischemic stroke/TIA patients who were treated at Thammasat Hospital from August, 2006 to July, 2007 and had already been on aspirin." | 3.74 | Aspirin non-responders in Thai ischemic stroke/TIA patients. ( Dharmasaroja, P, 2008) |
| "In the Prevention Regimen for Effectively Avoiding Second Strokes (PROFESS) trial, the combination of acetylsalicylic acid (50 mg) and extended-release dipyridamole (400 mg) (ASA+Dip) was compared with clopidogrel (75 mg) in patients with a recent transient ischaemic attack (TIA) or minor disabling stroke." | 3.74 | [Inhibition of platelet aggregation and angiotensin II-receptor blockade following TIA; the unexpected results of the Prevention Regimen For Effectively Avoiding Second Strokes (PROFESS) trial]. ( Kappelle, LJ, 2008) |
| " Patients were stratified according to their stroke risk (highest, high, low, or lowest) and antithrombotic medication (aspirin, warfarin, ticlopidine/clopidogrel, or none)." | 3.74 | Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation--a nationwide descriptive study in Taiwan. ( Cheng, CL; Cheng, MH; Kao Yang, YH; Lee, CH; Lin, LJ; Wung, DC, 2008) |
| "Oral anticoagulation prevents strokes in patients with atrial fibrillation but, for reasons that remain unclear, less than 40% of all patients with atrial fibrillation receive warfarin." | 3.74 | Values and preferences in oral anticoagulation in patients with atrial fibrillation, physicians' and patients' perspectives: protocol for a two-phase study. ( Alonso, R; Alonso-Coello, P; Charles, C; Coll-Vinent, B; Devereaux, P; Díaz, MG; Diez, AI; Gich, I; Guyatt, G; Montori, VM; Oliver, S; Roura, M; Ruiz, R; Schünemann, HJ; Solà, I; Souto, JC, 2008) |
| " Because of recurrent gastrointestinal bleeding episodes, 7 patients discontinued warfarin for a total duration of 39." | 3.74 | Low thromboembolic risk for patients with the Heartmate II left ventricular assist device. ( Boyle, A; Colvin-Adams, M; John, R; Joyce, L; Kamdar, F; Liao, K; Miller, L, 2008) |
| "Aspirin is an important therapeutic regimen to prevent the recurrent ischemic events or death after acute ischemic stroke." | 3.74 | ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy. ( Cha, JK; Jeon, HW; Kang, MJ, 2008) |
| "In patients undergoing coronary stenting, long-term dual antiplatelet therapy with aspirin and clopidogrel reduces atherothrombotic events but also increases the risk of bleeding." | 3.74 | Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. ( Angiolillo, DJ; Bass, TA; Della Rovere, F; Gavazzi, A; Lettieri, C; Mantovani, P; Mihalcsik, L; Molfese, M; Musumeci, G; Rossini, R; Sirbu, V, 2008) |
| "To determine the changes in platelet function, manifesting as deviations of their aggregation intensity, in persons with acute ischemic stroke and transient ischemic attacks, to evaluate the effect of aspirin on platelet aggregation, dependent upon degree of cerebral blood flow disturbances and patient's gender, and to compare these changes with those in healthy persons." | 3.74 | [The impact of acute cerebral blood flow disturbances on platelet aggregation]. ( Gaigalaite, V; Grybauskas, P; Ptasekas, J; Sabaliauskiene, Z, 2008) |
| "Based on the risk-benefit analysis, warfarin prophylaxis for cardioembolic stroke in Chagas' disease is recommended for patients with a score of 4-5 points, in whom the risk of CE overweighs the risk of a major bleeding." | 3.74 | Prevention strategies of cardioembolic ischemic stroke in Chagas' disease. ( Freitas, GR; Hasslocher-Moreno, A; Sousa, AS; Xavier, SS, 2008) |
| "05) of stroke with hypertension and diabetes mellitus; of myocardial infarction with hypertension, hypercholesterolemia, obesity, and smoking; and of peptic ulcer disease with aspirin, NSAIDs, and potassium." | 3.74 | Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. ( Bilker, WB; Lewis, JD; Schinnar, R; Strom, BL; Wang, X, 2007) |
| "Previously we studied 298 patients admitted to hospital with symptoms suggestive of an acute myocardial infarction (MI) despite treatment with aspirin, and 70 patients (23." | 3.74 | Variation and importance of aspirin resistance in patients with known cardiovascular disease. ( Haghfelt, T; Jørgensen, B; Korsholm, L; Kristensen, SR; Licht, PB; Mickley, H; Poulsen, TS, 2007) |
| "Patients from SPORTIF III (n=3407) and SPORTIF V (n=3922) trials were categorized by prior stroke/TIA (21%) versus no prior stroke/TIA (79%) and by treatment group (ximelagatran vs warfarin)." | 3.74 | Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials. ( Akins, PT; Albers, GW; Diener, HC; Feldman, HA; Newman, D; Spitzer, SG; Zoble, RG, 2007) |
| "Secondary post hoc analysis of an existing dataset consisting of 711 patients after coronary stenting (n = 601) and ischemic stroke (n = 110) treated previously with aspirin for at least 1 month, and then with aspirin + clopidogrel for at least 7 days was performed." | 3.74 | Combination antiplatelet therapy with aspirin and clopidogrel: the role of antecedent and concomitant doses of aspirin. An analysis of 711 patients. ( Atar, D; Malinin, AI; Serebruany, VL, 2007) |
| " Among the 76% (437/572) of patients with AF at high risk for stroke, 59% (257/437) used warfarin, 28% (123/437) used aspirin, and 24% (104/437) used neither." | 3.74 | Newly detected atrial fibrillation and compliance with antithrombotic guidelines. ( Dublin, S; French, B; Glazer, NL; Heckbert, SR; Hrachovec, JB; Jackson, LA; Psaty, BM; Siscovick, DS; Smith, NL, 2007) |
| "The present study was carried out to investigate the effect of the combination of an endothelin antagonist TAK-044 and an antiinflammatory agent aspirin in middle cerebral artery (MCA) occlusion model of acute ischemic stroke in rats." | 3.74 | Effect of combination of endothelin receptor antagonist (TAK-044) and aspirin in middle cerebral artery occlusion model of acute ischemic stroke in rats. ( Briyal, S; Gulati, A; Gupta, YK, 2007) |
| "The contribution of genetic factors to aspirin treatment failure (ATF) for secondary prevention is not settled in patients with ischemic stroke." | 3.74 | The BC genotype of the VNTR polymorphism of platelet glycoprotein Ibalpha is overrepresented in patients with recurrent stroke regardless of aspirin therapy. ( Amaro, S; Cervera, A; Chamorro, A; Obach, V; Reverter, JC; Tàssies, D, 2007) |
| "A goal of the Women's Health Study was to evaluate the balance of benefits and risks of low-dose aspirin in the primary prevention of stroke in healthy women." | 3.74 | CON: Should aspirin be used in all women older than 65 years to prevent stroke? ( Buring, JE, 2007) |
| "In clinical practice, early therapy with clopidogrel, in addition, to aspirin in patients with NSTEMI is associated with a significant reduction of the combined endpoint of death, non-fatal reinfarction and non-fatal stroke after one year." | 3.74 | Clopidogrel in addition to aspirin reduces one-year major adverse cardiac and cerebrovascular events in unselected patients with non-ST segment elevation myocardial infarction. ( Bauer, T; Gitt, AK; Gottwik, M; Heer, T; Jünger, C; Köth, O; Senges, J; Wienbergen, H; Zahn, R; Zeymer, U, 2008) |
| "Platelet function analyses, which included measures of platelet aggregation and activation, were performed in 173 T2DM patients with coronary artery disease on chronic treatment with aspirin and clopidogrel." | 3.74 | Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. ( Alfonso, F; Angiolillo, DJ; Bañuelos, C; Bass, TA; Bernardo, E; Costa, MA; Escaned, J; Fernandez-Ortiz, A; Guzman, LA; Hernández-Antolin, R; Jimenez-Quevedo, P; Macaya, C; Moreno, R; Palazuelos, J; Sabaté, M, 2007) |
| "In acute ischemic stroke and transient ischemic attack (TIA), aspirin is recommended to all patients (except immediately following thrombolysis)." | 3.74 | [Antithrombotic therapy in ischemic stroke and transient ischemic attack]. ( Husted, SE; Overgaard, K; Poulsen, TS, 2007) |
| "A total of 88 patients taking aspirin daily for the secondary prevention of stroke were included." | 3.74 | Can aspirin resistance be clinically predicted in stroke patients? ( Bang, OY; Choi, YJ; Huh, K; Joo, IS; Lee, PH; Seok, JI; Yoon, JH, 2008) |
| " Aspirin use has been shown to be effective in reducing the number of nonfatal myocardial infarction (MI) and fatal CHD, though studies of aspirin effects in women have found a significant reduction in ischemic stroke but no significant effect on fatal or nonfatal MI or CVD death." | 3.74 | Aspirin use in the prevention of cardiovascular events. ( Crutcher, JM; Daniels, C; Mallonee, S, 2007) |
| "We sought to assess the effect of clopidogrel on in-hospital events in unselected patients with acute ST elevation myocardial infarction (STEMI)." | 3.74 | Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial. ( Bauer, T; Gitt, A; Gottwik, M; Heer, T; Jünger, C; Koeth, O; Mark, B; Senges, J; Zahn, R; Zeymer, U, 2008) |
| "The relationship between nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and hemorrhagic stroke (HS) remains unclear." | 3.74 | Nonaspirin nonsteroidal anti-inflammatory drugs and hemorrhagic stroke risk: the Acute Brain Bleeding Analysis study. ( Choi, NK; Jeong, SW; Park, BJ; Yoon, BW; Yu, KH, 2008) |
| "We sought to examine the effectiveness of blinding secondary stroke prevention trials with a warfarin treatment arm in which the blinding system incorporates use of placebo warfarin dose modification schedules for patients in the placebo warfarin arm." | 3.74 | Use of dose modification schedules is effective for blinding trials of warfarin: evidence from the WASID study. ( Asbury, W; Chester, C; Chimowitz, M; Cotsonis, G; Hertzberg, V; Lynn, M, 2008) |
| " We report a patient, having used aspirin for secondary stroke prevention, who had an acute cerebellar hemorrhage after taking nattokinase 400 mg daily for 7 consecutive days." | 3.74 | Cerebellar hemorrhage provoked by combined use of nattokinase and aspirin in a patient with cerebral microbleeds. ( Chang, YY; Lai, SL; Lan, MY; Liu, JS; Wu, HS, 2008) |
| "The aim of this study was to investigate the relationship between aspirin resistance, ischaemic stroke subtype, stroke severity, and inflammatory cytokines." | 3.74 | Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity. ( Byrne, CD; Englyst, NA; Horsfield, G; Kwan, J, 2008) |
| "Clopidogrel and dipyridamole-aspirin are used frequently after stroke or transient ischemic attack." | 3.74 | Trends in usage of alternative antiplatelet therapy after stroke and transient ischemic attack. ( Hills, NK; Johnston, SC, 2008) |
| "Aspirin has been used for secondary prevention of myocardial infarction (MI) in individuals with coronary disease." | 3.74 | Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers. ( Eskola, M; Karhunen, PJ; Mikkelsson, J; Niemela, K; Nikus, K, 2008) |
| "To compare quality-adjusted survival and cost among 3 alternative therapies for patients with chronic atrial fibrillation: ximelagatran, warfarin, and aspirin." | 3.73 | Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. ( Gage, BF; O'Brien, CL, 2005) |
| " The cost-effectiveness of longer combination therapy depends critically on the balance of thrombotic event rates, durable efficacy, and the increased bleeding rate in patients taking clopidogrel." | 3.73 | A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. ( Heidenreich, PA; Schleinitz, MD, 2005) |
| "Utilizing data from the Global Registry of Acute Coronary Events, we studied 15 693 patients admitted with non-ST-segment elevation myocardial infarction (MI) or unstable angina, dividing them according to discharge medications: aspirin alone (group I); aspirin + clopidogrel (group II); aspirin + statin (group III); aspirin + clopidogrel + statin (group IV)." | 3.73 | Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. ( Agnelli, G; Dabbous, OH; Dibenedetto, D; Eagle, KA; Gore, JM; Kline-Rogers, EM; Lim, MJ; Mehta, RH; Spencer, FA, 2005) |
| "To assess the efficacy of aspirin plus extended-release dipyridamole compared with aspirin alone for the prevention of recurrent stroke among high-risk groups." | 3.73 | Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations. ( Diener, HC; Sacco, RL; Sivenius, J, 2005) |
| "The proportional benefit gained from the use of low dose aspirin by the prevention of myocardial infarctions (-389 in men, -321 in women) and ischaemic stroke (-19 in men and -35 in women) is offset by excess gastrointestinal (499 in men, 572 in women) and intracranial (76 in men, 54 in women) bleeding." | 3.73 | Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70. ( Bertram, M; Liew, D; Nelson, MR; Vos, T, 2005) |
| "We studied 137 patients undergoing antiplatelet therapy with clopidogrel and 336 patients with aspirin for the occurrence of neurological events (ischemic stroke and/or carotid revascularization)." | 3.73 | Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. ( Amighi, J; Brunner, M; Exner, M; Felber, K; Funk, M; Mannhalter, C; Minar, E; Mlekusch, W; Müller, M; Sabeti, S; Schillinger, M; Ziegler, S, 2005) |
| "We aimed to study the timing of aspirin prescription in ischaemic stroke comparing patients admitted to an acute stroke unit (ASU) directly or via a general medical ward." | 3.73 | Timing of aspirin and secondary preventative therapies in acute stroke: support for use of stroke units. ( MacLeod, MJ; Reid, J; Williams, D, 2005) |
| "Vascular events commonly recur in stroke patients on aspirin, and may reflect incomplete inhibition of platelet function with aspirin therapy." | 3.73 | Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. ( Brown, MM; Harrison, P; Lawrie, AS; Machin, SJ; Mackie, IJ; McCabe, DJ; Purdy, G; Sidhu, PS, 2005) |
| "To study the discontinuation of aspirin therapy as a risk factor for ischemic stroke (IS)." | 3.73 | Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. ( Bezerra, DC; Bogousslavsky, J; Maulaz, AB; Michel, P, 2005) |
| "Eligibility for tissue plasminogen activator (tPA), aspirin, stroke unit management and neuroprotection were assessed among incident stroke cases within the community-based North East Melbourne Stroke Incidence Study." | 3.73 | Stroke units, tissue plasminogen activator, aspirin and neuroprotection: which stroke intervention could provide the greatest community benefit? ( Dewey, HM; Donnan, GA; Gilligan, AK; Macdonell, RA; Sturm, JW; Thrift, AG, 2005) |
| "To determine the effect of access to ambulatory anticoagulation management services (AMS) on the rate of warfarin use in patients with atrial fibrillation." | 3.73 | Effect of access to anticoagulation management services on warfarin use in patients with atrial fibrillation. ( Burkiewicz, JS, 2005) |
| "Regular aspirin use was associated with increasing age, male gender, lower educational attainment, hypertension, diabetes, overweight, and histories of myocardial infarction, coronary heart disease, and stroke." | 3.73 | Racial differences in the use of aspirin: an important tool for preventing heart disease and stroke. ( Brown, DW; Croft, JB; Giles, WH; Greenlund, KJ; Shepard, D, 2005) |
| "The CREDO trial demonstrated the clinical efficacy of 12-month antiplatelet therapy with clopidogrel compared to standard 28-day treatment with a 27% relative reduction in the combined risk of death, myocardial infarction, or stroke in patients undergoing percutaneous coronary intervention (PCI) and being treated with aspirin." | 3.73 | The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. ( Jönsson, B; Lindgren, P; Ringborg, A, 2005) |
| "Our findings do not concur with the hypothesis that aspirin, dipyridamole, or the combination may be especially effective in preventing vascular events in patients with previous cerebral ischemia that was caused by LVD compared with SVD." | 3.73 | Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2. ( Algra, A; Ariesen, MJ; Kappelle, LJ, 2006) |
| " This phenomenon may explain the clinical advantages of Aggrenox, known to reduce ischemic events in post stroke patients as proven in clinical trials, though an additional antithrombotic benefit beyond the platelet inhibition by aspirin alone." | 3.73 | Dipyridamole decreases protease-activated receptor and annexin-v binding on platelets of post stroke patients with aspirin nonresponsiveness. ( Atar, D; Hanley, D; Jilma, B; Malinin, A; Pokov, A; Serebruany, V; Ziai, W, 2006) |
| "The rapid and significant decline of MES in our stroke and TIA patients suggests the possible efficacy of dual antiplatelet therapy with aspirin and clopidogrel in patients with MES and symptomatic large-artery occlusive disease." | 3.73 | Efficacy of dual antiplatelet therapy in cerebrovascular disease as demonstrated by a decline in microembolic signals. A report of eight cases. ( Chang, HM; Chen, CL; Esagunde, RU; Gan, HY; Lee, MP; Wong, KS; Wong, MC, 2006) |
| "We studied outpatients of 5 neurological ambulatory centers in an urban city, Valencia, all with a history of ischemic stroke who had received aspirin for at least 6 months." | 3.73 | Adherence to aspirin in secondary prevention of ischemic stroke. ( Ferrer, JM; Lago, A; Pareja, A; Ponz, A; Santos, MT; Tembl, JI; Vallés, J, 2006) |
| "Aspirin and statins are both effective for primary prevention of coronary heart disease (CHD), but their combined use has not been well studied." | 3.73 | Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. ( Earnshaw, S; Pignone, M; Pletcher, MJ; Tice, JA, 2006) |
| "The purpose of this study was to determine safety and tolerability of clopidogrel in children with arterial ischemic stroke (AIS)." | 3.73 | The risks and safety of clopidogrel in pediatric arterial ischemic stroke. ( Allen, A; deVeber, G; Hune, S; MacGregor, D; Rafay, MF; Soman, T, 2006) |
| " The strict adherence to aspirin and dipyridamole has led to no stroke or progression of the vasculopathy for 8 years." | 3.73 | Moyamoya syndrome in a splenectomized patient with beta-thalassemia intermedia. ( Hara, T; Kira, R; Ohga, S; Sanefuji, M; Torisu, H; Yoshiura, T, 2006) |
| "There is substantial interpatient variability in response to aspirin after an ischemic stroke or transient ischemic attack (TIA), as assessed by ex vivo effects of aspirin on platelet aggregation." | 3.73 | Sex difference in the antiplatelet effect of aspirin in patients with stroke. ( Brace, LD; Cavallari, LH; Helgason, CM; Nutescu, EA; Viana, MA, 2006) |
| "Warfarin can be more effective than aspirin for stroke prevention in elderly patients with atrial fibrillation, but in clinical practice, the usage rate of warfarin still remains low with insufficient monitoring." | 3.73 | [Comparative study of warfarin and aspirin for stroke prevention in elderly patients with atrial fibrillation]. ( Han, W; Shen, DT; Wang, YM, 2006) |
| "Millions of people around the world regularly consume aspirin, but its value in determining stroke severity is still not clear." | 3.73 | Does prior aspirin use reduce stroke mortality? ( Demirkaya, M; Karlikaya, G; Orken, C; Tireli, H; Varlbas, F, 2006) |
| " Bleeding complications occurred in 2 patients receiving aspirin, 1 patient receiving warfarin, and 5 patients who did not receive anticoagulant or antiplatelet therapy." | 3.73 | Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. ( Galor, A; Hoffman, GS; Lee, MS; Smith, SD, 2006) |
| "Our study demonstrates an increased risk of major bleeding in unselected patients receiving combination therapy with ASA and clopidogrel after UAP or NSTEMI." | 3.73 | [Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome]. ( Kjaer, J; Larsen, CH; Mickley, H; Møller, JE; Poulsen, TS, 2006) |
| "Aspirin is used in combination with anticoagulant therapy in patients with atrial fibrillation (AF), but evidence of additional efficacy is not available." | 3.73 | Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. ( Chaparro, S; Connolly, SJ; Flaker, GC; Goldman, S; Gruber, M; Halinen, MO; Halperin, JL; Horrow, J; Vahanian, A, 2006) |
| "Aspirin is the drug of choice in most patients with acute stroke, if thrombolysis is contraindicated." | 3.72 | [Anticoagulation and antiaggregation in neurological patients]. ( Arnold, M; Mattle, HP; Nedeltchev, K, 2003) |
| "The study assessed associations between visible infarction, time to randomisation, baseline neurological deficit, stroke syndrome, allocated aspirin or heparin treatment, recurrent haemorrhagic stroke, early death and six month functional outcome in the International Stroke Trial." | 3.72 | Visible infarction on computed tomography is an independent predictor of poor functional outcome after stroke, and not of haemorrhagic transformation. ( Lewis, SC; Mielke, O; Sandercock, PA; Wardlaw, JM; West, TM, 2003) |
| "In the recently published Warfarin Aspirin Recurrent Stroke Study (WARSS), a low-intensity anticoagulation regimen was used because of safety concerns." | 3.72 | Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage. ( , 2003) |
| "Medical records of all patients with atrial fibrillation admitted to acute internal medicine wards in April 2000 and between July and October 2001 were reviewed for details of antithrombotics given, results of international normalised ratio monitoring for patients receiving warfarin, side-effects, and additional risk factors for complications of atrial fibrillation." | 3.72 | Antithrombotic treatment of atrial fibrillation in a regional hospital in Hong Kong. ( Leung, CS; Tam, KM, 2003) |
| "The authors describe course and outcome of eight patients with ischemic stroke as the first thrombotic manifestation of antiphospholipid syndrome who received low-dose aspirin as prophylactic treatment." | 3.72 | Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome. ( de Groot, PG; Derksen, RH; Kappelle, LJ, 2003) |
| "Despite evidence-based guidelines, aspirin prescribing for the secondary prevention of stroke is sub-optimal." | 3.72 | Why are eligible patients not prescribed aspirin in primary care? A qualitative study indicating measures for improvement. ( Ashcroft, D; Bashford, J; Frischer, M; Short, D, 2003) |
| "Aspirin provides benefit in nearly all groups of patients with clinical manifestations of coronary heart disease." | 3.72 | Aspirin for cardiovascular disease prevention. ( Hung, J, 2003) |
| "Of 596 ischemic strokes, 32 percent occurred during warfarin therapy, 27 percent during aspirin therapy, and 42 percent during neither type of therapy." | 3.72 | Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. ( Chang, Y; Go, AS; Henault, LE; Hylek, EM; Jensvold, NG; Selby, JV; Singer, DE, 2003) |
| "The Patent foramen ovale In Cryptogenic Stroke Study (PICSS) evaluated transesophageal echocardiography findings in patients enrolled in the Warfarin-Aspirin Recurrent Stroke Study, a randomized double-blind trial to evaluate the efficacy of warfarin compared with aspirin." | 3.72 | Atrial anatomy in non-cardioembolic stroke patients: effect of medical therapy. ( Di Tullio, MR; Homma, S; Mohr, JP; Sacco, RL; Sciacca, RR, 2003) |
| "Two groups of patients were included: 1) patients that have suffered 1 stroke event and were thereafter under continuous treatment with aspirin 75-160 mg once daily (n=17); 2) patients that have suffered at least 2 stroke events, and aspirin 75-160 mg was prescribed after the 1(st) event (n=17)." | 3.72 | Increased sensitivity to ADP-aggregation in aspirin treated patients with recurrent ischemic stroke? ( Hillarp, A; Lethagen, S; Mattiasson, I, 2003) |
| "Using the CAPRIE database, we performed multivariate analyses for patients who had symptomatic atherosclerotic disease (ischemic stroke [IS] or myocardial infarction [MI]) in their medical history before enrollment in the Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial." | 3.72 | Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2004) |
| "Although warfarin was the most appropriate treatment in nearly all of this population at high risk for stroke, it was prescribed in fewer than two-thirds of patients." | 3.72 | Stroke prophylaxis in institutionalized elderly patients with atrial fibrillation. ( Bungard, TJ; Lau, E; Tsuyuki, RT, 2004) |
| "The decision support system incorporated the findings of 960 Markov models examining the decision to prescribe aspirin in the secondary prevention of stroke." | 3.72 | The development and evaluation of a computerised decision support system for primary care based upon 'patient profile decision analysis'. ( Bashford, J; Frischer, M; Short, D, 2003) |
| "The results with GP in acute ischemic stroke are promising and further studies should be initiated using especially tirofiban, but with monitoring by cerebral diffusion-weighted MRI before and after treatment." | 3.72 | [Efficacy and safety of treatment of acute ischemic stroke with glycoprotein IIb/IIIa receptor blocker in routine clinical practice]. ( Haerten, K; Krabbe, C; Raiber, M, 2004) |
| "We compared six-month death, myocardial infarction (MI), and stroke in patients with unstable angina or acute MI discharged while receiving low (<150 mg) or intermediate (> or =150 mg) aspirin therapy in the GUSTO IIb and PURSUIT trials (n = 20,521)." | 3.72 | Aspirin dose and six-month outcome after an acute coronary syndrome. ( Aronow, HD; Bhatt, DL; Califf, RM; Harrington, RA; Kandzari, DE; Kleiman, NS; Kong, DF; Quinn, MJ; Sapp, S; Topol, EJ, 2004) |
| "Aspirin, a low-cost intervention applicable to a large number of stroke patients (9153 first-ever cases), resulted in modest health benefits (946 DALYs saved) and a mean ICER (based on incidence costs) of US 1421 dollars per DALY saved." | 3.72 | Trial application of a Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS) to assist priority setting in stroke. ( Carter, R; Chambers, BR; Dewey, HM; Donnan, GA; Mihalopoulos, C; Moodie, ML; Thrift, AG, 2004) |
| "Aspirin is a common antiplatelet drug used in the prevention of ischemic stroke due to its inhibitory effect on platelet cyclooxygenase-1 (Cox-1)." | 3.72 | Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke. ( Hillarp, A; Lethagen, S; Mattiasson, I; Palmqvist, B; Villoutreix, BO, 2003) |
| "We studied 120 individuals divided into three equal groups: aspirin-free patients after ischemic stroke, post-stroke patients receiving aspirin (81-650 mg/daily), and aspirin-free subjects with multiple risk factors for vascular disease." | 3.72 | Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy. ( Atar, D; Hennekens, CH; Malinin, AI; Oshrine, BR; Sane, DC; Serebruany, VL; Takserman, A, 2004) |
| "Anticoagulation with warfarin is the most effective means of reducing stroke in AF." | 3.72 | Anticoagulation in atrial fibrillation. ( Anderson, M; Kirk, M, 2004) |
| "In part III of a series of papers on epidemiology and drug prevention of stroke and other thromboembolic complications of atrial fibrillation the authors present data on clinical pharmacology of aspirin as well as discussion of results of randomized trials in which cerebroprotective efficacy and safety of the use of aspirin for primary and secondary prevention of thromboembolism was studied in comparison with placebo and warfarin." | 3.72 | [Stroke and Other Thromboembolic Complications of Atrial Fibrillation. Part III. Prevention With Aspirin]. ( Batyraliev, TA; Kiktev, VG; Pershukov, IV; Preobrazhenskiĭ, DV; Sidorenko, BA, 2004) |
| "To assess the cost effectiveness of aspirin 25 mg plus dipyridamole 200 mg twice daily in the secondary prevention of ischaemic stroke, according to the French social security perspective, using efficacy data from the second European Stroke Prevention Study (ESPS-2)." | 3.72 | Economic assessment of the secondary prevention of ischaemic stroke with dipyridamole plus aspirin (Aggrenox/Asasantin) in France. ( Marissal, JP; Selke, B, 2004) |
| "1% was seen for the clopidogrel/ASA combination for the first primary outcome (death from cardiovascular causes, non-fatal myocardial infarction (MI), or stroke), compared to ASA alone." | 3.72 | A critical appraisal of the CURE trial: role of clopidogrel in non-ST-segment elevation acute coronary syndromes. ( Boucher, M; Pharand, C; Skidmore, B, 2004) |
| " Hospital admission data before and after the intervention revealed a significant increase in the use of warfarin in patients at high risk of stroke (33% vs 46% of eligible patients; p < 0." | 3.72 | A community-based educational intervention to improve antithrombotic drug use in atrial fibrillation. ( Jackson, SL; Peterson, GM; Vial, JH, 2004) |
| "Deep vein thrombosis (DVT) remains common in patients with acute ischemic stroke (AIS) receiving aspirin and graded compression stockings (considered standard thromboprophylaxis in the UK), most events occurring in patients with Barthel indices (BI) of <9 ('severe stroke') around the time of admission." | 3.72 | Screening for proximal deep vein thrombosis after acute ischemic stroke: a prospective study using clinical factors and plasma D-dimers. ( Coshall, C; Hunt, BJ; Kelly, J; Lewis, RR; Moody, A; Parmar, K; Rudd, A, 2004) |
| "Aspirin is widely used as an antiplatelet drug in patients with coronary heart disease." | 3.72 | Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. ( Abdelnoor, M; Arnesen, H; Pettersen, AA; Seljeflot, I, 2004) |
| "From a consecutive series of AF patients with first-ever ischemic stroke, we evaluated prospectively those with moderate to severe disability (grade 4-5 on the modified Rankin Scale) who were treated during a 5-year follow-up period with either warfarin or aspirin." | 3.72 | Anticoagulation influences long-term outcome in patients with nonvalvular atrial fibrillation and severe ischemic stroke. ( Manios, E; Moulopoulos, SD; Spengos, K; Toumanidis, S; Tsivgoulis, G; Vemmos, KN; Zakopoulos, N, 2004) |
| "Aspirin has been shown to reduce the risk of myocardial infarction and stroke." | 3.71 | Effect of increasing doses of aspirin on platelet aggregation among stroke patients. ( Bitanga, ES; Florento, L; Gan, R; Teleg, RA, 2002) |
| " If not taking Aspirin, the probabilities of stroke, myocardial infarction (MI), and major bleeding were given." | 3.71 | Differences in treatment preferences between persons who enrol and do not enrol in a clinical trial. ( Berquist, R; Hart, RG; Laupacis, A; Man-Son-Hing, M; O'Connor, AM, 2001) |
| "Epistaxis is a risk factor for ICH in middle-aged and elderly people, both independently and combined with the use of aspirin." | 3.71 | Use of aspirin, epistaxis, and untreated hypertension as risk factors for primary intracerebral hemorrhage in middle-aged and elderly people. ( Hillbom, M; Juvela, S; Saloheimo, P, 2001) |
| " The findings also suggest that older patients and those who have used aspirin before stroke are at higher risk of a severe HT on rtPA." | 3.71 | Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). ( Bluhmki, E; Larrue, V; Müller, A; von Kummer R, R, 2001) |
| "The objective of the study was to assess the association between aspirin use and the risk of stroke in a population-based study in the elderly." | 3.71 | Aspirin use and risk of stroke in the elderly: the Rotterdam Study. ( Bots, ML; Breteler, MM; Hofman, A; Koudstaal, PJ; Vokó, Z, 2001) |
| "Aspirin has been the mainstay of antiplatelet therapy in stroke prevention for 30 years." | 3.71 | Newer antiplatelet therapies in stroke prevention. ( Davis, SM; Donnan, GA, 2001) |
| " Thresholds were determined for the minimum reduction in risk of stroke necessary and the maximum increase in risk of excess bleeding acceptable for treatment with aspirin and warfarin in people with atrial fibrillation." | 3.71 | Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. ( Anderson, DR; Brownell, BF; Cox, JL; Devereaux, PJ; Flowerdew, GJ; Gardner, MJ; Nagpal, S; Putnam, W, 2001) |
| "Within a cross-sectional study, nested in a cohort we identified 931 patients with a recent ischemic stroke or TIA who were discharged with OAC or with one of the antiplatelet medications aspirin, clopidogrel, or the combination of aspirin and extended-release dipyridamole." | 3.71 | Current strategies of secondary prevention after a cerebrovascular event: the Vienna stroke registry. ( Lalouschek, W; Lang, W; Müllner, M, 2001) |
| "Patients with both patent foramen ovale and atrial septal aneurysm who have had a stroke constitute a subgroup at substantial risk for recurrent stroke, and preventive strategies other than aspirin should be considered." | 3.71 | Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. ( Arquizan, C; Cabanes, L; Coste, J; Derumeaux, G; Lamy, C; Mas, JL; Zuber, M, 2001) |
| "For older patients with atrial fibrillation and no other contraindications to antithrombotic therapy, a Markov decision-analytic model was used to determine the preferred treatment strategy (no antithrombotic therapy, long-term aspirin use, or long-term warfarin sodium use) based on their risk of major upper GI tract hemorrhage." | 3.71 | Balancing the risks of stroke and upper gastrointestinal tract bleeding in older patients with atrial fibrillation. ( Laupacis, A; Man-Son-Hing, M, 2002) |
| " Using a nested case-control design, we measured urinary 11-dehydro thromboxane B2 levels, a marker of in vivo thromboxane generation, in 488 cases treated with aspirin who had myocardial infarction, stroke, or cardiovascular death during 5 years of follow-up and in 488 sex- and age-matched control subjects also receiving aspirin who did not have an event." | 3.71 | Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. ( Eikelboom, JW; Hirsh, J; Johnston, M; Weitz, JI; Yi, Q; Yusuf, S, 2002) |
| " We aimed to compare the morbidity related to the treatment of atrial fibrillation with warfarin seen in one year at our hospital, with the morbidity in those patients in whom embolism was potentially preventable." | 3.71 | The morbidity related to atrial fibrillation at a tertiary centre in one year: 9.0% of all strokes are potentially preventable. ( Campbell, Do; Davis, S; Evans, A; Gerraty, R; Greenberg, P; Kilpatrick, C, 2002) |
| "2 were not affected by aspirin use and were not associated with thromboembolism after adjustment for age (P=0." | 3.70 | Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. ( Bovill, EG; Cornell, ES; Cushman, M; Feinberg, WM; Hart, RG; Lip, GY; Pearce, LA, 1999) |
| " Time trends were analysed for the use of aspirin, management of hypertension and atrial fibrillation prior to the presenting episode." | 3.70 | Secular trends in the management of hypertension and atrial fibrillation in patients presenting with stroke. ( Kalra, L; Perez, I; Smithard, DG, 2000) |
| "Large intervention studies suggest that aspirin may reduce mortality when given to patients who present with strokes or transient ischemic attacks." | 3.70 | Does prior use of aspirin affect outcome in ischemic stroke? ( Kalra, L; Perez, I; Smithard, DG; Sulch, D, 2000) |
| "This study assessed whether risk stratification in patients with atrial fibrillation (AF) in the community had a bearing on the likelihood of receiving aspirin or warfarin therapy." | 3.70 | Risk stratification in the management of atrial fibrillation in the community. ( Fahey, T; Godfrey, P; Rimmer, J, 1999) |
| "The value of warfarin in preventing stroke in patients with chronic atrial fibrillation is well established." | 3.70 | Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. ( Almoznino-Sarafian, D; Alon, I; Chachashvily, S; Cohen, N; Gorelik, O; Koopfer, M; Litvinjuk, V; Modai, D; Shteinshnaider, M, 2000) |
| " We compared the proportion of patients classified as having a low enough stroke risk to receive aspirin using published criteria from the Atrial Fibrillation Investigators (AFI), American College of Chest Physicians (ACCP), and the Stroke Prevention in Atrial Fibrillation Investigators (SPAF)." | 3.70 | Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. ( Borowsky, LH; Chang, Y; Go, AS; Henault, LE; Hylek, EM; Phillips, KA; Selby, JV; Singer, DE, 2000) |
| "Elderly men are more likely than elderly women to receive aspirin and ticlopidine and equally like to receive warfarin after a stroke." | 3.70 | Sex differences and similarities in the management and outcome of stroke patients. ( Austin, PC; Holroyd-Leduc, JM; Kapral, MK; Tu, JV, 2000) |
| "The goal of this health economic analysis was to asses the cost-effectiveness of a fixed combination of aspirin plus extended-release dipyridamole (ASA/ER-DP) or clopidogrel compared with ASA monotherapy for prevention of recurrent ischemic stroke." | 3.70 | Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis. ( Gondek, K; Shah, H, 2000) |
| "The Hypertension Optimal Treatment study was a large, randomized, multicenter study to determine the answers to two questions: 1) what is the optimal target blood pressure to be sought in the treatment of patients with moderate hypertension? and 2) does low dose aspirin therapy decrease morbidity and mortality in patients with hypertension? After 3." | 3.70 | The Hypertension Optimal Treatment Study: what did it give us? ( Bryg, RJ; Graettinger, WF, 1999) |
| "(1) In the acute phase of ischaemic stroke in patients free of thrombogenic heart disease, combined treatment with aspirin + moderate-dose unfractionated heparin reduces the risk of relapse and death." | 3.70 | Antiplatelet drugs in cardiovascular prevention: stroke: acute phase and secondary prevention. ( , 2000) |
| "(1) In patients with atrial fibrillation and a moderate embolic risk, aspirin reduces the risk of stroke and has a comparable risk-benefit ratio to oral anticoagulants." | 3.70 | Antiplatelet drugs in cardiovascular prevention: stroke prevention in patients with thrombogenic heart disease. ( , 2000) |
| "(1) Aspirin reduces the risk of myocardial infarction in men over 40 with no history of cardiovascular disease, and in hypertensive patients of both sexes over that age." | 3.70 | Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: primary prevention. ( , 2000) |
| "Compared with aspirin alone, use of the new antiplatelet regimens, including aspirin combined with dipyridamole and clopidogrel bisulfate, has been found to further reduce the risk of stroke and other vascular events in patients who have experienced stroke or transient ischemic attack." | 3.70 | Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. ( Bounameaux, H; Gaspoz, JM; Sarasin, FP, 2000) |
| "The recommended treatment of ischaemic stroke patients with atrial fibrillation (AF) is anticoagulation therapy with warfarin sodium and if this is contraindicated then aspirin should be used." | 3.70 | Which acute stroke patients with atrial fibrillation are prescribed warfarin therapy? Results from one-year's experience in Dundee. ( Craig, J; Goudie, BM; MacWalter, RS, 2000) |
| "To analyse the economic benefits, in comparison with placebo, of the secondary prevention of ischaemic stroke and myocardial infarction (MI) with lysine acetylsalicylate (Kardégic) in patients with a history of ischaemic stroke, MI or stable and unstable angina pectoris." | 3.70 | Economic assessment of the secondary prevention of ischaemic events with lysine acetylsalicylate. ( Lebrun, T; Marissal, JP; Selke, B, 2000) |
| " In this article, we outline the essential elements in the development and evaluation of a decision aid to help patients with atrial fibrillation choose, in consultation with their physicians, appropriate antithrombotic therapy (warfarin, aspirin, or no therapy) to prevent stroke." | 3.70 | Development of a decision aid for atrial fibrillation who are considering antithrombotic therapy. ( Anderson, DC; Blackshear, JL; Feldman, G; Hart, RG; Laupacis, A; Man-Son-Hing, M; O'Connor, AM, 2000) |
| "(1) Clopidogrel, an antiplatelet drug chemically similar to ticlopidine, is marketed in France for secondary prevention of thrombotic complications in patients with a history of myocardial infarction, ischaemic stroke or peripheral arterial disease." | 3.70 | Clopidogrel: new preparation. An alternative to aspirin. ( , 1999) |
| "(1) The clinical file on ticlopidine is based mainly on a placebo-controlled trial involving patients with lower-limb arterial disease, and two large double-blind trials in the post-stroke period, in which the comparator was a placebo in one and aspirin in the other." | 3.70 | Ticlopidine: a second look. No further use in routine practice. ( , 1999) |
| "It is unclear whether infarct location affects stroke recurrence after index ischemic stroke." | 3.30 | Stroke Recurrence and Antiplatelets in Posterior Versus Anterior Circulation Minor Stroke or Transient Ischemic Attack. ( Jing, J; Li, H; Li, Z; Liu, H; Meng, X; Wang, A; Wang, Y; Xu, Q, 2023) |
| "Stroke and bleeding are complications after transcatheter aortic valve replacement (TAVR)." | 3.30 | Sex Differences in Outcomes After Transcatheter Aortic Valve Replacement: A POPular TAVI Subanalysis. ( Brouwer, J; Nijenhuis, VJ; Ten Berg, JM; van Bergeijk, KH; van den Heuvel, AFM; van der Werf, HW; van Ginkel, DJ; Voors, AA; Wykrzykowska, JJ, 2023) |
| " The hazard of nonadherence to the assigned aspirin dosage was 46% higher in noninternet participants than internet participants." | 3.30 | Internet Versus Noninternet Participation in a Decentralized Clinical Trial: Lessons From the ADAPTABLE Study. ( Benziger, CP; Effron, MB; Girotra, S; Gupta, K; Harrington, RA; Hernandez, AF; Jones, WS; Kripalani, S; Mulder, H; Muñoz, D; Polonsky, TS; Robertson, HR; Rothman, RL; Sharlow, AG; Shen, R; VanWormer, JJ; Weissler, EH; Whittle, J; Wruck, L, 2023) |
| "Among patients with minor nondisabling acute ischemic stroke presenting within 4." | 3.30 | Dual Antiplatelet Therapy vs Alteplase for Patients With Minor Nondisabling Acute Ischemic Stroke: The ARAMIS Randomized Clinical Trial. ( Chen, HS; Cui, Y; Dong, YL; Guo, LY; Han, J; Huang, SM; Jiang, CH; Li, J; Li, JY; Li, YS; Li, Z; Lin, YZ; Lu, J; Ma, GB; Nguyen, TN; Piao, XY; Shen, LY; Wan, LS; Wang, DL; Wang, EQ; Wang, J; Wang, LX; Wang, RX; Wang, WZ; Xia, L; Yang, KH; Yang, QC; Zhang, H; Zhang, L; Zhou, ZH, 2023) |
| "Bleeding was defined using the International Society on Thrombosis and Haemostasis five-level ordered categorical scale: fatal, major, moderate, minor, none." | 3.30 | Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia. ( Appleton, JP; Bath, PM; Christensen, H; Dineen, RA; England, TJ; James, M; Krishnan, K; Montgomery, AA; Ranta, A; Robinson, TG; Sprigg, N; Woodhouse, LJ, 2023) |
| "Covert brain infarcts are associated with important neurological morbidity." | 3.11 | Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy. ( Ameriso, SF; Bereczki, D; Berkowitz, SD; Damgaard, D; Engelter, ST; Fiebach, JB; Gagliardi, RJ; Hart, RG; Kasner, SE; Mikulik, R; Muir, KW; Mundl, H; O'Donnell, MJ; Pearce, LA; Perera, KS; Puig, J; Saad, F; Shamalov, N; Sharma, M; Shoamanesh, A; Smith, EE; Toni, DS; Veltkamp, RC; Yoon, BW, 2022) |
| " We aimed to evaluate the dose-response relationship of milvexian in participants treated with dual antiplatelets." | 3.11 | Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention. ( Amarenco, P; Bereczki, D; Czlonkowska, A; Diener, HC; Donovan, M; Endres, M; Gailani, D; Hankey, GJ; Kahl, A; Kasner, SE; Li, D; Lutsep, HL; Molina, CA; Ntaios, G; Perera, V; Sharma, M; Shuaib, A; Toyoda, K; Tsivgoulis, G, 2022) |
| " The UNIVERSE Study evaluated the efficacy and safety of a novel liquid rivaroxaban formulation, using a body weight-adjusted dosing regimen, versus acetylsalicylic acid (ASA) in children post-Fontan." | 3.01 | Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study. ( Harris, KC; Jefferies, JL; Justino, H; Li, JS; Lu, W; McCrindle, BW; Michelson, AD; Miriam Pina, L; Nessel, K; Pablo Sandoval, J; Peluso, C; Suzana Horowitz, E; Van Bergen, AH, 2021) |
| "Vorapaxar is a novel antiplatelet therapy that inhibits thrombin-mediated platelet aggregation to prevent recurrence of ischemic events." | 3.01 | Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events - A Review on Vorapaxar. ( Aedma, SK; Combs, WG; Gupta, R; Kluck, B; Lin, M; Mehta, A; Patel, NC; Ranchal, P; Shah, R; Singh, S; Vyas, AV, 2023) |
| "Cardiac death (RR 0." | 3.01 | Clopidogrel Vs Aspirin Monotherapy Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis. ( Azhar, AZ; Baibhav, B; Cheung, JW; Rao, M; Tan, BE; Thakkar, S; Wong, PY, 2023) |
| "Aspirin was not associated with significant bleeding excess." | 3.01 | Fixed dose combination therapies in primary cardiovascular disease prevention in different groups: an individual participant meta-analysis. ( Dagenais, GR; Gao, P; Joseph, P; Malekzadeh, R; Pais, P; Roshandel, G; Yusuf, S, 2023) |
| "Asymptomatic carotid stenosis is when this narrowing occurs in people without a history or symptoms of this disease." | 3.01 | Pharmacological interventions for asymptomatic carotid stenosis. ( Cassola, N; Clezar, CN; Flumignan, CD; Flumignan, RL; Nakano, LC; Trevisani, VF, 2023) |
| "Keyword: antiplatelet therapy, acute ischemic stroke, secondary prevention, transient ischemic attack." | 3.01 | Clinical Updates on Antiplatelet Therapy for Secondary Prevention in Acute Ischemic Stroke. ( Chang, YM; Lee, TL; Sung, PS, 2023) |
| "Aspirin users were at significantly lower risk of all-cause mortality compared to nonusers (HR = 0." | 3.01 | Association between aspirin use and cardiovascular outcomes in ALLHAT participants with and without chronic kidney disease: A post hoc analysis. ( Bond, M; Conant, A; Desai, N; Rahman, M; Wilson, B, 2021) |
| "Patients with watershed infarction had higher risk of stroke recurrence than those without (17." | 2.94 | Higher early recurrence risk and potential benefit of dual antiplatelet therapy for minor stroke with watershed infarction: subgroup analysis of CHANCE. ( Atchaneeyasakul, K; Jing, J; Johnston, SC; Liebeskind, DS; Liu, L; Liu, X; Meng, X; Pan, Y; Pu, Y; Wang, A; Wang, Y; Zhao, X; Zou, X, 2020) |
| "Determining the right dosage of aspirin for the secondary prevention treatment of atherosclerotic cardiovascular disease (ASCVD) remains an unanswered and critical question." | 2.94 | Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. ( Ahmad, FS; Alvarado, G; Benziger, CP; Berdan, LG; Bradley, SM; Daugherty, SE; Effron, MB; Farrehi, P; Faulkner, M; Fintel, DJ; Fonarow, GC; Ford, DE; Geary, C; Girotra, S; Goldberg, YH; Gupta, K; Hammill, BG; Harrington, RA; Haynes, K; Hernandez, AF; Jain, SK; Jones, WS; Kraschnewski, J; Kripalani, S; Lampert, BC; Marquis-Gravel, G; McClay, JC; McTigue, KM; Merritt, JG; Metkus, T; Muñoz, D; Nallamothu, BK; Nauman, E; Pencina, MJ; Re, RN; Robertson, HR; Roe, MT; Roger, VL; Rothman, R; Seifein, H; Shah, RC; VanWormer, JL; Whittle, J; Zhou, L, 2020) |
| "Methods- Carotid atherosclerosis was analyzed either as the presence of mild (ie, 20%-49%) atherosclerotic stenosis or, separately, as the presence of carotid plaque." | 2.90 | Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis. ( Amarenco, P; Berkowitz, SD; Bornstein, N; Camps-Renom, P; Connolly, SJ; Cucchiara, B; Gagliardi, RJ; Hart, RG; Korompoki, E; Lang, W; Lavados, P; Makaritsis, K; Marti-Fabregas, J; Meseguer, E; Milionis, H; Mundl, H; Ntaios, G; Papavasileiou, V; Siegler, JE; Swaminathan, B; Vemmos, K, 2019) |
| "We examined new cancers diagnosed in relation to gastrointestinal or genitourinary bleeding among patients enrolled in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) and determined the hazard of new cancer diagnosis after bleeding at these sites." | 2.90 | Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. ( Aboyans, V; Alings, M; Anand, SS; Avezum, A; Berkowitz, SD; Bhatt, DL; Bosch, J; Connolly, SJ; Cook-Bruns, N; Eikelboom, JW; Felix, C; Fox, KAA; Hart, RG; Maggioni, AP; Moayyedi, P; O'Donnell, M; Rydén, L; Shestakovska, O; Verhamme, P; Widimsky, P; Yusuf, S; Zhu, J, 2019) |
| "Aspirin treatment may have reduced CVEs within a high CVE risk elderly population subgroup." | 2.90 | Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70). ( Ando, K; Goto, Y; Ikeda, Y; Ishizuka, N; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Uemura, Y; Yamazaki, T; Yokoyama, K, 2019) |
| "Major bleeding was the primary safety end point." | 2.90 | Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Johnston, SC; Knutsson, M; Ladenvall, P; Minematsu, K; Molina, CA; Röther, J; Wang, Y; Wong, KSL, 2019) |
| "Aspirin was used by 56." | 2.90 | Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes. ( Green, JB; Guimarães, PO; Holman, RR; Lokhnygina, Y; Lopes, RD; McGuire, DK; Peterson, ED; Stevens, SR, 2019) |
| "Acute minor ischemic stroke (AMIS) or transient ischemic attack (TIA) is a common cerebrovascular event with a considerable high recurrence." | 2.87 | Rationale and Study Design for a Single-Arm Phase IIa Study Investigating Feasibility of Preventing Ischemic Cerebrovascular Events in High-Risk Patients with Acute Non-disabling Ischemic Cerebrovascular Events Using Remote Ischemic Conditioning. ( Feng, WW; Ji, XM; Li, SJ; Liu, SM; Meng, R; Ovbiagele, B; Ren, CH; Song, HQ; Zhao, WL, 2018) |
| "The risk of bleeding is a major concern when oral anticoagulation is required to prevent stroke, and concomitant therapy with antiplatelet agents is required to minimize recurrent ischemic events." | 2.87 | An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rat ( Alexander, JH; Darius, H; Goodman, SG; Granger, CB; Liaw, D; Lopes, RD; Mehran, R; Vora, AN; Windecker, S, 2018) |
| "Intracranial atherosclerotic stenosis (ICAS) is one of the most frequent causes of stroke worldwide and confers one of the greatest risks of recurrent stroke compared with other causes of stroke." | 2.82 | Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment. ( Chimowitz, MI; Gutierrez, J; Hoh, BL; Turan, TN, 2022) |
| "Aspirin-HTPR was noted in 9." | 2.82 | Platelet Biomarkers in Patients with Atherosclerotic Extracranial Carotid Artery Stenosis: A Systematic Review. ( de Borst, GJ; Delaney, S; Hamilton, G; Kinsella, JA; McCabe, DJH; McMahon, J; Murphy, SJX; Naylor, AR; Offiah, C; Smith, DR; Subramanian, A, 2022) |
| "aspirin monotherapy was carried out, to determine optimal peri-operative management with these antiplatelet agents." | 2.82 | Editor's Choice - Peri-Operative Outcomes of Carotid Endarterectomy are Not Improved on Dual Antiplatelet Therapy vs. Aspirin Monotherapy: A Systematic Review and Meta-Analysis. ( Bissacco, D; Chechik, O; Chisci, E; Cusimano, MD; Ku, JC; Larrue, V; Macdonald, RL; Michelagnoli, S; Nasr, N; Pasarikovski, CR; Priola, SM; Rabinovich, Y; Settembrini, PG; Taslimi, S; Yang, VXD; Zuccato, J, 2022) |
| "Ischaemic strokes have traditionally been classified according to the TOAST criteria, in which strokes with unclear aetiology are classified as cryptogenic strokes." | 2.82 | Review and update of the concept of embolic stroke of undetermined source. ( Diener, HC; Easton, JD; Hart, RG; Kamel, H; Kasner, S; Ntaios, G, 2022) |
| "Cerebral small vessel disease is a progressive disease of the brain's deep perforating blood vessels." | 2.82 | Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia. ( Chiang, LLW; Hafdi, M; Kwan, J; Myint, PK; Quinn, TJ; Wong, LS, 2022) |
| "The coexistence of TS and acute cerebral infarction is rare." | 2.82 | Thyroid storm complicated by corpus callosum infarction in a young patient: A case report and literature review. ( Cai, Y; Gang, X; Li, C; Liu, X; Ren, L; Wang, G, 2022) |
| " In terms of cardiovascular and cerebrovascular adverse events, other 3 interventions were higher than L-DAPT (Std-DAPT [OR = 1." | 2.82 | Efficacy and safety of dual antiplatelet therapy after percutaneous coronary drug-eluting stenting: A network meta-analysis. ( Feng, T; Li, D; Luo, L; Ran, J; Tang, K; Wang, D; Wang, S; Wu, J; Xu, L; Yang, X; Zhang, L; Zhao, D, 2022) |
| "Acute stroke is the leading cause of disability in the UK and a leading cause of mortality worldwide." | 2.82 | Antiplatelet treatment for acute secondary prevention of non-cardioembolic minor stroke / transient ischaemic attack: an update for the acute physician. ( Appleton, JP; Bath, PM; Dawson, J; England, TJ; Eveson, D; Krishnan, K; Law, ZK; Mavilakandy, A; Minhas, JS; Mistri, A; Robinson, TG; Sprigg, N, 2022) |
| "Strokes are infrequent but potentially serious complications following carotid intervention, but antiplatelet therapy can reduce these risks." | 2.82 | Antiplatelet Therapy in Carotid Artery Stenting and Carotid Endarterectomy in the Asymptomatic Carotid Surgery Trial-2. ( Bulbulia, R; Coppi, G; de Borst, GJ; Halliday, A; Huibers, A, 2016) |
| "Patients with API (lacunar infarcts or branch atheromatous disease) admitted within 48 hours after onset were enrolled." | 2.82 | [Argatroban, Aspirin, and Clopidogrel Combination Therapy for Acute Penetrating Artery Infarction: A Pilot Study]. ( Kobayashi, Y; Mano, T; Matsuo, K; Nishi, R, 2016) |
| "Randomized patients with available aspirin dosing information in COGENT (N = 3,752) were divided into "low-dose" (≤ 100 mg) and "high-dose" (>100 mg) aspirin groups." | 2.82 | Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. ( Bhatt, DL; Cannon, CP; Cohen, M; Cryer, BL; Doros, G; Goldsmith, MA; Hsieh, WH; Laine, L; Lanas, A; Lapuerta, P; Liu, Y; Schnitzer, TJ; Shook, TL; Vaduganathan, M, 2016) |
| "The primary outcome is IS recurrence." | 2.80 | Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. ( Hoshino, H; Kimura, K; Minematsu, K; Naritomi, H; Origasa, H; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2015) |
| "Stroke is a leading cause of death and disability internationally." | 2.79 | Thrombolysis ImPlementation in Stroke (TIPS): evaluating the effectiveness of a strategy to increase the adoption of best evidence practice--protocol for a cluster randomised controlled trial in acute stroke care. ( Attia, JR; Bladin, CF; D'Este, CA; Henskens, F; Kerr, E; Lalor, E; Levi, CR; Lindley, RI; Longworth, M; Middleton, S; Parsons, MW; Paul, CL; Ryan, A; Sanson-Fisher, RW, 2014) |
| "A cause other than paradoxical embolism was usually apparent in patients with recurrent neurologic events." | 2.77 | Closure or medical therapy for cryptogenic stroke with patent foramen ovale. ( Adams, H; Albers, GW; Felberg, R; Furlan, AJ; Herrmann, H; Kar, S; Landzberg, M; Massaro, J; Mauri, L; Raizner, A; Reisman, M; Wechsler, L, 2012) |
| "Despite improvements in treatment, stroke still carries a high death toll and disability in Asia." | 2.76 | The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial. ( Horie, Y; Ikeda, Y; Uchiyama, S; Urano, Y; Yamaguchi, T, 2011) |
| "Background stroke care was limited and none of the patients received thrombolytic therapy." | 2.76 | The International Stroke Trial database. ( Członkowska, A; Niewada, M; Sandercock, PA, 2011) |
| "Aspirin has an antithrombotic action at low dose and anti-ischemic and anti-inflammatory properties, which are dose-related." | 2.76 | The role of aspirin in childhood tuberculous meningitis. ( Janse van Rensburg, A; Laubscher, JA; Schoeman, JF; Springer, P, 2011) |
| "Fatal bleeding was low and did not differ between groups." | 2.76 | Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bassand, JP; Becker, RC; Budaj, A; Cornel, JH; French, J; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Lassila, R; Lopez-Sendon, J; Mahaffey, KW; Storey, RF; Wallentin, L; Wojdyla, DM, 2011) |
| " These results suggest that administration of aspirin and cilostazol is safe for acute ischemic stroke." | 2.76 | Pilot study of the safety of starting administration of low-dose aspirin and cilostazol in acute ischemic stroke. ( Fujita, K; Higuchi, O; Kamezaki, T; Komatsu, Y; Kujiraoka, Y; Matsumura, A; Sato, N; Suzuki, K, 2011) |
| "Hemodialysis patients with type 2 diabetes exhibit an excessive cardiovascular risk and regularly receive heparin." | 2.75 | Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes. ( Berger, M; Krane, V; Lilienthal, J; Schambeck, C; Wanner, C; Winkler, K, 2010) |
| "Terutroban is a specific TP receptor antagonist with antithrombotic, antivasoconstrictive, and antiatherosclerotic properties, which may be of interest for the secondary prevention of ischemic stroke." | 2.74 | Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with ( Amarenco, P; Bousser, MG; Chamorro, A; Fisher, M; Ford, I; Fox, K; Hennerici, MG; Mattle, HP; Rothwell, PM, 2009) |
| " The number of patients with adverse events and bleeding complications, and their severity, were significantly greater in the triple therapy group (p<0." | 2.73 | A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. ( Bath, PM; England, T; Gray, LJ; Sare, GM; Sprigg, N; Willmot, MR; Zhao, L, 2008) |
| "The mechanism of stroke is believed to be thromboembolic in the majority of cases." | 2.73 | Antiplatelet therapy vs. anticoagulation in cervical artery dissection: rationale and design of the Cervical Artery Dissection in Stroke Study (CADISS). ( , 2007) |
| "Aspirin resistance has been shown to be a significant risk factor for recurrent cardiovascular ischaemic events." | 2.73 | A pilot study of resistance to aspirin in stroke patients. ( Bennett, D; Davis, SM; Eccleston, D; Macgregor, L; Yan, B, 2008) |
| "Hypertension is more commonly diagnosed in older patients with atrial fibrillation than in the general population." | 2.73 | A cross-sectional study of hypertension in an elderly population (75 years and over) with atrial fibrillation: secondary analysis of data from the Birmingham Atrial Fibrillation in the Aged (BAFTA) randomised controlled trial. ( Fletcher, K; Hobbs, FD; Hurley, V; Ireson, R; Lip, GY; Mant, J, 2007) |
| " Ten normal volunteer subjects underwent 3 randomized treatment sessions: aspirin 325 mg alone, ibuprofen 400 mg alone, and ibuprofen 400 mg, followed by dosing with aspirin 325 mg 2 hours thereafter." | 2.73 | Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis. ( Bates, V; Gengo, FM; Gengo, MF; Mager, DE; Rainka, M; Robson, M; Rubin, L, 2008) |
| "Hemorrhagic stroke is the most common type of obstetric stroke." | 2.72 | Stroke in Pregnancy: A Multidisciplinary Approach. ( Camargo, EC; Singhal, AB, 2021) |
| "Location of stenosis, type of qualifying event, and prior use of antithrombotic medications were not associated with increased risk." | 2.72 | Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. ( Benesch, CG; Chaturvedi, S; Chimowitz, MI; Cloft, HJ; Frankel, MR; Hertzberg, VS; Howlett-Smith, H; Jovin, TG; Kasner, SE; Levine, SR; Lynn, MJ; Romano, JG; Sila, CA; Stern, BJ, 2006) |
| "Aspirin resistance was defined as a mean aggregation of > or =70% with 10 microM ADP and > or =20% with 0." | 2.71 | A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. ( Gum, PA; Kottke-Marchant, K; Topol, EJ; Welsh, PA; White, J, 2003) |
| "Bleedings were documented in 19 versus four patients (W/A 5." | 2.71 | Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation. ( Edvardsson, N; Juul-Möller, S; Omblus, R; Pehrsson, K, 2003) |
| "Stroke and systemic thromboembolism are serious problems for patients with atrial fibrillation (AF), but their incidence can be substantially reduced by appropriate anticoagulation." | 2.71 | Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. ( Corley, SD; DiMarco, JP; Flaker, G; Greene, HL; Mitrani, G; Nemeth, M; Rosenfeld, LE; Safford, RE; Waldo, AL, 2005) |
| "In patients with symptomatic carotid artery stenosis, high-intensity transient signals detected by transcranial Doppler (TCD) have been related to particulate microemboli originating at the stenotic lesion." | 2.70 | Acetylsalicylic acid and microembolic events detected by transcranial Doppler in symptomatic arterial stenoses. ( Blaser, T; Goertler, M; Krueger, S; Lutze, G; Wallesch, CW, 2001) |
| "Both high blood pressure and low blood pressure were independent prognostic factors for poor outcome, relationships that appear to be mediated in part by increased rates of early recurrence and death resulting from presumed cerebral edema in patients with high blood pressure and increased coronary heart disease events in those with low blood pressure." | 2.70 | Blood pressure and clinical outcomes in the International Stroke Trial. ( Bath, PM; Leonardi-Bee, J; Phillips, SJ; Sandercock, PA, 2002) |
| "Major or severe bleeding (but not intracranial hemorrhage) was higher with orbofiban; it occurred in 2." | 2.69 | Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. ( Alexander, JC; Anders, RJ; Berink, P; Braunwald, E; Cannon, CP; Caspi, A; Charlesworth, A; Langer, A; Lopez-Sendon, J; McCabe, CH; Skene, A; Toman, J; Wilcox, RG, 2000) |
| "Fifty-two patients had symptomatic intracranial atherosclerosis and fulfilled entry criteria." | 2.69 | Symptomatic intracranial atherosclerosis: outcome of patients who fail antithrombotic therapy. ( Albers, GW; Thijs, VN, 2000) |
| "Piracetam was significantly superior to ASA in the secondary endpoint (P=0." | 2.69 | Piracetam versus acetylsalicylic acid in secondary stroke prophylaxis. A double-blind, randomized, parallel group, 2 year follow-up study. ( Evers, S; Fischer, M; Grotemeyer, KH; Husstedt, IW, 2000) |
| "Stroke has traditionally been classified according to the trial of ORG 10172 in acute stroke treatment (TOAST) criteria; however, the concept of cryptogenic stroke did not meet the operational criteria necessary to define patient populations eligible for randomized studies." | 2.66 | [Past and future of the ESUS concept]. ( Diener, HC; Endres, M, 2020) |
| "Main outcomes were stroke recurrence and major bleeding." | 2.66 | Aspirin or anticoagulation after cryptogenic stroke with patent foramen ovale: systematic review and meta-analysis of randomized controlled trials. ( Calabresi, P; Cupini, LM; Eusebi, P; Giannandrea, D; Ricci, S; Romoli, M, 2020) |
| "Although migraine improves or disappears during pregnancy, a significant association between migraine and hypertension (i." | 2.66 | The Potential Protective Role of Aspirin Against Migraine in Pregnant Women. ( Gong, Y; Liu, X, 2020) |
| "Recurrent stroke is common immediately following a transient ischemic attack (TIA) or ischemic stroke." | 2.61 | Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials. ( Abdalla, A; Ahmed, S; Al Qasmi, M; Bachuwa, G; Bhatt, DL; Chahine, A; Hassan, M; Haykal, T; Kheiri, B; Osman, M; Swaid, B, 2019) |
| "Treatment with aspirin alone ranked with high values both for primary and secondary endpoints (surface under the cumulative ranking curve of 70% and 82%, respectively)." | 2.61 | Medical and endovascular treatments of symptomatic intracranial stenosis. A Bayesian network meta-analysis. ( Agostoni, E; Consoli, A; Consoli, D; Grampa, G; Vidale, S, 2019) |
| "Aspirin has a complex matrix of benefits and risks, and its use in primary prevention requires individualized decision-making." | 2.58 | Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach. ( Ames, JM; Dugani, S; Manson, JE; Mora, S, 2018) |
| " Efficacy outcomes included ischemic stroke, stent thrombosis, major adverse cardiovascular event (MACE), all-cause mortality and myocardial infarction (MI); safety outcome was major bleeding." | 2.58 | Efficacy and safety of triple therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing coronary stenting: A meta-analysis. ( Huang, J; Liu, L; Tang, X; Zhang, X, 2018) |
| "Cardiogenic embolism is made less likely by ECG monitoring and echocardiography." | 2.55 | Secondary Stroke Prevention in Cryptogenic Stroke and Embolic Stroke of Undetermined Source (ESUS). ( Bernstein, R; Diener, HC; Hart, R, 2017) |
| "Stroke is one of the leading causes of death." | 2.55 | Genetic Signatures in Ischemic Stroke: Focus on Aspirin Resistance. ( Chaurasia, P; Munshi, A; Singh, S; Vasudeva, K, 2017) |
| " The combination of clopidogrel and aspirin is not recommended for long-term use (more than two to three years) because of increased bleeding risk." | 2.55 | Recurrent Ischemic Stroke: Strategies for Prevention. ( Garcellano, M; Oza, R; Rundell, K, 2017) |
| " There were differences in the effect of aspirin by dosage and treatment duration on overall stroke outcomes (P for interaction for all < 0." | 2.55 | Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. ( Khunti, K; Kunutsor, SK; Seidu, S, 2017) |
| "0) combined with ASA (mean dose ≥100 mg/day) and ASA." | 2.55 | Efficacy and safety of aspirin combined with warfarin after acute coronary syndrome : A meta-analysis. ( Huang, X; Li, J; Li, L; Shen, C; Wu, C; Zhang, P; Zhang, W, 2017) |
| "Cryptogenic stroke is one-fourth among cerebral infarction, but most of them could be ascribed to embolic stroke." | 2.53 | [ESUS (embolic stroke of undetermined sources)]. ( Kitagawa, K, 2016) |
| "Aspirin is likely to increase the risk of major bleeding events." | 2.53 | Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis. ( Brunskill, NJ; Dawson, S; Gray, LJ; Major, RW; Oozeerally, I; Riddleston, H, 2016) |
| "Aspirin has been shown to lower the incidence and the mortality of vascular disease and cancer but its wider adoption appears to be seriously impeded by concerns about gastrointestinal (GI) bleeding." | 2.53 | Systematic Review and Meta-Analysis of Randomised Trials to Ascertain Fatal Gastrointestinal Bleeding Events Attributable to Preventive Low-Dose Aspirin: No Evidence of Increased Risk. ( Chia, JW; Dolwani, S; Elwood, PC; Galante, J; Graziano, JM; Kelson, M; Lanas, A; Longley, M; Morgan, G; Morris, D; Phillips, CJ; Pickering, J; Roberts, SE; Soon, SS; Steward, W; Weightman, AL, 2016) |
| " Cilostazol-based TAPT compared with DAPT is associated with improved angiographic outcomes and decreased risk of TLR and TVR but does not reduce major cardiovascular events and is associated with an increase in minor adverse events." | 2.52 | Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. ( Bai, J; Chen, J; Chen, P; Eikelboom, JW; Gong, X; Kong, D; Li, C; Liu, J; Meng, H; Xu, L; Yang, Z; Zou, F, 2015) |
| "Aspirin has higher side effect risks and requires a longer time to achieve benefit." | 2.52 | Primary prevention: do the very elderly require a different approach? ( Schwartz, JB, 2015) |
| "5, and aspirin was administered at a dosage of 75 to 325 mg/d." | 2.52 | Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis. ( Chen, KP; Zhang, JT; Zhang, S, 2015) |
| " However, NSAIDs are associated with a number of adverse effects, especially in patients with cardiovascular disease (CVD)." | 2.52 | Safety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease. ( Cicci, JD; Danelich, IM; Lose, JM; Reed, BN; Tefft, BJ; Wright, SS, 2015) |
| " Although administration of antiplatelet agents has been confirmed to be one of the major approaches for secondary prevention of noncardioembolic stroke, the short-term or long-term use of aspirin plus clopidogrel for secondary stroke prevention remains to be controversial." | 2.52 | Dual antiplatelet therapy with clopidogrel and aspirin for secondary stroke prevention. ( Chen, W; Wang, Y, 2015) |
| "Warfarin has been the traditional choice, but the recently introduced novel oral anticoagulants offer similar efficacy with less bleeding risk." | 2.52 | Evolving strategies to prevent stroke and thromboembolism in nonvalvular atrial fibrillation. ( Hussein, A; Saliba, W; Wazni, OM, 2015) |
| "These events, previously called apoplexy, are now called strokes." | 2.50 | Stroke: transient ischemic attack. ( Silver, B; Wulf Silver, R, 2014) |
| "In the peripheral arteries, a thrombus superimposed on atherosclerosis contributes to the progression of peripheral artery disease (PAD), producing intermittent claudication (IC), ischemic necrosis, and, potentially, loss of the limb." | 2.50 | Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. ( Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E, 2014) |
| "Aspirin may cause teratogenicity and fetal toxicity, and perinatal mortality is increased." | 2.49 | Antithrombotic therapy for pregnant women. ( Toyoda, K, 2013) |
| "Aspirin has been recommended for primary prevention of cardiovascular disease (CVD) and cancer, but overall benefits are unclear." | 2.49 | Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trials. ( Clarke, A; Connock, M; Freeman, K; Grove, A; Gurung, B; Gurung, T; Johnson, S; Morrow, S; Ngianga-Bakwin, K; Stranges, S; Sutcliffe, P, 2013) |
| "Stroke is the second cause of death worldwide and one of the leading cause of disability." | 2.49 | Antiplatelets in stroke prevention. ( Buttà, C; Di Raimondo, D; Licata, G; Pinto, A; Tuttolomondo, A, 2013) |
| " The emergence of new anticoagulants that offer equal or superior efficacy, greater safety and the convenience of fixed oral dosing may make warfarin the less preferred option." | 2.48 | Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options. ( Halperin, JL; Varughese, CJ, 2012) |
| "However, unlike stroke, treatment of hyperlipidemia with statin class drugs or treatment of blood clotting abnormalities with acetylsalicylic acid do not appear to have an effect on VaD incidence or progression." | 2.48 | Pharmacological prevention and treatment of vascular dementia: approaches and perspectives. ( Baskys, A; Cheng, JX, 2012) |
| "Ischemic stroke is a major cause of death and disability worldwide." | 2.48 | Antiplatelet therapy in stroke prevention. ( Apostolakis, S; Lip, GY; Marín, F, 2012) |
| "Atherothrombosis is the major cause of mortality and morbidity in Western countries." | 2.48 | Thromboxane receptors antagonists and/or synthase inhibitors. ( Davì, G; Santilli, F; Vazzana, N, 2012) |
| "Stroke is a leading cause of death worldwide and the first cause of disability in the Western world." | 2.48 | Antiplatelet treatment in primary and secondary stroke prevention in women. ( Acciarresi, M; Caso, V; Paciaroni, M; Pezzella, FR; Santalucia, P, 2012) |
| "Stroke is one of the leading causes of disability; most are due to atherothrombotic mechanisms." | 2.47 | Current status of antiplatelet agents to prevent stroke. ( Benavente, OR; Field, TS, 2011) |
| "Bleeding is potentially the most significant antiplatelet-associated side effect." | 2.47 | Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events. ( Guthrie, R, 2011) |
| "Aspirin use was associated with a significantly lower risk of mortality (RR: 0." | 2.47 | Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis. ( Chambers, T; Gamble, JM; Mereu, L; Simpson, SH, 2011) |
| " Nevertheless, VKAs do require frequent coagulation monitoring and dose adjustment because of their variable dose-response profile, narrow therapeutic window, increased risk for bleeding complications and numerous food and drug interactions." | 2.47 | Challenges of stroke prevention in patients with atrial fibrillation in clinical practice. ( Hobbs, FD; Leach, I, 2011) |
| "Aspirin has been shown to reduce the risk of recurrent strokes, and the combination of aspirin and dipyridamole has repeatedly been shown to outperform aspirin alone." | 2.46 | Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review. ( Fung, K; Simmons, BB; Yeo, A, 2010) |
| "In the past, transient ischemic attack (TIA) was defined as any sudden, focal cerebral ischemic event with neurological deficit lasting <24 hours." | 2.46 | [New clinical concept and therapeutic strategy for TIA]. ( Urabe, T, 2010) |
| "Aspirin plus ER-DP has a greater bleeding rate than clopidogrel but a lower rate than aspirin (< or =325 mg/day) alone." | 2.45 | Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? ( Brahin, E; Dessain, S; Ezekowitz, MD; Gracely, E; Nagarakanti, R; Notaro, LA; Usman, MH, 2009) |
| "In acute intracerebral hemorrhage the beneficial effect of recombinant coagulation factor VII found in a small study could not be proved in a large phase III trial." | 2.45 | [Pharmacotherapy of stroke]. ( Bereczki, D, 2009) |
| "Most strokes are caused by a sudden blockage of an artery in the brain (called an ischaemic stroke) that is usually due to a blood clot." | 2.45 | Antiplatelet treatment in ischemic stroke treatment. ( Arnao, V; Di Raimondo, D; Di Sciacca, R; La Placa, S; Licata, G; Miceli, S; Milio, G; Pinto, A; Tuttolomondo, A, 2009) |
| "Stroke is the most serious complication." | 2.44 | Antithrombotic treatment in atrial fibrillation. ( Boos, CJ; Lip, GY, 2008) |
| "Aspirin has been the cornerstone of antiplatelet therapy for many decades, but in recent years, adenosine diphosphate (ADP) receptor antagonists, mainly clopidogrel and ticlopidine, and glycoprotein (GP) IIb/IIIa (integrin alpha IIb beta 3) inhibitors have also shown similar effectiveness." | 2.44 | Acute and long-term antiplatelet therapy. ( Goudevenos, JA; Mikhailidis, DP; Papathanasiou, AI; Tselepis, AD, 2008) |
| "Many aspects of acute management of transient ischemic attack, such as which patients should be hospitalized and choice of acute antithrombotic therapy, remain controversial because of a lack of evidence from controlled trials." | 2.44 | Transient ischemic attack: risk stratification and treatment. ( Cucchiara, B; Ross, M, 2008) |
| "Stroke is a leading cause of death, disability, and dependence." | 2.44 | The approach to optimizing stroke care. ( Panagos, PD, 2008) |
| "Stroke is a leading cause of death and the primary cause of serious, long-term disability in the United States." | 2.44 | Combination antiplatelet agents for secondary prevention of ischemic stroke. ( Saseen, JJ; Vande Griend, JP, 2008) |
| "Antiphospholipid syndrome is considered to be associated with a hypercoagulable state that leads to stroke and other ischemic events, and is currently diagnosed based on the modified Sapporo criteria that was proposed in 2006." | 2.44 | [Ischemic stroke with antiphospholipid antibody]. ( Kitagawa, Y; Ohkuma, H; Tokuoka, K, 2008) |
| "The grad A for treatment of acute stroke is recommended as IV-t-PA therapy, aspirin administration within 48 hours of stroke onset, and the management in stroke unit." | 2.44 | [Diagnosis and management for acute ischemic stroke]. ( Kimura, K, 2008) |
| "Atherothrombosis is a progressive and generalized pathologic process that affects the vascular system." | 2.44 | Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician. ( Brown, MT; Kikano, GE, 2007) |
| "As well as initiating thrombus formation at the site of a ruptured atherosclerotic plaque, platelets play a key role in vascular inflammation, through release of their own pro-inflammatory mediators and interactions with other relevant cell types (endothelial cells, leukocytes, and smooth muscle cells)." | 2.44 | Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. ( Badimon, JJ; Bhatt, DL; Herbert, JM; Lüscher, TF; Steinhubl, SR, 2007) |
| "Aspirin has long been established as a useful analgesic and antipyretic." | 2.44 | The discovery of aspirin's antithrombotic effects. ( Hoffhines, A; Miner, J, 2007) |
| "Ischemic stroke is a common complication after CABG." | 2.44 | Prevention of ischemic stroke: surgery. ( Chaturvedi, S; Rajamani, K, 2007) |
| "Aspirin is a less effective alternative, and any benefit of aspirin might be due to its favourable effects on arterial thrombosis caused by vascular disease." | 2.44 | Atrial fibrillation and stroke prevention. ( Lim, HS; Lip, GY, 2007) |
| " In secondary prevention, in a wide range of patients who have survived a prior myocardial infarction (MI), occlusive stroke, transient ischemic attack, as well as other high-risk conditions, long-term use of aspirin confers statistically significant and clinically important reductions in MI, stroke and CVD death." | 2.44 | The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease. ( Hennekens, CH; Schneider, WR, 2008) |
| "Cerebral ischaemic stroke is frequently a relapsing, if not chronic, disease." | 2.44 | Secondary stroke prevention: inside the vessels and beyond. ( Huber, R; Riepe, MW, 2008) |
| "Patients who have transient ischemic attack (TIA) or ischemic stroke are at a high risk of having a first or recurrent stroke." | 2.44 | Antiplatelet agents and randomized trials. ( Diener, HC, 2007) |
| "Aspirin resistance was assessed, using a variety of platelet function assays." | 2.44 | Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. ( Beattie, WS; Brister, SJ; Buchanan, MR; Krasopoulos, G, 2008) |
| "Aspirin has become the antiplatelet treatment standard against which several other antiplatelet agents have been shown to be more effective." | 2.44 | Antithrombotic and thrombolytic therapy for ischemic stroke. ( Cornett, O; Malhotra, S; Ocava, LC; Rosenbaum, DM; Singh, M, 2008) |
| "The short-term risk of stroke after transient ischemic attack (TIA) is about 10% to 20% in the first 3 months, with much of the risk front-loaded in the first week." | 2.43 | Stroke prevention. MATCHing therapy to the patient with TIA. ( Buchan, AM; Demchuk, AM; Hill, MD; Weir, NU, 2005) |
| " If the international normalized ratio (INR) was kept > 2 for a long period, by means of frequent check-ups and effective dosage adjustment, the chance of death, recurrent myocardial infarction or stroke was 30-50% lower than when acetylsalicylic acid only was used." | 2.43 | [Antithrombotic therapy after myocardial infarction: arguments for the use of acetylsalicylic acid and coumarin derivatives]. ( Brouwer, A; Verheugt, FW; Waskowsky, WM, 2005) |
| "Aspirin has been shown to be as effective as warfarin in the prevention of noncardioembolic ischaemic stroke, with significantly fewer bleeding complications." | 2.43 | Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke. ( Weinberger, J, 2005) |
| "Aspirin is a well-established medication in the treatment of atherothrombotic vascular disease." | 2.43 | Aspirin resistance in stroke: 2004. ( Sas, K; Sztriha, LK; Vecsei, L, 2005) |
| " As well, we highlight current research around optimal dosage and other issues related to aspirin administration." | 2.43 | What every emergency nurse needs to know about aspirin. ( Smith, S; Turris, SA, 2005) |
| " The optimum doses of antiplatelet drugs depend upon several variables, such as genetic and environmental factors, so that clinical and laboratory response for dosage varies for each patient." | 2.43 | Antiplatelet therapy in ischemic stroke. ( Káposzta, Z; Pongrácz, E, 2005) |
| "About 80% of strokes have ischemic origin." | 2.43 | [Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke]. ( Szapáry, L, 2005) |
| " Furthermore, (i) the optimal dosage of aspirin for complete inhibition of platelet aggregation by physiological agonists (i." | 2.43 | Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance. ( Christiaens, L; Macchi, L; Sorel, N, 2006) |
| "The Stroke Prevention Trial in Sickle Cell Anemia (STOP) reported a reduction in the number of overt clinical strokes experienced by those children with critically high transcranial Doppler velocities (>200 centimeters per second) who were chronically transfused." | 2.43 | Trials in sickle cell disease. ( Adams, RJ; Datta, AK; DeBaun, MR; Kirkham, FJ; Lerner, NB; Noetzel, M; Rees, DC, 2006) |
| "Hypertension that complicates preeclampsia in pregnancy is a disorder that requires special consideration in both prevention and pharmacologic treatment." | 2.43 | Pathophysiology and medical management of systemic hypertension in preeclampsia. ( Frishman, WH; Schlocker, SJ; Tejani, N; Veresh, M, 2006) |
| "Ischemic stroke is a leading cause of death and disability in the Western world." | 2.43 | Therapy for early reperfusion after stroke. ( Juttler, E; Kohrmann, M; Schellinger, PD, 2006) |
| "Many elderly patients with recurrent paroxysmal atrial fibrillation have high rates of stroke." | 2.42 | Lessons from the Stroke Prevention in Atrial Fibrillation trials. ( Anderson, DC; Halperin, JL; Hart, RG; Kronmal, RA; Marler, JR; McBride, R; Nasco, E; Pearce, LA; Sherman, DG; Talbert, RL, 2003) |
| "Dipyridamole has been studied as an antiplatelet agent for several decades." | 2.42 | Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke. ( Lenz, T; Wilson, A, 2003) |
| "Stroke is a treatable disease." | 2.42 | The 5 Ps of acute ischemic stroke treatment: parenchyma, pipes, perfusion, penumbra, and prevention of complications. ( Felberg, RA; Naidech, AM, 2003) |
| "Stroke is a preventable tragedy for nearly 750,000 people each year." | 2.42 | Medical prevention of stroke, 2003. ( Kirshner, HS, 2003) |
| "Aspirin also has been studied and is effective, but with a more modest benefit (relative risk reduction of 22%)." | 2.42 | Prevention of vascular events in patients with atrial fibrillation: evidence, guidelines, and practice. ( Connolly, SJ, 2003) |
| "The risk of TIA or stroke recurrence reaches 30-45%." | 2.42 | [Stenosis of the carotid arteries]. ( Kaźmierski, MK, 2003) |
| "The diagnosis of carotid stenosis is made after occurrence of a cerebral ischemic event or during an angiologic examination, mainly using Doppler/Duplex-sonography." | 2.42 | [Carotid stenosis: diagnosis, patient selection, therapy]. ( Barth, A, 2003) |
| "Aspirin has been studied and used most extensively." | 2.42 | Role of antiplatelet drugs in the prevention of cardiovascular events. ( Tendera, M; Wojakowski, W, 2003) |
| "Aspirin has been the first-line agent for stroke prevention for a long time." | 2.42 | Aggrenox((R)) versus other pharmacotherapy in preventing recurrent stroke. ( Redman, AR; Ryan, GJ, 2004) |
| "Pravastatin has a predominantly delayed antiatherogenic effect, and aspirin has an immediate antiplatelet effect, raising the possibility of additive clinical benefits." | 2.42 | Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses. ( Belder, R; Berry, DA; Berry, SM; Byington, RP; Fiedorek, FT; Ford, NF; Hennekens, CH; Jukema, JW; Natarajan, K; Pitt, B; Sacks, FM; Sheng-Lin, C; Tonkin, A; Walker, AJ, 2004) |
| "Stroke is the most feared complication of atrial fibrillation, and the risk of stroke increases markedly with age." | 2.42 | Trials of newer approaches to anticoagulation in atrial fibrillation. ( Cooper, HA, 2004) |
| "Patients with paroxysmal atrial fibrillation have a risk of thromboembolic complications probably equivalent to those with permanent atrial fibrillation." | 2.42 | [Anticoagulation therapy in paroxysmal atrial fibrillation]. ( Gjesdal, K; Risøe, C, 2004) |
| "Aspirin is the treatment of choice for stroke prevention in patients who do not require anticoagulation." | 2.42 | Transient ischemic attacks: Part II. Treatment. ( Solenski, NJ, 2004) |
| "Vascular dementia is one of the most frequently occurring dementia syndromes." | 2.42 | [Vascular dementia]. ( de Leeuw, FE; van Gijn, J, 2004) |
| "Aspirin treatment does not preclude control of underlying and comorbid conditions such as diabetes mellitus, hypertension, and dyslipidemia." | 2.41 | Aspirin in the prophylaxis of coronary artery disease. ( Mehta, P, 2002) |
| "Stroke is a major cause of morbidity and mortality." | 2.41 | A benefit-risk assessment of agents used in the secondary prevention of stroke. ( MacWalter, RS; Shirley, CP, 2002) |
| "Aspirin reduced all-cause mortality by 18%." | 2.41 | Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. ( Graham, DY; Weisman, SM, 2002) |
| "Patients suffering from a transient ischemic attack or stroke are particularly vulnerable to subsequent stroke." | 2.41 | Update on antiplatelet therapy for stroke prevention. ( Elkind, MS; Sacco, RL, 2000) |
| "Aspirin has a modest effect on reducing stroke." | 2.41 | [Antithrombotic therapy for stroke prevention in patients with atrial fibrillation]. ( Kitabatake, A; Kohya, T; Tomita, F, 2000) |
| "Stroke is the third most common cause of adult mortality in the United States." | 2.41 | Antithrombotic drugs for secondary stroke prophylaxis. ( Pettigrew, LC, 2001) |
| "Aspirin is a more potent inhibitor of Cox-1 than of Cox-2, unlike other non-steroidal anti-inflammatory drugs (NSAIDs), which have limited selectivity." | 2.41 | Vascular biology of thrombosis: platelet-vessel wall interactions and aspirin effects. ( Catella-Lawson, F, 2001) |
| "Aspirin has also demonstrated a potential ability to reduce the risk of deep venous thrombosis and pulmonary embolism." | 2.41 | An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I. ( Moyad, MA, 2001) |
| "Stroke is the third leading cause of death in the United States." | 2.41 | Antiplatelet therapy in secondary stroke prevention. ( Crawford, KM; Talbert, RL, 2001) |
| "Stroke is the third most common cause of adult mortality in the United States." | 2.41 | Antithrombotic drugs for prevention of recurrent stroke. ( Pettigrew, LC; Williams, SC, 2002) |
| "Four patients presented transient ischemic attacks, one amaurosis fugax, two suffered from a minor stroke, four had non-focalized ischemic cerebral symptoms and two were asymptomatic." | 2.40 | Fibromuscular dysplasia of the internal carotid artery. Personal experience with 13 cases and literature review. ( Limet, R; Sakalihasan, N; Van Damme, H, 1999) |
| "This review of the effectiveness of treatment for acute stroke and methods of secondary prevention shows that the highest priority for providers of a stroke service must be to establish a stroke unit and multidisciplinary team that delivers organised stroke care." | 2.40 | Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. ( Hankey, GJ; Warlow, CP, 1999) |
| "The therapeutic outcomes for acute ischemic stroke (AIS) with early neurological deterioration (END) are adverse." | 1.91 | Efficacy and Prognosis of Adjuvant Argatroban Treatment in Acute Ischemic Stroke Patients with Early Neurological Deterioration. ( Wu, T; Xu, S; Xu, Z; Zhang, W; Zhang, Y, 2023) |
| "Death, stroke, and device-related thrombus were also similar; major bleeding was slightly increased in DOAC/aspirin patients (DAPT = 2." | 1.91 | DAPT Is Comparable to OAC Following LAAC With WATCHMAN FLX: A National Registry Analysis. ( Allocco, DJ; Coylewright, M; Freeman, JV; Gibson, DN; Holmes, DR; Hsu, JC; Kapadia, SR; Nair, DG; Piccini, JP; Price, MJ; Yeh, RW, 2023) |
| "Aspirin nanoparticles were formulated in this study which may offer better therapeutic advantages over the conventional aspirin tablets in the prevention and management of acute myocardial infarction and ischaemic stroke." | 1.91 | Formulation of aspirin nanoparticles using solvent evaporation method and in vivo evaluation of its antithrombotic effect. ( Alhajj, L; Ovenseri Airemwen, C; Pozharani, LB, 2023) |
| "Although acute stroke is also relatively common in this population, two thirds of strokes are already evident on admission." | 1.72 | Imaging analysis of ischemic strokes due to blunt cerebrovascular injury. ( Abraham, MN; Abraham, PJ; Black, JA; Griffin, RL; Harrigan, MR; Holcomb, JB; Jansen, JO; Kerby, JD; Liptrap, EJ; Thaci, B, 2022) |
| "In multivariable Cox frailty regression, the adjusted risk of any adverse event through the 45-day follow-up visit were significantly lower for discharge on warfarin alone (HR: 0." | 1.72 | Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation. ( Curtis, JP; Daimee, UA; Doshi, SK; Du, C; Freeman, JV; Friedman, DJ; Gibson, D; Goldsweig, AM; Higgins, AY; Masoudi, FA; Minges, KE; Pereira, L; Price, MJ; Reddy, VY; Varosy, PD; Wang, Y, 2022) |
| " Dose-response and therapeutic window were investigated." | 1.72 | Synergistic Neuroprotection by a PAF Antagonist Plus a Docosanoid in Experimental Ischemic Stroke: Dose-Response and Therapeutic Window. ( Bazan, NG; Belayev, L; Khoutorova, L; Mukherjee, PK; Obenaus, A; Oria, RB; Petasis, NA; Reid, MM; Roque, CR, 2022) |
| "Aspirin prescription was associated with a reduced risk." | 1.72 | Long term survival after a first transient ischaemic attack in England: A retrospective matched cohort study. ( Bakbergenuly, I; Brown, B; Chutoo, P; Kulinskaya, E; Pchejetski, D; Steel, N, 2022) |
| "In Warfarin group lower educational status was associated with poor self-management; in Aspirin group, comorbidities and age < 65 years (P = ." | 1.72 | A descriptive cross-sectional study of self-management in patients with nonvalvular atrial fibrillation. ( Li, C; Liu, T; Shen, Q; Zhang, C; Zhang, Z; Zhu, H, 2022) |
| "VWF is critically involved in thrombus formation at sites of stenotic extracranial/intracranial arteries." | 1.62 | The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients. ( Buchtele, N; Gelbenegger, G; Gilbert, JC; Greisenegger, S; Jilma, B; Kovacevic, KD; Langer, A; Pabinger, I; Petroczi, K; Zhu, S, 2021) |
| " Patients received alternative drug dosing or antiplatelet agents other than clopidogrel only if this was prescribed for another diagnosis or they had a preexisting contraindication." | 1.62 | Comparison of Aspirin Monotherapy versus Dual Antiplatelet Therapy Following Coronary Artery Bypass Grafting. ( Hess, NR; Kilic, A; Sultan, I; Thoma, F; Wang, Y, 2021) |
| "Platelet thrombosis is the main pathogeny resulting in the low curability of ischemic stroke, a leading cause of mortality and disability worldwide." | 1.56 | Novel potent antiplatelet thrombotic agent derived from biguanide for ischemic stroke. ( Chen, Z; He, Y; Huang, W; Ji, C; Lee, KH; Li, S; Li, Y; Ming, Y; Morris-Natschke, SL; Niu, H; Wei, Z; Xin, G; Xing, Z; Yang, X; Yu, K; Zhang, B; Zhang, J; Zhang, X, 2020) |
| "We present a case of Broca aphasia that was initially interpreted as confusion." | 1.56 | Confusion vs Broca Aphasia: A Case Report. ( Wang, R; Wiley, C, 2020) |
| " Concomitant administration of single-dose DS-1040 with multiple-dose aspirin, multiple-dose clopidogrel, or single-dose enoxaparin, consistent with clinically relevant dose regimens, was safe and well tolerated with no serious treatment-emergent adverse events (TEAEs), TEAEs leading to discontinuation, bleeding-related TEAEs, and no significant changes in coagulation parameters." | 1.56 | Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin. ( Dishy, V; Kobayashi, F; Kochan, J; Limsakun, T; McPhillips, P; Mendell, J; Orihashi, Y; Pav, J; Pizzagalli, F; Rambaran, C; Vandell, AG; Warren, V; Zhou, J, 2020) |
| "The majority presented with recurrent transient ischemic attacks/minor strokes within a single vascular territory over days to weeks." | 1.56 | Focal Cerebral Arteriopathy in Young Adult Patients With Stroke. ( Cronin, S; Fanning, N; McKenna, MC, 2020) |
| "Neonatal ischemic stroke has a higher incidence than childhood stroke." | 1.56 | Preventive Effects of Neuroprotective Agents in a Neonatal Rat of Photothrombotic Stroke Model. ( Choi, SG; Kang, JW; Kim, DW; Kim, SK; Shin, HJ; Song, HJ; Yi, YY, 2020) |
| "Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) can be the only option for complete revascularization in some patients with diffuse coronary artery disease." | 1.56 | Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study. ( Feng, W; Song, Y; Tiemuerniyazi, X; Xu, F; Yan, H, 2020) |
| "After adjustment, 3-month DAPT was not inferior to longer DAPT after BP-SES implantation in terms of net adverse clinical events." | 1.56 | 1-Year Safety of 3-Month Dual Antiplatelet Therapy Followed by Aspirin or P2Y ( Ako, J; Hibi, K; Hioki, H; Hirohata, A; Ikari, Y; Ito, Y; Kinoshita, Y; Kozuma, K; Morino, Y; Nakagawa, Y; Nanasato, M; Shiode, N; Sonoda, S; Tanabe, K; Yamaguchi, J, 2020) |
| "TAT under TEG guidance appears to be a safe antiplatelet strategy in patients undergoing stenting for extracranial and/or intracranial artery stenosis." | 1.51 | The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease. ( Jiang, WJ; Li, C; Liu, AF; Qiu, H; Wang, K; Wu, Z; Zhang, Y; Zhou, J, 2019) |
| "Twenty-and-a-half syndrome is reported for the first time." | 1.51 | Twenty-and-a-half syndrome: a case report. ( Chouksey, D; Dani, R; Dube, M; Dubey, A, 2019) |
| "Primary delusional parasitosis is a psychiatric disorder with the delusion as an isolated manifestation, whereas secondary delusional parasitosis is a delusion occurring secondary to a psychiatric disorder, substance use, or medical illness." | 1.51 | Delusional parasitosis as presenting symptom of occipital lobe cerebrovascular accident. ( Haas, MRC; Haas, NL; Nicholson, A, 2019) |
| "To identify the ischemic stroke and transient ischemic attack (TIA) prevalence related to length of time of discontinuation of antiplatelet or vitamin K antagonist therapy, in a group of inpatients from a specialized neurological hospital in Brazil." | 1.51 | Stroke and transient ischemic attacks related to antiplatelet or warfarin interruption. ( Kowacs, PA; Macuco, ALB; Nascimento, MTMS; Rizelio, V; Sato, HK; Souza, RKM, 2019) |
| "Aspirin resistance was evaluated in aspirin-treated patients from the outpatient department." | 1.48 | PFA-100-measured aspirin resistance is the predominant risk factor for hospitalized cardiovascular events in aspirin-treated patients: A 5-year cohort study. ( Chen, HY; Chou, P, 2018) |
| "Although depressive disorders have been associated with increased risk of worse outcomes with cardiovascular diseases (CVDs), its relation with access to and quality of cardiovascular care is not well studied." | 1.48 | Impact of Depressive Disorder on Access and Quality of Care in Veterans With Prevalent Cardiovascular Disease. ( Butler, J; Lacey, M; Parikh, PB; Shroyer, AL; Srivastava, P, 2018) |
| "Post-LVAD strokes are an important cause of morbidity and reduced quality of life." | 1.48 | Cerebrovascular Accidents During Mechanical Circulatory Support: New Predictors of Ischemic and Hemorrhagic Strokes and Outcome. ( Ahmed, FS; Akbik, F; Feske, SK; Givertz, MM; Izzy, S; Renault, S; Rubin, DB; Smallwood, JA; Sylvester, KW; Vaitkevicius, H, 2018) |
| "A 37-year-old woman with idiopathic thrombocytopenic purpura (ITP) suffered from multiple trauma scheduled for open reduction and internal fixation for right tibial and left radius fracture five days after SAE." | 1.48 | Bilateral visual loss and cerebral infarction after spleen embolization in a trauma patient with idiopathic thrombocytopenic purpura: A case report. ( Chen, JY; Hung, KC; Lan, KM; Li, YY; Lin, WC; Sun, CK; Wang, WT, 2018) |
| "The participants were 5,696 adults with COPD with a first myocardial infarction (n = 2,850) or ischemic stroke (n = 3,010) and at least one acute exacerbation from the UK Clinical Practice Research Datalink with linked Hospital Episodes Statistics data." | 1.48 | Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic Obstructive Pulmonary Disease. ( Connell, O; Douglas, I; Müllerová, H; Pearce, N; Quint, JK; Rothnie, KJ; Smeeth, L, 2018) |
| " Major adverse cardiac and cerebrovascular events (MACCE) [death, myocardial infarction (MI), stroke, and unplanned reintervention] and thrombolysis in myocardial infarction (TIMI) bleeding (major/minor) were registered during hospitalization and follow-up." | 1.48 | Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction. ( Dannenberg, L; Dimitroulis, D; Golabkesh, M; Helten, C; Jung, C; Kelm, M; Knoop, B; Naguib, D; Pöhl, M; Polzin, A; Zeus, T, 2018) |
| "A one-dose-fits-all approach to use of aspirin has yielded only modest benefits in long-term prevention of cardiovascular events, possibly due to underdosing in patients of large body size and excess dosing in patients of small body size, which might also affect other outcomes." | 1.48 | Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. ( Belch, JFF; Cook, NR; Gaziano, JM; Mehta, Z; Morimoto, T; Price, JF; Roncaglioni, MC; Rothwell, PM, 2018) |
| "Cryptogenic stroke is a cerebral infarction where no source of cardioembolic events, no microangiopathy with lacunar infarcts, and no macroangiopathy with high-grade stenosis of the cerebral arteries can be detected." | 1.48 | [Ten key messages regarding embolic stroke of undetermined source and cryptogenic stroke]. ( Böttger, P; Buerke, M; Grond, M; Lemm, H, 2018) |
| "Stroke recurrence and mortality rates in patients receiving aspirin (N=34 679) were compared with those receiving clopidogrel (N=7611) during a 12-month follow-up period." | 1.48 | Comparison Between Aspirin and Clopidogrel in Secondary Stroke Prevention Based on Real-World Data. ( Chang, WL; Chen, CH; Chi, NF; Hsu, CY; Hu, CJ; Jeng, JS; Li, JY; Lien, LM; Lin, CH; Liu, CH; Sun, Y; Wen, CP, 2018) |
| "Aspirin use was updated at each clinic visit and considered as a time-varying covariate." | 1.46 | Aspirin and the risk of cardiovascular events in atherosclerosis patients with and without prior ischemic events. ( Bavry, AA; Bhatt, DL; Elbez, Y; Elgendy, IY; Mahmoud, AN; Sorbets, E; Steg, PG, 2017) |
| "Hemorrhagic stroke is not the only complication of thrombolysis, ischemic stroke can occur even if it is an extremely rare complication." | 1.46 | Ischemic stroke complicating thrombolytic therapy with tenecteplase for ST elevation myocardial infarction: two case reports. ( Arous, S; Bentaoune, T; El Ghali Benouna, M; Habbal, R; Haboub, M, 2017) |
| "Ischaemic stroke is a very uncommon, but severe complication of cisplatin-based chemotherapy." | 1.46 | Internal carotid artery occlusion and stroke as a complication of cisplatin-based chemotherapy for metastatic testicular germ cell tumour. ( Azam, M; Cerrud-Rodriguez, RC; Quinteros, MG, 2017) |
| ": A huge thrombus, developing after percutaneous left atrial appendage occlusion, has been successfully treated with dabigatran and aspirin as combination therapy." | 1.46 | Thrombosis on a left atrial appendage occluder device: the double-edged sword of stroke prevention strategies in atrial fibrillation. ( Baldi, M; Ciconte, G; Conti, M; Pappone, C; Saviano, M; Vicedomini, G, 2017) |
| "Given the high risk of stroke recurrence, antiplatelets followed by anticoagulation for secondary prevention were initiated." | 1.46 | Isolated left ventricular non-compaction (LVNC) and recurrent strokes: to anticoagulate or not to anticoagulate, that is the question. ( Abubakar, H; Hassan, AAI; Ibrahim, W; Subahi, A, 2017) |
| "Strokes were not observed in compliant patients who responded to antiplatelet agents." | 1.46 | Antiplatelet Therapy for Long-Term Management of Patients with Mechanical Aortic Prostheses. ( Bermúdez, D; Galera, Á; Garcia Rinaldi, R; Quinones, J; Quinones, S; Rodriguez-Acosta, J, 2017) |
| "Treatment with aspirin alone [hazard ratio (HR), 0." | 1.46 | Efficacy of aspirin and statins in primary prevention of cardiovascular mortality in uncomplicated hypertensive participants: a Korean national cohort study. ( Choi, D; Kang, SM; Kim, HC; Lee, CJ; Lee, SH; Oh, J; Park, S, 2017) |
| "Aspirin therapy was administered in all the 11 study hospitals." | 1.46 | Towards best practice in acute stroke care in Ghana: a survey of hospital services. ( Aikins, AD; Baatiema, L; Coombes, J; Mnatzaganian, G; Otim, M; Somerset, S, 2017) |
| "All the patients presented with carotid artery stenosis >70% (North American Symptomatic Carotid Endarterectomy Trial [NASCET] criteria), which was symptomatic in 42 patients (transient ischemic attack, n = 32; minor stroke, n = 10) and asymptomatic in 146." | 1.46 | Dual Antiplatelet Therapy Does Not Increase the Risk of Bleeding After Carotid Endarterectomy: Results of a Prospective Study. ( Calio', FG; Illuminati, G; Masci, F; Pizzardi, G; Ricco, JB; Schneider, F, 2017) |
| "The early recurrence of neurological symptoms (NR) after urgent aggressive best medical therapy (BMT) in symptomatic carotid stenosis is not well documented." | 1.43 | Risk of early recurrent stroke in symptomatic carotid stenosis after best medical therapy and before endarterectomy. ( Ellemann, K; Gottschalksen, B; Owen-Falkenberg, A; Shahidi, S, 2016) |
| "Aspirin resistance was measured by the PFA-100 system (collagen/epinephrine cartridge) and glycoprotein IIIa P1A1/A2 polymorphism was determined by PCR." | 1.43 | Aspirin resistance in cerebrovascular disease and the role of glycoprotein IIIa polymorphism in Turkish stroke patients. ( Ataç, BF; Bayraktar, N; Can, U; Çelikkol, C; Derle, E; Kibaroğlu, S; Öcal, R; Verdi, H, 2016) |
| "Rivaroxaban is an oral anticoagulant that acts as a direct, competitive factor Xa inhibitor." | 1.43 | Failure of old and new anticoagulants to prevent ischemic stroke in high-risk atrial fibrillation: a case report. ( Adamo, A; Bilora, F; Pomerri, F; Prandoni, P, 2016) |
| "Dual treatment with aspirin (5 mg kg(-1) ) and clopidogel (0." | 1.43 | A rabbit model of cerebral microembolic signals for translational research: preclinical validation for aspirin and clopidogrel. ( Chu, L; Desai, K; Gutstein, DE; Kurowski, S; Seiffert, D; Wang, X; Wu, W; Zhou, X, 2016) |
| "The major result events, included: (1) recurrence of ischemic stroke; (2) hemorrhagic transformation of ischemic stroke; (3) myocardial infarction; (4) the digestive hemorrhage." | 1.43 | [Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy]. ( Gao, P; Hu, YH; Tang, X; Wei, CL; Yang, C; Zhang, YQ, 2016) |
| "Minor stroke and transient ischemic attack are common disorders with high rate of subsequent disabling stroke." | 1.43 | High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome: Subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial. ( Li, J; Lin, J; Liu, L; Meng, X; Wang, A; Wang, C; Wang, Y; Zhao, X, 2016) |
| "In warfarin-treated patients, each 5% LVEF decrement significantly increased the stroke risk (adjusted hazard ratio, 1." | 1.43 | Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial. ( Anker, SD; Buchsbaum, R; Di Tullio, MR; Estol, CJ; Freudenberger, RS; Graham, S; Homma, S; Labovitz, AJ; Levin, B; Lip, GY; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Teerlink, JR; Thompson, JL, 2016) |
| "Aspirin (53." | 1.43 | Antithrombotic Medication Use and Misuse Among Patients with Intracranial Hemorrhage: A 16-Year, Lebanese, Single-Center Experience. ( Fahed, E; Ghauche, J; Maarrawi, J; Menassa-Moussa, L; Moussa, R; Nohra, G; Okais, N; Rahme, R; Rizk, T; Samaha, E, 2016) |
| "Stroke is the second largest cause of death worldwide." | 1.42 | Prospective evaluation of blood coagulability and effect of treatment in patients with stroke using rotational thromboelastometry. ( Evans, PA; Hawkins, K; Lawrence, M; Morris, RH; Potter, JF; Sabra, A; Stanford, SN; Storton, S; Wani, M; Williams, PR, 2015) |
| " With the exception of CVA, all adverse events were significantly higher in positive Tn T group as compared to negative Tn T group." | 1.42 | Relationship between Troponin Elevation, Cardiovascular History and Adverse Events in Patients with acute exacerbation of COPD. ( Campo, G; Ceconi, C; Contoli, M; Guerzoni, F; Malagù, M; Napoli, N; Papi, A; Pavasini, R; Punzetti, S, 2015) |
| "55% were treated in stroke unit (2% in INASC, p = 0." | 1.42 | Acute stroke unit improves stroke management-four years on from INASC. ( Cunningham, N; Keenan, R; Lyons, D; O'Connor, M; O'Malley, G; Peters, C; Shanahan, E, 2015) |
| "Stroke is the second largest cause of death worldwide." | 1.42 | The changes in clot microstructure in patients with ischaemic stroke and the effects of therapeutic intervention: a prospective observational study. ( Brown, MR; D'Silva, L; Davidson, SJ; Evans, PA; Evans, V; Hawkins, K; Lawrence, M; Morris, RH; Potter, JF; Sabra, A; Stanford, SN; Storton, S; Wani, M; Williams, PR, 2015) |
| "CABG had similar rates of cardiac death compared with PCI group (HR=0." | 1.42 | Clinical outcomes of multiple chronic total occlusions in coronary arteries according to three therapeutic strategies: Bypass surgery, percutaneous intervention and medication. ( Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Jang, WJ; Kim, BS; Kim, WS; Lee, SH; Lee, YT; Song, YB; Yang, JH, 2015) |
| "When aspirin was compared to no treatment, NCB was neutral or negative for both risk strata." | 1.42 | Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. ( Larsen, TB; Lip, GY; Nielsen, PB; Skjøth, F, 2015) |
| " Long-term use of aspirin plus clopidorel after CAS did not decrease the risk of ischemic stroke, composite vascular events, or death during 6 months of follow-up." | 1.42 | Is Extended Duration of Dual Antiplatelet Therapy After Carotid Stenting Beneficial? ( Huang, JY; Jhang, KM; Jian, ZH; Ku, WY; Liaw, YP; Nfor, ON; Tung, YC, 2015) |
| "Oral anticoagulation is the recommended treatment for stroke prevention in patients with atrial fibrillation." | 1.40 | Atrial fibrillation patients do not benefit from acetylsalicylic acid. ( Friberg, L; Själander, A; Själander, S; Svensson, PJ, 2014) |
| "Stroke is the major cause of death and decrease in the activities of daily living." | 1.40 | Neurovascular protection of cilostazol in stroke-prone spontaneous hypertensive rats associated with angiogenesis and pericyte proliferation. ( Abe, K; Deguchi, K; Ikeda, Y; Kono, S; Kurata, T; Liu, N; Liu, W; Omote, Y; Yamashita, T, 2014) |
| "Ischemic stroke is a fairly common complication after an AMI in patients with diabetes mellitus, but the risk of stroke has decreased during recent years." | 1.40 | Risk of ischemic stroke after an acute myocardial infarction in patients with diabetes mellitus. ( Bergström, L; Björklund, F; Jakobsson, S; Jernberg, T; Mooe, T; Söderström, L, 2014) |
| "Stroke is a traumatic complication in sickle cell anaemia (SCA) that is associated with significant morbidity and a risk of recurrent overt stroke of 2·2-6·4 events per 100 patient-years." | 1.40 | Outcome of overt stroke in sickle cell anaemia, a single institution's experience. ( Forsythe, A; Gordon, C; Iyer, R; Khan, M; Majumdar, S; Megason, G; Miller, M; Smith, MG, 2014) |
| "We described the cardioembolic (Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack [CHADS2]/Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack, Vascular disease, Age 65-75, Sex category i." | 1.40 | Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey. ( Crijns, HJ; Iorio, A; Lip, GY; Marcucci, M; Nieuwlaat, R; Pisters, R, 2014) |
| "adults have a heart attack or stroke, resulting in approximately 30 deaths every hour and, for nonfatal events, often leading to long-term disability." | 1.40 | Million hearts: prevalence of leading cardiovascular disease risk factors--United States, 2005-2012. ( George, MG; Gillespie, C; Jamal, A; Ritchey, MD; Wall, HK, 2014) |
| "Twenty-two cases of childhood bacterial meningitis complicated by stroke were identified." | 1.40 | Antithrombotic therapy for secondary stroke prevention in bacterial meningitis in children. ( Askalan, R; Bjornson, B; Boelman, C; deVeber, G; MacGregor, D; Moharir, M; Richrdson, S; Shroff, M; Yau, I, 2014) |
| "Giant cell arteritis is a common cause of headache in patients aged more than 50 years." | 1.40 | A stroke of bad luck. ( Joshi, Y; Nagasayi, S; White, S, 2014) |
| "Stroke is an important clinical problem and some strokes are caused by a cardiac thrombus." | 1.39 | 64-MDCT can depict the thrombi expanded from the left lower pulmonary vein to the left atrium in the patient with angina pectoris. ( Takeuchi, H, 2013) |
| "In selected low TE risk patients undergoing ablation for AF, a short period of periprocedural therapeutic anticoagulation with LMWH together with aspirin is an effective and safe strategy to prevent TE events." | 1.39 | Catheter ablation of atrial fibrillation in patients at low thrombo-embolic risk: efficacy and safety of a simplified periprocedural anticoagulation strategy. ( Acena, M; Berte, B; Bun, SS; De Meyer, G; Duytschaever, M; Tavernier, R; Van Heuverswyn, F; Vandekerckhove, Y, 2013) |
| "While a stroke or transient ischemic attack or history of systemic thromboembolism was detected in 15." | 1.39 | Epidemiology of atrial fibrillation in Turkey: preliminary results of the multicenter AFTER study. ( Acar, G; Akıl, MA; Arıbaş, A; Aydın, M; Bilik, MZ; Bulur, S; Cağlıyan, CE; Ergene, O; Ertaş, F; Gedik, S; Gül, M; Kahya Eren, N; Kanadaşı, M; Kaya, H; Kaya, Z; Köroğlu, B; Köse, N; Oylumlu, M; Ozhan, H; Simşek, Z; Ulgen, MS; Vatan, B; Yeter, E; Yıldız, A; Yılmaz, R; Yüksel, M, 2013) |
| "Aspirin is an essential component of peri-PCI pharmacotherapy." | 1.39 | The clinical outcomes of percutaneous coronary intervention performed without pre-procedural aspirin. ( Aronow, HD; Gurm, HS; Kenaan, M; Seth, M; Share, D; Wohns, D, 2013) |
| "Stroke is the second leading cause of death." | 1.39 | Neuroprotective effect of a new synthetic aspirin-decursinol adduct in experimental animal models of ischemic stroke. ( Ahn, JH; Cho, JH; Choi, JH; Her, S; Hwang, IK; Hyun, BH; Jun, JG; Kim, CK; Kim, IH; Kim, JS; Kim, YM; Kwon, SH; Kwon, YG; Lee, CH; Lee, JC; Lee, YL; Park, JH; Shin, BN; Suh, HW; Won, MH; Yan, BC; Yoo, KY, 2013) |
| "In the Asymptomatic Carotid Artery Stenosis trial (1995), medical management was defined as aspirin in addition to adequate control of comorbidities." | 1.39 | Efficacy of contemporary medical management for asymptomatic carotid artery stenosis. ( Ahn, JE; Chang, J; Chun, L; Landsman, N; Patel, KK; Rhee, K, 2013) |
| "About 80% of strokes are ischaemic." | 1.39 | Antithrombotic drugs and ischaemic stroke. ( , 2013) |
| "Aspirin resistance was more common in patients with MES (50% compared to 17." | 1.38 | Microembolic signals and aspirin resistance in patients with carotid stenosis. ( Dawson, J; Lees, KR; Quinn, T; Walters, MR, 2012) |
| "270 patients (93 with deep vein thrombosis (DVT) or pulmonary embolism (PE), and 177 with non-haemorrhagic stroke (cerebrovascular accident (CVA)) admitted between January 2006 and December 2010 with a discharge diagnosis of either DVT, PE or CVA, who had LAC and antiphospholipid antibodies measured within 6 months from their index admission." | 1.38 | High antiphospholipid antibody levels are associated with statin use and may reflect chronic endothelial damage in non-autoimmune thrombosis: cross-sectional study. ( Broder, A; Putterman, C; Tobin, JN, 2012) |
| "Stroke is a second cause of mortality worldwide and a leading cause of acquired disability in adults." | 1.38 | [Ulcerated plaques of the aorta as a cause of ischaemic stroke]. ( Hoffman, P; Kowalski, M; Michałowska, I; Rybicka, J, 2012) |
| "The risk for preeclampsia increased in patients who were positive for multiple antiphospholipid antibodies (aPL) (odds ratio (OR) 3." | 1.38 | Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study. ( Brinks, R; Fischer-Betz, R; Schneider, M; Specker, C, 2012) |
| "Warfarin treatment was associated with a decreased risk of stroke or systemic thromboembolism among patients with chronic kidney disease, whereas warfarin and aspirin were associated with an increased risk of bleeding." | 1.38 | Stroke and bleeding in atrial fibrillation with chronic kidney disease. ( Gislason, GH; Hommel, K; Kamper, AL; Køber, L; Lane, DA; Lindhardsen, J; Lip, GY; Olesen, JB; Torp-Pedersen, C, 2012) |
| "Aspirin (ASA) has been shown to reduce postoperative coronary artery bypass grafting (CABG) mortality and ischemic events; however, the timing of chronic ASA discontinuation before surgery is controversial because of concern about postoperative bleeding." | 1.37 | Effect of timing of chronic preoperative aspirin discontinuation on morbidity and mortality in coronary artery bypass surgery. ( Blackstone, E; Cho, L; Jacob, M; Smedira, N; Williams, S, 2011) |
| "An acute spontaneous spinal epidural hematoma (SSEH) is a rare spinal pathology." | 1.37 | Relapsed spontaneous spinal epidural hematoma associated with aspirin and clopidogrel. ( Cho, YR; Hong, BY; Kim, HS; Kim, HW; Ko, YJ; Lee, JI; Lim, SH, 2011) |
| "Secondary outcomes included stroke, congestive heart failure, and myocardial infarction." | 1.37 | Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. ( Albert, CM; Buring, JE; Chae, CU; Conen, D; Everett, BM; Glynn, RJ; Tedrow, UB, 2011) |
| "Cerebral infarction associated with ulcerative colitis is particularly rare, but clinically important because of its high morbidity and mortality." | 1.37 | Recurrent ischemic stroke in a patient with ulcerative colitis and high levels of lipoprotein (a). ( Bramanti, P; Calabrò, RS; Gervasi, G; Pezzini, A; Pollicino, P, 2011) |
| "Incidence of postoperative hemorrhage (early and delayed) was not significant (P = ." | 1.37 | Stopping anticoagulation before TURP does not appear to increase perioperative cardiovascular complications. ( Bariol, SV; Brooks, AJ; Drummond, M; Lau, HM; McDonald, C; Patel, MI; Raj, MD; Wang, AC; Woo, HH, 2011) |
| "The primary outcome was first recurrence of stroke of any type and the secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes." | 1.37 | Level of systolic blood pressure within the normal range and risk of recurrent stroke. ( Bath, PM; Cotton, D; Diener, HC; Donnan, GA; Martin, RH; Ovbiagele, B; Vinisko, R; Yusuf, S, 2011) |
| "We assessed the safety of thrombolysis under APs in 11,865 patients compliant with the European license criteria and recorded between 2002 and 2007 in the Safe Implementation of Treatments in Stroke (SITS) International Stroke Thrombolysis Register (SITS-ISTR)." | 1.36 | Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. ( Ahmed, N; Diedler, J; Ford, GA; Lees, KR; Luijckx, GJ; Overgaard, K; Ringleb, P; Soinne, L; Sykora, M; Uyttenboogaart, M; Wahlgren, N, 2010) |
| "Aspirin use was reported in 50% of patients: 68." | 1.36 | Aspirin use in elderly women receiving medication therapy management services. ( Cooke, CE; Lee, HY; Tong, YP; Xing, S, 2010) |
| "Wepfer's category of 'serous apoplexy' assumed that extravasation of blood serum might lead to compression of brain substance and blockage of 'nerve pores' through which mental 'spirit' was supposed to flow." | 1.36 | Facts versus theories: an everlasting struggle. The Johann Jakob Wepfer Award 2010. ( van Gijn, J, 2010) |
| "Giant cell arteritis (GCA) or temporal arteritis (TA) with polymyalgia rheumatica (PMR) is among the most common reasons for long-term steroid prescription." | 1.36 | Concise guidance: diagnosis and management of giant cell arteritis. ( Dasgupta, B, 2010) |
| " New and emerging oral alternatives to warfarin promise to combine the advantages of oral dosing and effective anticoagulation with improvements in safety, leading to reduced monitoring and dose adjustment." | 1.36 | A pharmacoeconomic perspective on stroke prevention in atrial fibrillation. ( Fendrick, AM, 2010) |
| " In these patients, we recommend use of the combination of aspirin and extended-release dipyridamole (25/200 mg bid) over aspirin (Grade 1A) and suggest clopidogrel over aspirin (Grade 2B), and recommend avoiding long-term use of the combination of aspirin and clopidogrel (Grade 1B)." | 1.35 | Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). ( Albers, GW; Amarenco, P; Easton, JD; Sacco, RL; Teal, P, 2008) |
| "Syphilis is a treatable condition, screening in pregnancy is both cost effective and cost beneficial." | 1.35 | Stroke in pregnancy associated with syphilis. ( Baker, PN; Bowring, J; Mahto, M; Mandal, D, 2008) |
| "Ischemic stroke was reported in 57." | 1.35 | [Secondary prevention with clopidogrel or acetylsalicylic acid after acute cerebrovascular event. Health services research study of private primary care specialists]. ( Diehm, C; Köfüncü, E; Pittrow, D; Sander, D; Schwertfeger, M, 2008) |
| "None experienced strokes or transient ischemic attacks." | 1.35 | Low incidence of neurologic events during long-term support with the HeartMate XVE left ventricular assist device. ( Dia, M; Gallagher, C; Silver, MA; Slaughter, MS; Sobieski, MA, 2008) |
| "Despite aspirin's established role in the treatment of atherosclerotic vascular disease, considerable controversy exists regarding its most effective dosing strategy." | 1.35 | Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial). ( Amarenco, P; Aronow, HD; Califf, RM; Davis, S; Diener, HC; Easton, JD; Ferguson, J; Fitzgerald, DJ; Graffagnino, C; Harrington, RA; Koudstaal, PJ; Shuaib, A; Theroux, P; Topol, EJ; Vallee, M; Van de Werf, F, 2008) |
| "Stroke is an important outcome in cerebrovascular disease trials in the elderly, but it may be trumped by coronary heart disease as a more common end point." | 1.35 | Challenges of designing trials for the primary prevention of stroke. ( Gorelick, PB, 2009) |
| "Combined carotid stenting and cardiac surgery, performed in the same operating room under only heparin and aspirin, seems a safe and effective strategy for the treatment of patients with concomitant carotid and cardiac disease." | 1.35 | Safety and effectiveness of combining carotid artery stenting with cardiac surgery: preliminary results of a single-center experience. ( Capuano, F; Faraglia, V; Palombo, G; Rizzo, L; Sinatra, R; Stella, N; Taurino, M, 2009) |
| "Age and left bundle branch block were strong negative predictors for early reperfusion therapy in patients with prior antithrombotic treatment." | 1.35 | Impact of chronic antithrombotic therapy on hospital course of patients with acute myocardial infarction. ( Bauer, T; Bestehorn, K; Gitt, A; Jünger, C; Koeth, O; Senges, J; Towae, F; Zahn, R; Zeymer, U, 2009) |
| "Aspirin use was associated with a lower risk of cardiovascular events (adjusted hazard ratio, 0." | 1.35 | Aspirin use, dose, and clinical outcomes in postmenopausal women with stable cardiovascular disease: the Women's Health Initiative Observational Study. ( Berger, JS; Brown, DL; Burke, GL; Kostis, JB; Langer, RD; Oberman, A; Wassertheil-Smoller, S; Wong, ND, 2009) |
| "Although intracerebral hemorrhage (ICH) has been described in patients with CADASIL, the cause of such ICH is still unknown." | 1.35 | Aspirin-associated intracerebral hemorrhage in a patient with CADASIL. ( Choi, JC; Kang, JH; Kang, SY; Lee, JS; Oh, JH, 2008) |
| "Stroke is associated with elevation of several proinflammatory cytokines such as tumor necrosis factor alpha (TNF-alpha) and interleukin (IL)-8 that are correlated with central nervous system (CNS) injury." | 1.34 | TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents. ( Al-Bahrani, A; Bakhiet, M; Shaath, H; Taha, S, 2007) |
| "Embolism is a dreaded complication of infective endocarditis (IE)." | 1.34 | Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis. ( Anavekar, NS; Baddour, LM; Chandrasekaran, K; Haddad, C; Khandaker, MH; Mirzoyev, Z; Steckelberg, JM; Tleyjeh, IM; Wilson, WR, 2007) |
| "A temporary middle cerebral artery occlusion (tMCAO) model was used in 80 Wistar rats to evaluate whether a high dose of Aspirin (40 mg/kg) applied with different initiation time points after stroke onset (30 min, 3 h, 6 h, 12 h, 20 rats for each time group) and followed by repeated administration (1, 2 and 3 days) is neuroprotective." | 1.34 | Neuroprotection by early and delayed treatment of acute stroke with high dose aspirin. ( Berger, C; Grau, A; Schwab, S; Zheng, Z, 2007) |
| "Patients with transient ischemic attack (TIA) or ischemic stroke carry a risk of recurrent stroke of between 5% and 20% per year." | 1.33 | Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling? ( Diener, HC, 2006) |
| "The cumulative 10 year mortality and recurrence rate were 92." | 1.33 | Efficacy of anticoagulation for secondary stroke prevention in older people with non-valvular atrial fibrillation: a prospective case series study. ( Manios, E; Peppes, V; Spengos, K; Tsivgoulis, G; Vemmos, K; Zakopoulos, N, 2005) |
| "The risk of stroke is reduced with primary PTCA (OR = 0." | 1.33 | Primary angioplasty in acute myocardial infarction: Hypothetical estimate of superiority over aspirin or untreated controls. ( Massel, D, 2005) |
| "The prognosis of traumatic dissection of the internal carotid artery is worse than for spontaneous dissections." | 1.33 | Endovascular stent-assisted angioplasty in the management of traumatic internal carotid artery dissections. ( Ben-Hur, T; Cohen, JE; Gomori, JM; Rajz, G; Umansky, F, 2005) |
| "Treatment with aspirin and ceftriaxone followed by trimethoprim-sulfamethoxazole resulted in a good neurological recovery and complete remission of the malabsorption syndrome." | 1.33 | A patient with cerebral Whipple's disease and a stroke-like syndrome. ( De Simone, C; Famularo, G; Minisola, G, 2005) |
| "(2) Aspirin has been tested in several placebo-controlled trials and has a positive risk-benefit balance, preventing about 5 deaths per 1000 patients with ischaemic stroke." | 1.33 | Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparin. ( , 2005) |
| "To report procedure-related complications and neurological adverse events of unprotected over-the-wire (OTW) and protected rapid exchange (RX) carotid artery stenting (CAS) in a single-center patient series during an 8-year period." | 1.33 | Procedure-related complications and early neurological adverse events of unprotected and protected carotid stenting: temporal trends in a consecutive patient series. ( Ahmadi, A; Amighi, J; Boltuch, J; Dick, P; Minar, E; Mlekusch, W; Sabeti, S; Schillinger, M; Schlager, O, 2005) |
| "However, the ratio of stroke to ischemic heart disease is still different between the East and West." | 1.33 | Regional differences in incidence and management of stroke - is there any difference between Western and Japanese guidelines on antiplatelet therapy? ( Shinohara, Y, 2006) |
| "Cryptogenic stroke is part of the disease of stress-induced cerebrovascular disease." | 1.33 | A new theory of cryptogenic stroke and its relationship to patent foramen ovale; or, the puzzle of the missing extra risk. ( Eggers, AE, 2006) |
| "Stroke is a major health problem worldwide." | 1.33 | Effects of policosanol on patients with ischemic stroke: a pilot open study. ( Alvarez, E; Fernández, JC; Fernández, L; Gámez, R; Illnait, J; Más, R; Mendoza, S; Ortega, LL; Sánchez, J, 2006) |
| "Poststroke recurrence rate was low (7." | 1.32 | Ischaemic stroke in young people: a prospective and long-term follow-up study. ( Carerj, S; Di Perri, R; Epifanio, A; Gallitto, G; Gangemi, S; Granata, A; La Spina, P; Leggiadro, N; Manganaro, A; Musolino, R; Tripodi, F, 2003) |
| "Aspirin treatment for primary prevention is safe and useful at an annual coronary event risk > or = 1." | 1.32 | [Anticoagulation and antiaggregation in cardiac patients]. ( Meyer, BJ, 2003) |
| "Two of the intracerebral hemorrhages occurred in the site where asymptomatic MBs were found at baseline." | 1.32 | Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke. ( Fan, YH; Lam, WW; Mok, VC; Wong, KS; Zhang, L, 2003) |
| " The drug's effect as well as adverse effects should be actively sought, and dosage alterations made in order to enhance the drug's effect." | 1.32 | Introduction to monitoring. What is what you prescribed actually doing? ( George, A; Shakib, S, 2003) |
| "Early administration of a combined regimen of clopidogrel and aspirin following off-pump CABG is safe and is associated with a relatively low incidence of major adverse cardiac events, bleeding, PE, and DVT." | 1.32 | A feasibility study of the safety and efficacy of a combined clopidogrel and aspirin regimen following off-pump coronary artery bypass grafting. ( Benhameid, O; Endo, M; Shennib, H, 2003) |
| " The lesser long-term pharmacodynamic potency of aspirin relative to clopidogrel raises the prospect of the need for more effective antiplatelet agents or a synergistic combination therapy for stroke prevention in the future." | 1.32 | Serial changes in platelet activation in patients after ischemic stroke: role of pharmacodynamic modulation. ( Chang, HW; Chang, YY; Chen, MC; Chen, SS; Chen, WH; Kao, YF; Lai, SL; Lan, MY; Liu, JS; Yip, HK, 2004) |
| "Stroke is a devastating complication in patients with prosthetic valves, but characterization of its late occurrence from a large cohort is lacking." | 1.32 | Late incidence and determinants of stroke after aortic and mitral valve replacement. ( Bédard, PJ; Goldstein, WG; Hendry, PJ; Masters, RG; Mesana, TG; Pipe, AL; Rubens, FD; Ruel, M, 2004) |
| "Hypertension was a more common risk factor in AS patients (69% AS patients vs." | 1.32 | Risk factors and in-hospital outcomes in stroke and myocardial infarction patients. ( Ivanusa, M; Ivanusa, Z, 2004) |
| "The prevalence of all VTE, proximal deep vein thrombosis (PDVT), and pulmonary embolism (PE) after 21 days were 40%, 18%, and 12%, increasing to 63%, 30%, and 20% in patients with Barthel indices (BI) of < or =9 2 days after stroke (BI-2< or =9)." | 1.32 | Venous thromboembolism after acute ischemic stroke: a prospective study using magnetic resonance direct thrombus imaging. ( Coshall, C; Hunt, BJ; Kelly, J; Lewis, RR; Moody, A; Rudd, A, 2004) |
| "Strokes were subtyped according to inferred mechanism." | 1.32 | Thrombin generation in non-cardioembolic stroke subtypes: the Hemostatic System Activation Study. ( Barzegar, S; Bauer, K; Costigan, T; Furie, KL; Kistler, JP; Mohr, JP; Rosenberg, R; Rosner, B; Sciacca, R; Thompson, JL; Thornell, B, 2004) |
| "Patients suffering from a transient ischemic attack (TIA) or ischemic stroke are at high risk of a recurrent stroke." | 1.32 | [Secondary prevention of stroke with antiplatelet drugs]. ( Diener, HC, 2004) |
| "Different approaches to treatment of acute stroke include restoring blood flow by thrombolysis, neuroprotection, and early secondary prevention with aspirin." | 1.32 | Acute stroke. ( Markus, H, 2003) |
| "Once stroke has occurred, it is not recommended to initiate an anticoagulation (unfractioned or low molecular weight heparin) within the first hours." | 1.31 | [Anticoagulation in permanent atrial fibrillation after 75 years of age]. ( Tilly-Gentric, A, 2002) |
| "Unfortunately, VBA transient ischemic attacks (TIAs) herald a lethal or devastating event within 5 years in 25 to 30% of patients." | 1.31 | Stent-assisted angioplasty of intracranial vertebrobasilar atherosclerosis: an initial experience. ( Barr, JD; Furlan, AJ; Katzan, I; Krieger, D; Markarian, GZ; Masaryk, TJ; Perl, J; Rasmussen, PA; Sila, C, 2000) |
| "Aspirin was used regularly by 37% of those with CVD and by 13% of those with risk factors only Adjusted odds of regular aspirin use were significantly greater for individuals with CVD than for those with one CVD risk factor (odds ratio [OR] = 4." | 1.31 | Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. ( Fagot-Campagna, A; Narayan, KM; Rolka, DB, 2001) |
| " It is indicated, at a dosage of 75 mg/day, for the reduction of atherosclerotic events including myocardial infarction, ischaemic stroke and vascular death in patients with atherosclerosis manifested by recent stroke, myocardial infarction or established peripheral vascular disease." | 1.31 | [Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)]. ( Scheen, AJ, 2001) |
| "Stroke is highly prevalent in long-term care." | 1.31 | Clinical correlates and drug treatment of residents with stroke in long-term care. ( Lapane, KL; Quilliam, BJ, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 32 (1.26) | 18.2507 |
| 2000's | 1019 (40.09) | 29.6817 |
| 2010's | 1132 (44.53) | 24.3611 |
| 2020's | 359 (14.12) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, Y | 6 |
| Jiang, J | 1 |
| Zhang, Z | 11 |
| Yu, P | 2 |
| Wang, L | 5 |
| Xu, C | 2 |
| Liu, W | 3 |
| Wang, Y | 121 |
| Zhang, G | 2 |
| Zhong, H | 2 |
| Du, J | 1 |
| Wu, J | 4 |
| Ling, J | 1 |
| Wang, X | 15 |
| Li, T | 4 |
| Liu, J | 3 |
| Lai, Y | 3 |
| Ji, H | 4 |
| Peng, S | 1 |
| Tian, J | 3 |
| Zhang, Y | 17 |
| Huang, Z | 4 |
| Wan, X | 1 |
| Xu, J | 11 |
| Sheng, X | 1 |
| Hua, K | 2 |
| Yang, C | 4 |
| Xin, G | 1 |
| Ming, Y | 1 |
| Ji, C | 1 |
| Wei, Z | 1 |
| Li, S | 3 |
| Morris-Natschke, SL | 1 |
| Zhang, X | 9 |
| Yu, K | 2 |
| Li, Y | 15 |
| Zhang, B | 5 |
| Zhang, J | 8 |
| Xing, Z | 1 |
| He, Y | 4 |
| Chen, Z | 7 |
| Yang, X | 7 |
| Niu, H | 1 |
| Lee, KH | 1 |
| Huang, W | 2 |
| Kitagawa, K | 5 |
| Anand, SS | 13 |
| Hiatt, W | 1 |
| Dyal, L | 7 |
| Bauersachs, R | 1 |
| Berkowitz, SD | 23 |
| Branch, KRH | 4 |
| Debus, S | 1 |
| Fox, KAA | 12 |
| Liang, Y | 4 |
| Muehlhofer, E | 5 |
| Nehler, M | 1 |
| Haskell, LP | 2 |
| Patel, M | 1 |
| Szarek, M | 2 |
| Yusuf, S | 55 |
| Eikelboom, J | 10 |
| Bonaca, MP | 6 |
| Joseph, P | 2 |
| Roshandel, G | 2 |
| Gao, P | 6 |
| Pais, P | 9 |
| Lonn, E | 4 |
| Xavier, D | 2 |
| Avezum, A | 9 |
| Zhu, J | 9 |
| Liu, L | 42 |
| Sliwa, K | 1 |
| Gamra, H | 1 |
| Bangdiwala, SI | 7 |
| Teo, K | 2 |
| Diaz, R | 12 |
| Dans, A | 1 |
| Lopez-Jaramillo, P | 4 |
| Prabhakaran, D | 6 |
| Castellano, JM | 1 |
| Fuster, V | 4 |
| Rodgers, A | 2 |
| Huffman, MD | 2 |
| Bosch, J | 19 |
| Dagenais, GR | 9 |
| Malekzadeh, R | 2 |
| Maksimova, MY | 1 |
| Ryu, WS | 4 |
| Schellingerhout, D | 1 |
| Hong, KS | 17 |
| Jeong, SW | 2 |
| Kim, BJ | 10 |
| Kim, JT | 8 |
| Lee, KB | 7 |
| Park, TH | 8 |
| Park, SS | 4 |
| Park, JM | 11 |
| Kang, K | 6 |
| Cho, YJ | 8 |
| Park, HK | 3 |
| Lee, BC | 9 |
| Yu, KH | 10 |
| Oh, MS | 7 |
| Lee, SJ | 10 |
| Kim, JG | 7 |
| Cha, JK | 13 |
| Kim, DH | 6 |
| Lee, J | 16 |
| Han, MK | 5 |
| Park, MS | 8 |
| Choi, KH | 7 |
| Nahrendorf, M | 1 |
| Bae, HJ | 9 |
| Kim, DE | 8 |
| Sharma, M | 18 |
| Smith, EE | 9 |
| Pearce, LA | 22 |
| Shoamanesh, A | 8 |
| Perera, KS | 6 |
| Coutts, SB | 6 |
| Damgaard, D | 2 |
| Ameriso, SF | 8 |
| Rha, JH | 6 |
| Modrau, B | 1 |
| Yoon, BW | 10 |
| Romano, M | 1 |
| Messé, SR | 5 |
| Barlinn, J | 1 |
| Lambeck, J | 1 |
| Saad, F | 2 |
| Mundl, H | 13 |
| Connolly, SJ | 43 |
| Hart, RG | 64 |
| McCrindle, BW | 1 |
| Michelson, AD | 1 |
| Van Bergen, AH | 1 |
| Suzana Horowitz, E | 1 |
| Pablo Sandoval, J | 1 |
| Justino, H | 1 |
| Harris, KC | 1 |
| Jefferies, JL | 1 |
| Miriam Pina, L | 1 |
| Peluso, C | 1 |
| Nessel, K | 1 |
| Lu, W | 1 |
| Li, JS | 1 |
| Chacón-Aponte, AA | 1 |
| Durán-Vargas, EA | 1 |
| Lozada-Martínez, ID | 1 |
| Picón-Jaimes, YA | 1 |
| Janjua, T | 1 |
| Moscote-Salazar, LR | 1 |
| Lv, H | 2 |
| Yang, Z | 2 |
| Wu, H | 4 |
| Liu, M | 5 |
| Mao, X | 2 |
| Liu, X | 14 |
| Ding, H | 1 |
| Shi, Z | 1 |
| Zhou, Y | 6 |
| Liu, Q | 4 |
| Chen, K | 1 |
| Li, Z | 18 |
| Dong, Q | 6 |
| Ma, J | 2 |
| Han, Y | 8 |
| Kim, CJ | 1 |
| Park, MW | 1 |
| Kim, MC | 1 |
| Choo, EH | 1 |
| Hwang, BH | 1 |
| Lee, KY | 2 |
| Choi, YS | 1 |
| Kim, HY | 4 |
| Yoo, KD | 1 |
| Jeon, DS | 2 |
| Shin, ES | 4 |
| Jeong, YH | 1 |
| Seung, KB | 5 |
| Jeong, MH | 5 |
| Yim, HW | 1 |
| Ahn, Y | 2 |
| Chang, K | 1 |
| Morton, M | 1 |
| Kubiak-Balcerewicz, K | 1 |
| Sarnowska, A | 1 |
| Fiszer, U | 1 |
| Marcaccio, CL | 2 |
| Patel, PB | 2 |
| Liang, P | 2 |
| Rastogi, V | 2 |
| Stangenberg, L | 2 |
| Jim, J | 2 |
| Schneider, PA | 2 |
| Schermerhorn, ML | 2 |
| Falasconi, G | 1 |
| Gaspardone, C | 1 |
| Godino, C | 2 |
| Gaspardone, A | 1 |
| Radinovic, A | 1 |
| Pannone, L | 1 |
| Leo, G | 1 |
| Posteraro, GA | 1 |
| Slavich, M | 1 |
| Melillo, F | 2 |
| Marzi, A | 1 |
| D'Angelo, G | 1 |
| Limite, LR | 1 |
| Frontera, A | 1 |
| Brugliera, L | 1 |
| Agricola, E | 1 |
| Margonato, A | 1 |
| Della Bella, P | 1 |
| Mazzone, P | 1 |
| Dai, L | 3 |
| Yan, H | 4 |
| Pan, Y | 25 |
| Meng, X | 37 |
| Li, H | 37 |
| Lv, WH | 1 |
| Dong, JZ | 1 |
| Du, X | 2 |
| Hu, R | 1 |
| He, L | 4 |
| Long, DY | 1 |
| Sang, CH | 1 |
| Jia, CQ | 1 |
| Feng, L | 2 |
| Li, X | 7 |
| Ning, M | 1 |
| Chen, X | 3 |
| Cui, YK | 1 |
| Tang, RB | 1 |
| Ma, CS | 1 |
| Gupta, R | 1 |
| Lin, M | 2 |
| Mehta, A | 1 |
| Aedma, SK | 1 |
| Shah, R | 3 |
| Ranchal, P | 1 |
| Vyas, AV | 1 |
| Singh, S | 3 |
| Kluck, B | 1 |
| Combs, WG | 1 |
| Patel, NC | 1 |
| Barry, HC | 1 |
| Xu, X | 1 |
| Wang, H | 7 |
| Du, Y | 1 |
| Wang, J | 9 |
| Kasner, SE | 15 |
| Puig, J | 1 |
| Fiebach, JB | 1 |
| Muir, KW | 3 |
| Veltkamp, RC | 2 |
| Toni, DS | 2 |
| Shamalov, N | 3 |
| Gagliardi, RJ | 5 |
| Mikulik, R | 9 |
| Engelter, ST | 2 |
| Bereczki, D | 6 |
| O'Donnell, MJ | 8 |
| Rigual, R | 2 |
| Ruiz-Ares, G | 1 |
| Rodriguez-Pardo, J | 1 |
| Fernández-Prieto, A | 1 |
| Navia, P | 1 |
| Novo, JR | 1 |
| Alonso de Leciñana, M | 1 |
| Alonso-Singer, P | 1 |
| Fuentes, B | 1 |
| Díez-Tejedor, E | 1 |
| Marquis-Gravel, G | 4 |
| Hammill, BG | 5 |
| Mulder, H | 4 |
| Roe, MT | 9 |
| Robertson, HR | 4 |
| Wruck, LM | 3 |
| Sharlow, A | 2 |
| Harris, DF | 2 |
| Pohlman, FW | 1 |
| Hernandez, AF | 8 |
| Jones, WS | 9 |
| Yang, Y | 3 |
| Zhang, S | 4 |
| Li, F | 5 |
| Zhu, B | 1 |
| Fang, S | 1 |
| Qin, S | 1 |
| Tai, WA | 2 |
| Minhas, JS | 3 |
| Chithiramohan, T | 1 |
| Barnes, SC | 1 |
| Clough, RH | 1 |
| Kadicheeni, M | 1 |
| Beishon, LC | 1 |
| Robinson, T | 1 |
| Kang, MK | 1 |
| Chang, DI | 2 |
| Chung, JW | 1 |
| Jung, KH | 2 |
| Chang, JY | 1 |
| Kim, BK | 4 |
| Shin, DI | 5 |
| Rostanski, SK | 2 |
| Kvernland, A | 2 |
| Liberman, AL | 1 |
| de Havenon, A | 7 |
| Henninger, N | 3 |
| Mac Grory, B | 5 |
| Kim, AS | 10 |
| Easton, JD | 33 |
| Johnston, SC | 58 |
| Yaghi, S | 5 |
| Piccini, JP | 8 |
| Poli, S | 3 |
| Weiss, M | 1 |
| Xian, Y | 7 |
| Feng, W | 4 |
| Abraham, PJ | 1 |
| Black, JA | 1 |
| Griffin, RL | 1 |
| Abraham, MN | 1 |
| Liptrap, EJ | 1 |
| Thaci, B | 1 |
| Holcomb, JB | 1 |
| Kerby, JD | 1 |
| Harrigan, MR | 5 |
| Jansen, JO | 1 |
| Kamarova, M | 1 |
| Baig, S | 1 |
| Patel, H | 1 |
| Monks, K | 1 |
| Wasay, M | 1 |
| Ali, A | 1 |
| Redgrave, J | 1 |
| Majid, A | 2 |
| Bell, SM | 1 |
| Whiteley, WN | 3 |
| Canavan, M | 2 |
| Gutierrez, J | 3 |
| Turan, TN | 9 |
| Hoh, BL | 4 |
| Chimowitz, MI | 14 |
| Subramanian, A | 1 |
| Delaney, S | 1 |
| Murphy, SJX | 4 |
| Smith, DR | 2 |
| Offiah, C | 1 |
| McMahon, J | 1 |
| de Borst, GJ | 4 |
| Naylor, AR | 4 |
| Hamilton, G | 3 |
| Kinsella, JA | 7 |
| McCabe, DJH | 4 |
| Chen, S | 7 |
| Cai, D | 1 |
| He, J | 3 |
| Wu, Q | 2 |
| Huang, P | 2 |
| Zhou, L | 5 |
| Sun, H | 3 |
| van der Steen, W | 1 |
| van de Graaf, RA | 1 |
| Chalos, V | 1 |
| Lingsma, HF | 1 |
| van Doormaal, PJ | 1 |
| Coutinho, JM | 1 |
| Emmer, BJ | 1 |
| de Ridder, I | 1 |
| van Zwam, W | 1 |
| van der Worp, HB | 3 |
| van der Schaaf, I | 1 |
| Gons, RAR | 1 |
| Yo, LSF | 1 |
| Boiten, J | 1 |
| van den Wijngaard, I | 1 |
| Hofmeijer, J | 1 |
| Martens, J | 1 |
| Schonewille, W | 1 |
| Vos, JA | 1 |
| Tuladhar, AM | 1 |
| de Laat, KF | 1 |
| van Hasselt, B | 1 |
| Remmers, M | 1 |
| Vos, D | 1 |
| Rozeman, A | 1 |
| Elgersma, O | 1 |
| Uyttenboogaart, M | 2 |
| Bokkers, RPH | 1 |
| van Tuijl, J | 1 |
| Boukrab, I | 1 |
| van den Berg, R | 1 |
| Beenen, LFM | 1 |
| Roosendaal, SD | 1 |
| Postma, AA | 1 |
| Krietemeijer, M | 1 |
| Lycklama, G | 1 |
| Meijer, FJA | 1 |
| Hammer, S | 1 |
| van der Hoorn, A | 1 |
| Yoo, AJ | 2 |
| Gerrits, D | 1 |
| Truijman, MTB | 1 |
| Zinkstok, S | 1 |
| Koudstaal, PJ | 17 |
| Manschot, S | 1 |
| Kerkhoff, H | 2 |
| Nieboer, D | 1 |
| Berkhemer, O | 1 |
| Wolff, L | 1 |
| van der Sluijs, PM | 1 |
| van Voorst, H | 1 |
| Tolhuisen, M | 1 |
| Roos, YBWEM | 1 |
| Majoie, CBLM | 1 |
| Staals, J | 1 |
| van Oostenbrugge, RJ | 1 |
| Jenniskens, SFM | 1 |
| van Dijk, LC | 1 |
| den Hertog, HM | 1 |
| van Es, ACGM | 1 |
| van der Lugt, A | 1 |
| Dippel, DWJ | 1 |
| Roozenbeek, B | 1 |
| Ku, JC | 1 |
| Taslimi, S | 1 |
| Zuccato, J | 1 |
| Pasarikovski, CR | 1 |
| Nasr, N | 1 |
| Chechik, O | 2 |
| Chisci, E | 1 |
| Bissacco, D | 1 |
| Larrue, V | 3 |
| Rabinovich, Y | 2 |
| Michelagnoli, S | 1 |
| Settembrini, PG | 1 |
| Priola, SM | 1 |
| Cusimano, MD | 1 |
| Yang, VXD | 1 |
| Macdonald, RL | 1 |
| Pop, R | 3 |
| Severac, F | 1 |
| Hasiu, A | 1 |
| Mihoc, D | 1 |
| Mangin, PH | 1 |
| Chibbaro, S | 1 |
| Simu, M | 1 |
| Tudor, R | 1 |
| Gheoca, R | 1 |
| Quenardelle, V | 1 |
| Wolff, V | 1 |
| Beaujeux, R | 1 |
| Kucherenko, SS | 1 |
| Alekseeva, TM | 1 |
| Fan, H | 2 |
| Liu, T | 4 |
| Zhang, K | 3 |
| Ren, J | 2 |
| Li, J | 16 |
| Wu, X | 3 |
| Niu, X | 3 |
| Matsuzono, K | 1 |
| Fujimoto, S | 4 |
| Aoki, J | 4 |
| Ozawa, T | 1 |
| Kimura, K | 11 |
| Ma, L | 1 |
| Zaidat, OO | 3 |
| Gronseth, GS | 2 |
| Culebras, A | 3 |
| Furlan, AJ | 5 |
| Goldstein, LB | 6 |
| Gonzalez, NR | 1 |
| Latorre, JG | 1 |
| Nguyen, TN | 2 |
| Sangha, RS | 1 |
| Schneck, MJ | 3 |
| Singhal, AB | 2 |
| Wechsler, LR | 1 |
| Rabinstein, AA | 2 |
| Dolan O'Brien, M | 1 |
| Silsbee, H | 1 |
| Fletcher, JJ | 1 |
| Dehghani, P | 1 |
| Cao, D | 4 |
| Baber, U | 6 |
| Nicolas, J | 2 |
| Sartori, S | 4 |
| Pivato, CA | 1 |
| Dangas, G | 5 |
| Angiolillo, DJ | 12 |
| Briguori, C | 4 |
| Cohen, DJ | 5 |
| Collier, T | 4 |
| Dudek, D | 4 |
| Gibson, M | 1 |
| Gil, R | 4 |
| Huber, K | 14 |
| Kaul, U | 4 |
| Kornowski, R | 4 |
| Krucoff, MW | 2 |
| Kunadian, V | 5 |
| Mehta, S | 3 |
| Moliterno, DJ | 2 |
| Ohman, EM | 8 |
| Escaned, J | 5 |
| Sardella, G | 4 |
| Sharma, SK | 2 |
| Shlofmitz, R | 3 |
| Weisz, G | 4 |
| Witzenbichler, B | 3 |
| Pocock, S | 7 |
| Mehran, R | 13 |
| Pomero, F | 1 |
| Galli, E | 1 |
| Bellesini, M | 2 |
| Maroni, L | 1 |
| Squizzato, A | 2 |
| D'Ascenzo, F | 3 |
| DE Filippo, O | 1 |
| Angelini, F | 1 |
| Piroli, F | 1 |
| DE Lio, G | 1 |
| Bocchino, PP | 1 |
| Baldetti, L | 1 |
| Chieffo, A | 2 |
| Saglietto, A | 2 |
| Omedè, P | 1 |
| Montefusco, A | 1 |
| Conrotto, F | 2 |
| de Ferrari, GM | 2 |
| Tan, BE | 1 |
| Wong, PY | 1 |
| Baibhav, B | 1 |
| Thakkar, S | 1 |
| Azhar, AZ | 1 |
| Rao, M | 2 |
| Cheung, JW | 1 |
| Xu, H | 3 |
| Fonarow, GC | 7 |
| Bhatt, DL | 51 |
| Schwamm, LH | 6 |
| Peterson, ED | 10 |
| Zhang, L | 7 |
| Wu, Y | 6 |
| Fan, Y | 1 |
| He, Z | 1 |
| He, P | 2 |
| Liang, J | 1 |
| Caroff, J | 2 |
| Aubert, L | 1 |
| Lavenu-Bombled, C | 1 |
| Figueiredo, S | 1 |
| Habchi, K | 1 |
| Cortese, J | 1 |
| Eugene, F | 1 |
| Ognard, J | 1 |
| Tahon, F | 1 |
| Forestier, G | 1 |
| Ifergan, H | 1 |
| Zhu, F | 1 |
| Hak, JF | 1 |
| Reyre, A | 1 |
| Laubacher, M | 1 |
| Traore, A | 1 |
| Desilles, JP | 1 |
| Derraz, I | 1 |
| Moreno, R | 3 |
| Bintner, M | 1 |
| Charbonnier, G | 1 |
| Le Bras, A | 1 |
| Veunac, L | 1 |
| Gariel, F | 1 |
| Redjem, H | 1 |
| Sedat, J | 1 |
| Tessier, G | 1 |
| Dumas, V | 1 |
| Gauberti, M | 1 |
| Chivot, C | 1 |
| Consoli, A | 3 |
| Bricout, N | 1 |
| Tuilier, T | 1 |
| Guedon, A | 1 |
| Thouant, P | 1 |
| Bellanger, G | 1 |
| Zannoni, R | 1 |
| Soize, S | 1 |
| Richter, JS | 1 |
| Heck, O | 1 |
| Mihalea, C | 1 |
| Burel, J | 1 |
| Girot, JB | 1 |
| Shotar, E | 1 |
| Gazzola, S | 1 |
| Boulouis, G | 2 |
| Kerleroux, B | 1 |
| Mohammadifard, N | 1 |
| Taheri, M | 1 |
| Haghighatdoost, F | 1 |
| Grau, N | 1 |
| Najafian, J | 1 |
| Sadeghi, M | 2 |
| Talaei, M | 1 |
| Sarrafzadegan, N | 1 |
| Bor, WL | 1 |
| de Veer, AJW | 1 |
| Olie, RH | 1 |
| Rikken, SAOF | 1 |
| Chan Pin Yin, DRPP | 1 |
| Herrman, JPR | 1 |
| Vrolix, M | 3 |
| Meuwissen, M | 1 |
| Vandendriessche, T | 1 |
| van Mieghem, C | 1 |
| Magro, M | 2 |
| Bennaghmouch, N | 3 |
| Hermanides, R | 1 |
| Adriaenssens, T | 2 |
| Dewilde, WJM | 2 |
| Ten Berg, JM | 8 |
| Eikelboom, JW | 34 |
| Tyrwitt, J | 1 |
| Neumann, C | 1 |
| Tasto, C | 1 |
| Alings, M | 7 |
| Leong, DP | 2 |
| Lonn, EM | 2 |
| Piegas, LS | 2 |
| Widimsky, P | 12 |
| Parkhomenko, AN | 2 |
| Probstfield, JL | 2 |
| Rydén, L | 4 |
| Pogosova, N | 3 |
| Keltai, K | 5 |
| Keltai, M | 3 |
| Ertl, G | 2 |
| Stoerk, S | 1 |
| Dans, AL | 3 |
| Lanas, F | 4 |
| Torp-Pedersen, C | 12 |
| Maggioni, AP | 8 |
| Commerford, PJ | 4 |
| Guzik, TJ | 3 |
| Vanassche, T | 3 |
| Verhamme, P | 3 |
| O'Donnell, M | 15 |
| Tonkin, AM | 2 |
| Varigos, JD | 4 |
| Vinereanu, D | 6 |
| Felix, C | 3 |
| Kim, JH | 6 |
| Ibrahim, KS | 1 |
| Lewis, BS | 7 |
| Metsarinne, KP | 1 |
| Aboyans, V | 7 |
| Steg, PG | 28 |
| Hori, M | 6 |
| Kakkar, A | 1 |
| Lamy, A | 1 |
| Shah, J | 1 |
| Liu, S | 4 |
| Yu, W | 1 |
| Chen, W | 13 |
| Jing, J | 23 |
| Lin, J | 27 |
| Jiang, Y | 11 |
| Bath, PM | 39 |
| Xu, AD | 1 |
| Amarenco, P | 32 |
| Denison, H | 11 |
| Evans, SR | 11 |
| Himmelmann, A | 7 |
| James, S | 9 |
| Knutsson, M | 6 |
| Ladenvall, P | 8 |
| Molina, CA | 15 |
| Gallagher, H | 1 |
| Dumbleton, J | 1 |
| Maishman, T | 1 |
| Whitehead, A | 1 |
| Moore, MV | 1 |
| Fuat, A | 1 |
| Fitzmaurice, D | 5 |
| Henderson, RA | 1 |
| Lord, J | 1 |
| Griffith, KE | 2 |
| Stevens, P | 1 |
| Taal, MW | 1 |
| Stevenson, D | 1 |
| Fraser, SD | 1 |
| Lown, M | 1 |
| Hawkey, CJ | 1 |
| Roderick, PJ | 1 |
| Venketasubramanian, N | 2 |
| Davidson, KW | 1 |
| Barry, MJ | 1 |
| Mangione, CM | 1 |
| Cabana, M | 1 |
| Chelmow, D | 1 |
| Coker, TR | 1 |
| Davis, EM | 1 |
| Donahue, KE | 1 |
| Jaén, CR | 1 |
| Krist, AH | 1 |
| Kubik, M | 1 |
| Li, L | 6 |
| Ogedegbe, G | 1 |
| Pbert, L | 1 |
| Ruiz, JM | 1 |
| Stevermer, J | 1 |
| Tseng, CW | 1 |
| Wong, JB | 1 |
| Arutyunov, GP | 1 |
| Amelin, AV | 1 |
| Voznyuk, IA | 1 |
| Kulesh, AA | 1 |
| Maximova, MY | 1 |
| Mkrtchyan, VR | 1 |
| Putilina, MV | 1 |
| Sorokoumov, VA | 1 |
| Fonyakin, AV | 2 |
| Khasanova, DR | 1 |
| Freeman, JV | 2 |
| Higgins, AY | 1 |
| Du, C | 1 |
| Friedman, DJ | 1 |
| Daimee, UA | 1 |
| Minges, KE | 1 |
| Pereira, L | 1 |
| Goldsweig, AM | 2 |
| Price, MJ | 2 |
| Reddy, VY | 4 |
| Gibson, D | 1 |
| Doshi, SK | 3 |
| Varosy, PD | 1 |
| Masoudi, FA | 2 |
| Curtis, JP | 1 |
| Diener, HC | 50 |
| Kasner, S | 1 |
| Kamel, H | 1 |
| Ntaios, G | 14 |
| Feler, J | 1 |
| Chuck, C | 1 |
| Anderson, M | 2 |
| Poggi, J | 1 |
| Sweeney, J | 1 |
| Moldovan, K | 1 |
| Jayaraman, MV | 1 |
| McTaggart, R | 1 |
| Torabi, R | 1 |
| Ebell, MH | 3 |
| Tasoudis, PT | 1 |
| Kyriakoulis, IG | 1 |
| Sagris, D | 3 |
| Valgimigli, M | 15 |
| Smits, PC | 1 |
| Frigoli, E | 1 |
| Bongiovanni, D | 1 |
| Tijssen, J | 2 |
| Hovasse, T | 1 |
| Mafragi, A | 1 |
| Ruifrok, WT | 1 |
| Karageorgiev, D | 1 |
| Aminian, A | 2 |
| Garducci, S | 1 |
| Merkely, B | 2 |
| Routledge, H | 1 |
| Ando, K | 7 |
| Diaz Fernandez, JF | 1 |
| Cuisset, T | 2 |
| Nesa Malik, FT | 1 |
| Halabi, M | 1 |
| Belle, L | 1 |
| Din, J | 1 |
| Beygui, F | 1 |
| Abhyankar, A | 1 |
| Reczuch, K | 1 |
| Pedrazzini, G | 1 |
| Heg, D | 2 |
| Vranckx, P | 10 |
| Bahit, MC | 2 |
| Vora, AN | 3 |
| Wojdyla, DM | 6 |
| Thomas, L | 5 |
| Goodman, SG | 7 |
| Aronson, R | 2 |
| Jordan, JD | 1 |
| Kolls, BJ | 1 |
| Dombrowski, KE | 1 |
| Halvorsen, S | 6 |
| Berwanger, O | 2 |
| Windecker, S | 15 |
| Granger, CB | 17 |
| Alexander, JH | 10 |
| Lopes, RD | 18 |
| Clarke, A | 3 |
| Reddin, C | 1 |
| Murphy, R | 2 |
| Wang, A | 25 |
| Tian, X | 3 |
| Zuo, Y | 3 |
| Xie, X | 13 |
| Zhao, X | 42 |
| Wang, F | 4 |
| Chen, G | 2 |
| Del Brutto, VJ | 2 |
| Cronin, L | 4 |
| Kleine, E | 4 |
| Grauer, C | 3 |
| Brueckmann, M | 6 |
| Toyoda, K | 9 |
| Schellinger, PD | 6 |
| Lyrer, P | 4 |
| Chutinet, A | 1 |
| Bladin, CF | 2 |
| Estol, CJ | 8 |
| Sacco, RL | 34 |
| Zhou, LW | 1 |
| Kraler, L | 1 |
| Lansberg, MG | 2 |
| Ajabnoor, AM | 1 |
| Zghebi, SS | 1 |
| Parisi, R | 1 |
| Ashcroft, DM | 1 |
| Rutter, MK | 1 |
| Doran, T | 1 |
| Carr, MJ | 1 |
| Mamas, MA | 2 |
| Kontopantelis, E | 1 |
| Wang, D | 16 |
| Reid, MM | 1 |
| Obenaus, A | 1 |
| Mukherjee, PK | 1 |
| Khoutorova, L | 1 |
| Roque, CR | 1 |
| Petasis, NA | 1 |
| Oria, RB | 1 |
| Belayev, L | 1 |
| Bazan, NG | 1 |
| Jin, A | 2 |
| Yang, H | 2 |
| Cheng, J | 2 |
| Wang, Z | 9 |
| Micieli, A | 1 |
| Singh, N | 1 |
| Jahn, B | 1 |
| Siebert, U | 1 |
| Menon, BK | 2 |
| Demchuk, AM | 6 |
| Zhu, Q | 1 |
| Deng, X | 1 |
| Ma, Y | 2 |
| Shi, T | 1 |
| Uchiyama, S | 23 |
| Okamura, S | 1 |
| Omae, K | 1 |
| Hoshino, H | 4 |
| Minematsu, K | 14 |
| Yamaguchi, T | 8 |
| Al-Abdouh, A | 1 |
| Abusnina, W | 1 |
| Mhanna, M | 1 |
| Radideh, Q | 1 |
| Alzu'bi, H | 1 |
| Rmilah, AA | 1 |
| Jabri, A | 1 |
| Barbarawi, M | 1 |
| Obeidat, K | 2 |
| Alabduh, T | 1 |
| Michos, ED | 1 |
| Alnabelsi, T | 1 |
| Paul, TK | 1 |
| Fan, X | 1 |
| Du, W | 1 |
| Liang, X | 2 |
| Chen, Y | 6 |
| Shi, J | 2 |
| Sun, L | 2 |
| Shen, W | 1 |
| Zheng, F | 2 |
| Stavrinou, P | 1 |
| Hu, W | 1 |
| Kwan, J | 2 |
| Hafdi, M | 1 |
| Chiang, LLW | 1 |
| Myint, PK | 4 |
| Wong, LS | 1 |
| Quinn, TJ | 3 |
| Kostev, K | 1 |
| Tanislav, C | 1 |
| Matsouaka, R | 1 |
| Laskowitz, DT | 2 |
| Maisch, L | 1 |
| Hannah, D | 1 |
| Fosbøl, EL | 2 |
| Johnson, M | 1 |
| Chutoo, P | 1 |
| Kulinskaya, E | 1 |
| Bakbergenuly, I | 1 |
| Steel, N | 1 |
| Pchejetski, D | 1 |
| Brown, B | 1 |
| Xu, Y | 4 |
| Jiang, L | 2 |
| Yao, D | 1 |
| Guo, L | 1 |
| Patel, RJ | 1 |
| Marmor, R | 1 |
| Dakour, H | 1 |
| Elsayed, N | 1 |
| Ramachandran, M | 1 |
| Malas, MB | 1 |
| Huang, HY | 1 |
| Lin, SY | 1 |
| Katz, AJ | 1 |
| Sheu, JJ | 1 |
| Lin, FJ | 1 |
| Wang, CC | 1 |
| Wu, CH | 1 |
| Yang, B | 1 |
| Zhao, S | 1 |
| Yuan, L | 1 |
| Huang, F | 1 |
| Mazur, PK | 1 |
| Arghami, A | 1 |
| Macielak, SA | 1 |
| Nei, SD | 1 |
| Viehman, JK | 1 |
| King, KS | 1 |
| Daly, RC | 1 |
| Crestanello, JA | 1 |
| Schaff, HV | 2 |
| Dearani, JA | 1 |
| Kenney, LB | 1 |
| Ames, BL | 1 |
| Huang, MS | 1 |
| Yock, T | 1 |
| Bowers, DC | 1 |
| Nekhlyudov, L | 1 |
| Williams, D | 2 |
| Hudson, MM | 1 |
| Ullrich, NJ | 1 |
| Beerkens, FJ | 1 |
| Claessen, B | 1 |
| Marx, S | 1 |
| Kastrati, A | 10 |
| Sharma, S | 3 |
| Gibson, CM | 6 |
| Zi, W | 2 |
| Song, J | 1 |
| Qiu, Z | 2 |
| Kong, W | 1 |
| Huang, J | 5 |
| Luo, W | 1 |
| Sang, H | 1 |
| Yang, J | 3 |
| Tian, Y | 2 |
| Hu, J | 1 |
| Saver, JL | 13 |
| Nogueira, RG | 1 |
| Yang, Q | 3 |
| Maclean, MA | 1 |
| Touchette, CJ | 1 |
| Duda, T | 1 |
| Almojuela, A | 1 |
| Bergeron, D | 1 |
| Kameda-Smith, M | 1 |
| Persad, ARL | 1 |
| Sader, N | 1 |
| Alant, J | 1 |
| Christie, SD | 1 |
| Lim, ST | 2 |
| Murphy, SM | 2 |
| Coughlan, T | 7 |
| O'Neill, D | 13 |
| Tierney, S | 6 |
| Egan, B | 6 |
| Collins, DR | 6 |
| McCarthy, AJ | 1 |
| Lim, SY | 1 |
| Cox, D | 3 |
| Scalia, L | 1 |
| Calderone, D | 1 |
| Capodanno, D | 5 |
| Lutsep, HL | 7 |
| Tsivgoulis, G | 5 |
| Czlonkowska, A | 6 |
| Shuaib, A | 6 |
| Endres, M | 9 |
| Gailani, D | 1 |
| Kahl, A | 1 |
| Donovan, M | 1 |
| Perera, V | 1 |
| Li, D | 6 |
| Hankey, GJ | 31 |
| Cai, Y | 1 |
| Ren, L | 1 |
| Li, C | 5 |
| Gang, X | 1 |
| Wang, G | 1 |
| Mele, F | 1 |
| Gendarini, C | 1 |
| Pantoni, L | 2 |
| Cruz Silva, J | 1 |
| Constâncio, V | 1 |
| Lima, P | 1 |
| Anacleto, G | 1 |
| Fonseca, M | 1 |
| Runge, A | 1 |
| Brazel, D | 1 |
| Pakbaz, Z | 1 |
| Katsanos, AH | 4 |
| Kishi, T | 1 |
| Kitajima, A | 1 |
| Yamanouchi, K | 1 |
| Hirooka, Y | 1 |
| Toda, S | 1 |
| Takamori, A | 1 |
| Fujimoto, K | 2 |
| Kishi, C | 1 |
| Tomiyoshi, Y | 1 |
| Miklík, R | 1 |
| Jiravský, O | 1 |
| Shen, Q | 2 |
| Zhang, C | 3 |
| Zhu, H | 4 |
| Moustafa, B | 1 |
| Testai, FD | 2 |
| Chen, P | 2 |
| Lazar, A | 1 |
| Ding, J | 2 |
| Siracuse, JJ | 1 |
| Patel, VI | 3 |
| Morrissey, NJ | 1 |
| Yeom, S | 1 |
| Comi, AM | 1 |
| Abtan, J | 2 |
| Elbez, Y | 3 |
| Ducrocq, G | 2 |
| Goto, S | 3 |
| Smith, SC | 2 |
| Eagle, KA | 2 |
| Fox, K | 6 |
| Harrington, RA | 16 |
| Leiter, LA | 3 |
| Mehta, SR | 13 |
| Simon, T | 4 |
| Petrov, I | 2 |
| Sinnaeve, PR | 1 |
| Lev, E | 1 |
| Bueno, H | 1 |
| Wilson, P | 1 |
| Luo, L | 1 |
| Wang, S | 5 |
| Tang, K | 1 |
| Xu, L | 3 |
| Feng, T | 1 |
| Ran, J | 1 |
| Zhao, D | 1 |
| O'Brien, EC | 1 |
| Curtis, LH | 2 |
| Liu, H | 4 |
| Shao, T | 2 |
| Yang, T | 1 |
| Cheng, Y | 4 |
| Zhang, T | 1 |
| Hou, X | 1 |
| Cen, K | 1 |
| Cui, Y | 4 |
| Feng, X | 4 |
| Marnat, G | 1 |
| Finistis, S | 1 |
| Sibon, I | 3 |
| Mazighi, M | 1 |
| Clarençon, F | 1 |
| Rosso, C | 1 |
| Dargazanli, C | 1 |
| Darcourt, J | 1 |
| Olivot, JM | 1 |
| Janot, K | 1 |
| Moulin, S | 2 |
| Bourcier, R | 1 |
| Richard, S | 1 |
| Arquizan, C | 2 |
| Vannier, S | 1 |
| Richter, S | 1 |
| Gentric, JC | 1 |
| Papagiannaki, C | 1 |
| Naggara, O | 1 |
| Eker, OF | 1 |
| Lapergue, B | 1 |
| Gory, B | 1 |
| Gaba, P | 3 |
| Leong, D | 3 |
| Aref, HM | 3 |
| El-Khawas, H | 3 |
| Elbassiouny, A | 3 |
| Shokri, HM | 3 |
| Zeinhom, MG | 3 |
| Roushdy, TM | 3 |
| Goel, A | 2 |
| Malik, AH | 2 |
| Andreotti, F | 3 |
| Geisler, T | 4 |
| Collet, JP | 5 |
| Gigante, B | 2 |
| Gorog, DA | 2 |
| Lip, GYH | 11 |
| Morais, J | 5 |
| Navarese, EP | 4 |
| Patrono, C | 6 |
| Rocca, B | 4 |
| Rubboli, A | 2 |
| Sibbing, D | 2 |
| Storey, RF | 12 |
| Verheugt, FWA | 3 |
| Vilahur, G | 2 |
| Fijałkowski, Ł | 2 |
| Skubiszewska, M | 2 |
| Grześk, G | 2 |
| Koech, FK | 2 |
| Nowaczyk, A | 2 |
| Gorenflo, MP | 2 |
| Davis, PB | 2 |
| Kendall, EK | 2 |
| Olaker, VR | 2 |
| Kaelber, DC | 2 |
| Xu, R | 3 |
| Suo, Y | 3 |
| Krishnan, K | 5 |
| Law, ZK | 2 |
| Robinson, TG | 5 |
| Sprigg, N | 9 |
| Mavilakandy, A | 2 |
| England, TJ | 6 |
| Eveson, D | 2 |
| Mistri, A | 2 |
| Dawson, J | 6 |
| Appleton, JP | 5 |
| Caldeira, D | 2 |
| Marques Antunes, M | 2 |
| Alves, M | 2 |
| Pinto, FJ | 2 |
| Cao, M | 1 |
| Yuan, J | 2 |
| Chen, J | 4 |
| Xu, Q | 6 |
| Wyers, MC | 1 |
| Chen, C | 13 |
| Shan, L | 1 |
| Long, X | 1 |
| Guo, C | 1 |
| Huo, Y | 1 |
| Lu, L | 1 |
| Zhu, D | 1 |
| Van den Eynde, J | 1 |
| Possner, M | 1 |
| Alahdab, F | 1 |
| Veldtman, G | 1 |
| Goldstein, BH | 1 |
| Rathod, RH | 1 |
| Hoskoppal, AK | 1 |
| Saraf, A | 1 |
| Feingold, B | 1 |
| Alsaied, T | 1 |
| Gao, Y | 4 |
| Han, S | 1 |
| Wang, C | 24 |
| Wang, T | 1 |
| Eckstein, J | 4 |
| Lam, A | 1 |
| Cheema, AN | 1 |
| Marcucci, R | 2 |
| Berteotti, M | 1 |
| Gragnano, F | 1 |
| Galli, M | 1 |
| Cavallari, I | 1 |
| Renda, G | 2 |
| Capranzano, P | 1 |
| Santilli, F | 2 |
| Cirillo, P | 1 |
| Calabrò, P | 2 |
| Patti, G | 2 |
| De Caterina, R | 10 |
| Yuan, F | 2 |
| Connolly, S | 8 |
| Belanger, J | 1 |
| Marsden, T | 1 |
| Tang, C | 1 |
| Swaminathan, B | 6 |
| Renters, M | 1 |
| Nishiyama, Y | 1 |
| Otsuka, T | 1 |
| Sakai, N | 2 |
| Okada, Y | 6 |
| Origasa, H | 6 |
| Naritomi, H | 3 |
| Houkin, K | 2 |
| Yamaguchi, K | 2 |
| Matsumoto, M | 3 |
| Tominaga, T | 2 |
| Tomimoto, H | 1 |
| Terayama, Y | 1 |
| Yasuda, S | 2 |
| Arambam, P | 1 |
| Sinha, SK | 1 |
| Abhaichand, R | 1 |
| Parida, AK | 1 |
| Banker, D | 1 |
| Mody, R | 1 |
| Khan, A | 1 |
| Sharma, R | 2 |
| Moorthy, N | 1 |
| Chandra, S | 1 |
| Koduganti, SC | 1 |
| Garg, R | 1 |
| Sarma, PR | 1 |
| Agrawal, DK | 1 |
| Reddy, KMK | 1 |
| Bangalore, S | 3 |
| Li, LG | 1 |
| Ma, X | 2 |
| Zheng, N | 1 |
| Zhong, J | 2 |
| Su, J | 1 |
| Liu, C | 1 |
| Landi, A | 1 |
| Oliva, A | 1 |
| Piccolo, R | 4 |
| Angiolillo, D | 1 |
| Atar, D | 8 |
| Jüni, P | 4 |
| Leonardi, S | 3 |
| Montalescot, G | 7 |
| Niebauer, J | 1 |
| Price, S | 1 |
| Völler, H | 1 |
| Duan, C | 1 |
| Xiong, Y | 5 |
| Gu, H | 2 |
| Yang, KX | 1 |
| Hao, M | 1 |
| Quan, X | 1 |
| Ding, Y | 4 |
| Yuan, M | 1 |
| Yuan, Z | 3 |
| Wang, R | 3 |
| Zhao, Y | 3 |
| Kang, J | 3 |
| Kim, JY | 1 |
| Cho, KH | 6 |
| Kim, YS | 1 |
| Choi, JK | 1 |
| Lee, K | 5 |
| Park, KY | 2 |
| Jeong, HB | 1 |
| Kwon, DH | 1 |
| Lee, M | 8 |
| Gwak, DS | 1 |
| Choi, JC | 7 |
| Kang, CH | 1 |
| Kwon, JH | 5 |
| Kim, WJ | 4 |
| Yum, KS | 1 |
| Sohn, SI | 6 |
| Hong, JH | 3 |
| Park, H | 1 |
| Kim, C | 2 |
| Lee, SH | 9 |
| Gorelick, PB | 10 |
| Norrving, B | 5 |
| Lang, AE | 1 |
| Shu, L | 1 |
| Furie, KL | 5 |
| Kim, A | 1 |
| Qadura, M | 1 |
| Syed, MH | 1 |
| Anand, S | 1 |
| Weissler, EH | 2 |
| Stebbins, A | 2 |
| Wruck, L | 2 |
| Muñoz, D | 5 |
| Gupta, K | 5 |
| Girotra, S | 6 |
| Whittle, J | 5 |
| Benziger, CP | 5 |
| Polonsky, TS | 4 |
| Bradley, SM | 3 |
| Merritt, JG | 3 |
| Zemon, DN | 2 |
| Clares de Andrade, JB | 1 |
| Mohr, JP | 21 |
| Lima, FO | 1 |
| de Carvalho, JJF | 1 |
| Maia Barros, LC | 1 |
| Pontes-Neto, OM | 2 |
| de Abreu, GQ | 1 |
| Silva, GS | 1 |
| Bhatia, K | 2 |
| Ladd, LM | 1 |
| Carr, KH | 1 |
| Di Napoli, M | 2 |
| McCullough, LD | 2 |
| Hosseini Farahabadi, M | 1 |
| Alsbrook, DL | 1 |
| Hinduja, A | 1 |
| Ortiz Garcia, JG | 1 |
| Sabbagh, SY | 1 |
| Jafarli, A | 1 |
| Divani, AA | 2 |
| Kim, JS | 8 |
| Kang, Y | 1 |
| Sohn, SH | 1 |
| Hwang, HY | 1 |
| Huang, D | 2 |
| Hu, Y | 3 |
| He, Q | 1 |
| Diao, L | 1 |
| Zhong, P | 1 |
| Manunga, J | 1 |
| Pedersen, C | 1 |
| Stanberry, L | 1 |
| Pai, A | 1 |
| Skeik, N | 1 |
| Sullivan, TM | 2 |
| Wang, Q | 3 |
| Wu, C | 3 |
| Qu, X | 1 |
| He, X | 1 |
| Ma, S | 1 |
| Qiu, M | 1 |
| Xu, S | 1 |
| Zhang, W | 6 |
| Xu, Z | 3 |
| Wu, T | 4 |
| Yuan, B | 3 |
| Xu, A | 5 |
| Feng, Y | 1 |
| Liu, B | 1 |
| Zhao, J | 1 |
| Huang, X | 4 |
| Zhang, ZM | 1 |
| Lin, ZH | 1 |
| Zhu, GL | 1 |
| van Bergeijk, KH | 1 |
| van Ginkel, DJ | 1 |
| Brouwer, J | 1 |
| Nijenhuis, VJ | 1 |
| van der Werf, HW | 1 |
| van den Heuvel, AFM | 1 |
| Voors, AA | 1 |
| Wykrzykowska, JJ | 3 |
| Klail, T | 1 |
| Sedova, P | 1 |
| Vinklarek, JF | 1 |
| Kovacova, I | 1 |
| Bar, M | 2 |
| Cihlar, F | 1 |
| Cernik, D | 1 |
| Kočí, L | 1 |
| Jura, R | 1 |
| Herzig, R | 2 |
| Husty, J | 1 |
| Kocher, M | 1 |
| Kovar, M | 1 |
| Nevšímalová, M | 1 |
| Raupach, J | 1 |
| Rocek, M | 1 |
| Sanak, D | 3 |
| Sevcik, P | 1 |
| Skoloudik, D | 2 |
| Sramek, M | 1 |
| Vanicek, J | 1 |
| Vaško, P | 1 |
| Vaclavik, D | 1 |
| Tomek, A | 1 |
| Chou, CL | 1 |
| Chung, CH | 1 |
| Hsu, YH | 2 |
| Wu, CC | 1 |
| Sun, CA | 1 |
| Chien, WC | 1 |
| Tang, SE | 1 |
| Fann, LY | 1 |
| Kar, S | 2 |
| Alkhouli, M | 1 |
| Camm, AJ | 4 |
| Coylewright, M | 3 |
| Gibson, MC | 1 |
| Gurol, ME | 1 |
| Mansour, M | 1 |
| Nair, DG | 2 |
| Natale, A | 2 |
| Pocock, SJ | 2 |
| Reddy, VR | 1 |
| Saliba, W | 4 |
| Christen, T | 1 |
| Allocco, DJ | 2 |
| Ellenbogen, KA | 1 |
| Leon, MB | 2 |
| Komen, JJ | 1 |
| Hunt, NB | 1 |
| Pottegård, A | 1 |
| Hjemdahl, P | 2 |
| Wettermark, B | 2 |
| Olesen, M | 1 |
| Bennie, M | 1 |
| Mueller, T | 1 |
| Carragher, R | 1 |
| Karlstad, Ø | 1 |
| Kjerpeseth, LJ | 1 |
| Klungel, OH | 1 |
| Forslund, T | 2 |
| Bultasova, L | 1 |
| Rohan, V | 1 |
| Ulehlova, J | 1 |
| Slavik, L | 1 |
| Lee, YJ | 2 |
| Je, NK | 2 |
| Chikumbanje, MM | 1 |
| Raza, S | 2 |
| Barham, L | 1 |
| Shen, R | 2 |
| Sharlow, AG | 2 |
| Kripalani, S | 3 |
| Effron, MB | 4 |
| VanWormer, JJ | 2 |
| Rothman, RL | 3 |
| Ma, F | 1 |
| Wen, X | 1 |
| Tang, Q | 1 |
| Park, D | 1 |
| Lim, HS | 2 |
| Kang, MJ | 2 |
| Lee, JH | 8 |
| Yoon, SY | 1 |
| Kim, HS | 11 |
| Chen, HS | 3 |
| Zhou, ZH | 3 |
| Zhang, H | 4 |
| Wang, LX | 2 |
| Wang, WZ | 1 |
| Shen, LY | 1 |
| Guo, LY | 1 |
| Wang, EQ | 1 |
| Wang, RX | 1 |
| Han, J | 3 |
| Dong, YL | 1 |
| Lin, YZ | 1 |
| Yang, QC | 1 |
| Li, JY | 3 |
| Xia, L | 1 |
| Ma, GB | 1 |
| Lu, J | 2 |
| Jiang, CH | 1 |
| Huang, SM | 1 |
| Wan, LS | 1 |
| Piao, XY | 1 |
| Li, YS | 1 |
| Yang, KH | 1 |
| Wang, DL | 1 |
| Woodhouse, LJ | 4 |
| Christensen, H | 7 |
| Dineen, RA | 3 |
| James, M | 3 |
| Montgomery, AA | 2 |
| Ranta, A | 3 |
| Cloud, GC | 1 |
| Williamson, JD | 1 |
| Thao, LTP | 1 |
| Tran, C | 1 |
| Eaton, CB | 2 |
| Wolfe, R | 3 |
| Nelson, MR | 3 |
| Reid, CM | 2 |
| Newman, AB | 1 |
| Lockery, J | 2 |
| Fitzgerald, SM | 1 |
| Murray, AM | 2 |
| Shah, RC | 3 |
| Woods, RL | 3 |
| Donnan, GA | 16 |
| McNeil, JJ | 3 |
| Björn, R | 1 |
| Lehto, J | 1 |
| Malmberg, M | 1 |
| Anttila, V | 1 |
| Airaksinen, KEJ | 3 |
| Gunn, J | 1 |
| Kiviniemi, T | 1 |
| Claiborne Johnston, S | 1 |
| Clezar, CN | 1 |
| Flumignan, CD | 1 |
| Cassola, N | 1 |
| Nakano, LC | 1 |
| Trevisani, VF | 1 |
| Flumignan, RL | 1 |
| Li, M | 5 |
| Lin, H | 3 |
| Ge, F | 2 |
| Lee, TL | 1 |
| Chang, YM | 1 |
| Sung, PS | 1 |
| Yin, R | 1 |
| Gardener, H | 2 |
| Ying, H | 1 |
| Gutierrez, CM | 2 |
| Jameson, AM | 1 |
| Rose, DZ | 4 |
| Alkhachroum, A | 1 |
| Foster, D | 1 |
| Dong, C | 2 |
| Ancheta, S | 1 |
| Sur, NB | 2 |
| Gordon Perue, G | 1 |
| Rundek, T | 2 |
| Asdaghi, N | 1 |
| Romano, JG | 6 |
| Sleem, A | 1 |
| Re, RN | 3 |
| Pepine, CJ | 3 |
| Jain, SK | 3 |
| Farrehi, PM | 1 |
| Knowlton, KU | 2 |
| Spirito, A | 1 |
| Han, YL | 2 |
| Krucoff, M | 2 |
| Vogel, B | 1 |
| Moliterno, D | 2 |
| Shlofmitz, RA | 1 |
| Yang, S | 3 |
| Park, KW | 7 |
| Hur, SH | 4 |
| Lee, NH | 3 |
| Hwang, D | 1 |
| Yang, HM | 3 |
| Ahn, HS | 1 |
| Cha, KS | 2 |
| Jo, SH | 1 |
| Ryu, JK | 1 |
| Suh, IW | 1 |
| Choi, HH | 1 |
| Woo, SI | 1 |
| Han, JK | 2 |
| Koo, BK | 5 |
| Algarni, RA | 1 |
| Althagafi, AA | 1 |
| Alshehri, S | 1 |
| Alshibani, M | 1 |
| Alshargi, O | 1 |
| Brorson, JR | 2 |
| Giurcanu, M | 1 |
| Prabhakaran, S | 2 |
| Jia, W | 2 |
| Cruz-Flores, S | 1 |
| Holmes, DR | 2 |
| Kapadia, SR | 2 |
| Hsu, JC | 2 |
| Gibson, DN | 1 |
| Yeh, RW | 4 |
| Bykov, VV | 1 |
| Bykova, AV | 1 |
| Motov, VS | 1 |
| Larchenko, VV | 1 |
| Chernysheva, GA | 1 |
| Smol'yakova, VI | 1 |
| Aliev, OI | 1 |
| Khazanov, VA | 1 |
| Vengerovskii, AI | 1 |
| Udut, VV | 1 |
| Liang, C | 1 |
| Shi, D | 1 |
| Xie, H | 1 |
| Liang, F | 1 |
| Alhajj, L | 1 |
| Ovenseri Airemwen, C | 1 |
| Pozharani, LB | 1 |
| Riva, L | 1 |
| Di Pasquale, G | 3 |
| Xu, ZQ | 1 |
| Xu, ZH | 1 |
| Zhang, N | 4 |
| Serruys, PW | 4 |
| Takahashi, K | 3 |
| Chichareon, P | 3 |
| Kogame, N | 3 |
| Tomaniak, M | 3 |
| Modolo, R | 3 |
| Chang, CC | 2 |
| Komiyama, H | 1 |
| Soliman, O | 1 |
| de Winter, RJ | 2 |
| Ferrario, M | 3 |
| Dominici, M | 2 |
| Buszman, P | 2 |
| Bolognese, L | 2 |
| Tumscitz, C | 4 |
| Benit, E | 2 |
| Stoll, HP | 2 |
| Hamm, C | 6 |
| Onuma, Y | 3 |
| Colombo, A | 5 |
| Lang, W | 6 |
| Siegler, JE | 1 |
| Lavados, P | 5 |
| Bornstein, N | 5 |
| Meseguer, E | 3 |
| Cucchiara, B | 3 |
| Camps-Renom, P | 1 |
| Makaritsis, K | 3 |
| Korompoki, E | 4 |
| Papavasileiou, V | 2 |
| Marti-Fabregas, J | 3 |
| Milionis, H | 6 |
| Vemmos, K | 5 |
| Tirschwell, DL | 2 |
| Taylor, BL | 1 |
| Elvira Ruiz, G | 1 |
| Caro Martínez, C | 1 |
| Flores Blanco, PJ | 1 |
| Cerezo Manchado, JJ | 1 |
| Albendín Iglesias, H | 1 |
| Lova Navarro, A | 1 |
| Arregui Montoya, F | 1 |
| García Alberola, A | 1 |
| Pascual Figal, DA | 1 |
| Bailén Lorenzo, JL | 1 |
| Manzano-Fernández, S | 1 |
| Vidyanti, AN | 1 |
| Chan, L | 1 |
| Lin, CL | 1 |
| Muo, CH | 1 |
| Hsu, CY | 4 |
| Chen, YC | 1 |
| Wu, D | 1 |
| Hu, CJ | 2 |
| Held, C | 6 |
| Andersson, M | 2 |
| Ridderstråle, W | 2 |
| Leonsson-Zachrisson, M | 2 |
| Liu, Y | 5 |
| Opolski, G | 3 |
| Zateyshchikov, D | 1 |
| Ge, J | 2 |
| Nicolau, JC | 3 |
| Corbalán, R | 5 |
| Cornel, JH | 5 |
| Farrant, M | 5 |
| Adelman, EE | 2 |
| Cucchiara, BL | 2 |
| Barsan, WG | 2 |
| Tillman, HJ | 1 |
| Elm, JJ | 4 |
| Lindblad, AS | 4 |
| Palesch, YY | 4 |
| Zhao, W | 3 |
| Pauls, K | 1 |
| Walsh, KB | 1 |
| Bernstein, RA | 5 |
| de Vries, TI | 1 |
| Westerink, J | 1 |
| Dorresteijn, JAN | 2 |
| van der Graaf, Y | 3 |
| Visseren, FLJ | 2 |
| Shestakovska, O | 11 |
| Cook-Bruns, N | 1 |
| Moayyedi, P | 1 |
| Majidi, S | 2 |
| Luby, M | 1 |
| Lynch, JK | 1 |
| Hsia, AW | 1 |
| Benson, RT | 1 |
| Kalaria, CP | 1 |
| Nadareishvili, Z | 2 |
| Latour, LL | 1 |
| Leigh, R | 1 |
| Catapano, JS | 1 |
| Israr, S | 1 |
| Whiting, AC | 1 |
| Hussain, OM | 1 |
| Snyder, LA | 1 |
| Albuquerque, FC | 2 |
| Ducruet, AF | 1 |
| Nakaji, P | 2 |
| Lawton, MT | 1 |
| Weinberg, JA | 1 |
| Zabramski, JM | 1 |
| Ng, KKH | 2 |
| Nayar, S | 1 |
| Catanese, L | 2 |
| Ozturk, S | 3 |
| Bornstein, NM | 1 |
| Pagola, J | 2 |
| Liu, YY | 1 |
| Sen, S | 2 |
| Georgiopoulos, G | 2 |
| Perlepe, K | 1 |
| Pateras, K | 1 |
| Cha, JY | 1 |
| Džavík, V | 1 |
| Gurbel, P | 2 |
| Hamm, CW | 3 |
| Henry, T | 1 |
| Marx, SO | 1 |
| Oldroyd, K | 1 |
| Watanabe, H | 2 |
| Domei, T | 1 |
| Morimoto, T | 7 |
| Natsuaki, M | 4 |
| Shiomi, H | 4 |
| Toyota, T | 2 |
| Ohya, M | 1 |
| Suwa, S | 3 |
| Takagi, K | 1 |
| Nanasato, M | 3 |
| Hata, Y | 1 |
| Yagi, M | 1 |
| Suematsu, N | 1 |
| Yokomatsu, T | 1 |
| Takamisawa, I | 1 |
| Doi, M | 1 |
| Noda, T | 1 |
| Okayama, H | 1 |
| Seino, Y | 1 |
| Tada, T | 3 |
| Sakamoto, H | 1 |
| Hibi, K | 2 |
| Abe, M | 4 |
| Kawai, K | 1 |
| Nakao, K | 2 |
| Tanabe, K | 2 |
| Ikari, Y | 2 |
| Hanaoka, KI | 1 |
| Morino, Y | 2 |
| Kozuma, K | 2 |
| Kadota, K | 3 |
| Furukawa, Y | 3 |
| Nakagawa, Y | 4 |
| Kimura, T | 7 |
| Lee, JS | 10 |
| Zheng, Y | 3 |
| Lieschke, F | 1 |
| Schaefer, JH | 1 |
| Foerch, C | 1 |
| van Leyen, K | 1 |
| Gieling, E | 1 |
| de Vries, F | 3 |
| Williams, R | 1 |
| van Onzenoort, HAW | 1 |
| de Boer, A | 3 |
| Ten Cate, V | 1 |
| Kramers, C | 2 |
| Burden, A | 1 |
| Feeley, TM | 5 |
| Walsh, RA | 1 |
| Harbison, JA | 1 |
| Madhavan, P | 1 |
| O'Neill, SM | 1 |
| Colgan, MP | 1 |
| Moran, N | 1 |
| Meaney, JF | 1 |
| Kim, SM | 1 |
| Jung, JM | 3 |
| Kwon, SU | 9 |
| Bello, NA | 2 |
| Miller, EC | 2 |
| Cleary, KL | 1 |
| Wapner, R | 2 |
| Chowdhary, S | 1 |
| Eitel, I | 1 |
| Zweiker, R | 1 |
| Ong, P | 1 |
| Ottesen, MM | 1 |
| Tijssen, JGP | 2 |
| Garg, S | 2 |
| Carrie, D | 2 |
| Dannenberg, L | 5 |
| Metzen, D | 1 |
| Zako, S | 2 |
| Pöhl, M | 2 |
| Mourikis, P | 2 |
| Helten, C | 3 |
| Trojovsky, K | 2 |
| Naguib, D | 3 |
| Konsek, D | 2 |
| Knoop, B | 2 |
| Ayhan, A | 1 |
| Hohlfeld, T | 6 |
| Petzold, T | 1 |
| Levkau, B | 4 |
| Veulemans, V | 1 |
| Zeus, T | 5 |
| Kelm, M | 5 |
| Polzin, A | 5 |
| Pouru, JP | 1 |
| Jaakkola, S | 1 |
| Lund, J | 1 |
| Biancari, F | 1 |
| Saraste, A | 1 |
| Chernov, D | 1 |
| Karavassilis, ME | 1 |
| Hassan, F | 1 |
| Bhandari, M | 1 |
| Gelbenegger, G | 2 |
| Postula, M | 1 |
| Pecen, L | 1 |
| Lesiak, M | 1 |
| Schoergenhofer, C | 1 |
| Jilma, B | 7 |
| Hengstenberg, C | 2 |
| Siller-Matula, JM | 3 |
| Bestari, MB | 1 |
| Joewono, IR | 1 |
| Popkirov, S | 1 |
| Healey, JS | 9 |
| Gladstone, DJ | 3 |
| Kimpton, J | 1 |
| Khong, T | 1 |
| Welsh, RC | 3 |
| Bode, C | 1 |
| Gersh, B | 1 |
| Kwon, HS | 1 |
| Lee, D | 1 |
| Lee, MH | 1 |
| Yu, S | 5 |
| Lim, JS | 1 |
| Lee, EJ | 3 |
| Kang, DW | 7 |
| Sandner, SE | 2 |
| Schunkert, H | 5 |
| Wiedemann, D | 2 |
| Misfeld, M | 2 |
| Böning, A | 2 |
| Tebbe, U | 1 |
| Nowak, B | 2 |
| Stritzke, J | 1 |
| Laufer, G | 3 |
| von Scheidt, M | 3 |
| Moriarty, F | 1 |
| Liao, YWB | 1 |
| Wang, TKM | 1 |
| Yang, M | 2 |
| Wiley, C | 1 |
| Park, JH | 6 |
| Kim, YJ | 3 |
| Wong, LKS | 2 |
| Hwang, YH | 2 |
| Heo, SH | 4 |
| Ahn, SH | 2 |
| Seo, WK | 2 |
| Navarro, JC | 2 |
| Kim, EG | 2 |
| Kim, S | 2 |
| Nam, HS | 1 |
| Gili, S | 1 |
| Bertaina, M | 1 |
| Iannaccone, M | 1 |
| Cammann, VL | 1 |
| Di Vece, D | 1 |
| Kato, K | 1 |
| Szawan, KA | 1 |
| Frangieh, AH | 1 |
| Boffini, B | 1 |
| Annaratone, M | 1 |
| Sarcon, A | 1 |
| Levinson, RA | 1 |
| Franke, J | 1 |
| Napp, LC | 1 |
| Jaguszewski, M | 1 |
| Noutsias, M | 1 |
| Münzel, T | 1 |
| Knorr, M | 1 |
| Heiner, S | 1 |
| Katus, HA | 2 |
| Burgdorf, C | 1 |
| Thiele, H | 1 |
| Bauersachs, J | 1 |
| Tschöpe, C | 1 |
| Pieske, BM | 1 |
| Rajan, L | 1 |
| Michels, G | 1 |
| Pfister, R | 1 |
| Cuneo, A | 1 |
| Jacobshagen, C | 2 |
| Hasenfuß, G | 1 |
| Karakas, M | 1 |
| Koenig, W | 1 |
| Rottbauer, W | 1 |
| Said, SM | 1 |
| Braun-Dullaeus, RC | 1 |
| Banning, A | 1 |
| Cuculi, F | 1 |
| Kobza, R | 1 |
| Fischer, TA | 1 |
| Vasankari, T | 1 |
| Dworakowski, R | 1 |
| MacCarthy, P | 1 |
| Kaiser, C | 1 |
| Osswald, S | 1 |
| Galiuto, L | 1 |
| Crea, F | 1 |
| Dichtl, W | 1 |
| Franz, WM | 1 |
| Empen, K | 1 |
| Felix, SB | 1 |
| Delmas, C | 1 |
| Lairez, O | 1 |
| El-Battrawy, I | 1 |
| Akin, I | 1 |
| Borggrefe, M | 1 |
| Horowitz, JD | 1 |
| Kozel, M | 1 |
| Tousek, P | 1 |
| Gilyarova, E | 1 |
| Shilova, A | 1 |
| Gilyarov, M | 1 |
| Biondi-Zoccai, G | 2 |
| Winchester, DE | 1 |
| Ukena, C | 1 |
| Neuhaus, M | 1 |
| Bax, JJ | 1 |
| Prasad, A | 2 |
| Di Mario, C | 1 |
| Böhm, M | 1 |
| Gasparini, M | 1 |
| Ruschitzka, F | 1 |
| Bossone, E | 1 |
| Citro, R | 1 |
| Rinaldi, M | 2 |
| Lüscher, T | 1 |
| Ghadri, JR | 1 |
| Templin, C | 1 |
| Paciaroni, M | 4 |
| Ince, B | 1 |
| Hu, B | 3 |
| Jeng, JS | 3 |
| Kutluk, K | 1 |
| Lou, M | 1 |
| Parfenov, V | 1 |
| Wong, KSL | 5 |
| Zamani, B | 1 |
| Paek, D | 1 |
| Min Han, J | 1 |
| Del Aguila, M | 1 |
| Schneider, DJ | 1 |
| McMahon, SR | 1 |
| Ehle, GL | 1 |
| Chava, S | 1 |
| Taatjes-Sommer, HS | 1 |
| Meagher, S | 1 |
| Zhao, G | 3 |
| Lin, F | 1 |
| Shao, X | 1 |
| Gong, Y | 4 |
| Yang, D | 3 |
| Lei, H | 2 |
| Cheng, Z | 2 |
| Guo, D | 2 |
| Zhang, Q | 4 |
| Zhang, F | 1 |
| Hohnloser, SH | 11 |
| de Veer, A | 1 |
| Nordaby, M | 2 |
| Miede, C | 1 |
| Oldgren, J | 3 |
| Cannon, CP | 9 |
| Zuo, Z | 1 |
| Kumar, A | 1 |
| Shariff, M | 1 |
| Doshi, R | 1 |
| Pu, Y | 2 |
| Zou, X | 2 |
| Atchaneeyasakul, K | 1 |
| Liebeskind, DS | 1 |
| Rosińska, J | 1 |
| Maciejewska, J | 1 |
| Narożny, R | 1 |
| Kozubski, W | 3 |
| Łukasik, M | 1 |
| Mo, J | 2 |
| Schlemm, L | 1 |
| Schlemm, E | 1 |
| Gitin, A | 1 |
| Pfeffer, MA | 4 |
| DeMets, DL | 1 |
| Hennekens, CH | 14 |
| Freitas-Silva, M | 2 |
| Medeiros, R | 2 |
| Nunes, JPL | 1 |
| Randall, B | 1 |
| Andersen, G | 2 |
| Iversen, HK | 1 |
| Roine, RO | 1 |
| Sjostrand, C | 1 |
| Rhodes, JF | 1 |
| Søndergaard, L | 1 |
| Elm, J | 2 |
| Willey, JZ | 2 |
| Biros, MH | 1 |
| Ross, MA | 1 |
| Limsakun, T | 1 |
| Dishy, V | 1 |
| Mendell, J | 1 |
| Pizzagalli, F | 1 |
| Pav, J | 1 |
| Kochan, J | 1 |
| Vandell, AG | 1 |
| Rambaran, C | 1 |
| Kobayashi, F | 1 |
| Orihashi, Y | 1 |
| Warren, V | 1 |
| McPhillips, P | 1 |
| Zhou, J | 3 |
| Bell, H | 1 |
| Steinfort, B | 1 |
| Pasalic, L | 1 |
| Dexter, M | 1 |
| Pencina, MJ | 2 |
| Berdan, LG | 2 |
| Faulkner, M | 1 |
| Nallamothu, BK | 1 |
| Fintel, DJ | 3 |
| Ford, DE | 2 |
| Daugherty, SE | 2 |
| Nauman, E | 2 |
| Kraschnewski, J | 1 |
| Ahmad, FS | 2 |
| Haynes, K | 3 |
| Metkus, T | 1 |
| McClay, JC | 2 |
| Geary, C | 1 |
| Lampert, BC | 1 |
| Seifein, H | 1 |
| Roger, VL | 2 |
| Alvarado, G | 1 |
| Goldberg, YH | 2 |
| VanWormer, JL | 1 |
| Farrehi, P | 2 |
| McTigue, KM | 2 |
| Rothman, R | 1 |
| Richards, A | 1 |
| Jackson, NJ | 1 |
| Cheng, EM | 1 |
| Bryg, RJ | 2 |
| Brown, A | 1 |
| Towfighi, A | 2 |
| Sanossian, N | 2 |
| Barry, F | 1 |
| Li, N | 1 |
| Vickrey, BG | 1 |
| Pande, SD | 1 |
| Win, MM | 1 |
| Khine, AA | 1 |
| Zaw, EM | 1 |
| Manoharraj, N | 1 |
| Lolong, L | 1 |
| Tin, AS | 1 |
| McKenna, MC | 1 |
| Fanning, N | 1 |
| Cronin, S | 1 |
| Wojdyla, D | 2 |
| Cainzos-Achirica, M | 1 |
| Miedema, MD | 2 |
| McEvoy, JW | 1 |
| Al Rifai, M | 1 |
| Greenland, P | 1 |
| Dardari, Z | 1 |
| Budoff, M | 1 |
| Blumenthal, RS | 1 |
| Yeboah, J | 1 |
| Duprez, DA | 1 |
| Mortensen, MB | 1 |
| Dzaye, O | 1 |
| Hong, J | 1 |
| Nasir, K | 1 |
| Blaha, MJ | 1 |
| Shoji, S | 1 |
| Sawano, M | 1 |
| Sandhu, AT | 1 |
| Heidenreich, PA | 2 |
| Shiraishi, Y | 1 |
| Ikemura, N | 1 |
| Ueno, K | 1 |
| Suzuki, M | 1 |
| Numasawa, Y | 1 |
| Fukuda, K | 1 |
| Kohsaka, S | 1 |
| Fox, KA | 20 |
| Keller, L | 1 |
| Nagaraj, TA | 1 |
| Snider, MJ | 1 |
| Davidson, E | 1 |
| Weiss, R | 1 |
| Afzal, M | 1 |
| Veltkamp, R | 5 |
| Romoli, M | 1 |
| Giannandrea, D | 1 |
| Eusebi, P | 1 |
| Cupini, LM | 1 |
| Ricci, S | 3 |
| Calabresi, P | 1 |
| Clemens, KK | 1 |
| Woodward, M | 2 |
| Neal, B | 1 |
| Zinman, B | 1 |
| Wu, XT | 1 |
| He, RR | 1 |
| Liang, SZ | 1 |
| Ye, GY | 1 |
| Ding, SB | 1 |
| Kent, DM | 2 |
| Kizer, JR | 1 |
| Homma, S | 17 |
| Rosterman, L | 1 |
| Carroll, JD | 1 |
| Ishida, K | 1 |
| Sangha, N | 1 |
| Jordan, F | 1 |
| McGuinness, B | 1 |
| Passmore, P | 1 |
| Kelly, JP | 1 |
| Tudur Smith, C | 1 |
| Murphy, K | 1 |
| Devane, D | 1 |
| Gencer, B | 1 |
| Li, XS | 1 |
| Gurmu, Y | 1 |
| Morrow, DA | 3 |
| Cohen, M | 5 |
| Johanson, P | 1 |
| Hazen, SL | 1 |
| Sabatine, MS | 3 |
| Chiarito, M | 1 |
| Sanz-Sánchez, J | 1 |
| Cannata, F | 1 |
| Sturla, M | 1 |
| Panico, C | 1 |
| Regazzoli, D | 1 |
| Reimers, B | 2 |
| Condorelli, G | 2 |
| Ferrante, G | 3 |
| Stefanini, GG | 1 |
| Wein, T | 1 |
| Lindsay, MP | 1 |
| Poppe, A | 1 |
| Bell, A | 1 |
| Casaubon, LK | 1 |
| Foley, N | 1 |
| Cox, J | 2 |
| Douketis, J | 2 |
| Field, T | 1 |
| Gioia, L | 1 |
| Habert, J | 1 |
| Lang, E | 1 |
| Papoushek, C | 2 |
| Semchuk, W | 1 |
| Udell, JA | 1 |
| Lawrence, S | 1 |
| Mountain, A | 1 |
| Gubitz, G | 4 |
| Dowlatshahi, D | 2 |
| Simard, A | 1 |
| de Jong, A | 1 |
| Brainin, M | 1 |
| Donnan, G | 2 |
| Gdovinová, Z | 1 |
| Kleinig, TJ | 1 |
| Martins, S | 1 |
| Meyerhoff, J | 1 |
| Milling, T | 1 |
| Pfeilschifter, W | 1 |
| Reif, M | 1 |
| Schäbitz, WR | 2 |
| Leventis, I | 1 |
| Elshafei, MN | 1 |
| Imam, Y | 1 |
| Mohamed, MFH | 1 |
| AlSaud, AE | 1 |
| Ahmed, MS | 1 |
| Saeid, R | 1 |
| Ali, M | 1 |
| Abdallah, IM | 1 |
| Parray, AS | 1 |
| Danjuma, MI | 1 |
| Yi, YY | 1 |
| Shin, HJ | 1 |
| Choi, SG | 1 |
| Kang, JW | 1 |
| Song, HJ | 1 |
| Kim, SK | 2 |
| Kim, DW | 1 |
| Albay, CEQ | 1 |
| Leyson, FGD | 1 |
| Cheng, FC | 1 |
| Gager, GM | 1 |
| Winter, MP | 1 |
| Lang, IM | 1 |
| Toma, A | 1 |
| Prüller, F | 1 |
| Wallner, M | 1 |
| Kolesnik, E | 1 |
| von Lewinski, D | 1 |
| Mohamed-Hussein, AAR | 1 |
| Aly, KME | 1 |
| Ibrahim, MAA | 1 |
| Spence, JD | 7 |
| Tiemuerniyazi, X | 1 |
| Song, Y | 3 |
| Xu, F | 2 |
| Gryaznov, AA | 1 |
| Saeyeldin, A | 1 |
| Abdelbaky, M | 1 |
| Zafar, MA | 1 |
| Tanweer, M | 1 |
| Papanikolaou, D | 1 |
| Imran, M | 1 |
| Ziganshin, BA | 1 |
| Elefteriades, JA | 1 |
| Jin, J | 2 |
| Huang, L | 1 |
| Luo, C | 2 |
| Han, Z | 7 |
| Ge, W | 1 |
| Ong, E | 1 |
| Guidoux, C | 1 |
| Lavallée, PC | 1 |
| Hobeanu, C | 1 |
| Charles, H | 1 |
| Labreuche, J | 1 |
| Cabrejo, L | 1 |
| Martin-Bechet, A | 1 |
| Nighoghossian, N | 1 |
| Scheitz, JF | 1 |
| Pare, G | 4 |
| Peacock, WF | 4 |
| Nolte, CH | 3 |
| Krahn, T | 1 |
| Wu, B | 4 |
| Shi, L | 2 |
| Xanthopoulos, A | 1 |
| Tryposkiadis, K | 1 |
| Triposkiadis, F | 1 |
| Fukamachi, K | 1 |
| Soltesz, EG | 1 |
| Young, JB | 1 |
| Wolski, K | 1 |
| Blackstone, EH | 1 |
| Starling, RC | 1 |
| Edward, JA | 1 |
| Gopal, RK | 1 |
| Albers, GW | 23 |
| Jonasson, J | 6 |
| Wong, KL | 2 |
| Darius, H | 6 |
| Slivka, A | 1 |
| Rink, C | 1 |
| Paoletto, D | 1 |
| Sen, CK | 1 |
| Firstenfeld, A | 1 |
| Povedano, GP | 2 |
| Ferrari, J | 2 |
| Smilowitz, NR | 1 |
| Berger, JS | 4 |
| Chon, MK | 1 |
| Jung, SM | 1 |
| Lee, SY | 2 |
| Hwang, KW | 1 |
| Choi, JH | 4 |
| Park, YH | 1 |
| Chun, KJ | 1 |
| Jing, Q | 1 |
| Wang, B | 1 |
| Qiao, S | 1 |
| Hara, H | 2 |
| van Klaveren, D | 1 |
| Ono, M | 1 |
| Kawashima, H | 1 |
| Gao, C | 1 |
| Niethammer, M | 1 |
| Fontos, G | 1 |
| Angioi, M | 1 |
| Ribeiro, VG | 1 |
| Barbato, E | 2 |
| Leandro, S | 1 |
| Verbeeck, J | 1 |
| Sharif, F | 1 |
| Darmon, A | 1 |
| Mas, JL | 7 |
| Cacoub, P | 3 |
| Billaut-Laden, I | 1 |
| Mueller, AA | 1 |
| Vaidya, A | 1 |
| Tarter, LL | 1 |
| Klein, JP | 2 |
| Barkoudah, E | 1 |
| Southwell, BG | 2 |
| Eder, M | 2 |
| Finnegan, J | 2 |
| Luepker, RV | 3 |
| Duval, S | 3 |
| Russell, C | 2 |
| Graves, RN | 1 |
| Namboodri, A | 1 |
| Lanthier, L | 1 |
| Huard, G | 1 |
| Plourde, ME | 1 |
| Cauchon, M | 1 |
| Ou, Z | 1 |
| Liang, Z | 1 |
| Deng, W | 1 |
| Wu, Z | 2 |
| Jiang, H | 2 |
| Ouyang, F | 1 |
| Xing, S | 2 |
| Zeng, J | 4 |
| McDonald, DD | 1 |
| Srisopa, P | 1 |
| Sticchi, A | 1 |
| Verolino, G | 1 |
| Pasceri, V | 1 |
| Vizzi, V | 1 |
| Brscic, E | 1 |
| Casu, G | 1 |
| Golino, P | 1 |
| Russo, V | 1 |
| Rapacciuolo, A | 1 |
| Boccuzzi, G | 1 |
| Mangieri, A | 1 |
| Pagnotta, PA | 1 |
| Trifan, G | 1 |
| Hillmann, M | 1 |
| Elgendy, IY | 3 |
| Fanning, L | 1 |
| Wong, ICK | 2 |
| Chan, EW | 1 |
| Mongkhon, P | 1 |
| Man, KKC | 1 |
| Wei, L | 1 |
| Leung, WK | 1 |
| Darzins, P | 1 |
| Bell, JS | 1 |
| Ilomaki, J | 1 |
| Lau, WCY | 1 |
| Dong, Y | 1 |
| Ao, X | 1 |
| Fu, B | 1 |
| Dong, L | 1 |
| Hamilton, F | 1 |
| Arnold, D | 1 |
| Henley, W | 1 |
| Payne, RA | 1 |
| Reeh, KW | 1 |
| Casanova, A | 1 |
| Störk, S | 2 |
| A A Fox, K | 1 |
| Huang, K | 1 |
| Cheng, CL | 3 |
| Yang, YK | 1 |
| Abdul Rahman, L | 1 |
| Cotsonis, G | 4 |
| Almallouhi, E | 1 |
| Holmstedt, CA | 1 |
| Kaplovitch, E | 1 |
| Abola, MT | 1 |
| Makkar, RR | 1 |
| Saito, S | 1 |
| Neumann, FJ | 4 |
| Hermiller, J | 1 |
| Picon, H | 1 |
| Toelg, R | 1 |
| Maksoud, A | 1 |
| Chehab, BM | 1 |
| Wang, LJ | 1 |
| Yu, Z | 1 |
| Zhou, H | 2 |
| Shan, B | 1 |
| Fu, J | 4 |
| Feng, Q | 1 |
| Jin, X | 1 |
| Guimarães, HP | 1 |
| de Barros E Silva, PGM | 1 |
| Liporace, IL | 1 |
| Sampaio, RO | 1 |
| Tarasoutchi, F | 1 |
| Paixão, M | 1 |
| Hoffmann-Filho, CR | 1 |
| Patriota, R | 1 |
| Leiria, TLL | 1 |
| Lamprea, D | 1 |
| Precoma, DB | 1 |
| Atik, FA | 1 |
| Silveira, FS | 1 |
| Farias, FR | 1 |
| Barreto, DO | 1 |
| Almeida, AP | 1 |
| Zilli, AC | 1 |
| de Souza Neto, JD | 1 |
| Cavalcante, MA | 1 |
| Figueira, FAMS | 1 |
| Junior, RA | 1 |
| Moisés, VA | 1 |
| Mesas, CE | 1 |
| Ardito, RV | 1 |
| Kalil, PSA | 1 |
| Paiva, MSMO | 1 |
| Maldonado, JGA | 1 |
| de Lima, CEB | 1 |
| D'Oliveira Vieira, R | 1 |
| Laranjeira, L | 1 |
| Kojima, F | 1 |
| Damiani, L | 1 |
| Nakagawa, RH | 1 |
| Dos Santos, JRY | 1 |
| Sampaio, BS | 1 |
| Campos, VB | 1 |
| Saraiva, JFK | 1 |
| Fonseca, FH | 1 |
| Pinto, IM | 1 |
| Magalhães, CC | 1 |
| Ferreira, JFM | 1 |
| Pavanello, R | 1 |
| Cavalcanti, AB | 1 |
| Weng, JC | 1 |
| Jiao, YM | 1 |
| Fu, WL | 1 |
| Huo, R | 1 |
| Yan, ZH | 1 |
| Xu, HY | 1 |
| Cao, Y | 4 |
| Zhao, JZ | 1 |
| Bulwa, Z | 1 |
| Saleh Velez, FG | 1 |
| Pinto, CB | 1 |
| Kaushik, A | 1 |
| Deora, S | 1 |
| Choudhary, R | 1 |
| You, SC | 1 |
| Rho, Y | 1 |
| Bikdeli, B | 1 |
| Kim, J | 3 |
| Siapos, A | 1 |
| Weaver, J | 1 |
| Londhe, A | 1 |
| Cho, J | 1 |
| Park, J | 1 |
| Schuemie, M | 1 |
| Suchard, MA | 1 |
| Madigan, D | 1 |
| Hripcsak, G | 1 |
| Gupta, A | 1 |
| Reich, CG | 1 |
| Ryan, PB | 1 |
| Park, RW | 1 |
| Krumholz, HM | 1 |
| Ajufo, E | 1 |
| Ayers, CR | 1 |
| Vigen, R | 1 |
| Joshi, PH | 1 |
| Rohatgi, A | 1 |
| de Lemos, JA | 2 |
| Khera, A | 1 |
| Xie, J | 1 |
| Geng, L | 1 |
| Guo, Y | 2 |
| Kinoshita, Y | 1 |
| Hioki, H | 1 |
| Ito, Y | 4 |
| Yamaguchi, J | 1 |
| Shiode, N | 1 |
| Ako, J | 3 |
| Hirohata, A | 1 |
| Sonoda, S | 1 |
| Kargiotis, O | 1 |
| Ng, VWS | 1 |
| Siu, CW | 5 |
| Chiu, PKC | 1 |
| Kng, CPL | 1 |
| Jamieson, E | 1 |
| Lam, MPS | 1 |
| Iguchi, Y | 3 |
| Urabe, T | 4 |
| Yamagami, H | 3 |
| Todo, K | 3 |
| Idomari, K | 3 |
| Kaneko, N | 3 |
| Iwanaga, T | 3 |
| Terasaki, T | 3 |
| Tanaka, R | 3 |
| Yamamoto, N | 3 |
| Tsujino, A | 4 |
| Nomura, K | 3 |
| Abe, K | 4 |
| Uno, M | 4 |
| Matsuoka, H | 3 |
| Yamagata, S | 3 |
| Yamamoto, Y | 3 |
| Yonehara, T | 3 |
| Inoue, T | 4 |
| Yagita, Y | 5 |
| Wang, HY | 1 |
| Cai, ZX | 1 |
| Yin, D | 1 |
| Yang, YJ | 1 |
| Song, WH | 1 |
| Dou, KF | 1 |
| Carnicelli, AP | 1 |
| Hong, H | 2 |
| Giugliano, RP | 1 |
| Patel, MR | 4 |
| Wallentin, L | 11 |
| Ruff, CT | 2 |
| Hill, MD | 9 |
| Zhao, T | 1 |
| Zhou, C | 2 |
| Lin, W | 1 |
| Desai, N | 1 |
| Wilson, B | 1 |
| Bond, M | 1 |
| Conant, A | 1 |
| Rahman, M | 1 |
| Wong, YS | 1 |
| Tsai, CF | 1 |
| Ong, CT | 1 |
| Schofield, JR | 1 |
| Hughes, HN | 1 |
| Birlea, M | 1 |
| Hassell, KL | 1 |
| Wiśniewski, A | 1 |
| Ullah, W | 1 |
| Zghouzi, M | 1 |
| Ahmad, B | 1 |
| Biswas, S | 1 |
| Zaher, N | 1 |
| Sattar, Y | 1 |
| Pacha, HM | 1 |
| Velagapudi, P | 3 |
| Fichman, DL | 1 |
| Alraies, MC | 1 |
| Horev, A | 2 |
| Zlotnik, Y | 1 |
| Borodetsky, V | 1 |
| Biederko, R | 1 |
| Star, M | 1 |
| Zvenigorodsky, V | 1 |
| Shelef, I | 1 |
| Ifergane, G | 1 |
| Xu, D | 1 |
| Hou, K | 1 |
| Gou, X | 1 |
| Lv, N | 1 |
| Fang, W | 1 |
| Geraskina, LA | 1 |
| Kovacevic, KD | 1 |
| Greisenegger, S | 1 |
| Langer, A | 3 |
| Buchtele, N | 1 |
| Pabinger, I | 1 |
| Petroczi, K | 1 |
| Zhu, S | 1 |
| Gilbert, JC | 1 |
| Wittbrodt, E | 1 |
| Bhalla, N | 1 |
| Sundell, KA | 1 |
| Hunt, P | 1 |
| Wong, ND | 2 |
| Kuster, M | 1 |
| Mellström, C | 1 |
| Kim, SJ | 2 |
| Kwon, OD | 1 |
| Choi, HC | 1 |
| Cho, B | 1 |
| Lin, X | 1 |
| Guan, Y | 1 |
| Camargo, EC | 1 |
| Tefferi, A | 1 |
| Szuber, N | 1 |
| Pardanani, A | 1 |
| Hanson, CA | 1 |
| Vannucchi, AM | 1 |
| Barbui, T | 1 |
| Gangat, N | 1 |
| Xue, X | 1 |
| Akao, M | 2 |
| Kaikita, K | 2 |
| Matoba, T | 1 |
| Nakamura, M | 3 |
| Miyauchi, K | 1 |
| Hagiwara, N | 1 |
| Hirayama, A | 2 |
| Matsui, K | 1 |
| Ogawa, H | 6 |
| Hess, NR | 1 |
| Sultan, I | 1 |
| Thoma, F | 1 |
| Kilic, A | 1 |
| Scavasine, VC | 1 |
| Barbosa, RM | 1 |
| Lopes Neto, FDN | 1 |
| Germininani, FMB | 1 |
| Bazan, R | 1 |
| Zétola, VF | 1 |
| Massaro, AR | 1 |
| Lange, MC | 1 |
| Ewbank, F | 1 |
| Birks, J | 1 |
| Bulters, D | 1 |
| Chen, M | 2 |
| Sun, J | 2 |
| Zhang, PP | 1 |
| Li, W | 5 |
| Mo, BF | 1 |
| Chen, TZ | 1 |
| Tang, X | 5 |
| Li, YG | 1 |
| Alušík, Š | 1 |
| Paluch, Z | 1 |
| Yerasi, C | 1 |
| Forrestal, BJ | 1 |
| Case, BC | 1 |
| Ben-Dor, I | 1 |
| Satler, LF | 1 |
| Rogers, T | 1 |
| Mintz, GS | 1 |
| Waksman, R | 1 |
| Traenka, C | 1 |
| Gensicke, H | 1 |
| Schaedelin, SA | 1 |
| Luft, AR | 1 |
| Simonetti, BG | 1 |
| Fischer, U | 2 |
| Michel, P | 7 |
| Sirimarco, G | 1 |
| Kägi, G | 1 |
| Vehoff, J | 1 |
| Nedeltchev, K | 8 |
| Kahles, T | 2 |
| Kellert, L | 1 |
| Rosenbaum, S | 1 |
| von Rennenberg, R | 1 |
| Sztajzel, R | 1 |
| Leib, SL | 1 |
| Jung, S | 3 |
| Gralla, J | 1 |
| Bruni, N | 1 |
| Seiffge, D | 1 |
| Feil, K | 1 |
| Polymeris, AA | 1 |
| Steiner, L | 1 |
| Hamann, J | 1 |
| Bonati, LH | 1 |
| Brehm, A | 1 |
| De Marchis, GM | 1 |
| Peters, N | 2 |
| Stippich, C | 1 |
| Wegener, S | 1 |
| Psychogios, MN | 1 |
| Arnold, M | 7 |
| Milojevic, M | 1 |
| Zimpfer, D | 1 |
| Zellmer, S | 1 |
| Dalen, JE | 6 |
| Goldberg, RJ | 3 |
| Waterbrook, A | 1 |
| Wylie, L | 1 |
| Alpert, JS | 1 |
| Honig, A | 1 |
| Sacagiu, T | 1 |
| Filioglo, A | 1 |
| Simaan, N | 1 |
| Kalish, Y | 1 |
| Gomori, JM | 2 |
| Leker, RR | 1 |
| Cohen, JE | 3 |
| Jain, V | 1 |
| Aggarwal, D | 1 |
| Vaduganathan, M | 2 |
| Arora, S | 1 |
| Hussain, Z | 1 |
| Uberoi, G | 1 |
| Tafur, A | 1 |
| Ricciardi, M | 1 |
| Qamar, A | 2 |
| Rostanski, S | 1 |
| Johnston, C | 1 |
| Olesen, KKW | 1 |
| Heide-Jørgensen, U | 1 |
| Thim, T | 1 |
| Thomsen, RW | 2 |
| Bøtker, HE | 2 |
| Sørensen, HT | 4 |
| Maeng, M | 2 |
| Crenshaw, DL | 1 |
| Anderson, RD | 1 |
| Handberg, EM | 2 |
| Manning, BR | 1 |
| Riley, D | 1 |
| DeWalt, DA | 1 |
| Hess, R | 1 |
| Kraschnewski, JL | 1 |
| Campbell, JR | 1 |
| Bell, DS | 1 |
| Paranjape, A | 1 |
| Qualls, LG | 1 |
| Modrow, MF | 1 |
| Marcus, GM | 2 |
| Carton, TW | 1 |
| Waitman, LR | 1 |
| Kho, AN | 1 |
| Shenkman, EA | 1 |
| Kaushal, R | 1 |
| Antman, EM | 2 |
| Davidson, DR | 1 |
| Edgley, K | 1 |
| Brown, LS | 1 |
| McCormick, TE | 1 |
| Alikhaani, JD | 1 |
| Gregoire, KC | 1 |
| Shantsila, E | 2 |
| Kozieł, M | 1 |
| Lip, GY | 63 |
| Li, ZX | 1 |
| Gu, HQ | 1 |
| Fisher, M | 7 |
| Wang, YJ | 2 |
| Sheth, KN | 1 |
| Lansberg, M | 1 |
| Tirschwell, D | 1 |
| Mistry, E | 1 |
| Violi, F | 1 |
| Cammisotto, V | 1 |
| Pignatelli, P | 1 |
| Hamburg, NM | 1 |
| Creager, MA | 3 |
| Bálint, A | 1 |
| Tornyos, D | 1 |
| El Alaoui El Abdallaoui, O | 1 |
| Kupó, P | 1 |
| Komócsi, A | 1 |
| Bahrani, S | 1 |
| Teimouri-Jervekani, Z | 1 |
| El Otmani, H | 1 |
| Berrada, M | 1 |
| Abdulhakeem, Z | 1 |
| Bellakhdar, S | 1 |
| El Moutawakil, B | 2 |
| Abdoh Rafai, M | 1 |
| Sanderson, NC | 1 |
| Parker, WAE | 1 |
| Han, M | 1 |
| Kuang, J | 1 |
| Tu, J | 1 |
| Starcevich, K | 1 |
| Peng, C | 1 |
| Yin, S | 1 |
| Yi, Y | 1 |
| Sebök, M | 1 |
| Hostettler, IC | 1 |
| Keller, E | 1 |
| Rautalin, IM | 1 |
| Coert, BA | 1 |
| Vandertop, WP | 1 |
| Post, R | 1 |
| Sardeha, A | 1 |
| Tjerkstra, MA | 1 |
| Regli, L | 1 |
| Verbaan, D | 1 |
| Germans, MR | 1 |
| Hilkens, NA | 1 |
| Algra, A | 24 |
| Csiba, L | 3 |
| Hacke, W | 13 |
| Kappelle, LJ | 13 |
| Leys, D | 11 |
| Greving, JP | 1 |
| Condello, F | 1 |
| Liccardo, G | 1 |
| Lin, L | 1 |
| Zhong, B | 1 |
| Xu, DP | 1 |
| Krim, SR | 1 |
| Bennett, A | 1 |
| Pfeffer, M | 5 |
| Campbell, PT | 1 |
| Thai, S | 1 |
| Baetz, B | 1 |
| Wever-Pinzon, J | 1 |
| Eiswirth, C | 1 |
| Desai, S | 1 |
| Ventura, HO | 1 |
| Huang, WY | 2 |
| Ovbiagele, B | 14 |
| Krantz, MJ | 1 |
| Debus, SE | 1 |
| Hsia, J | 2 |
| Nehler, MR | 1 |
| Hess, CN | 3 |
| Capell, WH | 1 |
| Bracken, T | 1 |
| Mátyás, L | 1 |
| Krievins, DK | 1 |
| Nault, P | 1 |
| Stefanov, S | 1 |
| Hiatt, WR | 1 |
| Bauersachs, RM | 1 |
| Stolk, LM | 1 |
| Ebbelaar, C | 1 |
| Schalekamp, T | 1 |
| Souverein, P | 1 |
| Ten Cate-Hoek, A | 1 |
| Burden, AM | 2 |
| Ghamasaee, P | 1 |
| Carr, K | 1 |
| Johnson, J | 1 |
| Grandhi, R | 1 |
| Melkonian, M | 1 |
| Jarzebowski, W | 1 |
| Pautas, E | 1 |
| Siguret, V | 1 |
| Belmin, J | 1 |
| Lafuente-Lafuente, C | 1 |
| Christophe, BR | 1 |
| Mehta, SH | 1 |
| Garton, AL | 1 |
| Sisti, J | 1 |
| Connolly, ES | 2 |
| Rao, Z | 2 |
| Zheng, H | 2 |
| Dong, K | 3 |
| Mahmoud, AN | 2 |
| Elgendy, AY | 1 |
| Rambarat, C | 1 |
| Mahtta, D | 1 |
| Bavry, AA | 4 |
| Fiolaki, A | 1 |
| Kyritsis, AP | 1 |
| Papadaki, S | 1 |
| Kosmidou, M | 1 |
| Moschonas, IC | 1 |
| Tselepis, AD | 3 |
| Giannopoulos, S | 1 |
| Cai, H | 1 |
| Cai, B | 3 |
| Zhou, S | 2 |
| Cao, L | 3 |
| Guo, H | 1 |
| Sun, W | 5 |
| Yan, B | 3 |
| Davis, SM | 7 |
| Van de Werf, F | 2 |
| Secemsky, EA | 2 |
| Kereiakes, DJ | 2 |
| Cutlip, DE | 2 |
| Massaro, JM | 2 |
| Apruzzese, PK | 2 |
| Mauri, L | 5 |
| Leon Guerrero, CR | 1 |
| Gandhy, S | 1 |
| Burger, KM | 1 |
| Sigounas, D | 1 |
| Pagnotta, P | 1 |
| Guimarães, PO | 2 |
| Abdul-Rahim, AH | 1 |
| Flaker, GC | 4 |
| Hanna, M | 2 |
| Lees, KR | 9 |
| McMurray, JJV | 1 |
| Sorbets, E | 1 |
| Rodés-Cabau, J | 1 |
| Masson, JB | 1 |
| Garcia Del Blanco, B | 1 |
| Pelletier, M | 1 |
| Webb, JG | 1 |
| Al-Qoofi, F | 1 |
| Généreux, P | 3 |
| Maluenda, G | 1 |
| Thoenes, M | 1 |
| Paradis, JM | 1 |
| Chamandi, C | 1 |
| Serra, V | 1 |
| Dumont, E | 1 |
| Côté, M | 1 |
| Choi, HI | 1 |
| Ahn, JM | 2 |
| Kang, SH | 2 |
| Lee, PH | 3 |
| Kang, SJ | 3 |
| Lee, SW | 4 |
| Kim, YH | 6 |
| Lee, CW | 3 |
| Park, SW | 3 |
| Park, DW | 3 |
| Park, SJ | 4 |
| Ohnuki, Y | 2 |
| Kohara, S | 1 |
| Shimizu, M | 1 |
| Takizawa, S | 1 |
| Rosafio, F | 1 |
| Lelli, N | 1 |
| Mimmi, S | 1 |
| Vandelli, L | 1 |
| Bigliardi, G | 1 |
| Dell'Acqua, ML | 1 |
| Picchetto, L | 1 |
| Pentore, R | 1 |
| Ferraro, D | 1 |
| Trenti, T | 1 |
| Nichelli, P | 1 |
| Zini, A | 1 |
| Richman, IB | 1 |
| Owens, DK | 1 |
| Arous, S | 1 |
| Haboub, M | 1 |
| El Ghali Benouna, M | 1 |
| Bentaoune, T | 1 |
| Habbal, R | 1 |
| Cerrud-Rodriguez, RC | 1 |
| Quinteros, MG | 1 |
| Azam, M | 1 |
| Wium-Andersen, IK | 1 |
| Wium-Andersen, MK | 1 |
| Jørgensen, MB | 1 |
| Osler, M | 1 |
| Tao, Y | 1 |
| Iijima, R | 3 |
| Shinke, T | 1 |
| Okada, H | 1 |
| Anzai, H | 1 |
| Tanaka, H | 1 |
| Ueda, Y | 1 |
| Takiuchi, S | 1 |
| Nishida, Y | 1 |
| Ohira, H | 1 |
| Kawaguchi, K | 1 |
| Kadotani, M | 1 |
| Niinuma, H | 1 |
| Omiya, K | 1 |
| Morita, T | 1 |
| Zen, K | 1 |
| Yasaka, Y | 1 |
| Inoue, K | 1 |
| Ishiwata, S | 1 |
| Ochiai, M | 1 |
| Hamasaki, T | 1 |
| Yokoi, H | 2 |
| Park, SM | 1 |
| Jeong, H | 1 |
| Jung, MH | 1 |
| Hong, MK | 5 |
| Bang, CS | 1 |
| Kim, CY | 1 |
| Yuan, C | 1 |
| Zhong, L | 1 |
| Huang, RC | 1 |
| Aunes, M | 1 |
| Bokelund-Singh, S | 1 |
| Held, P | 8 |
| Jahreskog, M | 1 |
| Jiang, M | 1 |
| You, JHS | 1 |
| Morris, JG | 1 |
| Carter, EL | 1 |
| Martin, SA | 1 |
| Rao, NM | 2 |
| Wu, YL | 2 |
| Jolobe, OMP | 1 |
| Bernstein, R | 1 |
| Hart, R | 6 |
| Im, E | 1 |
| Cho, YH | 1 |
| Suh, Y | 1 |
| Cho, DK | 1 |
| Her, AY | 2 |
| Kang, WC | 2 |
| Yun, KH | 1 |
| Yoo, SY | 1 |
| Cheong, SS | 2 |
| Shin, DH | 2 |
| Ahn, CM | 1 |
| Ko, YG | 2 |
| Choi, D | 3 |
| Jang, Y | 4 |
| Karmali, KN | 1 |
| Spengos, K | 3 |
| Manios, E | 3 |
| Elisaf, M | 1 |
| Kirchhof, P | 2 |
| Blank, BF | 1 |
| Calvert, M | 1 |
| Chlouverakis, G | 1 |
| Goette, A | 1 |
| Huening, A | 1 |
| Simantirakis, E | 1 |
| Vardas, P | 1 |
| Ming, T | 1 |
| Cong, Y | 1 |
| Larsen, SB | 1 |
| Grove, EL | 3 |
| Neergaard-Petersen, S | 1 |
| Würtz, M | 2 |
| Hvas, AM | 1 |
| Kristensen, SD | 3 |
| Harada, Y | 1 |
| Michel, J | 1 |
| Lohaus, R | 1 |
| Mayer, K | 1 |
| Emmer, R | 1 |
| Lahmann, AL | 1 |
| Colleran, R | 1 |
| Giacoppo, D | 1 |
| Wolk, A | 1 |
| Tölg, R | 1 |
| Seyfarth, M | 1 |
| Zrenner, B | 1 |
| Wöhrle, J | 1 |
| Kufner, S | 1 |
| Morath, T | 1 |
| Ibrahim, T | 1 |
| Bernlochner, I | 1 |
| Fischer, M | 2 |
| Laugwitz, KL | 1 |
| Mehilli, J | 2 |
| Byrne, RA | 2 |
| Schulz-Schüpke, S | 1 |
| Fidan, E | 1 |
| Cummings, DD | 1 |
| Manole, MD | 1 |
| Han, YF | 1 |
| Dai, QL | 1 |
| Chen, XL | 1 |
| Xiong, YY | 1 |
| Yin, Q | 2 |
| Xu, GL | 1 |
| Zhu, WS | 1 |
| Zhang, RL | 1 |
| Ma, MM | 1 |
| Liu, WH | 1 |
| Liu, XF | 1 |
| Feres, F | 3 |
| Abizaid, A | 3 |
| Gilard, M | 2 |
| Morice, MC | 2 |
| Palmerini, T | 2 |
| Stone, GW | 4 |
| Shiels, MS | 1 |
| Purdue, MP | 1 |
| Freedman, ND | 1 |
| Abnet, CC | 1 |
| Hollenbeck, AR | 1 |
| Hayes, RB | 1 |
| Silverman, DT | 1 |
| Berndt, SI | 1 |
| Benedetto, U | 2 |
| Bianco, M | 1 |
| Moretti, C | 1 |
| D'Onofrio, A | 1 |
| Agrifoglio, M | 1 |
| Ribichini, F | 1 |
| Tarantini, G | 1 |
| D'Amico, M | 1 |
| Salizzoni, S | 1 |
| Xie, S | 1 |
| He, W | 1 |
| Wei, D | 1 |
| Parsons, MR | 1 |
| Stoner, MC | 1 |
| Doyle, A | 1 |
| Mix, D | 1 |
| Cameron, SJ | 1 |
| McDonald, MM | 1 |
| Almaghrabi, TS | 1 |
| Saenz, DM | 1 |
| Cai, C | 2 |
| Rahbar, MH | 1 |
| Choi, HA | 1 |
| Grotta, JC | 1 |
| Chang, TR | 1 |
| Ciconte, G | 1 |
| Conti, M | 1 |
| Baldi, M | 1 |
| Saviano, M | 1 |
| Vicedomini, G | 1 |
| Pappone, C | 1 |
| Sun, X | 1 |
| Dong, W | 1 |
| Cai, X | 1 |
| Jiang, W | 4 |
| Fang, Q | 1 |
| Vasudeva, K | 1 |
| Chaurasia, P | 1 |
| Munshi, A | 4 |
| Subahi, A | 1 |
| Hassan, AAI | 1 |
| Abubakar, H | 1 |
| Ibrahim, W | 1 |
| Chen, HY | 1 |
| Chou, P | 1 |
| Qiu, J | 1 |
| Grine, K | 1 |
| Hawks, MK | 1 |
| Dixon, MA | 1 |
| Oza, R | 1 |
| Rundell, K | 1 |
| Garcellano, M | 1 |
| Chigonda, TG | 1 |
| Chatora, GT | 1 |
| Ngwende, GW | 1 |
| Miller, RF | 1 |
| Ferrand, RA | 1 |
| de Veer, AJWM | 2 |
| Bode, K | 1 |
| Mahmoodi, BK | 2 |
| Kirpach, B | 1 |
| Gilbertson, D | 1 |
| Ernst, ME | 2 |
| Williamson, J | 1 |
| Dagenais, G | 1 |
| Metsarinne, K | 1 |
| Ha, JW | 2 |
| Avezum, AA | 2 |
| Lisheng, L | 1 |
| Yusoff, K | 1 |
| Cook Bruns, N | 1 |
| Kakkar, AK | 1 |
| Misselwitz, F | 2 |
| Chen, E | 1 |
| Branch, K | 1 |
| Lekic, T | 1 |
| Manaktala, R | 1 |
| Kluger, J | 3 |
| Fluschnik, N | 1 |
| Becher, PM | 1 |
| Schnabel, R | 1 |
| Blankenberg, S | 1 |
| Westermann, D | 1 |
| González-Pérez, A | 4 |
| Gaist, D | 2 |
| de Abajo, FJ | 1 |
| Sáez, ME | 3 |
| García Rodríguez, LA | 4 |
| Hirono, J | 1 |
| Sanaki, H | 1 |
| Kitada, K | 1 |
| Sada, H | 1 |
| Suzuki, A | 1 |
| Lie, LK | 1 |
| Segi-Nishida, E | 1 |
| Nakagawa, K | 1 |
| Hasegawa, H | 1 |
| Robertson, L | 1 |
| Yeoh, SE | 1 |
| Ramli, A | 1 |
| Lee, CH | 5 |
| Lee, JY | 2 |
| Park, GM | 1 |
| Choi, YJ | 3 |
| Nam, CW | 1 |
| Cho, JH | 2 |
| Shin, WY | 1 |
| Seo, JB | 1 |
| Choi, SW | 1 |
| Min, PK | 1 |
| Her, SH | 1 |
| Beridze, M | 2 |
| Duley, L | 2 |
| Flaherty, K | 2 |
| Havard, D | 1 |
| Heptinstall, S | 3 |
| Markus, HS | 9 |
| Randall, M | 1 |
| Scutt, P | 2 |
| Venables, GS | 3 |
| Navi, BB | 1 |
| Marshall, RS | 1 |
| Bobrow, D | 1 |
| Singer, S | 1 |
| Stone, JB | 1 |
| DeSancho, MT | 1 |
| DeAngelis, LM | 1 |
| Cappellari, M | 1 |
| Turcato, G | 1 |
| Forlivesi, S | 1 |
| Zivelonghi, C | 1 |
| Bovi, P | 1 |
| Bonetti, B | 1 |
| Toni, D | 11 |
| Elmariah, S | 1 |
| Doros, G | 2 |
| Benavente, OR | 8 |
| Steinhubl, SR | 6 |
| Hsieh, WH | 2 |
| Antigüedad-Muñoz, J | 1 |
| de la Riva, P | 1 |
| Arenaza Choperena, G | 1 |
| Muñoz Lopetegi, A | 1 |
| Andrés Marín, N | 1 |
| Fernández-Eulate, G | 1 |
| Moreno Valladares, M | 1 |
| Martínez Zabaleta, M | 1 |
| Maksym, J | 1 |
| Mazurek, T | 1 |
| Kochman, J | 1 |
| Grygier, M | 1 |
| Kapłon-Cieślicka, A | 1 |
| Marchel, M | 1 |
| Lodziński, P | 1 |
| Piątkowski, R | 1 |
| Wilimski, R | 1 |
| Czub, P | 1 |
| Fojt, A | 1 |
| Karolczak, N | 1 |
| Hendzel, P | 1 |
| Kitagawa, T | 1 |
| Yamamoto, J | 2 |
| Kureshima, M | 1 |
| Maeda, H | 1 |
| Nishizawa, S | 1 |
| Liu, SM | 1 |
| Zhao, WL | 1 |
| Song, HQ | 1 |
| Meng, R | 1 |
| Li, SJ | 1 |
| Ren, CH | 1 |
| Ji, XM | 1 |
| Feng, WW | 1 |
| Weise, FK | 2 |
| Bordignon, S | 1 |
| Perrotta, L | 1 |
| Konstantinou, A | 1 |
| Bologna, F | 1 |
| Nagase, T | 1 |
| Chun, KRJ | 2 |
| Schmidt, B | 2 |
| Yeo, KK | 2 |
| Armstrong, EJ | 2 |
| López, JE | 1 |
| Chen, DC | 2 |
| Westin, GG | 2 |
| Li, CS | 1 |
| Anderson, D | 3 |
| Hua, A | 1 |
| Singapuri, A | 1 |
| Amsterdam, EA | 2 |
| Chiamvimonvat, N | 1 |
| Laird, JR | 2 |
| Madelaire, C | 1 |
| Gislason, G | 2 |
| Kristensen, SL | 3 |
| Bjerre, J | 1 |
| D'Souza, M | 1 |
| Gustafsson, F | 1 |
| Kober, L | 2 |
| Schou, M | 1 |
| Lin, A | 1 |
| Kumar, S | 3 |
| de Lusignan, S | 1 |
| McGovern, A | 1 |
| Correa, A | 1 |
| Hriskova, M | 1 |
| Gatenby, P | 1 |
| Jones, S | 1 |
| Goldsmith, D | 1 |
| Verma, A | 2 |
| Ha, ACT | 1 |
| Hindricks, G | 1 |
| Wyse, DG | 1 |
| Champagne, J | 1 |
| Essebag, V | 1 |
| Wells, G | 1 |
| Gupta, D | 1 |
| Heidbuchel, H | 1 |
| Sanders, P | 1 |
| Birnie, DH | 1 |
| Kopin, D | 1 |
| Sherwood, MW | 1 |
| Parkhomenko, A | 5 |
| Labovitz, DL | 1 |
| Dhamoon, MS | 1 |
| Dugani, S | 1 |
| Ames, JM | 1 |
| Manson, JE | 3 |
| Mora, S | 1 |
| Lee, S | 2 |
| Gao, R | 1 |
| Su, G | 1 |
| Zhang, A | 1 |
| Shen, L | 1 |
| Cohen, P | 1 |
| Musisca, N | 1 |
| Binder, W | 1 |
| Rahmani, MR | 1 |
| Shamsizadeh, A | 1 |
| Moghadam-Ahmadi, A | 1 |
| Kaeidi, A | 1 |
| Allahtavakoli, M | 1 |
| Feldberg, J | 1 |
| Patel, P | 2 |
| Farrell, A | 1 |
| Sivarajahkumar, S | 1 |
| Cameron, K | 1 |
| Battistella, M | 1 |
| Dávalos, A | 5 |
| Cunha, L | 4 |
| Lindgren, A | 4 |
| Arauz, A | 6 |
| Gagliardi, R | 1 |
| Tatlisumak, T | 2 |
| Brouns, R | 2 |
| DeVries Basson, MM | 1 |
| Muir, K | 2 |
| Pater, C | 2 |
| Weitz, J | 1 |
| Kirsch, B | 2 |
| Peters, G | 3 |
| Themeles, E | 2 |
| Schmidt, M | 3 |
| Horváth-Puhó, E | 2 |
| Henderson, VW | 1 |
| Christiansen, CF | 2 |
| Chae, SC | 1 |
| Chae, IH | 3 |
| Seong, IW | 2 |
| Chae, JK | 2 |
| Cho, MC | 2 |
| Kang, HJ | 3 |
| Kalantri, A | 1 |
| Kalantri, S | 1 |
| Pitts-Tucker, T | 1 |
| Small, J | 1 |
| Chi, G | 1 |
| Jamil, A | 1 |
| Radulovic, M | 1 |
| Jamil, U | 1 |
| Balouch, MA | 1 |
| Marszalek, J | 1 |
| Karimi, Z | 1 |
| Pahlavani, S | 1 |
| Jafarizade, M | 1 |
| Shaukat, H | 1 |
| Kalayci, A | 1 |
| Srivastava, P | 1 |
| Butler, J | 1 |
| Shroyer, AL | 1 |
| Lacey, M | 2 |
| Parikh, PB | 1 |
| Raza, SA | 1 |
| Durm, LB | 1 |
| Mahmoud, GA | 1 |
| Rahman, H | 3 |
| Henriquez, L | 1 |
| Davis, B | 1 |
| Nahab, F | 1 |
| Izzy, S | 1 |
| Rubin, DB | 1 |
| Ahmed, FS | 1 |
| Akbik, F | 1 |
| Renault, S | 1 |
| Sylvester, KW | 2 |
| Vaitkevicius, H | 1 |
| Smallwood, JA | 1 |
| Givertz, MM | 1 |
| Feske, SK | 3 |
| Wang, WT | 1 |
| Li, YY | 1 |
| Lin, WC | 1 |
| Chen, JY | 1 |
| Lan, KM | 1 |
| Sun, CK | 1 |
| Hung, KC | 1 |
| Liu, CY | 1 |
| Chen, HC | 1 |
| Rothnie, KJ | 1 |
| Connell, O | 1 |
| Müllerová, H | 1 |
| Smeeth, L | 1 |
| Pearce, N | 1 |
| Douglas, I | 1 |
| Quint, JK | 1 |
| Dai, Z | 1 |
| Liu, R | 2 |
| Hao, Y | 1 |
| Xu, G | 4 |
| Davda, N | 1 |
| Osman, C | 1 |
| Barsan, W | 3 |
| Conwit, RA | 1 |
| De Vries Basson, MM | 1 |
| Sheridan, P | 2 |
| Weitz, JI | 3 |
| Joyner, C | 3 |
| Yi, X | 12 |
| Chai, Z | 2 |
| Zhou, Q | 8 |
| Huang, R | 1 |
| Ding, L | 2 |
| Peng, B | 1 |
| Schmaier, AA | 1 |
| Fyfe, I | 1 |
| Kalantzi, KI | 1 |
| Ntalas, IV | 1 |
| Chantzichristos, VG | 1 |
| Tsoumani, ME | 1 |
| Adamopoulos, D | 1 |
| Asimakopoulos, C | 1 |
| Bourdakis, A | 1 |
| Darmanis, P | 1 |
| Dimitriadou, A | 1 |
| Gkiokas, S | 1 |
| Ipeirotis, K | 1 |
| Kitikidou, K | 1 |
| Klonaris, I | 1 |
| Kostaki, A | 1 |
| Logothetis, D | 1 |
| Mainas, K | 1 |
| Mais, T | 1 |
| Maragiannis, A | 1 |
| Martiadou, K | 1 |
| Mavronasos, K | 1 |
| Michelongonas, I | 1 |
| Mitropoulos, D | 1 |
| Papadimitriou, G | 1 |
| Papadopoulos, A | 1 |
| Papaioakeim, M | 1 |
| Sofillas, K | 1 |
| Stabola, S | 1 |
| Stefanakis, E | 1 |
| Stergiou, D | 1 |
| Thoma, M | 1 |
| Zenetos, A | 1 |
| Zisekas, S | 1 |
| Goudevenos, JA | 2 |
| Panagiotakos, DB | 1 |
| Cohn, SL | 1 |
| Litin, SC | 1 |
| Bundrick, JB | 1 |
| Liaw, D | 2 |
| Yao, JC | 1 |
| Cui, M | 1 |
| Pan, MM | 1 |
| Gu, ZC | 1 |
| Li, WY | 1 |
| Giustino, G | 2 |
| Redfors, B | 1 |
| Kirtane, AJ | 1 |
| Dangas, GD | 2 |
| Maehara, A | 1 |
| McAndrew, T | 1 |
| Farhan, S | 2 |
| Rinaldi, MJ | 1 |
| Metzger, DC | 1 |
| Henry, TD | 1 |
| Cox, DA | 2 |
| Duffy, PL | 1 |
| Mazzaferri, EL | 1 |
| Brodie, BR | 1 |
| Stuckey, TD | 1 |
| Ben-Yehuda, O | 1 |
| Almas, A | 1 |
| Ghazni, MS | 1 |
| Hashmani, S | 1 |
| Mushtaq, Z | 1 |
| Rollini, F | 1 |
| Gwon, HC | 3 |
| Franchi, F | 1 |
| Dimitroulis, D | 1 |
| Golabkesh, M | 1 |
| Jung, C | 2 |
| Khatri, P | 2 |
| Kleindorfer, DO | 2 |
| Devlin, T | 1 |
| Sawyer, RN | 2 |
| Starr, M | 1 |
| Mejilla, J | 1 |
| Broderick, J | 1 |
| Chatterjee, A | 1 |
| Jauch, EC | 2 |
| Levine, SR | 6 |
| Vagal, A | 1 |
| Purdon, B | 1 |
| Devenport, J | 1 |
| Pavlov, A | 1 |
| Yeatts, SD | 2 |
| Wang, CW | 1 |
| Su, LL | 1 |
| Hua, QJ | 1 |
| Fan, YN | 1 |
| Xi, TT | 1 |
| Liu, YX | 1 |
| Ji, SB | 1 |
| Rothwell, PM | 17 |
| Cook, NR | 5 |
| Gaziano, JM | 6 |
| Price, JF | 2 |
| Belch, JFF | 1 |
| Roncaglioni, MC | 2 |
| Mehta, Z | 2 |
| Khan, SU | 2 |
| Talluri, S | 1 |
| Lekkala, M | 1 |
| Khan, MS | 2 |
| Riaz, H | 2 |
| Shah, H | 3 |
| Kaluski, E | 3 |
| Sattur, S | 1 |
| Schwill, S | 1 |
| Krug, K | 1 |
| Peters-Klimm, F | 1 |
| van Lieshout, J | 1 |
| Laux, G | 1 |
| Szecsenyi, J | 1 |
| Wensing, M | 1 |
| Mazlan-Kepli, W | 1 |
| Berry, C | 1 |
| Walters, M | 1 |
| Chen, L | 1 |
| Cao, S | 1 |
| Kitano, T | 1 |
| Matsubara, S | 1 |
| Donadini, MP | 1 |
| Barlas, RS | 1 |
| Loke, YK | 2 |
| Bettencourt-Silva, JH | 2 |
| Ford, I | 6 |
| Clark, AB | 1 |
| Bowles, KM | 1 |
| Metcalf, AK | 1 |
| Potter, JF | 5 |
| Hirsch, AT | 3 |
| O'Byrne, S | 1 |
| Ma, C | 2 |
| Liu, AF | 1 |
| Wang, K | 2 |
| Qiu, H | 1 |
| Jiang, WJ | 1 |
| Goyal, N | 1 |
| Kerro, A | 1 |
| Krishnan, R | 1 |
| Malhotra, K | 1 |
| Pandhi, A | 1 |
| Duden, P | 1 |
| Deep, A | 1 |
| Shahripour, RB | 1 |
| Bryndziar, T | 1 |
| Nearing, K | 1 |
| Chulpayev, B | 1 |
| Chang, J | 2 |
| Zand, R | 1 |
| Alexandrov, AW | 1 |
| Alexandrov, AV | 6 |
| Böttger, P | 1 |
| Grond, M | 4 |
| Lemm, H | 1 |
| Buerke, M | 1 |
| Khan, SI | 1 |
| Shihata, WA | 1 |
| Andrews, KL | 1 |
| Lee, MKS | 1 |
| Moore, XL | 1 |
| Jefferis, AM | 1 |
| Vinh, A | 1 |
| Gaspari, T | 1 |
| Dragoljevic, D | 1 |
| Jennings, GL | 1 |
| Murphy, AJ | 1 |
| Chin-Dusting, JPF | 1 |
| Ueda, P | 1 |
| Jernberg, T | 4 |
| Alfredsson, J | 1 |
| Erlinge, D | 2 |
| Omerovic, E | 1 |
| Persson, J | 1 |
| Ravn-Fischer, A | 1 |
| Tornvall, P | 1 |
| Svennblad, B | 1 |
| Varenhorst, C | 3 |
| Brotons, C | 1 |
| Coppolecchia, R | 1 |
| Cricelli, C | 1 |
| Howard, G | 11 |
| Pearson, TA | 4 |
| Ruilope, LM | 1 |
| Tendera, M | 2 |
| Tognoni, G | 2 |
| Regenhardt, RW | 1 |
| Biseko, MR | 1 |
| Shayo, AF | 1 |
| Mmbando, TN | 1 |
| Grundy, SJ | 1 |
| Saadi, A | 1 |
| Wibecan, L | 1 |
| Kharal, GA | 1 |
| Parker, R | 1 |
| Mateen, FJ | 1 |
| Okeng'o, K | 1 |
| Fathy, S | 1 |
| Shahin, MH | 1 |
| Langaee, T | 1 |
| Khalil, BM | 1 |
| Saleh, A | 1 |
| Sabry, NA | 1 |
| Schaalan, MF | 1 |
| El Wakeel, LL | 1 |
| Cavallari, LH | 3 |
| Garcia Rinaldi, R | 1 |
| Rodriguez-Acosta, J | 1 |
| Bermúdez, D | 1 |
| Galera, Á | 1 |
| Quinones, S | 1 |
| Quinones, J | 1 |
| Ibrahim, A | 1 |
| Kiernan, TJ | 1 |
| Frieden, RW | 1 |
| Lutsep, H | 2 |
| Nedeltechev, K | 1 |
| Perera, K | 2 |
| Santo, G | 2 |
| Olavarria, V | 1 |
| Bangdiwala, S | 1 |
| Sindet-Pedersen, C | 1 |
| Lamberts, M | 4 |
| Staerk, L | 1 |
| Nissen Bonde, A | 1 |
| Pallisgaard, JL | 1 |
| Lock Hansen, M | 1 |
| Gislason, GH | 7 |
| Olesen, JB | 7 |
| Dalugama, C | 1 |
| Gawarammana, IB | 1 |
| Horyniecki, M | 1 |
| Łącka-Gaździk, B | 1 |
| Niewiadomska, E | 1 |
| Mazur, B | 1 |
| Śnit, M | 1 |
| Łabuz-Roszak, B | 2 |
| Wernly, B | 1 |
| Lichtenauer, M | 1 |
| Hoppe, UC | 1 |
| Lauten, A | 1 |
| Meier, B | 4 |
| Sanchez-Lopez, J | 1 |
| Fernandez-Travieso, JC | 1 |
| Illnait-Ferrer, J | 1 |
| Fernandez-Dorta, L | 1 |
| Mendoza-Castano, S | 1 |
| Mas-Ferreiro, R | 1 |
| Mesa-Angarica, M | 1 |
| Reyes-Suarez, P | 1 |
| Tong, S | 1 |
| Joseph, J | 1 |
| Jia, L | 1 |
| Li, R | 2 |
| Yin, X | 1 |
| Chi, NF | 1 |
| Wen, CP | 1 |
| Liu, CH | 2 |
| Chen, CH | 2 |
| Lien, LM | 2 |
| Lin, CH | 1 |
| Chang, WL | 1 |
| Gruber, P | 1 |
| Hlavica, M | 1 |
| Berberat, J | 1 |
| Victor Ineichen, B | 1 |
| Diepers, M | 1 |
| Remonda, L | 2 |
| Ricco, JB | 2 |
| Sillesen, H | 1 |
| Kakkos, S | 1 |
| Halliday, A | 2 |
| Vega de Ceniga, M | 1 |
| Cunningham, TK | 1 |
| Draper, H | 1 |
| Rajesh, U | 1 |
| Luo, H | 1 |
| M'Pembele, R | 1 |
| Wolff, G | 1 |
| Brockmeyer, M | 1 |
| Schulze, V | 1 |
| Kheiri, B | 1 |
| Osman, M | 1 |
| Abdalla, A | 1 |
| Haykal, T | 1 |
| Swaid, B | 1 |
| Ahmed, S | 2 |
| Chahine, A | 1 |
| Hassan, M | 1 |
| Bachuwa, G | 1 |
| Al Qasmi, M | 1 |
| Ornello, R | 1 |
| Carolei, A | 2 |
| Aguilar-Salinas, P | 1 |
| Agnoletto, GJ | 1 |
| Brasiliense, LBC | 1 |
| Santos, R | 1 |
| Granja, MF | 1 |
| Gonsales, D | 1 |
| Aghaebrahim, A | 1 |
| Sauvageau, E | 1 |
| Hanel, RA | 1 |
| Hao, Q | 5 |
| Tampi, M | 1 |
| Foroutan, F | 1 |
| Siemieniuk, RA | 1 |
| Guyatt, G | 4 |
| Prasad, K | 1 |
| Siemieniuk, R | 1 |
| Lytvyn, L | 1 |
| Heen, AF | 1 |
| Agoritsas, T | 1 |
| Vandvik, PO | 2 |
| Gorthi, SP | 1 |
| Fisch, L | 1 |
| Jusufovic, M | 1 |
| Muller, J | 1 |
| Booth, B | 1 |
| Horton, E | 1 |
| Fraiz, A | 1 |
| Siemieniuk, J | 1 |
| Fobuzi, AC | 1 |
| Katragunta, N | 1 |
| Rochwerg, B | 1 |
| Sugawara, M | 3 |
| Goto, Y | 1 |
| Yamazaki, T | 3 |
| Teramoto, T | 3 |
| Oikawa, S | 3 |
| Shimada, K | 3 |
| Ishizuka, N | 3 |
| Murata, M | 3 |
| Yokoyama, K | 3 |
| Uemura, Y | 2 |
| Ikeda, Y | 5 |
| Sherban, A | 1 |
| Armon, C | 1 |
| Rapoport, M | 1 |
| Masjuan, J | 2 |
| Salido, L | 1 |
| DeFelipe, A | 1 |
| Hernández-Antolín, R | 2 |
| Fernández-Golfín, C | 1 |
| Cruz-Culebras, A | 1 |
| Matute, C | 1 |
| Vera, R | 1 |
| Pérez-Torre, P | 1 |
| Zamorano, JL | 1 |
| Boehme, AK | 1 |
| Chung, NT | 1 |
| Wang, SS | 1 |
| Lacey, JV | 1 |
| Lakshminarayan, K | 2 |
| Zhong, C | 1 |
| Woo, D | 1 |
| Elkind, MSV | 1 |
| Bushnell, C | 3 |
| Khan, SA | 1 |
| Khan, B | 1 |
| Latham, SB | 1 |
| Sang, W | 1 |
| Wei, M | 1 |
| Berkelmans, GFN | 1 |
| Gudbjörnsdottir, S | 1 |
| Wild, SH | 1 |
| Franzen, S | 1 |
| Chalmers, J | 1 |
| Davis, BR | 1 |
| Poulter, NR | 1 |
| Spijkerman, AM | 1 |
| Pressel, SL | 1 |
| Gupta, AK | 1 |
| van der Schouw, YT | 1 |
| Svensson, AM | 1 |
| Read, SH | 1 |
| Eliasson, B | 1 |
| Varigos, J | 1 |
| Tonkin, A | 3 |
| Maggioni, A | 1 |
| Bruns, NC | 1 |
| Coppens, M | 3 |
| Eikelboom, JWA | 1 |
| Loewen, PS | 1 |
| Bansback, N | 1 |
| Hicklin, J | 1 |
| Andrade, JG | 1 |
| Kapanen, AI | 1 |
| Kwan, L | 1 |
| Lynd, LD | 1 |
| McClean, A | 1 |
| MacGillivray, J | 1 |
| Salmasi, S | 1 |
| Pokorney, SD | 1 |
| Gersh, BJ | 6 |
| Ahmad, A | 1 |
| Al-Khatib, SM | 1 |
| Blank, M | 1 |
| DiBattiste, P | 1 |
| Hedrich, O | 1 |
| Hylek, EM | 7 |
| Kline-Rogers, E | 1 |
| Mendys, P | 1 |
| Mirro, MJ | 1 |
| Naccarelli, G | 1 |
| Rutman, H | 1 |
| Stockbridge, N | 1 |
| Temple, R | 1 |
| Vidale, S | 1 |
| Agostoni, E | 1 |
| Grampa, G | 1 |
| Consoli, D | 1 |
| Wutzler, A | 1 |
| Krogias, C | 2 |
| Grau, A | 2 |
| Heuschmann, PU | 1 |
| Haeusler, KG | 2 |
| Boucher, AA | 1 |
| Taylor, JM | 1 |
| Luchtman-Jones, L | 1 |
| Dube, M | 1 |
| Dani, R | 1 |
| Dubey, A | 1 |
| Chouksey, D | 1 |
| Yin, T | 1 |
| Gou, J | 1 |
| He, H | 1 |
| Röther, J | 3 |
| Melis, M | 1 |
| Lu, BC | 1 |
| Shi, XJ | 1 |
| Liang, L | 2 |
| Dong, N | 1 |
| Liu, ZZ | 1 |
| Jiang, Z | 1 |
| Elkind, M | 1 |
| Lucky, M | 1 |
| Fekete, Z | 1 |
| Levi, C | 1 |
| King, A | 2 |
| Madigan, J | 1 |
| Norris, J | 1 |
| Medlinskiene, K | 1 |
| Fay, M | 1 |
| Petty, D | 1 |
| Kang, EY | 1 |
| Lin, YH | 2 |
| Wang, NK | 1 |
| Yeung, L | 1 |
| Wu, WC | 1 |
| Sun, CC | 1 |
| Kang, JH | 2 |
| Hung, MJ | 1 |
| Chen, TH | 2 |
| Jing, Y | 2 |
| Yue, X | 1 |
| Sumaya, W | 1 |
| Franzone, A | 2 |
| McFadden, E | 1 |
| Serruys, P | 1 |
| Liebetrau, C | 1 |
| Janssens, L | 1 |
| Zurakowski, A | 1 |
| van Geuns, RJ | 1 |
| Slagboom, T | 1 |
| Bryniarski, K | 1 |
| Naber, C | 2 |
| Prokopczuk, J | 1 |
| Steg, G | 1 |
| Nasir, F | 1 |
| Hammad, T | 1 |
| Meyer, MA | 1 |
| Phan, HT | 1 |
| Gall, SL | 1 |
| Blizzard, CL | 1 |
| Lannin, NA | 1 |
| Thrift, AG | 5 |
| Anderson, CS | 2 |
| Grimley, R | 1 |
| Castley, HC | 1 |
| Hand, P | 1 |
| Cadilhac, DA | 1 |
| Wang, XH | 1 |
| Tao, L | 1 |
| Li, XQ | 2 |
| Krzyzanowski, B | 1 |
| Manson, SM | 1 |
| Eder, MM | 1 |
| Kne, L | 1 |
| Oldenburg, N | 1 |
| Peterson, K | 1 |
| Kim, D | 1 |
| Nah, HW | 2 |
| Du, F | 1 |
| Epstein, AE | 1 |
| Karlinski, M | 1 |
| Miao, Z | 1 |
| Uchino, K | 2 |
| Alkuwaiti, FA | 1 |
| Elghoneimy, Y | 1 |
| Ghazal, S | 1 |
| Zheng, W | 1 |
| Xie, L | 1 |
| Mao, Q | 1 |
| Tong, W | 1 |
| Zhou, D | 2 |
| Azzalini, L | 1 |
| Greenberg, B | 1 |
| Neaton, JD | 1 |
| Anker, SD | 10 |
| Byra, WM | 1 |
| Cleland, JGF | 1 |
| Deng, H | 1 |
| Fu, M | 1 |
| La Police, DA | 1 |
| Lam, CSP | 1 |
| Mehra, MR | 1 |
| Nessel, CC | 3 |
| Spiro, TE | 1 |
| van Veldhuisen, DJ | 1 |
| Vanden Boom, CM | 1 |
| Zannad, F | 1 |
| Tillman, H | 1 |
| Kirkpatrick, AC | 1 |
| Vincent, AS | 1 |
| Dale, GL | 1 |
| Prodan, CI | 1 |
| Cho, DJ | 1 |
| Jeong, SK | 1 |
| Dimmitt, SB | 1 |
| Floyd, CN | 1 |
| Ferner, RE | 1 |
| Chen, ZW | 1 |
| Wu, CK | 1 |
| Yang, YH | 1 |
| Huang, JW | 1 |
| Wu, VC | 1 |
| Lee, JK | 2 |
| Chen, PC | 1 |
| Lin, LY | 1 |
| Stevens, SR | 2 |
| Lokhnygina, Y | 3 |
| Green, JB | 1 |
| McGuire, DK | 2 |
| Holman, RR | 1 |
| Ma, Q | 1 |
| Chung, H | 1 |
| Shambhu, S | 1 |
| Roe, M | 1 |
| Cziraky, M | 1 |
| Di Tullio, MR | 15 |
| Koch, S | 2 |
| García-Rivera, EJ | 1 |
| Zevallos, JC | 1 |
| Burgin, WS | 1 |
| Goldberger, JJ | 1 |
| Neuzil, P | 2 |
| de Potter, T | 1 |
| van der Heyden, J | 1 |
| Tromp, SC | 1 |
| Rensing, B | 1 |
| Jiresova, E | 1 |
| Dujka, L | 1 |
| Lekesova, V | 1 |
| Tse, D | 1 |
| Kreuzer, J | 1 |
| Cotton, D | 8 |
| Chernyatina, M | 1 |
| Ferro, JM | 3 |
| Kallmünzer, B | 1 |
| Krupinski, J | 2 |
| Lemmens, R | 3 |
| Odinak, M | 1 |
| Nishikawa, M | 1 |
| Takeda, Y | 1 |
| Isomura, N | 1 |
| Tanigawa, T | 1 |
| Tsukahara, K | 1 |
| Takayama, T | 1 |
| Kato, M | 2 |
| Nishikawa, H | 1 |
| Nishimura, Y | 1 |
| Isshiki, T | 1 |
| Chandra, A | 1 |
| Geng, X | 1 |
| Tong, Y | 1 |
| Du, H | 1 |
| Jacobs, MS | 1 |
| van Hulst, M | 1 |
| Adeoye, AM | 1 |
| Tieleman, RG | 3 |
| Postma, MJ | 1 |
| Owolabi, MO | 1 |
| Tanaka, K | 1 |
| Isobe, M | 1 |
| Zhang, XG | 1 |
| Zhu, XQ | 1 |
| Xue, J | 1 |
| Li, ZZ | 1 |
| Jiang, HY | 1 |
| Hu, L | 1 |
| Yue, YH | 1 |
| Harskamp, RE | 1 |
| Chen, XP | 1 |
| Wei, DC | 1 |
| Chen, SQ | 1 |
| He, WZ | 1 |
| Chow, CK | 1 |
| Meng, Q | 1 |
| Xu, GM | 1 |
| Xu, SY | 1 |
| Xi, FC | 1 |
| Wu, XW | 1 |
| Li, CX | 2 |
| Gaziano, TA | 1 |
| Pandya, A | 1 |
| Sy, S | 1 |
| Jardim, TV | 1 |
| Ogden, JM | 1 |
| Weinstein, MC | 1 |
| Harima, K | 1 |
| Honda, S | 1 |
| Mikami, K | 1 |
| Kitajima, M | 1 |
| Urushizaka, M | 1 |
| Tomisawa, T | 1 |
| Hagii, J | 1 |
| Metoki, H | 1 |
| Yasujima, M | 1 |
| Osanai, T | 1 |
| Berberich, A | 1 |
| Gumbinger, C | 1 |
| Ringleb, PA | 4 |
| Zheng, L | 1 |
| Xiang, L | 1 |
| Hao, Z | 1 |
| Satani, N | 1 |
| Giridhar, K | 1 |
| Wewior, N | 1 |
| Norris, DD | 1 |
| Olson, SD | 1 |
| Aronowski, J | 1 |
| Savitz, SI | 1 |
| Chatterjee, S | 1 |
| Dubey, S | 1 |
| Lahiri, D | 1 |
| Ray, BK | 1 |
| Wangqin, R | 1 |
| Judge, C | 1 |
| Ruttledge, S | 1 |
| Loughlin, E | 1 |
| Gorey, S | 1 |
| Costello, M | 1 |
| Nolan, A | 1 |
| Ferguson, J | 2 |
| Halloran, MO | 1 |
| O'Canavan, M | 1 |
| Zurita, KG | 1 |
| Pearson, C | 1 |
| Sethi, P | 1 |
| Vora, N | 1 |
| Baigent, C | 2 |
| Tscharre, M | 1 |
| Bruno, V | 1 |
| Rohla, M | 1 |
| Egger, F | 1 |
| Weiss, TW | 1 |
| Hübl, W | 1 |
| Willheim, M | 1 |
| Wojta, J | 1 |
| Geppert, A | 1 |
| Freynhofer, MK | 1 |
| Meyer, C | 1 |
| McNally, JS | 1 |
| Alexander, M | 1 |
| Chung, L | 1 |
| Patel, V | 1 |
| Ramachandran, B | 1 |
| Omar, I | 1 |
| Bouasquevisque, DS | 1 |
| Haas, NL | 1 |
| Nicholson, A | 1 |
| Haas, MRC | 1 |
| Rizelio, V | 1 |
| Macuco, ALB | 1 |
| Sato, HK | 1 |
| Nascimento, MTMS | 1 |
| Souza, RKM | 1 |
| Kowacs, PA | 1 |
| Karimi, M | 1 |
| Haghpanah, S | 1 |
| Pishdad, P | 1 |
| Zahedi, Z | 1 |
| Parand, S | 1 |
| Safaei, S | 1 |
| Chun, YH | 1 |
| Wada, H | 1 |
| Esato, M | 1 |
| Hashimoto, T | 1 |
| Hasegawa, K | 1 |
| Tsuji, H | 1 |
| Furuke, K | 1 |
| Sabir, IN | 1 |
| Matthews, GD | 1 |
| Huang, CL | 1 |
| Nietlispach, F | 1 |
| Gloekler, S | 1 |
| Krause, R | 1 |
| Shakir, S | 1 |
| Schmid, M | 1 |
| Khattab, AA | 1 |
| Wenaweser, P | 1 |
| Yu, X | 1 |
| Chen, F | 2 |
| Luo, Y | 1 |
| Ren, X | 1 |
| Lv, S | 1 |
| Dharmasaroja, PA | 1 |
| Muengtaweepongsa, S | 1 |
| Sae-Lim, S | 1 |
| Helft, G | 1 |
| Le Feuvre, C | 1 |
| Georges, JL | 1 |
| Leclercq, F | 1 |
| Eltchaninoff, H | 2 |
| Furber, A | 1 |
| Prunier, F | 1 |
| Sebagh, L | 1 |
| Cattan, S | 1 |
| Cayla, G | 1 |
| Vicaut, E | 1 |
| Metzger, JP | 1 |
| Lee, WH | 1 |
| Chu, CY | 1 |
| Hsu, PC | 1 |
| Su, HM | 1 |
| Lin, TH | 1 |
| Voon, WC | 1 |
| Lai, WT | 3 |
| Sheu, SH | 1 |
| Lau, AY | 2 |
| Leung, TW | 8 |
| Huang, Y | 6 |
| Suwanwela, NC | 3 |
| Tan, KS | 2 |
| Ratanakorn, D | 3 |
| Wong, KS | 15 |
| Kolos, I | 1 |
| Loukianov, M | 1 |
| Dupik, N | 1 |
| Boytsov, S | 1 |
| Deev, A | 1 |
| Holmes, D | 3 |
| Meves, SH | 2 |
| Hummel, T | 1 |
| Endres, HG | 2 |
| Mayböck, N | 1 |
| Kaiser, AF | 1 |
| Schröder, KD | 1 |
| Rüdiger, K | 1 |
| Overbeck, U | 2 |
| Mumme, A | 1 |
| Mügge, A | 1 |
| Neubauer, H | 2 |
| Takeuchi, H | 1 |
| Tofler, GH | 1 |
| Spinaze, M | 1 |
| Shaw, E | 1 |
| Buckley, T | 1 |
| Glasser, SP | 2 |
| Hovater, MK | 1 |
| Lackland, DT | 2 |
| Cushman, M | 4 |
| Howard, VJ | 4 |
| Attia, JR | 2 |
| Pearce, R | 1 |
| Torpy, JM | 1 |
| Livingston, EH | 1 |
| Duytschaever, M | 1 |
| Berte, B | 1 |
| Acena, M | 1 |
| De Meyer, G | 1 |
| Bun, SS | 1 |
| Van Heuverswyn, F | 1 |
| Vandekerckhove, Y | 1 |
| Tavernier, R | 1 |
| Bang, OY | 3 |
| Ertaş, F | 2 |
| Kaya, H | 1 |
| Kaya, Z | 1 |
| Bulur, S | 1 |
| Köse, N | 1 |
| Gül, M | 1 |
| Kahya Eren, N | 1 |
| Cağlıyan, CE | 1 |
| Köroğlu, B | 1 |
| Vatan, B | 1 |
| Acar, G | 1 |
| Yüksel, M | 1 |
| Bilik, MZ | 1 |
| Gedik, S | 2 |
| Simşek, Z | 1 |
| Akıl, MA | 1 |
| Yılmaz, R | 1 |
| Oylumlu, M | 1 |
| Arıbaş, A | 1 |
| Yıldız, A | 1 |
| Aydın, M | 1 |
| Yeter, E | 1 |
| Kanadaşı, M | 1 |
| Ergene, O | 1 |
| Ozhan, H | 1 |
| Ulgen, MS | 1 |
| Sood, MM | 2 |
| Larkina, M | 1 |
| Thumma, JR | 1 |
| Tentori, F | 1 |
| Gillespie, BW | 1 |
| Fukuhara, S | 1 |
| Mendelssohn, DC | 1 |
| Chan, K | 1 |
| de Sequera, P | 1 |
| Komenda, P | 1 |
| Rigatto, C | 1 |
| Robinson, BM | 1 |
| Keating, GM | 1 |
| White, JR | 1 |
| Palacio, S | 2 |
| Anderson, DC | 5 |
| Birnbaum, LA | 1 |
| Suanprasert, N | 1 |
| Yadee, T | 1 |
| Mahasirimongkol, S | 1 |
| Jongjaroenprasert, W | 1 |
| Tantirithisak, T | 1 |
| Sharma, V | 3 |
| Dadheech, S | 2 |
| Kaul, S | 3 |
| Jyothy, A | 3 |
| Apostolakis, S | 2 |
| Sayers, RD | 1 |
| McCarthy, MJ | 1 |
| Bown, MJ | 1 |
| Nasim, A | 1 |
| Dennis, MJ | 1 |
| London, NJ | 1 |
| Bell, PR | 1 |
| Zuurbier, SM | 1 |
| Vermeer, SE | 1 |
| Hilkens, PH | 1 |
| Roos, YB | 5 |
| Soejima, H | 2 |
| Nakayama, M | 2 |
| Okada, S | 2 |
| Sakuma, M | 1 |
| Uemura, S | 2 |
| Kanauchi, M | 1 |
| Doi, N | 2 |
| Jinnouchi, H | 2 |
| Sugiyama, S | 2 |
| Waki, M | 2 |
| Saito, Y | 2 |
| Sorkin, GC | 1 |
| Dumont, TM | 1 |
| Wach, MM | 1 |
| Eller, JL | 1 |
| Mokin, M | 2 |
| Natarajan, SK | 1 |
| Baxter, MS | 1 |
| Snyder, KV | 1 |
| Levy, EI | 4 |
| Hopkins, LN | 1 |
| Siddiqui, AH | 2 |
| Cui, L | 1 |
| Jia, J | 1 |
| Xia, H | 1 |
| Stöllberger, C | 3 |
| Finsterer, J | 3 |
| Conrad, MF | 3 |
| Boulom, V | 1 |
| Baloum, V | 1 |
| Mukhopadhyay, S | 1 |
| Garg, A | 1 |
| Cambria, RP | 2 |
| Weimar, C | 6 |
| Sha, N | 1 |
| Weber, R | 7 |
| Dinicolantonio, JJ | 1 |
| Lavie, CJ | 1 |
| Fares, H | 1 |
| Menezes, AR | 1 |
| O'Keefe, JH | 1 |
| Messerli, FH | 2 |
| Valles, J | 2 |
| Lago, A | 3 |
| Moscardo, A | 1 |
| Tembl, J | 1 |
| Parkhutik, V | 1 |
| Santos, MT | 2 |
| D'Amelio, M | 1 |
| Terruso, V | 1 |
| Famoso, G | 1 |
| Di Benedetto, N | 1 |
| Realmuto, S | 1 |
| Valentino, F | 1 |
| Ragonese, P | 1 |
| Savettieri, G | 1 |
| Aridon, P | 1 |
| Sambu, N | 1 |
| Radhakrishnan, A | 1 |
| Englyst, N | 1 |
| Weir, N | 1 |
| Curzen, N | 1 |
| Xia, YP | 1 |
| Mao, L | 1 |
| García-Rodríguez, LA | 1 |
| Morton, J | 1 |
| Cookson, C | 1 |
| Wadiwala, MF | 2 |
| Kamal, AK | 9 |
| McCormack, T | 1 |
| Assiri, A | 1 |
| Al-Majzoub, O | 1 |
| Kanaan, AO | 3 |
| Donovan, JL | 3 |
| Silva, M | 1 |
| Zhou, G | 1 |
| Zhou, X | 3 |
| Battenhouse, H | 1 |
| Conwit, R | 3 |
| Dillon, C | 1 |
| Lindblad, A | 1 |
| Morgenstern, L | 1 |
| Poisson, SN | 1 |
| Palesch, Y | 4 |
| Lane, DA | 11 |
| Raichand, S | 1 |
| Moore, D | 1 |
| Connock, M | 2 |
| Fry-Smith, A | 1 |
| Fitzmaurice, DA | 1 |
| Thompson, JL | 15 |
| Sanford, AR | 3 |
| Mann, DL | 7 |
| Levin, B | 10 |
| Pullicino, PM | 8 |
| Freudenberger, RS | 7 |
| Teerlink, JR | 8 |
| Graham, S | 8 |
| Massie, BM | 3 |
| Labovitz, AJ | 7 |
| Gabriel, AP | 2 |
| Lok, DJ | 8 |
| Ponikowski, P | 8 |
| Qian, M | 5 |
| Haddad, H | 1 |
| Diek, M | 1 |
| Douiri, A | 1 |
| McKevitt, C | 1 |
| Emmett, ES | 1 |
| Rudd, AG | 1 |
| Wolfe, CD | 1 |
| Amaro, S | 2 |
| Llull, L | 1 |
| Urra, X | 1 |
| Obach, V | 4 |
| Cervera, Á | 4 |
| Chamorro, Á | 9 |
| Kansal, AR | 1 |
| Pokora, T | 1 |
| Sorensen, SV | 2 |
| Stiefelhagen, P | 4 |
| Barnett, HJ | 2 |
| Laidlaw, JJ | 1 |
| Suh, SY | 1 |
| Oh, PC | 1 |
| Choi, H | 1 |
| Moon, CI | 1 |
| Han, SH | 1 |
| Ahn, T | 1 |
| Choi, IS | 1 |
| Shin, EK | 1 |
| Tanguay, JF | 1 |
| Bell, AD | 1 |
| Ackman, ML | 1 |
| Bauer, RD | 1 |
| Cartier, R | 1 |
| Chan, WS | 1 |
| Roussin, A | 1 |
| Schnell, G | 1 |
| Verma, S | 2 |
| Wong, G | 1 |
| Kalita, J | 2 |
| Kumar, P | 1 |
| Misra, UK | 2 |
| Kun, L | 1 |
| He, B | 1 |
| Park, JJ | 1 |
| Park, BE | 1 |
| Rhew, JY | 1 |
| Jeon, HK | 1 |
| Oh, JH | 3 |
| Hwang, KK | 1 |
| Yoon, JH | 2 |
| Moon, KW | 1 |
| Kwon, HM | 2 |
| Kenaan, M | 1 |
| Seth, M | 1 |
| Aronow, HD | 3 |
| Wohns, D | 1 |
| Share, D | 1 |
| Gurm, HS | 1 |
| Jastrzębska, M | 1 |
| Chełstowski, K | 1 |
| Wódecka, A | 1 |
| Siennicka, A | 1 |
| Clark, J | 1 |
| Nowacki, P | 1 |
| Yan, BC | 1 |
| Shin, BN | 1 |
| Ahn, JH | 1 |
| Kim, IH | 1 |
| Lee, JC | 1 |
| Yoo, KY | 1 |
| Hwang, IK | 1 |
| Lee, YL | 1 |
| Suh, HW | 1 |
| Jun, JG | 1 |
| Kwon, YG | 1 |
| Kim, YM | 1 |
| Kwon, SH | 1 |
| Her, S | 1 |
| Hyun, BH | 1 |
| Kim, CK | 1 |
| Won, MH | 1 |
| Chiang, FT | 1 |
| Shyu, KG | 1 |
| Wu, CJ | 1 |
| Mar, GY | 1 |
| Hou, CJ | 1 |
| Li, AH | 1 |
| Wen, MS | 1 |
| Lin, SJ | 2 |
| Kuo, CT | 1 |
| Kuo, C | 1 |
| Li, YH | 1 |
| Hwang, JJ | 1 |
| Reilly, PA | 1 |
| Lehr, T | 1 |
| Haertter, S | 1 |
| Ezekowitz, MD | 6 |
| Nehmiz, G | 1 |
| Chabriat, H | 2 |
| Maeder, P | 2 |
| Gass, A | 2 |
| Bracoud, L | 2 |
| Hennerici, M | 3 |
| Smock, A | 1 |
| Jensevik, K | 2 |
| Sundström, A | 1 |
| Hasvold, P | 1 |
| Lagerqvist, B | 2 |
| Mahaffey, KW | 7 |
| White, HD | 7 |
| Becker, RC | 5 |
| Halperin, JL | 16 |
| Singer, DE | 11 |
| Califf, RM | 6 |
| Breithardt, G | 2 |
| Malloy, RJ | 1 |
| Silva, MA | 1 |
| Ding, D | 1 |
| Aylward, P | 2 |
| Husted, S | 5 |
| McMurray, JJ | 1 |
| Pouleur, H | 1 |
| Verheugt, FW | 14 |
| Själander, S | 1 |
| Själander, A | 3 |
| Svensson, PJ | 3 |
| Friberg, L | 2 |
| Ahn, JE | 1 |
| Landsman, N | 1 |
| Rhee, K | 1 |
| Chun, L | 1 |
| Patel, KK | 1 |
| Campo, G | 3 |
| Tebaldi, M | 2 |
| Biscaglia, S | 1 |
| Ferrari, R | 2 |
| Derdeyn, CP | 5 |
| Lynn, MJ | 10 |
| Fiorella, D | 4 |
| Janis, LS | 3 |
| Montgomery, J | 2 |
| Nizam, A | 1 |
| Lane, BF | 3 |
| Barnwell, SL | 2 |
| Waters, MF | 3 |
| Hourihane, JM | 2 |
| Chiu, D | 2 |
| Klucznik, RP | 2 |
| Clark, JM | 2 |
| McDougall, CG | 2 |
| Johnson, MD | 2 |
| Pride, GL | 2 |
| Lynch, JR | 1 |
| Rumboldt, Z | 2 |
| Cloft, HJ | 3 |
| Costa, RA | 1 |
| Marin-Neto, JA | 1 |
| Botelho, RV | 1 |
| King, SB | 1 |
| Negoita, M | 1 |
| de Paula, JE | 1 |
| Mangione, JA | 1 |
| Meireles, GX | 1 |
| Castello, HJ | 1 |
| Nicolela, EL | 1 |
| Perin, MA | 1 |
| Devito, FS | 1 |
| Labrunie, A | 1 |
| Salvadori, D | 1 |
| Gusmão, M | 1 |
| Staico, R | 1 |
| Costa, JR | 1 |
| de Castro, JP | 1 |
| Abizaid, AS | 1 |
| Castilla-Guerra, L | 2 |
| Navas-Alcántara, MS | 2 |
| Fernández-Moreno, MC | 1 |
| Nosul, M | 1 |
| Kolb, GF | 1 |
| Lau, YC | 1 |
| Mansoor, AH | 1 |
| Mujtaba, MT | 1 |
| Silver, B | 2 |
| Roccella, EJ | 1 |
| Deutsch, AF | 1 |
| Fornage, M | 1 |
| George, MG | 4 |
| Kissela, BM | 1 |
| Kittner, SJ | 2 |
| Lichtman, JH | 1 |
| Lisabeth, LD | 1 |
| Qian, Y | 1 |
| Bi, Q | 1 |
| Arslan, Y | 1 |
| Yoldaş, TK | 1 |
| Zorlu, Y | 1 |
| van den Donk, M | 1 |
| Opstelten, W | 1 |
| Oprea, AD | 1 |
| Popescu, WM | 1 |
| Sutcliffe, P | 1 |
| Gurung, T | 1 |
| Freeman, K | 2 |
| Johnson, S | 1 |
| Ngianga-Bakwin, K | 1 |
| Grove, A | 1 |
| Gurung, B | 1 |
| Morrow, S | 1 |
| Stranges, S | 1 |
| Zhao, R | 1 |
| Feng, XY | 1 |
| Zhang, M | 1 |
| Shen, XL | 1 |
| Su, JJ | 1 |
| Liu, JR | 1 |
| Enomoto, Y | 1 |
| Tokue, M | 1 |
| Ito, N | 1 |
| Nagashima, Y | 1 |
| Araki, T | 1 |
| Yamazaki, K | 1 |
| Utsunomiya, M | 1 |
| Itaya, H | 1 |
| Shiba, M | 1 |
| Sugi, K | 1 |
| Gouya, G | 1 |
| Arrich, J | 1 |
| Wolzt, M | 1 |
| Gurbel, PA | 5 |
| Pirker-Kees, A | 1 |
| Omote, Y | 1 |
| Deguchi, K | 1 |
| Kono, S | 1 |
| Liu, N | 1 |
| Kurata, T | 1 |
| Yamashita, T | 4 |
| Takahashi, S | 1 |
| Mizuno, O | 1 |
| Sakaguchi, T | 1 |
| Yamada, T | 1 |
| Inuyama, L | 1 |
| Jakobsson, S | 1 |
| Bergström, L | 1 |
| Björklund, F | 1 |
| Söderström, L | 1 |
| Mooe, T | 1 |
| Lee, YS | 4 |
| Lassen, JF | 1 |
| Mikkelsen, AP | 1 |
| Sørensen, R | 2 |
| Køber, L | 5 |
| Hansen, ML | 4 |
| Pinto, A | 3 |
| Di Raimondo, D | 3 |
| Tuttolomondo, A | 3 |
| Buttà, C | 1 |
| Licata, G | 3 |
| Pecoraro, R | 1 |
| Arnao, V | 2 |
| Clemente, G | 1 |
| Della Corte, V | 1 |
| Maida, C | 1 |
| Simonetta, I | 1 |
| Fernandez-Moreno, Mdel C | 1 |
| Jimenez-Gonzalo, F | 1 |
| Dinh, T | 3 |
| Baur, LH | 1 |
| Pisters, R | 4 |
| Kamp, O | 1 |
| Smeets, JL | 1 |
| Cheriex, EC | 1 |
| Lindeboom, JE | 1 |
| Heesen, WF | 1 |
| Prins, MH | 1 |
| Crijns, HJ | 5 |
| Alcocer, F | 1 |
| Novak, Z | 1 |
| Combs, BR | 1 |
| Lowman, B | 1 |
| Passman, MA | 1 |
| Mujib, M | 1 |
| Jordan, WD | 1 |
| Dorian, P | 4 |
| Kongnakorn, T | 5 |
| Phatak, H | 2 |
| Rublee, DA | 1 |
| Kuznik, A | 1 |
| Lanitis, T | 5 |
| Liu, LZ | 1 |
| Iloeje, U | 1 |
| Hernandez, L | 1 |
| Ice, DS | 1 |
| Shapiro, TA | 1 |
| Gnall, EM | 1 |
| Kowey, PR | 3 |
| Wooley, RH | 1 |
| Swanson, S | 1 |
| Williams, JE | 2 |
| Stern, BJ | 4 |
| Chaturvedi, S | 8 |
| Kase, CS | 4 |
| Gronseth, G | 1 |
| Synhorst, D | 2 |
| Volkov, I | 1 |
| Chen, CY | 1 |
| Lee, KT | 1 |
| Lee, CT | 2 |
| Huang, YB | 1 |
| Ciccone, A | 1 |
| Motto, C | 1 |
| Abraha, I | 1 |
| Cozzolino, F | 1 |
| Santilli, I | 1 |
| Majumdar, S | 1 |
| Miller, M | 1 |
| Khan, M | 6 |
| Gordon, C | 1 |
| Forsythe, A | 1 |
| Smith, MG | 1 |
| Megason, G | 1 |
| Iyer, R | 1 |
| Jabbari, E | 1 |
| Sethuraman, S | 1 |
| Sekaran, L | 1 |
| Lin, AH | 1 |
| Oakley, LS | 1 |
| Phan, HL | 1 |
| Shutt, BJ | 1 |
| Birgersdotter-Green, U | 1 |
| Francisco, GM | 1 |
| Chi, W | 2 |
| Kirkman, MA | 2 |
| Citerio, G | 1 |
| Smith, M | 2 |
| Paul, CL | 1 |
| Levi, CR | 2 |
| D'Este, CA | 1 |
| Parsons, MW | 2 |
| Lindley, RI | 2 |
| Henskens, F | 1 |
| Lalor, E | 1 |
| Longworth, M | 1 |
| Middleton, S | 1 |
| Ryan, A | 1 |
| Kerr, E | 1 |
| Sanson-Fisher, RW | 1 |
| Sandercock, PA | 10 |
| Counsell, C | 1 |
| Tseng, MC | 1 |
| Cecconi, E | 1 |
| Song, PS | 1 |
| Song, YB | 2 |
| Yang, JH | 2 |
| Hahn, JY | 2 |
| Choi, SH | 2 |
| Davis, S | 3 |
| Jones, EF | 1 |
| Cohen, AA | 1 |
| Heiss, WD | 2 |
| Kaste, M | 6 |
| Laouénan, C | 1 |
| Young, D | 1 |
| Macleod, M | 1 |
| George, PM | 1 |
| Foreman, PM | 1 |
| Griessenauer, CJ | 2 |
| Falola, M | 1 |
| McCoach, CE | 1 |
| Bang, H | 1 |
| Huang, H | 1 |
| Yu, J | 2 |
| Cao, G | 1 |
| Zhou, M | 2 |
| Tobin, WO | 5 |
| Kavanagh, GF | 2 |
| O'Donnell, JS | 2 |
| McGrath, RT | 1 |
| Murphy, RP | 5 |
| McCabe, DJ | 10 |
| Ross, S | 1 |
| Eriksson, N | 1 |
| Gerstein, HC | 2 |
| Rose, L | 1 |
| Ridker, PM | 7 |
| Chasman, DI | 1 |
| McCarthy, M | 1 |
| Alonso-Coello, P | 3 |
| Montori, VM | 3 |
| Díaz, MG | 2 |
| Devereaux, PJ | 2 |
| Mas, G | 1 |
| Diez, AI | 2 |
| Solà, I | 2 |
| Roura, M | 2 |
| Souto, JC | 2 |
| Oliver, S | 2 |
| Ruiz, R | 2 |
| Coll-Vinent, B | 2 |
| Gich, I | 2 |
| Schünemann, HJ | 2 |
| Wulf Silver, R | 1 |
| de Vos-Koppelaar, NC | 1 |
| de Vogel, EM | 1 |
| Zock, E | 1 |
| Dieleman, HG | 1 |
| Levitan, B | 1 |
| Burton, P | 2 |
| Poulos, C | 1 |
| Brett Hauber, A | 1 |
| Berlin, JA | 1 |
| Cotté, FE | 1 |
| Gaudin, AF | 1 |
| Kachaner, I | 1 |
| Durand-Zaleski, I | 1 |
| Marcucci, M | 2 |
| Nieuwlaat, R | 2 |
| Iorio, A | 2 |
| Meng, H | 1 |
| Kong, D | 1 |
| Gong, X | 1 |
| Bai, J | 1 |
| Zou, F | 1 |
| Ritchey, MD | 1 |
| Wall, HK | 1 |
| Gillespie, C | 1 |
| Jamal, A | 1 |
| Censori, B | 1 |
| Liu, G | 2 |
| Zhao, K | 1 |
| Hwang, G | 1 |
| Song, KS | 1 |
| Villavicencio, JB | 1 |
| Suroto, NS | 1 |
| Park, NM | 1 |
| Jeong, EA | 1 |
| Kwon, OK | 1 |
| Bai, W | 1 |
| Duan, Z | 1 |
| Cai, Q | 1 |
| Liu, D | 1 |
| Ma, M | 1 |
| McCullough, L | 1 |
| Jacobson, L | 1 |
| De Geer, A | 1 |
| Legrand, V | 1 |
| Chenu, P | 1 |
| Martinez, C | 1 |
| Dens, J | 1 |
| Gach, O | 1 |
| Boland, J | 1 |
| Claeys, MJ | 1 |
| Magne, J | 1 |
| Wijns, W | 1 |
| Wilcox, R | 1 |
| Iqbal, K | 1 |
| Costigan, T | 2 |
| Lopez-Sendon, J | 5 |
| Ramos, Y | 1 |
| Taylor, J | 1 |
| Davidai, G | 1 |
| Gorelick, P | 5 |
| Lipton, RB | 1 |
| Sacco, R | 3 |
| Michalczyk, MJ | 1 |
| Opalacz, A | 1 |
| LaMuraglia, GM | 1 |
| Di Minno, G | 3 |
| Spadarella, G | 1 |
| Cafaro, G | 1 |
| Petitto, M | 1 |
| Lupoli, R | 1 |
| Di Minno, A | 1 |
| de Gaetano, G | 1 |
| Tremoli, E | 3 |
| Turagam, MK | 2 |
| Agrawal, H | 1 |
| Mittal, M | 1 |
| Kocheril, AG | 2 |
| Aggarwal, K | 1 |
| de los Rios, F | 1 |
| Berkowitz, AL | 2 |
| Westover, MB | 2 |
| Bianchi, MT | 2 |
| Chou, SH | 2 |
| Boelman, C | 1 |
| Shroff, M | 1 |
| Yau, I | 2 |
| Bjornson, B | 1 |
| Richrdson, S | 1 |
| deVeber, G | 5 |
| MacGregor, D | 2 |
| Moharir, M | 2 |
| Askalan, R | 3 |
| Cuzick, J | 2 |
| Thorat, MA | 2 |
| Bosetti, C | 1 |
| Brown, PH | 1 |
| Burn, J | 1 |
| Ford, LG | 1 |
| Jacobs, EJ | 1 |
| Jankowski, JA | 1 |
| La Vecchia, C | 1 |
| Law, M | 1 |
| Meyskens, F | 1 |
| Senn, HJ | 1 |
| Umar, A | 1 |
| Torjesen, I | 1 |
| Tang, Y | 1 |
| Peng, Y | 1 |
| Köklü, E | 1 |
| Arslan, Ş | 1 |
| Yüksel, İÖ | 1 |
| Bayar, N | 1 |
| Koç, P | 1 |
| Zinkstok, SM | 4 |
| Beenen, LF | 1 |
| Majoie, CB | 1 |
| Marquering, HA | 1 |
| de Haan, RJ | 3 |
| Lee, YM | 1 |
| Chang, CY | 1 |
| Yen, TL | 1 |
| Geraldine, P | 1 |
| Lan, CC | 1 |
| Sheu, JR | 1 |
| Lee, JJ | 1 |
| Guo, X | 2 |
| Tang, B | 1 |
| Amiri-Nikpour, MR | 1 |
| Nazarbaghi, S | 1 |
| Hamdi-Holasou, M | 1 |
| Rezaei, Y | 1 |
| Lieven, A | 1 |
| Annemans, L | 1 |
| Thijs, V | 3 |
| Marbaix, S | 1 |
| Lauw, MN | 1 |
| Yang, F | 2 |
| He, F | 1 |
| Xia, C | 1 |
| Zhang, JH | 1 |
| Li, FP | 1 |
| Lv, Y | 2 |
| Weisel, RD | 1 |
| Nussmeier, N | 1 |
| Newman, MF | 1 |
| Pearl, RG | 1 |
| Wechsler, AS | 1 |
| Ambrosio, G | 2 |
| Pitt, B | 2 |
| Clare, RM | 1 |
| Pieper, KS | 2 |
| Mongero, L | 1 |
| Reece, TL | 1 |
| Yau, TM | 1 |
| Fremes, S | 1 |
| Menasché, P | 1 |
| Lira, A | 1 |
| Ferguson, TB | 1 |
| Wändell, P | 3 |
| von Euler, M | 1 |
| Hasselström, J | 1 |
| Thompson, PL | 1 |
| Aryal, MR | 1 |
| Karmacharya, P | 1 |
| Pandit, A | 1 |
| Hakim, F | 1 |
| Pathak, R | 1 |
| Mainali, NR | 1 |
| Ukaigwe, A | 1 |
| Mahmood, M | 1 |
| Badal, M | 1 |
| Fortuin, FD | 1 |
| Silber, T | 1 |
| Ziemann, U | 2 |
| Ernemann, U | 1 |
| Bischof, F | 1 |
| Aguiar, C | 1 |
| McLeod, E | 1 |
| Chatzitheofilou, I | 1 |
| Fonseca Santos, I | 1 |
| Pereira, S | 1 |
| Liao, D | 1 |
| Chi, L | 3 |
| Lemesle, G | 2 |
| Lamblin, N | 2 |
| Meurice, T | 2 |
| Tricot, O | 2 |
| Lallemant, R | 1 |
| Nugue, O | 1 |
| Delomez, M | 1 |
| Equine, O | 1 |
| Tondeux, S | 1 |
| Bauters, C | 2 |
| Cairns, JA | 2 |
| Mitchell, LB | 1 |
| Macle, L | 1 |
| Stiell, IG | 1 |
| Gladstone, D | 1 |
| McMurtry, MS | 1 |
| Cox, JL | 2 |
| Ivers, N | 1 |
| Leblanc, K | 1 |
| Nattel, S | 2 |
| Freudenberger, R | 1 |
| Mann, D | 1 |
| Arkin, JM | 1 |
| Joly, B | 1 |
| Menard, AL | 1 |
| Ozkul-Wermester, O | 2 |
| Triquenot-Bagan, A | 1 |
| Guegan-Massardier, E | 1 |
| Borg, JY | 1 |
| Le Cam-Duchez, V | 1 |
| Hováth-Puhó, E | 1 |
| Petersen, KL | 1 |
| Lee, JT | 1 |
| Lin, RT | 1 |
| Po, HL | 2 |
| Lin, HJ | 1 |
| Sun, MH | 1 |
| Sun, MC | 1 |
| Chern, CM | 1 |
| Chiu, HC | 1 |
| Hu, HH | 2 |
| Chiou, HY | 1 |
| Chen, ST | 3 |
| Ma, H | 2 |
| Ho, CW | 1 |
| Ho, MH | 1 |
| Chan, PH | 4 |
| Hai, JJ | 3 |
| Cheung, E | 1 |
| Yeung, CY | 1 |
| Lau, KK | 1 |
| Chan, KH | 1 |
| Lau, CP | 1 |
| Leung, GK | 1 |
| Tse, HF | 5 |
| Elwood, P | 1 |
| Morgan, G | 2 |
| Deitelzweig, SB | 1 |
| Swindle, JP | 1 |
| Makenbaeva, D | 1 |
| Cooper-DeHoff, RM | 1 |
| Geersing, GJ | 1 |
| Nagasayi, S | 1 |
| White, S | 2 |
| Joshi, Y | 1 |
| Ferrario, MM | 1 |
| Veronesi, G | 1 |
| Stanford, SN | 3 |
| Sabra, A | 3 |
| Lawrence, M | 3 |
| Morris, RH | 3 |
| Storton, S | 3 |
| Wani, M | 3 |
| Hawkins, K | 2 |
| Williams, PR | 2 |
| Evans, PA | 3 |
| Bonde, AN | 1 |
| Kamper, AL | 2 |
| Hansen, PR | 2 |
| Hommel, K | 2 |
| Johansson, S | 3 |
| Nagy, P | 1 |
| Rodríguez, LA | 1 |
| Chýlová, M | 1 |
| Moťovská, Z | 1 |
| Osmančík, P | 1 |
| Procházka, B | 1 |
| Kalvach, P | 1 |
| Pu, J | 1 |
| Malaguit, J | 1 |
| Xie, YM | 1 |
| Yang, W | 1 |
| Wang, YY | 1 |
| Zhuang, Y | 1 |
| Zheng, M | 1 |
| Shang, X | 1 |
| Yan, C | 1 |
| Hu, D | 3 |
| Schwartz, JB | 1 |
| Wu, IC | 2 |
| Hsieh, HM | 2 |
| Wu, MT | 2 |
| Sandhu, RK | 1 |
| McAlister, FA | 1 |
| Zhang, JT | 1 |
| Chen, KP | 1 |
| Mu, Y | 1 |
| Tayama, D | 1 |
| Robson, K | 1 |
| Dineen, R | 1 |
| Huan, Y | 1 |
| Agayeva, N | 2 |
| Gungor, L | 1 |
| Topcuoglu, MA | 3 |
| Arsava, EM | 3 |
| Kelley, BJ | 1 |
| McClure, LA | 5 |
| Unverzagt, FW | 1 |
| Kissela, B | 1 |
| Kleindorfer, D | 2 |
| Wadley, VG | 1 |
| Xiao, F | 1 |
| Pan, S | 1 |
| Costa, F | 1 |
| Moscarella, E | 1 |
| Ando, G | 1 |
| Oreto, G | 1 |
| Zijlstra, F | 1 |
| Ganti, L | 1 |
| Jickling, GC | 1 |
| Abdel-Rahman, I | 1 |
| Murphy, C | 1 |
| Skjøth, F | 4 |
| Rasmussen, LH | 5 |
| Larsen, TB | 4 |
| Huisman, MV | 2 |
| Pavasini, R | 1 |
| Malagù, M | 1 |
| Punzetti, S | 1 |
| Napoli, N | 1 |
| Guerzoni, F | 1 |
| Papi, A | 1 |
| Ceconi, C | 1 |
| Contoli, M | 1 |
| Horie, N | 1 |
| Kaminogo, M | 1 |
| Izumo, T | 1 |
| Hayashi, K | 1 |
| Nagata, I | 1 |
| Shanahan, E | 1 |
| Keenan, R | 1 |
| Cunningham, N | 1 |
| O'Malley, G | 1 |
| O'Connor, M | 1 |
| Lyons, D | 1 |
| Peters, C | 1 |
| Angoulvant, D | 1 |
| Villejoubert, O | 1 |
| Bejan-Angoulvant, T | 1 |
| Ivanes, F | 1 |
| Saint Etienne, C | 1 |
| Fauchier, L | 2 |
| Argulian, E | 1 |
| Conen, D | 2 |
| Choi, MJ | 1 |
| Nam, TS | 2 |
| Kim, BC | 2 |
| Kim, MK | 2 |
| Ye, S | 2 |
| Buchsbaum, R | 6 |
| Yamaji, K | 1 |
| Shizuta, S | 2 |
| Tazaki, J | 2 |
| Kato, Y | 1 |
| Hayano, M | 1 |
| Tamura, T | 1 |
| Shirotani, M | 1 |
| Miki, S | 1 |
| Matsuda, M | 1 |
| Takahashi, M | 1 |
| Ishii, K | 1 |
| Tanaka, M | 1 |
| Aoyama, T | 1 |
| Doi, O | 1 |
| Hattori, R | 1 |
| Takizawa, A | 2 |
| Takatsu, Y | 1 |
| Shinoda, E | 1 |
| Eizawa, H | 2 |
| Takeda, T | 1 |
| Lee, JD | 2 |
| Inoko, M | 1 |
| Hamasaki, S | 1 |
| Horie, M | 1 |
| Nohara, R | 2 |
| Kambara, H | 1 |
| Fujiwara, H | 2 |
| Mitsudo, K | 2 |
| Nobuyoshi, M | 2 |
| Kita, T | 2 |
| Gonçalves, L | 1 |
| Nunes, JP | 1 |
| Carlsson, AC | 2 |
| Gasevic, D | 1 |
| Sundquist, J | 2 |
| Sundquist, K | 2 |
| Jolobe, OM | 2 |
| Thompson, DD | 1 |
| Murray, GD | 2 |
| Candelise, L | 1 |
| Lefaucheur, R | 1 |
| Bourre, B | 1 |
| Maltête, D | 1 |
| Wallon, D | 1 |
| Liu, F | 2 |
| Tantry, US | 3 |
| D'Silva, L | 2 |
| Brown, MR | 1 |
| Evans, V | 2 |
| Davidson, SJ | 1 |
| Gandhi, S | 2 |
| Schwalm, JD | 2 |
| Velianou, JL | 1 |
| Natarajan, MK | 2 |
| Farkouh, ME | 2 |
| Danelich, IM | 1 |
| Wright, SS | 1 |
| Lose, JM | 1 |
| Tefft, BJ | 1 |
| Cicci, JD | 1 |
| Reed, BN | 1 |
| Hassell, ME | 1 |
| Hildick-Smith, D | 1 |
| Durand, E | 1 |
| Kikkert, WJ | 1 |
| Wiegerinck, EM | 1 |
| Stabile, E | 1 |
| Ussia, GP | 1 |
| Baan, J | 1 |
| Rubino, P | 1 |
| Barbanti, M | 1 |
| Tamburino, C | 1 |
| Poliacikova, P | 1 |
| Blanchard, D | 2 |
| Piek, JJ | 1 |
| Delewi, R | 1 |
| Park, TE | 1 |
| Yusuff, J | 1 |
| Gross, BA | 1 |
| Ben, H | 1 |
| Takabayashi, N | 1 |
| Murata, K | 1 |
| Tanaka, S | 1 |
| Kawakami, K | 1 |
| Musumeci, G | 3 |
| Lettieri, C | 2 |
| Limbruno, U | 1 |
| Senni, M | 1 |
| Guagliumi, G | 2 |
| Valsecchi, O | 1 |
| Rossini, R | 2 |
| Blann, AD | 1 |
| Chung, JE | 1 |
| Choi, YR | 1 |
| Seong, JM | 1 |
| La, HO | 1 |
| Gwak, HS | 1 |
| Lahham, S | 1 |
| Nelson, D | 1 |
| Li, WH | 1 |
| Kim, BS | 2 |
| Jang, WJ | 1 |
| Kim, WS | 1 |
| Lee, YT | 1 |
| Su, Y | 1 |
| Cheng, X | 1 |
| Alderazi, YJ | 1 |
| An, J | 1 |
| Niu, F | 1 |
| Lang, DT | 1 |
| Jazdzewski, KP | 1 |
| Le, PT | 1 |
| Rashid, N | 1 |
| Meissner, B | 1 |
| Mendes, R | 1 |
| Dills, DG | 1 |
| Aranda, G | 1 |
| Bruno, A | 4 |
| Cheng, B | 2 |
| Nielsen, PB | 2 |
| Choi, SM | 1 |
| Sennesael, AL | 1 |
| Dogné, JM | 1 |
| Spinewine, A | 1 |
| Rothman, KJ | 1 |
| Paquette, M | 1 |
| Teutsch, C | 1 |
| Dubner, SJ | 1 |
| Zint, K | 1 |
| Elsaesser, A | 1 |
| Bartels, DB | 1 |
| Peng, SA | 1 |
| Fosbol, EL | 1 |
| Saucedo, JF | 1 |
| Wang, TY | 2 |
| Tziomalos, K | 2 |
| Giampatzis, V | 2 |
| Bouziana, SD | 2 |
| Spanou, M | 2 |
| Kostaki, S | 2 |
| Papadopoulou, M | 2 |
| Dourliou, V | 1 |
| Sofogianni, A | 1 |
| Savopoulos, C | 2 |
| Hatzitolios, AI | 2 |
| Kurniawan, M | 1 |
| Harris, S | 1 |
| Hermawan, D | 1 |
| Prihartono, J | 1 |
| Dias, A | 1 |
| Franco, E | 1 |
| Koshkelashvili, N | 1 |
| Bhalla, V | 1 |
| Pressman, GS | 1 |
| Hebert, K | 1 |
| Figueredo, VM | 1 |
| Tan, S | 1 |
| Xiao, X | 1 |
| Rothlisberger, JM | 1 |
| Fang, J | 1 |
| Burton, A | 1 |
| Bartels, A | 1 |
| Sarpong, Y | 1 |
| Coberly, J | 1 |
| Hughes, N | 1 |
| Litt, J | 1 |
| Quick, J | 1 |
| Kessel, J | 1 |
| Nelson, C | 1 |
| Coughenour, J | 1 |
| Barnes, SL | 1 |
| Litofsky, NS | 1 |
| Hammer, RD | 1 |
| Ahmad, S | 1 |
| Mani, H | 1 |
| Ahluwalia, S | 1 |
| Mardekian, J | 1 |
| Leng, X | 2 |
| Soo, Y | 3 |
| Rosenqvist, M | 1 |
| Coignion, C | 1 |
| Poli, M | 1 |
| Sagnier, S | 1 |
| Freyburger, G | 1 |
| Renou, P | 2 |
| Debruxelles, S | 1 |
| Rouanet, F | 1 |
| Lambden, S | 1 |
| Fabiaña, N | 1 |
| Ramaswami, AP | 1 |
| Ang, ES | 1 |
| De Silva, DA | 1 |
| Cotsonis, GA | 2 |
| Arif, SA | 2 |
| D'Souza, J | 1 |
| Gil, M | 1 |
| Gim, S | 1 |
| Davis, KA | 1 |
| Miyares, MA | 1 |
| Dietrich, E | 2 |
| Wang, P | 1 |
| Xin, H | 1 |
| Duffy, C | 1 |
| Jhang, KM | 1 |
| Huang, JY | 2 |
| Nfor, ON | 1 |
| Jian, ZH | 1 |
| Tung, YC | 1 |
| Ku, WY | 1 |
| Liaw, YP | 2 |
| Peota, C | 1 |
| Bai, Y | 1 |
| van den Bergh, WM | 1 |
| Lansink-Hartgring, AO | 1 |
| van Duijn, AL | 1 |
| Engström, AE | 1 |
| Lahpor, JR | 1 |
| Slooter, AJ | 1 |
| Singletary, EM | 1 |
| Zideman, DA | 1 |
| De Buck, ED | 1 |
| Chang, WT | 1 |
| Jensen, JL | 1 |
| Swain, JM | 1 |
| Woodin, JA | 1 |
| Blanchard, IE | 1 |
| Herrington, RA | 1 |
| Pellegrino, JL | 1 |
| Hood, NA | 1 |
| Lojero-Wheatley, LF | 1 |
| Markenson, DS | 1 |
| Yang, HJ | 1 |
| Smith, ER | 1 |
| Yip, PS | 1 |
| Hai, J | 1 |
| Chan, TM | 1 |
| Lo, WK | 1 |
| Christiansen, CB | 1 |
| Pallisgaard, J | 1 |
| Gerds, TA | 1 |
| Jørgensen, ME | 1 |
| Numé, AK | 1 |
| Carlson, N | 1 |
| Sanford, A | 1 |
| Vazquez, FJ | 1 |
| Gonzalez, JP | 1 |
| Gándara, E | 1 |
| Sternberg, Z | 2 |
| Chichelli, T | 2 |
| Sternberg, D | 1 |
| Sawyer, R | 1 |
| Ching, M | 2 |
| Janicke, D | 2 |
| Ambrus, JL | 1 |
| Munschauer, F | 1 |
| McDonough, CW | 1 |
| Royster, AJ | 1 |
| Sheehan, TO | 1 |
| Burkley, B | 1 |
| Langaee, TY | 1 |
| Mocco, J | 1 |
| Zuckerman, SL | 1 |
| Mummareddy, N | 1 |
| Stephens, ML | 1 |
| Ingram, C | 1 |
| Shaffer, CM | 1 |
| Denny, JC | 1 |
| Brilliant, MH | 1 |
| Kitchner, TE | 1 |
| Linneman, JG | 1 |
| Roden, DM | 1 |
| Johnson, JA | 1 |
| Ng, KH | 1 |
| Samorodskaya, IV | 1 |
| Bolotova, EV | 1 |
| Boytsov, SA | 1 |
| Ko, YC | 1 |
| Yeo, MJ | 1 |
| Yu, FJ | 1 |
| Wu, MC | 1 |
| Wu, TS | 1 |
| Hussein, A | 1 |
| Wazni, OM | 1 |
| Huibers, A | 1 |
| Bulbulia, R | 1 |
| Coppi, G | 1 |
| Huguelet, J | 1 |
| Virani, SS | 1 |
| Ko, Y | 1 |
| Zhao, L | 5 |
| Liao, L | 1 |
| Hu, F | 1 |
| Shahidi, S | 1 |
| Owen-Falkenberg, A | 1 |
| Gottschalksen, B | 1 |
| Ellemann, K | 1 |
| Angelopoulou, SM | 1 |
| Tsopozidi, M | 1 |
| Schurtz, G | 1 |
| Lemaire, N | 1 |
| Caudmont, S | 1 |
| Philias, A | 1 |
| Ketelers, R | 1 |
| Simon, DN | 1 |
| Ansell, J | 1 |
| Go, AS | 5 |
| Kowey, P | 1 |
| Chang, P | 1 |
| Derle, E | 1 |
| Öcal, R | 1 |
| Kibaroğlu, S | 1 |
| Çelikkol, C | 1 |
| Bayraktar, N | 1 |
| Verdi, H | 1 |
| Ataç, BF | 1 |
| Can, U | 1 |
| Murphy, SJ | 1 |
| Coughlan, CA | 1 |
| Tobin, O | 1 |
| Kinsella, J | 1 |
| Lonergan, R | 1 |
| Gutkin, M | 1 |
| Dormuth, CR | 1 |
| Filion, KB | 1 |
| Platt, RW | 1 |
| Akehurst, RL | 1 |
| Armstrong, SO | 1 |
| Amorosi, SL | 1 |
| Brereton, N | 1 |
| Hertz, DS | 1 |
| Mrdovic, I | 1 |
| Čolić, M | 1 |
| Savic, L | 1 |
| Krljanac, G | 1 |
| Kruzliak, P | 1 |
| Lasica, R | 1 |
| Asanin, M | 1 |
| Stanković, S | 1 |
| Marinkovic, J | 1 |
| Qian, J | 1 |
| Potpara, TS | 1 |
| Dan, GA | 1 |
| Trendafilova, E | 1 |
| Goda, A | 1 |
| Kusljugic, Z | 1 |
| Manola, S | 1 |
| Music, L | 1 |
| Musetescu, R | 1 |
| Badila, E | 1 |
| Mitic, G | 1 |
| Paparisto, V | 1 |
| Dimitrova, ES | 1 |
| Polovina, MM | 1 |
| Petranov, SL | 1 |
| Djergo, H | 1 |
| Loncar, D | 1 |
| Bijedic, A | 1 |
| Brusich, S | 1 |
| Mărginean, A | 1 |
| Bănescu, C | 1 |
| Moldovan, V | 1 |
| Scridon, A | 1 |
| Mărginean, M | 1 |
| Bălaşa, R | 1 |
| Maier, S | 1 |
| Ţăruşi, M | 1 |
| Dobreanu, M | 1 |
| Nishi, R | 1 |
| Mano, T | 1 |
| Kobayashi, Y | 2 |
| Matsuo, K | 1 |
| Merli, GJ | 1 |
| Weitz, HH | 1 |
| Mochalina, N | 1 |
| Jöud, A | 1 |
| Carlsson, M | 1 |
| Sandberg, MEC | 1 |
| Juhlin, T | 1 |
| Wald, NJ | 2 |
| Luteijn, JM | 1 |
| Morris, JK | 1 |
| Taylor, D | 1 |
| Oppenheimer, P | 1 |
| Jones, DW | 1 |
| Goodney, PP | 1 |
| Nolan, BW | 1 |
| Rzucidlo, EM | 1 |
| Powell, RJ | 1 |
| Cronenwett, JL | 1 |
| Stone, DH | 1 |
| Allende, M | 1 |
| Molina, E | 1 |
| Guruceaga, E | 1 |
| Tamayo, I | 1 |
| González-Porras, JR | 1 |
| Gonzalez-López, TJ | 1 |
| Toledo, E | 1 |
| Rabal, O | 1 |
| Ugarte, A | 1 |
| Roldán, V | 2 |
| Rivera, J | 1 |
| Oyarzabal, J | 1 |
| Montes, R | 1 |
| Hermida, J | 1 |
| Niu, PP | 1 |
| Guo, ZN | 1 |
| Jin, H | 1 |
| Xing, YQ | 1 |
| Cryer, BL | 1 |
| Lanas, A | 2 |
| Schnitzer, TJ | 1 |
| Shook, TL | 1 |
| Lapuerta, P | 1 |
| Goldsmith, MA | 1 |
| Laine, L | 1 |
| Guo, R | 2 |
| Ruan, Z | 1 |
| Chang, T | 1 |
| Chin, CT | 1 |
| Boden, WE | 6 |
| Neely, B | 3 |
| Neely, ML | 3 |
| Leiva-Pons, JL | 3 |
| Gottlieb, S | 4 |
| Dalby, AJ | 3 |
| Armstrong, PW | 6 |
| Winters, KJ | 4 |
| Schiele, F | 1 |
| Baker, D | 1 |
| Wilsmore, B | 1 |
| Narasimhan, S | 1 |
| Kuder, J | 1 |
| Goodrich, E | 2 |
| Dellborg, M | 1 |
| Dalby, A | 1 |
| Špinar, J | 2 |
| Abola, MTB | 1 |
| Jensen, EC | 1 |
| Braunwald, E | 5 |
| Watanabe, E | 1 |
| Yamamoto, M | 1 |
| Kodama, I | 1 |
| Inoue, H | 2 |
| Atarashi, H | 2 |
| Okumura, K | 3 |
| Kodani, E | 1 |
| Okuyama, Y | 1 |
| Chishaki, A | 1 |
| Kiyono, K | 1 |
| Jang, MU | 1 |
| Whitlock, EP | 2 |
| Burda, BU | 1 |
| Williams, SB | 1 |
| Guirguis-Blake, JM | 1 |
| Evans, CV | 1 |
| Dehmer, SP | 1 |
| Maciosek, MV | 1 |
| Flottemesch, TJ | 1 |
| LaFrance, AB | 1 |
| Kunutsor, SK | 1 |
| Seidu, S | 1 |
| Khunti, K | 2 |
| Ikeda, S | 1 |
| Matsuda, S | 1 |
| Koretsune, Y | 3 |
| Montouchet, C | 1 |
| Watanabe-Fujinuma, E | 1 |
| Evers, T | 1 |
| Rossi, B | 1 |
| Ruff, L | 1 |
| Briere, JB | 1 |
| Holzgreve, H | 1 |
| Shiue, HJ | 1 |
| Sands, KA | 1 |
| Davis, K | 1 |
| Freedman, SB | 1 |
| Van Gelder, I | 1 |
| Gianni, C | 1 |
| Potpara, T | 1 |
| Rienstra, M | 1 |
| Alansari, SA | 1 |
| Riaz, T | 1 |
| Luni, FK | 2 |
| Khan, AR | 1 |
| Riaz, IB | 1 |
| Krasuski, RA | 1 |
| Hagström, E | 1 |
| Hafley, G | 1 |
| Sidhu, MS | 1 |
| Hong, SJ | 1 |
| Bliden, KP | 1 |
| Chaudhary, R | 1 |
| Byun, S | 1 |
| Navarro, MA | 1 |
| Gosch, KL | 1 |
| Spertus, JA | 1 |
| Rumsfeld, JS | 1 |
| Ho, PM | 1 |
| Rubino, F | 1 |
| Bilora, F | 1 |
| Adamo, A | 1 |
| Pomerri, F | 1 |
| Prandoni, P | 2 |
| Pieper, D | 1 |
| Levine, DL | 1 |
| Thati, N | 1 |
| Madhavan, R | 1 |
| Mateo, M | 1 |
| Cardozo, L | 1 |
| Lepczyk, MB | 1 |
| Dadjou, Y | 1 |
| Safavi, S | 1 |
| Kojuri, J | 1 |
| Zeng, X | 2 |
| Liu, P | 1 |
| Fu, C | 1 |
| Kurowski, S | 1 |
| Wu, W | 2 |
| Desai, K | 1 |
| Chu, L | 1 |
| Gutstein, DE | 1 |
| Seiffert, D | 1 |
| Whalen, JD | 1 |
| Davies, G | 2 |
| Du, M | 2 |
| Oguz, M | 2 |
| Bash, LD | 1 |
| Ozer-Stillman, I | 1 |
| Tan, L | 1 |
| Nao, J | 1 |
| Hu, H | 1 |
| Kong, Y | 1 |
| Shimada, YJ | 1 |
| Bansilal, S | 1 |
| Wiviott, SD | 2 |
| James, SK | 2 |
| Erschoff, V | 1 |
| Bönner, F | 1 |
| Gliem, M | 1 |
| Jander, S | 2 |
| Asher, E | 1 |
| Abu-Much, A | 1 |
| Goldenberg, I | 1 |
| Segev, A | 1 |
| Sabbag, A | 1 |
| Mazin, I | 1 |
| Shlezinger, M | 1 |
| Atar, S | 1 |
| Zahger, D | 1 |
| Polak, A | 1 |
| Beigel, R | 1 |
| Matetzky, S | 2 |
| Cheng, W | 1 |
| Zhang, YQ | 1 |
| Wei, CL | 1 |
| Hu, YH | 1 |
| Timmis, A | 1 |
| Rapsomaniki, E | 1 |
| Chung, SC | 1 |
| Pujades-Rodriguez, M | 1 |
| Moayyeri, A | 1 |
| Stogiannis, D | 1 |
| Shah, AD | 1 |
| Pasea, L | 1 |
| Denaxas, S | 1 |
| Emmas, C | 1 |
| Hemingway, H | 1 |
| Maddox, TM | 1 |
| Kennedy, K | 1 |
| Katz, DF | 1 |
| Marzec, LN | 1 |
| Lubitz, SA | 1 |
| Gehi, AK | 1 |
| Turakhia, MP | 1 |
| Major, RW | 1 |
| Oozeerally, I | 1 |
| Dawson, S | 1 |
| Riddleston, H | 1 |
| Gray, LJ | 6 |
| Brunskill, NJ | 1 |
| Barra, ME | 1 |
| Fanikos, J | 1 |
| Connors, JM | 1 |
| Piazza, G | 1 |
| Goldhaber, SZ | 4 |
| Lin, Y | 2 |
| Terrosu, P | 1 |
| Savino, K | 1 |
| Maiello, M | 1 |
| Pelliccia, F | 1 |
| Palmiero, P | 1 |
| Su, TH | 1 |
| Chan, YL | 1 |
| Lin, LC | 1 |
| Wen, YW | 1 |
| Lee, TH | 3 |
| Yu, L | 1 |
| Peng, X | 1 |
| Kim, GM | 1 |
| Sohn, CH | 1 |
| Deng, QQ | 1 |
| Tang, J | 1 |
| Markus, H | 3 |
| Huang, YN | 2 |
| Zhao, H | 1 |
| Fu, JH | 1 |
| Saw, J | 1 |
| Bennell, MC | 1 |
| Singh, SM | 1 |
| Wijeysundera, HC | 1 |
| Björck, F | 1 |
| Renlund, H | 1 |
| Wester, P | 1 |
| Hoshi, T | 1 |
| Sato, A | 1 |
| Nogami, A | 1 |
| Gosho, M | 1 |
| Aonuma, K | 1 |
| Nelson, S | 1 |
| Cloonan, L | 1 |
| Kanakis, AS | 1 |
| Fitzpatrick, KM | 1 |
| Shideler, KI | 1 |
| Perilla, AS | 1 |
| Rost, NS | 1 |
| Jackson, LR | 1 |
| Cyr, DD | 1 |
| Martinez, F | 2 |
| Lüscher, TF | 2 |
| Magnus Ohman, E | 1 |
| Camaro, C | 1 |
| Damen, SA | 1 |
| Brouwer, MA | 2 |
| Kedhi, E | 1 |
| Verdoia, M | 1 |
| Barbieri, L | 1 |
| Rognoni, A | 1 |
| van T Hof, AW | 1 |
| Ligtenberg, E | 1 |
| de Boer, MJ | 1 |
| Suryapranata, H | 1 |
| De Luca, G | 1 |
| Fahed, E | 1 |
| Ghauche, J | 1 |
| Rahme, R | 1 |
| Okais, N | 1 |
| Samaha, E | 1 |
| Nohra, G | 1 |
| Rizk, T | 1 |
| Maarrawi, J | 1 |
| Menassa-Moussa, L | 1 |
| Moussa, R | 1 |
| Snyder, A | 1 |
| Fletcher, RH | 1 |
| Priglinger, ML | 1 |
| Gargiulo, G | 1 |
| Ariotti, S | 1 |
| Santucci, A | 1 |
| Baldo, A | 1 |
| Magnani, G | 1 |
| Marino, M | 1 |
| Esposito, G | 1 |
| Ophuis, TO | 1 |
| Ruda, M | 2 |
| Jensen, E | 1 |
| Raheemullah, A | 1 |
| Laurence, TN | 1 |
| de Waha, A | 1 |
| Sandner, S | 1 |
| Boening, A | 1 |
| Koch-Buettner, K | 1 |
| Hammel, D | 1 |
| Hambrecht, R | 1 |
| Danner, BC | 1 |
| Schöndube, FA | 1 |
| Goerlach, G | 1 |
| Fischlein, T | 1 |
| Schmoeckel, M | 1 |
| Oberhoffer, M | 1 |
| Schulz, R | 1 |
| Walther, T | 1 |
| Ziegelhöffer, T | 1 |
| Knosalla, C | 2 |
| Schönrath, F | 1 |
| Beyersdorf, F | 1 |
| Siepe, M | 1 |
| Attmann, T | 1 |
| Mohr, FW | 1 |
| Sievers, HH | 1 |
| Joost, A | 1 |
| Putman, LM | 1 |
| Zeymer, U | 5 |
| Radke, PW | 1 |
| Lange, R | 1 |
| Cremer, J | 1 |
| Hellkamp, A | 1 |
| Ward, SA | 1 |
| Raniga, P | 1 |
| Ferris, NJ | 1 |
| Storey, E | 1 |
| Bailey, MJ | 1 |
| Brodtmann, A | 1 |
| Yates, PA | 1 |
| Trevaks, RE | 1 |
| Egan, GF | 1 |
| Peng, LL | 1 |
| Zhao, YQ | 1 |
| Zhou, ZY | 1 |
| Zhao, M | 1 |
| Chen, XM | 1 |
| Chen, LY | 1 |
| Cai, YF | 2 |
| Li, JL | 1 |
| Huang, M | 1 |
| Čulić, V | 1 |
| Landman, GW | 1 |
| Kleefstra, N | 1 |
| Dawood, FZ | 1 |
| Judd, S | 1 |
| Limdi, NA | 1 |
| Meschia, JF | 2 |
| Herrington, DM | 1 |
| Soliman, EZ | 1 |
| Liu, Z | 1 |
| Moorin, R | 1 |
| Worthington, J | 1 |
| Tofler, G | 1 |
| Bartlett, M | 1 |
| Khan, R | 1 |
| Makam, RC | 1 |
| Erskine, N | 1 |
| McManus, DD | 1 |
| Lessard, D | 1 |
| Gore, JM | 3 |
| Yarzebski, J | 1 |
| Doly, JS | 1 |
| Lorian, E | 1 |
| Desormais, I | 1 |
| Constans, J | 1 |
| Bura Rivière, A | 1 |
| Lacroix, P | 1 |
| Russo, NW | 1 |
| Petrucci, G | 1 |
| Zhang, P | 1 |
| Shen, C | 1 |
| Rosenberg, K | 2 |
| Moris, D | 2 |
| Avgerinos, E | 2 |
| Deng, L | 1 |
| Ferri, LA | 1 |
| Morici, N | 1 |
| Grosseto, D | 1 |
| Tortorella, G | 1 |
| Bossi, I | 1 |
| Sganzerla, P | 1 |
| Cacucci, M | 1 |
| Sibilio, G | 1 |
| Tondi, S | 1 |
| Toso, A | 1 |
| Gandolfo, N | 1 |
| Ravera, A | 1 |
| Mariani, M | 1 |
| Corrada, E | 1 |
| Di Ascenzo, L | 1 |
| Petronio, AS | 1 |
| Cavallini, C | 1 |
| Moffa, N | 1 |
| De Servi, S | 2 |
| Savonitto, S | 1 |
| Holzmann, M | 1 |
| Ärnlöv, J | 1 |
| Johansson, SE | 1 |
| Elwood, PC | 3 |
| Galante, J | 1 |
| Chia, JW | 1 |
| Dolwani, S | 1 |
| Graziano, JM | 1 |
| Kelson, M | 1 |
| Longley, M | 1 |
| Phillips, CJ | 1 |
| Pickering, J | 2 |
| Roberts, SE | 1 |
| Soon, SS | 1 |
| Steward, W | 1 |
| Morris, D | 1 |
| Weightman, AL | 1 |
| Carrero, JJ | 1 |
| Szummer, K | 1 |
| Evans, M | 1 |
| Spaak, J | 1 |
| Meisner, C | 1 |
| Schreieck, J | 1 |
| Zuern, CS | 1 |
| Nägele, T | 1 |
| Brachmann, J | 1 |
| Jung, W | 1 |
| Gahn, G | 1 |
| Schmid, E | 1 |
| Bäezner, H | 1 |
| Keller, T | 1 |
| Petzold, GC | 1 |
| Schrickel, JW | 1 |
| Liman, J | 1 |
| Wachter, R | 1 |
| Schön, F | 1 |
| Schabet, M | 1 |
| Lindner, A | 1 |
| Ludolph, AC | 1 |
| Kimmig, H | 1 |
| Schlegel, U | 1 |
| Gawaz, M | 1 |
| Athanasakis, K | 1 |
| Boubouchairopoulou, N | 1 |
| Karampli, E | 1 |
| Tarantilis, F | 1 |
| Savvari, P | 1 |
| Bilitou, A | 1 |
| Kyriopoulos, J | 1 |
| Hsiao, KC | 1 |
| Hung, TW | 1 |
| Chang, HR | 1 |
| Alosh, M | 1 |
| Huque, MF | 1 |
| Bretz, F | 1 |
| D'Agostino, RB | 2 |
| Guimarães, AH | 1 |
| van Es, GA | 1 |
| Wildgoose, P | 1 |
| Volkl, AA | 1 |
| Zazula, A | 1 |
| Thomitzek, K | 1 |
| Hemmrich, M | 1 |
| Wong, CW | 1 |
| Owais, T | 1 |
| Rouman, M | 1 |
| Breuer, M | 1 |
| Hüter, L | 1 |
| Fuchs, J | 1 |
| Lauer, B | 1 |
| Kuntze, T | 1 |
| Ping, Y | 1 |
| Dai, H | 1 |
| Jalal, Z | 1 |
| Dinet, ML | 1 |
| Combes, N | 1 |
| Pillois, X | 1 |
| Iriart, X | 1 |
| Thambo, JB | 1 |
| Zuo, FT | 1 |
| Wu, HJ | 1 |
| Su, N | 1 |
| Liu, JQ | 1 |
| Dong, AQ | 1 |
| van Diepen, S | 1 |
| Hamza, TH | 1 |
| Siami, FS | 1 |
| Pasala, T | 1 |
| Hoo, JS | 1 |
| Lockhart, MK | 1 |
| Waheed, R | 1 |
| Sengodan, P | 1 |
| Alexander, J | 1 |
| Della Riva, D | 1 |
| Bacchi Reggiani, L | 1 |
| Sangiorgi, D | 1 |
| Angelini, GD | 2 |
| Pufulete, M | 1 |
| White, J | 2 |
| Darteyre, S | 1 |
| Renaud, C | 1 |
| Fluss, J | 1 |
| Laporte, S | 1 |
| Bertoletti, L | 1 |
| Chabrier, S | 1 |
| Lee, CJ | 1 |
| Oh, J | 1 |
| Kang, SM | 1 |
| Kim, HC | 1 |
| Park, S | 1 |
| Song, H | 1 |
| Hou, C | 1 |
| Cao, Q | 1 |
| Wang, M | 1 |
| Ji, X | 1 |
| Baatiema, L | 1 |
| Otim, M | 1 |
| Mnatzaganian, G | 1 |
| Aikins, AD | 1 |
| Coombes, J | 1 |
| Somerset, S | 1 |
| Illuminati, G | 1 |
| Schneider, F | 1 |
| Pizzardi, G | 1 |
| Masci, F | 1 |
| Calio', FG | 1 |
| Chen, YT | 1 |
| Chen, HT | 1 |
| Chao, PW | 1 |
| Kuo, SC | 1 |
| Ou, SM | 1 |
| Shih, CJ | 1 |
| Gieling, EM | 1 |
| van den Ham, HA | 1 |
| van Onzenoort, H | 1 |
| Bos, J | 1 |
| Bakoyiannis, C | 1 |
| Achilles, A | 1 |
| Mohring, A | 1 |
| Piayda, K | 1 |
| Lee, H | 1 |
| Lim, SW | 1 |
| Rha, SW | 3 |
| Bae, JW | 2 |
| Jeon, DW | 1 |
| Oh, SK | 1 |
| Chase, M | 1 |
| Li, XG | 1 |
| Ma, N | 1 |
| Sun, SS | 1 |
| Miao, ZR | 1 |
| Zhao, ZG | 1 |
| Wood, H | 1 |
| Ou, L | 1 |
| Nakagawa, I | 1 |
| Park, HS | 2 |
| Wada, T | 1 |
| Yokoyama, S | 1 |
| Yamada, S | 1 |
| Motoyama, Y | 1 |
| Kichikawa, K | 1 |
| Nakase, H | 1 |
| Boos, CJ | 1 |
| Biller, J | 3 |
| Halkes, PH | 6 |
| Guiraud-Chaumeil, B | 2 |
| Yatsu, FM | 1 |
| Belvís, R | 1 |
| Pagonabarraga, J | 1 |
| Santamaría, A | 1 |
| Kulisevsky, J | 1 |
| Papathanasiou, AI | 1 |
| Mikhailidis, DP | 1 |
| Teramoto, S | 1 |
| Yamamoto, H | 3 |
| Yamaguchi, Y | 1 |
| Ishii, M | 1 |
| Hibi, S | 1 |
| Kume, H | 1 |
| Ouchi, Y | 1 |
| Sztriha, LK | 3 |
| Vécsei, L | 3 |
| Gallagher, AM | 2 |
| Rietbrock, S | 2 |
| Plumb, J | 1 |
| van Staa, TP | 2 |
| Teal, P | 3 |
| Greco, F | 1 |
| Fiumara, A | 1 |
| Sorge, G | 1 |
| Pavone, L | 1 |
| Diener, C | 1 |
| Bowring, J | 1 |
| Mahto, M | 1 |
| Mandal, D | 1 |
| Baker, PN | 1 |
| Prineas, R | 1 |
| Prince, V | 1 |
| You, Z | 1 |
| Neundörfer, B | 1 |
| Hudsmith, L | 1 |
| Thorne, S | 1 |
| Clift, P | 1 |
| Sarafoff, N | 1 |
| Ndrepepa, G | 1 |
| Dörrler, K | 1 |
| Schulz, S | 1 |
| Byrne, R | 1 |
| Schömig, A | 1 |
| Karepov, V | 1 |
| Tolpina, G | 1 |
| Kuliczkowski, W | 1 |
| Serebruany, V | 5 |
| Swain, S | 1 |
| Turner, C | 1 |
| Tyrrell, P | 1 |
| Rudd, A | 4 |
| Ross, M | 1 |
| Michaud, K | 1 |
| Hallenbeck, JM | 1 |
| Wolfe, F | 1 |
| Hoover, PL | 1 |
| Mold, JW | 3 |
| Henderson, GR | 1 |
| Mead, GE | 1 |
| van Dijke, ML | 1 |
| Ramsay, S | 1 |
| McDowall, MA | 1 |
| Dennis, M | 3 |
| England, T | 2 |
| Willmot, MR | 1 |
| Sare, GM | 3 |
| Dharmasaroja, P | 1 |
| Marmagkiolis, K | 1 |
| Nikolaidis, IG | 1 |
| Politis, T | 1 |
| Goldstein, L | 1 |
| Alberts, MJ | 7 |
| Ruan, Y | 1 |
| Bridges, JS | 1 |
| Kumar, K | 1 |
| Raphael, JA | 1 |
| Acharjee, S | 1 |
| Welty, FK | 1 |
| Thaler, DE | 1 |
| Ounpuu, S | 2 |
| Lawton, WA | 2 |
| Martin, RH | 4 |
| Bath, P | 5 |
| Chan, BP | 3 |
| Dahlöf, B | 2 |
| De Keyser, J | 3 |
| Estol, C | 3 |
| Gu, V | 2 |
| Hermansson, K | 4 |
| Hilbrich, L | 2 |
| Lu, C | 3 |
| Machnig, T | 2 |
| Roberts, R | 3 |
| Skvortsova, V | 2 |
| Vandermaelen, C | 2 |
| Voigt, T | 2 |
| Weber, M | 2 |
| Zimmermann, N | 1 |
| Sander, D | 2 |
| Schwertfeger, M | 1 |
| Köfüncü, E | 1 |
| Diehm, C | 1 |
| Pittrow, D | 1 |
| Panagos, PD | 1 |
| Biggerstaff, BJ | 1 |
| Jackson, D | 1 |
| Lam, SK | 1 |
| Owen, A | 3 |
| Turtzo, LC | 1 |
| Koton, S | 1 |
| Howard, SC | 3 |
| Warlow, CP | 4 |
| Murphy, MF | 1 |
| Jolly, SS | 1 |
| Pogue, J | 10 |
| Haladyn, K | 1 |
| Peters, RJ | 2 |
| Rupprecht, HJ | 4 |
| Vande Griend, JP | 1 |
| Saseen, JJ | 1 |
| Bennett, D | 2 |
| Macgregor, L | 1 |
| Eccleston, D | 1 |
| Suri, MF | 2 |
| Hussein, HM | 1 |
| Abdelmoula, MM | 1 |
| Qureshi, AI | 3 |
| Schwarz, M | 1 |
| Bode, Ch | 1 |
| Lin, LJ | 1 |
| Cheng, MH | 1 |
| Wung, DC | 1 |
| Kao Yang, YH | 1 |
| Slaughter, MS | 3 |
| Sobieski, MA | 1 |
| Gallagher, C | 1 |
| Dia, M | 1 |
| Silver, MA | 1 |
| Devereaux, P | 1 |
| Charles, C | 1 |
| Alonso, R | 1 |
| Kitagawa, Y | 3 |
| Ohkuma, H | 1 |
| Tokuoka, K | 2 |
| Rouhl, RP | 1 |
| Lodder, J | 1 |
| Moulin, T | 2 |
| Woimant, F | 3 |
| Geeganage, C | 3 |
| De Deyn, PP | 3 |
| Ringelstein, EB | 5 |
| Vallee, M | 1 |
| Graffagnino, C | 2 |
| Fitzgerald, DJ | 1 |
| Theroux, P | 2 |
| Topol, EJ | 15 |
| John, R | 3 |
| Kamdar, F | 1 |
| Liao, K | 1 |
| Colvin-Adams, M | 1 |
| Miller, L | 1 |
| Joyce, L | 1 |
| Boyle, A | 2 |
| Bassand, JP | 3 |
| Chrolavicius, S | 5 |
| Jolly, S | 2 |
| Selim, M | 1 |
| Lemaitre, RN | 1 |
| Rice, K | 1 |
| Marciante, K | 1 |
| Bis, JC | 1 |
| Lumley, TS | 1 |
| Wiggins, KL | 1 |
| Smith, NL | 2 |
| Heckbert, SR | 2 |
| Psaty, BM | 2 |
| Jeon, HW | 1 |
| Palareti, G | 1 |
| Molfese, M | 1 |
| Mihalcsik, L | 1 |
| Mantovani, P | 1 |
| Sirbu, V | 1 |
| Bass, TA | 2 |
| Della Rovere, F | 1 |
| Gavazzi, A | 1 |
| Boncoraglio, GB | 1 |
| Bodini, A | 1 |
| Brambilla, C | 1 |
| Corsini, E | 1 |
| Carriero, MR | 1 |
| Parati, EA | 1 |
| Maidan, L | 1 |
| Hanhart, J | 1 |
| Koskas, P | 1 |
| Obadia, M | 1 |
| Le Mer, Y | 1 |
| Sahel, JA | 1 |
| Paques, M | 1 |
| Minnerup, J | 1 |
| Berger, CT | 1 |
| Wolbers, M | 1 |
| Meyer, P | 1 |
| Daikeler, T | 1 |
| Hess, C | 1 |
| Chang, HM | 3 |
| Wong, MC | 2 |
| Sabaliauskiene, Z | 1 |
| Grybauskas, P | 1 |
| Gaigalaite, V | 1 |
| Ptasekas, J | 1 |
| Sousa, AS | 1 |
| Xavier, SS | 1 |
| Freitas, GR | 2 |
| Hasslocher-Moreno, A | 1 |
| Chourkani, N | 1 |
| Sibai, M | 1 |
| Moutaouakil, F | 1 |
| Rafai, M | 1 |
| Bourezgui, M | 1 |
| Slassi, I | 1 |
| Cartwright, MS | 1 |
| White, DL | 1 |
| Miller, LM | 1 |
| Roach, ES | 1 |
| Kovács, KR | 1 |
| Eckermann, S | 1 |
| Coory, M | 1 |
| Willan, AR | 1 |
| Palombo, G | 1 |
| Stella, N | 1 |
| Faraglia, V | 1 |
| Rizzo, L | 1 |
| Capuano, F | 1 |
| Sinatra, R | 1 |
| Taurino, M | 1 |
| Yu, SC | 2 |
| Lam, WW | 2 |
| Chan, AY | 1 |
| Wong, LK | 2 |
| Ke, XJ | 1 |
| Yu, YF | 1 |
| Guo, ZL | 1 |
| Xu, K | 1 |
| Hai, H | 1 |
| Zhang, AH | 1 |
| Peng, H | 1 |
| Søgaard, KK | 1 |
| Christensen, S | 1 |
| Johnsen, SP | 2 |
| Baron, JA | 1 |
| Zytkiewicz, M | 1 |
| Giełwanowska, L | 1 |
| Wojtasińska, E | 1 |
| Psuja, P | 1 |
| Zawilska, K | 1 |
| Park, MK | 1 |
| Smith, PC | 1 |
| Wanserski, G | 1 |
| Neher, JO | 1 |
| Helms, AK | 1 |
| Drogan, O | 1 |
| Luben, RN | 1 |
| Wareham, NJ | 1 |
| Bingham, SA | 1 |
| Khaw, KT | 1 |
| Hegge, KA | 1 |
| Ross, JS | 1 |
| Halm, EA | 1 |
| Bravata, DM | 1 |
| Tay, KH | 1 |
| Plumb, JM | 2 |
| Chang, YJ | 2 |
| Ryu, SJ | 2 |
| Chen, JR | 1 |
| Yip, PK | 1 |
| Chiu, TF | 1 |
| van Gijn, J | 14 |
| Collins, JF | 1 |
| Ammon, SE | 2 |
| Cleland, JG | 5 |
| Ezekowitz, M | 2 |
| Jafri, SM | 2 |
| Krol, WF | 1 |
| O'Connor, CM | 2 |
| Schulman, KA | 1 |
| Warren, SR | 1 |
| Galesic, M | 1 |
| Garcia-Retamero, R | 1 |
| Gigerenzer, G | 1 |
| Wolff, T | 1 |
| Miller, T | 1 |
| Ko, S | 1 |
| Stulman, J | 1 |
| McGinn, T | 1 |
| Korenstein, D | 1 |
| Georgiadis, D | 5 |
| von Buedingen, HC | 1 |
| Valko, P | 1 |
| Sarikaya, H | 1 |
| Rousson, V | 1 |
| Mattle, HP | 9 |
| Bousser, MG | 8 |
| Baumgartner, RW | 8 |
| McMahon, GS | 1 |
| Webster, SE | 2 |
| Hayes, PD | 2 |
| Jones, CI | 2 |
| Goodall, AH | 2 |
| Bower, EA | 1 |
| Girard, DE | 1 |
| Eisen, DP | 1 |
| Corey, GR | 1 |
| McBryde, ES | 1 |
| Fowler, VG | 1 |
| Miro, JM | 1 |
| Cabell, CH | 1 |
| Street, AC | 1 |
| Paiva, MG | 1 |
| Ionac, A | 1 |
| Tan, RS | 2 |
| Tribouilloy, C | 1 |
| Pachirat, O | 1 |
| Jones, SB | 1 |
| Chipigina, N | 1 |
| Pan, A | 1 |
| Ravasio, V | 1 |
| Gattringer, R | 1 |
| Chu, VH | 1 |
| Bayer, AS | 1 |
| Balucani, C | 1 |
| Cordonnier, C | 2 |
| Telman, G | 2 |
| Kouperberg, E | 2 |
| Sprecher, E | 2 |
| Yarnitsky, D | 2 |
| Usman, MH | 1 |
| Notaro, LA | 1 |
| Nagarakanti, R | 1 |
| Brahin, E | 1 |
| Dessain, S | 1 |
| Gracely, E | 1 |
| Hennerici, MG | 4 |
| Pye, M | 1 |
| Russo, C | 1 |
| Jin, Z | 2 |
| Momary, KM | 1 |
| Shapiro, NL | 1 |
| Brace, LD | 3 |
| Shord, SS | 1 |
| Grossi, E | 2 |
| Viana, MA | 2 |
| Helgason, CM | 3 |
| Nutescu, EA | 2 |
| Gensini, GF | 2 |
| Conti, AA | 1 |
| Famakin, BM | 1 |
| Khalil, S | 1 |
| Mohanaruban, K | 1 |
| Haq, S | 1 |
| Boysen, G | 6 |
| Preobrazhenskiĭ, DV | 5 |
| Dewilde, S | 2 |
| Monz, BU | 1 |
| Le Tourneau, T | 1 |
| Lim, V | 1 |
| Inamo, J | 1 |
| Miller, FA | 1 |
| Mahoney, DW | 1 |
| Enriquez-Sarano, M | 1 |
| De Schryver, EL | 6 |
| Murphy, P | 1 |
| Csoboth, I | 1 |
| Matyus, A | 1 |
| Gabara, K | 1 |
| Boncz, I | 1 |
| Shah, N | 1 |
| DeLeon, D | 1 |
| Schwiebert, LP | 1 |
| Lökk, J | 1 |
| Beckman, JA | 1 |
| Mega, JL | 1 |
| Mohanavelu, S | 1 |
| Poulter, R | 1 |
| Hricak, V | 1 |
| Barnathan, ES | 1 |
| Bordes, P | 1 |
| Witkowski, A | 1 |
| Markov, V | 1 |
| Oppenheimer, L | 1 |
| Duygu, H | 1 |
| Acet, H | 1 |
| Eren, NK | 1 |
| Nazli, C | 1 |
| Ergene, AO | 1 |
| Robbins, MS | 1 |
| Markowitz, S | 1 |
| Saleeb, M | 1 |
| Swerdlow, ML | 1 |
| Mabie, PC | 1 |
| Schrör, K | 3 |
| Jacobs, LG | 1 |
| Billett, HH | 1 |
| Dinglas, C | 1 |
| Jumaquio, L | 1 |
| Alvarez-Sabín, J | 3 |
| Penalba, A | 1 |
| Quintana, M | 1 |
| García-Bonilla, L | 1 |
| Montaner, J | 1 |
| Lin, YJ | 1 |
| Hseuh, IH | 1 |
| Boyle, AJ | 1 |
| Russell, SD | 2 |
| Teuteberg, JJ | 1 |
| Moazami, N | 1 |
| Pagani, FD | 2 |
| Frazier, OH | 1 |
| Heatley, G | 1 |
| Farrar, DJ | 2 |
| Sabaeva, E | 1 |
| Booze, C | 1 |
| Atar, OD | 1 |
| Eisert, C | 2 |
| Hanley, D | 4 |
| Ni, Y | 1 |
| Fieuws, S | 2 |
| Calvin, AD | 1 |
| Aggarwal, NR | 1 |
| Murad, MH | 1 |
| Shi, Q | 1 |
| Elamin, MB | 1 |
| Geske, JB | 1 |
| Fernandez-Balsells, MM | 1 |
| Albuquerque, FN | 1 |
| Lampropulos, JF | 1 |
| Erwin, PJ | 1 |
| Smith, SA | 1 |
| Bal Dit Sollier, C | 1 |
| Crassard, I | 2 |
| Simoneau, G | 1 |
| Bergmann, JF | 2 |
| Drouet, L | 1 |
| Chua, D | 1 |
| Legal, M | 1 |
| Shalansky, SJ | 1 |
| Lee, YE | 1 |
| DeZee, KJ | 1 |
| Richard, T | 1 |
| Butaffuoco, F | 1 |
| Vanhaeverbeek, M | 1 |
| Shalimar, S | 1 |
| Pangtey, GS | 1 |
| Singh, KK | 1 |
| Iuliano, L | 1 |
| Di Matteo, A | 1 |
| Straface, G | 1 |
| Sudlow, CL | 3 |
| Mason, G | 1 |
| Maurice, JB | 1 |
| Wedderburn, CJ | 1 |
| Hennekens, C | 1 |
| Depta, JP | 1 |
| Di Sciacca, R | 1 |
| La Placa, S | 1 |
| Milio, G | 1 |
| Miceli, S | 1 |
| Godeneche, G | 1 |
| Sorel, N | 2 |
| Ragot, S | 2 |
| Chomel, JC | 1 |
| Neau, JP | 2 |
| Macchi, L | 4 |
| Earnshaw, SR | 1 |
| Wilson, M | 1 |
| Mauskopf, J | 1 |
| Joshi, AV | 1 |
| Vermeulen, M | 2 |
| Stam, J | 2 |
| Rist, PM | 1 |
| Berger, K | 2 |
| Buring, JE | 9 |
| Kurth, T | 2 |
| Kan, LP | 1 |
| Chu, KM | 1 |
| Lin, GM | 1 |
| Ha, SW | 1 |
| Guo, JJ | 1 |
| Xu, E | 3 |
| Lin, QY | 1 |
| Zeng, GL | 1 |
| Xie, HF | 1 |
| Sharma, JC | 3 |
| Vassallo, M | 1 |
| Ross, IN | 1 |
| Meyer, D | 1 |
| Lee, BH | 1 |
| Park, JS | 2 |
| Kwak, JJ | 1 |
| Hwang, ES | 1 |
| Choi, DH | 1 |
| Pak, HN | 1 |
| Bauer, T | 3 |
| Gitt, A | 2 |
| Zahn, R | 3 |
| Jünger, C | 3 |
| Koeth, O | 2 |
| Towae, F | 1 |
| Bestehorn, K | 1 |
| Senges, J | 3 |
| Bilodeau, ML | 1 |
| Simon, DI | 2 |
| Dosh, K | 1 |
| Berger, PB | 5 |
| Marso, S | 1 |
| van Lente, F | 1 |
| Brennan, DM | 4 |
| Charnigo, R | 1 |
| Steinhubl, S | 2 |
| Brown, DL | 3 |
| Burke, GL | 1 |
| Oberman, A | 1 |
| Kostis, JB | 1 |
| Langer, RD | 1 |
| Wassertheil-Smoller, S | 2 |
| Okuma, H | 1 |
| Yasuda, T | 1 |
| Takagi, S | 1 |
| Diedler, J | 1 |
| Ahmed, N | 3 |
| Sykora, M | 1 |
| Overgaard, K | 2 |
| Luijckx, GJ | 2 |
| Soinne, L | 1 |
| Ford, GA | 3 |
| Wahlgren, N | 2 |
| Ringleb, P | 1 |
| Lukasik, M | 2 |
| Rozalski, M | 1 |
| Luzak, B | 1 |
| Michalak, S | 2 |
| Watala, C | 2 |
| Bhindi, R | 1 |
| Ormerod, OJ | 1 |
| Welchering, T | 1 |
| Torgano, G | 1 |
| Zecca, B | 1 |
| Monzani, V | 1 |
| Maestroni, A | 1 |
| Rossi, P | 1 |
| Cazzaniga, M | 1 |
| Manganaro, D | 1 |
| Boiti, C | 1 |
| Zilioli, E | 1 |
| Borutti, G | 1 |
| Falaschi, F | 1 |
| Mandelli, C | 1 |
| Hopps, S | 1 |
| Marcy, TR | 1 |
| Wait, SD | 1 |
| Abla, AA | 1 |
| Killory, BD | 1 |
| Starke, RM | 1 |
| Spetzler, RF | 1 |
| Pullicino, P | 4 |
| Jordan, LC | 1 |
| Rafay, MF | 2 |
| Smith, SE | 1 |
| Zamel, KM | 1 |
| Ashwal, S | 1 |
| Glick, JA | 1 |
| Brophy, GM | 1 |
| Ahmad, M | 1 |
| Salehian, O | 1 |
| Krane, V | 1 |
| Berger, M | 1 |
| Lilienthal, J | 1 |
| Winkler, K | 1 |
| Schambeck, C | 1 |
| Wanner, C | 1 |
| Sever, PS | 1 |
| Fowkes, FG | 1 |
| Stewart, MC | 1 |
| Butcher, I | 1 |
| Leng, GC | 1 |
| Pell, AC | 1 |
| Lowe, GD | 1 |
| Burke, JP | 1 |
| Sander, S | 2 |
| Zarotsky, V | 1 |
| Henk, H | 1 |
| Simmons, BB | 2 |
| Yeo, A | 1 |
| Fung, K | 1 |
| Gao, F | 1 |
| Zhou, YJ | 1 |
| Wang, ZJ | 1 |
| Shen, H | 1 |
| Liu, XL | 1 |
| Nie, B | 1 |
| Yan, ZX | 1 |
| Yang, SW | 1 |
| Jia, de A | 1 |
| Yu, M | 1 |
| Flaker, G | 7 |
| Hohnloser, S | 4 |
| Lawrence, J | 3 |
| Han, KH | 1 |
| Yun, SC | 1 |
| Lee, SG | 1 |
| Yoon, J | 1 |
| Yang, JY | 1 |
| Lee, BK | 1 |
| Chung, WS | 1 |
| Lim, DS | 1 |
| Kim, KS | 1 |
| Nah, DY | 1 |
| Jang, JS | 1 |
| Geraghty, OC | 2 |
| Kennedy, J | 3 |
| Chandratheva, A | 2 |
| Marquardt, L | 1 |
| Buchan, AM | 4 |
| Nannucci, S | 1 |
| Pescini, F | 1 |
| Valenti, R | 2 |
| Ciolli, L | 1 |
| Bianchi, S | 1 |
| Dotti, MT | 1 |
| Inzitari, D | 2 |
| Gelosa, P | 1 |
| Ballerio, R | 1 |
| Banfi, C | 1 |
| Nobili, E | 1 |
| Gianella, A | 1 |
| Pignieri, A | 1 |
| Brioschi, M | 1 |
| Guerrini, U | 1 |
| Castiglioni, L | 1 |
| Blanc-Guillemaud, V | 1 |
| Lerond, L | 1 |
| Sironi, L | 1 |
| Chollate, P | 1 |
| Koh, A | 1 |
| Reiffel, JA | 1 |
| Myerburg, R | 1 |
| Naccarelli, GV | 1 |
| Packer, DL | 1 |
| Pratt, CM | 1 |
| Reiter, MJ | 1 |
| Waldo, AL | 3 |
| Ansara, AJ | 1 |
| Nisly, SA | 1 |
| Koehler, JM | 1 |
| Nordmeyer, ST | 1 |
| Gross, H | 1 |
| Naka, Y | 1 |
| Conte, JV | 1 |
| Aaronson, KD | 1 |
| Sundareswaran, KS | 1 |
| Scacciatella, P | 1 |
| Butera, G | 2 |
| Amato, G | 1 |
| Tomassini, F | 1 |
| Giorgi, M | 1 |
| Marra, S | 1 |
| Crown, N | 1 |
| Mysak, T | 1 |
| Frisher, M | 1 |
| Short, D | 3 |
| Bashford, J | 3 |
| Nair, PP | 1 |
| Chaudhari, D | 1 |
| Bhuriya, R | 1 |
| Arora, R | 1 |
| Bots, ML | 2 |
| Laurent, S | 1 |
| Touboul, PJ | 1 |
| Pan, SL | 1 |
| Lien, IN | 1 |
| Taomoto, K | 1 |
| Ohnishi, H | 1 |
| Kuga, Y | 1 |
| Nakashima, K | 1 |
| Ichioka, T | 1 |
| Kodama, Y | 1 |
| Kubota, H | 1 |
| Hirose, T | 2 |
| Hayashi, M | 1 |
| Kinugasa, C | 1 |
| Paul, NL | 1 |
| Campos-Outcalt, D | 1 |
| Quinn, T | 2 |
| Rafferty, M | 1 |
| Higgins, P | 1 |
| Ray, G | 1 |
| Walters, MR | 4 |
| Jeon, SB | 1 |
| Song, HS | 1 |
| Kim, HJ | 2 |
| Lee, HY | 2 |
| Tong, YP | 1 |
| Cooke, CE | 1 |
| Benbassat, J | 1 |
| Baumal, R | 1 |
| Herishanu, Y | 1 |
| Frankel, MR | 3 |
| Labresh, KA | 1 |
| Ellrodt, G | 1 |
| Piccardi, B | 1 |
| Sarti, C | 2 |
| Okura, H | 1 |
| Budaj, A | 5 |
| Lu, N | 1 |
| Emery, J | 1 |
| Nitschmann, S | 2 |
| Fischer, D | 1 |
| Haentjes, J | 1 |
| Klein, G | 1 |
| Schieffer, B | 1 |
| Drexler, H | 1 |
| Meyer, GP | 1 |
| Schaefer, A | 1 |
| Lee, SP | 1 |
| Suh, JW | 1 |
| Choi, DJ | 1 |
| Kwon, TG | 1 |
| Bae, JH | 1 |
| Itshayek, E | 1 |
| Joyner, CD | 2 |
| Afzal, R | 2 |
| Mallonee, S | 2 |
| Daniels, CG | 1 |
| Cline, TL | 1 |
| Memtsoudis, SG | 1 |
| Sharrock, NE | 1 |
| Dandel, M | 1 |
| Hetzer, R | 1 |
| Sidorenko, BA | 4 |
| Fettser, DV | 1 |
| Batyraliev, TA | 4 |
| Niiazova-Karben, ZA | 1 |
| Besnili, F | 1 |
| Kumbhani, DJ | 2 |
| Shinohara, Y | 5 |
| Katayama, Y | 1 |
| Handa, S | 1 |
| Matsuoka, K | 1 |
| Ohashi, Y | 1 |
| Tanahashi, N | 2 |
| Genka, C | 1 |
| Kusuoka, H | 1 |
| Nishimaru, K | 1 |
| Tsushima, M | 1 |
| Sawada, T | 1 |
| Hamada, C | 1 |
| Clausen, MT | 1 |
| Fog-Petersen, ML | 1 |
| Raunsø, J | 1 |
| Gadsbøll, N | 1 |
| Folke, F | 1 |
| Andersen, SS | 1 |
| Schramm, TK | 1 |
| Abildstrøm, SZ | 1 |
| Poulsen, HE | 1 |
| Rothberg, MB | 1 |
| Dasgupta, B | 1 |
| Pignone, M | 3 |
| Williams, CD | 1 |
| Ibrahim, MM | 1 |
| Sebastian, J | 1 |
| Hussain, M | 1 |
| Al-Hussain, F | 1 |
| Molina, C | 1 |
| Khan, K | 1 |
| Saqqur, M | 1 |
| Dippel, DW | 4 |
| Maasland, L | 1 |
| Halkes, P | 1 |
| Rosenbaum, A | 1 |
| Rizvi, AZ | 1 |
| Alden, PB | 1 |
| Tretinyak, AS | 1 |
| Graber, JN | 1 |
| Goldman, JA | 1 |
| Schlitt, A | 1 |
| Greer, DM | 1 |
| Aydinalp, A | 1 |
| Atar, I | 1 |
| Altin, C | 1 |
| Gülmez, O | 1 |
| Atar, A | 1 |
| Açikel, S | 1 |
| Bozbaş, H | 1 |
| Yildirir, A | 1 |
| Müderrisoğlu, H | 1 |
| Bektas, F | 1 |
| Soyuncu, S | 1 |
| Sani, Y | 2 |
| Schevchuck, A | 2 |
| Fong, A | 2 |
| De Deyn, P | 2 |
| Sanchez-Ross, M | 1 |
| Waller, AH | 1 |
| Maher, J | 1 |
| Klapholz, M | 1 |
| Haider, B | 1 |
| Kral, M | 1 |
| Vlachova, I | 1 |
| Bartkova, A | 1 |
| Hlustik, P | 1 |
| Kovacik, M | 1 |
| Kanovsky, P | 1 |
| Bischoff, A | 1 |
| Maron, BA | 1 |
| Shekar, PS | 1 |
| Venker, C | 1 |
| Stracke, P | 1 |
| Berlit, P | 1 |
| Diehl, RR | 1 |
| Kurre, W | 1 |
| Sorgenfrei, U | 1 |
| Krämer, M | 1 |
| Chapot, R | 1 |
| Zhang, D | 1 |
| Field, TS | 1 |
| Shimokhina, NIu | 1 |
| Petrova, MM | 1 |
| Savchenko, AA | 1 |
| Nobili, A | 1 |
| Tettamanti, M | 1 |
| Pasina, L | 1 |
| Marengoni, A | 1 |
| Salerno, F | 1 |
| Corrao, S | 1 |
| Mannucci, PM | 1 |
| Sakata, T | 1 |
| Kario, K | 1 |
| Pierzhała, PA | 1 |
| Trautsolt, W | 1 |
| Kumor, K | 1 |
| Ogasawara, K | 1 |
| Bugnicourt, JM | 2 |
| Roussel, B | 1 |
| Garcia, PY | 2 |
| Canaple, S | 1 |
| Lamy, C | 2 |
| Godefroy, O | 2 |
| Stavrakis, S | 1 |
| Stoner, JA | 1 |
| Azar, M | 1 |
| Wayangankar, S | 1 |
| Thadani, U | 1 |
| O'Carroll, R | 1 |
| Whittaker, J | 1 |
| Hamilton, B | 1 |
| Johnston, M | 2 |
| Sudlow, C | 6 |
| Fedorov, A | 1 |
| Chibisova, Y | 1 |
| Szymaszek, A | 1 |
| Alexandrov, M | 1 |
| Gall, C | 1 |
| Sabel, BA | 1 |
| Naqvi, I | 1 |
| Husain, MR | 1 |
| Khealani, BA | 1 |
| Akai, Y | 1 |
| Cea Soriano, L | 1 |
| Hill, C | 1 |
| Cay, S | 1 |
| Cagirci, G | 1 |
| Aydogdu, S | 1 |
| Balbay, Y | 1 |
| Sen, N | 1 |
| Maden, O | 1 |
| Demir, AD | 1 |
| Erbay, AR | 1 |
| Nidhinandana, S | 3 |
| Changchit, S | 1 |
| Jacob, M | 1 |
| Smedira, N | 1 |
| Blackstone, E | 1 |
| Williams, S | 1 |
| Cho, L | 1 |
| Tapp, LD | 1 |
| Zhao, HJ | 1 |
| Zheng, ZT | 1 |
| Wang, ZH | 1 |
| Li, SH | 1 |
| Zhong, M | 1 |
| Ay, H | 1 |
| Golitsyn, S | 1 |
| Talajic, M | 1 |
| Jansky, P | 2 |
| Commerford, P | 1 |
| Sim, KH | 1 |
| Van Mieghem, W | 1 |
| Lanas-Zanetti, F | 1 |
| Gonzalez-Hermosillo, A | 1 |
| Munawar, M | 1 |
| Lewis, G | 1 |
| Pokov, I | 1 |
| Thevathasan, L | 1 |
| Kao, YH | 1 |
| Lai, ML | 1 |
| White, CL | 2 |
| Pearce, L | 2 |
| Pergola, P | 1 |
| Roldan, A | 2 |
| Benavente, MF | 2 |
| Coffey, C | 1 |
| Szychowski, JM | 3 |
| Heberling, PA | 1 |
| Bazan, C | 1 |
| Vidal-Pergola, G | 1 |
| Talbert, R | 1 |
| Lim, SH | 1 |
| Hong, BY | 1 |
| Cho, YR | 1 |
| Lee, JI | 1 |
| Kim, HW | 1 |
| Ko, YJ | 1 |
| Sharma, N | 1 |
| McArthur, KS | 1 |
| Hamid, SA | 1 |
| Mamji, S | 1 |
| Baig, SM | 1 |
| Kumagai, N | 1 |
| Breet, NJ | 1 |
| van Werkum, JW | 1 |
| Bouman, HJ | 1 |
| Kelder, JC | 1 |
| Harmsze, AM | 1 |
| Hackeng, CM | 1 |
| Dechartres, A | 1 |
| Albaladejo, P | 1 |
| Mantz, J | 1 |
| Samama, CM | 1 |
| Ravaud, P | 1 |
| Tubach, F | 1 |
| Urano, Y | 1 |
| Horie, Y | 1 |
| Ozben, S | 1 |
| Ozben, B | 1 |
| Tanrikulu, AM | 1 |
| Ozer, F | 1 |
| Ozben, T | 1 |
| Niewada, M | 1 |
| Członkowska, A | 1 |
| Jowett, S | 1 |
| Bryan, S | 2 |
| Mant, J | 4 |
| Fletcher, K | 4 |
| Roalfe, A | 2 |
| Hobbs, FD | 5 |
| Stecker, EC | 1 |
| Fendrick, AM | 1 |
| Poisson, S | 1 |
| Borja, J | 1 |
| García-Rafanell, J | 1 |
| Guthrie, R | 1 |
| Charlot, M | 1 |
| Ahlehoff, O | 1 |
| Selmer, C | 1 |
| Lindhardsen, J | 2 |
| Madsen, JK | 2 |
| van Gaalen, J | 1 |
| van Dijk, EJ | 1 |
| van Deuren, M | 1 |
| de Leeuw, FE | 2 |
| Nelson, M | 1 |
| McGrath, E | 1 |
| O'Conghaile, A | 1 |
| Dinneen, SF | 1 |
| Oczkowski, C | 1 |
| Raju, N | 1 |
| Sobieraj-Teague, M | 1 |
| Hirsh, J | 3 |
| Tchan, M | 1 |
| Sillence, D | 1 |
| Chae, CU | 1 |
| Glynn, RJ | 1 |
| Tedrow, UB | 1 |
| Everett, BM | 1 |
| Albert, CM | 1 |
| Morales-Vidal, S | 1 |
| Flaster, MS | 1 |
| Tate, J | 1 |
| Lisabeth, L | 1 |
| Koo, J | 1 |
| Han, MG | 1 |
| Jung, SW | 1 |
| Fox, KM | 1 |
| de Cordoüe, A | 1 |
| Fratacci, MD | 1 |
| Mahawish, KM | 1 |
| Heikinheimo, T | 1 |
| Schoeman, JF | 1 |
| Janse van Rensburg, A | 1 |
| Laubscher, JA | 1 |
| Springer, P | 1 |
| Hogg, C | 1 |
| Tracy, M | 1 |
| Simpson, SH | 1 |
| Gamble, JM | 1 |
| Mereu, L | 1 |
| Chambers, T | 1 |
| Garg, N | 1 |
| Rajpurohit, N | 1 |
| Calabrò, RS | 1 |
| Pezzini, A | 2 |
| Gervasi, G | 1 |
| Pollicino, P | 1 |
| Bramanti, P | 1 |
| Lin, KW | 1 |
| Lynch, DR | 1 |
| Vidal-Jordana, A | 1 |
| Barroeta-Espar, I | 1 |
| Sáinz Pelayo, MP | 1 |
| Mateo, J | 1 |
| Delgado-Mederos, R | 1 |
| Pujol Lereis, VA | 1 |
| Ameriso, S | 1 |
| Carroll, K | 1 |
| Horrow, J | 3 |
| Leach, I | 1 |
| Kilaru, R | 1 |
| Mohan, P | 1 |
| Goodman, S | 1 |
| Flather, M | 1 |
| Husted, SE | 4 |
| Cools, F | 1 |
| Ruzyllo, W | 3 |
| White, H | 1 |
| Geraldes, M | 1 |
| Dworacki, G | 1 |
| Kufel-Grabowska, J | 1 |
| Golanski, J | 1 |
| Feher, A | 1 |
| Pusch, G | 1 |
| Harang, G | 1 |
| Gasztonyi, B | 1 |
| Papp, E | 1 |
| Werling, D | 1 |
| Menyhart, M | 1 |
| Komaromy, H | 1 |
| Szapary, L | 2 |
| Feher, G | 1 |
| Oyama, N | 1 |
| Kawamura, M | 1 |
| Sugiyama, Y | 1 |
| Terasaki, Y | 1 |
| Omura-Matsuoka, E | 1 |
| Sasaki, T | 1 |
| Di Minno, MN | 1 |
| Guida, A | 1 |
| Camera, M | 1 |
| Colli, S | 1 |
| Mono, ML | 2 |
| Geister, L | 1 |
| Galimanis, A | 1 |
| Praz, F | 1 |
| Wolff, S | 1 |
| Findling, O | 1 |
| Wahl, A | 2 |
| Georgiadis, AL | 1 |
| Cordina, SM | 1 |
| Vazquez, G | 1 |
| Tariq, N | 1 |
| Adams, HP | 4 |
| Lee, JM | 2 |
| Seo, JH | 1 |
| Hong, DM | 1 |
| Bahk, JH | 1 |
| Kim, KB | 1 |
| Jeon, Y | 1 |
| Awad, HH | 1 |
| Zubaid, M | 1 |
| Alsheikh-Ali, AA | 1 |
| Al Suwaidi, J | 1 |
| Anderson, FA | 1 |
| Bhattacharya, P | 1 |
| Abbate, R | 2 |
| Torbey, MT | 1 |
| Raj, MD | 1 |
| McDonald, C | 1 |
| Brooks, AJ | 1 |
| Drummond, M | 1 |
| Lau, HM | 1 |
| Patel, MI | 1 |
| Bariol, SV | 1 |
| Wang, AC | 1 |
| Woo, HH | 1 |
| Shah, BR | 1 |
| Olson, DM | 1 |
| Pan, W | 1 |
| Bushnell, CD | 1 |
| Asinger, RW | 4 |
| Herzog, CA | 1 |
| Chiu, FC | 1 |
| Wang, TD | 1 |
| Shih, FY | 1 |
| Lin, JW | 2 |
| Huang, CH | 1 |
| Chen, WJ | 1 |
| Chen, MF | 1 |
| Parodi, G | 1 |
| Gori, AM | 1 |
| Migliorini, A | 1 |
| Giusti, B | 1 |
| Buonamici, P | 1 |
| Antoniucci, D | 1 |
| Fraenkel, L | 1 |
| Street, RL | 1 |
| Fried, TR | 1 |
| Murillo, L | 1 |
| Márquez, JM | 1 |
| Tamayo, A | 1 |
| Cantú, C | 2 |
| Roldan, FJ | 1 |
| Vargas-Barrón, J | 1 |
| Barinagarrementeria, F | 2 |
| Darkhabani, Z | 1 |
| Binning, MJ | 1 |
| Rodríguez-Yáñez, M | 1 |
| Arias-Rivas, S | 1 |
| Fernández-Ferro, J | 1 |
| Leira, R | 1 |
| Castillo, J | 2 |
| Blanco, M | 1 |
| Sackett, DL | 1 |
| Nakamura, T | 2 |
| Tsuruta, S | 1 |
| Ge, L | 1 |
| Niu, G | 1 |
| Han, X | 1 |
| Kasahara, Y | 1 |
| Nakagomi, T | 1 |
| Matsuyama, T | 1 |
| Stern, D | 1 |
| Taguchi, A | 1 |
| Ng, J | 1 |
| Fang, MC | 3 |
| Eldrup, N | 1 |
| Budtz-Lilly, J | 1 |
| Laustsen, J | 1 |
| Bibby, BM | 1 |
| Paaske, WP | 1 |
| Wang, QS | 1 |
| Chen, XY | 3 |
| Han, JH | 2 |
| Mok, V | 2 |
| Vinisko, R | 1 |
| French, J | 1 |
| Lassila, R | 1 |
| Dorresteijn, JA | 1 |
| Visseren, FL | 1 |
| Paynter, NP | 1 |
| Wassink, AM | 1 |
| Aw, D | 1 |
| Chitose, T | 1 |
| Hokimoto, S | 1 |
| Oshima, S | 1 |
| Miyao, Y | 1 |
| Shimomura, H | 1 |
| Tsunoda, R | 1 |
| Maruyama, H | 1 |
| Yamamoto, K | 1 |
| Mizobe, M | 1 |
| Nakamura, S | 1 |
| Romero-Ortuno, R | 1 |
| O'Shea, D | 1 |
| Inoue, Y | 1 |
| Mücke, S | 1 |
| Grotemeyer, KH | 2 |
| Stahlhut, L | 1 |
| Husstedt, IW | 2 |
| Evers, S | 2 |
| Al-Hazzani, A | 2 |
| Prabha, TS | 1 |
| Rao, PP | 1 |
| Bajorek, BV | 1 |
| Ren, S | 1 |
| Krings, T | 1 |
| Fujita, K | 1 |
| Komatsu, Y | 1 |
| Sato, N | 1 |
| Higuchi, O | 1 |
| Kujiraoka, Y | 1 |
| Kamezaki, T | 1 |
| Suzuki, K | 2 |
| Matsumura, A | 1 |
| Radovic, V | 1 |
| Mehta, B | 1 |
| Farooq, O | 1 |
| Munschauer, FE | 1 |
| Coleman, CI | 2 |
| Straznitskas, AD | 1 |
| Sobieraj, DM | 1 |
| Anglade, MW | 2 |
| Barreto, AD | 1 |
| Krishnan, E | 1 |
| Pandya, BJ | 1 |
| Lingala, B | 1 |
| Hariri, A | 1 |
| Dabbous, O | 1 |
| Grau, AJ | 3 |
| Wanke, I | 2 |
| Möller-Hartmann, C | 2 |
| Gizewski, ER | 2 |
| Blatchford, J | 2 |
| Forsting, M | 2 |
| Warach, S | 2 |
| Diehl, A | 2 |
| Acelajado, MC | 1 |
| Oparil, S | 1 |
| Del Zotto, E | 1 |
| Ritelli, M | 1 |
| Drera, B | 1 |
| Gamba, M | 1 |
| Giossi, A | 1 |
| Volonghi, I | 1 |
| Costa, P | 1 |
| Barlati, S | 1 |
| Gasparotti, R | 1 |
| Padovani, A | 1 |
| Colombi, M | 1 |
| Benavente, O | 4 |
| Geeganage, CM | 1 |
| Dengler, R | 2 |
| Bath, MW | 1 |
| Littrell, R | 1 |
| Frieden, TR | 1 |
| Blakeman, DE | 1 |
| Mohl, S | 1 |
| You, JJ | 1 |
| Howard, PA | 1 |
| Eckman, MH | 1 |
| Schulman, S | 2 |
| Hughes, M | 1 |
| Spencer, FA | 3 |
| Manning, WJ | 2 |
| Whitlock, RP | 1 |
| Sun, JC | 1 |
| Fremes, SE | 1 |
| Rubens, FD | 2 |
| Teoh, KH | 1 |
| Lang, ES | 1 |
| Nguyen-Huynh, MN | 1 |
| Schwartz, NE | 2 |
| Sonnenberg, FA | 1 |
| Guyatt, GH | 1 |
| Akl, EA | 1 |
| Silvestry, S | 1 |
| Zhao, N | 1 |
| Diehl, J | 1 |
| Johkura, K | 1 |
| Yoshida, TN | 1 |
| Kudo, Y | 1 |
| Nakae, Y | 1 |
| Momoo, T | 1 |
| Kuroiwa, Y | 1 |
| Kate, MP | 1 |
| Renard, D | 1 |
| Larue, A | 1 |
| Taieb, G | 1 |
| Jeanjean, L | 1 |
| Labauge, P | 1 |
| Zhou, YH | 1 |
| Wei, X | 1 |
| Ye, XF | 1 |
| Wu, MJ | 1 |
| Xu, JF | 1 |
| Qin, YY | 1 |
| Sidddiqi, SA | 1 |
| Yaemsiri, S | 1 |
| Tinker, L | 1 |
| Rosamond, W | 1 |
| He, K | 1 |
| Broder, A | 1 |
| Tobin, JN | 1 |
| Putterman, C | 1 |
| Menon, AK | 1 |
| Götzenich, A | 1 |
| Sassmannshausen, H | 1 |
| Haushofer, M | 1 |
| Autschbach, R | 1 |
| Spillner, JW | 1 |
| Paikin, JS | 1 |
| Reisman, M | 1 |
| Massaro, J | 1 |
| Adams, H | 1 |
| Felberg, R | 1 |
| Herrmann, H | 1 |
| Landzberg, M | 1 |
| Raizner, A | 1 |
| Wechsler, L | 2 |
| Monti, M | 1 |
| Percoco, G | 1 |
| Castriota, F | 1 |
| Colombo, F | 1 |
| Fucà, G | 1 |
| Kubbajeh, M | 1 |
| Cangiano, E | 1 |
| Minarelli, M | 1 |
| Scalone, A | 1 |
| Cavazza, C | 1 |
| Frangione, A | 1 |
| Borghesi, M | 1 |
| Marchesini, J | 1 |
| Parrinello, G | 1 |
| Mazya, M | 1 |
| Egido, JA | 1 |
| Agarwal, S | 1 |
| Hachamovitch, R | 1 |
| Menon, V | 1 |
| Leal, MA | 1 |
| Jesurum, JT | 1 |
| Fuller, CJ | 1 |
| Murinova, N | 1 |
| Truva, CM | 1 |
| Lucas, SM | 1 |
| Pretell, EJ | 1 |
| Del Brutto, OH | 1 |
| Meyer, BC | 1 |
| Meissner, I | 1 |
| Demaerschalk, BM | 1 |
| Coffey, CS | 3 |
| Irby, LH | 1 |
| Peri, K | 1 |
| Pergola, PE | 1 |
| Soo, YO | 1 |
| Siu, DY | 1 |
| Abrigo, J | 1 |
| Ng, N | 1 |
| Ahuja, AT | 1 |
| Mejia, V | 1 |
| del Valle, ML | 1 |
| Carey, KM | 1 |
| Comee, MR | 1 |
| Goldstein, Y | 1 |
| Behrbalk, E | 1 |
| Kaufman, E | 1 |
| Swarbrick, M | 1 |
| Fitzgerald, C | 1 |
| Delgado, MG | 1 |
| Mauri, G | 1 |
| Vega, J | 1 |
| Varughese, CJ | 1 |
| Iwabuchi, M | 1 |
| Ehara, N | 1 |
| Mizoguchi, T | 1 |
| Mitsuoka, H | 1 |
| Inada, T | 1 |
| Araki, M | 1 |
| Kaburagi, S | 1 |
| Taniguchi, R | 1 |
| Nakano, A | 1 |
| Rybicka, J | 1 |
| Kowalski, M | 1 |
| Michałowska, I | 1 |
| Hoffman, P | 1 |
| Fischer-Betz, R | 1 |
| Specker, C | 1 |
| Brinks, R | 1 |
| Schneider, M | 1 |
| Tong, X | 1 |
| Sonnenfeld, N | 1 |
| Hong, Y | 1 |
| Petrie, C | 1 |
| Kilickesmez, KO | 1 |
| Kocas, C | 1 |
| Abaci, O | 1 |
| Okcun, B | 1 |
| Gorcin, B | 1 |
| Gurmen, T | 1 |
| Hawkins, N | 1 |
| Azoulay, L | 1 |
| Dell'Aniello, S | 1 |
| Simon, TA | 1 |
| Langleben, D | 1 |
| Renoux, C | 1 |
| Suissa, S | 1 |
| Meng, J | 1 |
| Hagstrom, K | 1 |
| Alshatwi, AA | 1 |
| Foody, JM | 1 |
| Funk, M | 2 |
| Alexander, KP | 2 |
| Baskys, A | 1 |
| Cheng, JX | 1 |
| Mokrushin, AA | 1 |
| Pavlinova, LI | 1 |
| Paolasso, E | 1 |
| Schoenefeld, E | 1 |
| Donas, K | 1 |
| Radicke, A | 1 |
| Osada, N | 1 |
| Austermann, M | 1 |
| Torsello, G | 1 |
| Geng, DF | 1 |
| Jin, DM | 1 |
| Deng, J | 1 |
| Wang, JF | 1 |
| Shevelev, VI | 1 |
| Kanorskiĭ, SG | 1 |
| Burton, TM | 1 |
| Yu, Y | 1 |
| Monsalvo, ML | 1 |
| Lang, K | 1 |
| Reyes-Iglesias, Y | 1 |
| Yavagal, DR | 1 |
| Arnarsdottir, L | 1 |
| Hjalmarsson, C | 1 |
| Bokemark, L | 1 |
| Andersson, B | 1 |
| Ruwald, MH | 1 |
| Hansen, CM | 1 |
| Karasoy, D | 1 |
| Van Hattum, ES | 1 |
| Tangelder, MJ | 2 |
| Lawson, JA | 3 |
| Moll, FL | 2 |
| Lin, WH | 1 |
| Zhao, YD | 1 |
| Marín, F | 3 |
| Ten Cate, H | 1 |
| Davì, G | 2 |
| Vazzana, N | 1 |
| Brenck, J | 1 |
| Meade, T | 2 |
| Clemmensen, P | 1 |
| Ardissino, D | 2 |
| Topacio, GO | 1 |
| Pavlides, G | 1 |
| Goudev, AR | 1 |
| Oto, A | 1 |
| Tseng, CD | 1 |
| Gasparovic, V | 1 |
| Cinteză, M | 1 |
| McLendon, RC | 1 |
| Brown, EB | 1 |
| Aylward, PE | 1 |
| Hochman, JS | 1 |
| Namazi, MH | 1 |
| Mohagheghi, A | 1 |
| Ostovaneh, MR | 1 |
| Sepanlou, SG | 1 |
| Farzadfar, F | 1 |
| Jafari, E | 1 |
| Danaei, G | 1 |
| Caso, V | 2 |
| Santalucia, P | 1 |
| Acciarresi, M | 1 |
| Pezzella, FR | 1 |
| Worthmann, H | 1 |
| Schumacher, H | 1 |
| Schwartz, A | 1 |
| Eisert, WG | 1 |
| Lichtinghagen, R | 1 |
| Weissenborn, K | 1 |
| Peng, Q | 1 |
| Ding, M | 2 |
| Hong, Z | 2 |
| Yao, C | 2 |
| Krishnan, M | 1 |
| Ali, S | 1 |
| Iyer, RS | 1 |
| Rossen, JD | 1 |
| Chalouhi, N | 1 |
| Wassef, SN | 1 |
| Thomas, J | 1 |
| Abel, TJ | 1 |
| Jabbour, PM | 1 |
| Kung, DK | 1 |
| Hasan, DM | 1 |
| Guirguis-Blake, J | 1 |
| Collins, R | 2 |
| Vanstreels, L | 1 |
| Molenberghs, G | 1 |
| Voigt, JU | 1 |
| Kaatz, S | 1 |
| Giger, JN | 1 |
| Brannon, CB | 1 |
| Vellimana, AK | 1 |
| Kadkhodayan, Y | 1 |
| Rich, KM | 1 |
| Cross, DT | 1 |
| Moran, CJ | 1 |
| Zazulia, AR | 1 |
| Chicoine, MR | 1 |
| Dacey, RG | 1 |
| Zipfel, GJ | 1 |
| McGrath, RA | 1 |
| Broderick, S | 1 |
| Newby, LK | 2 |
| Shaw, LK | 1 |
| Lai, PT | 1 |
| Chen, SY | 1 |
| Ho, YP | 1 |
| Chiang, YY | 1 |
| Hsu, HY | 1 |
| Piotrponikowski, P | 1 |
| Filippatos, G | 1 |
| Neely, M | 1 |
| Chan, MY | 1 |
| Brown, E | 1 |
| Jakubowski, JA | 1 |
| Simma, B | 1 |
| Höliner, I | 1 |
| Luetschg, J | 1 |
| Hsu, LC | 1 |
| Fuh, JL | 1 |
| Badri, M | 1 |
| Saeed, W | 1 |
| Sardar, MR | 1 |
| Zheng, AS | 1 |
| Churilov, L | 1 |
| Colley, RE | 1 |
| Goh, C | 1 |
| Martins, SC | 1 |
| Pieri, A | 1 |
| Moro, CH | 1 |
| Jesus, PA | 1 |
| Longo, A | 1 |
| Evaristo, EF | 1 |
| Carvalho, JJ | 1 |
| Fernandes, JG | 1 |
| Oliveira-Filho, J | 1 |
| Kumar, G | 1 |
| Goyal, MK | 1 |
| Nirantharakumar, K | 1 |
| Marshall, T | 1 |
| Schlieper, G | 1 |
| Krüger, T | 1 |
| Floege, J | 1 |
| Baumann, M | 1 |
| Seifert, CL | 1 |
| Poppert, H | 1 |
| Tangri, N | 1 |
| Grosser, T | 1 |
| Fries, S | 1 |
| Kapoor, SC | 1 |
| Grant, GR | 1 |
| FitzGerald, GA | 2 |
| Fleming, JB | 1 |
| Richards, BF | 1 |
| Cava, LP | 1 |
| Curé, JK | 1 |
| Younan, DS | 1 |
| Barlinn, K | 1 |
| Taylor, T | 1 |
| Hanna, EB | 1 |
| Simonsen, CZ | 1 |
| Wu, HC | 1 |
| Wordsworth, DR | 1 |
| Halsey, T | 1 |
| Griffiths, R | 1 |
| Parker, MJ | 1 |
| Thomson, RM | 1 |
| Nilanont, Y | 1 |
| Hanchaiphiboolkul, S | 1 |
| Pimpak, T | 1 |
| Tatsanavivat, P | 1 |
| Saposnik, G | 1 |
| Poungvarin, N | 1 |
| Sievert, H | 1 |
| Buchbinder, M | 1 |
| Longstreth, WT | 2 |
| Kronmal, RA | 3 |
| Christenson, RH | 1 |
| Gross, R | 1 |
| Brey, RL | 3 |
| Elkind, MS | 3 |
| Seliger, SL | 1 |
| deFilippi, CR | 1 |
| Zykov, VP | 1 |
| Komarova, IB | 1 |
| Lagman-Bartolome, AM | 1 |
| Pontigon, AM | 1 |
| MacGregor, DL | 1 |
| Kossorotoff, M | 1 |
| Thompson, SG | 1 |
| Higgins, JP | 1 |
| Wallace, JL | 1 |
| Ignarro, LJ | 1 |
| Fiorucci, S | 1 |
| van Es, RF | 1 |
| Jonker, JJ | 1 |
| Deckers, JW | 2 |
| Grobbee, DE | 1 |
| Lilly, LS | 1 |
| Rollins, G | 2 |
| Aponte, JJ | 1 |
| Planas, AM | 1 |
| Chan, A | 1 |
| Warlow, C | 2 |
| Lopez-Yunez, AM | 1 |
| Lew, SJ | 1 |
| Lim, JK | 1 |
| Cuadrado, MJ | 1 |
| Sandercock, P | 7 |
| Yamazaki, M | 3 |
| Iwata, M | 3 |
| Elliott, RA | 1 |
| Woodward, MC | 1 |
| Oborne, CA | 1 |
| Mehta, P | 1 |
| MacWalter, RS | 2 |
| Shirley, CP | 1 |
| Teo, KK | 1 |
| Hall, A | 1 |
| Latini, R | 1 |
| Weisman, SM | 3 |
| Graham, DY | 1 |
| Gan, R | 2 |
| Teleg, RA | 1 |
| Florento, L | 1 |
| Bitanga, ES | 1 |
| Jenkinson, D | 1 |
| Man-Son-Hing, M | 4 |
| Berquist, R | 1 |
| O'Connor, AM | 2 |
| Laupacis, A | 6 |
| Gabis, LV | 1 |
| Yangala, R | 1 |
| Lenn, NJ | 1 |
| Penka, M | 1 |
| Tilly-Gentric, A | 1 |
| Hayek, E | 1 |
| Griffin, B | 1 |
| Mann, JT | 1 |
| Fry, ET | 1 |
| DeLago, A | 1 |
| Wilmer, C | 1 |
| van Walraven, C | 4 |
| Petersen, P | 5 |
| Chang, Y | 3 |
| Hellemons, B | 1 |
| Comarow, A | 1 |
| Ono, A | 1 |
| Fujita, T | 2 |
| Musolino, R | 1 |
| La Spina, P | 1 |
| Granata, A | 1 |
| Gallitto, G | 1 |
| Leggiadro, N | 1 |
| Carerj, S | 1 |
| Manganaro, A | 1 |
| Tripodi, F | 1 |
| Epifanio, A | 1 |
| Gangemi, S | 1 |
| Di Perri, R | 1 |
| Diner, BM | 1 |
| Ornato, JP | 3 |
| Aronow, WS | 2 |
| Levenson, D | 1 |
| Pollack, CV | 1 |
| Rasmussen, A | 1 |
| Christensen, J | 1 |
| Clemmensen, PM | 1 |
| Dalsgaard, NJ | 1 |
| Dam, H | 1 |
| Hindberg, I | 1 |
| Lunde, M | 1 |
| Plenge, P | 1 |
| Mellerup, E | 1 |
| Kovich, O | 1 |
| Otley, CC | 1 |
| Zhao, F | 3 |
| Blumenthal, M | 1 |
| Wittlinger, T | 1 |
| Maillard, L | 1 |
| Sprague, D | 1 |
| Loewen, P | 1 |
| Reiners, S | 1 |
| Lichy, C | 2 |
| Buggle, F | 2 |
| Ruf, A | 1 |
| Meyer, BJ | 1 |
| Dörffler-Melly, J | 1 |
| Schmidli, J | 1 |
| Mahler, F | 1 |
| Wardlaw, JM | 3 |
| West, TM | 1 |
| Lewis, SC | 3 |
| Mielke, O | 1 |
| Matías-Guiu, J | 3 |
| Torres, F | 3 |
| Jiménez, MD | 1 |
| Melo, T | 1 |
| Gum, PA | 1 |
| Kottke-Marchant, K | 1 |
| Welsh, PA | 1 |
| Jönsson, B | 2 |
| Hansson, L | 2 |
| Stålhammar, NO | 1 |
| Schaeffner, ES | 1 |
| Serebruany, VL | 7 |
| Malinin, AI | 5 |
| Sane, DC | 3 |
| Gerschutz, GP | 1 |
| Tong, DC | 2 |
| Hamann, GF | 1 |
| Glahn, J | 1 |
| Busse, O | 3 |
| Lee, KM | 1 |
| Bae, HR | 2 |
| Lim, YJ | 1 |
| Cheon, SM | 1 |
| Wells, GA | 1 |
| Gullov, AL | 1 |
| Hellemons, BS | 1 |
| Koefed, BG | 1 |
| McBride, R | 2 |
| Nasco, E | 1 |
| Sherman, DG | 1 |
| Talbert, RL | 2 |
| Marler, JR | 1 |
| Berge, E | 4 |
| Sivenius, J | 4 |
| Ziegler, BK | 1 |
| Hildebrandt, PR | 1 |
| Nielsen, HK | 1 |
| Leung, CS | 1 |
| Tam, KM | 1 |
| Conway, DS | 2 |
| Chin, BS | 2 |
| Richardson, D | 1 |
| Kelly, M | 1 |
| Ruland, S | 2 |
| Hung, E | 1 |
| Harris, Y | 1 |
| Kittner, S | 1 |
| Leurgans, S | 1 |
| Edvardsson, N | 1 |
| Juul-Möller, S | 1 |
| Omblus, R | 1 |
| Pehrsson, K | 1 |
| Rudnicka, AR | 1 |
| Ashby, D | 1 |
| Brennan, P | 1 |
| Law, MR | 1 |
| Derksen, RH | 1 |
| de Groot, PG | 1 |
| Yarnell, J | 1 |
| O'Brien, JR | 1 |
| Ben Shlomo, Y | 1 |
| Schmülling, S | 1 |
| Rudolf, J | 1 |
| Strotmann-Tack, T | 1 |
| Schneweis, S | 1 |
| Sobesky, J | 1 |
| Thiel, A | 1 |
| Frischer, M | 2 |
| Ashcroft, D | 1 |
| Lenz, T | 1 |
| Wilson, A | 1 |
| Hung, J | 1 |
| Andersen, HR | 1 |
| Nielsen, TT | 1 |
| Vesterlund, T | 1 |
| Grande, P | 1 |
| Abildgaard, U | 1 |
| Thayssen, P | 1 |
| Pedersen, F | 1 |
| Mortensen, LS | 1 |
| Vaur, L | 1 |
| Danchin, N | 1 |
| Hanania, G | 1 |
| Cambou, JP | 1 |
| Lablanche, JM | 1 |
| Clerson, P | 1 |
| Gueret, P | 1 |
| Felberg, RA | 1 |
| Naidech, AM | 1 |
| Kirshner, HS | 2 |
| Mant, JW | 1 |
| Richards, SH | 1 |
| Murray, E | 3 |
| Banting, M | 1 |
| Rahman, J | 1 |
| Allan, T | 1 |
| Raftery, J | 1 |
| Fan, YH | 1 |
| Mok, VC | 1 |
| Warburton, E | 6 |
| Jensvold, NG | 1 |
| Henault, LE | 2 |
| Selby, JV | 2 |
| Shalaev, SV | 1 |
| Mahé, I | 1 |
| Grenard, AS | 1 |
| Caulin, C | 1 |
| Gere, J | 1 |
| Minier, D | 1 |
| Osseby, GV | 1 |
| Couvreur, G | 1 |
| Moreau, T | 1 |
| Giroud, M | 1 |
| Sciacca, RR | 5 |
| Eidelman, RS | 1 |
| Hebert, PR | 2 |
| Kopecky, SL | 3 |
| Valentin, V | 1 |
| Dudderidge, TJ | 1 |
| Arya, M | 1 |
| Young, J | 1 |
| Davies, AJ | 1 |
| Jonas, S | 2 |
| Grieco, G | 2 |
| Ito, E | 1 |
| Takahashi, A | 1 |
| Kuzuhara, S | 1 |
| Nakajima, M | 1 |
| Kaźmierski, MK | 1 |
| Boccara, F | 2 |
| Cohen, A | 4 |
| Christian, JB | 1 |
| Lapane, KL | 3 |
| Toppa, RS | 1 |
| Griffin, G | 1 |
| Sarma, GR | 1 |
| Roy, AK | 1 |
| Haberl, R | 1 |
| Bogousslavsky, J | 6 |
| Schwerzmann, M | 1 |
| Seiler, Ch | 1 |
| Barth, A | 1 |
| Wojakowski, W | 1 |
| Shakib, S | 1 |
| George, A | 1 |
| Mattiasson, I | 2 |
| Lethagen, S | 2 |
| Hillarp, A | 2 |
| Bonnefoy, E | 1 |
| Chabaud, S | 1 |
| Lapostolle, F | 1 |
| Dubien, PY | 1 |
| Cristofini, P | 1 |
| Leizorovicz, A | 1 |
| Touboul, P | 1 |
| Rödén-Jüllig, A | 1 |
| Britton, M | 1 |
| Malmkvist, K | 1 |
| Leijd, B | 1 |
| Bergman, DL | 1 |
| Molner, E | 1 |
| Jovanovic, BD | 1 |
| Ushiwata, I | 1 |
| Teruya, J | 1 |
| Bryant, CA | 1 |
| Mangoni, AA | 1 |
| Jackson, SH | 1 |
| Williams, A | 1 |
| Redman, AR | 2 |
| Ryan, GJ | 1 |
| Colwell, JA | 1 |
| Sulter, G | 1 |
| Elting, JW | 1 |
| Maurits, N | 1 |
| Luyckx, GJ | 1 |
| Nagpal, S | 2 |
| Putnam, W | 2 |
| Flowerdew, G | 1 |
| Gardner, M | 1 |
| Weston, C | 1 |
| Rao, U | 1 |
| Sacks, FM | 1 |
| Jukema, JW | 1 |
| Byington, RP | 1 |
| Berry, DA | 1 |
| Berry, SM | 1 |
| Ford, NF | 1 |
| Walker, AJ | 1 |
| Natarajan, K | 1 |
| Sheng-Lin, C | 1 |
| Fiedorek, FT | 1 |
| Belder, R | 1 |
| Shennib, H | 1 |
| Endo, M | 1 |
| Benhameid, O | 1 |
| Landzberg, MJ | 1 |
| Khairy, P | 1 |
| Teal, PA | 1 |
| Keir, SL | 1 |
| Seymour, J | 1 |
| Lewis, S | 2 |
| Dennis, MS | 1 |
| Cairns, J | 1 |
| Cooper, HA | 1 |
| Chnupa, P | 1 |
| Abzieher, C | 1 |
| Länger, T | 1 |
| Klem, I | 1 |
| Hartl, E | 1 |
| Wehinger, C | 1 |
| Schneider, B | 1 |
| Tilley, BC | 1 |
| Murphy, A | 2 |
| Lu, Y | 1 |
| Costigan, TM | 1 |
| Rhine, C | 1 |
| Triplett, DA | 1 |
| Lau, E | 1 |
| Bungard, TJ | 1 |
| Tsuyuki, RT | 1 |
| Sila, CA | 4 |
| Bellelli, G | 1 |
| Trabucchi, M | 1 |
| Herlitz, J | 2 |
| Holm, J | 2 |
| Peterson, M | 2 |
| Karlson, BW | 2 |
| Haglid Evander, M | 1 |
| Erhardt, L | 2 |
| Grübler, B | 1 |
| Robb-Nicholson, C | 2 |
| Brass, LM | 3 |
| Cimminiello, C | 1 |
| Jo, WS | 1 |
| Shin, HC | 1 |
| Ho, JM | 1 |
| Kim, JW | 1 |
| MacAllister, R | 1 |
| Hingorani, AD | 1 |
| Casas, JP | 1 |
| Haerten, K | 1 |
| Krabbe, C | 1 |
| Raiber, M | 1 |
| Boddy, AW | 1 |
| Dukovic, DA | 1 |
| Brandt, T | 1 |
| Van Kooten, F | 1 |
| Leebeek, FW | 1 |
| van Vliet, HH | 1 |
| Mehicevic, A | 1 |
| Li, SS | 1 |
| Quinn, MJ | 1 |
| Sapp, S | 1 |
| Kleiman, NS | 1 |
| Kong, DF | 1 |
| Kandzari, DE | 1 |
| Moonis, M | 1 |
| Moodie, ML | 1 |
| Carter, R | 1 |
| Mihalopoulos, C | 1 |
| Chambers, BR | 2 |
| Dewey, HM | 3 |
| Palmqvist, B | 1 |
| Villoutreix, BO | 1 |
| McKevitt, FM | 1 |
| Macdonald, S | 2 |
| Cleveland, TJ | 1 |
| Gaines, PA | 1 |
| Feely, J | 1 |
| Risøe, C | 1 |
| Gjesdal, K | 1 |
| Crotty, M | 1 |
| Whitehead, C | 1 |
| Rowett, D | 1 |
| Halbert, J | 1 |
| Weller, D | 1 |
| Finucane, P | 1 |
| Esterman, A | 1 |
| Tan, KT | 1 |
| Rotta-Escalante, R | 1 |
| Vila, J | 1 |
| Domínguez, R | 1 |
| Abiusi, G | 1 |
| Famulari, A | 1 |
| Rey, R | 1 |
| Bauso-Tosselli, L | 1 |
| Gori, H | 1 |
| Reich, E | 1 |
| Chatterjee, K | 1 |
| Fall, S | 1 |
| Barer, D | 1 |
| Solenski, NJ | 1 |
| Hanley, DF | 2 |
| Ferguson, JJ | 1 |
| Barber, A | 1 |
| Charleston, A | 1 |
| Anderson, N | 1 |
| Spriggs, D | 1 |
| Bennett, P | 1 |
| Thomas, K | 1 |
| Baker, Y | 1 |
| Calvo-Romero, JM | 1 |
| Sato, H | 2 |
| Fukunami, M | 1 |
| Kodama, K | 1 |
| Yamada, Y | 1 |
| Fujii, K | 1 |
| Greenspon, AJ | 1 |
| Dawson, D | 1 |
| Hellkamp, AS | 2 |
| Silver, M | 1 |
| Schron, E | 1 |
| Goldman, L | 1 |
| Lee, KL | 1 |
| Lamas, GA | 1 |
| Oshrine, BR | 1 |
| Takserman, A | 2 |
| Negri, M | 1 |
| Martignoni, A | 1 |
| Baccheschi, J | 1 |
| Santilli, G | 1 |
| Marchesi, E | 1 |
| Schroth, G | 1 |
| Loher, TJ | 1 |
| Stepper, F | 1 |
| Sturzenegger, M | 1 |
| Schuknecht, B | 1 |
| Arjomand, H | 1 |
| Yip, HK | 2 |
| Chen, SS | 1 |
| Liu, JS | 3 |
| Chang, HW | 2 |
| Kao, YF | 1 |
| Lan, MY | 3 |
| Chang, YY | 2 |
| Lai, SL | 2 |
| Chen, WH | 1 |
| Chen, MC | 2 |
| Schwark, C | 2 |
| Kirk, M | 1 |
| Helø, OH | 1 |
| Kastrup, J | 1 |
| Economides Muñoz, C | 1 |
| Singh, BN | 1 |
| Bredie, SJ | 2 |
| Wollersheim, H | 1 |
| Thien, T | 2 |
| Vadivelu, MK | 1 |
| Kiktev, VG | 3 |
| Pershukov, IV | 3 |
| Payne, DA | 1 |
| Ross Naylor, A | 1 |
| Findlay, I | 1 |
| Jafri, S | 1 |
| Sutton, G | 1 |
| Falk, R | 1 |
| Bulpitt, C | 1 |
| Prentice, C | 1 |
| Trainer, A | 1 |
| Poole-Wilson, PA | 1 |
| Ruel, M | 1 |
| Masters, RG | 1 |
| Bédard, PJ | 1 |
| Pipe, AL | 1 |
| Goldstein, WG | 1 |
| Hendry, PJ | 1 |
| Mesana, TG | 1 |
| Ivanusa, M | 1 |
| Ivanusa, Z | 1 |
| Marissal, JP | 2 |
| Selke, B | 2 |
| Robertson, SL | 1 |
| Mayer, JB | 1 |
| Guthmann, R | 1 |
| Shields, TM | 1 |
| Lindberg, M | 1 |
| Boucher, M | 2 |
| Pharand, C | 1 |
| Skidmore, B | 1 |
| Peters, R | 1 |
| Lakkis, N | 1 |
| Kelly, J | 3 |
| Lewis, RR | 3 |
| Coshall, C | 2 |
| Moody, A | 3 |
| Hunt, BJ | 3 |
| Maeda, K | 1 |
| Sakai, T | 1 |
| Hira, K | 1 |
| Sato, TS | 1 |
| Bito, S | 1 |
| Asai, A | 1 |
| Hayano, K | 1 |
| Matsumura, S | 1 |
| Yamashiro, S | 1 |
| Fukui, T | 1 |
| Harrison, P | 5 |
| Sidhu, PS | 3 |
| Brown, MM | 5 |
| Machin, SJ | 3 |
| Stuckey, T | 1 |
| Tcheng, JE | 2 |
| Turco, M | 1 |
| Griffin, JJ | 1 |
| Lansky, AJ | 1 |
| Grines, CL | 1 |
| Garcia, E | 1 |
| Rosenberg, R | 1 |
| Bauer, K | 1 |
| Rosner, B | 1 |
| Sciacca, R | 1 |
| Barzegar, S | 1 |
| Thornell, B | 1 |
| Kistler, JP | 2 |
| Kassem-Moussa, H | 1 |
| Tasissa, G | 1 |
| Simes, RJ | 1 |
| Bhapkar, MV | 1 |
| Jackson, SL | 1 |
| Peterson, GM | 1 |
| Vial, JH | 1 |
| Luchins, D | 1 |
| Gage, BF | 2 |
| Boode, BS | 1 |
| Frey, JL | 1 |
| Tran, H | 1 |
| Fuller, R | 2 |
| Kriszbacher, I | 1 |
| Koppán, M | 1 |
| Bódis, J | 1 |
| van Breda, EJ | 1 |
| van Gemert, HM | 1 |
| Bachman, DS | 2 |
| Cheng, TI | 1 |
| Cheng, TJ | 1 |
| Chiang, SC | 1 |
| Petit, E | 1 |
| Brizard, A | 1 |
| Nicholls, C | 1 |
| Sani, M | 1 |
| Freestone, B | 1 |
| Rothwell, P | 3 |
| Laguta, PS | 1 |
| Panchenko, EP | 1 |
| Leonardi-Bee, J | 4 |
| Yatsu, F | 1 |
| Dewey, ME | 1 |
| Lehtonen, A | 1 |
| Salomaa, V | 1 |
| Immonen-Räihä, P | 1 |
| Mähönen, M | 1 |
| Tuomilehto, J | 2 |
| Torppa, J | 1 |
| Lane, D | 1 |
| Zakopoulos, N | 2 |
| Peppes, V | 1 |
| Kimyai-Asadi, A | 1 |
| Jih, MH | 1 |
| Goldberg, LH | 1 |
| Tytgat, SH | 1 |
| Laman, DM | 1 |
| Rijken, AM | 1 |
| Klicks, R | 1 |
| Voorwinde, A | 1 |
| Ultee, JM | 1 |
| Van Duijn, H | 1 |
| Evander, MH | 1 |
| Weir, NU | 2 |
| Waskowsky, WM | 1 |
| Brouwer, A | 1 |
| Kiechl, S | 1 |
| Massel, D | 1 |
| Eriksson, P | 2 |
| O'Brien, CL | 1 |
| Parmar, K | 1 |
| Schleinitz, MD | 1 |
| Lim, MJ | 1 |
| Dabbous, OH | 1 |
| Agnelli, G | 2 |
| Kline-Rogers, EM | 1 |
| Dibenedetto, D | 1 |
| Mehta, RH | 1 |
| Gandjour, J | 2 |
| Zeindler, J | 1 |
| Weinberger, J | 2 |
| Fletcher, S | 1 |
| Weaver, C | 1 |
| May, J | 1 |
| Fox, S | 1 |
| Willmot, M | 1 |
| Heptinstal, S | 1 |
| Ben-Hur, T | 1 |
| Rajz, G | 1 |
| Umansky, F | 1 |
| Lee, IM | 1 |
| Gordon, D | 1 |
| Levin, RI | 1 |
| Sas, K | 2 |
| Schwaninger, M | 2 |
| Ascione, R | 1 |
| Ghosh, A | 1 |
| Rogers, CA | 1 |
| Monk, C | 1 |
| Howlett-Smith, H | 2 |
| Hertzberg, VS | 2 |
| Benesch, CG | 2 |
| Jovin, TG | 2 |
| Koroshetz, WJ | 1 |
| Pettersen, AA | 1 |
| Seljeflot, I | 1 |
| Abdelnoor, M | 3 |
| Arnesen, H | 2 |
| Segal, H | 2 |
| Blasbery, K | 1 |
| Furtado, C | 1 |
| Silver, L | 2 |
| Sherif, C | 1 |
| Dick, P | 2 |
| Sabeti, S | 3 |
| Mlekusch, W | 3 |
| Amighi, J | 3 |
| Ahmadi, R | 1 |
| Lalouschek, W | 2 |
| Minar, E | 3 |
| Schillinger, M | 3 |
| Chung, MK | 1 |
| Burkhardt, JD | 1 |
| Klein, AL | 1 |
| Droste, DW | 1 |
| Kaps, M | 1 |
| Siebler, M | 3 |
| El-Chami, MF | 1 |
| Hanna, IR | 1 |
| Helmy, T | 1 |
| Block, PC | 1 |
| Turris, SA | 1 |
| Smith, S | 1 |
| Morton, JA | 1 |
| Newton, J | 1 |
| Gray, CS | 1 |
| Cappelli, R | 1 |
| Ceccarelli, E | 1 |
| Di Gianfilippo, G | 1 |
| Donati, C | 1 |
| Emsley, HC | 1 |
| Forconi, S | 1 |
| Hopkins, SJ | 1 |
| Masotti, L | 1 |
| Paciucci, A | 1 |
| Papa, F | 1 |
| Roncacci, S | 1 |
| Sander, K | 1 |
| Smith, CJ | 1 |
| Stefanini, A | 1 |
| Weber, D | 1 |
| Gommans, J | 1 |
| Sye, D | 1 |
| MacDonald, A | 1 |
| Vemmos, KN | 1 |
| Toumanidis, S | 1 |
| Moulopoulos, SD | 1 |
| Liew, D | 1 |
| Bertram, M | 1 |
| Vos, T | 1 |
| Reverter, JC | 3 |
| Ziegler, S | 1 |
| Felber, K | 1 |
| Exner, M | 1 |
| Brunner, M | 1 |
| Müller, M | 1 |
| Mannhalter, C | 1 |
| Katira, R | 1 |
| Chauhan, A | 1 |
| More, RS | 1 |
| Hansen, DB | 2 |
| Reid, J | 1 |
| MacLeod, MJ | 1 |
| Schaerlig, E | 1 |
| Scott, PM | 1 |
| DiMarco, JP | 1 |
| Corley, SD | 1 |
| Greene, HL | 1 |
| Safford, RE | 1 |
| Rosenfeld, LE | 1 |
| Mitrani, G | 1 |
| Nemeth, M | 1 |
| Liou, CW | 1 |
| Meier, JM | 1 |
| Delabays, A | 1 |
| Girod, G | 1 |
| Eeckhout, E | 1 |
| Garnier, LF | 1 |
| Rouesnel, P | 1 |
| Espitalier, F | 1 |
| Mackie, IJ | 2 |
| Lawrie, AS | 2 |
| Purdy, G | 2 |
| Indredavik, B | 1 |
| Rohweder, G | 1 |
| Lydersen, S | 1 |
| Pongrácz, E | 1 |
| Káposzta, Z | 1 |
| Costa, J | 1 |
| Famularo, G | 1 |
| Minisola, G | 1 |
| De Simone, C | 1 |
| Larroche, C | 1 |
| Chadenat, ML | 1 |
| Chaunu, MP | 1 |
| Abad, S | 1 |
| Casassus, P | 1 |
| Dhôte, R | 1 |
| Maulaz, AB | 1 |
| Bezerra, DC | 2 |
| Barker, PC | 1 |
| Nowak, C | 1 |
| King, K | 1 |
| Mosca, RS | 1 |
| Bove, EL | 1 |
| Goldberg, CS | 1 |
| Norris, JW | 1 |
| Biondi, A | 1 |
| Katz, JM | 1 |
| Vallabh, J | 1 |
| Segal, AZ | 1 |
| Gobin, YP | 1 |
| Weir, E | 1 |
| Watt, H | 1 |
| McQueen, MJ | 1 |
| Gilligan, AK | 1 |
| Sturm, JW | 1 |
| Macdonell, RA | 1 |
| Gebel, JM | 1 |
| Beinart, SC | 1 |
| Kolm, P | 1 |
| Veledar, E | 1 |
| Mahoney, EM | 1 |
| Bouin, O | 1 |
| Gabriel, S | 1 |
| Jackson, J | 1 |
| Chen, R | 1 |
| Caro, J | 1 |
| Topol, E | 1 |
| Weintraub, WS | 1 |
| Ziai, W | 2 |
| Pokov, AN | 1 |
| Fahey, CD | 1 |
| Bybee, KA | 1 |
| Powell, BD | 1 |
| Valeti, U | 1 |
| Rosales, AG | 1 |
| Mullany, C | 1 |
| Wright, RS | 1 |
| Rothberg, M | 1 |
| Feasby, T | 1 |
| Holloway, R | 1 |
| Cohen, SN | 3 |
| Cote, R | 1 |
| Hess, D | 2 |
| Saver, J | 1 |
| Stern, B | 1 |
| Wilterdink, J | 1 |
| Edwards, SJ | 1 |
| Burkiewicz, JS | 1 |
| Jamieson, DG | 2 |
| Parekh, A | 1 |
| Hartung, HP | 1 |
| Ouriel, K | 1 |
| Wholey, MH | 1 |
| Fayad, P | 1 |
| Katzen, BT | 1 |
| Whitlow, P | 1 |
| Frentzko, M | 1 |
| Kuntz, RE | 1 |
| Hopkins, N | 1 |
| Satler, L | 1 |
| Mishkel, G | 1 |
| Yadav, JS | 3 |
| Boltuch, J | 1 |
| Schlager, O | 1 |
| Ahmadi, A | 1 |
| Blann, A | 1 |
| Miyasaka, Y | 1 |
| Barnes, ME | 1 |
| Cha, SS | 1 |
| Seward, JB | 1 |
| Bailey, KR | 1 |
| Iwasaka, T | 1 |
| Tsang, TS | 1 |
| Zee, RY | 1 |
| Diehl, KA | 1 |
| Aguilar, M | 1 |
| Kroft, LJ | 1 |
| Kübler, W | 1 |
| Brown, DW | 1 |
| Shepard, D | 1 |
| Giles, WH | 2 |
| Greenlund, KJ | 1 |
| Croft, JB | 1 |
| Ringborg, A | 1 |
| Lindgren, P | 1 |
| Ederhy, S | 2 |
| Meuleman, C | 1 |
| Hammoudi, N | 1 |
| Janower, S | 1 |
| Øverlie, H | 1 |
| Kerty, E | 1 |
| Ariesen, MJ | 1 |
| Landolfi, R | 1 |
| Malinin, A | 1 |
| Pokov, A | 1 |
| García-Honrubia, A | 1 |
| Climent, V | 1 |
| Sogorb, F | 1 |
| Tatu-Chiţoiu, G | 1 |
| Teodorescu, C | 1 |
| Dan, M | 1 |
| Guran, M | 1 |
| Căpraru, P | 1 |
| Istrăţescu, O | 1 |
| Tatu-Chiţoiu, A | 1 |
| Bumbu, A | 1 |
| Chioncel, V | 1 |
| Arvanitopol, S | 1 |
| Dorobanţu, M | 1 |
| Berrouschot, J | 1 |
| Schwetlick, B | 1 |
| von Twickel, G | 1 |
| Fischer, C | 1 |
| Uhlemann, H | 1 |
| Siegemund, T | 1 |
| Siegemund, A | 2 |
| Roessler, A | 1 |
| Poston, RS | 1 |
| White, C | 1 |
| Gu, J | 1 |
| Brown, J | 1 |
| Gammie, J | 1 |
| Pierson, RN | 1 |
| Lee, A | 1 |
| Connerney, I | 1 |
| Avari, T | 1 |
| Christenson, R | 1 |
| Tandry, U | 1 |
| Griffith, BP | 1 |
| Ishikawa, K | 1 |
| Kitabatake, A | 2 |
| Ogawa, S | 1 |
| Maruyama, Y | 1 |
| Yokota, Y | 1 |
| Fukuyama, T | 1 |
| Doi, Y | 1 |
| Mochizuki, S | 1 |
| Izumi, T | 1 |
| Takekoshi, N | 1 |
| Yoshida, K | 1 |
| Hiramori, K | 1 |
| Mitka, M | 1 |
| Polidori, MC | 1 |
| Praticó, D | 1 |
| Ingegni, T | 1 |
| Mariani, E | 1 |
| Spazzafumo, L | 1 |
| Del Sindaco, P | 1 |
| Cecchetti, R | 1 |
| Yao, Y | 1 |
| Cherubini, A | 1 |
| Stahl, W | 1 |
| Sies, H | 1 |
| Senin, U | 1 |
| Mecocci, P | 1 |
| Avanzini, F | 1 |
| Pangrazzi, I | 1 |
| Gray, L | 1 |
| Weaver, CS | 1 |
| Murphy, S | 1 |
| Esagunde, RU | 1 |
| Lee, MP | 1 |
| Gan, HY | 1 |
| Chen, CL | 1 |
| Christiaens, L | 2 |
| Pijak, MR | 1 |
| Caplan, LR | 1 |
| Kimura, Y | 1 |
| Buchanan, MR | 2 |
| Tembl, JI | 1 |
| Pareja, A | 1 |
| Ponz, A | 1 |
| Ferrer, JM | 1 |
| Gür, S | 1 |
| Yilmaz, G | 1 |
| Akova, YA | 1 |
| Earnshaw, S | 1 |
| Tice, JA | 1 |
| Pletcher, MJ | 1 |
| Soman, T | 1 |
| Hune, S | 1 |
| Allen, A | 1 |
| Black, HR | 2 |
| Cohen, EA | 2 |
| Flather, MD | 3 |
| Haffner, SM | 1 |
| Mak, KH | 3 |
| Weber, MA | 2 |
| Fabry-Ribaudo, L | 2 |
| Booth, J | 1 |
| Sanefuji, M | 1 |
| Ohga, S | 2 |
| Kira, R | 1 |
| Yoshiura, T | 1 |
| Torisu, H | 1 |
| Hara, T | 2 |
| Kirmani, JF | 1 |
| Safdar, A | 1 |
| Sayed, MA | 1 |
| Pande, RU | 1 |
| Ferguson, R | 1 |
| Hershey, LA | 1 |
| Qazi, KJ | 1 |
| Dalainas, I | 1 |
| Nano, G | 1 |
| Ikeda, U | 1 |
| Calvet, D | 1 |
| Touzé, E | 1 |
| Lip, GH | 1 |
| Testa, L | 1 |
| Trotta, G | 1 |
| Abbate, A | 1 |
| Agostoni, P | 1 |
| Biondi-Zoccai, GG | 1 |
| Brinker, AD | 1 |
| Swartz, L | 1 |
| Hoyos, L | 1 |
| Espinoza, C | 1 |
| Román, G | 1 |
| Brömsen, J | 1 |
| Blumenstein, M | 1 |
| Casella, G | 1 |
| Greco, C | 1 |
| Perugini, E | 1 |
| Pallotti, MG | 1 |
| Pavesi, PC | 1 |
| Kirkham, FJ | 1 |
| Lerner, NB | 1 |
| Noetzel, M | 1 |
| DeBaun, MR | 1 |
| Datta, AK | 1 |
| Rees, DC | 1 |
| Adams, RJ | 2 |
| Debette, S | 1 |
| Horton, HL | 1 |
| Han, W | 1 |
| Shen, DT | 1 |
| Wang, YM | 1 |
| Assadian, A | 1 |
| Eidher, U | 1 |
| Senekowitsch, C | 1 |
| Rotter, R | 1 |
| Löchli, S | 1 |
| Hagmüller, GW | 1 |
| Knöbl, P | 1 |
| Habib, GB | 1 |
| Cooper, NJ | 1 |
| Sutton, AJ | 1 |
| Lu, G | 1 |
| Wallaschofski, H | 1 |
| Lohmann, T | 1 |
| Hild, E | 1 |
| Kobsar, A | 1 |
| Spilcke-Liss, E | 1 |
| Hentschel, B | 1 |
| Stumpf, C | 1 |
| Daniel, WG | 1 |
| Garlichs, CD | 1 |
| Eigenthaler, M | 1 |
| Eggers, AE | 1 |
| Roffi, M | 2 |
| Coffey, JB | 1 |
| Oh, R | 1 |
| Chairangsarit, P | 1 |
| Sithinamsuwan, P | 1 |
| Niyasom, S | 1 |
| Udommongkol, C | 1 |
| Suwantamee, J | 1 |
| Worrall, BB | 1 |
| Johnston, KC | 1 |
| Kamalesh, M | 1 |
| Shima, K | 1 |
| Hurley, V | 1 |
| Ireson, R | 1 |
| von Maxen, A | 1 |
| Wille, H | 1 |
| Schoenhoefer, PS | 1 |
| Kurukulasuriya, LR | 1 |
| Govindarajan, G | 1 |
| Sowers, J | 1 |
| Llinas, RH | 1 |
| Bartolucci, AA | 1 |
| Malani, AK | 1 |
| Ammar, H | 1 |
| Thompson, CA | 1 |
| Schaefer, WM | 1 |
| Koch, KC | 1 |
| Noth, J | 1 |
| Buell, U | 1 |
| Weiss, PH | 1 |
| Heeg, B | 1 |
| van Gestel, A | 1 |
| Hout, Bv | 1 |
| Olsen, J | 1 |
| Haghfelt, TH | 1 |
| Ferguson, C | 1 |
| Body, R | 1 |
| Karlikaya, G | 1 |
| Varlbas, F | 1 |
| Demirkaya, M | 1 |
| Orken, C | 1 |
| Tireli, H | 1 |
| Hender, J | 1 |
| Harris, D | 1 |
| Richard, B | 1 |
| Dawson, A | 1 |
| Khanna, P | 1 |
| Ortega, LL | 1 |
| Sánchez, J | 1 |
| Más, R | 1 |
| Fernández, L | 1 |
| Mendoza, S | 1 |
| Gámez, R | 1 |
| Fernández, JC | 1 |
| Illnait, J | 1 |
| Alvarez, E | 1 |
| Lee, MS | 1 |
| Smith, SD | 1 |
| Galor, A | 1 |
| Hoffman, GS | 1 |
| Holten, KB | 1 |
| Kjaer, J | 1 |
| Larsen, CH | 1 |
| Poulsen, TS | 3 |
| Møller, JE | 1 |
| Mickley, H | 2 |
| Lewis, JD | 1 |
| Schinnar, R | 1 |
| Bilker, WB | 1 |
| Strom, BL | 1 |
| Gruber, M | 1 |
| Goldman, S | 1 |
| Chaparro, S | 1 |
| Vahanian, A | 1 |
| Halinen, MO | 1 |
| Kakar, P | 1 |
| Frishman, WH | 1 |
| Veresh, M | 1 |
| Schlocker, SJ | 1 |
| Tejani, N | 1 |
| Dalal, PM | 1 |
| Mishra, NK | 1 |
| Bhattacharjee, M | 1 |
| Bhat, P | 1 |
| Derendorf, H | 1 |
| Kramer, J | 1 |
| Abraham, J | 1 |
| Teven, CM | 1 |
| Jones, PA | 1 |
| Juttler, E | 1 |
| Kohrmann, M | 1 |
| Ibayashi, S | 1 |
| Yasumori, K | 1 |
| Fukui, D | 1 |
| Uwatoko, T | 1 |
| Makihara, N | 1 |
| Schindler, B | 1 |
| Terashi, H | 1 |
| Miyazaki, K | 1 |
| Tsutsumi, Y | 1 |
| Hashimoto, S | 1 |
| Karpha, M | 1 |
| Kristensen, SR | 1 |
| Korsholm, L | 1 |
| Haghfelt, T | 1 |
| Jørgensen, B | 1 |
| Licht, PB | 1 |
| Krakauer, JW | 1 |
| Sechenova, O | 1 |
| Cheng, Hy | 1 |
| Akins, PT | 1 |
| Feldman, HA | 1 |
| Zoble, RG | 1 |
| Newman, D | 1 |
| Spitzer, SG | 1 |
| Power, ML | 1 |
| Cross, SP | 1 |
| Roberts, S | 1 |
| Tyrrell, PJ | 1 |
| Pamukcu, B | 1 |
| Oflaz, H | 1 |
| Onur, I | 1 |
| Oncul, A | 1 |
| Ozcan, M | 1 |
| Umman, B | 1 |
| Mercanoglu, F | 1 |
| Meric, M | 1 |
| Nisanci, Y | 1 |
| Einhäupl, K | 1 |
| Sacco, S | 1 |
| Glazer, NL | 1 |
| Dublin, S | 1 |
| French, B | 1 |
| Jackson, LA | 1 |
| Hrachovec, JB | 1 |
| Siscovick, DS | 1 |
| Moussouttas, M | 1 |
| Al-Bahrani, A | 1 |
| Taha, S | 1 |
| Shaath, H | 1 |
| Bakhiet, M | 1 |
| Strong, SH | 1 |
| Sylaja, PN | 1 |
| Liao, JK | 1 |
| Amory, JK | 1 |
| Amory, DW | 1 |
| Grossman, CM | 1 |
| Chan, S | 1 |
| Ros, S | 1 |
| You, KY | 1 |
| Nhem, S | 1 |
| Salle, JY | 1 |
| Dudognon, P | 1 |
| Daviet, JC | 1 |
| Anavekar, NS | 2 |
| Tleyjeh, IM | 1 |
| Mirzoyev, Z | 1 |
| Steckelberg, JM | 1 |
| Haddad, C | 1 |
| Khandaker, MH | 1 |
| Wilson, WR | 1 |
| Chandrasekaran, K | 1 |
| Baddour, LM | 1 |
| Ng, PW | 1 |
| Tsoi, TH | 1 |
| Li, HL | 1 |
| Fong, WC | 1 |
| Yeung, J | 1 |
| Wong, CK | 1 |
| Yip, KK | 1 |
| Gao, H | 1 |
| Wong, HB | 1 |
| Aldandashi, S | 1 |
| Noor, R | 1 |
| Wang, CX | 1 |
| Uddin, G | 1 |
| Lee, CR | 1 |
| North, KE | 1 |
| Bray, MS | 1 |
| Couper, DJ | 1 |
| Heiss, G | 1 |
| Zeldin, DC | 1 |
| Hu, T | 2 |
| Gogol, M | 1 |
| Kikano, GE | 1 |
| Brown, MT | 1 |
| Weber, AA | 1 |
| Junghans, U | 1 |
| Schumacher, M | 1 |
| Hilgevoord, AA | 1 |
| de Vries, JP | 1 |
| van der Mee, M | 1 |
| van de Pavoordt, HD | 1 |
| Ackerstaff, RG | 1 |
| Waddy, SP | 1 |
| Liu, CL | 1 |
| Liao, SJ | 1 |
| Zeng, JS | 1 |
| Xie, LC | 1 |
| Shi, XG | 1 |
| Huang, RX | 1 |
| Pischon, T | 1 |
| Möhlig, M | 1 |
| Hoffmann, K | 1 |
| Spranger, J | 1 |
| Weikert, C | 1 |
| Willich, SN | 1 |
| Pfeiffer, AF | 1 |
| Boeing, H | 1 |
| Watson, T | 1 |
| Briyal, S | 1 |
| Gulati, A | 1 |
| Gupta, YK | 1 |
| Badimon, JJ | 1 |
| Herbert, JM | 1 |
| Miner, J | 1 |
| Hoffhines, A | 1 |
| Tàssies, D | 1 |
| Rajamani, K | 1 |
| Marshall, G | 1 |
| Rankin, AC | 1 |
| Dudley, N | 1 |
| Keating, N | 1 |
| Benninger, DH | 1 |
| Stöckli, E | 1 |
| Wang, TH | 1 |
| Garcia, D | 1 |
| Hylek, E | 1 |
| Helton, TJ | 1 |
| Duggal, S | 1 |
| Roukoz, H | 1 |
| Okajima, K | 1 |
| Abe, Y | 1 |
| Salameh, MJ | 1 |
| Freilinger, T | 1 |
| Riedel, E | 1 |
| Holtmannspötter, M | 1 |
| Dichgans, M | 1 |
| Atkins, D | 1 |
| Sedrakyan, A | 1 |
| Shih, C | 1 |
| Mosca, L | 1 |
| Gitt, AK | 1 |
| Köth, O | 1 |
| Heer, T | 2 |
| Wienbergen, H | 1 |
| Gottwik, M | 2 |
| Ryckborst, KJ | 1 |
| Eliasziw, M | 2 |
| Bernardo, E | 1 |
| Sabaté, M | 1 |
| Jimenez-Quevedo, P | 1 |
| Costa, MA | 1 |
| Palazuelos, J | 1 |
| Alfonso, F | 1 |
| Bañuelos, C | 1 |
| Guzman, LA | 1 |
| Macaya, C | 1 |
| Fernandez-Ortiz, A | 1 |
| Schmaier, AH | 1 |
| Aguilar, MI | 1 |
| Seres, E | 1 |
| Boda, K | 1 |
| Lenti, L | 1 |
| Csifcsak, G | 1 |
| Kovacs, N | 1 |
| Seok, JI | 1 |
| Joo, IS | 1 |
| Huh, K | 1 |
| McCabe, CH | 2 |
| Murphy, SA | 1 |
| Riesmeyer, J | 1 |
| Weerakkody, G | 1 |
| Diug, B | 1 |
| Lowthian, J | 1 |
| Evans, S | 1 |
| Zheng, Z | 1 |
| Schwab, S | 1 |
| Berger, C | 1 |
| Mori, A | 2 |
| Yonemura, K | 2 |
| Hashimoto, Y | 2 |
| Hirano, T | 2 |
| Uchino, M | 2 |
| Pajitnev, D | 1 |
| Magnani, JW | 1 |
| Crutcher, JM | 1 |
| Daniels, C | 1 |
| Gengo, FM | 2 |
| Rubin, L | 1 |
| Robson, M | 2 |
| Rainka, M | 2 |
| Gengo, MF | 2 |
| Mager, DE | 1 |
| Bates, V | 2 |
| Schneider, WR | 1 |
| Salzman, BE | 1 |
| Zhu, HW | 1 |
| McMillan, AS | 1 |
| McGrath, C | 1 |
| Li, LS | 1 |
| Samaranayake, LP | 1 |
| Riepe, MW | 1 |
| Huber, R | 1 |
| Krasopoulos, G | 1 |
| Brister, SJ | 1 |
| Beattie, WS | 1 |
| Kang, SY | 1 |
| Mark, B | 1 |
| Smout, J | 1 |
| Cleanthis, M | 1 |
| Stansby, G | 1 |
| Forrest, A | 1 |
| Hourihane, M | 1 |
| Fu, Y | 1 |
| Guo, JW | 1 |
| You, JS | 1 |
| Liang, WX | 1 |
| Huang, PX | 1 |
| Choi, NK | 1 |
| Park, BJ | 1 |
| Ryding, AD | 1 |
| Banning, AP | 1 |
| Hertzberg, V | 1 |
| Chimowitz, M | 1 |
| Lynn, M | 1 |
| Chester, C | 1 |
| Asbury, W | 1 |
| Syed, A | 1 |
| Cuthbertson, FC | 1 |
| Micheli, S | 1 |
| Schwammenthal, Y | 1 |
| Tsabari, R | 1 |
| Shenkman, B | 1 |
| Schwartz, R | 1 |
| Lubetsky, A | 1 |
| Orion, D | 1 |
| Israeli-Korn, S | 1 |
| Chapman, J | 1 |
| Savion, N | 1 |
| Varon, D | 1 |
| Tanne, D | 1 |
| Umasankar, U | 1 |
| Carroll, TJ | 1 |
| Famuboni, A | 1 |
| Patel, MD | 1 |
| Starke, ID | 1 |
| Wu, HS | 1 |
| Ishizuka, T | 1 |
| Niwa, A | 1 |
| Tabuchi, M | 1 |
| Ooshima, K | 1 |
| Higashino, H | 1 |
| Smoot, EC | 1 |
| Reaume, KT | 1 |
| Regal, RE | 1 |
| Dorsch, MP | 1 |
| Englyst, NA | 1 |
| Horsfield, G | 1 |
| Byrne, CD | 1 |
| Albers, G | 1 |
| Furie, K | 1 |
| Halperin, J | 1 |
| Harbaugh, R | 1 |
| Katzan, I | 2 |
| Kelly-Hayes, M | 1 |
| Kenton, EJ | 1 |
| Marks, M | 1 |
| Hills, NK | 1 |
| Verro, P | 1 |
| Nguyen, D | 1 |
| Olsson, SB | 1 |
| Capucci, A | 1 |
| Garwood, CL | 1 |
| Corbett, TL | 1 |
| Pandey, D | 1 |
| Valika, A | 1 |
| Cursio, J | 1 |
| Mergy, J | 1 |
| Allal, J | 1 |
| Cornett, O | 1 |
| Ocava, LC | 1 |
| Singh, M | 1 |
| Malhotra, S | 1 |
| Rosenbaum, DM | 1 |
| Lambert, C | 1 |
| Lianting, J | 1 |
| Chan, ES | 1 |
| Samama, MM | 2 |
| Mikkelsson, J | 1 |
| Eskola, M | 1 |
| Nikus, K | 1 |
| Karhunen, PJ | 1 |
| Niemela, K | 1 |
| Smith, PJ | 1 |
| Hurlen, M | 1 |
| Bonnaire, B | 1 |
| Lepage, L | 1 |
| Lefranc, M | 1 |
| Gao, X | 1 |
| Fan, D | 1 |
| Wong, K | 1 |
| Xiao, J | 1 |
| Ling, GS | 1 |
| Akyuz, A | 1 |
| Bolayir, E | 1 |
| Dener, S | 1 |
| Topalkara, K | 1 |
| Topaktas, S | 1 |
| Van Damme, H | 1 |
| Sakalihasan, N | 1 |
| Limet, R | 1 |
| Smith, NM | 1 |
| Pathansali, R | 1 |
| Harker, LA | 1 |
| Boissel, JP | 1 |
| Pilgrim, AJ | 1 |
| Gent, M | 1 |
| Eikelboom, BC | 2 |
| Rubattu, S | 1 |
| Ridker, P | 1 |
| Stampfer, MJ | 1 |
| Volpe, M | 1 |
| Lindpaintner, K | 1 |
| Perez, I | 4 |
| Melbourn, A | 1 |
| Kalra, L | 4 |
| Newell, DW | 1 |
| Futterman, LG | 1 |
| Lemberg, L | 1 |
| Escolar, G | 1 |
| Revilla, M | 1 |
| Vila, N | 1 |
| Ordinas, A | 1 |
| Feinberg, WM | 1 |
| Cornell, ES | 1 |
| Bovill, EG | 1 |
| Rifai, N | 1 |
| Tracy, RP | 1 |
| Patel, ST | 1 |
| Haser, PB | 1 |
| Korn, P | 1 |
| Bush, HL | 1 |
| Deitch, JS | 1 |
| Kent, KC | 1 |
| Goldman, ME | 1 |
| Zabalgoitia, M | 2 |
| Safford, R | 1 |
| Koehler, J | 1 |
| Blackshear, JL | 2 |
| Fenster, PE | 1 |
| Strauss, R | 1 |
| Pennock, GD | 1 |
| Rothbart, RM | 2 |
| Ferro, D | 1 |
| Basili, S | 1 |
| Roccaforte, S | 1 |
| Di Franco, M | 1 |
| Cipollone, F | 1 |
| Ciabattoni, G | 1 |
| Smithard, DG | 2 |
| Henney, JE | 1 |
| McAnulty, JH | 1 |
| SoRelle, R | 3 |
| Chambers, M | 1 |
| Hutton, J | 1 |
| Gladman, J | 1 |
| Jagasia, DH | 1 |
| Williams, B | 1 |
| Ranhosky, A | 1 |
| Overell, JR | 1 |
| Weir, CJ | 1 |
| Walker, A | 1 |
| Newcombe, H | 1 |
| Edds, W | 1 |
| Newton, W | 1 |
| Sulch, D | 1 |
| Fahey, T | 1 |
| Rimmer, J | 1 |
| Godfrey, P | 1 |
| Ellis, SJ | 1 |
| Hans, R | 1 |
| Masson, C | 1 |
| Vallée, JP | 1 |
| Niclot, P | 1 |
| Ford, ES | 1 |
| Nakstad, PH | 1 |
| Sandset, PM | 2 |
| Rasmussen, PA | 1 |
| Perl, J | 1 |
| Barr, JD | 1 |
| Markarian, GZ | 1 |
| Sila, C | 1 |
| Krieger, D | 1 |
| Masaryk, TJ | 1 |
| Dunbabin, DW | 2 |
| Hobbs, R | 1 |
| Taylor, FC | 1 |
| Ebrahim, S | 1 |
| Neuhaus, KL | 1 |
| Kjeldsen, SE | 1 |
| Kolloch, RE | 1 |
| Leonetti, G | 1 |
| Mallion, JM | 1 |
| Zanchetti, A | 1 |
| Elmfeldt, D | 1 |
| Warnold, I | 1 |
| Cohen, N | 1 |
| Almoznino-Sarafian, D | 1 |
| Alon, I | 1 |
| Gorelik, O | 1 |
| Koopfer, M | 1 |
| Chachashvily, S | 1 |
| Shteinshnaider, M | 1 |
| Litvinjuk, V | 1 |
| Modai, D | 1 |
| Leifer, D | 1 |
| Stern, S | 1 |
| Altkorn, D | 1 |
| Levinson, W | 1 |
| Klijn, CJ | 1 |
| van Buren, PA | 1 |
| Tulleken, CA | 1 |
| Thun, MJ | 1 |
| Meade, TW | 2 |
| Brennan, PJ | 2 |
| Tomita, F | 1 |
| Kohya, T | 1 |
| Phillips, KA | 1 |
| Borowsky, LH | 1 |
| Wilcox, RG | 1 |
| Caspi, A | 1 |
| Berink, P | 1 |
| Toman, J | 1 |
| Charlesworth, A | 1 |
| Anders, RJ | 1 |
| Alexander, JC | 1 |
| Skene, A | 1 |
| Bhagat, K | 1 |
| Tisocki, K | 1 |
| Pereira, AC | 3 |
| Steinberg, J | 1 |
| Holroyd-Leduc, JM | 1 |
| Kapral, MK | 1 |
| Austin, PC | 1 |
| Tu, JV | 1 |
| Thijs, VN | 1 |
| Thomas, DP | 1 |
| Gondek, K | 1 |
| Ward, M | 1 |
| Albert, MA | 1 |
| Graettinger, WF | 1 |
| Argentino, C | 1 |
| Fieschi, C | 1 |
| Cates, C | 2 |
| Schafer, A | 1 |
| Baker, WH | 1 |
| Toole, JF | 1 |
| Sarasin, FP | 1 |
| Gaspoz, JM | 1 |
| Bounameaux, H | 1 |
| Niessen, LW | 1 |
| Limburg, M | 1 |
| Craig, J | 1 |
| Goudie, BM | 1 |
| Lebrun, T | 1 |
| Gallai, V | 1 |
| McNulty, SJ | 1 |
| Hutchinson, D | 1 |
| Hardy, KJ | 1 |
| Feldman, G | 1 |
| Devuyst, G | 1 |
| Weksler, BB | 1 |
| Lenz, TL | 1 |
| Hilleman, DE | 1 |
| Siegel, AM | 1 |
| Sandor, P | 1 |
| Kollias, SS | 1 |
| Dechambre, S | 1 |
| Duprez, T | 1 |
| Cosnard, G | 1 |
| Saloheimo, P | 1 |
| Juvela, S | 1 |
| Hillbom, M | 1 |
| von Kummer R, R | 1 |
| Müller, A | 1 |
| Bluhmki, E | 1 |
| Lewis, HD | 1 |
| Meade , TW | 1 |
| Vokó, Z | 1 |
| Hofman, A | 1 |
| Breteler, MM | 1 |
| Sanmuganathan, PS | 1 |
| Ghahramani, P | 1 |
| Jackson, PR | 1 |
| Wallis, EJ | 1 |
| Ramsay, LE | 1 |
| Skerrett, PJ | 1 |
| Fischman, J | 1 |
| Suzuki, Y | 1 |
| Umemura, K | 1 |
| Rolka, DB | 1 |
| Fagot-Campagna, A | 1 |
| Narayan, KM | 1 |
| Bergmann, SR | 1 |
| Farquhar, D | 1 |
| Scheen, AJ | 2 |
| Matteoli, S | 1 |
| Trappolini, M | 1 |
| Chillotti, FM | 1 |
| Maxim, R | 1 |
| Pettigrew, LC | 3 |
| Kipp, A | 1 |
| Bertrand-Hardy, JM | 1 |
| Humphreys, M | 1 |
| Goertler, M | 1 |
| Blaser, T | 1 |
| Krueger, S | 1 |
| Lutze, G | 1 |
| Wallesch, CW | 1 |
| Signorini, DF | 1 |
| Quilliam, BJ | 2 |
| Sexton, RC | 1 |
| Nair, GV | 1 |
| Davis, CJ | 1 |
| McKenzie, ME | 1 |
| Lowry, DR | 1 |
| Akkerhuis, KM | 1 |
| Lincoff, AM | 1 |
| Boersma, E | 1 |
| Anderson, K | 1 |
| Balog, C | 1 |
| Simoons, ML | 1 |
| Tokunaga, Y | 1 |
| Suita, S | 1 |
| Matsushima, T | 1 |
| Olson, J | 1 |
| Huntington, J | 1 |
| Kaye, GC | 1 |
| Godtfredsen, J | 1 |
| Peterson, P | 1 |
| Kalashnikova, LA | 1 |
| Nasonov, EL | 1 |
| Aleksandrova, EN | 1 |
| Kosheleva, NM | 1 |
| Reshetniak, TM | 1 |
| Salozhin, KV | 1 |
| Gattis, WA | 1 |
| Larsen, RL | 1 |
| O'Gara, PT | 1 |
| Gheorghiade, M | 1 |
| Daly, R | 1 |
| Lindenstrom, E | 1 |
| Friis, P | 1 |
| Marttila, R | 1 |
| Olsson, J | 1 |
| Orgogozo, J | 1 |
| Ringelstein, B | 1 |
| van der Sande, J | 1 |
| Turpie, AG | 1 |
| Catella-Lawson, F | 1 |
| Müller, TH | 1 |
| Mor, V | 1 |
| Guillon, B | 1 |
| Planchon, B | 1 |
| Magne, C | 1 |
| Barrier, JH | 1 |
| Delanty, N | 1 |
| Kantor, J | 1 |
| McConnell, JP | 2 |
| Cheryk, LA | 1 |
| Durocher, A | 1 |
| Bang, NU | 2 |
| Fleck, JD | 1 |
| Williams, L | 1 |
| Sträter, R | 1 |
| Kurnik, K | 1 |
| Heller, C | 1 |
| Schobess, R | 1 |
| Luigs, P | 1 |
| Nowak-Göttl, U | 1 |
| Anderson, DR | 1 |
| Gardner, MJ | 1 |
| Flowerdew, GJ | 1 |
| Brownell, BF | 1 |
| Bajzer, CT | 1 |
| Chew, DP | 1 |
| Ziada, KM | 1 |
| Mukherjee, D | 1 |
| Evans, A | 2 |
| Yu, G | 1 |
| Wilterdink, JL | 1 |
| Bendixen, B | 1 |
| Woolson, RF | 1 |
| Clarke, WR | 1 |
| Hansen, MD | 1 |
| Müllner, M | 1 |
| Zuber, M | 1 |
| Cabanes, L | 1 |
| Derumeaux, G | 1 |
| Coste, J | 1 |
| Prisco, D | 1 |
| Pengo, V | 1 |
| Dalton, B | 1 |
| Evans, MF | 1 |
| Moyad, MA | 1 |
| Mansbach, HH | 1 |
| Tietjen, GE | 1 |
| Ducharme, J | 1 |
| Currie, T | 1 |
| Ovens, H | 1 |
| Rutledge, T | 1 |
| Thompson, J | 1 |
| Reilly, M | 1 |
| Hayden, M | 1 |
| Phillips, C | 1 |
| Mulrow, C | 1 |
| Nordt, T | 1 |
| Lazar, RM | 1 |
| Jackson, CM | 1 |
| Powers, WJ | 1 |
| Wollersheim, HC | 1 |
| Crawford, KM | 1 |
| Du, ZD | 1 |
| Cao, QL | 1 |
| Joseph, A | 1 |
| Koenig, P | 1 |
| Heischmidt, M | 1 |
| Waight, DJ | 1 |
| Rhodes, J | 1 |
| Brorson, J | 1 |
| Hijazi, ZM | 1 |
| Marchioli, R | 1 |
| Schweiger, C | 1 |
| Tavazzi, L | 1 |
| Valagussa, F | 1 |
| Tufano, A | 1 |
| Cerbone, AM | 1 |
| Doggrell, SA | 1 |
| Yi, Q | 1 |
| Libby, P | 1 |
| Chessa, M | 1 |
| Carminati, M | 1 |
| Hsi, DH | 1 |
| Alaimo, DJ | 1 |
| Pinsky, DJ | 1 |
| Broekman, MJ | 1 |
| Peschon, JJ | 1 |
| Stocking, KL | 1 |
| Ramasamy, R | 1 |
| Kiss, S | 1 |
| Choudhri, TF | 1 |
| McTaggart, RA | 1 |
| Liao, H | 1 |
| Drosopoulos, JH | 1 |
| Price, VL | 1 |
| Marcus, AJ | 1 |
| Maliszewski, CR | 1 |
| Phillips, SJ | 1 |
| Williams, SC | 1 |
| Allen, LC | 1 |
| Jakovljević, D | 1 |
| Rossignol, P | 1 |
| La Batida Alanore, A | 1 |
| Roueff, S | 1 |
| Bobrie, G | 1 |
| Plouin, PF | 1 |
| Kilpatrick, C | 1 |
| Gerraty, R | 1 |
| Campbell, Do | 1 |
| Greenberg, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424] | Phase 3 | 27,395 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Multicenter, Randomized, Double-blind, Double-dummy, Active-comparator, Event-driven, Superiority Phase III Study of Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With a Recent Embolic Stroke of Undetermined Source (ESUS),[NCT02313909] | Phase 3 | 7,213 participants (Actual) | Interventional | 2014-12-23 | Terminated (stopped due to Study halted early due to no efficacy improvement over aspirin at an interim analysis and very little chance of showing overall benefit if study were completed) | ||
| A Prospective, Open-Label, Active-Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Rivaroxaban for Thromboprophylaxis in Pediatric Subjects 2 to 8 Years of Age After the Fontan Procedure[NCT02846532] | Phase 3 | 112 participants (Actual) | Interventional | 2016-11-16 | Completed | ||
| A Prospective, Multicenter, Randomized, Open-label Trial to Compare Efficacy and Safety of Clopidogrel vs Ticagrelor in Stabilized Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention; TicAgrelor Versus CLOpidogrel in Stabili[NCT02018055] | Phase 4 | 2,590 participants (Actual) | Interventional | 2014-02-14 | Completed | ||
| Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029] | Phase 3 | 4,881 participants (Actual) | Interventional | 2010-05-28 | Terminated (stopped due to The trial was halted by the DSMB.) | ||
| Stent-Assisted Coiling Followed by Ticagrelor Monotherapy Instead of Dual Antiplatelet Therapy in Endovascular Treatment of Unruptured Intracranial Aneurysm (SAC-TIDE) ---a Pilot Study[NCT06015477] | 180 participants (Anticipated) | Interventional | 2023-09-01 | Not yet recruiting | |||
| INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE[NCT03871517] | Phase 4 | 5,438 participants (Actual) | Interventional | 2019-06-03 | Completed | ||
| Aspirin to Target Arterial Events in Chronic Kidney Disease[NCT03796156] | Phase 3 | 25,210 participants (Anticipated) | Interventional | 2019-02-25 | Recruiting | ||
| Randomized, Double-blind, Evaluation in Secondary Stroke Prevention Comparing the EfficaCy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate (110 mg or 150 mg, Oral b.i.d.) Versus Acetylsalicylic Acid (100 mg Oral q.d.) in Patients With Embol[NCT02239120] | Phase 3 | 5,390 participants (Actual) | Interventional | 2014-11-27 | Completed | ||
| A Randomised, Double-Blind, Multinational Study to Prevent Major Vascular Events With Ticagrelor Compared to Aspirin (ASA) in Patients With Acute Ischaemic Stroke or TIA.[NCT01994720] | Phase 3 | 13,307 participants (Actual) | Interventional | 2014-01-07 | Completed | ||
| Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen[NCT03023020] | 4,579 participants (Actual) | Interventional | 2017-04-04 | Completed | |||
| An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Int[NCT02415400] | Phase 4 | 4,614 participants (Actual) | Interventional | 2015-06-04 | Completed | ||
| Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II[NCT04078737] | Phase 3 | 6,412 participants (Actual) | Interventional | 2019-09-23 | Completed | ||
| Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke[NCT00979589] | Phase 3 | 5,100 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| LACunar Intervention (LACI-2) Trial-2: Assessment of Safety and Efficacy of Cilostazol and Isosorbide Mononitrate to Prevent Recurrent Lacunar Stroke and Progression of Cerebral Small Vessel Disease.[NCT03451591] | Phase 2/Phase 3 | 363 participants (Actual) | Interventional | 2018-01-08 | Completed | ||
| A Multicenter, Randomized, Double Blind Study to Compare the Efficacy Between Cilostazol and Aspirin on White Matter Changes by Cerebral Small Vessel Disease[NCT01932203] | Phase 4 | 255 participants (Actual) | Interventional | 2013-07-17 | Active, not recruiting | ||
| Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White[NCT00847860] | Phase 4 | 200 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Stroke and Coated-Platelets - A Translational Research Initiative[NCT04698031] | Phase 4 | 152 participants (Anticipated) | Interventional | 2022-03-30 | Recruiting | ||
| Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation (CAF Trial)[NCT03061006] | Phase 4 | 101 participants (Actual) | Interventional | 2017-04-03 | Completed | ||
| A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ti[NCT01991795] | Phase 3 | 19,271 participants (Actual) | Interventional | 2014-02-10 | Completed | ||
| Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness[NCT02697916] | 15,076 participants (Actual) | Interventional | 2016-04-30 | Completed | |||
| Predictors of the Unfavourable Outcomes in Acute Ischemic Stroke Patients Treated With Alteplase, a Multi-centre Prospective Study[NCT06058884] | Phase 4 | 592 participants (Actual) | Interventional | 2022-01-03 | Completed | ||
| HELicobacter Pylori Screening to Prevent Gastrointestinal Bleeding in Patients With Acute Myocardial Infarction Trial Based on the SWEDEHEART Registry (HELP-SWEDEHEART)[NCT05024864] | 22,000 participants (Anticipated) | Interventional | 2021-11-17 | Recruiting | |||
| Pilot, Non-masked, Randomized Clinical Trial for Evaluation of Stroke Rate in Patients With Blunt Cerebrovascular Injury (BCVI) Treated With Oral Acetylsalicylic Acid (ASA) 81 mg Versus ASA 325 mg (BASA).[NCT05868525] | Phase 4 | 98 participants (Anticipated) | Interventional | 2024-04-30 | Recruiting | ||
| Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242] | Phase 4 | 9,006 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Ischemic And Bleeding Risk Assessment After TAVR (FOCUS ONE Registry)[NCT06000943] | 2,500 participants (Anticipated) | Observational [Patient Registry] | 2023-08-01 | Recruiting | |||
| GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation[NCT01813435] | Phase 3 | 15,991 participants (Actual) | Interventional | 2013-07-01 | Completed | ||
| A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared With Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation TiCAB- Ticagrelor in CABG[NCT01755520] | Phase 3 | 1,893 participants (Actual) | Interventional | 2013-04-24 | Terminated (stopped due to DSMB Interim Analyses) | ||
| A Multicenter, Double Blind, Factorial Design, Phase IV Trial to Compare the Efficacy and Safety of Cilostazol Long-term Treatment With Aspirin in Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage for the Prevention of Cerebral Hemorrhage and[NCT01013532] | Phase 4 | 1,600 participants (Anticipated) | Interventional | 2009-06-30 | Active, not recruiting | ||
| Low-dose Aspirin Therapy in Patients With Non-Cardioembolic Ischemic Stroke and Microbleeds[NCT04504864] | Phase 4 | 400 participants (Anticipated) | Interventional | 2020-10-01 | Recruiting | ||
| International Multicenter Registry on Takotsubo Cardiomyopathy[NCT01947621] | 4,000 participants (Anticipated) | Observational | 2011-01-31 | Recruiting | |||
| Ticagrelor Versus Clopidogrel in Ischemic Stroke. a Randomized Double-blinded Controlled Trial[NCT05553613] | Phase 3 | 900 participants (Actual) | Interventional | 2022-10-01 | Completed | ||
| Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke, a Randomized Controlled Trial[NCT06120725] | Phase 3 | 580 participants (Actual) | Interventional | 2021-09-01 | Completed | ||
| Novel Biomarkers of Thrombotic Risk[NCT02505217] | 200 participants (Actual) | Observational | 2015-07-31 | Completed | |||
| A Phase 1, Open-label, 2-period, Fixed-sequence Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion Coadministered With Clopidogrel in Healthy Subjects[NCT02560688] | Phase 1 | 22 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| A PHASE 1, OPEN LABEL, SINGLE DOSE STUDY, TO ASSESS THE SAFETY AND TOLERABILITY OF A SINGLE IV DOSE OF DS-1040B AFTER 5 DAYS OF ASPIRIN TREATMENT IN HEALTHY SUBJECTS[NCT02071004] | Phase 1 | 18 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| "RCT of an Intervention to Enable Stroke Survivors in Los Angeles County Hospitals to Stay Within the Guidelines (SUSTAIN)"[NCT00861081] | 410 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myoca[NCT01225562] | Phase 3 | 21,379 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Comparison of Mirror Therapy and PNF on Lower Extremity Function in Chronic Stroke Patients.[NCT05948384] | 36 participants (Anticipated) | Interventional | 2023-07-24 | Recruiting | |||
| An Investigation Into The Impact Of Enteric Coated Of Aspirin In Patients With Newly Diagnosed Ischemic Stroke. Non-randomized Interventional Controlled Clinical Trial.[NCT04330872] | Phase 4 | 42 participants (Actual) | Interventional | 2019-08-26 | Completed | ||
| A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared With ASA in the Prevention of Stroke and Death in Patients With Acute Ischaemic Stroke or Tra[NCT03354429] | Phase 3 | 11,016 participants (Actual) | Interventional | 2018-01-22 | Completed | ||
| Genotype Guided Antiplatelet Therapy In Ischemic Stroke[NCT05763862] | 350 participants (Anticipated) | Interventional | 2023-04-24 | Recruiting | |||
| A REAl-life Study on Short-term Dual Antiplatelet Treatment in Patients With Ischemic Stroke or Transient Ischemic Attack[NCT05476081] | 1,067 participants (Anticipated) | Observational [Patient Registry] | 2021-02-03 | Recruiting | |||
| Extended Antiplatelet Therapy With Clopidogrel Alone Versus Clopidogrel Plus Aspirin After Completion of 9- to 12-month Dual Antiplatelet Therapy for ACS Patients With Both High Bleeding and Ischemic Risk.[NCT03431142] | Phase 4 | 7,700 participants (Anticipated) | Interventional | 2018-02-12 | Recruiting | ||
| XIENCE 28 Global Study[NCT03355742] | 963 participants (Actual) | Interventional | 2018-02-09 | Completed | |||
| A Safety Evaluation of 3-month Dual Antiplatelet Therapy in Subjects at High Risk of Bleeding Undergoing Percutaneous Coronary Intervention With XIENCE.[NCT03218787] | 2,047 participants (Actual) | Interventional | 2017-07-19 | Completed | |||
| XIENCE 28 USA Study[NCT03815175] | 1,605 participants (Actual) | Interventional | 2019-02-25 | Completed | |||
| A Phase 2, Randomized, Open Label, Non-Inferiority Clinical Trial to Explore the Safety and Efficacy of Rivaroxaban Compared With Vitamin K Antagonism in Patients With Atrial Fibrillation With Bioprosthetic Mitral Valves - RIVER[NCT02303795] | Phase 2 | 1,005 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| The Clinical Benefit and Risk of Oral Aspirin for Patients Who Have Unruptured Intracranial Aneurysm Combined With Cerebral Ischemia[NCT02846259] | 2,135 participants (Anticipated) | Observational [Patient Registry] | 2016-01-31 | Recruiting | |||
| Aspirin Treatment for Small Unruptured InTracranial Aneurysms With Ischemic cereBrovascuLar diseasE (AT-SUITABLE): a Phase 3, Multicenter, Prospective, Randomized, Open-label, Blinded-endpoint Controlled Trial[NCT05907902] | Phase 3 | 824 participants (Anticipated) | Interventional | 2023-07-01 | Not yet recruiting | ||
| Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study)[NCT02642419] | Phase 4 | 2,200 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| Aspirin Discontinuation After Left Atrial Appendage Occlusion in Atrial Fibrillation[NCT03821883] | 1,120 participants (Anticipated) | Interventional | 2020-06-01 | Recruiting | |||
| Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD[NCT02046460] | Phase 4 | 194 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve. A Randomized Study (the ARTE Trial)[NCT02640794] | Phase 4 | 222 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial)[NCT01559298] | Phase 4 | 178 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Nobori Dual Antiplatelet Therapy as Appropriate Duration.[NCT01514227] | Phase 4 | 3,773 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Comparison of Efficacy and Safety Between Aspirin and Clopidogrel in the Atrial Fibrillation With Low or Moderate Stroke Risk[NCT02960126] | Phase 3 | 1,500 participants (Anticipated) | Interventional | 2016-11-30 | Not yet recruiting | ||
| Effects of High-dose Statin Treatments on Patients With Aspirin Mono Antiplatelet Therapy 12-months After Drug-eluting Stents Implantation: a Randomized Controlled Study[NCT01557075] | Phase 4 | 2,000 participants (Anticipated) | Interventional | 2010-07-31 | Recruiting | ||
| Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes - An Investigator-driven, Prospective, Randomised, Double-blind, Multi-centre Trial Initiated by the European Society of Cardiology and AFNET[NCT02618577] | Phase 3 | 2,608 participants (Actual) | Interventional | 2016-02-29 | Terminated (stopped due to following a recommendation from the data safety and monitoring board due to safety concerns and a tendency towards futility.) | ||
| Aspirin in Reducing Events in the Elderly[NCT01038583] | 19,114 participants (Actual) | Observational | 2010-01-31 | Active, not recruiting | |||
| Influence of Rivaroxaban 2.5 mg Two Times a Day for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic Peripheral Arterial Disease (PAD) - a Randomised Controlled Trial[NCT04305028] | 100 participants (Anticipated) | Observational | 2021-03-10 | Not yet recruiting | |||
| Effects of Edoxaban on Platelet Aggregation in Patients With Stable Coronary Artery Disease[NCT05122455] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2021-09-14 | Recruiting | ||
| DUAL Pathway Inhibition (Low-dose Rivaroxaban and Aspirin) as Compared to Aspirin Only to Improve Endothelial Function in Peripheral Artery Disease.[NCT04218656] | Phase 4 | 159 participants (Actual) | Interventional | 2020-06-08 | Completed | ||
| Feasibility of Applying Remote Ischemic Conditioning in Secondary Prevention in Patients With Minor Ischemic Stroke or Transient Ischemic Attack -A Single-arm Futility Study[NCT03004820] | 167 participants (Actual) | Interventional | 2016-12-06 | Completed | |||
| Impact of Catheter Ablation of Atrial Tachyarrhythmias on ABC Stroke and ABC Bleeding Risk Scores[NCT05635864] | 150 participants (Anticipated) | Observational | 2021-06-03 | Recruiting | |||
| A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation[NCT00412984] | Phase 3 | 20,976 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| A Multicenter, Single Arm, Open Label, Phase IV Study to Evaluate Safety and to Describe the Incidence of Major Cardiovascular Events of Ticagrelor in Chinese Patients With Acute Coronary Syndrome(ACS)[NCT01870921] | Phase 4 | 2,004 participants (Actual) | Interventional | 2013-06-26 | Completed | ||
| Stent Implantation Versus Balloon Dilation for Acute Anterior Circulation Tandem Occlusion: A Multicenter, Prospective, Randomized, Open-label, Blinded End-point Trial[NCT05902000] | 222 participants (Anticipated) | Interventional | 2023-06-14 | Recruiting | |||
| Trial of PCSK9 Inhibition in Patients With Acute Stroke and Symptomatic Intracranial Atherosclerosis - a Prospective, Randomized, Open-label, Blinded End-point Study With High-resolution MR Vessel Wall Imaging[NCT05001984] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-08-01 | Recruiting | ||
| Early Intensive Medical Therapy for the Prevention of Early Neurological Deterioration in Branch Atheromatous Disease[NCT04824911] | Phase 2 | 424 participants (Anticipated) | Interventional | 2021-03-23 | Recruiting | ||
| Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)[NCT05995600] | Phase 4 | 400 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| The Origin and Role of Thromboembolism in the Pathogenesis of Ischaemic Stroke[NCT05636748] | 120 participants (Anticipated) | Observational | 2023-02-28 | Recruiting | |||
| Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events[NCT02616497] | Phase 4 | 1,220 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents[NCT00638794] | 8,575 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)[NCT02072226] | Phase 3 | 313 participants (Actual) | Interventional | 2014-05-31 | Terminated (stopped due to The study was terminated due to slow enrollment.) | ||
| Efficacy and Safety of Tirofiban in Patients With Acute Branch Atheromatous Disease (BAD)- Related Stroke (BRANT)[NCT06037889] | Phase 3 | 516 participants (Anticipated) | Interventional | 2023-11-09 | Recruiting | ||
| Efficacy and Safety of Clopidogrel for Primary Prevention in Patients With Subclinical Coronary Atherosclerosis Identified on Imaging[NCT05845489] | Phase 4 | 9,930 participants (Anticipated) | Interventional | 2023-03-09 | Recruiting | ||
| A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Assess the Efficacy (Reduction of Cardiovascular Disease Events) and Safety of 100 mg Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular [NCT00501059] | Phase 3 | 12,546 participants (Actual) | Interventional | 2007-07-05 | Completed | ||
| The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin[NCT03869268] | Phase 4 | 72 participants (Actual) | Interventional | 2019-04-24 | Completed | ||
| Japanese Primary Prevention Project With Aspirin in the Elderly With One or More Risk Factors of Vascular Events: JPPP[NCT00225849] | Phase 4 | 10,000 participants | Interventional | 2005-03-31 | Recruiting | ||
| Testing a Community Intervention to Increase Aspirin Use for Primary Prevention of Cardiovascular Disease[NCT02607917] | 10,800 participants (Actual) | Interventional | 2015-02-16 | Completed | |||
| Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial[NCT04696120] | Phase 2 | 200 participants (Anticipated) | Interventional | 2021-03-02 | Not yet recruiting | ||
| A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban With Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects With Heart Failure and Significant Coronary Artery Diseas[NCT01877915] | Phase 3 | 5,081 participants (Actual) | Interventional | 2013-09-10 | Completed | ||
| TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Sitagliptin in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control[NCT00790205] | Phase 3 | 14,671 participants (Actual) | Interventional | 2008-12-10 | Completed | ||
| Disparities in Stroke Outcomes and Care Delivery in Patients With Atrial Fibrillation: FLorida Puerto Rico Atrial Fibrillation Stroke Study (FLiPER-AF)[NCT03627806] | 104,308 participants (Actual) | Observational [Patient Registry] | 2010-01-01 | Completed | |||
| Carotid Artery Implant for Trapping Upstream Emboli for Preventing Stroke in Atrial Fibrillation Patients[NCT03571789] | 25 participants (Actual) | Interventional | 2017-09-12 | Active, not recruiting | |||
| Cilostazol Stroke Prevention Study for Antiplatelet Combination[NCT01995370] | Phase 4 | 1,884 participants (Actual) | Interventional | 2013-12-13 | Completed | ||
| Multicenter Randomized, Double-blind, Placebo-controlled, Clinical Trial of Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients (Asperum)[NCT04808895] | Phase 3 | 204 participants (Anticipated) | Interventional | 2021-04-01 | Not yet recruiting | ||
| Clinical Study Evaluating the Gastroprotective Effect of Carvedilol in Patients With Ischemic Heart Disease on Aspirin Therapy[NCT05553717] | 66 participants (Anticipated) | Interventional | 2022-10-31 | Not yet recruiting | |||
| Comparison of Clinical Outcomes After Left Atrial Appendage Closure or Oral Anticoagulation in Patients With Atrial Fibrillation: A Retrospective Propensity Matched Study[NCT02787525] | 1,000 participants (Actual) | Observational | 2016-07-31 | Completed | |||
| Optimal Duration of Dual Antiplatelet Therapy After Drug Eluting Stent (DES) Implantation[NCT00822536] | Phase 4 | 1,798 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Carotid Endarterectomy Versus Optimal Medical Treatment of Asymptomatic High Grade Carotid Artery Stenosis[NCT00805311] | Phase 4 | 400 participants (Actual) | Interventional | 2009-04-30 | Terminated (stopped due to Due to the clear advantage of carotid endarterectomy) | ||
| Vitamin K Supplementation to Improve INR Stability in Patients on Hemodialysis Taking Warfarin for Atrial Fibrillation[NCT02324686] | Phase 2 | 3 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| China Registry of Non-disabling Ischemic Cerebrovascular Events: A Prospective Multi-center, National Registry Trail[NCT03079674] | 10,000 participants (Anticipated) | Observational [Patient Registry] | 2017-06-01 | Not yet recruiting | |||
| Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke (ATAMIS): a Parallel Randomized, Open-label, Multicenter, Prospective Study[NCT02869009] | Phase 3 | 3,000 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis in Real-World Clinical Observations: a Prospective, Multicenter, Open-access, Single-arm Clinical Study[NCT05644314] | 144 participants (Anticipated) | Interventional | 2022-05-01 | Recruiting | |||
| Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial[NCT00041938] | Phase 3 | 2,305 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Randomised Controlled Prospective Trial of Early Administration of Aspirin After Systemic Thrombolysis in Acute Ischemic Stroke[NCT02921360] | 120 participants (Anticipated) | Interventional | 2016-08-31 | Active, not recruiting | |||
| Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet [NCT01267734] | Phase 4 | 3,750 participants (Anticipated) | Interventional | 2010-06-30 | Recruiting | ||
| Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atria[NCT00262600] | Phase 3 | 18,113 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A Monitor System for the Safety of Dabigatran Anticoagulation Treatment in Nonvalvular Atrial Fibrillation[NCT02414035] | 1,496 participants (Actual) | Observational | 2015-03-22 | Completed | |||
| A Retrospective Epidemiological Study to Investigate Outcome and Mortality With Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients[NCT01623700] | 78,000 participants (Actual) | Observational | 2006-01-31 | Active, not recruiting | |||
| Transient Electrocardiogram Assessment in Stroke Evaluation[NCT03301662] | 100 participants (Anticipated) | Observational | 2017-10-09 | Not yet recruiting | |||
| PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286] | Phase 4 | 1,700 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis[NCT00576693] | Phase 3 | 451 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Stroke Imaging Package Study of Intracranial Atherosclerosis[NCT03719820] | 550 participants (Anticipated) | Observational [Patient Registry] | 2018-11-14 | Recruiting | |||
| Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging[NCT05907629] | 300 participants (Anticipated) | Observational | 2023-12-30 | Not yet recruiting | |||
| Evolocumab Added to Statin Therapy in Patients With Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS)---a Pilot Study[NCT05741086] | Phase 3 | 80 participants (Anticipated) | Interventional | 2023-04-15 | Recruiting | ||
| China Angioplasty & Stenting for Symptomatic Intracranial Severe Stenosis (CASSISS): a New, Prospective, Multi-center, Randomized Controlled Trial in China[NCT01763320] | Phase 3 | 380 participants (Actual) | Interventional | 2014-03-05 | Completed | ||
| Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor Zotarolimus - Eluting Stent in the Real World Clinical Practice - Optimize Trial[NCT01113372] | Phase 4 | 3,119 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure[NCT03088072] | Phase 4 | 75 participants (Anticipated) | Interventional | 2017-03-23 | Recruiting | ||
| Randomized Evaluation of Decision Support Interventions for Atrial Fibrillation[NCT04357288] | 1,200 participants (Anticipated) | Interventional | 2020-12-16 | Active, not recruiting | |||
| Prevention of New Vascular Events in Patients With Brain Infarction or Peripheral Embolism and Thoracic Aortic Plaques ≥ 4 mm in Thickness in the Aortic Arch or Descending Aortic Upstream to the Embolized Artery[NCT00235248] | Phase 3 | 350 participants (Actual) | Interventional | 2002-02-28 | Completed | ||
| Arterial Imaging of Inflammation and Resolution After Endovascular Surgery[NCT03590769] | Phase 1 | 9 participants (Actual) | Interventional | 2017-06-01 | Completed | ||
| Comparison of Dual-Antiplatelet and Triple-Antiplatelet Preparation Using P2Y12 Assay in Patients With High On-Treatment Platelet Reactivity Undergoing Stent-Assisted Coil Embolization for An Unruptured Intracranial Aneurysm[NCT03581409] | Phase 4 | 198 participants (Actual) | Interventional | 2018-10-24 | Completed | ||
| Optimal Duration of Dual Antiplatelet Therapy After Stent-assisted Coiling of Unruptured Intracranial Aneurysms: A Prospective Randomized Multicenter Trial[NCT05257824] | Phase 4 | 528 participants (Anticipated) | Interventional | 2022-06-23 | Recruiting | ||
| Minocycline for Acute Ischemic Stroke Undergoing Endovascular Treatment Due to Basilar Artery Occlusion: a Randomized, Open-label, Proof of Concept Study[NCT05512910] | Phase 4 | 90 participants (Anticipated) | Interventional | 2022-12-13 | Recruiting | ||
| The Effect Of Acadesine On Clinically Significant Adverse Cardiovascular and Cerebrovascular Events In High-Risk Subjects Undergoing Coronary Artery Bypass Graft (CABG) Surgery Using Cardiopulmonary Bypass (Protocol No. P05633): RED-CABG Trial (Reduction [NCT00872001] | Phase 3 | 3,080 participants (Actual) | Interventional | 2009-04-30 | Terminated | ||
| Pharmacokinetics and Pharmacodynamics of Apixaban in End-stage Renal Disease Patients on Hemodialysis[NCT02672709] | Phase 4 | 7 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| The Effect of Nurse Practitioner-Led Care on Health Related Quality Of Life in Adult Patients With Atrial Fibrillation - A Randomized Trial[NCT02745236] | 150 participants (Actual) | Interventional | 2016-07-31 | Completed | |||
| A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM[NCT02334969] | Phase 4 | 2,200 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Registry of Left Atrial Appendage Occlusion With WATCHMAN® Device in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic Kidney Disease on Hemodialysis[NCT03446794] | 300 participants (Actual) | Observational [Patient Registry] | 2018-03-14 | Completed | |||
| Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835] | 1,492 participants (Anticipated) | Observational [Patient Registry] | 2019-08-01 | Recruiting | |||
| Prediction of Atrial Fibrillation in Patients With Embolic Stroke of Undetermined Source (AF-ESUS)[NCT02766205] | 500 participants (Anticipated) | Observational [Patient Registry] | 2016-06-30 | Enrolling by invitation | |||
| Randomized,Double-blind Trial Comparing the Effects of a Rivaroxaban Regimen During the First 30 Days,Versus Aspirin for the Acute Treatment of TIA or Minor Stroke[NCT01923818] | Phase 2/Phase 3 | 3,700 participants (Anticipated) | Interventional | 2013-09-30 | Not yet recruiting | ||
| Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double-blind Trial[NCT00496769] | Phase 3 | 6,421 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| MULTIcentric Study About RESistance to CLOpidogrel in Dual Antiplatelet Therapy for Carotid Stenting[NCT05566301] | 1,140 participants (Anticipated) | Observational | 2021-09-02 | Recruiting | |||
| Carotid Stenosis Management During COVID-19 Era - Best Medical Intervention Alone (CASCOM Pilot Study): A Prospective Observational Study[NCT04947046] | 120 participants (Anticipated) | Observational | 2020-03-11 | Recruiting | |||
| A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease[NCT00557921] | Phase 3 | 5,000 participants (Anticipated) | Interventional | 2007-12-31 | Terminated (stopped due to Terminated by Sponsor) | ||
| A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed[NCT00699998] | Phase 3 | 9,326 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Ticagrelol Versus Aspirin in Ischemic Stroke[NCT03884530] | Phase 3 | 169 participants (Actual) | Interventional | 2019-05-01 | Completed | ||
| A Prospective Multicenter Clinical Study of Aspirin for Prophylaxis in Patients With Hereditary or Acquired Thrombotic Thrombocytopenic Purpura[NCT05568147] | Phase 2/Phase 3 | 100 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | ||
| Impact of IntraVascular UltraSound Guidance on Outcomes of Xience Prime Stents in Long Lesions (IVUS-XPL Study)[NCT01308281] | 1,079 participants (Actual) | Interventional | 2010-10-31 | Completed | |||
| Dipyrone Nullifies Aspirin Antiplatelet Effects in Stroke-Patients[NCT02148939] | 61 participants (Actual) | Observational | 2014-05-31 | Completed | |||
| A Multicenter Prospective observationaL Study to evAluate the effecT of Clopidogrel on the prEvention of Major vascuLar Events According to the gEnotype of Cytochrome P450 2C19 in Ischemic Stroke paTients; PLATELET Study[NCT04072705] | 2,927 participants (Actual) | Observational | 2019-09-20 | Completed | |||
| COMbination of Clopidogrel and Aspirin for Prevention of REcurrence in Acute Atherothrombotic Stroke Study: Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial[NCT00814268] | Phase 4 | 358 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization[NCT03953547] | 88 participants (Actual) | Observational | 2018-01-01 | Completed | |||
| Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI)[NCT01777503] | Phase 4 | 2,000 participants (Anticipated) | Interventional | 2012-11-30 | Recruiting | ||
| REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145] | Phase 4 | 40 participants (Actual) | Interventional | 2020-06-23 | Completed | ||
| Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes[NCT02556203] | Phase 3 | 1,653 participants (Actual) | Interventional | 2015-12-16 | Terminated (stopped due to Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator) | ||
| Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. The ANDES Trial[NCT03568890] | Phase 4 | 510 participants (Anticipated) | Interventional | 2018-09-01 | Recruiting | ||
| Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM)[NCT00086450] | Phase 3 | 1,900 participants (Actual) | Interventional | 2004-04-30 | Active, not recruiting | ||
| Aspirin Resistance in Obstructive Sleep Apnea Patients (ARISA Trial)[NCT03930875] | 63 participants (Actual) | Observational | 2017-12-12 | Completed | |||
| Non-steroidal Anti-inflammatory Drugs Impair the Platelet Inhibiting Effect of Acetylsalicylic Acid in Coronary Artery Disease Patients[NCT01402804] | 85 participants (Actual) | Observational | 2011-07-31 | Completed | |||
| The Optimal Regimen of Medical Treatment in Endovascular Therapy in Ischemic Cerebrovascular Disease Based on Clopidogrel Resistance[NCT01925872] | 2,000 participants (Anticipated) | Observational | 2013-05-31 | Enrolling by invitation | |||
| A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal S[NCT00977938] | Phase 4 | 25,682 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Comparative Study of Clinical Efficacy and Safety of Different Clopidogrel Salts in Patients With Cardiovascular Disease. A Multi-center Non-interventional Clinical Trial.[NCT02126982] | 1,500 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis[NCT00153062] | Phase 4 | 20,332 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| Prevalence of Aspirin Resistance in Ischemic Stroke Patients at Assiut University Hospital[NCT05151263] | 133 participants (Anticipated) | Observational | 2023-11-01 | Not yet recruiting | |||
| Comparison of Efficacy and Safety Among DAbigatran, RIvaroxaban, and ApixabaN in Patients HavinG Non-Valvular Atrial Fibrillation in Taiwan (DARING-AF Study)[NCT02666157] | Phase 4 | 3,672 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Randomized, Multinational, Double-blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy.[NCT00335452] | Phase 3 | 25,086 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Clinical and Functional Effects of Cardiac Contractility Modulation in Chagas Heart Disease: a Randomized Study - Contractility - FIX-Chagas[NCT05519046] | 60 participants (Anticipated) | Interventional | 2022-05-06 | Recruiting | |||
| CSP #442 - Warfarin and Antiplatelet Therapy Study in Patients With Congestive Heart Failure (WATCH)[NCT00007683] | Phase 3 | 1,587 participants (Anticipated) | Interventional | 1998-10-31 | Completed | ||
| The Role of Additional Antiplatelet Therapy in the Ischemic Stroke With Atrial Fibrillation and Co-morbiD Atherosclerosis During edOxaban treatmeNt. (ADD-ON) Study, Multicenter Registry-based Analysis[NCT04010955] | 1,200 participants (Anticipated) | Observational [Patient Registry] | 2019-10-01 | Recruiting | |||
| A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00249873] | Phase 3 | 7,554 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Patent Foramen Ovale in Cryptogenic Stroke Study[NCT00697151] | Phase 4 | 630 participants (Actual) | Interventional | 1993-06-30 | Completed | ||
| Implantation of CERENOVUS ENTERPRISE 2 Intracranial Stent in Patients With Severe Symptomatic Intracranial Atherosclerotic Stenosis: A Multicenter, Prospective and Single-Arm Study in China[NCT05316311] | 194 participants (Anticipated) | Interventional | 2022-05-24 | Recruiting | |||
| The Predictive Value of Retinal Vascular Signs for Patients With Intracranial Artery Stenosis: A Prospective, Continuity Study, Cross-sectional Study[NCT05270746] | 1,000 participants (Anticipated) | Observational | 2022-02-27 | Not yet recruiting | |||
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Subjects With Acute Coron[NCT00402597] | Phase 2 | 3,490 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Fixed-dose Combination Therapy (PolyPill) in Primary and Secondary Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians[NCT01271985] | Phase 3 | 8,410 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation[NCT02176265] | 31 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| Correlation of Clopidogrel Therapy Discontinuation in REAL-world Patients Treated With Drug-Eluting Stent Implantation and Late Coronary Arterial Thrombotic Events[NCT00484926] | Phase 4 | 2,000 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Evaluation of the Long-term Safety After Zotarolimus-Eluting Stent, Sirolimus-Eluting Stent, or PacliTaxel-Eluting Stent Implantation for Coronary Lesions - Late Coronary Arterial Thrombotic Events[NCT00590174] | Phase 4 | 1,175 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| A Randomized Double Blind Placebo Controlled Trial of Adjunctive Dexamethasone for the Treatment of HIV-infected Adults With Tuberculous Meningitis[NCT03092817] | Phase 3 | 520 participants (Actual) | Interventional | 2017-05-25 | Active, not recruiting | ||
| A Randomized Double Blind Placebo Controlled Non-inferiority Trial of Adjunctive Dexamethasone for the Treatment of HIV-uninfected Adults With Tuberculous Meningitis Stratified by Leukotriene A4 Hydrolase Genotype[NCT03100786] | Phase 3 | 640 participants (Anticipated) | Interventional | 2018-02-08 | Recruiting | ||
| Influence of CILostazol-based Triple Anti-platelet Therapy ON Ischemic Complication After Drug-eluting stenT Implantation[NCT00776828] | Phase 4 | 960 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events: A Pilot Study[NCT01945268] | Phase 4 | 107 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934] | Phase 4 | 64 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | ||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events[NCT02762851] | Phase 4 | 5,000 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| Post-marketing Study of Cilostazol: Study to Confirm Efficacy in Preventing Recurrent Cerebral Infarction in Comparison With Aspirin[NCT00234065] | Phase 4 | 2,800 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| CHoosing Triple or Double therApy in the Era of nOac for patientS Undergoing PCI: the CHAOS a Multicenter Study.[NCT03558295] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2018-05-01 | Recruiting | |||
| Triple Antithrombotic Therapy in Cardiac Patients Requiring Revascularization[NCT03889574] | 84 participants (Actual) | Observational | 2019-02-26 | Completed | |||
| Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial[NCT00110448] | Phase 4 | 2,539 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| Assessment of Low-dose ASA Discontinuation Risk Associated With Concomitant PPI Use During the First Year of ASA Therapy for Secondary Prevention[NCT01888575] | 35,604 participants (Actual) | Observational | 2012-09-30 | Completed | |||
| The Risk of Uncomplicated Peptic Ulcer in a Cohort of Secondary Prevention Aspirin Users[NCT01814943] | 39,000 participants (Actual) | Observational | 2012-11-30 | Completed | |||
| Antithrombotic Therapy After Left Atrial Appendage Occlusion: Double Antiplatelet Therapy vs Apixaban[NCT05632445] | Phase 4 | 160 participants (Actual) | Interventional | 2019-05-01 | Completed | ||
| Interventional Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in High-risk Patients With Atrial Fibrillation (PRAGUE-17 Study)[NCT02426944] | Phase 4 | 400 participants (Anticipated) | Interventional | 2015-10-13 | Completed | ||
| RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial[NCT02942407] | Phase 4 | 154 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome[NCT02295475] | Phase 4 | 48 participants (Actual) | Interventional | 2014-12-10 | Completed | ||
| Secondary Prevention of Small Subcortical Strokes (SPS3) Trial[NCT00059306] | Phase 3 | 3,020 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| TEC4Home Stroke - Assessing the Feasibility of Home Telemonitoring Technology in Managing Hypertension Among Stroke/TIA Patients. Pilot Study at Vancouver Stroke Program in Collaboration With TEC4Home Heart Failure Team[NCT03712033] | 50 participants (Actual) | Observational | 2018-03-01 | Completed | |||
| Do Point-of-care Platelet Function Assays Predict Clinical Outcomes in Clopidogrel Pre-treated Patients Undergoing Elective PCI. (The POPular Study)[NCT00352014] | 1,000 participants (Anticipated) | Observational | 2006-01-31 | Completed | |||
| JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme, Phase III Study to Compare the Preventive Effect of Recurrent Brain Infarction and Safety of Aggrenox (Combination Drug Containing Sustained-release Dipyridamole 200 mg/Acetylsalicylic Acid[NCT00311402] | Phase 3 | 1,295 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| The Double-Blind, Randomized, Multi-Center, and Active Controlled Trial for Efficacy and Safety of Cilostazol in Acute Ischemic Stroke[NCT00272454] | Phase 4 | 468 participants (Anticipated) | Interventional | 2006-01-31 | Completed | ||
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh[NCT00391872] | Phase 3 | 18,624 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy[NCT02049762] | Phase 4 | 29 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET Trial A Drug Reduction Study for Patients With Acute Coronary Syndrome in the Unified Health System[NCT04360720] | Phase 3 | 3,400 participants (Anticipated) | Interventional | 2020-10-15 | Recruiting | ||
| Apixaban for Prevention of Acute Ischemic Events - 2 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects With a Recent Acute Coronary Syndrome[NCT00831441] | Phase 3 | 7,484 participants (Actual) | Interventional | 2009-03-31 | Terminated | ||
| Intracranial Stenting in Non-acute Symptomatic Ischemic Stroke: an Open-label, Randomised Controlled Trial[NCT05063630] | 300 participants (Anticipated) | Interventional | 2019-05-01 | Recruiting | |||
| Clinical Registration Trial of Intracranial Stenting for Patients With Symptomatic Intracranial Artery Stenosis:A Prospective Multi-center, Registry Trial[NCT01994161] | 840 participants (Anticipated) | Observational [Patient Registry] | 2012-12-31 | Recruiting | |||
| Wingspan One Year Vascular Imaging Events and Neurologic Outcomes (WOVEN)[NCT04221984] | 129 participants (Actual) | Observational [Patient Registry] | 2019-11-12 | Completed | |||
| Registry of Emergent Large veSsel oCclUsion duE to IntraCranial AtherosclerosiS[NCT05403593] | 600 participants (Anticipated) | Observational [Patient Registry] | 2021-12-15 | Recruiting | |||
| A Prospective, Multi-center, Randomized Controlled Study to Evaluate the Safety and Efficacy of the Maurora® Sirolimus-Eluting Stent Versus the Apollo Stent in Intracranial Atherosclerotic Stenosis(Maurora ICAS Trial)[NCT05719883] | 156 participants (Anticipated) | Interventional | 2023-02-20 | Recruiting | |||
| Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)[NCT00004732] | 2,502 participants (Actual) | Interventional | 2000-12-31 | Completed | |||
| Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial: a Prospective, Randomized, Open-labelled, Blinded End-point Trial (DREAM-PRIDE)[NCT04948749] | 792 participants (Anticipated) | Interventional | 2021-07-02 | Recruiting | |||
| The Effect of Early Administration of PCSK9 Inhibitor, Alirocumab to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile, a Single Center Study, Registry Based, Pragmatic, Prospective Trial[NCT06083961] | Phase 4 | 200 participants (Anticipated) | Interventional | 2023-10-15 | Not yet recruiting | ||
| REsponsiveness to CLOpidogrel and Stent-related Events in Acute Coronary. Reclose 2-ACS Registry[NCT01231035] | 1,789 participants (Actual) | Observational | 2008-09-30 | Completed | |||
| EValuation of REsidual Platelet REactivity After Acute Coronary Syndrome in HIV-infected Patients. The EVERE2ST-HIV Study.[NCT02380391] | 260 participants (Actual) | Observational | 2013-12-31 | Completed | |||
| "PGDT With the Hypotension Prediction Index to Reduce the Number and Duration of Intraoperative Hypotension and the Incidence of Renal Failure in Patients Undergoing Lung Surgery"[NCT04149314] | 142 participants (Actual) | Interventional | 2019-11-20 | Completed | |||
| Prevalence of Low Response to Clopidogrel in Patients After Acute Ischemic Stroke.[NCT01843361] | 159 participants (Actual) | Observational | 2010-07-31 | Completed | |||
| Antiplatelet Therapy in Secondary Prevention for Patient With Silent Brain Infarction[NCT03318744] | 3,400 participants (Anticipated) | Interventional | 2018-01-31 | Not yet recruiting | |||
| Comparison of Accidents and Their Circumstances With Oral Anticoagulants. The CACAO Study[NCT02376777] | 4,162 participants (Actual) | Observational | 2014-04-30 | Completed | |||
| Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation[NCT03021928] | Phase 3 | 200 participants (Actual) | Interventional | 2017-06-14 | Active, not recruiting | ||
| Anticoagulant-associated Intracranial Hemorrhage: Patient Characteristics and Outcomes From National Institute of Neurology and Neurosurgery Manuel Velasco: Single-Center Observational Study[NCT06168838] | 1,200 participants (Anticipated) | Observational | 2023-08-09 | Recruiting | |||
| A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex® Septal Closure System Versus Best Medical Therapy in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism [NCT00201461] | Phase 2/Phase 3 | 900 participants (Anticipated) | Interventional | 2003-06-30 | Active, not recruiting | ||
| Risk Stratification for Subclinical Leaflet Thrombosis Post TAVI Using Thromboelastography[NCT03649594] | 100 participants (Anticipated) | Observational | 2020-10-01 | Recruiting | |||
| Intra-patient Randomized Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT Follow up[NCT02785237] | 70 participants (Actual) | Interventional | 2016-06-30 | Completed | |||
| A Prospective, Nonrandomized, Study Comparing the Use of Aspirin and Intraoperative Blood Loss and Postoperative Complications Following Open Inguinal Hernia Repair.[NCT02084615] | 300 participants (Anticipated) | Interventional | 2014-08-31 | Enrolling by invitation | |||
| Low-Dose Tenecteplase in Covid-19 Patients With Acute Pulmonary Embolism: A Randomized, Double-Blind, Placebo-Controlled Trial[NCT04558125] | Phase 4 | 2 participants (Actual) | Interventional | 2020-09-08 | Terminated (stopped due to Identification of eligible patients was slower than anticipated.) | ||
| Cilostazol Stroke Prevention Study-a Randomized, Double Blind, Double Dummy, Parallel Comparative, Multicenter Clinical Trial[NCT00202020] | Phase 3 | 720 participants | Interventional | 2004-05-31 | Completed | ||
| Laboratory Implications of Non Obstructive Atherosclerotic Plaques Identified by Multiple Detector Coronary Angiotomography[NCT03632785] | 90 participants (Actual) | Observational | 2017-03-27 | Completed | |||
| Mechanism Based Resistance to Aspirin[NCT00948987] | Phase 1 | 400 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| [NCT02937025] | Phase 1/Phase 2 | 154 participants (Anticipated) | Interventional | 2017-01-31 | Not yet recruiting | ||
| WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation (PROTECT AF)[NCT00129545] | Phase 2/Phase 3 | 800 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF: The CORRAL-AF Study[NCT04684212] | 2,931 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | |||
| Feasibility and Prognostic Role of Percutaneous Left Atrial Appendage Closure in Patients With Heart Failure and Atrial Fibrillation at High Risk for Cerebrovascular Events[NCT04472871] | 300 participants (Anticipated) | Observational | 2020-07-20 | Not yet recruiting | |||
| AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke[NCT03192215] | Phase 3 | 1,015 participants (Actual) | Interventional | 2018-01-19 | Terminated (stopped due to The DSMB halted the trial prematurely due to futility without any safety concerns.) | ||
| A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2)[NCT00140465] | Phase 4 | 60 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| Early and Long-Term Outcome of Elective Stenting of the Infarct-Related Artery in Patients With Viability in the Infarct-Area Early After Acute Myocardial Infarction. The VIAMI-Trial.[NCT00149591] | 300 participants | Interventional | 2001-04-30 | Active, not recruiting | |||
| Non-randomized, Open-label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions[NCT00735280] | Phase 4 | 2,505 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| The Effect of Inducing the Cytochrome P450 System on the Pharmacodynamic Efficacy of Clopidogrel[NCT01330589] | 0 participants (Actual) | Interventional | 2011-04-30 | Withdrawn (stopped due to Inability to enroll subjects and changes in standard of care for PCI) | |||
| Approaches to Chronic Occlusions With Sirolimus Stents-Cypher (ACROSS-Cypher) Total Occlusion Study of Coronary Arteries 4 Trial[NCT00378612] | Phase 3 | 200 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.[NCT00222261] | Phase 4 | 1,001 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Effectiveness of Polypill for Primary Prevention of Cardiovascular Disease (PolyPars): Study Design and Rationale for a Pragmatic Cluster Randomized Controlled Trial[NCT03459560] | Phase 3 | 4,415 participants (Actual) | Interventional | 2015-12-20 | Active, not recruiting | ||
| Comparative Randomized Single-blind Trial of Amiloride in Coronary Heart Disease[NCT01231165] | Phase 2/Phase 3 | 70 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Improving Equitable Acces and Adherence to Secondary Prevention Therapy With a Fixed-Dose Combination Drug[NCT01321255] | Phase 3 | 2,118 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| In-hospital Versus After-discharge Complete Revascularization in STEMI Patients With Multivessel Disease.[NCT04743154] | 250 participants (Actual) | Interventional | 2018-01-20 | Completed | |||
| English: Current Perspective of the Status of Anticoagulation in Clinical Practice in Primare Care. Spanish: Perspectiva Actual de la sitUación de la anticoaguLación en la práctica clínica de Atención Primaria.[NCT02273609] | 1,524 participants (Actual) | Observational | 2014-02-28 | Completed | |||
| A Prospective Randomized Controlled Study of Additonal Left Atrial Appendage Electrical Isolation in Catheter Ablation Combined With Left Atrial Appendage Occlusion of Persistent Atrial Fibrillation[NCT04897204] | 120 participants (Anticipated) | Interventional | 2021-06-01 | Not yet recruiting | |||
| Rehabilitation of Patients With Atrial Fibrillation[NCT03035539] | 58 participants (Actual) | Interventional | 2012-05-31 | Completed | |||
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome)[NCT00272311] | Phase 4 | 70 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention[NCT00413309] | 30 participants (Anticipated) | Interventional | 2006-04-30 | Completed | |||
| Platelet Function in Resuscitated Patients[NCT02914795] | 99 participants (Actual) | Observational | 2015-06-30 | Completed | |||
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation & Endothelial Function in Secondary Prevention (Pts w/Chronic Stable Coronary Disease)[NCT00272337] | Phase 4 | 37 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Smartwatches for Detection of Atrial Fibrillation (AFib) in Secondary Prevention of Cryptogenic Stroke - WATCH AFib A Prospective, Intraindividual-controlled, Multicenter Clinical Study[NCT06005233] | 400 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | |||
| [NCT00000561] | Phase 3 | 0 participants | Interventional | 1995-06-30 | Completed | ||
| Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?[NCT00228423] | Phase 2 | 113 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women[NCT00000479] | Phase 3 | 39,876 participants (Actual) | Interventional | 1992-09-30 | Completed | ||
| Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed | |||
| Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery[NCT03445273] | 1,800 participants (Anticipated) | Observational [Patient Registry] | 2018-11-21 | Not yet recruiting | |||
| Phase III Study of Pharos Vitesse Neurovascular Stent System Compared to Best Medical Therapy for the Treatment of Ischemic Disease[NCT00816166] | Phase 2/Phase 3 | 125 participants (Actual) | Interventional | 2008-10-31 | Terminated | ||
| An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis[NCT00929383] | 82 participants (Actual) | Observational | 2009-02-28 | Completed | |||
| PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis[NCT03507374] | Early Phase 1 | 20 participants (Actual) | Interventional | 2018-10-30 | Terminated (stopped due to Funding withdrawn) | ||
| Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Phase II, Multicentre; Randomised, Dose-finding, Double-blind and Placebo Controlled Superiority Study With Parallel Groups[NCT01645306] | Phase 2 | 158 participants (Actual) | Interventional | 2013-03-08 | Completed | ||
| [NCT00000556] | Phase 3 | 0 participants | Interventional | 1995-03-31 | Completed | ||
| Silent Atrial Fibrillation - Screening of High-risk Groups for Atrial Fibrillation (The Silence Study)[NCT02893215] | 1,622 participants (Anticipated) | Observational [Patient Registry] | 2016-11-30 | Recruiting | |||
| Does Acetaminophen Potentiate the Gastroduodenal Mucosal Injury of Aspirin? A Prospective, Randomized, Pilot Study.[NCT00594867] | Phase 4 | 94 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Antiplatelet Therapy in HIV - Antiplatelet and Immune Modulating Effects of Aspirin or Clopidogrel in Subjects With HIV[NCT02559414] | Phase 2 | 55 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Intensified Antiplatelet Therapy in Post-PCI Patients With High On-treatment Platelet Reactivity: the OPTIMA-2 Trial[NCT01955200] | Phase 4 | 1,724 participants (Actual) | Interventional | 2013-10-05 | Completed | ||
| A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low[NCT00050817] | Phase 3 | 15,603 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial[NCT00161070] | Phase 4 | 4,500 participants | Interventional | 1997-07-31 | Completed | ||
| Does Pretreatment With Persantin Reduce Periprocedural Troponin-I Release in Patients Undergoing Elective Single Vessel PCI[NCT00767663] | Phase 4 | 30 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00243178] | Phase 3 | 6,706 participants (Actual) | Interventional | 2003-07-31 | Terminated | ||
| PERcutaneouS Coronary intErventions in Patients Treated With Oral Anticoagulant Therapy[NCT03392948] | 1,080 participants (Anticipated) | Observational [Patient Registry] | 2018-02-09 | Active, not recruiting | |||
| Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol[NCT02403349] | Phase 4 | 105 participants (Actual) | Interventional | 2012-05-31 | Active, not recruiting | ||
| Effects of Task-oriented Progressive Resistance Strength Training and Balance Exercises in Functional Performance on Lower Limb in Individuals With Stroke[NCT04820660] | 18 participants (Actual) | Interventional | 2019-03-01 | Completed | |||
| Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER)[NCT00109382] | Phase 2/Phase 3 | 500 participants (Anticipated) | Interventional | 2003-05-31 | Completed | ||
| The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093] | 280 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI With Biologically Active Stents (P2BiTO) Registry[NCT01967615] | 4,500 participants (Actual) | Observational | 2015-01-31 | Completed | |||
| Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention[NCT01456364] | Phase 4 | 70 participants (Anticipated) | Interventional | 2011-09-30 | Recruiting | ||
| CARDIOBASE Bern PCI Registry[NCT02241291] | 10,000 participants (Anticipated) | Observational | 2009-03-31 | Recruiting | |||
| PPD Trial Pilot Study: Plavix, Prasugrel and Drug Eluting Stents[NCT01103843] | 1,000 participants (Anticipated) | Interventional | 2010-04-30 | Recruiting | |||
| Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg Twice Daily in Elderly Patients With Acute Coronary Syndrome (ACS)[NCT04739384] | Phase 3 | 50 participants (Actual) | Interventional | 2021-04-01 | Completed | ||
| A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention[NCT00097591] | Phase 3 | 13,619 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study[NCT00995514] | 4,471 participants (Actual) | Observational | 2009-10-31 | Terminated (stopped due to Administrative reasons) | |||
| Evaluation of a Strategy Guided by Imaging Versus Systematic Coronary Angiography in Elderly Patients With Ischemia: a Multicentric Randomized Non Inferiority Trial.[NCT03289728] | 1,756 participants (Anticipated) | Interventional | 2018-04-04 | Recruiting | |||
| Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes[NCT03347435] | 889 participants (Actual) | Interventional | 2013-06-30 | Terminated (stopped due to Ethics Committe decision) | |||
| The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation[NCT01099566] | Phase 4 | 20 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction)[NCT02428374] | Phase 4 | 300 participants (Anticipated) | Interventional | 2015-05-31 | Recruiting | ||
| Correlation Between Bleeding Complication and Treatment Failure on P2Y12 Inhibitors and Its Predictions Based on Cipherome's Pharmacogenomic Technology[NCT04580602] | 200 participants (Actual) | Observational | 2020-10-07 | Completed | |||
| A Randomized Clinical Trial on the Effect of Powered Toothbrushing and an Antimicrobial Mouth Rinse on Dental Plaque, Pathogenic Microorganisms and Health of Stroke Survivors During Rehabilitation.[NCT03003871] | 94 participants (Actual) | Interventional | 2013-04-30 | Completed | |||
| Phase II, Randomized, Crossover, Single Blind, Safety Trial of DABIGATRAN Versus ASA for Preventing Ischaemic Brain Lesions in Patients Affected by CADASIL[NCT01361763] | Phase 2 | 50 participants (Anticipated) | Interventional | 2011-06-30 | Recruiting | ||
| A Double Blind, Placebo Controlled, Randomized, Multicenter Study to Investigate CHInese Medicine NeuroAid Efficacy on Stroke Recovery[NCT00554723] | Phase 3 | 1,100 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| [NCT00005496] | 0 participants | Observational | 1998-09-30 | Completed | |||
| [NCT00005493] | 0 participants | Observational | 1998-04-30 | Completed | |||
| Evaluation of Diagnostic and Predictive Capabilities of Novel Application of Carotid Carotid Stenosis Pressure Gradient Measurement in Patients Undergoing Percutaneous Carotid Angioplasty and Stenting (CAS).[NCT06123767] | 200 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | |||
| Acute Ischaemic STROKE: From LABoratory to(2) the Patient's BED. Retrospective Study of Blood Biomarkers and Neuroimaging as Predictors of Cerebral Edema, Extension of Ischemic Injury and Functional Outcome[NCT05725694] | 200 participants (Anticipated) | Observational | 2015-10-01 | Enrolling by invitation | |||
| The Effect of Serum LDL Lowering on Aspirin Resistance[NCT00466154] | 40 participants | Interventional | 2005-07-31 | Completed | |||
| Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913] | Phase 3 | 300 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Prevention of Ischemic Events in Patients With Peripheral Arterial Disease by the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice[NCT00761969] | 1,455 participants (Actual) | Observational | 2004-12-31 | Completed | |||
| Evaluation of Platelet Aggregation and Adenosine Levels in Patients With Coronary Artery Disease and Chronic Kidney Dysfunction Taking Dual Antiplatelet Therapy With Aspirin and Clopidogrel or Ticagrelor[NCT03039205] | Phase 2 | 90 participants (Actual) | Interventional | 2017-11-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 313 |
| Rivaroxaban 5mg + Aspirin Placebo | 366 |
| Rivaroxaban Placebo + Aspirin 100mg | 378 |
Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 282 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 389 |
| Rivaroxaban 5mg + Aspirin Placebo | 453 |
| Rivaroxaban Placebo + Aspirin 100mg | 516 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 329 |
| Rivaroxaban 5mg + Aspirin Placebo | 397 |
| Rivaroxaban Placebo + Aspirin 100mg | 450 |
Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 379 |
| Rivaroxaban 5mg + Aspirin Placebo | 448 |
| Rivaroxaban Placebo + Aspirin 100mg | 496 |
Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 353 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 288 |
| Rivaroxaban 5mg + Aspirin Placebo | 255 |
| Rivaroxaban Placebo + Aspirin 100mg | 170 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 138 |
Major bleeding event (as per ISTH), defined as bleeding event that met at least one of following: fatal bleeding; symptomatic bleeding in a critical area or organ (intraarticular, intramuscular with compartment syndrome, intraocular, intraspinal, pericardial, or retroperitoneal); symptomatic intracranial haemorrhage; clinically overt bleeding associated with a recent decrease in the hemoglobin level of greater than or equal to (>=) 2 grams per decilitre (g/dL) (20 grams per liter [g/L]; 1.24 millimoles per liter [mmol/L]) compared to the most recent hemoglobin value available before the event; clinically overt bleeding leading to transfusion of 2 or more units of packed red blood cells or whole blood. The results were based on classification of events that have been positively adjudicated as major bleeding events. Incidence rate estimated as number of subjects with incident events divided by cumulative at-risk time, where subject is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 1.82 |
| Acetylsalicylic Acid 100 mg OD | 0.67 |
All-cause mortality includes all deaths of participants due to any cause. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 1.88 |
| Acetylsalicylic Acid 100 mg OD | 1.50 |
Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. Cardiovascular death includes death due to hemorrhage and death with undetermined/unknown cause. Systemic embolism is defined as abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms. The diagnosis of myocardial infarction requires the combination of: 1)evidence of myocardial necrosis (either changes in cardiac biomarkers or post-mortem pathological findings); and 2)supporting information derived from the clinical presentation, electrocardiographic changes, or the results of myocardial or coronary artery imaging. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 6.20 |
| Acetylsalicylic Acid 100 mg OD | 5.85 |
Non-major clinically relevant bleeding was defined as non-major overt bleeding but required medical attention (example: hospitalization, medical treatment for bleeding), and/or was associated with the study drug interruption of more than 14 days. The results were based on the outcome events at or after randomization until the efficacy cut-off date. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 3.52 |
| Acetylsalicylic Acid 100 mg OD | 2.32 |
Intracranial hemorrhage included all bleeding events that occurred in intracerebral, sub arachnoidal as well as subdural or epidural sites. The below table displays results for all randomized participants and the outcomes at or after randomization until the efficacy cut-off date. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 0.70 |
| Acetylsalicylic Acid 100 mg OD | 0.35 |
Life-threatening bleeding was defined as a subset of major bleeding that met at least one of the following criteria: 1) fatal bleeding; 2) symptomatic intracranial haemorrhage; 3) reduction in hemoglobin of at least 5 g/dl (50 g/l; 3.10 mmol/L); 4) transfusion of at least 4 units of packed red cells or whole blood; 5) associated with hypotension requiring the use of intravenous inotropic agents; 6) necessitated surgical intervention. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 1.02 |
| Acetylsalicylic Acid 100 mg OD | 0.43 |
Components of composite efficacy outcome (adjudicated) includes stroke (ischemic, hemorrhagic, and undefined stroke, TIA with positive neuroimaging) and systemic embolism. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 5.14 |
| Acetylsalicylic Acid 100 mg OD | 4.78 |
"Disabling stroke is defined as stroke with modified Rankin score (mRS) greater than or equal to (>=) 4 as assessed by investigator. mRS spans 0-6, running from perfect health to death. A score of 0-3 indicates functional status ranging from no symptoms to moderate disability (defined in the mRS as requiring some help, but able to walk without assistance); mRS 4-6 indicates functional status ranging from moderately severe disability (unable to walk or to attend to own bodily needs without assistance)through to death. CV death includes death due to hemorrhage and death with undetermined/unknown cause. Diagnosis of myocardial infarction requires combination of: 1) evidence of myocardial necrosis either changes in cardiac biomarkers or post-mortem pathological findings); 2) supporting information derived from clinical presentation, electrocardiographic changes, or results of myocardial or coronary artery imaging." (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) | ||||
|---|---|---|---|---|---|
| Stroke | Ischemic stroke | Disabling stroke | CV death(includes death due to hemorrhage) | Myocardial infarction | |
| Acetylsalicylic Acid 100 mg OD | 4.71 | 4.56 | 0.84 | 0.66 | 0.67 |
| Rivaroxaban 15 mg OD | 5.11 | 4.71 | 1.20 | 0.99 | 0.49 |
Absolute prothrombin time was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 0.5-1.5 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 15.46 |
| Rivaroxaban (Part B) | 18.02 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 1.5-4 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 16.58 |
| Rivaroxaban (Part B) | 18.76 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 0.5-1.5 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 17.95 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 1.5-4 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 18.73 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 6-8 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 16.13 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: Up to 3 hours predose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 15.21 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 0.5-1.5 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 20.13 |
| Rivaroxaban (Part B) | 18.89 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 2.5-4 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 19.14 |
| Rivaroxaban (Part B) | 19.69 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: Up to 3 hours predose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 17.59 |
| Rivaroxaban (Part B) | 16.45 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 0.5-1.5 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 31.4 |
| Rivaroxaban (Part B) | 30.69 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 0.5-1.5 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 66.93 |
| Rivaroxaban (Part B) | 99.46 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 1.5-4 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 74.06 |
| Rivaroxaban (Part B) | 104.57 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 6-8 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 74.21 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 0.5-1.5 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part B) | 110.90 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 2.5-4 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part B) | 93.48 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: Up to 3 hours predose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 60.51 |
| Rivaroxaban (Part B) | 53.41 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 1.5-4 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 32.83 |
| Rivaroxaban (Part B) | 30.25 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 0.5-1.5 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 36.17 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average for the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 1.5-4 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 37.58 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 6-8 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 32.83 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: Up to 3 hours predose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 33.08 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 0.5-1.5 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 26.60 |
| Rivaroxaban (Part B) | 31.15 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 2.5-4 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 26.74 |
| Rivaroxaban (Part B) | 31.67 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: Up to 3 hours predose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 25.36 |
| Rivaroxaban (Part B) | 28.70 |
TEAEs were defined as those adverse events (AEs) that occurred from the first day of study drug to the last day of study drug + 2 days inclusive. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. (NCT02846532)
Timeframe: Up to 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban (Part A) | 91.7 |
| Rivaroxaban (Part B) | 85.9 |
| Aspirin (Part B) | 85.3 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 0.5-1.5 hours postdose
| Intervention | micrograms per liter (mcg/L) (Mean) |
|---|---|
| Rivaroxaban (Part A) | 46.69 |
| Rivaroxaban (Part B) | 92.86 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 1.5-4 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 86.62 |
| Rivaroxaban (Part B) | 103.61 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 0.5-1.5 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 107.58 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 1.5-4 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 147.18 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 6-8 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 66.81 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: Up to 3 hours predose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 36.58 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 0.5-1.5 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 86.25 |
| Rivaroxaban (Part B) | 94.12 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 2.5-4 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 96.67 |
| Rivaroxaban (Part B) | 102.99 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: Up to 3 hours predose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 38.23 |
| Rivaroxaban (Part B) | 29.41 |
Thrombotic event was defined as the appearance of a new thrombotic burden within the cardiovascular system on either routine surveillance or clinically indicated imaging, or the occurrence of a clinical event known to be strongly associated with thrombus (such as cardioembolic stroke, pulmonary embolism). The event included ischemic stroke, pulmonary embolism, venous thrombosis, arterial/intracardiac thrombosis, and other thrombosis. (NCT02846532)
Timeframe: Up to 12 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any thrombotic event | Ischemic stroke | Pulmonary embolism | Venous thrombosis | Arterial/intracardiac thrombosis | Other thrombosis | |
| Aspirin (Part B) | 8.8 | 2.9 | 0 | 5.9 | 0 | 0 |
| Rivaroxaban (Part A) | 8.3 | 0 | 0 | 8.3 | 0 | 0 |
| Rivaroxaban (Part B) | 1.6 | 0 | 1.6 | 0 | 0 | 0 |
Bleeding events were categorized into major, clinically relevant non-major bleeding (CRNM), and trivial bleeding events. Major bleeding: overt bleeding and associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more; or leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults; or occurring in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; or contributing to death. CRNM bleeding: overt bleeding not meeting the criteria for major bleeding but associated with: Medical intervention, or Unscheduled contact with a physician, cessation of study treatment, or Discomfort for the subject such as pain, or Impairment of activities of daily life. Trivial bleeding: any other overt bleeding event that does not meet criteria for CRNM bleeding. (NCT02846532)
Timeframe: Up to 12 months
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Any bleeding event | Major Bleeding | Clinically relevant non-major bleeding | Trivial bleeding | |
| Aspirin (Part B) | 41.2 | 0 | 8.8 | 35.3 |
| Rivaroxaban (Part A) | 33.3 | 0 | 8.3 | 25.0 |
| Rivaroxaban (Part B) | 35.9 | 1.6 | 6.3 | 32.8 |
Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 141 |
| Placebo | 167 |
Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 121 |
| Placebo | 160 |
Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 18 |
| Placebo | 12 |
Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 6 |
| Placebo | 4 |
Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 5 |
| Placebo | 3 |
Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 116 |
| Placebo | 156 |
Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 112 |
| Placebo | 155 |
Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 23 |
| Placebo | 10 |
Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 17 |
| Placebo | 7 |
Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 40 |
| Placebo | 13 |
Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 10 |
| Placebo | 7 |
Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 0 |
Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 2 |
Adjudicated composite of non-fatal stroke, non-fatal myocardial infarction (MI), or cardiovascular death is a key secondary endpoint. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 4.80 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 5.40 |
Adjudicated fatal bleeding was defined as a bleeding event which the Independent Event Adjudication Committee (IAC) determined as the primary cause of death or contributed directly to death. The annualised event rate represents the average number of events per patient during a 1-year period. Because there were 0 events in one treatment group, the hazard ratio is unable to be calculated. (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 0.00 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 0.05 |
"Adjudicated intracranial haemorrhage comprised the subtypes of intracerebral bleeds, intraventricular bleeds, subdural bleeds, epidural bleeds, and subarachnoid bleeds. Microbleeds did not qualify as intracranial haemorrhage, except when they were symptomatic.~The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 0.67 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 0.63 |
Adjudicated ischaemic stroke is a key secondary endpoint. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 3.97 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 4.71 |
"Major bleeds were to be classified as life-threatening if they met one or more of the following criteria: fatal bleed, symptomatic intracranial bleed, reduction in haemoglobin of at least 5 grams/ deciliter (g/dL), transfusion of at least 4 units of packed red blood cells (equivalent to 9 units in Japan), associated with hypotension requiring the use of intravenous inotropic agents, or necessitated surgical intervention.~The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 0.76 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 0.91 |
Adjudicated recurrent stroke (ischemic, hemorrhagic, or unspecified) is presented. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, approximately 43 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 4.09 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 4.80 |
All-cause death is presented. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 1.24 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 1.28 |
"This was the sum of all major and minor bleeds (Minor bleeds were clinical bleeds that did not fulfil the criteria for major bleeds), regardless of severity.~The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 15.21 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 11.64 |
Disabling stroke (modified Rankin Scale greater than or equal to 4, as determined 3 months after recurrent stroke) is presented. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 0.55 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 0.93 |
"First major bleed is primary safety endpoint. Major bleeds were defined according to the International Society of Thrombosis and Haemostasis (ISTH) definition as follows:~Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome and/or,~Bleeding (which should be overt) associated with a reduction in haemoglobin of at least 2 grams/ decilitre (g/dL) (1.24 millimoles Per Litre (mmol/L)), or leading to transfusion of ≥2 units of blood or packed cells (equivalent to ≥4.5 units in Japan); the haemoglobin drop should be considered to be due to and temporally related to the bleeding event and/or,~Fatal bleed. The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 1.84 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 1.33 |
"EQ-5D index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: End of treatment visit (Day 90+-7d)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.85 |
| ASA 100 mg | 0.84 |
"EQ-5D index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: Premature treatment discontinuation visit(<15 days after last dose)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.72 |
| ASA 100 mg | 0.68 |
"EQ-5D (EuroQol five dimensions questionnaire) index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: Visit 1 (Enrolment)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.70 |
| ASA 100 mg | 0.70 |
"EQ-5D (EuroQol five dimensions questionnaire) index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: Visit 2 (Day 7+-2d)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.80 |
| ASA 100 mg | 0.79 |
Participants with stroke, MI, death or life-threatening bleeding. If no event, censoring occures at the minimum of (last date of event assessment, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 457 |
| ASA 100 mg | 508 |
"Analysis of severity of stroke and overall disability of patients, using the modified Rankin Score, mRS.~Modified Rankin Score:~0 - No symptoms.~- No significant disability. Able to carry out all usual activities, despite some symptoms.~- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.~- Moderate disability. Requires some help, but able to walk unassisted.~- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.~- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.~- Dead.~Disability defined as mRS > 1.~Odds ratio and p-value are calculated for ticagrelor versus ASA from a logistic regression model with treatment group, history of stroke and NIHSS (National Institutes of Health Stroke Scale) at baseline as explanatory variables." (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 1107 |
| ASA 100 mg | 1194 |
Participants with all-cause death. If no event, censoring at the minimum of (last date of event assessment, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 68 |
| ASA 100 mg | 58 |
Participants with ischaemic stroke, MI or CV death. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 423 |
| ASA 100 mg | 475 |
Participants with stroke, MI or death. If no event, censoring occures at the minimum of (last date of event assessment, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 442 |
| ASA 100 mg | 497 |
Participants with CV death. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 41 |
| ASA 100 mg | 35 |
Participants with disabling stroke. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 277 |
| ASA 100 mg | 307 |
Participants with fatal stroke. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 18 |
| ASA 100 mg | 17 |
Participants with ischaemic stroke. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 385 |
| ASA 100 mg | 441 |
Participants with MI. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97) (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 25 |
| ASA 100 mg | 21 |
"Participants with PLATO Major bleeding. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97).~PLATO Major bleeding is defined as a bleed that is any one of:~Fatal~Intracranial (excluding asymptomatic haemorrhagic transformations of ischemic brain infarctions and excluding micro-hemorrhages <10 mm evident only on gradient-echo MRI)~Intrapericardial bleed with cardiac tamponade~Hypovolaemic shock or severe hypotension due to bleeding and requiring pressors or surgery~Significantly disabling (eg. intraocular with permanent vision loss)~Clinically overt or apparent bleeding associated with a decrease in Hb of more than 30 g/L (1.9 mmol/L; 0.465 mmol/L)~Transfusion of 2 or more units (whole blood or packed red blood cells [PRBCs]) for bleeding." (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 31 |
| ASA 100 mg | 38 |
Participants discontinuation of study drug due to any bleeding adverse event. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). (NCT01994720)
Timeframe: Time from first dose and up to and including 7 days following the date of last dose of the study
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 82 |
| ASA 100 mg | 37 |
Participants with stroke. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97) (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 390 |
| ASA 100 mg | 450 |
"Change from baseline to end of treatment visit in NIHSS (National Institutes of Health Stroke Scale):~0 No stroke symptoms 1-4 Minor stroke 5-15 Moderate stroke 16-20 Moderate to severe stroke 21-42 Severe stroke." (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=-5 | -4 | -3 | -2 | -1 | 0 | 1 | 2 | 3 | 4 | 5 | >5 | Missing | |
| ASA 100 mg | 127 | 438 | 810 | 1073 | 1131 | 683 | 79 | 31 | 16 | 11 | 6 | 14 | 450 |
| Ticagrelor 90 mg | 132 | 403 | 779 | 1088 | 1099 | 681 | 67 | 28 | 18 | 13 | 6 | 10 | 474 |
"Time to first occurrence during the time the participants were treated with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 24.66 |
| Vitamin K Antagonist | 35.79 |
"Time to first death or ischenic event during the 6-month treatment period with aspirin or placebo.~N is the number of participants treated with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with death or ischemic events in each treatment group during the 6-month treatment period.~Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Acetylsalicylic Acid Film Coated Tablet | 15.28 |
| Placebo Matching Acetylsalicylic Acid Film Coated Tablet | 17.73 |
"Time to first all-cause death or all-cause hospitalization during the during the 6-month treatment period with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 57.24 |
| Vitamin K Antagonist | 69.19 |
"Time to first all-cause death or all-cause hospitalization during the 6-month period of treatment with aspirin or placebo.~N is the number of participants treated with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Acetylsalicylic Acid Film Coated Tablet | 65.72 |
| Placebo Matching Acetylsalicylic Acid Film Coated Tablet | 60.56 |
"Time to first ISTH major or CRNM bleeding during the 6-month period of treatment with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with major or CRNM bleeding divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 24.66 |
| Vitamin K Antagonist | 35.79 |
"Time to first ISTH major or CRNM bleeding during the treatment period of 6 months with aspirin or placebo.~N is the number of participants with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Acetylsalicylic Acid Film Coated Tablet | 40.51 |
| Placebo Matching Acetylsalicylic Acid Film Coated Tablet | 21.03 |
"Time to first occurrence during the 6-month treatment period with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with death or ischemic events in each treatment group during the during the 6-month period of treatment.~Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 15.85 |
| Vitamin K Antagonist | 17.17 |
Participants with all-cause death. If no event, censoring occurs at the earliest of PACD and last endpoint assessment date. Includes deaths based on publically available vital status data in patients who have withdrawn consent. (NCT01991795)
Timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 579 |
| Ticagrelor Placebo | 592 |
Participants with Cardiovascular (CV) death, myocardial infarction (MI) or stroke. If no event, censoring occurs at the earliest of PACD, last endpoint assessment date and non-CV death date. (NCT01991795)
Timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 736 |
| Ticagrelor Placebo | 818 |
Participants with Cardiovascular (CV) death. If no event, censoring occurs at the earliest of PACD, last endpoint assessment date and non-CV death date. (NCT01991795)
Timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 364 |
| Ticagrelor Placebo | 357 |
Participants with ischaemic stroke. If no event, censoring occurs at the earliest of PACD, last endpoint assessment date and death date. (NCT01991795)
Timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 152 |
| Ticagrelor Placebo | 191 |
Participants with myocardial infarction. If no event, censoring occurs at the earliest of primary analysis censoring date (PACD), last endpoint assessment date and death date (NCT01991795)
Timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 274 |
| Ticagrelor Placebo | 328 |
Participants with permanent discontinuation of study medication due to any bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and the date of last dose of study medication (NCT01991795)
Timeframe: From randomisation to 7 days following the date of last dose of study medication. Maximum duration of exposure was 59 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 466 |
| Ticagrelor Placebo | 125 |
Participants with PLATO major bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and 7 days following the date of last dose of study medication (NCT01991795)
Timeframe: From randomisation to 7 days following the date of last dose of study medication. Maximum duration of exposure was 59 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 310 |
| Ticagrelor Placebo | 145 |
Participants with TIMI major bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and 7 days following the date of last dose of study medication (NCT01991795)
Timeframe: From randomisation to 7 days following the date of last dose of study medication. Maximum duration of exposure was 59 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 206 |
| Ticagrelor Placebo | 100 |
Participants with TIMI major or minor bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and 7 days following the date of last dose of study medication (NCT01991795)
Timeframe: From randomisation to 7 days following the date of last dose of study medication. Maximum duration of exposure was 59 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 285 |
| Ticagrelor Placebo | 129 |
(NCT02697916)
Timeframe: Time of randomization through study completion, approximately 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA 81mg | 315 |
| ASA 325mg | 357 |
(NCT02697916)
Timeframe: Time of randomization through study completion, approximately 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA 81mg | 590 |
| ASA 325mg | 569 |
(NCT02697916)
Timeframe: Time of randomization through study completion, approximately 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA 81mg | 53 |
| ASA 325mg | 44 |
(NCT02697916)
Timeframe: Time of randomization through study completion, approximately 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA 81mg | 228 |
| ASA 325mg | 213 |
(NCT02697916)
Timeframe: Time of randomization through study completion, approximately 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA 81mg | 102 |
| ASA 325mg | 92 |
(NCT02697916)
Timeframe: Time of randomization through study completion, approximately 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA 81mg | 471 |
| ASA 325mg | 446 |
Quality of life measures are based on an ordinal scale from 1-5, where 1 corresponds to the best outcome and 5 to the worst. Model-based mean score estimates are obtained from mixed models of each quality of life measure. (NCT02697916)
Timeframe: 2 years
| Intervention | score on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Describe Current Health | Able to Run Errands and Shop | In the past 7 Days, Felt Depressed | In the past 7 Days, Felt Fatigued | In the past 7 Days, Problems with Sleep | Trouble doing Regular Activities | In the past 7 Days, Pain interfered | |
| ASA 325mg | 2.8 | 1.66 | 1.7 | 2.27 | 2.10 | 1.88 | 2.02 |
| ASA 81mg | 2.77 | 1.65 | 1.69 | 2.25 | 2.06 | 1.84 | 2.06 |
Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 141 |
| Aspirin + Ticagrelor | 250 |
Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 135 |
| Aspirin + Ticagrelor | 137 |
"BARC definition. We only considered BARC 3 or 5 for this secondary safety endpoint.~Type 3: Clinical, laboratory, and/or imaging evidence of bleeding with:~Type 3a:~Overt bleeding + Hb drop of 3 to < 5 g/dL (provided Hb drop is related to bleed)~Any transfusion with overt bleeding~Type 3b:~Overt bleeding + Hb drop ≥5 g/dL (provided Hb drop is related to bleed)~Cardiac tamponade~Bleeding requiring surgical intervention (excluding dental/nasal/skin/haemorrhoid)~Bleeding requiring intravenous vasoactive agents~Type 3c:~Intracranial haemorrhage (does not include microbleeds or haemorrhagic transformation, does include intraspinal)~Subcategories confirmed by autopsy or imaging or lumbar puncture~Intraocular bleed compromising vision. Type 5: Fatal bleeding~Type 5a:~• Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious~Type 5b:~Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation" (NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 163 |
| Reference Treatment Strategy | 169 |
Number of Participants with a composite of all-cause mortality or non-fatal new Q-wave MI up to 2 years post randomisation. (NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 304 |
| Reference Treatment Strategy | 349 |
shown are the first event per event type for each patient only. Multiple events of the same type within the same patient are disregarded (NCT01813435)
Timeframe: 2-year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 362 |
| Reference Treatment Strategy | 416 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 64 |
| Reference Treatment Strategy | 64 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 739 |
| Reference Treatment Strategy | 793 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 80 |
| Reference Treatment Strategy | 82 |
(NCT01813435)
Timeframe: 2-year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 224 |
| Reference Treatment Strategy | 253 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 248 |
| Reference Treatment Strategy | 250 |
(NCT01813435)
Timeframe: 2-year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 83 |
| Reference Treatment Strategy | 103 |
number of participants with the occurrence of a bleeding event leading the participant to seek medical attention (NCT02505217)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| High FcγRIIa Expression | 6 |
| Low FcγRIIa Expression | 6 |
number of participants with myocardial infarction, stroke, and/or death (NCT02505217)
Timeframe: average duration of follow-up 19 months
| Intervention | Participants (Count of Participants) |
|---|---|
| High FcγRIIa Expression | 17 |
| Low FcγRIIa Expression | 6 |
Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 5.1 |
| Ticagrelor 60 mg | 4.7 |
| Placebo | 5.2 |
A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of >= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug (NCT01225562)
Timeframe: First dosing up to 48 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.6 |
| Ticagrelor 60 mg | 2.3 |
| Placebo | 1.1 |
Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.9 |
| Ticagrelor 60 mg | 2.9 |
| Placebo | 3.4 |
Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 7.8 |
| Ticagrelor 60 mg | 7.8 |
| Placebo | 9.0 |
Participants with bleeding event that fulfils serious adverse event criteria and is categorised as GUSTO Moderate/Severe. GUSTO is a bleeding scale (GUSTO = Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries). GUSTO Severe bleeding is defined as any of the following: (1) fatal bleeding, (2) intracranial bleeding, or (3) bleeding that caused haemodynamic compromise requiring intervention. GUSTO Moderate bleeding is a bleeding requiring transfusion of whole blood or packed red blood cells without haemodynamic compromise (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 36 |
| PLACEBO | 11 |
Participants with bleeding event that fulfils serious adverse event criteria and is categorised as GUSTO Severe. GUSTO is a bleeding scale (GUSTO = Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries). GUSTO Severe bleeding is defined as any of the following: (1) fatal bleeding, (2) intracranial bleeding, or (3) bleeding that caused haemodynamic compromise requiring intervention (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 28 |
| PLACEBO | 7 |
Participants with subsequent stroke or death (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 303 |
| PLACEBO | 362 |
Participants with ICH or fatal bleeding event (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 22 |
| PLACEBO | 6 |
Number of participants with ischaemic stroke (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 276 |
| PLACEBO | 345 |
The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death.0 - No symptoms,1 - No significant disability. Able to carry out all usual activities, despite some symptoms. 2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3 - Moderate disability. Requires some help, but able to walk unassisted. 4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6 - Dead. (NCT03354429)
Timeframe: Visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 1282 |
| PLACEBO | 1284 |
Participants with premature permanent discontinuation of IP due to bleeding (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 152 |
| PLACEBO | 32 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 43 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 13 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 30 |
"Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 27 |
"Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 16 |
"Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 11 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 6 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 3 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 3 |
"TLR is defined as any repeat percutaneous intervention of the target lesion (the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent) or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not CI by the investigator prior to repeat angiography.~A revascularization is considered CI if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if any one below occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g: Doppler flow velocity reserve, fractional flow reserve);~A TLR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 10 |
"TLR is defined as any repeat percutaneous intervention of the target lesion (the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent) or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not CI by the investigator prior to repeat angiography.~A revascularization is considered CI if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if any one below occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g: Doppler flow velocity reserve, fractional flow reserve);~A TLR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 7 |
"TLR is defined as any repeat percutaneous intervention of the target lesion (the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent) or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not CI by the investigator prior to repeat angiography.~A revascularization is considered CI if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if any one below occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g: Doppler flow velocity reserve, fractional flow reserve);~A TLR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 3 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 9 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 5 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 70 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 29 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 41 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 45 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 22 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 23 |
"Net Adverse Clinical Endpoint (NACE):~A composite rate of all-cause death, all myocardial infarction (modified Academic Research Consortium [ARC]), stent thrombosis (ARC definite or probable), stroke or major bleeding (Bleeding defined by the Bleeding Academic Research Consortium [BARC] type 2-5)" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 121 |
"Net Adverse Clinical Endpoint (NACE):~A composite rate of all-cause death, all myocardial infarction (modified Academic Research Consortium [ARC]), stent thrombosis (ARC definite or probable), stroke or major bleeding (Bleeding defined by the Bleeding Academic Research Consortium [BARC] type 2-5)" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 55 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 0 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 42 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 21 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 21 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 44 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 22 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 22 |
"Bleeding per Bleeding Academic Research Consortium (BARC)definitions are as follows:~Type 0~Type 1~Type 2~Type 3~Type 4~Type 5~Where, Type 0 indicates no bleeding and type 5 indicates fatal bleeding." (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| BARC Type 2-5 | BARC Type 3-5 | |
| XIENCE | 61 | 27 |
"Bleeding per Bleeding Academic Research Consortium (BARC)definitions are as follows:~Type 0~Type 1~Type 2~Type 3~Type 4~Type 5~Where, Type 0 indicates no bleeding and type 5 indicates fatal bleeding." (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| BARC Type 2-5 | BARC Type 3-5 | |
| XIENCE | 19 | 7 |
"Bleeding per Bleeding Academic Research Consortium (BARC)definitions are as follows:~Type 0~Type 1~Type 2~Type 3~Type 4~Type 5~Where, Type 0 indicates no bleeding and type 5 indicates fatal bleeding." (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| BARC Type 2-5 | BARC Type 3-5 | |
| XIENCE | 44 | 20 |
"Net Adverse Clinical Endpoint (NACE):~A composite rate of all-cause death, all myocardial infarction (modified Academic Research Consortium [ARC]), stent thrombosis (ARC definite or probable), stroke or major bleeding (Bleeding defined by the Bleeding Academic Research Consortium [BARC] type 2-5)" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 2 | 5 | 10 | 15 | 40 |
"All Death:~All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death:~Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death:~Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 54 |
"All Myocardial Infarction (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL~TV-MI: All infarcts that cannot be clearly attributed to a vessel other than the target vessel will be considered related to the target vessel." (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 48 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 21 |
"Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography.~Clinically Indicated [CI] Revascularization:~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test~A TLR/TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 16 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 26 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 67 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions are as follows:~Type 3a: Overt bleeding plus Hemoglobin(Hb) drop of 3 to < 5 g/dL; Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL; Cardiac tamponade; Bleeding requiring surgical intervention for control; Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage;Subcategories confirmed by autopsy or imaging or lumbar puncture; Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48 h; Reoperation after closure of sternotomy for the purpose of controlling bleeding; Transfusion of ≥ 5 U whole blood or packed red blood cells within a 48-h period; Chest tube output ≥ 2L within a 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding or autopsy or imaging confirmation" (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 41 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 66 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 70 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block, development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI: CK-MB > URL or Troponin > URL with baseline value < UR~The propensity score for each individual was calculated using a logistic regression model that included the study group as the outcome & the baseline demographic, clinical and procedural covariates as the predictors" (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 5.4 | 6.7 | 4.0 | 3.6 | 5.8 | 6.9 |
"Type 2: Any overt, actionable sign of hemorrhage~Type 3a: Overt bleeding plus Hb drop of 3 to < 5g/dL;Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL;Cardiac tamponade;Bleeding requiring surgical intervention for control;Bleeding requiring IV vasoactive agents~Type 3c: ICH; Subcategories confirmed by autopsy/imaging/lumbar puncture;Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48h;Reoperation after closure of sternotomy for the purpose of controlling bleeding;Transfusion of ≥ 5 U whole blood or packed RBC within 48h;Chest tube output ≥ 2L within 24h~Type 5: Fatal bleeding~The propensity score for each individual was calculated using a logistic regression model that included the study group as the outcome & the baseline demographic, clinical and procedural covariates as the predictors." (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 5.1 | 3.9 | 2.7 | 5.4 | 6.0 | 7.7 |
"All Death:~All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even inpatients with coexisting potentially fatal non-cardiac disease (e.g. cancer,infection) should be classified as cardiac.~Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death:~Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death:~Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 64 |
"All Death:~All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even inpatients with coexisting potentially fatal non-cardiac disease (e.g. cancer,infection) should be classified as cardiac.~Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death:~Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death:~Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 23 |
"All Death:~All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even inpatients with coexisting potentially fatal non-cardiac disease (e.g. cancer,infection) should be classified as cardiac.~Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death:~Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death:~Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 40 |
"All Myocardial Infarction (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL~TV-MI: All infarcts that cannot be clearly attributed to a vessel other than the target vessel will be considered related to the target vessel." (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 41 |
"All Myocardial Infarction (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL~TV-MI: All infarcts that cannot be clearly attributed to a vessel other than the target vessel will be considered related to the target vessel." (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 18 |
"All Myocardial Infarction (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL~TV-MI: All infarcts that cannot be clearly attributed to a vessel other than the target vessel will be considered related to the target vessel." (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 24 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 11 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 7 |
"Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography.~Clinically Indicated [CI] Revascularization:~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test~A TLR/TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 18 |
"Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography.~Clinically Indicated [CI] Revascularization:~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test~A TLR/TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 8 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g.,Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 29 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g.,Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 15 |
"Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography.~Clinically Indicated [CI] Revascularization:~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test~A TLR/TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 10 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g.,Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 14 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 103 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 46 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 57 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URLwith baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 68 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URLwith baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 35 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URLwith baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 33 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions are as follows:~Type 3a: Overt bleeding plus Hemoglobin(Hb) drop of 3 to < 5 g/dL; Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL; Cardiac tamponade; Bleeding requiring surgical intervention for control; Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage;Subcategories confirmed by autopsy or imaging or lumbar puncture; Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48 h; Reoperation after closure of sternotomy for the purpose of controlling bleeding; Transfusion of ≥ 5 U whole blood or packed red blood cells within a 48-h period; Chest tube output ≥ 2L within a 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding; no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy or imaging confirmation" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 49 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions are as follows:~Type 3a: Overt bleeding plus Hemoglobin(Hb) drop of 3 to < 5 g/dL; Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL; Cardiac tamponade; Bleeding requiring surgical intervention for control; Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage;Subcategories confirmed by autopsy or imaging or lumbar puncture; Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48 h; Reoperation after closure of sternotomy for the purpose of controlling bleeding; Transfusion of ≥ 5 U whole blood or packed red blood cells within a 48-h period; Chest tube output ≥ 2L within a 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding; no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy or imaging confirmation" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 33 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions are as follows:~Type 3a: Overt bleeding plus Hemoglobin(Hb) drop of 3 to < 5 g/dL; Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL; Cardiac tamponade; Bleeding requiring surgical intervention for control; Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage;Subcategories confirmed by autopsy or imaging or lumbar puncture; Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48 h; Reoperation after closure of sternotomy for the purpose of controlling bleeding; Transfusion of ≥ 5 U whole blood or packed red blood cells within a 48-h period; Chest tube output ≥ 2L within a 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding; no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy or imaging confirmation" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 18 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 0 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 69 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 35 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 34 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 77 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 38 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 39 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI Definition (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Peripheral MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 3.5 | 4.3 | 4.1 | 2.6 | 2.7 | 3.9 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI Definition (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Peripheral MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 6.7 | 4.3 | 6.7 | 6.0 | 7.9 | 8.4 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI Definition (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Peripheral MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 3.2 | 0.0 | 2.7 | 3.4 | 5.5 | 4.4 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions:~Type 2: Any overt, actionable sign of hemorrhage~Type 3a: Overt bleeding plus Hb drop of 3 to < 5g/dL;Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL;Cardiac tamponade;Bleeding requiring surgical intervention for control;Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage; Subcategories confirmed by autopsy/imaging/lumbar puncture;Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48h;Reoperation after closure of sternotomy for the purpose of controlling bleeding;Transfusion of ≥ 5 U whole blood/packed red blood cells within a 48h period;Chest tube output ≥ 2L within 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding;no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy/imaging confirmation" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 7.1 | 6.5 | 6.8 | 5.4 | 6.8 | 10.1 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions:~Type 2: Any overt, actionable sign of hemorrhage~Type 3a: Overt bleeding plus Hb drop of 3 to < 5g/dL;Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL;Cardiac tamponade;Bleeding requiring surgical intervention for control;Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage; Subcategories confirmed by autopsy/imaging/lumbar puncture;Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48h;Reoperation after closure of sternotomy for the purpose of controlling bleeding;Transfusion of ≥ 5 U whole blood/packed red blood cells within a 48h period;Chest tube output ≥ 2L within 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding;no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy/imaging confirmation" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 2.5 | 2.2 | 1.4 | 3.1 | 2.0 | 3.7 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions:~Type 2: Any overt, actionable sign of hemorrhage~Type 3a: Overt bleeding plus Hb drop of 3 to < 5g/dL;Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL;Cardiac tamponade;Bleeding requiring surgical intervention for control;Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage; Subcategories confirmed by autopsy/imaging/lumbar puncture;Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48h;Reoperation after closure of sternotomy for the purpose of controlling bleeding;Transfusion of ≥ 5 U whole blood/packed red blood cells within a 48h period;Chest tube output ≥ 2L within 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding;no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy/imaging confirmation" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 4.9 | 4.3 | 5.5 | 2.3 | 5.2 | 7.0 |
All bleeding events include major bleeding, CRNM bleeding (see Outcome Measure 12 Description for definitions), plus events of minor bleeding and fatal bleeding. Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding. Fatal bleeding is defined as a bleeding event that the Clinical Events Committee determines is the primary cause of death or contributes directly to death. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 2356 |
| Warfarin | 3060 |
ISTH Bleeding Criteria: Major bleeding=a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more, and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 327 |
| Warfarin | 462 |
Death was defined as all-cause mortality. All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided. Cardiovascular=deaths due to ischemic and hemorrhagic stroke, SE, myocardial infarction (MI), sudden death, heart failure, other cardiovascular, and unobserved deaths. Non-cardiovascular=all deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death). (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 603 |
| Warfarin | 669 |
Major bleeding=bleeding that is clinically overt and that either resulted in a decrease in hemoglobin of 2 g/dL or more over a 24-hour period, led to a transfusion of 2 or more units of packed red blood cells, occurred in a critical site, or led to death. CRNM bleeding=bleeding that is clinically overt, that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event, that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding, or a change in antithrombotic therapy. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 613 |
| Warfarin | 877 |
Net-Clinical Benefit = Composite of stroke, systemic embolism and ISTH major bleeding. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 459 |
| Warfarin | 608 |
For descriptions of Stroke and SE, see Outcome Measure 1. For description of Major bleeding, see Outcome Measure 3. (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 229 |
| Warfarin | 285 |
All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided. Cardiovascular=deaths due to ischemic and hemorrhagic stroke, SE, MI, sudden death, heart failure, other cardiovascular, and unobserved deaths. Non-cardiovascular=all deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death). (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | Number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 3.52 |
| Warfarin | 3.94 |
Rate=number of adjudicated major (ISTH) bleed events per 100 patient years. ISTH Bleeding Criteria: Major bleeding=a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | Number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 2.13 |
| Warfarin | 3.09 |
Rate=Number of adjudicated stroke or SE events per 100 patient years. Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction). Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing. (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | Number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 1.27 |
| Warfarin | 1.60 |
"Rate=number of all bleeding events per 100 patient years. All bleeding events include major bleeding, CRNM bleeding (see Outcome Measure 12 Description for definitions), plus events of minor bleeding and fatal bleeding. Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding. Fatal bleeding is defined as a bleeding event that the Clinical Events Committee determines is the primary cause of death or contributes directly to death." (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 18.08 |
| Warfarin | 25.82 |
(NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | Number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 3.21 |
| Warfarin | 4.06 |
Rate=number of major or CRNM bleed events per 100 patient years. Major=clinically overt and either 1) resulted in a decrease in hemoglobin of 2 g/dL or more, or 2) led to a transfusion of 2 or more units of packed red blood cells, or 3) occurred in a critical site, or 4) led to death. CRNM bleeding=clinically overt, but satisfied no additional criteria required to be adjudicated as a major bleeding event, and led to either 1) hospital admission for bleeding or 2) physician guided medical or surgical treatment for bleeding or 3) a change in antithrombotic therapy. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | number of events / 100 patient years (Number) |
|---|---|
| Apixaban | 4.07 |
| Warfarin | 6.01 |
Rate=number of events of net-clinical benefit per 100 patient years. Net-Clinical Benefit = Composite of stroke, systemic embolism and ISTH major bleeding (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | Number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 3.01 |
| Warfarin | 4.09 |
AE: all SAEs or AEs with onset from first dose through 2 days (AEs) or 30 days (SAEs) after the last dose of blinded study drug (BSD). SAE: all SAEs with onset from first dose through 30 days after the last dose of BSD. Bleeding AE: all serious or non-serious bleeding-related AEs with onset from first dose through 2 days after the last dose of BSD. Discontinuations due to AE: all SAEs or AEs with onset from first dose of BSD and with action taken=drug discontinued. Deaths: all deaths occurring from first dose through 30 days after the last dose of BSD. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| AE | SAE | Bleeding AE | Discontinuations due to AE | Deaths | |
| Apixaban | 7406 | 3182 | 2288 | 688 | 429 |
| Warfarin | 7521 | 3302 | 2961 | 758 | 468 |
All suspected efficacy events were adjudicated by the Central Events Committee (CEC). Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction). Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing. (NCT00412984)
Timeframe: "Time to first event in Intended Treatment Period: started on day of randomization, ended at efficacy cut-off date (date target number of primary efficacy events [448] was expected to have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | participants (Number) | ||
|---|---|---|---|
| Ischemic or Unspecified Stroke | Hemorrhagic Stroke | Systemic Embolism | |
| Apixaban | 159 | 38 | 15 |
| Warfarin | 173 | 76 | 16 |
Rate=number of adjudicated GUSTO bleeding events per 100 patient years. GUSTO Bleeding Criteria: GUSTO severe (or life-threatening) bleeding: either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention. GUSTO moderate bleeding: bleeding that requires blood transfusion but does not result in hemodynamic compromise. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | Number of events per 100 patient years (Number) | |
|---|---|---|
| Severe (n=80, 172)) | Severe or Moderate (n=199, 328) | |
| Apixaban | 0.52 | 1.29 |
| Warfarin | 1.13 | 2.18 |
Rate=number of adjudicated TIMI bleeding events per 100 patient years. TIMI Bleeding Criteria: Major bleeding=Intracranial bleeding and/or clinically overt bleeding associated with ≥5 gm/dL fall in Hgb or 15% fall in hematocrit (Hct) from baseline, accounting for transfusions. Minor bleeding=Clinically overt bleeding associated with ≥3 gm/dL fall in Hgb or a ≥10% fall in Hct from baseline, accounting for transfusions. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | Number of events per 100 patient years (Number) | |
|---|---|---|
| Major (n=148, 256) | Major or Minor (n=239, 370) | |
| Apixaban | 0.96 | 1.55 |
| Warfarin | 1.69 | 2.46 |
Diagnosis for an acute or evolving MI=elevation of creatine kinase-MB isoenzyme (CK-MB) or Troponin T or I ≥ 2 × the upper limit of normal (ULN), or if no CK-MB or troponin values are available, a total CK ≥ 2×ULN, or new, significant (≥0.04 s) Q waves in ≥2 contiguous leads. For descriptions of Stroke and SE, see Outcome Measure 1. (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | Number of events per 100 patient years (Number) | |||
|---|---|---|---|---|
| Ischemic or Unspecified Stroke (n=162, 175) | Hemorrhagic Stroke (n=40, 78) | Systemic Embolism (n=15, 17) | Myocardial Infarction (n=90, 102) | |
| Apixaban | 0.97 | 0.24 | 0.09 | 0.53 |
| Warfarin | 1.05 | 0.47 | 0.10 | 0.61 |
Diagnosis for an acute or evolving MI=elevation of CK-MB or Troponin T or I ≥ 2 × the ULN, or if no CK-MB or troponin values are available, a total CK ≥ 2×ULN, or new, significant (≥0.04 s) Q waves in ≥2 contiguous leads. For descriptions of Stroke and SE, see Outcome Measure 1. For description of ACD, see Outcome Measure 5. (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | Number of events per 100 patient years (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Stroke / SE / Major Bleeding (n=521, 666) | Stroke / SE / All-Cause Death (ACD) (n=752, 837) | Stroke / SE / Major Bleeding / ACD (n=1009, 1168) | Stroke / SE / MI / ACD (n=810, 906) | Ischemic or Unspecified Stroke / ACD (n=725, 796) | Hemorrhagic Stroke / ACD (n=622, 703) | SE / ACD (n=613, 679) | MI / ACD (n=663, 740) | |
| Apixaban | 3.17 | 4.49 | 6.13 | 4.85 | 4.32 | 3.68 | 3.63 | 3.93 |
| Warfarin | 4.11 | 5.04 | 7.20 | 5.49 | 4.78 | 4.20 | 4.05 | 4.43 |
Combination of CV death, MI, and stroke (NCT01870921)
Timeframe: 12 months
| Intervention | Participants (Number) |
|---|---|
| Ticargrelor | 85 |
SAEs except the blending events which have aleady been reported as SAEs. (NCT01870921)
Timeframe: 12 months
| Intervention | Participants (Number) |
|---|---|
| Ticargrelor | 116 |
PLATO-defined fatal/life threatening, major, major+minor,major+minor+minimal (NCT01870921)
Timeframe: 12 months
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Fatal/life threatening | Major | Major + minor | Major + minor + minimal | |
| Ticargrelor | 17 | 27 | 93 | 426 |
Reported here is the percentage of participants who died due to any cause during the study. (NCT02072226)
Timeframe: From baseline to Day 90
| Intervention | percentage of participants (Number) |
|---|---|
| Alteplase + Aspirin Placebo | 0.6 |
| Alteplase Placebo + Aspirin | 0 |
Reported here is the percentage of participants who died due to stroke and neurological disorders. (NCT02072226)
Timeframe: From baseline to Day 90
| Intervention | percentage of participants (Number) |
|---|---|
| Alteplase + Aspirin Placebo | 0 |
| Alteplase Placebo + Aspirin | 0 |
mRS score was determined by the investigator. The mRS is a 7 point scale (0-6) with 0: No symptoms at all, 1: No significant disability despite symptoms, able to carry out all usual duties and activities, 2: Slight disability, unable to carry out all previous activities but able to look after own affairs without assistance, 3: Moderate disability requiring some help, but able to walk without assistance, 4: Moderately severe disability, unable to walk without assistance and unable to attend to own bodily needs without assistance, 5: Severe disability, bedridden, incontinent and requiring constant nursing care and attention, 6: death prior to Day 90. Reported is the percentage of participants with scores of 0 or 1 on the mRS. (NCT02072226)
Timeframe: Day 90
| Intervention | percentage of participants (Number) |
|---|---|
| Alteplase + Aspirin Placebo | 78.2 |
| Alteplase Placebo + Aspirin | 81.5 |
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. (NCT02072226)
Timeframe: From baseline up to Day 90: Non-serious adverse events were collected through the Day 30 visit. Serious adverse events were collected through the end of study at Day 90.
| Intervention | percentage of participants (Number) |
|---|---|
| Alteplase + Aspirin Placebo | 77.3 |
| Alteplase Placebo + Aspirin | 68.0 |
A serious adverse event (SAE) was defined as any experience that suggested a significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here. (NCT02072226)
Timeframe: From baseline to Day 90
| Intervention | percentage of participants (Number) |
|---|---|
| Alteplase + Aspirin Placebo | 26.0 |
| Alteplase Placebo + Aspirin | 13.1 |
ICH was considered symptomatic if it was not seen on computed tomography (CT) or magnetic resonance imaging (MRI) scan at baseline and any neurologic decline was attributed to it by the local investigator. To detect intracranial hemorrhage, neuroimaging (CT or MRI) scan was performed at 22 to 36 hours after study drug administration. (NCT02072226)
Timeframe: Within 36 hours after study drug administration on Day 1
| Intervention | percentage of participants (Number) |
|---|---|
| Alteplase + Aspirin Placebo | 3.2 |
| Alteplase Placebo + Aspirin | 0 |
mRS score was determined by the investigator. The mRS is a 7 point scale (0-6) with 0: No symptoms at all, 1: No significant disability despite symptoms, able to carry out all usual duties and activities, 2: Slight disability, unable to carry out all previous activities but able to look after own affairs without assistance, 3: Moderate disability requiring some help, but able to walk without assistance, 4: Moderately severe disability, unable to walk without assistance and unable to attend to own bodily needs without assistance, 5: Severe disability, bedridden, incontinent and requiring constant nursing care and attention, 6: death before Day 90. Reported are the percentages of participants for all scores on the mRS. (NCT02072226)
Timeframe: Day 90
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| mRS at Day 90 - 0 | mRS at Day 90 - 1 | mRS at Day 90 - 2 | mRS at Day 90 - 3 | mRS at Day 90 - 4 | mRS at Day 90 - 5 or 6 (death) | |
| Alteplase + Aspirin Placebo | 44.9 | 33.3 | 11.5 | 2.6 | 5.1 | 2.6 |
| Alteplase Placebo + Aspirin | 50.3 | 31.2 | 11.5 | 3.2 | 2.5 | 1.3 |
To detect ICH, neuroimaging (CT or MRI) scan was performed at 22 to 36 hours after study drug administration. (NCT02072226)
Timeframe: Within 36 hours after study drug administration on Day 1
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Any ICH within 36 hours reported by site | Any ICH within 36 hours reported by central reader | |
| Alteplase + Aspirin Placebo | 7.1 | 7.1 |
| Alteplase Placebo + Aspirin | 2.6 | 3.3 |
Global favorable recovery is an integrated assessment of participants who meet the following: mRS Score 0-1, National Institutes of Health Stroke Scale (NIHSS) Score 0-1, Barthel Index [BI] greater than or equal to 95, and Glasgow Outcome Scale [GOS] equal to 1. mRS Score 0-1: 0= No symptoms at all, 1= No significant disability despite symptoms, able to carry out all usual duties and activities. NIHSS Score 0-1: 0= No stroke symptoms and 1= Minor stroke symptoms. BI is a 10 question index with a total score range of 0-100 with 100 being the best outcome. GOS =1: Good recovery. Reported here are the percentages of participants who achieved a favorable score on each of these scales. (NCT02072226)
Timeframe: Day 90
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| mRS 0 - 1 at Day 90 | NIHSS 0 - 1 at Day 90 | BI >= 95 at Day 90 | GOS = 1 at Day 90 | |
| Alteplase + Aspirin Placebo | 78.2 | 85.0 | 79.3 | 81.5 |
| Alteplase Placebo + Aspirin | 81.5 | 81.7 | 88.7 | 85.6 |
(NCT00501059)
Timeframe: Until follow-up (approximately 6 years)
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| all-cause mortality | all cancers excluding non-melanoma skin cancer | colon cancer | |
| Acetylsalicylic Acid (Aspirin, BAYE4465) | 2.55 | 4.02 | 0.48 |
| Placebo | 2.57 | 3.76 | 0.41 |
*all other CV death without fatal MI and fatal stroke. (NCT00501059)
Timeframe: Until follow-up (approximate 6 years)
| Intervention | Percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| MI, stroke, CV death, UA or TIA | MI, stroke or CV death | MI | Non-fatal MI | Stroke | CV death* | UA | TIA | All-cause mortality | |
| Acetylsalicylic Acid (Aspirin, BAYE4465) Per-protocol | 3.40 | 2.72 | 0.98 | 0.84 | 1.06 | 0.69 | 0.21 | 0.50 | 2.85 |
| Placebo Per-protocol | 4.19 | 3.45 | 1.84 | 1.53 | 0.95 | 0.66 | 0.28 | 0.49 | 2.58 |
(NCT00501059)
Timeframe: Until follow-up (approximate 6 years)
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| MI, stroke, CV death, UA or TIA | MI, stroke or CV death | non-fatal MI | |
| Acetylsalicylic Acid (Aspirin, BAYE4465) | 4.29 | 3.32 | 1.40 |
| Placebo | 4.48 | 3.47 | 1.56 |
The percentages of subjects with the efficacy endpoints of confirmed MI, stroke, cardiovascular death, UA and TIA are reported separately. *all other CV death without fatal MI and fatal stroke (NCT00501059)
Timeframe: Until follow-up (approximately 6 years)
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| MI | stroke | CV death* | UA | TIA | |
| Acetylsalicylic Acid (Aspirin, BAYE4465) | 1.52 | 1.20 | 0.61 | 0.32 | 0.67 |
| Placebo | 1.78 | 1.07 | 0.62 | 0.32 | 0.72 |
(NCT00501059)
Timeframe: Until follow-up (approximate 6 years)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Total | Mild | Moderate | Severe | |
| Acetylsalicylic Acid (Aspirin, BAYE4465) | 61 | 42 | 15 | 4 |
| Placebo | 29 | 22 | 5 | 2 |
The time to event was defined as the number of days from the date of randomization to the date of the event confirmed by adjudication. The numbers of days for milestones when 1%, 2%, 3% and 4% of the subjects have reached endpoint events were estimated from Kaplan-Meier-Analyses. (NCT00501059)
Timeframe: Until follow-up (approximately 6 years)
| Intervention | Days (Count of Units) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Days until 1% subjects had all-cause mortality | Days until 2% subjects had all-cause mortality | Days until 3% subjects had all-cause mortality | Days until 4% subjects had all-cause mortality | Days until 1% subjects had all cancer excl. NMSC | Days until 2% subjects had all cancer excl. NMSC | Days until 3% subjects had all cancer excl. NMSC | Days until 4% subjects had all cancer excl. NMSC | Days until 1% subjects had colon cancer | Days until 2% subjects had colon cancer | Days until 3% subjects had colon cancer | Days until 4% subjects had colon cancer | |
| Acetylsalicylic Acid (Aspirin, BAYE4465) | 838 | 1493 | 1970 | NA | 374 | 849 | 1164 | 1542 | NA | NA | NA | NA |
| Placebo | 938 | 1460 | 1963 | NA | 420 | 805 | 1276 | 1751 | NA | NA | NA | NA |
The time to Composite outcome consisting of the first occurrence of cardiovascular death, MI, or stroke (ischemic, hemorrhagic, or unknown) was defined as the number of days from the date of randomization to the date of the event confirmed by adjudication. The numbers of days for milestones when 1%, 2%, 3% and 4% of the subjects have reached endpoint events were estimated from Kaplan-Meier-Analyses. (NCT00501059)
Timeframe: Until follow-up (approximate 6 years)
| Intervention | Days (Count of Units) | |||
|---|---|---|---|---|
| Days until 1% subjects had an efficacy event | Days until 2% subjects had an efficacy event | Days until 3% subjects had an efficacy event | Days until 4% subjects had an efficacy event | |
| Acetylsalicylic Acid (Aspirin, BAYE4465) | 678 | 1167 | 1599 | 1949 |
| Placebo | 522 | 1053 | 1501 | 1930 |
The primary efficacy endpoint was a composite outcome consisting of the first occurrence of confirmed MI, stroke, cardiovascular death, UA, TIA. The time to event was defined as the number of days from the date of randomization to the date of the event confirmed by adjudication. The numbers of days for milestones when 1%, 2%, 3% and 4% of the subjects have reached endpoint events were estimated from Kaplan-Meier-Analyses. (NCT00501059)
Timeframe: Until follow-up (approximate 6 years)
| Intervention | Days (Count of Units) | |||
|---|---|---|---|---|
| Days until 1% subjects had an efficacy event | Days until 2% subjects had an efficacy event | Days until 3% subjects had an efficacy event | Days until 4% subjects had an efficacy event | |
| Acetylsalicylic Acid (Aspirin, BAYE4465) | 528 | 889 | 1225 | 1630 |
| Placebo | 381 | 796 | 1134 | 1582 |
The time to event was defined as the number of days from the date of randomization to the date of the event confirmed by adjudication. The numbers of days for milestones when 1%, 2%, 3% and 4% of the subjects have reached endpoint events were estimated from Kaplan-Meier-Analyses. (NCT00501059)
Timeframe: Until follow-up (approximately 6 years)
| Intervention | Days (Count of Units) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Days until 1% subjects had non-fatal MI | Days until 2% subjects had non-fatal MI | Days until 1% subjects had total MI | Days until 2% subjects had total MI | Days until 1% subjects had non-fatal stroke | Days until 2% subjects had non-fatal stroke | Days until 1% subjects had total stroke | Days until 2% subjects had total stroke | Days until 1% subjects had cardiovascular death | Days until 2% subjects had cardiovascular death | Days until 1% subjects had UA | Days until 2% subjects had UA | Days until 1% subjects had TIA | Days until 2% subjects had TIA | |
| Acetylsalicylic Acid (Aspirin, BAYE4465) | 1309 | NA | 1216 | 2128 | 1576 | NA | 1543 | NA | NA | NA | NA | NA | NA | NA |
| Placebo | 1085 | 2121 | 1014 | 1906 | 1650 | NA | 1627 | NA | NA | NA | NA | NA | NA | NA |
Event rate of all-Cause Mortality (ACM) or re-Hospitalization for worsening heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 24.84 |
| Placebo | 24.57 |
Event Rate of all-cause mortality (ACM), MI, or stroke were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 patient [pt]-year [yr]) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 13.44 |
| Placebo | 14.27 |
Event rate of bleeding events and required Hospitalization were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to 227 Weeks
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 1.52 |
| Placebo | 1.16 |
Event rate of cardio vascular death were assessed. CV death included deaths due to spontaneous bleeding, MI, stroke, worsening HF and arrhythmias, death due to CV procedures and sudden death. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 9.46 |
| Placebo | 9.96 |
Event rate of cardio vascular (CV) death or re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 23.32 |
| Placebo | 23.46 |
Event rate of ISTH major bleeding event were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to 227 Weeks
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 2.04 |
| Placebo | 1.21 |
Event rate due to cardio vascular events were assessed. Hospitalization for a CV Event required that participants be hospitalized (in-patient or emergency department) for greater than 24 hours and must have met the following criterion:Discharge summary with primary reason for admission listed as CV in nature (example, bleeding, arrhythmia, ACS, MI) other than HF which was captured in the HF re-hospitalization. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 13.30 |
| Placebo | 14.04 |
Event rate of re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 17.24 |
| Placebo | 17.45 |
Event rate of either fatal bleeding or bleeding into critical space with potential for permanent disability were assessed. Fatal bleeding event was death within 7 days after a bleeding event which required hospitalization or met International Society on Thrombosis and Haemostasis(ISTH) major bleeding definition criteria. Fatal bleeding events included those met criteria in 3 categories: 1: Any ISTH major bleeding event consider primary cause of death by investigator; 2: Any ISTH major bleeding event not considered to be primary cause of death by investigator but resulted in death within 7 days;3: Any bleeding event resulted in hospital stay and death within 7 days. Bleeding into critical space with potential for permanent disability included 7 critical spaces: intracranial, intraspinal, intraocular. Event rate estimated based on time to first occurrence of event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to 227 Weeks
| Intervention | Event rate per 100 patient-year (Number) | |
|---|---|---|
| Fatal Bleeding | Critical Space Bleeding with Permanent Disability | |
| Placebo | 0.22 | 0.48 |
| Rivaroxaban | 0.22 | 0.32 |
Percent incidence of all-cause mortality is reported as the percentage of participants who died due to any cause. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 7.5 |
| Placebo | 7.3 |
Percent incidence of all-cause mortality is reported as the percentage of participants who died due to any cause. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 4.7 |
| Placebo | 4.3 |
Percent incidence of CHF requiring hospitalization was reported as the percentage of participants who were admitted to the hospital for CHF. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 3.1 |
| Placebo | 3.1 |
Percent incidence of CHF requiring hospitalization was reported as the percentage of participants who were admitted to the hospital for CHF. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 2.8 |
| Placebo | 2.8 |
Chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 9.7 |
| Placebo | 13.2 |
Chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 8.6 |
| Placebo | 11.9 |
Primary composite CV endpoint of MACE plus which includes CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 9.6 |
| Placebo | 9.6 |
CV composite endpoint of MACE which includes CV-related death, nonfatal MI, or nonfatal stroke. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 10.2 |
| Placebo | 10.2 |
CV composite endpoint of MACE which includes CV-related death, nonfatal MI, or nonfatal stroke. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 8.4 |
| Placebo | 8.3 |
Primary composite CV endpoint of MACE plus which includes CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 11.4 |
| Placebo | 11.6 |
In participants not receiving insulin at baseline, time to addition of first co-interventional agent (i.e., next oral AHA or chronic insulin, where chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.) (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 21.7 |
| Placebo | 27.9 |
In participants not receiving insulin at baseline, time to addition of first co-interventional agent (i.e., next oral antihyperglycemic agent [AHA] or chronic insulin, where chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.) (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 18.9 |
| Placebo | 24.5 |
HbA1c is a measure of the percentage of glycated hemoglobin in the blood. Estimated mean difference between sitagliptin and placebo controlling for baseline HbA1c and region. (NCT00790205)
Timeframe: Baseline and up to 4 years
| Intervention | Percentage of HbA1c (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Month 4: Sitagliptin, n= 6772; Placebo, n= 6738 | Month 8: Sitagliptin, n= 6478; Placebo, n= 6414 | Month 12: Sitagliptin, n= 6448; Placebo, n= 6384 | Month 24: Sitagliptin, n= 6105; Placebo, n= 5975 | Month 36: Sitagliptin, n= 3521; Placebo, n= 3439 | Month 48: Sitagliptin, n= 1432; Placebo, n= 1383 | Month 60: Sitagliptin, n= 123; Placebo, n= 128 | |
| Placebo | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
| Sitagliptin | -0.3 | -0.2 | -0.2 | -0.1 | -0.1 | 0.0 | 0.0 |
HbA1c is a measure of the percentage of glycated hemoglobin in the blood. Estimated mean difference between sitagliptin and placebo controlling for baseline HbA1c and region. (NCT00790205)
Timeframe: Baseline and up to 4 years
| Intervention | Percentage of HbA1c (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Month 4; Sitagliptin, n=6632, Placebo, n=6588 | Month 8; Sitagliptin, n=6294, Placebo, n=6197 | Month 12; Sitagliptin, n=6217, Placebo, n=6092 | Month 24; Sitagliptin, n=5668, Placebo, n=5475 | Month 36; Sitagliptin, n=3227, Placebo, n=3083 | Month 48; Sitagliptin, n=1271, Placebo, n=1224 | Month 60; Sitagliptin, n=106, Placebo, n=108 | |
| Placebo | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | 0.0 |
| Sitagliptin | -0.3 | -0.3 | -0.2 | -0.1 | -0.1 | 0.0 | -0.1 |
Change in renal function based on eGFR using the MDRD method. (NCT00790205)
Timeframe: Baseline and up to 5 years
| Intervention | mL/min/1.73 m^2 (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Month 4; Sitagliptin, n=3949; Placebo, n=3977 | Month 8; Sitagliptin, n=3687; Placebo, n=3648 | Month 12; Sitagliptin, n=5082; Placebo, n=5015 | Month 24; Sitagliptin, n=5157; Placebo, n=5071 | Month 36; Sitagliptin, n=3037; Placebo, n=2942 | Month 48; Sitagliptin, n=1237; Placebo, n=1210 | Month 60; Sitagliptin, n=93; Placebo, n=106 | |
| Placebo | -0.8 | -0.9 | -0.5 | -1.7 | -1.6 | -2.8 | -5.7 |
| Sitagliptin | -1.8 | -2.4 | -1.8 | -3.2 | -3.8 | -4.0 | -4.2 |
Change in renal function based on estimated glomerular filtration rate [eGFR] using the Modification of Diet in Renal Disease [MDRD] method. (NCT00790205)
Timeframe: Baseline and up to 5 years
| Intervention | mL/min/1.73 m^2 (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Month 4; Sitagliptin, n= 3859; Placebo, n= 3864 | Month 8; Sitagliptin, n= 3562; Placebo, n= 3501 | Month 12; Sitagliptin, n=4912, Placebo, n=4778 | Month 24; Sitagliptin, n=4782, Placebo, n=4637 | Month 36; Sitagliptin, n=2776, Placebo, n=2614 | Month 48; Sitagliptin, n=1096, Placebo, n=1056 | Month 60; Sitagliptin, n=79, Placebo, n=88 | |
| Placebo | -0.8 | -0.9 | -0.5 | -1.7 | -1.6 | -2.8 | -6.4 |
| Sitagliptin | -1.9 | -2.5 | -1.8 | -3.1 | -3.7 | -3.7 | -3.5 |
Change from baseline reflects the difference between the urine albumin:creatinine ratio reported time point and baseline value. (NCT00790205)
Timeframe: Baseline and up to 5 years
| Intervention | g/mol Creatinine (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Month 4; n=677, n=713 | Month 8; n=658, n=624 | Month 12; n=1167, n=1115 | Month 24; n=1011, n=964 | Month 36; n=537, n=553 | Month 48; n=265, n=256 | Month 60; n=14, n=18 | |
| Placebo | -1.4 | 0.5 | 1.2 | 3.1 | 3.9 | 1.6 | 6.4 |
| Sitagliptin | -2.1 | 2.1 | 1.3 | 0.5 | 2.6 | 1.9 | -2.5 |
Change from baseline reflects the difference between the urine albumin:creatinine ratio reported time point and baseline value. (NCT00790205)
Timeframe: Baseline and up to 5 years
| Intervention | g/mol Creatinine (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Month 4; Sitagliptin, n=664; Placebo, n=688 | Month 8; Sitagliptin, n=635; Placebo, n=597 | Month 12; Sitagliptin, n=1126; Placebo, n=1059 | Month 24; Sitagliptin, n=930; Placebo, n=892 | Month 36; Sitagliptin, n=488; Placebo, n=513 | Month 48; Sitagliptin, n=238; Placebo, n=233 | Month 60; Sitagliptin, n=13; Placebo, n=17 | |
| Placebo | -1.4 | 0.2 | 1.2 | 3.2 | 4.0 | 1.5 | 4.8 |
| Sitagliptin | -2.2 | 1.7 | 0.8 | 0.7 | 2.5 | 1.3 | -2.7 |
The time, in years, from randomization to the first to occur of ischemic stroke, intracerebral hemorrhage, or death, up to a maximum of 6 years. Event rate per 100 patient years = 100*(number of subjects with event)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization until the date of the first to occur of ischemic stroke, intracerebral hemorrhage, or death, up to 6 years
| Intervention | events per 100 patient-years (Number) |
|---|---|
| Aspirin | 7.93 |
| Warfarin | 7.47 |
Time, in years, from randomization to death component of secondary composite outcome. This measure counts only deaths that were not preceded by heart failure hospitalization, myocardial infarction, ischemic stroke, or intracerebral hemorrhage. Event rate per 100 patient years = 100*(number of subjects who died)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of death component of secondary composite outcome, up to 6 years
| Intervention | events per 100 patient years (Number) |
|---|---|
| Aspirin | 4.41 |
| Warfarin | 4.43 |
Time, in years, from date of randomization to date of heart failure hospitalization, up to 6 years. Includes hospitalizations for heart failure during follow-up that were not preceded by myocardial infarction. Event rate per 100 patient years = 100*(number of subjects with heart failure hospitalization)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of heart failure hospitalization component of secondary composite outcome, up to 6 years
| Intervention | events per 100 patient years (Number) |
|---|---|
| Aspirin | 5.67 |
| Warfarin | 6.79 |
Time, in years, from date of randomization to date of intracerebral hemorrhage component of secondary composite outcome. Includes only intracerebral hemorrhages not preceded by myocardial infarction or heart failure hospitalization. Event rate per 100 patient years = 100*(number of subjects with intracerebral hemorrhage)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of intracerebral hemorrhage component of secondary composite outcome, up to 6 years
| Intervention | events per 100 patient years (Number) |
|---|---|
| Aspirin | 0.06 |
| Warfarin | 0.11 |
Ischemic stroke component of secondary composite endpoint. Includes only ischemic strokes that were not preceded by a myocardial infarction or heart failure hospitalization. The number of ischemic strokes that are components of the secondary outcome does not therefore match the number of ischemic strokes that are components of the primary outcome. Event rate per 100 patient years = 100*(number of subjects with ischemic stroke)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1)of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of ischemic stroke component of secondary composite outcome, up to 6 years
| Intervention | events per 100 patient years (Number) |
|---|---|
| Aspirin | 1.14 |
| Warfarin | 0.57 |
Time, in years, from date of randomization to date of myocardial infarction, up to 6 years. Includes only myocardial infarctions that occurred during follow-up, before any heart failure hospitalization. Event rate per 100 patient years = 100*(number of subjects with myocardial infarction)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of myocardial infarction component of secondary composite outcome, up to 6 years
| Intervention | events per 100 patient years (Number) |
|---|---|
| Aspirin | 0.87 |
| Warfarin | 0.80 |
"The time, in years, from date of randomization to the date of the first to occur of hospitalization for heart failure, myocardial infarction, ischemic stroke, intracerebral hemorrhage, or death, up to 6 years.~Event rate per 100 patient years = 100*(number of subjects with event)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25." (NCT00041938)
Timeframe: From randomization to the first to occur of hospitalization for heart failure, myocardial infarction, ischemic stroke, intracerebral hemorrhage, or death, up to a maximum of 6 years.
| Intervention | events per 100 patient-years (Number) |
|---|---|
| Aspirin | 12.15 |
| Warfarin | 12.70 |
Time, in years, from date of randomization to date of death component of primary composite outcome. Event rate per 100 patient years = 100*(number of subjects who died)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of death component of primary composite outcome, up to 6 years
| Intervention | events per 100 patient-years (Number) |
|---|---|
| Aspirin | 6.52 |
| Warfarin | 6.63 |
Time, in years, from date of randomization to date of intracerebral hemorrhage component of primary composite outcome. Event rate per 100 patient years = 100*(number of subjects with intracerebral hemorrhage)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of intracerebral hemorrhage component of primary composite outcome, up to 6 years
| Intervention | rate per 100 patient years (Number) |
|---|---|
| Aspirin | 0.05 |
| Warfarin | 0.12 |
Time, in years, from date of randomization to date of ischemic stroke component of primary composite outcome, up to 6 years. Event rate per 100 patient years = 100*(number of subjects with ischemic stroke)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of ischemic stroke component of primary composite outcome, up to 6 years
| Intervention | rate per 100 patient years (Number) |
|---|---|
| Aspirin | 1.36 |
| Warfarin | 0.72 |
Rate/100 patient-years of major hemorrhage. Includes all major hemorrhages in any patient. Major hemorrhage was defined as intracerebral, epidural, subdural, subarachnoid, spinal intramedullary, or retinal hemorrhage; any other bleeding causing a decline in the hemoglobin level of more than 2 g per deciliter in 48 hours; or bleeding requiring transfusion of 2 or more units of whole blood, hospitalization, or surgical intervention. Event rate per 100 patient years = 100*(number of major hemorrhage events)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization until end of scheduled follow-up, up to 6 years
| Intervention | events per 100 patient years (Number) |
|---|---|
| Aspirin | 0.87 |
| Warfarin | 1.78 |
Rate per 100 patient years of minor hemorrhage. Includes all minor hemorrhages. Minor hemorrhage was defined as any non-major hemorrhage. Event rate per 100 patient years = 100*(number of minor hemorrhage events)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1)of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization until the end of scheduled follow-up, up to 6 years
| Intervention | events per 100 patient-years (Number) |
|---|---|
| Aspirin | 7.34 |
| Warfarin | 11.6 |
Number of subjects with abnormal liver function test (LFT), i.e., ALT/AST>3xULN and total bilirubin > 2 x ULN (NCT00262600)
Timeframe: 36 months
| Intervention | participants (Number) |
|---|---|
| Dabigatran 110 mg | 11 |
| Dabigatran 150 mg | 14 |
| Warfarin | 21 |
Time to first occurrence of stroke or systemic embolic event. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 1.54 |
| Dabigatran 150 mg | 1.11 |
| Warfarin | 1.71 |
Time to first occurrence of stroke, SEE or all cause death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 4.85 |
| Dabigatran 150 mg | 4.32 |
| Warfarin | 5.20 |
Time to first occurrence of stroke, systemic embolic event, pulmonary embolism, myocardial infarction including silent myocardial infarction or vascular death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 4.26 |
| Dabigatran 150 mg | 3.68 |
| Warfarin | 4.35 |
"Yearly event rate of bleeds. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25~Major bleeds are adjudicated, whereas minor bleeds are investigator reported." (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) | |
|---|---|---|
| Major bleeds | Minor bleeds | |
| Dabigatran 110 mg | 2.99 | 13.16 |
| Dabigatran 150 mg | 3.55 | 14.85 |
| Warfarin | 3.81 | 16.37 |
Patients with clinical relevant abnormalities for intracerebral hemorrhage, other intracranial hemorrhage (ICH) (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage)] (Number) | |
|---|---|---|
| intracerebral hemorrhage | intracranial hemorrhage (ICH) | |
| Dabigatran 110 mg | 0.12 | 0.23 |
| Dabigatran 150 mg | 0.10 | 0.32 |
| Warfarin | 0.38 | 0.76 |
Any stroke (ischemic, parenchymal brain hemorrhage, subarachnoid or intraventricular hemorrhage) or death within 30 days after enrollment OR any stroke (ischemic, parenchymal brain hemorrhage, subarachnoid or intraventricular hemorrhage) or death within 30 days of any revascularization procedure of the qualifying symptomatic intracranial artery done during follow-up, OR an ischemic stroke in the territory of the symptomatic intracranial artery from day 31 after study entry to completion of follow-up. (NCT00576693)
Timeframe: Mean length of follow-up was 2.4 years
| Intervention | participants (Number) |
|---|---|
| Intensive Medical Management Plus Stenting | 52 |
| Intensive Medical Management Alone | 34 |
Incidence of all-cause death, non-fatal stroke, or need for mechanical support for SLVD (any component and composite) through post-operative Day 28 during and following CABG and administration of acadesine or placebo. Components defined as follows: All-cause death: Death from any cause, Non-fatal Stoke: occurrence of a stoke that was confirmed and adjudicated by Clinical Endpoints Committee that did not result in death, and Mechanical Support for SLVD: New use of any mechanical support for ≥1 hour for treatment of low cardiac output. (NCT00872001)
Timeframe: Up to Post-Operative Day 28
| Intervention | Percentage of Participants (Number) | |||
|---|---|---|---|---|
| Composite of All Events | All-Cause Death | Non-Fatal Stroke | Need for Mechanical Support for SLVD | |
| Acadesine | 4.9 | 1.9 | 1.7 | 2.2 |
| Placebo | 4.9 | 1.7 | 1.7 | 2.3 |
Incidence of cardiovascular death, non-fatal stroke, and need for mechanical support for SLVD (any component and composite) through post-operative Day 28 during and following CABG and administration of acadesine or placebo. Components defined as follows: Cardiovascular death: Death due to cardiovascular causes, Non-fatal Stroke: occurrence of a stroke that was confirmed and adjudicated by Clinical Endpoints Committee that did not result in death, and Mechanical Support for SLVD: New use of any mechanical support for ≥1 hour for treatment of low cardiac output. (NCT00872001)
Timeframe: Up to Post-Operative Day 28
| Intervention | Percentage of Participants (Number) | |||
|---|---|---|---|---|
| Composite of All Events | Cardiovascular Death | Non-Fatal Stroke | Need for Mechanical Support for SLVD | |
| Acadesine | 4.8 | 1.7 | 1.7 | 2.2 |
| Placebo (Normal Saline) | 4.7 | 1.6 | 1.7 | 2.3 |
Event rate=percent of participants with an event divided by the total participants in the arm. (NCT00496769)
Timeframe: Randomization to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)
| Intervention | Percentage of events per year (Number) |
|---|---|
| Apixaban, 2.5 or 5 mg Twice Daily | 4.21 |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 6.35 |
Event rate=percent of participants with an event divided by the total participants in the arm. Intended-treatment period=date of randomization to the efficacy cutoff date, which was to be the date on which at least 226 unrefuted original primary efficacy events occurred (date revised to May 28, 2010 following cessation of study for superior efficacy.) (NCT00496769)
Timeframe: Randomization to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)
| Intervention | Percentage of events (Number) |
|---|---|
| Apixaban, 2.5 or 5 mg Twice Daily | 1.62 |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 3.63 |
Event rate=percent of participants with an event divided by the total participants in the arm. (NCT00496769)
Timeframe: Day 1 to first bleeding event up to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)
| Intervention | Percentage of events per year (Number) |
|---|---|
| Apixaban, 2.5 or 5 mg Twice Daily | 10.85 |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 8.32 |
Event rate=percent of participants with an event divided by the total participants in the arm. (NCT00496769)
Timeframe: Randomization to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)
| Intervention | Percentage of events per year (Number) | ||
|---|---|---|---|
| All-cause death (n=111, 140) | Net clinical benefit (n=163, 220) | Vascular death (n=84, 96) | |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 4.42 | 7.13 | 3.03 |
| Apixaban, 2.5 or 5 mg Twice Daily | 3.51 | 5.23 | 2.65 |
Event rate=percent of participants with an event divided by the total participants in the arm. (NCT00496769)
Timeframe: First dose of study drug (Day 1) to the earlier of a patient's discontinuation of double-blind study drug or the attainment of at least 226 primary efficacy events up to May 28, 2010
| Intervention | Percentage of events per year (Number) | ||
|---|---|---|---|
| Major bleeding | Major or CRNM bleeding | All bleeding | |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 0.92 | 3.24 | 8.32 |
| Apixaban, 2.5 or 5 mg Twice Daily | 1.41 | 4.46 | 10.85 |
BL=baseline, LLN=lower limit of normal, ULN=upper limit of normal. Hemoglobin (g/dL), low: BL>2 or value ≤8; hematocrit(%), low: <0.75*BL; erythrocytes (*10^6 cells/μL), low: <0.75*BL; platelet count (*10^9 cells/L),low: <100*10^9 cells/L; leukocytes (*10^3 cells/μL), low if <0.8*BL and BL
Timeframe: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin, low (n=1956, 1893) | Hemoglobin, high (n=1956, 1893) | Hematocrit, low (n=1728, 1687) | Hematocrit, high (n=1728, 1687) | Erythrocytes, low (n=1728, 1687) | Erythrocytes, high (n=1728, 1687) | Platelet count, low (n=2148, 2098) | Platelet count, high (n=2148, 2098) | Leukocytes, low (n=1738, 1698) | Leukocytes, high (n=1738, 1698) | Neutrophils (absolute), low (n=2170, 2138) | Neutrophils (absolute), high (n=2170, 2138) | Eosinophils (absolute), low (n=2170, 2138) | Eosinophils (absolute), high (n=2170, 2138) | Basophils (absolute), low (n=2170, 2138) | Basophils (absolute), high (n=2170, 2138) | Monocytes (absolute), low (n=2170, 2138) | Monocytes (absolute), high (n=2170, 2138) | Lymphocytes (absolute), low (n=2170, 2138) | Lymphocytes (absolute), high (n=2170, 2138) | Alkaline phosphatase (ALP), low (n=2781, 2758) | ALP, high (n=2781, 2758) | Aspartate phosphatase (AST), low (n=2779, 2753) | AST, high (n=2779, 2753) | Alanine aminotransferase (ALT), low (n=2779, 2753) | ALT, high (n=2779, 2753) | Bilirubin (total), low (n=2781, 2758) | Bilirubin (total), high (n=2781, 2758) | Bilirubin (direct), low (n=2773, 2750) | Bilirubin (direct), high (n=2773, 2750) | Blood urea nitrogen (BUN), low (n=2201, 2172) | BUN, high (n=2201, 2172) | Creatinine, low (n=2209, 2178) | Creatinine, high (n=2209, 2178) | |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 120 | 0 | 9 | 0 | 12 | 0 | 10 | 0 | 14 | 18 | 1 | 0 | 0 | 68 | 0 | 0 | 0 | 2 | 62 | 5 | 0 | 27 | 0 | 33 | 0 | 31 | 0 | 43 | 0 | 248 | 0 | 50 | 0 | 71 |
| Apixaban, 2.5 or 5 mg Twice Daily | 131 | 0 | 13 | 0 | 12 | 0 | 7 | 0 | 12 | 14 | 2 | 0 | 0 | 48 | 0 | 0 | 0 | 0 | 52 | 4 | 0 | 34 | 0 | 28 | 0 | 23 | 0 | 30 | 0 | 241 | 0 | 42 | 0 | 67 |
LLN=lower limit of normal; ULN=upper limit of normal; BL=baseline. Sodium, serum (mEq/L):low if <0.95*BL and BL
Timeframe: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug
| Intervention | Participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sodium (serum), low (n=1768, 1740) | Sodium (serum), high (n=1768, 1740) | Potassium (serum), low (n=1763, 1737) | Potassium (serum), high (n=1763, 1737) | Chloride (serum), low (n=1768, 1740) | Chloride (serum), high (n=1768, 1740) | Calcium (total), low (n=106, 109) | Calcium (total), high (n=106, 109) | Bicarbonate, low (n=1664, 1619) | Bicarbonate, high (n=1664, 1619) | |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 6 | 2 | 8 | 28 | 3 | 1 | 0 | 0 | 0 | 0 |
| Apixaban, 2.5 or 5 mg Twice Daily | 2 | 1 | 6 | 20 | 0 | 0 | 0 | 0 | 0 | 0 |
ULN=upper limit of normal; LLN=lower limit of normal; BL=baseline. Creatine kinase (U/L), high:>5*ULN; protein, total(g/L):low if <0.90*BL when BL
Timeframe: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug
| Intervention | Participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Creatine kinase, low (n=2780, 2758) | Creatine kinase, high (n=2780, 2758) | Protein (total), low (n=103, 109) | Protein (total), high (n=103, 109) | Uric acid, low (n=386, 390) | Uric acid, high (n=386, 390) | Glucose (urine), low (n=2, 3) | Glucose (urine), high (n=2, 3) | Protein (urine), low (n=3, 5) | Protein (urine), high (n=3, 5) | Blood (urine), low (n=3, 5) | Blood (urine), high (n=3, 5) | Leukocyte esterase (urine), low (n=3,5) | Leukocyte esterase (urine), high (n=3,5) | Red blood cells (RBC) (urine), low (n=2,2) | RBC (urine), high (n=2,2) | White blood cells (urine), low (n=2,2) | WBC (urine), high (n=2,2) | |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 0 | 25 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Apixaban, 2.5 or 5 mg Twice Daily | 0 | 13 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. (NCT00496769)
Timeframe: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| AEs | SAEs | Bleeding AEs | Discontinuations due to AE | Deaths | |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 1925 | 804 | 259 | 362 | 115 |
| Apixaban, 2.5 or 5 mg Twice Daily | 1833 | 657 | 281 | 266 | 91 |
The percentage of participants is the total number of participants experiencing an all-cause death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 10.61 |
| Prasugrel: 75 Years of Age or Older | 27.04 |
| Clopidogrel: <75 Years of Age | 11.12 |
| Clopidogrel: 75 Years of Age or Older | 26.83 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 10.06 |
| Prasugrel: 75 Years of Age or Older | 24.64 |
| Clopidogrel: <75 Years of Age | 10.96 |
| Clopidogrel: 75 Years of Age or Older | 24.13 |
The percentage of participants is the total number of participants experiencing a CV death or nonfatal MI divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 9.61 |
| Prasugrel: 75 Years of Age or Older | 22.53 |
| Clopidogrel: <75 Years of Age | 10.21 |
| Clopidogrel: 75 Years of Age or Older | 22.69 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, nonfatal stroke or re-hospitalization for a recurrent UA divided by number of participants in the treatment arm. Endpoints events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 12.13 |
| Prasugrel: 75 Years of Age or Older | 26.27 |
| Clopidogrel: <75 Years of Age | 12.83 |
| Clopidogrel: 75 Years of Age or Older | 25.67 |
Brain natriuretic peptide (BNP) is secreted by the ventricles of the heart in response to hemodynamic stress and is a biomarker associated with increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 6 Months
| Intervention | picograms per milliliter (pg/mL) (Geometric Mean) | |
|---|---|---|
| Day 30 | 6 Months (n=725, 125, 701, 174) | |
| Clopidogrel: <75 Years of Age | 319.345 | 250.982 |
| Clopidogrel: 75 Years of Age or Older | 951.359 | 722.750 |
| Prasugrel: <75 Years of Age | 313.494 | 253.434 |
| Prasugrel: 75 Years of Age or Older | 1082.396 | 770.132 |
C-Reactive Protein (CRP) is a biomarker associated with inflammation and increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and Month 6
| Intervention | milligrams per liter (mg/L) (Geometric Mean) | |
|---|---|---|
| Day 30 | 6 Months (n=755, 143, 745, 178) | |
| Clopidogrel: <75 Years of Age | 2.287 | 2.149 |
| Clopidogrel: 75 Years of Age or Older | 2.226 | 1.543 |
| Prasugrel: <75 Years of Age | 2.330 | 2.272 |
| Prasugrel: 75 Years of Age or Older | 2.441 | 1.593 |
Seattle Angina Questionnaire (SAQ) is a validated, disease-specific questionnaire containing 11 questions (Q) yielding 5 summary scales related to angina: physical limitations, angina stability, angina frequency, treatment satisfaction and disease perception. In this study only angina frequency and the physical limitations scales were assessed. Anginal Frequency was assessed using Q3 and Q4 which consists of a Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how often a patient is having symptoms now. Physical limitations was assessed using Q1 which contains 9 items each assessed via Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how much a participant's condition is hampering their ability to do what they want to do. Scale scores are transformed to a 0-100 by subtracting the lowest possible score, dividing by the range of the scale, and multiplying by 100. Higher values equal better quality of life. (NCT00699998)
Timeframe: Baseline and follow-up (24 months)
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline, physical limitations | Baseline, angina frequency | 24 Months, physical limitations (n=420, 412) | 24 Months, angina frequency (n=420, 412) | |
| Clopidogrel | 67.0 | 73.1 | 74.5 | 89.5 |
| Prasugrel | 67.8 | 73.6 | 75.1 | 89.7 |
Variation in the genes encoding the cytochrome P450 (CYP) enzymes (CYP2C19) can reduce the ability to metabolize clopidogrel and a reduced platelet response and have been associated with increased rates of CV events including CV death. Participants were classified as extensive metabolizers (EM); reduced metabolizers (RM); or unknown (UNK) metabolizers based on their CYP2C19 genotype. Possible extensive metabolizer (EM) phenotypes include EM=extensive metabolizer, UM=ultra-rapid metabolizer, and EM (non-UM) that are not UM. Possible reduced metabolizer (RM) phenotypes include IM=intermediate metabolizer and PM=poor metabolizer. Genotypes associated with each predicted phenotype are presented; predicted phenotype is presented first followed by the genotype. Percentage=(number of participants with the predicted phenotype and genotype divided by the total number of participants per arm) multiplied by 100. (NCT00699998)
Timeframe: Baseline
| Intervention | percentage participants with geneotype (Number) | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UM, *1/*17 | UM, *17/*17 | EM (non-UM), *1/*1 | IM, *1/*2 | IM, *1/*3 | IM, *1/*4 | IM, *1/*6 | IM, *1/*8 | PM, *2/*2 | PM, *2/*3 | PM, *2/*4 | PM, *2/*6 | PM, *2/*8 | PM, *3/*3 | UNK, *1/*10 | UNK, *1/*13 | UNK, *1/*9 | UNK, *1/*9, *9/*17 | UNK, *13/*17 | UNK, *2/*13 | UNK, *2/*17 | UNK, *2/*9 | UNK, *3/*17 | UNK, *4/*17 | UNK, *4/*9 | UNK, *6/*17 | UNK, *8/*17 | UNK, *9/*17 | UNK, Undefined genotype | |
| Clopidogrel: <75 Years of Age | 25.1 | 5.4 | 35.7 | 19.8 | 0.5 | 0.1 | 0.0 | 0.4 | 4.3 | 0.3 | 0.2 | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.8 | 0.1 | 0.0 | 0.2 | 0.0 | 0.0 | 0.1 | 0.0 | 0.5 |
| Clopidogrel: 75 Years of Age or Older | 21.8 | 4.3 | 41.2 | 19.7 | 0.6 | 0.3 | 0.2 | 0.3 | 3.8 | 0.3 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.2 | 0.0 | 0.3 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.6 |
| Prasugrel: <75 Years of Age | 24.0 | 5.1 | 38.8 | 18.6 | 0.8 | 0.4 | 0.0 | 0.1 | 3.9 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 6.3 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.7 |
| Prasugrel: 75 Years of Age or Older | 25.0 | 3.6 | 42.1 | 18.3 | 0.6 | 0.0 | 0.2 | 0.5 | 2.2 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 6.1 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 |
Platelet aggregation was measured by as measured by Accumetrics Verify Now™ P2Y12. Results were reported in P2Y12 Reaction Units (PRU). PRU represents the rate and extent of adenosine (ADP)-stimulated platelet aggregation. Lower values indicate greater P2Y12 platelet inhibition and lower platelet activity and aggregation. ANCOVA Model was used and values were corrected for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 12 Months
| Intervention | P2Y12 Reaction Units (PRU) (Least Squares Mean) | |
|---|---|---|
| Day 30 | Month 12 (n=386, 76, 400, 103) | |
| Clopidogrel: <75 Years of Age | 193.489 | 199.003 |
| Clopidogrel: 75 Years of Age or Older | 200.285 | 181.360 |
| Prasugrel: <75 Years of Age | 93.280 | 94.529 |
| Prasugrel: 75 Years of Age or Older | 151.872 | 135.096 |
All deaths, regardless of possible relatedness, with the exception of 1 event, were adjudicated by the Clinical Endpoint Committee (CEC) and are reported in this table. The 1 event which was not adjudicated was a result of the revocation of consent by the participant prior to their death. Deaths possibly related to study drug in the opinion of the investigator are also contained in the Serious Adverse Event (SAE) module. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | participants (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Congestive Heart Failure | Cardiogenic Shock | Cardiac Rupture | Myocardial Infarction | Dysrhythmia | Stent Thrombosis | Directly Related to Revascularization-CABG or PCI | Intracranial Hemorrhage | Non-Hemorrhagic Stroke | Sudden death due to cardiovascular event | Pulmonary Embolism | Stroke, unknown type | Other Cardiovascular Event | Cardiovascular event, unknown type | Accidental | Trauma | Hemorrhage, not intracranial | Infection | Malignancy | Suicide | Other Non-Cardiovascular event | Cause unknown (nonadjudicated event) | |
| Clopidogrel: <75 Years of Age | 13 | 10 | 0 | 24 | 6 | 0 | 1 | 4 | 4 | 70 | 2 | 0 | 0 | 45 | 1 | 0 | 0 | 16 | 14 | 0 | 8 | 0 |
| Clopidogrel: 75 Years of Age or Older | 23 | 9 | 0 | 21 | 3 | 0 | 1 | 1 | 3 | 43 | 1 | 0 | 1 | 45 | 1 | 1 | 4 | 17 | 11 | 0 | 6 | 0 |
| Prasugrel: <75 Years of Age | 10 | 8 | 0 | 16 | 5 | 0 | 1 | 2 | 4 | 75 | 0 | 0 | 6 | 40 | 1 | 2 | 1 | 14 | 14 | 1 | 8 | 0 |
| Prasugrel: 75 Years of Age or Older | 21 | 4 | 1 | 24 | 2 | 0 | 1 | 1 | 4 | 39 | 1 | 1 | 1 | 41 | 0 | 3 | 1 | 21 | 7 | 0 | 4 | 1 |
Composite of CV-death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism (per adjudication). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 83 |
| Antiplatelet | 68 |
Composite of BARC 2,3 or 5 bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 148 |
| Antiplatelet | 85 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 14 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 68 |
| Antiplatelet | 63 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 105 |
| Antiplatelet | 78 |
ISTH major bleeds (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 49 |
| Antiplatelet | 30 |
The net-clinical-benefit defined as the adjudicated composite of all-cause death, any stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep vein thrombosis, non-CNS systemic embolism (efficacy); VARC life-threatening, disabling and VARC major bleeds (safety). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 137 |
| Antiplatelet | 100 |
PBE is defined according to VARC (Valve Academic Research Consortium) definitions as the adjudicated composite of: Life-threatening, disabling or major bleeding. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 46 |
| Antiplatelet | 31 |
Composite of TIMI major and minor bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 42 |
| Antiplatelet | 24 |
median 3.8 years of follow-up (NCT00086450)
Timeframe: Measured at Year 5
| Intervention | percentage of participants (Number) |
|---|---|
| Percutaneous Coronary Intervention | 26.6 |
| Coronary Artery Bypass Graft | 18.7 |
(NCT00086450)
Timeframe: Measured at Year 5
| Intervention | percentage of participants (Number) |
|---|---|
| Percutaneous Coronary Intervention | 16.3 |
| Coronary Artery Bypass Graft | 10.9 |
(NCT00086450)
Timeframe: Measured at Year 1
| Intervention | percentage of participants (Number) |
|---|---|
| Percutaneous Coronary Intervention | 16.8 |
| Coronary Artery Bypass Graft | 11.8 |
Major adverse cardiovascular and cerebrovascular events (NCT00086450)
Timeframe: Measured at Day 30
| Intervention | percentage of participants (Number) |
|---|---|
| Percutaneous Coronary Intervention | 4.8 |
| Coronary Artery Bypass Graft | 5.2 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 1.70 |
| Propensity-matched BMS | 2.61 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.69 |
| DES 12-month DAPT | 1.45 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.40 |
| DES 12-month DAPT | 1.35 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.03 |
| BMS 12-month DAPT | 0.90 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.09 |
| BMS 12-month DAPT | 1.05 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.74 |
| DES 12-month DAPT | 1.88 |
The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.53 |
| DES 12-month DAPT | 1.57 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 11.37 |
| Propensity-matched BMS | 13.24 |
(NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.04 |
| BMS 12-month DAPT | 4.69 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.68 |
| BMS 12-month DAPT | 5.48 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 5.62 |
| DES 12-month DAPT | 6.49 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 4.34 |
| DES 12-month DAPT | 5.92 |
Number of patients with any of stroke, myocardial infarction, vascular death (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 1333 |
| Clopidogrel | 1333 |
Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 1367 |
| Placebo | 1463 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 916 |
| Clopidogrel | 898 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 880 |
| Placebo | 934 |
(NCT00153062)
Timeframe: Randomization to final patient contact
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 125 |
| Placebo | 151 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Clopidogrel 300/75/75 mg + ASA Low Dose | 267 |
| Clopidogrel 300/75/75 mg + ASA High Dose | 290 |
| Clopidogrel 600/150/75 mg + ASA Low Dose | 282 |
| Clopidogrel 600/150/75 mg + ASA High Dose | 240 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel + ASA High Dose | 527 | 211 | 251 | 65 |
| Clopidogrel + ASA Low Dose | 546 | 231 | 260 | 55 |
"The primary endpoint is the first occurrence of any of the following events:~Cardiovascular death (any death with a clear cardiovascular or unknown cause),~Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal)~Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal)~reported between the randomization and Day 30 (inclusive), and validated by the blinded Event Adjudication Committee (EAC)." (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel 300/75/75 mg + ASA | 557 | 222 | 274 | 61 |
| Clopidogrel 600/150/75 mg + ASA | 522 | 226 | 237 | 59 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel 300/75/75 mg + ASA | 392 | 132 | 225 | 35 |
| Clopidogrel 600/150/75 mg + ASA | 330 | 130 | 172 | 28 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding | - Severe bleeding | - Major but not severe bleeding | |
| Clopidogrel + ASA High Dose | 282 | 216 | 73 |
| Clopidogrel + ASA Low Dose | 285 | 215 | 74 |
Major bleeding is defined as any severe bleeding (associated with any of the following: death, leading to a drop in hemoglobin ≥ 5 g/dl, significant hypotension with the need for inotropic agents, symptomatic intracranial hemorrhage, requirement for surgery or for a transfusion ≥ 4 units of red blood cells or equivalent whole blood) and other major bleeding (significantly disabling bleeding, or intraocular bleeding leading to significant loss of vision or bleeding requiring transfusion of 2-3 units of red blood cells or equivalent whole blood) after validation by the independent EAC. (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding | - Severe bleeding | - Major but not severe bleeding | |
| Clopidogrel 300/75/75 mg + ASA | 255 | 195 | 65 |
| Clopidogrel 600/150/75 mg + ASA | 313 | 236 | 83 |
This includes definite stent thrombosis (confirmed by angiography or evidence of recent thrombus determined at autopsy or by examination of tissue retrieved following thrombectomy) and probable stent thrombosis (unexplained death having occurred after intracoronary stenting or, MI related to acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any obvious cause) after validation by the EAC. (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Stent trombosis | - Definite | - Probable | |
| Clopidogrel 300/75/75 mg + ASA | 200 | 111 | 89 |
| Clopidogrel 600/150/75 mg + ASA | 135 | 58 | 77 |
The number of participants with at least one major bleeding, validated by the Event Adjudication Committee are counted over the duration of the follow-up (including after permanent discontinuation of the study drug). (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 251 |
| Placebo + ASA | 162 |
The considered event is death from any cause. The analysis is performed on the time from randomization to this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 825 |
| Placebo + ASA | 841 |
The event is the occurence of stroke (nonfatal or fatal, ischemic, hemorrhagic or of uncertain type) after validation of the Event Adjudication Committee . The analysis is performed on the time from randomization to the occurrence of this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 296 |
| Placebo + ASA | 408 |
"The primary event is the first occurence of any adjudicated component of the following cluster over the duration of follow-up :~stroke (nonfatal or fatal)~myocardial infarction (nonfatal or fatal)~non-CNS systemic embolism~vascular death~The primary efficacy analysis is performed on the time from randomization to this primary event. Numbers of patients with the composite event over the duration of the follow-up are presented by arm group." (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| All components | - Myocardial Infarction (fatal or not) | - Stroke (fatal or not) | - Non-CNS systemic embolism | - Vascular death | |
| Clopidogrel + ASA | 832 | 84 | 285 | 50 | 413 |
| Placebo + ASA | 924 | 105 | 391 | 48 | 380 |
The number of patients who died due to any cause or had a first occurrence of MI (including repeat MI) or stroke (ischemic, hemorrhagic or unknown) or severe recurrent ischemia requiring revascularization from the time of randomization to the last date of patient contact. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 83 |
| Riva 5 mg Total Daily Dose (TDD) | 23 |
| Riva 10 mg TDD | 55 |
| Riva 15 mg TDD | 27 |
| Riva 20 mg TDD | 36 |
The number of patients with the composite endpoint of cardiovascular death or MI or stroke that occurred from the time of randomization to the last date of patient contact. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 63 |
| Riva 5 mg Total Daily Dose (TDD) | 18 |
| Riva 10 mg TDD | 40 |
| Riva 15 mg TDD | 21 |
| Riva 20 mg TDD | 21 |
The number of patients who died due to any cause or had a first occurrence of MI (or repeat MI), or stroke, or severe recurrent ischemia requiring revascularization, or TIMI (major or minor bleeding) from the time of randomization to the last date of patient contact to assess the net clinical benefit of rivaroxaban. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 88 |
| Riva 5 mg Total Daily Dose (TDD) | 24 |
| Riva 10 mg TDD | 71 |
| Riva 15 mg TDD | 35 |
| Riva 20 mg TDD | 48 |
The number of patients who died due to any cause or had a first occurrence of MI (or repeat MI) or stroke from the time of randomization to the last date of patient contact. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 66 |
| Riva 5 mg Total Daily Dose (TDD) | 18 |
| Riva 10 mg TDD | 40 |
| Riva 15 mg TDD | 21 |
| Riva 20 mg TDD | 22 |
The number of patients who died due to any cause from the time of randomization to the last date of patient contact. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 18 |
| Riva 5 mg Total Daily Dose (TDD) | 11 |
| Riva 10 mg TDD | 9 |
| Riva 15 mg TDD | 4 |
| Riva 20 mg TDD | 9 |
The number of patients with a first occurrence of a TIMI clinically significant bleeding event that occurred from the time of randomization to the time of the last patient contact. TIMI clinically significant bleeding events included TIMI minor bleeding events, TIMI major bleeding events, or any bleeding that required medical attention. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 36 |
| Riva 5 mg Total Daily Dose (TDD) | 17 |
| Riva 10 mg TDD | 109 |
| Riva 15 mg TDD | 43 |
| Riva 20 mg TDD | 89 |
Number of deaths from any cause. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints. (NCT00234065)
Timeframe: From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 13 |
| Aspirin | 13 |
The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction, or occurrence of cerebral haemorrhage, subarachnoid haemorrhage, transient ischaemic attack, angina pectris, myocardial infarction, heart failure, or haemorrhage requiring hospital admission. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints. (NCT00234065)
Timeframe: From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 138 |
| Aspirin | 186 |
The endpoint in this measure is a composite endpoint of the first occurrence of cerebral haemorrhage, subarachnoid haemorrhage or haemorrhage requiring hospital admission. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints. (NCT00234065)
Timeframe: From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 23 |
| Aspirin | 57 |
The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction or the first occurrence of transient ischaemic attack. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints. (NCT00234065)
Timeframe: From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 86 |
| Aspirin | 103 |
(NCT00234065)
Timeframe: From start of treatment to end of follow-up period (mean follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 72 |
| Aspirin | 88 |
The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction, or occurrence of cerebral haemorrhage or subarachnoid haemorrhage. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints. (NCT00234065)
Timeframe: From start of treatment to end of follow-up period ( follow-up periods : 29 months [Standard Deviation 16, range 1-59 months])
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 82 |
| Aspirin | 119 |
Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0-12 hours after the dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Apixaban 2.5 mg | 59.7 |
| Apixaban 5 mg | 97.9 |
Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0-12 hours after the dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Apixaban 2.5 mg | 28.2 |
| Apixaban 5mg | 49.7 |
Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0 to 12 hours after dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose
| Intervention | ng*h/mL (Geometric Mean) |
|---|---|
| Apixaban 2.5 mg | 507 |
| Apixaban 5mg | 868 |
"Assess the safety of apixaban versus warfarin regarding ISTH major bleeding or clinically relevant non-major bleeding events in patients with NVAF (nonvalvular atrial fibrillation) and ESRD (end-stage renal disease) on hemodialysis.~Major bleeding event is defined as:Acute clinically overt bleeding (including access site related bleeding) accompanied by 1 or more of the following: Decrease in Hgb of 2g/dL or more with overt bleeding; Transfusion of 2 or more units of packed RBCs in the setting of an overt bleeding event; Bleeding within a critical site. Hemorrhagic stroke (primary or infarction with hemorrhagic conversion) were classified as major bleeds.~Non-major bleeding event is defined as: Acute or sub-acute clinically overt bleeding (including access site related bleeding) that does not meet criteria for major bleeding & results in Hospital admission for bleeding, physician guided medical or surgical treatment for bleeding, or change in antithrombotic therapy" (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 21 |
| Warfarin | 16 |
Evaluate mortality rates for those participants randomized to warfarin and apixaban in patients with NVAF and ESRD on hemodialysis (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 21 |
| Warfarin | 13 |
"Adjudcated stroke defined as a new, non-traumatic episode of focal or global neurological dysfunction of sudden onset caused by central nervous system (CNS) vascular injury as a result of hemorrhage or infarction and not due to a readily identifiable non-vascular cause (i.e. brain tumor). CNS includes brain, spinal cord and retina. The required duration of the deficit is ≥ 24 hours.~Events with neurologic deficit lasting for < 24 hours and an imaging modality showing evidence of an acute stroke will be counted as stroke as well.~A retinal ischemic event (embolism, infarction) will be considered a stroke" (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 2 |
| Warfarin | 2 |
Number of participants experiencing adjudicated stroke or systemic embolism. (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 2 |
| Warfarin | 2 |
"Evaluate those experiencing stroke, systemic embolism, ISTH major bleeding, or all-cause mortality for those randomized to warfarin and apixaban in patients with NVAF and ESRD on hemodialysis~Definitions of stroke and systemic embolism are provided under the measurement description of the secondary outcomes for each individual event. Definition of major bleed is provided in outcome measurement description of the primary outcome measure." (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 27 |
| Warfarin | 29 |
"Adjudicated diagnosis of systemic arterial embolism (Non-pulmonary, non-cranial events) will require a positive clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), which is supported by evidence of embolism/thrombosis from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.~Clinical presentation would include:~Abrupt development of pain, absent pulses, pallor, and/or paresis in an extremity (at least an entire digit) without previous severe claudication or findings of severe peripheral vascular disease.~Renal embolism will be diagnosed when sudden flank pain or a change in renal laboratory findings occurred.~Abdominal vascular/visceral embolism was considered definite if acute abdominal symptoms or referred symptoms developed along with a change in abdominal examination or appropriate laboratory values." (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 0 |
| Warfarin | 0 |
Evaluate days between time from initiation to discontinuation of randomized therapy. (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Days (Mean) |
|---|---|
| Apixaban | 304.4 |
| Warfarin | 279.6 |
ACS contains acute myocardial infarction (MI), unstable angina and sudden cardiac death. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 9 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 16 |
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 12 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 7 |
This is a composite endpoint of cerebral infarction, brain (cerebral) hemorrhage, subarachnoid haemorrhage and major bleeding. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 71 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 55 |
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 45 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 32 |
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 13 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 13 |
This is a composite endpoint of cerebral infarction, transient ischemic attack (TIA), acute myocardial infarction (MI), unstable angina and sudden death attributable to thromboembolism. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 57 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 51 |
This endpoints were defined as pulmonary embolism, retinal vascular disorder, deep vein thrombosis, peripheral artery obstruction and vascular intervention. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 11 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 6 |
This is a composite endpoint of cerebral infarction, brain (cerebral) hemorrhage and subarachnoid haemorrhage. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 57 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 39 |
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 0 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 1 |
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 3 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 3 |
Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 901 |
| CLOPIDOGREL | 1065 |
Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1290 |
| CLOPIDOGREL | 1456 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 569 |
| CLOPIDOGREL | 668 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 864 |
| CLOPIDOGREL | 1014 |
Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 961 |
| CLOPIDOGREL | 929 |
Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 619 |
| CLOPIDOGREL | 654 |
Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 329 |
| CLOPIDOGREL | 341 |
Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 399 |
| CLOPIDOGREL | 506 |
Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 353 |
| CLOPIDOGREL | 442 |
Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1339 |
| CLOPIDOGREL | 1215 |
Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 504 |
| CLOPIDOGREL | 593 |
Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 362 |
| CLOPIDOGREL | 306 |
Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 235 |
| CLOPIDOGREL | 180 |
Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 125 |
| CLOPIDOGREL | 106 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 21 |
| CLOPIDOGREL | 16 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 84 |
| CLOPIDOGREL | 51 |
Bleeding events were adjudicated by the Adjudication Committee and classified according to Thrombolysis in Myocardial Infarction (TIMI) major, minor, minimal, and International Society on Thrombosis and Hemostasis (ISTH) major and clinically relevant non-major bleeding (CRNM) criteria. The adjudicated results based on TIMI and ISTH classifications, and programmatically identified events (not adjudicated) according to Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) classification were used in the analyses of bleeding endpoints. GUSTO Bleed Criteria included Severe or life-threatening: Intracranial hemorrhage, or bleeding that causes hemodynamic compromise requiring intervention; Moderate: Bleeding that requires a blood transfusion, but does not result in hemodynamic compromise; Mild: Bleeding that does not meet criteria for either severe or moderate bleeding. Treatment Period=events with onset from first dose to last dose plus 2 days. (NCT00831441)
Timeframe: From first dose to first occurrence of event (Bleeding) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 16.33 |
| Apixaban 5 mg BID | 39.98 |
Event rate was percent of participants with an event of cardiovascular (CV) death, myocardial infarction (MI), or ischemic stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Study was terminated early and last patient, last visit was in Year 2. Only events confirmed by the adjudication committee were included in the analyses. CV death included deaths due to CV causes (eg, cardiogenic shock, heart failure, arrhythmia/sudden death, cardiac rupture, ischemic stroke, pulmonary embolism, venous/arterial thrombotic events) and other sudden deaths for which an alternative cause was not identified. Intended Treatment Period: the period that started on the day of randomization and ended at the efficacy cut-off date (cut-off date: the date all sites were informed that study drug should be discontinued for all participants, 18 November 2010). (NCT00831441)
Timeframe: Randomization (Day 1) to first event (CV death, MI, ischemic stroke), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 13.96 |
| Apixaban 5 mg BID | 13.20 |
"Cause of death was determined by the principal condition that caused the death, not the immediate mode of death.~CV death: included deaths due to CV causes. Non-CV death: included non-CV deaths caused primarily by a malignancy, infection, bleeding, trauma, non-CV system organ failure, or non-CV surgery. Unknown: included deaths that were not attributable to one of the above categories of CV death or to a non-CV cause. MI accounted whether the participant had a recent PCI or CABG surgery. Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause. Only events confirmed by the adjudication committee were included in analyses. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination)." (NCT00831441)
Timeframe: Randomization (Day 1) to first event (All Cause Death, MI, or Stroke), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 15.65 |
| Apixaban 5 mg BID | 15.48 |
Event rate was percent of participants with an event of CV death, fatal bleed, MI, or stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. CV death included deaths due to CV causes; Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause; Fatal bleeding defined as bleeding that Adjudication Committee determined was the primary cause of death or contributed directly to death; MI took into account whether the participant had a recent PCI or CABG surgery. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination). (NCT00831441)
Timeframe: Randomization (Day 1) to first event (CV death, Fatal Bleed, MI, or stroke), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 14.27 |
| Apixaban 5 mg BID | 13.97 |
Event rate was percent of participants with an event of CV death, MI, unstable angina (UA), or ischemic stroke (number of participants with event/number randomized) per 100-pt years. Only events confirmed by the adjudication committee were included in the analyses. Each type of event was counted once per participant, but participants could have been counted in multiple categories. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination). (NCT00831441)
Timeframe: Randomization (Day 1) to first event (CV death, MI, UA, Ischemic Stroke, up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 17.95 |
| Apixaban 5 mg BID | 16.92 |
ISTH Major bleed: acute clinically overt bleeding accompanied by one or more of the following: A decrease in Hgb of 2 g/dL or more over 24 hours; A transfusion of 2 or more units of packed RBCs; Bleeding that occurs in at least one of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; Bleeding that was fatal. CRNM: acute clinically overt bleeding that did not satisfy additional criteria required for the bleeding event to be defined as a major bleeding event and meets at least one of the following: Hospital admission for bleeding; Physician guided medical or surgical treatment for bleeding; Change in anti-thrombotic treatment (anticoagulant or antiplatelet) therapy. Bleeding events were adjudicated by the Adjudication Committee. Treatment Period=events with onset from first dose to last dose plus 2 days. (NCT00831441)
Timeframe: From first dose to first occurrence of event (ISTH major or CRNM bleed) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 2.29 |
| Apixaban 5 mg BID | 6.15 |
ISTH Criteria: Acute clinically overt bleeding defined as new onset, visible bleeding or signs or symptoms suggestive of bleeding confirmed by imaging techniques, which can detect the presence of blood (eg, ultrasound, CT, MRI). Major bleeding: acute clinically overt bleeding accompanied by one or more of the following: A decrease in Hgb of 2 g/dL or more over 24 hours; A transfusion of 2 or more units of packed red blood cells (RBCs); Bleeding that occurs in at least one of the following sites: intracranial, intraspinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; Bleeding that was fatal. Bleeding events were adjudicated by the Adjudication Committee. Event rate was percent of participants with an event (number with event/number randomized) per 100-pt years. Treatment Period=events with onset from first dose to last dose plus 2 days. (NCT00831441)
Timeframe: From first dose to first occurrence of event (ISTH major bleed) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 2.04 |
| Apixaban 5 mg BID | 5.13 |
TIMI Major Bleed Criteria: Fatal bleeding, intracranial hemorrhage, and clinically overt bleeding with a hemoglobin (Hgb) drop of ≥ 5 grams per deciliter (g/dL), or ≥15% absolute decrease in hematocrit. To account for transfusions, Hgb measurements were adjusted for transfusions. A transfusion of 1 unit of blood was assumed to result in an increase by 1 g/dL in Hgb or 3% in hematocrit. Event rate was percent of participants with an event of Major Bleed as per TIMI (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Treatment Period=events with onset from first dose to last dose plus 2 days. (NCT00831441)
Timeframe: From first dose to first occurrence of event (TIMI major bleeding) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 0.91 |
| Apixaban 5 mg BID | 2.40 |
MI took into account whether the participant had a recent percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery. Selected key criteria: Elevation of cardiac biomarkers (eg, Creatine Kinase MB fraction (CKMB), Troponin T, Troponin I) above the upper reference limit (URL) plus ischemic symptoms, ECG changes, or imaging evidence of new loss of viable myocardium or new regional wall motion abnormality; Death of CV etiology with new ST-segment elevation or left bundle branch block (LBBB) or fresh intracoronary thrombus by angiography or at autopsy occurring before biomarkers could be obtained or before their appearance in the blood; Following a PCI, elevation of cardiac biomarkers more than 3*URL; Following CABG surgery, elevation of cardiac biomarkers more than 5*URL; New, significant (≥0.04 s) Q waves in ≥2 contiguous leads; Pathologic findings of acute MI. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off notice. (NCT00831441)
Timeframe: Randomization (Day 1) to first event (MI), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 9.20 |
| Apixaban 5 mg BID | 8.59 |
Stent thrombosis: Definite stent thrombosis considered to have occurred by either angiographic or pathological confirmation; Probable stent thrombosis considered to have occurred in the following cases: any unexplained death within the first 30 days after stent implantation; irrespective of the time after the procedure, any MI that was related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause; Possible stent thrombosis considered to have occurred with any unexplained death from 30 days after intracoronary stenting until end of study (in Year 2). Event rate was percent of participants with an event of stent thrombosis (number with event/number randomized) per 100-pt years. Only events confirmed by the adjudication committee were included in the analyses. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off notice of study termination. (NCT00831441)
Timeframe: Randomization (Day 1) to first event (stent thrombosis), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 2.21 |
| Apixaban 5 mg BID | 1.61 |
Event rate was percent of participants with an event of stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause (ie, brain tumor). All strokes were classified as hemorrhagic (documentation on imaging (eg computed tomography scan or magnetic resonance imaging) of hemorrhage in the cerebral parenchyma, or a subdural or subarachnoid hemorrhage), non-hemorrhagic/ischemic stroke, ischemic stroke with hemorrhagic conversion, or type unknown. Intended Treatment Period: the period that started on the day of randomization (Day 1) and ended at the efficacy cut-off date (notification of study termination). (NCT00831441)
Timeframe: Randomization (Day 1) to first event (stroke), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 1.85 |
| Apixaban 5 mg BID | 1.65 |
Unstable Angina (UA) defined as worsening or recurrent severe or repetitive angina symptoms at rest lasting at least 10 minutes with at least 2 of the following: New and dynamic electrocardiogram (ECG) changes; angina symptoms leading to inpatient hospitalization; angina symptoms leading to an unplanned or urgent cardiac catheterization, with or without revascularization, that showed evidence of hemodynamically and clinically significant stenosis. Event rate was percent of participants with an event of unstable angina (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Intended Treatment Period: the period that started on the day of randomization and ended at the efficacy cut-off date (cut-off date: the date all sites were informed that study drug should be discontinued for all participants, 18 November 2010). (NCT00831441)
Timeframe: Randomization (Day 1) to first event of UA, up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 4.21 |
| Apixaban 5 mg BID | 3.95 |
The primary aim of CREST is to assess if the efficacy of CAS differs from that of CEA in preventing stroke, myocardial infarction and death during a 30-day peri-procedural period, or ipsilateral stroke over the follow-up period in patients with symptomatic (>=50%) or asymptomatic (>=60%) extracranial carotid stenosis. Four-year follow-up, proportions reflecting the absolute efficacy of carotid-artery stenting (CAS) over that of carotid endarterectomy (CEA) were based on Kaplan-Meier survival estimates at the end of the 4 years. (NCT00004732)
Timeframe: 30 days and 4 years
| Intervention | Percentage (Mean) |
|---|---|
| Carotid-Artery Stenting | 7.2 |
| Carotid Endarterectomy | 6.8 |
4-year follow-up, proportions reflecting the absolute efficacy of carotid-artery stenting (CAS) over that of carotid endarterectomy (CEA) were based on Kaplan-Meier survival estimates at the end of the 4 years. (NCT00004732)
Timeframe: 4 years
| Intervention | Percentage (Mean) | |
|---|---|---|
| Men | Women | |
| Carotid Endarterectomy | 6.8 | 6.7 |
| Carotid-Artery Stenting | 6.2 | 8.9 |
A Bayesian model allowed for sequential evaluation of the primary endpoints, event rates reported per 100 patient-years (calculated as 100*N events/Total patient-years) (NCT00129545)
Timeframe: 5 years
| Intervention | events per 100 pt yrs (Number) |
|---|---|
| Implantable Device | 2.2 |
| Warfarin Control | 3.7 |
Implant procedure success is defined as the delivery and release of a WATCHMAN Device into the LAA. (NCT00129545)
Timeframe: Initial implant procedure
| Intervention | percentage of implant attempts (Number) |
|---|---|
| WATCHMAN | 90.9 |
Serious bleeding events evaluated by the Clinical Events Committee included pericardial effusion requiring drainage, cranial bleeding events due to any source, gastrointestinal bleeds requiring transfusion, and any bleeding related to the device or procedure that necessitates an operation. (NCT00129545)
Timeframe: 5 years
| Intervention | Events per 100 pt-yrs (Number) |
|---|---|
| Implantable Device | 3.5 |
| Warfarin Control | 3.2 |
Changes in Heme oxygenase (HO-1) a downstream target of nitric oxide (NO) formation. (NCT00272311)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| Arm 1 of 5 Randomized Treatment Arms | 27.6 |
| Arm 2 of 5 Randomized Treatment Arms | 27.0 |
| Arm 3 of 5 Randomized Treatment Arms | 31.4 |
| Arm 4 of 5 Randomized Treatment Arms | 25.7 |
| Arm 5 of 5 Randomized Treatment Arms | 28.3 |
(NCT02914795)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Non-resuscitated Myocardial Infarction | 0 |
| Resuscitated Myocardial Infarction | 3 |
Median (Inter-Quartile Range) Collagen AUC values on Day 3 measured with optical aggregometry The more light signal is detected, the better thrombocyte function is. (NCT02914795)
Timeframe: day 3
| Intervention | AU*min (Median) |
|---|---|
| Non-resuscitated Myocardial Infarction | 109 |
| Resuscitated Myocardial Infarction | 253.8 |
Heme oxygenase a downstream target of nitric oxide formation (NCT00272337)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| 1 of 5 Randomized Treatment Arms | 10.0 |
| 2 of 5 Randomized Treatment Arms | 11.2 |
| 3 of 5 Randomized Treatment Arms | 10.0 |
| 4 of 5 Randomized Treatment Arms | 11.0 |
| 5 of 5 Randomized Treatment Arms | 9.6 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 4 |
| Placebo | 5 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 1 |
| Placebo | 0 |
Postoperative angiogram 12 months post-CABG (NCT00228423)
Timeframe: One year following surgery
| Intervention | percentage (Number) |
|---|---|
| 75mg Clopidogrel | 94.3 |
| Placebo | 93.2 |
IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed (NCT00228423)
Timeframe: One year following surgery
| Intervention | mm (Mean) |
|---|---|
| 75mg Clopidogrel | 4.1 |
| Placebo | 4.5 |
(NCT00000479)
Timeframe: Average follow-up 10.1 years
| Intervention | participants (Number) | |
|---|---|---|
| Total invasive cancer | Cancer death | |
| Aspirin + Vitamin E | 716 | 152 |
| Aspirin Only | 722 | 132 |
| Both Placebos | 706 | 143 |
| Vitamin E Only | 721 | 156 |
(NCT00000479)
Timeframe: Average follow-up 10.1 years
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Major cardiovascular event | Stroke | Myocardial infarction | Cardiovascular death | |
| Aspirin + Vitamin E | 232 | 108 | 102 | 54 |
| Aspirin Only | 245 | 113 | 96 | 66 |
| Both Placebos | 272 | 133 | 99 | 74 |
| Vitamin E Only | 250 | 133 | 94 | 52 |
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 189 |
| Placebo Arm | 230 |
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1078 |
| Placebo Arm | 1153 |
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 78 |
| Placebo Arm | 101 |
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 303 |
| Placebo Arm | 353 |
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 134 |
| Placebo Arm | 152 |
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 141 |
| Placebo Arm | 166 |
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 42 |
| Placebo Arm | 30 |
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 352 |
| Placebo Arm | 325 |
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 264 |
| Placebo Arm | 309 |
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 668 |
| Placebo Arm | 754 |
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1506 |
| Placebo Arm | 1564 |
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 214 |
| Placebo Arm | 246 |
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 26 |
| Placebo Arm | 25 |
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 54 |
| Placebo Arm | 43 |
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 9 |
| Placebo Arm | 12 |
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 23 |
| Placebo Arm | 30 |
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 290 |
| Placebo Arm | 333 |
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 8 |
| Placebo Arm | 21 |
"The primary effectiveness endpoint was a composite of the two following outcomes:~Stroke in the same territory (distal to the target lesion) as the presenting event within 12 months of randomization~Hard Transient Ischemic Attack (TIA) in the same territory (distal to the target lesion) as the presenting event from day 2 through month 12 post-randomization~A subject was deemed to be a primary endpoint success if neither of these outcomes occurred.~The Kaplan-Meier success rate at 12-months post-operatively was calculated with Kaplan-Meier time-to-event methodology, where the time variable for patients who were successful (no stroke within 12 months or hard TIA between 2 days and 12 months) was censored at the time of last follow-up, and the time variable for patients who were not successful (had a stroke within 12 months or hard TIA between 2 days and 12 months) was censored at the time of the first event (stroke with 12 months or hard TIA between 2 days and 12 months)." (NCT00816166)
Timeframe: One Year
| Intervention | percent probability (Number) |
|---|---|
| Stent Group | 62.24 |
| Medical Therapy Group | 83.68 |
"Any stroke or neurological death at NCT00929383)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Patients Treated With a Wingspan Stent | 12 |
The cumulative stroke rate at 12 months (any stroke or neurological death /= 31 days is 15.9% or 13 events per 82 patients (NCT00929383)
Timeframe: 12 months
| Intervention | participants (Number) |
|---|---|
| Patients Treated With a Wingspan Stent | 13 |
The rate of recurrent ischemic stroke from 31 days to 12 months post procedure was 1.3% or 1 event per 77 patients analyzed. (NCT00929383)
Timeframe: 12 Months
| Intervention | participants (Number) |
|---|---|
| Patients Treated With a Wingspan Stent | 1 |
"The rate of restenosis at 12 months was defined as the degree of residual stenosis greater than 50% as determined by the study sites using the WASID method. There was a 10.4% rate of restenosis >50% or 8 patients out of 77 analyzed. The differences in this analysis population N=77 vs. ITT N= 82 populations results from exclusion of N=4 patients with no stent implanted and N=1 patient who died prior to any follow up measures of restenosis.~The WASID method is a standardized protocol for measuring intracranial arterial stenosis.~[1-(Dstenosis/Dnormal)] x100=% stenosis (where D=vessel diameter)" (NCT00929383)
Timeframe: 12 Months
| Intervention | participants (Number) |
|---|---|
| Patients Treated With a Wingspan Stent | 8 |
The number of Wingspan Stents successfully deployed across the target lesion. (NCT00929383)
Timeframe: Peri-procedural
| Intervention | patients w stent implanted (Number) |
|---|---|
| Patients Treated With a Wingspan Stent | 78 |
"Anti-drug antibodies were measured at baseline and 3 month after IMP application.~Number of patients with positive anti-drug antibodies compared to baseline are counted." (NCT01645306)
Timeframe: 3 month (+/- 1 month) after IMP application
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| 40 mg Revacept | 0 |
| 120 mg Revacept | 0 |
patients with any stroke & TIA, myocardial infarction & percutaneous coronary intervention (PCI), death or bleeding within one year (365 days) after IMP application. (NCT01645306)
Timeframe: 365 days after IMP application
| Intervention | Number of Events (Number) |
|---|---|
| Placebo | 19 |
| 40 mg Revacept | 15 |
| 120 mg Revacept | 10 |
patients with major bleedings occuring within 90 days after IMP application (NCT01645306)
Timeframe: 90 days after IMP application
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 5 |
| 40 mg Revacept | 6 |
| 120 mg Revacept | 4 |
The number of new diffusion weighted imaging (DWI) lesion(s) reported. (1 day after intervention compared to baseline). (NCT01645306)
Timeframe: 1 day post intervention
| Intervention | Number of new lesions (Mean) |
|---|---|
| Placebo | 1.2 |
| 40 mg Revacept | 1.0 |
| 120 mg Revacept | 0.6 |
patients with any stroke or TIA occuring within 90 days after IMP application. (NCT01645306)
Timeframe: 90 days after IMP application
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 6 |
| 40 mg Revacept | 6 |
| 120 mg Revacept | 4 |
All adverse events were assessed during complete study period (~ 1 year after IMP application). (NCT01645306)
Timeframe: ~ 365 days after IMP application (whole study period)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| patients with adverse events | patients with drug related AEs | patients with serious AEs | patients with drug related serious AEs | patients with AE with fatal outcome events | |
| 120 mg Revacept | 32 | 2 | 15 | 0 | 1 |
| 40 mg Revacept | 41 | 10 | 17 | 4 | 0 |
| Placebo | 35 | 4 | 17 | 1 | 0 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to endothelial function. (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 14.06 |
| Placebo Follow up | 13.84 |
| Aspirin Baseline | 11.18 |
| Aspirin Randomization | 12.11 |
| Clopidogrel Baseline | 13.06 |
| Clopidogrel Randomization | 12.29 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to immune activity (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 15.53 |
| Placebo Follow up | 15.43 |
| Aspirin Baseline | 13.15 |
| Aspirin Follow up | 14.96 |
| Clopidogrel Baseline | 16.03 |
| Clopidogrel Follow up | 14.85 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to inflammation (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 69.45 |
| Placebo Follow up | 80.33 |
| Aspirin Baseline | 82.04 |
| Aspirin Randomization | 62.00 |
| Clopidogrel Baseline | 78.86 |
| Clopidogrel Randomization | 39.88 |
(NCT02559414)
Timeframe: Baseline, 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 69.45 |
| Placebo Follow up | 80.33 |
| Aspirin Baseline | 82.04 |
| Aspirin Randomization | 62.00 |
| Clopidogrel Baseline | 78.86 |
| Clopidogrel Randomization | 39.88 |
The primary objective of these analyses will be to compare the effects of aspirin versus control and clopidogrel versus control for the outcome of platelet activity. Aspirin is expected to decrease arachidonic acid-induced platelet aggregation by 50% versus control. Clopidogrel is expected to decrease ADP-induced platelet aggregation by 50% versus control. (NCT02559414)
Timeframe: Baseline, 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 72.35 |
| Placebo Follow up | 79.11 |
| Aspirin Baseline | 72.79 |
| Aspirin Randomization | 26.77 |
| Clopidogrel Baseline | 71.07 |
| Clopidogrel Randomization | 65.00 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
The endpoint in this measure is a combination of all-cause death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 692 |
| Clopidogrel | 822 |
The endpoint in this measure is a combination of CV death, nonfatal MI, nonfatal stroke, or rehospitalization for cardiac ischemic events. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 797 |
| Clopidogrel | 938 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 502 | 573 |
| Prasugrel | 389 | 462 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. The data is presented by the study population, which is represented as follows: 1) subjects who presented with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI), 2) subjects who presented with ST segment elevation myocardial infarction (STEMI), and 3) all subjects with acute coronary syndromes (ACS) (i.e. all subjects with UA/NSTEMI or STEMI). (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) | ||
|---|---|---|---|
| UA/NSTEMI (n=5044, n=5030) | STEMI (n=1769, n=1765) | All ACS (n=6813, n=6795) | |
| Clopidogrel | 565 | 216 | 781 |
| Prasugrel | 469 | 174 | 643 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or UTVR. Results are reported for the All ACS subject population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 504 | 588 |
| Prasugrel | 399 | 472 |
TIMI classification for major and minor bleeding in the subset of subjects who did not undergo a coronary artery bypass operation (CABG) were defined as follows: Major bleeding: any intracranial hemorrhage (ICH) OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 grams/deciliter (gm/dL)from baseline. Minor Bleeding: any clinically overt bleeding associated with a fall in Hgb of ≥3 gm/dL but <5 gm/dL from baseline. Major bleeding events were further examined as events that were deemed life threatening and/or fatal. (NCT00097591)
Timeframe: First dose of study drug up to 15 months (while at risk)
| Intervention | Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| TIMI Major or Minor Bleeding | TIMI Major Bleeding | TIMI Major Bleeding - Life-threatening (LT) | LT - Fatal | LT - Symptomatic intracranial hemorrage (ICH) | LT - Requiring inotropes | LT - Requiring surgical intervention | LT - Requiring transfusion (>=4 units) | TIMI Minor Bleeding | |
| Clopidogrel | 231 | 111 | 56 | 5 | 17 | 8 | 19 | 30 | 125 |
| Prasugrel | 303 | 146 | 85 | 21 | 19 | 21 | 19 | 45 | 164 |
Total number of deaths, cardiovascular deaths, non-fatal myocardial infarctions, ischemic strokes and critical limb ischemia. (NCT00761969)
Timeframe: 5 years:
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Death of all causes | Cardiovascular death | Non-fatal myocardial infarction | Non-fatal ischemic stroke | Critical limb ischemia | |
| Control | 47 | 17 | 21 | 14 | 0 |
| Peripheral Arterial Disease | 112 | 51 | 50 | 22 | 11 |
Incidence of coronary, carotid and peripheral arterial revascularization procedures (NCT00761969)
Timeframe: 5 years
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Peripheral arterial revascularization | Coronary revascularization | carotid revascularization | Abdominal aortic revascularization | |
| Control | 2 | 20 | 8 | 0 |
| Peripheral Arterial Disease | 183 | 64 | 31 | 6 |
597 reviews available for aspirin and Stroke
| Article | Year |
|---|---|
Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events - A Review on Vorapaxar.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Peripheral Arterial Di | 2023 |
Efficacy and safety of clopidogrel and/or aspirin for ischemic stroke/transient ischemic attack: An overview of systematic reviews and meta-analysis.
Topics: Aspirin; Brain Ischemia; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hu | 2021 |
Oral antiplatelet therapy for acute ischaemic stroke.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; Randomized Contro | 2022 |
Antiplatelet Use in Ischemic Stroke.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Stroke; Platelet Aggre | 2022 |
Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment.
Topics: Aspirin; Constriction, Pathologic; Humans; Intracranial Arteriosclerosis; Platelet Aggregation Inhib | 2022 |
Platelet Biomarkers in Patients with Atherosclerotic Extracranial Carotid Artery Stenosis: A Systematic Review.
Topics: Aspirin; Biomarkers; Blood Platelets; Carotid Stenosis; Humans; Platelet Aggregation Inhibitors; Str | 2022 |
Editor's Choice - Peri-Operative Outcomes of Carotid Endarterectomy are Not Improved on Dual Antiplatelet Therapy vs. Aspirin Monotherapy: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Carotid Stenosis; Endarterectomy, Carotid; Hematoma; Hemorrhage; Hemorrhagi | 2022 |
P2Y12 inhibitors plus aspirin for acute treatment and secondary prevention in minor stroke and high-risk transient ischemic attack: A systematic review and meta-analysis.
Topics: Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Ischemic Stroke; Platelet Ag | 2022 |
Duration and kind of dual antiplatelet therapy for acute coronary syndrome patients: a network meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Middle Aged; Myocardial Infarctio | 2023 |
Clopidogrel Vs Aspirin Monotherapy Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.
Topics: Aspirin; Clopidogrel; Death; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; P | 2023 |
Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Humans; Ischemic Attack, Transient; | 2022 |
Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement.
Topics: Adult; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Computer Simulation; Hemorrhage; Huma | 2022 |
Review and update of the concept of embolic stroke of undetermined source.
Topics: Administration, Oral; Anticoagulants; Aspirin; Embolic Stroke; Humans; Intracranial Embolism; Ischem | 2022 |
Review and update of the concept of embolic stroke of undetermined source.
Topics: Administration, Oral; Anticoagulants; Aspirin; Embolic Stroke; Humans; Intracranial Embolism; Ischem | 2022 |
Review and update of the concept of embolic stroke of undetermined source.
Topics: Administration, Oral; Anticoagulants; Aspirin; Embolic Stroke; Humans; Intracranial Embolism; Ischem | 2022 |
Review and update of the concept of embolic stroke of undetermined source.
Topics: Administration, Oral; Anticoagulants; Aspirin; Embolic Stroke; Humans; Intracranial Embolism; Ischem | 2022 |
Review and update of the concept of embolic stroke of undetermined source.
Topics: Administration, Oral; Anticoagulants; Aspirin; Embolic Stroke; Humans; Intracranial Embolism; Ischem | 2022 |
Review and update of the concept of embolic stroke of undetermined source.
Topics: Administration, Oral; Anticoagulants; Aspirin; Embolic Stroke; Humans; Intracranial Embolism; Ischem | 2022 |
Review and update of the concept of embolic stroke of undetermined source.
Topics: Administration, Oral; Anticoagulants; Aspirin; Embolic Stroke; Humans; Intracranial Embolism; Ischem | 2022 |
Review and update of the concept of embolic stroke of undetermined source.
Topics: Administration, Oral; Anticoagulants; Aspirin; Embolic Stroke; Humans; Intracranial Embolism; Ischem | 2022 |
Review and update of the concept of embolic stroke of undetermined source.
Topics: Administration, Oral; Anticoagulants; Aspirin; Embolic Stroke; Humans; Intracranial Embolism; Ischem | 2022 |
Clopidogrel Monotherapy versus Aspirin Monotherapy in Patients with Established Cardiovascular Disease: Systematic Review and Meta-Analysis.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platel | 2022 |
Comparison of Aspirin and P2Y
Topics: Aspirin; Brain Ischemia; Hemorrhage; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; Secon | 2023 |
Does prior use of antiplatelet therapy modify the effect of dual antiplatelet therapy in transient ischaemic attack/minor ischaemic stroke: A systematic review and meta-analysis.
Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Ischemic Str | 2022 |
P2Y12 Inhibitors versus Aspirin Monotherapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Disease Events: A Systematic Review and Meta-analysis.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Infarction; Percut | 2022 |
A systematic review and meta-analysis for the primary prevention of high risk of stroke by Nao-an capsules.
Topics: Aspirin; Humans; Primary Prevention; Stroke | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Apixaban for Anticoagulation After Robotic Mitral Valve Repair.
Topics: Aftercare; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Hemorrhage; Humans; Male; Middle Ag | 2023 |
Antiplatelet therapy after noncardioembolic ischemic stroke or transient ischemic attack.
Topics: Anticoagulants; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Factor XI; Fibrinolyt | 2022 |
Thyroid storm complicated by corpus callosum infarction in a young patient: A case report and literature review.
Topics: Adult; Aspirin; Cerebral Infarction; Corpus Callosum; Humans; Magnetic Resonance Imaging; Male; Stro | 2022 |
The use of dual antiplatelet therapy for ischemic cerebrovascular events.
Topics: Aspirin; Atherosclerosis; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Ischemic St | 2023 |
Stroke in sickle cell disease and the promise of recent disease modifying agents.
Topics: Adult; Anemia, Sickle Cell; Anticoagulants; Aspirin; Cerebral Infarction; Humans; Hydroxyurea; Strok | 2022 |
Acetylsalicylic acid in primary prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Drugs, Essential; Humans; Platelet Aggregation Inhibitors; Primary | 2022 |
Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Stroke; Platelet Aggre | 2022 |
Updates on Sturge-Weber Syndrome.
Topics: Aspirin; Brain; Humans; Seizures; Stroke; Sturge-Weber Syndrome | 2022 |
Efficacy and safety of dual antiplatelet therapy after percutaneous coronary drug-eluting stenting: A network meta-analysis.
Topics: Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
Antiplatelet therapy for secondary prevention of lacunar stroke: a systematic review and network meta-analysis.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Network Meta-Analysis; Platelet | 2023 |
Acetylsalicylic Acid-Primus Inter Pares in Pharmacology.
Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Stroke | 2022 |
Acetylsalicylic Acid-Primus Inter Pares in Pharmacology.
Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Stroke | 2022 |
Acetylsalicylic Acid-Primus Inter Pares in Pharmacology.
Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Stroke | 2022 |
Acetylsalicylic Acid-Primus Inter Pares in Pharmacology.
Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Stroke | 2022 |
Antiplatelet treatment for acute secondary prevention of non-cardioembolic minor stroke / transient ischaemic attack: an update for the acute physician.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; | 2022 |
Antiplatelet treatment for acute secondary prevention of non-cardioembolic minor stroke / transient ischaemic attack: an update for the acute physician.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; | 2022 |
Antiplatelet treatment for acute secondary prevention of non-cardioembolic minor stroke / transient ischaemic attack: an update for the acute physician.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; | 2022 |
Antiplatelet treatment for acute secondary prevention of non-cardioembolic minor stroke / transient ischaemic attack: an update for the acute physician.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; | 2022 |
Thromboprophylaxis in Patients With Fontan Circulation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Fontan Procedure; Hemorrhage; Hu | 2023 |
Acetylsalicylic Acid (Aspirin) for Primary Prevention of Cardiovascular Events in Patients with Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Hemorrhage; Humans; Myocardial Infarction; Prim | 2023 |
Early identification and treatment for peripheral arterial disease in patients with ischemic cerebrovascular disease.
Topics: Aspirin; Atherosclerosis; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Stro | 2023 |
Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis.
Topics: Aspirin; Atherosclerosis; Bayes Theorem; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combina | 2023 |
Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines.
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack | 2023 |
Efficacy and Safety of Ticagrelor versus Aspirin and Clopidogrel for Stroke Prevention in Patients with Vascular Disease: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Intracranial Hemorrhages; Ische | 2023 |
Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; East Asian People; Hemorrhage; Humans; Myocardial Inf | 2023 |
Fixed dose combination therapies in primary cardiovascular disease prevention in different groups: an individual participant meta-analysis.
Topics: Aged; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Drug Combinations; Hemorrhage; Huma | 2023 |
Clinical Efficacy of the Huo Xue Hua Yu Method Combined with Aspirin in the Treatment of Acute Cerebral Infarction: A Systematic Evaluation and Meta-analysis.
Topics: Acute Disease; Aspirin; Brain Ischemia; Cerebral Infarction; Drugs, Chinese Herbal; Humans; Stroke; | 2023 |
Pharmacological interventions for asymptomatic carotid stenosis.
Topics: Aspirin; Atherosclerosis; Atorvastatin; Carotid Stenosis; Chlorthalidone; Fluvastatin; Hemorrhage; H | 2023 |
Ticagrelor plus aspirin in patients with minor ischemic stroke and transient ischemic attack: a network meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Isc | 2023 |
Clinical Updates on Antiplatelet Therapy for Secondary Prevention in Acute Ischemic Stroke.
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Humans; Ischemic Attack, Transient; Ischemic Stroke; Plat | 2023 |
Comprehensive systematic review and meta-analysis on anticoagulants and aspirin for stroke prevention in non-valvular atrial fibrillation patients.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Stroke; Warfarin | 2023 |
Antithrombotic Treatment in Cryptogenic Stroke Patients With Patent Foramen Ovale: Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Foramen Ovale, Patent; Humans; Ischemic Attack, Transi | 2019 |
Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Intracranial He | 2019 |
Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Female; Humans; Hydroxymethylglutaryl-CoA | 2019 |
Aspirin vs. P2Y12 Inhibitor Rivalry: Which One Can be Continued During Gastrointestinal Bleeding.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Gastrointestinal Hemorrhag | 2019 |
Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Chronic Disease; Coronary Artery Dis | 2019 |
A comparison of contemporary versus older studies of aspirin for primary prevention.
Topics: Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Neo | 2020 |
Antithrombotic regimen for patients with cardiac indication for dual antiplatelet therapy and anticoagulation: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug | 2020 |
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrenc | 2019 |
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrenc | 2019 |
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrenc | 2019 |
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrenc | 2019 |
[Past and future of the ESUS concept].
Topics: Anticoagulants; Aspirin; Humans; Intracranial Embolism; Randomized Controlled Trials as Topic; Strok | 2020 |
Aspirin or anticoagulation after cryptogenic stroke with patent foramen ovale: systematic review and meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Aspirin; Foramen Ovale, Patent; Humans; Ischemic Stroke; Middle Aged; Randomized Con | 2020 |
Sex Disparities in Cardiovascular Outcome Trials of Populations With Diabetes: A Systematic Review and Meta-analysis.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Dis | 2020 |
Effect of P2Y12 inhibitor monotherapy versus dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: systematic review and meta-analysis.
Topics: Aspirin; Cause of Death; Heart Diseases; Humans; Myocardial Infarction; Outcome Assessment, Health C | 2020 |
Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Age | 2020 |
Monotherapy with a P2Y
Topics: Aged; Aspirin; Atherosclerosis; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Female; He | 2020 |
Transient Ischemic Attack.
Topics: Aspirin; Brain; Clopidogrel; Diagnosis, Differential; Diffusion Magnetic Resonance Imaging; Drug The | 2020 |
Bleeding risk comparison between direct oral anticoagulants at doses approved for atrial fibrillation and aspirin: systematic review, meta-analysis and meta-regression.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Stroke; Venous Thromboem | 2020 |
Dual versus mono antiplatelet therapy for acute non- cardio embolic ischemic stroke or transient ischemic attack, an efficacy and safety analysis - updated meta-analysis.
Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; | 2020 |
Perioperative Cardiovascular Risk Assessment and Management for Noncardiac Surgery: A Review.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagul | 2020 |
New Horizons in Pharmacologic Therapy for Secondary Stroke Prevention.
Topics: Anti-Inflammatory Agents; Aspirin; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Fibrinolyt | 2020 |
The Potential Protective Role of Aspirin Against Migraine in Pregnant Women.
Topics: Aspirin; Drug Administration Schedule; Drug Dosage Calculations; Endothelium, Vascular; Female; Huma | 2020 |
The 2020 breakthroughs in early secondary prevention: dual antiplatelet therapy versus single antiplatelet therapy.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Early Medical Intervention; Hemorrh | 2021 |
Multifactorial Background for a Low Biological Response to Antiplatelet Agents Used in Stroke Prevention.
Topics: Aspirin; Biological Availability; Clopidogrel; Drug Interactions; Drug Resistance; Humans; Ischemic | 2021 |
Meta-Analysis Comparing the Safety and Efficacy of Single vs Dual Antiplatelet Therapy in Post Transcatheter Aortic Valve Implantation Patients.
Topics: Aortic Valve Stenosis; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemi | 2021 |
[The new Epoch of Antithrombotic Therapy in the Long-Term Prevention of a non-Cardioembolic Stroke].
Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Ri | 2021 |
Aspirin Alone Versus Dual Antiplatelet Therapy after Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis.
Topics: Aortic Valve; Aspirin; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Huma | 2022 |
Stroke in Pregnancy: A Multidisciplinary Approach.
Topics: Aspirin; Brain Diseases; Cardiomyopathies; Cesarean Section; Eclampsia; Embolism, Paradoxical; Femal | 2021 |
Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies.
Topics: Adolescent; Adult; Aspirin; Calreticulin; Disease-Free Survival; Erythrocyte Transfusion; Female; Fo | 2021 |
A meta-analysis of aspirin and subarachnoid hemorrhage in patients with intracranial aneurysms yields different results to the general population.
Topics: Aneurysm, Ruptured; Aspirin; Humans; Intracranial Aneurysm; Prospective Studies; Stroke; Subarachnoi | 2022 |
Usefulness of Antiplatelet Therapy After Transcatheter Aortic Valve Implantation.
Topics: Aortic Valve Stenosis; Aspirin; Cause of Death; Clopidogrel; Dual Anti-Platelet Therapy; Endothelium | 2021 |
Dual Antiplatelet Therapy Versus Aspirin in Patients With Stroke or Transient Ischemic Attack: Meta-Analysis of Randomized Controlled Trials.
Topics: Aspirin; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggreg | 2021 |
Anticoagulation versus placebo for heart failure in sinus rhythm.
Topics: Administration, Oral; Anticoagulants; Aspirin; Cardiomyopathy, Dilated; Chronic Disease; Heart Failu | 2021 |
P2Y12 Inhibitors Plus Aspirin Versus Aspirin Alone in Patients With Minor Stroke or High-Risk Transient Ischemic Attack.
Topics: Aspirin; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemic Attack, Transient; Purinergic P2Y | 2021 |
Thrombosis in Covid-19 and non-Covid-19 pneumonia: role of platelets.
Topics: Aspirin; Blood Platelets; COVID-19; COVID-19 Drug Treatment; Humans; Myocardial Infarction; SARS-CoV | 2021 |
Contemporary Medical Management of Peripheral Artery Disease.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Chronic Limb-Threatening Ischemia; Exercise; Fibr | 2021 |
Thrombotic Events and Anticoagulants in Beta-thalassemia Patients with Focus on Anticoagulants for Atrial Fibrillation: A Brief Review.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; beta-Thalassemia; Hemorrhage; Hu | 2022 |
Ticagrelor: clinical development and future potential.
Topics: Aspirin; Brain Ischemia; Humans; Platelet Aggregation Inhibitors; Stroke; Ticagrelor | 2021 |
Clinical Effects of Dual Antiplatelet Therapy or Aspirin Monotherapy after Acute Minor Ischemic Stroke or Transient Ischemic Attack, a Meta-Analysis.
Topics: Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Ischemic Stroke; Platelet Ag | 2021 |
Triple Antithrombotic Therapy in Patients With Left Ventricular Assist Devices.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Gastrointestinal Hemorrhage | 2022 |
P2Y12 receptor inhibitor plus aspirin versus aspirin treated within 24 hours of acute noncardioembolic ischemic stroke or TIA: Meta-analysis.
Topics: Aspirin; Cerebral Infarction; Drug Therapy, Combination; Hemorrhage; Humans; Intracranial Hemorrhage | 2022 |
Bleeding risk of antiplatelet drugs compared with oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido | 2017 |
Current and future perspectives on the treatment of cerebral ischemia.
Topics: Aspirin; Brain Ischemia; Fibrinolytic Agents; Humans; Stroke; Thrombolytic Therapy; Tissue Plasminog | 2017 |
Efficacy and safety of aspirin in patients with peripheral vascular disease: An updated systematic review and meta-analysis of randomized controlled trials.
Topics: Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Intracranial Hemorrhages; Myocardial Infarction; P | 2017 |
Aspirin's Benefits Were Previously Underestimated and Are Primarily Accrued in the Acute Setting.
Topics: Aspirin; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke | 2017 |
High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: A systematic review and meta-analysis.
Topics: Aspirin; Blood Platelets; Brain Ischemia; Clopidogrel; Drug Resistance; Humans; Platelet Aggregation | 2017 |
Dual Antiplatelet Therapy Continuation Beyond 1 Year After Drug-Eluting Stents: A Meta-Analysis of Randomized Trials.
Topics: Aged; Aspirin; Bayes Theorem; Chi-Square Distribution; Coronary Disease; Coronary Thrombosis; Drug A | 2017 |
Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cause of Death; Female; Fibrinolytic Agents; Hum | 2017 |
Aspirin for Primary Prevention.
Topics: Age Factors; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Diabetes Mellitus; Gastrointest | 2017 |
[Impact of different antithrombotic therapy strategy on prognosis in coronary heart disease patients combining with atrial fibrillation: a meta analysis].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Fibrinolytic Agents; He | 2017 |
Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Plat | 2017 |
Secondary Stroke Prevention in Cryptogenic Stroke and Embolic Stroke of Undetermined Source (ESUS).
Topics: Aspirin; Embolism; Humans; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke; Terminolog | 2017 |
Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy: An Individual Participant Data Analysis.
Topics: Aged; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Administration Schedule; | 2017 |
Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: A comparison between the DAPT study and 9 other trials evaluating DAPT duration.
Topics: Aspirin; Cardiovascular Diseases; Databases, Factual; Drug-Eluting Stents; Hemorrhage; Humans; Myoca | 2017 |
Genetic Signatures in Ischemic Stroke: Focus on Aspirin Resistance.
Topics: Animals; Aspirin; Brain Ischemia; Drug Resistance; Fibrinolytic Agents; Genome-Wide Association Stud | 2017 |
Prolonged Dual Antiplatelet Therapy After MI Reduces Major Adverse Cardiac Events.
Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Hemorrhage; Humans; Mortality; Myocardi | 2017 |
Recurrent Ischemic Stroke: Strategies for Prevention.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Male; P | 2017 |
Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Drug Interact | 2018 |
Role of Antiplatelet Therapy in Stroke Prevention in Patients With Atrial Fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Female; Humans; Male; | 2017 |
Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Aspirin; Hemorrhage; Humans; Myocardial Infarction; Randomized | 2017 |
Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy, Combination; Female; He | 2018 |
Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach.
Topics: Aspirin; Atrial Fibrillation; Hemorrhage; Humans; Myocardial Ischemia; Platelet Aggregation Inhibito | 2018 |
A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Embolism; Glomerular | 2019 |
Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a systematic review and meta-analysis.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Intracranial Hemorrhages; | 2018 |
Clinical pearls in perioperative medicine.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2018 |
Efficacy and safety of triple therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing coronary stenting: A meta-analysis.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Combinations; Drug-Related Side Effects and Adverse | 2018 |
Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention.
Topics: Aspirin; Cardiovascular Diseases; Fibrinolytic Agents; Humans; Stroke | 2018 |
Meta-analysis of efficacy and safety of dual antiplatelet therapy versus aspirin monotherapy after coronary artery bypass grafting.
Topics: Aged; Aspirin; Coronary Artery Bypass; Coronary Thrombosis; Dual Anti-Platelet Therapy; Female; Graf | 2019 |
Use of online promotion to encourage patient awareness of aspirin use to prevent heart attack and stroke.
Topics: Aspirin; Health Knowledge, Attitudes, Practice; Health Promotion; Humans; Myocardial Infarction; Sea | 2018 |
Antithrombotic strategies after interventional left atrial appendage closure: an update.
Topics: Anticoagulants; Antifibrinolytic Agents; Aspirin; Atrial Appendage; Atrial Fibrillation; Embolism; H | 2018 |
Triple antithrombotic therapy in patients with atrial fibrillation undergoing PCI: current evidence and practice.
Topics: Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Percutaneous C | 2018 |
Triple therapy: worth the risk?
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Synergism; Drug Therapy, Combination; Factor Xa Inhibitor | 2018 |
Optimal Antiplatelet Therapy in Moderate to Severe Asymptomatic and Symptomatic Carotid Stenosis: A Comprehensive Review of the Literature.
Topics: Aspirin; Asymptomatic Diseases; Carotid Stenosis; Clopidogrel; Dipyridamole; Drug Therapy, Combinati | 2019 |
Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hemor | 2019 |
Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack | 2018 |
[TREATMENT WITH DUAL ANTIPLATELET THERAPY FOR SECONDARY PREVENTION OF STROKE - PROS AND CONS].
Topics: Aspirin; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Secondary Prevention; S | 2018 |
Short-term versus long-term triple antithrombotic therapy for patients with coronary stents and requiring oral anticoagulation: a meta-analysis of randomized clinical trials.
Topics: Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; He | 2019 |
Omission of aspirin in patients taking oral anticoagulation after percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Age Factors; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Coronary Artery Disease; Dru | 2019 |
Medical and endovascular treatments of symptomatic intracranial stenosis. A Bayesian network meta-analysis.
Topics: Anticoagulants; Aspirin; Bayes Theorem; Cerebrovascular Disorders; Constriction, Pathologic; Endovas | 2019 |
Aspirin in childhood acute ischemic stroke: The evidence for treatment and efficacy testing.
Topics: Aspirin; Blood Platelets; Brain Ischemia; Humans; Platelet Aggregation Inhibitors; Practice Guidelin | 2019 |
Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease?
Topics: Acute Coronary Syndrome; Aged; Algorithms; Aspirin; Cardiovascular Diseases; Coronary Artery Disease | 2019 |
Optimal Duration of Aspirin Plus Clopidogrel After Ischemic Stroke or Transient Ischemic Attack.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Human | 2019 |
Aortic Valve
Topics: Adult; Aortic Valve; Aspirin; Clopidogrel; Echocardiography, Transesophageal; Humans; Magnetic Reson | 2018 |
Antithrombotic dose: Some observations from published clinical trials.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Dose-Response Relations | 2019 |
Early Secondary Prevention in Transient Ischemic Attack (TIA) and Minor Stroke.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Pla | 2019 |
Atrial Fibrillation in Africa-An Under-Reported and Unrecognized Risk Factor for Stroke: A Systematic Review.
Topics: Adolescent; Adult; Africa; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Epidemiologic Methods | 2019 |
Polypills for primary prevention of cardiovascular disease.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Coronary Disease; Drug Combinations; Huma | 2019 |
Aspirin Versus Clopidogrel Monotherapy for the Treatment of Patients with Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; | 2019 |
Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Cerebral Revascularization; Clopidogrel; Cytochro | 2019 |
Non vitamin K oral anticoagulants versus antiplatelets in embolic stroke of undetermined source: most updated evidence.
Topics: Administration, Oral; Anticoagulants; Aspirin; Humans; Intracranial Embolism; Platelet Aggregation I | 2019 |
Aspirin for primary prevention of stroke in individuals without cardiovascular disease-A meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Humans; Primary Prevention; Stroke | 2020 |
Role of aspirin in primary prevention of cardiovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag | 2019 |
Role of aspirin in primary prevention of cardiovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag | 2019 |
Role of aspirin in primary prevention of cardiovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag | 2019 |
Role of aspirin in primary prevention of cardiovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag | 2019 |
Subclinical Cerebrovascular Disease: Epidemiology and Treatment.
Topics: Aged; Aged, 80 and over; Aspirin; Asymptomatic Diseases; Brain Infarction; Dementia; Female; Humans; | 2019 |
Antiplatelet Therapy in Cerebral Small Vessel Disease.
Topics: Aspirin; Cerebral Hemorrhage; Cerebral Small Vessel Diseases; Clopidogrel; Drug Therapy, Combination | 2019 |
Antithrombotic therapy in atrial fibrillation: aspirin is rarely the right choice.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Administration Schedule; Drug Interactions; Femal | 2013 |
Antiplatelet therapy for preventing stroke in patients with chronic kidney disease.
Topics: Aspirin; Cerebrovascular Circulation; Cohort Studies; Endothelium, Vascular; Female; Hemorrhage; Hum | 2013 |
Apixaban: a review of its use for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Embolism; Fibrinolytic Agents; Humans; Pyrazoles; Pyridones; Stroke; W | 2013 |
Use of antiplatelet drugs in stroke prevention: time for a rethink?
Topics: Aspirin; Early Diagnosis; Female; Humans; Male; Platelet Aggregation Inhibitors; Primary Prevention; | 2013 |
Effect of addition of clopidogrel to aspirin on stroke incidence: Meta-analysis of randomized trials.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Incidence; Male; Middle Aged; | 2015 |
Pharmacokinetic considerations for antithrombotic therapies in stroke.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Cilostazol; Clopidogrel; Factor | 2013 |
Closing the loop: a 21-year audit of strategies for preventing stroke and death following carotid endarterectomy.
Topics: Angioscopy; Aspirin; Carotid Artery Diseases; Clinical Protocols; Clopidogrel; Drug Therapy, Combina | 2013 |
[Secondary prevention with clopidogrel after TIA or stroke].
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; N | 2013 |
Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke.
Topics: Aspirin; Cilostazol; Humans; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke; Tetrazol | 2013 |
The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a systematic review.
Topics: Aspirin; Bleeding Time; Clopidogrel; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggreg | 2013 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpr | 2013 |
The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials.
Topics: Aged; Aspirin; Dipyridamole; Female; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; Male; | 2013 |
Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Hemorrhage; Humans; Ischemi | 2013 |
Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Cost-Benef | 2013 |
Unique experiences with intercontinental trials in stroke - part II.
Topics: Aspirin; Canada; Fibrinolytic Agents; Humans; Longitudinal Studies; Mitral Valve Prolapse; Randomize | 2013 |
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; | 2013 |
Antithrombotic therapy for pregnant women.
Topics: Aspirin; Contraindications; Cooperative Behavior; Dose-Response Relationship, Drug; Drug Labeling; F | 2013 |
Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Human | 2013 |
The challenge of stroke prevention with intracranial arterial stenosis.
Topics: Aspirin; Carotid Artery, Common; Carotid Stenosis; Clopidogrel; Constriction, Pathologic; Drug Thera | 2013 |
Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis.
Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Hemorrhage; Humans; Mal | 2013 |
Antiplatelet therapy to prevent recurrent stroke: Three good options.
Topics: Aspirin; Carotid Stenosis; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Secon | 2013 |
Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Air Pollution; American Heart Association; | 2014 |
Systematic study of cilostazol on secondary stroke prevention: a meta-analysis.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Disease Progression; Humans; Incidenc | 2013 |
[Important changes in the Dutch College of General Practitioners (NHG) practice guideline 'Atrial fibrillation': revised practice guideline issued].
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; General Practice; Huma | 2013 |
Perioperative management of antiplatelet therapy.
Topics: Aspirin; Blood Coagulation; Coronary Artery Disease; Humans; Perioperative Care; Platelet Activation | 2013 |
Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trials.
Topics: Aspirin; Cerebral Hemorrhage; Female; Gastrointestinal Hemorrhage; Humans; Male; Neoplasms; Platelet | 2013 |
Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis.
Topics: Adenosine; Aged; Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel; Cohort Studie | 2014 |
Antiplatelets in stroke prevention.
Topics: Animals; Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Preventi | 2013 |
Stroke subtypes and their possible implication in stroke prevention drug strategies.
Topics: Animals; Antihypertensive Agents; Aspirin; Atherosclerosis; Blood Pressure; Dipyridamole; Humans; Pl | 2013 |
Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Dru | 2014 |
Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Brain Ischemia; Humans; Immunoglobulin Fab Fragments; In | 2014 |
The intensive care management of acute ischemic stroke: an overview.
Topics: Airway Management; Anticoagulants; Aspirin; Decompressive Craniectomy; Endovascular Procedures; Fibr | 2014 |
Oral antiplatelet therapy for acute ischaemic stroke.
Topics: Aspirin; Brain Ischemia; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Randomized Controlle | 2014 |
Stroke: transient ischemic attack.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain; Clopidogrel; Diffusion Magnetic Resonance I | 2014 |
Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; M | 2015 |
Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence.
Topics: Animals; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Recurrence; Stroke; Ticlopid | 2014 |
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Int | 2014 |
Antithrombotics in atrial fibrillation and coronary disease.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Coronary Artery D | 2014 |
Estimates of benefits and harms of prophylactic use of aspirin in the general population.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Gastrointestinal Hemorrhage; Humans; Male; | 2015 |
Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Risk; Safety; Strok | 2014 |
Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co | 2014 |
Dual versus single antiplatelet therapy in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Myocardial Infarc | 2015 |
[Added value of clopidogrel in cardiology and neurology].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; | 2014 |
The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population--an updated meta-analysis.
Topics: Acute Disease; Asian People; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Chronic Disease; Cil | 2014 |
Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Pla | 2015 |
Primary prevention: do the very elderly require a different approach?
Topics: Aged, 80 and over; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Dementia; Humans; Hydr | 2015 |
Brief history of patent foramen ovale and stroke.
Topics: Aspirin; Endovascular Procedures; Foramen Ovale, Patent; Humans; Randomized Controlled Trials as Top | 2015 |
Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Hemorr | 2015 |
Misconceptions and Facts About Atrial Fibrillation.
Topics: Administration, Oral; Alcohol Drinking; Anticoagulants; Aspirin; Asymptomatic Diseases; Atrial Fibri | 2015 |
Targeting aspirin in acute disabling ischemic stroke: an individual patient data meta-analysis of three large randomized trials.
Topics: Aspirin; Brain Ischemia; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Intracranial Hemorr | 2015 |
P2Y12 receptor inhibitors for secondary prevention of ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggre | 2015 |
Comparison of Dual-antiplatelet Therapy to Mono-antiplatelet Therapy After Transcatheter Aortic Valve Implantation: Systematic Review and Meta-analysis.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Clopidogrel; Drug Therapy, Combination; Fem | 2015 |
Safety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Pressur | 2015 |
Antiplatelet therapy following transcatheter aortic valve implantation.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Cardiac Catheteriz | 2015 |
Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation.
Topics: Age Factors; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Como | 2015 |
Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Drug | 2015 |
Dual Antiplatelet Therapy of Clopidogrel and Aspirin in Secondary Prevention of Ischemic Stroke: Evidence and Indications.
Topics: Antiplatyhelmintic Agents; Aspirin; Brain Ischemia; Clopidogrel; Evidence-Based Medicine; Humans; St | 2015 |
Clopidogrel and Aspirin versus Aspirin Alone for Stroke Prevention: A Meta-Analysis.
Topics: Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Stroke; Ticlopidine | 2015 |
Antiplatelet therapies for secondary stroke prevention: an update on clinical and cost-effectiveness.
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Drug Therapy, Combination; Humans; Platel | 2015 |
Dual antiplatelet therapy with clopidogrel and aspirin for secondary stroke prevention.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine; Gastrointestinal Hemorrhag | 2015 |
Challenges in the Anesthetic and Intensive Care Management of Acute Ischemic Stroke.
Topics: Anesthesia; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Critical Care; Decompressive Craniecto | 2016 |
Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
Topics: Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Half-Life; Hemorrhage; Humans; L | 2015 |
Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic | 2015 |
Part 9: First Aid: 2015 International Consensus on First Aid Science With Treatment Recommendations.
Topics: Airway Management; Aspirin; Asthma; Cardiopulmonary Resuscitation; Chest Pain; Emergencies; Emergenc | 2015 |
Structural causes of ischemic and hemorrhagic stroke in children: moyamoya and arteriovenous malformations.
Topics: Adolescent; Aspirin; Brain Ischemia; Cerebral Angiography; Cerebral Revascularization; Child; Child, | 2015 |
Aspirin Compared to Low Intensity Anticoagulation in Patients with Non-Valvular Atrial Fibrillation. A Systematic Review and Meta-Analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Embolism; Hum | 2015 |
[Acetylsalicylic acid for the prevention of primary myocardial infarction and ischemic stroke].
Topics: Aspirin; Chemoprevention; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors | 2015 |
Evolving strategies to prevent stroke and thromboembolism in nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Dabigatran; Equipment and Supplies; | 2015 |
Aspirin for the Primary Prevention of Cardiovascular Disease: In Need of Clarity.
Topics: Aspirin; Cardiovascular Diseases; Humans; Primary Prevention; Randomized Controlled Trials as Topic; | 2016 |
[Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack].
Topics: Aspirin; Clopidogrel; Databases, Factual; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic At | 2015 |
Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
Topics: Aspirin; Cilostazol; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Hemorrhage; Humans; Ische | 2016 |
Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Recurrenc | 2016 |
Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force.
Topics: Adult; Aspirin; Cardiovascular Diseases; Fibrinolytic Agents; Gastrointestinal Hemorrhage; Hemorrhag | 2016 |
Stroke Prevention in Atrial Fibrillation in Patients With Chronic Kidney Disease.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Creatinine; Diabetes C | 2016 |
Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials.
Topics: Aspirin; Cardiovascular Diseases; Diabetic Angiopathies; Diabetic Cardiomyopathies; Evidence-Based M | 2017 |
Atrial fibrillation.
Topics: Ablation Techniques; Anticoagulants; Aspirin; Atrial Fibrillation; Dizziness; Dyspnea; Electric Coun | 2016 |
Safety and Use of Anticoagulation After Aortic Valve Replacement With Bioprostheses: A Meta-Analysis.
Topics: Anticoagulants; Aortic Valve; Aspirin; Bioprosthesis; Drug Administration Schedule; Heart Valve Dise | 2016 |
Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Random | 2016 |
Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events.
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Secondary | 2016 |
WITHDRAWN: Chuanxiong preparations for preventing stroke.
Topics: Adult; Aspirin; Drugs, Chinese Herbal; Fibrinolytic Agents; Humans; Ligusticum; Randomized Controlle | 2016 |
[ESUS (embolic stroke of undetermined sources)].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Blood Coagulation Disorders; Clinical Trials as Topic; | 2016 |
Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis.
Topics: Adult; Aspirin; Blood Pressure; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as T | 2016 |
Aspirin use for primary prevention in elderly patients.
Topics: Aged; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregat | 2016 |
Patent foramen ovale and cryptogenic stroke: from studies to clinical practice: Position paper of the Italian Chapter, International Society Cardiovascular Ultrasound.
Topics: Anticoagulants; Aspirin; Cardiac Catheterization; Echocardiography; Embolism, Paradoxical; Foramen O | 2016 |
Aspirin, stroke and drug-drug interactions.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Drug In | 2016 |
Efficacy and safety of aspirin combined with warfarin after acute coronary syndrome : A meta-analysis.
Topics: Acute Coronary Syndrome; Adult; Aged; Anticoagulants; Aspirin; Causality; Comorbidity; Dose-Response | 2017 |
Systematic Review and Meta-Analysis of Randomised Trials to Ascertain Fatal Gastrointestinal Bleeding Events Attributable to Preventive Low-Dose Aspirin: No Evidence of Increased Risk.
Topics: Aspirin; Drug-Related Side Effects and Adverse Reactions; Gastrointestinal Hemorrhage; Humans; Myoca | 2016 |
Anticoagulation for stroke prevention in elderly patients with non-valvular atrial fibrillation: what are the obstacles?
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Hemorrhage; Humans; Risk Assessment | 2016 |
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.
Topics: Acute Coronary Syndrome; Analysis of Variance; Aspirin; Blood Vessel Prosthesis Implantation; Clopid | 2017 |
Antithrombotic treatment in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Combinations; Fibrinolytic Agents; Humans; Platel | 2008 |
Aspirin nonresponse in patients with arterial causes of ischemic stroke: considerations in detection and management.
Topics: Aspirin; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Secondary Prevention; | 2008 |
Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; I | 2008 |
Clopidogrel in secondary ischemic stroke prevention.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Evidence- | 2008 |
Acute and long-term antiplatelet therapy.
Topics: Acute Coronary Syndrome; Aspirin; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Plate | 2008 |
Transient ischemic attack: risk stratification and treatment.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Endarterectomy, Carotid; Humans; Ischemic Attack | 2008 |
Acetylsalicylic acid + extended-release dipyridamole combination therapy for secondary stroke prevention.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibito | 2008 |
Approach to and management of the acute stroke patient with atrial fibrillation: a literature review.
Topics: Anticoagulants; Antifibrinolytic Agents; Aspirin; Atrial Fibrillation; Factor VIIa; Heparin; Humans; | 2008 |
Polypill: for Pollyanna.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Drug Therapy; | 2008 |
I've heard the terms "atrial flutter" and "atrial fibrillation" used interchangeably when describing certain heart-rhythm disorders, but I thought atrial flutter was a less-serious condition. Can you elaborate?
Topics: Anti-Arrhythmia Agents; Aspirin; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Diagnosis, | 2008 |
Clinical implications of aspirin resistance.
Topics: Aspirin; Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Resistance; | 2008 |
The approach to optimizing stroke care.
Topics: Aspirin; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combination; Emergenc | 2008 |
Sex differences in stroke.
Topics: Acute Disease; Age Factors; Animals; Aspirin; Atrial Fibrillation; Carotid Stenosis; Cerebrovascular | 2008 |
Combination antiplatelet agents for secondary prevention of ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combinat | 2008 |
[Ischemic stroke with antiphospholipid antibody].
Topics: Age of Onset; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Biom | 2008 |
ESPRIT: is aspirin plus dipyridamole superior to aspirin alone in TIA or minor stroke patients?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug Therapy, Combination; Female; H | 2008 |
Digestion of the antiplatelets comparison of PRoFESS: 18-7=1?
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Mi | 2009 |
Multifunctional actions of approved and candidate stroke drugs.
Topics: Albumins; Animals; Antihypertensive Agents; Aspirin; Brain Ischemia; Clopidogrel; Cytidine Diphospha | 2009 |
What's new in stroke? The top 10 studies of 2006-2008. Part I.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Evidence-Based Medici | 2008 |
[Antithrombotic therapy in primary and secondary stroke prevention of cardiac patients and in acute stroke].
Topics: Acute Disease; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Administration Schedule; Fibrinoly | 2009 |
[Diagnosis and management for acute ischemic stroke].
Topics: Activities of Daily Living; Aspirin; Diagnostic Imaging; Humans; Length of Stay; Methacrylates; Neur | 2008 |
FPIN's clinical inquiries. Aspirin in patients with acute ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Education, Medical; Evidence-Based Medicine; Fibr | 2009 |
Antiplatelet agents for prevention of recurrent ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Practic | 2009 |
Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force.
Topics: Age Factors; Aged; Aspirin; Cardiovascular Diseases; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2009 |
Antiplatelet drugs for ischemic stroke prevention.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; | 2009 |
Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble?
Topics: Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dipyridamole; Drug Com | 2009 |
Secondary stroke prevention with antithrombotic drugs.
Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Cyclooxygenase Inhibitors; Dipyridamole; Drug | 2010 |
Antithrombotic therapies in cerebrovascular disease: what should we use as secondary prevention in patients with carotid artery disease?
Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Stenosis; Clopidogrel; Dipyridamole; Drug Therapy, | 2009 |
[100 years of successful drug discovery. The history of aspirin].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Germany; History, 19th Century | 2009 |
[Pharmacotherapy of stroke].
Topics: Acute Disease; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Fibrinolytic Agents; Humans; Hungary; N | 2009 |
Is there a decline in the vascular event rate after transient ischemic attack or stroke in antiplatelet trials?
Topics: Aged; Aspirin; Double-Blind Method; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; P | 2009 |
Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes.
Topics: Aspirin; Cardiovascular Diseases; Diabetic Angiopathies; Female; Fibrinolytic Agents; Humans; Hypert | 2009 |
Management of nonvalvular atrial fibrillation: a comprehensive approach.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; P | 2009 |
Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation I | 2009 |
[Pravastatin and acetylsalycilic acid fixed-combination: a strategy to improve cardiovascular outcomes].
Topics: Aspirin; Atherosclerosis; Coronary Disease; Drug Combinations; Humans; Hydroxymethylglutaryl-CoA Red | 2007 |
Antiplatelet treatment in ischemic stroke treatment.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2009 |
Polypill: the evidence and the promise.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Drug Combinations; Humans; Hydroxymethylg | 2009 |
Model-based cost-effectiveness analyses for the treatment of acute stroke events: a review and summary of challenges.
Topics: Acute Disease; Aspirin; Cost-Benefit Analysis; Decision Support Techniques; Fibrinolytic Agents; Hum | 2009 |
Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Benzimidazoles; Clopidogrel; Cost- | 2010 |
Antiplatelets and stroke outcomes: state of the science.
Topics: Arachidonic Acid; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Clopidogrel; Dipy | 2009 |
Antithrombotic treatment for the primary prevention of stroke in patients with non valvular atrial fibrillation: a reappraisal of the evidence and network meta analysis.
Topics: Aspirin; Atrial Fibrillation; Bayes Theorem; Fibrinolytic Agents; Humans; Risk Factors; Stroke; Warf | 2010 |
Chuanxiong preparations for preventing stroke.
Topics: Adult; Aspirin; Drugs, Chinese Herbal; Fibrinolytic Agents; Humans; Ligusticum; Randomized Controlle | 2010 |
Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review.
Topics: American Heart Association; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; I | 2010 |
Aspirin dosing for the prevention and treatment of ischemic stroke: an indication-specific review of the literature.
Topics: Aspirin; Atherosclerosis; Carotid Artery Diseases; Dose-Response Relationship, Drug; Endothelium, Va | 2010 |
Economy class syndrome complicated by stroke: a rare condition due to paradoxical embolism--a case report and review of the literature.
Topics: Aircraft; Anticoagulants; Aspirin; Clopidogrel; Echocardiography; Embolism, Paradoxical; Foramen Ova | 2011 |
Safety of fixed-dose aspirin-extended-release dipyridamole in patients with ischemic heart disease.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Drug-Related Side | 2010 |
Newer anticoagulants as an alternate to warfarin in atrial fibrillation: a changing paradigm.
Topics: Animals; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials, Phase II as Topic; Factor Xa | 2011 |
Vasoactive drugs for acute stroke.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Aspirin; Blood Pressure; Hemoglobins; Humans; | 2010 |
A critical review of aspirin in the secondary prevention of noncardioembolic ischaemic stroke.
Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Endarterectomy, Carotid; Fibrinolytic Agents; Hu | 2010 |
[Acetylsalicylic acid in the primary and secondary prevention of vascular disease].
Topics: Aspirin; Cerebral Hemorrhage; Germany; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregati | 2010 |
Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention.
Topics: Aspirin; Blood-Brain Barrier; Cilostazol; Clopidogrel; Dipyridamole; Drug Interactions; Drug Therapy | 2010 |
Asymptomatic carotid stenosis: natural history versus therapy.
Topics: Aspirin; Atherosclerosis; Carotid Stenosis; Endarterectomy, Carotid; Fibrinolytic Agents; Humans; St | 2010 |
[Thienopyridines in the treatment and prevention of cardiovascular diseases. Part V. Combination of clopidogrel and acetylsalicylic acid in the treatment of stable patients with atherothrombotic cardiovascular diseases].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Cardiovascular D | 2010 |
Aspirin for primary prevention of cardiovascular disease in diabetes mellitus.
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Complications; Drug Resistance; Female; Gastrointes | 2010 |
[New aspects on "triple therapy" after coronary stent implantation].
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; | 2010 |
Aspirin and antiplatelet agent resistance: implications for prevention of secondary stroke.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Second | 2010 |
Aspirin for the prevention of cardiovascular morbidity.
Topics: Aspirin; Cardiovascular Diseases; Diabetic Angiopathies; Female; Humans; Male; Myocardial Infarction | 2010 |
Oral antiplatelet therapy in stroke prevention. Minireview.
Topics: Administration, Oral; Aspirin; Clopidogrel; Dipyridamole; Drug Combinations; Humans; Ischemic Attack | 2010 |
Current status of antiplatelet agents to prevent stroke.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibito | 2011 |
[Treatment for cervical carotid artery stenosis using evidenced-based medicine].
Topics: Angioplasty; Aspirin; Carotid Stenosis; Endarterectomy, Carotid; Evidence-Based Medicine; Humans; Ra | 2010 |
Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Dose-Response Relationship, Drug; Hemorrha | 2011 |
Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin.
Topics: Asian People; Aspirin; Brain Ischemia; Cause of Death; Cilostazol; Gastrointestinal Hemorrhage; Huma | 2011 |
"Triple therapy" rather than "triple threat": a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment.
Topics: Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Heart Disease | 2011 |
Antiplatelet resistance in stroke.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Drug Resistance; Humans; P | 2011 |
Diagnosis and management of transient ischaemic attack and ischaemic stroke in the acute phase.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Diagnosis, Differential; Diagnostic Imaging; | 2011 |
Incidental atrial fibrillation and its management.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Heart Rate; Humans; Risk Assessme | 2011 |
Secondary prevention in the acute and early chronic phase after ischaemic stroke and transient ischaemic attacks with antiplatelet drugs--is antiplatelet monotherapy still reasonable?
Topics: Abciximab; Acute Disease; Antibodies, Monoclonal; Aspirin; Chronic Disease; Clopidogrel; Delayed-Act | 2011 |
Prevention of stroke following transient ischemic attack.
Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Brain; Carotid Stenosis; Clin | 2011 |
Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Headache; Hemorrhage; Humans; Ischemi | 2011 |
Validity of composite outcomes in meta-analyses of stroke prevention trials: the case of aspirin.
Topics: Aspirin; Humans; Myocardial Infarction; Outcome Assessment, Health Care; Platelet Aggregation Inhibi | 2011 |
Effect of aspirin on mortality in the primary prevention of cardiovascular disease.
Topics: Adult; Aged; Aspirin; Cardiovascular Agents; Cause of Death; Female; Gastrointestinal Hemorrhage; Hu | 2011 |
Pregnancy and stroke risk in women.
Topics: Aspirin; Brain Ischemia; Female; Fibrinolytic Agents; Humans; Hypertension, Pregnancy-Induced; Plate | 2011 |
Gender differences in the primary prevention of stroke with aspirin.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Female; Fibrinolytic Agents; Humans; Male; Meta-An | 2011 |
Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors; Primar | 2011 |
Clopidogrel hydrogen sulphate for atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; Platel | 2011 |
Stroke prevention in atrial fibrillation: current status and near-future directions.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Aspirin; Atrial Fibrillation; Contrain | 2011 |
Challenges of stroke prevention in patients with atrial fibrillation in clinical practice.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Monitoring; Humans; Stroke; Vitamin K | 2011 |
The role of aspirin for stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Evidence-Based Medicine; Fi | 2011 |
New insights in antiplatelet therapy for patients with ischemic stroke.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Humans; I | 2011 |
[Japanese Guidelines for the Management of Stroke 2009 : important revised points necessary for the neurologist].
Topics: Aspirin; Atorvastatin; Cilostazol; Diabetes Complications; Dyslipidemias; Evidence-Based Medicine; H | 2010 |
[Results of the Cilostazol Stroke Prevention Study II (CSPS II): a randomized controlled trial for the comparison of cilostazol and aspirin in stroke patients].
Topics: Aspirin; Cilostazol; Gastrointestinal Hemorrhage; Humans; Japan; Platelet Aggregation Inhibitors; Ra | 2010 |
[New clinical concept and therapeutic strategy for TIA].
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Diffusion Magnetic Resonance Imaging; Humans; Ischemic Attac | 2010 |
[Clopidogrel and stroke].
Topics: Acute Disease; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; Inflamm | 2011 |
Antiplatelets in secondary stroke prevention: should clopidogrel be the first choice?
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Ischemia; Ischemic Attack, Transient; Platelet Aggregati | 2012 |
[Review of major randomized clinical trials: carotid endarterectomy versus drug therapy].
Topics: Aspirin; Carotid Stenosis; Endarterectomy, Carotid; Humans; Platelet Aggregation Inhibitors; Randomi | 2011 |
Atrial fibrillation.
Topics: Administration, Oral; Algorithms; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillati | 2012 |
Adjunctive and alternative approaches to current reperfusion therapy.
Topics: Aspirin; Electric Stimulation Therapy; Endovascular Procedures; Fibrinogen; Fibrinolytic Agents; Hep | 2012 |
Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Datab | 2012 |
Apixaban for the prevention of stroke in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials, Phase II as Topic; Clinical Trials, P | 2012 |
Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocar | 2012 |
Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Brain Ischemia; Clopidogrel; | 2012 |
Aspirin in stroke prevention in nonvalvular atrial fibrillation and stable vascular disease: an era of new anticoagulants.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Guidelines as Topic; Humans; Stroke; Vascular Diseases | 2012 |
[Patent foramen ovale and stroke].
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Foramen Ovale, Patent; Humans; Platelet Aggregation In | 2012 |
A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
Topics: Antihypertensive Agents; Aspirin; Atenolol; Cardiovascular Diseases; Drug Combinations; Humans; Hydr | 2012 |
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogr | 2012 |
Investigating incoherence gives insight: clopidogrel is equivalent to extended-release dipyridamole plus aspirin in secondary stroke prevention.
Topics: Aspirin; Clopidogrel; Confounding Factors, Epidemiologic; Dipyridamole; Drug Therapy, Combination; H | 2012 |
Pharmacological prevention and treatment of vascular dementia: approaches and perspectives.
Topics: Alzheimer Disease; Antihypertensive Agents; Aspirin; Cholinesterase Inhibitors; Cognition; Dementia, | 2012 |
Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.
Topics: Acute Coronary Syndrome; Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cil | 2012 |
Antiplatelet therapy in stroke prevention.
Topics: Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Primary Prevention; Randomized Contro | 2012 |
Challenges in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Therapy, C | 2012 |
Thromboxane receptors antagonists and/or synthase inhibitors.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Clinical Trials as Topic | 2012 |
Antiplatelet therapy in cerebrovascular disorders.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Clopidogrel; Dipyridamole; Humans; Platelet Aggr | 2012 |
Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Ischemia; Myocardia | 2012 |
Cardiovascular disease prevention using fixed dose pharmacotherapy in Iran: updated meta-analyses and mortality estimation.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; | 2012 |
Antiplatelet treatment in primary and secondary stroke prevention in women.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Humans; Naphthalenes; Platele | 2012 |
Adding ACE inhibitors or ARBs to standard therapy for stable ischemic heart disease.
Topics: Adrenergic beta-Antagonists; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2012 |
Therapy in pediatric stroke.
Topics: Adolescent; Anticoagulants; Aspirin; Child; Fibrinolytic Agents; Humans; Practice Guidelines as Topi | 2013 |
Warfarin versus aspirin for prevention of stroke in heart failure: a meta-analysis of randomized controlled clinical trials.
Topics: Anticoagulants; Aspirin; Female; Heart Failure; Humans; Intracranial Hemorrhages; Male; Middle Aged; | 2013 |
Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biomarkers; Echocardiography; Female; Fibrinolyt | 2013 |
Risk-benefit profile of warfarin versus aspirin in patients with heart failure and sinus rhythm: a meta-analysis.
Topics: Anticoagulants; Aspirin; Chi-Square Distribution; Female; Fibrinolytic Agents; Heart Failure; Humans | 2013 |
Acute ischemic cerebrovascular events on antiplatelet therapy: what is the optimal prevention strategy?
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Humans; Life S | 2013 |
Aspirin and clopidogrel for prevention of ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Platel | 2013 |
[Secondary prevention of ischemic stroke in children].
Topics: Anticoagulants; Aspirin; Child; Heparin; Heparin, Low-Molecular-Weight; Humans; Secondary Prevention | 2012 |
Potential cardioprotective actions of no-releasing aspirin.
Topics: Animals; Apoptosis; Arteriosclerosis; Aspirin; Caspase Inhibitors; Cell Adhesion; Cyclic GMP; Cytoki | 2002 |
The management of stroke patients by neurologists: common questions and new observations.
Topics: Angioplasty; Anticoagulants; Antihypertensive Agents; Aspirin; Carotid Stenosis; Case Management; Cl | 2002 |
Treatment and monitoring of patients with antiphospholipid antibodies and thrombotic history (Hughes syndrome).
Topics: Acute Disease; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Drug Monitoring; Heparin, Low-Mol | 2002 |
Stroke management.
Topics: Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Combined Modality Therapy; Humans; Neuroprotectiv | 2002 |
[Strategy for circulatory disturbance].
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Arginine; Aspirin; Clinical Trials as Topic; Hepa | 2001 |
Aspirin in the prophylaxis of coronary artery disease.
Topics: Aspirin; Brain Ischemia; Coronary Disease; Dipyridamole; Drug Therapy, Combination; Humans; Myocardi | 2002 |
A benefit-risk assessment of agents used in the secondary prevention of stroke.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Antihypertensive Agents; Aspirin; Clinical | 2002 |
Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review.
Topics: Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Drug | 2002 |
Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Gastrointestinal Hemorrhage; Humans; My | 2002 |
Better stroke management.
Topics: Aspirin; Female; Humans; Hypertension; Male; Platelet Aggregation Inhibitors; Practice Guidelines as | 2002 |
Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials.
Topics: Acute Disease; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Fibrinolytic Agents; Heparin | 2002 |
Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Hemor | 2002 |
Aspirin and its rivals. As your options increase, your choices get harder.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Fibrinolytic Agents; Hu | 2002 |
Update on aspirin in the treatment and prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation | 2002 |
Evidence-based emergency medicine. Anticoagulation or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Fl | 2003 |
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische | 2003 |
Utility of platelet adp receptor antagonism in the emergency department: a review.
Topics: Aspirin; California; Clopidogrel; Coronary Disease; Critical Care; Drug Utilization; Emergency Servi | 2003 |
Ever decreasing circles: advances in antiplatelet therapy and anticoagulation.
Topics: Animals; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Human | 2003 |
Stroke management.
Topics: Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Combined Modality Therapy; Humans; Neuroprotectiv | 2002 |
[The best of thrombosis in 2002].
Topics: Abciximab; Angioplasty; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Ster | 2003 |
[Secondary prevention after ischemic stroke].
Topics: Administration, Oral; Angioplasty, Balloon; Anticholesteremic Agents; Anticoagulants; Aspirin; Atorv | 2003 |
Oral anticoagulants in patients with coronary artery disease.
Topics: Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Int | 2003 |
Preventing stroke in patients with atrial fibrillation: current treatments and new concepts.
Topics: Aspirin; Atrial Appendage; Atrial Fibrillation; Azetidines; Benzylamines; Clopidogrel; Dipyridamole; | 2003 |
Evidence with antiplatelet therapy and ADP-receptor antagonists.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Purinergic | 2003 |
A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin.
Topics: Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Decision Support Techniques; Fibrinolytic Ag | 2003 |
Lessons from the Stroke Prevention in Atrial Fibrillation trials.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Randomized Controlled Tri | 2003 |
Anticoagulants for prevention of ischemic stroke: current concepts.
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Humans; Platelet Aggregation Inhibitors; Secondar | 2003 |
Anticoagulants for acute ischemic stroke.
Topics: Acute Disease; Anticoagulants; Aspirin; Humans; Platelet Aggregation Inhibitors; Randomized Controll | 2003 |
North American perspective of antiplatelet agents.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trials as Topic; Drug Therapy, Combinati | 2003 |
Anticoagulants versus antiplatelet agents for acute ischemic stroke.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Heparin; Humans; Odds Ratio; Platelet Aggregation Inhibitor | 2003 |
[Clopidogrel: background information and use in clinical practice].
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Fibrinol | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clinical Trials as Topic; Clopidogrel; Dipyridamole | 2003 |
The 5 Ps of acute ischemic stroke treatment: parenchyma, pipes, perfusion, penumbra, and prevention of complications.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Heparin; Humans; Stroke; Thrombolytic Therapy | 2003 |
Medical prevention of stroke, 2003.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Diet; Female; Humans; Hyp | 2003 |
Prevention of vascular events in patients with atrial fibrillation: evidence, guidelines, and practice.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Contraindications; Controlled Cl | 2003 |
Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Combinations; Evidence-Based Medicine; Humans; Plate | 2003 |
Stroke management.
Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Cerebral Hemorrhage; Humans; Neuroprotective Agent | 2003 |
[Antiplatelet drugs in prevention of complications of arteriosclerotic diseases: it is necessary to move beyond aspirin].
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Death, Sudden, Cardiac; Drug Therapy, Combination; Hu | 2003 |
[Which antithrombotic treatment should be used in the treatment of an elderly patient with chronic atrial fibrillation?].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibril | 2003 |
[Indications for anticoagulant use in secondary prevention of strokes].
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cardiovas | 2003 |
An update on aspirin in the primary prevention of cardiovascular disease.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; | 2003 |
Potential value of triple antiplatelet therapy for secondary stroke prevention.
Topics: Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; | 2003 |
[Stenosis of the carotid arteries].
Topics: Angioplasty, Balloon; Aspirin; Brain Ischemia; Carotid Stenosis; Endarterectomy; Humans; Recurrence; | 2003 |
Coronary artery disease and stroke in HIV-infected patients: prevention and pharmacological therapy.
Topics: Anticoagulants; Antiretroviral Therapy, Highly Active; Aspirin; Cardiomyopathies; Comorbidity; Coron | 2003 |
Are anticoagulants better than antiplatelet agents for treatment of acute ischemic stroke?
Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Evidence-Based Medicine; Humans; Plate | 2003 |
[Treatment of acute stroke -- an overview].
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Aspirin; Brain Edema; Case-Control Studies; Cereb | 2003 |
[Stroke prevention].
Topics: Administration, Oral; Aged; Anticoagulants; Antihypertensive Agents; Aspirin; Carotid Stenosis; Cont | 2003 |
[Atrial fibrillation and stroke].
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrilla | 2003 |
[Lacunar infarcts].
Topics: Adult; Aged; Aspirin; Autopsy; Brain; Carotid Stenosis; Cerebral Infarction; Dementia; Female; Fibri | 2003 |
[Cryptogenic stroke and patent foramen ovale].
Topics: Administration, Oral; Adult; Anticoagulants; Aspirin; Echocardiography, Transesophageal; Follow-Up S | 2003 |
[Carotid stenosis: diagnosis, patient selection, therapy].
Topics: Aged; Aged, 80 and over; Angiography, Digital Subtraction; Angioplasty, Balloon; Aspirin; Carotid St | 2003 |
Aspirin and stroke prevention.
Topics: Aspirin; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Humans; Platelet Aggregation I | 2003 |
Role of antiplatelet drugs in the prevention of cardiovascular events.
Topics: Aspirin; Benzamidines; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Oximes; | 2003 |
Stroke, dementia, and drug delivery.
Topics: Anticholesteremic Agents; Anticoagulants; Aspirin; Clinical Trials as Topic; Dementia; Fibrinolytic | 2004 |
The role of aspirin in cardiovascular diseases--forgotten benefits?
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Myo | 2004 |
The role of aspirin in cardiovascular diseases--forgotten benefits?
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Myo | 2004 |
The role of aspirin in cardiovascular diseases--forgotten benefits?
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Myo | 2004 |
The role of aspirin in cardiovascular diseases--forgotten benefits?
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Myo | 2004 |
Aggrenox((R)) versus other pharmacotherapy in preventing recurrent stroke.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Cost-Benefit Analysis; Delayed-Action | 2004 |
Antiplatelet drugs in cardiovascular diseases.
Topics: Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Drug Resistance; Humans; Myocardial Infarctio | 2003 |
Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
Topics: Aged; Anticholesteremic Agents; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Female; | 2004 |
Indications for the closure of patent foramen ovale.
Topics: Anticoagulants; Aspirin; Balloon Occlusion; Decision Making; Decompression Sickness; Heart Septal De | 2004 |
Recent clinical trial results with antiplatelet therapy: implications in stroke prevention.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Myocardial Infarction; Pla | 2004 |
Ongoing and planned trials of antiplatelet therapy in the acute and long-term management of patients with ischaemic brain syndromes: setting a new standard of care.
Topics: Aspirin; Brain Ischemia; Disease Management; Humans; Patient Care; Platelet Aggregation Inhibitors; | 2004 |
What is the best imaging strategy for acute stroke?
Topics: Aged; Aspirin; Brain; Cerebral Hemorrhage; Costs and Cost Analysis; Decision Support Techniques; Hum | 2004 |
Trials of newer approaches to anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Clopidogrel; Humans; Interna | 2004 |
The role of warfarin and aspirin in secondary prevention of stroke.
Topics: Anticoagulants; Aspirin; Clopidogrel; Heart Septal Defects, Atrial; Humans; Ischemic Attack, Transie | 2004 |
Antiplatelet therapy for acute stroke: aspirin and beyond.
Topics: Acute Disease; Aspirin; Humans; Platelet Aggregation Inhibitors; Stroke | 2004 |
Anticoagulation for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Randomized Controlled Tr | 2004 |
Antiplatelet treatment for secondary prevention of acute ischemic stroke and transient ischemic attacks: mechanisms, choices and possible emerging patterns of use.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dipyridamole; Drug Combinations; Human | 2003 |
[Anticoagulation therapy in paroxysmal atrial fibrillation].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Platelet Aggregation Inhi | 2004 |
Atrial fibrillation: should we target platelets or the coagulation pathway?
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Risk Assessment; | 2003 |
Oral anticoagulants vs. aspirin for stroke prevention in patients with non-valvular atrial fibrillation: the verdict is in.
Topics: Administration, Oral; Anticoagulants; Aspirin; Humans; Meta-Analysis as Topic; Randomized Controlled | 2003 |
Transient ischemic attacks: Part II. Treatment.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Antihypertensive Agents; Aspirin; Female; | 2004 |
Warfarin for atrial fibrillation: the end of an era?
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Fibrinolytic Agents; Humans | 2004 |
Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Hemor | 2004 |
Clopidogrel in the management of cerebrovascular events.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Drug Costs; Drug Therapy, Combination; Humans; Platelet Aggr | 2004 |
[Treatment of ischemic heart disease with the platelet aggregation inhibitor clopidogrel].
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Therapy, Combination; Humans; Myoc | 2004 |
Antithrombotic therapies for stroke prevention in atrial fibrillation.
Topics: Aged; Ambulatory Care Facilities; Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylam | 2004 |
Low-dose aspirin for primary prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Fibrinolytic Agents; Humans; Myocardial Infarction; Platelet Aggre | 2003 |
[Vascular dementia].
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Aspirin; Cyclooxygenase Inhibitors; Dementia, Vascular; F | 2004 |
Clinical inquiries. Does combining aspirin and warfarin decrease the risk of stroke for patients with nonvalvular atrial fibrillation?
Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Drug Therapy, C | 2004 |
Management of metabolic syndrome: aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Metabolic Syndrome; Stroke | 2004 |
Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cohort Studie | 2004 |
The results of MATCH: light or heat?
Topics: Aspirin; Clopidogrel; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Humans; Ischem | 2004 |
Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
Topics: Administration, Oral; Angina Pectoris; Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopido | 2004 |
ALS lessons learned from other neurological diseases. Stroke.
Topics: Amyotrophic Lateral Sclerosis; Anticoagulants; Aspirin; Humans; Intracranial Arteriovenous Malformat | 2004 |
Stroke prevention.
Topics: Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Humans; | 2003 |
[Aspirin in the treatment and prevention of stroke].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Stroke | 2004 |
Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials.
Topics: Aspirin; Blood Pressure; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Female; Humans; Is | 2005 |
Perioperative primary stroke: is aspirin cessation to blame?
Topics: Aged; Aspirin; Carcinoma, Basal Cell; Diagnosis, Differential; Drug Administration Schedule; Humans; | 2004 |
New possibilities in anticoagulant management of atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Clopidogrel; Humans; Oligosa | 2004 |
Stroke: advances in therapy.
Topics: Aspirin; Carotid Stenosis; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Drug Thera | 2005 |
[Clinical guidelines for stroke].
Topics: Anticoagulants; Antipyrine; Arginine; Aspirin; Brain Edema; Edaravone; Fibrinolytic Agents; Free Rad | 2004 |
Secondary prevention of recurrent stroke.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Diabetes Complications; Endarterectomy; Endarterecto | 2005 |
Stroke management.
Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Humans; Neuroprotective Agents; Stroke; Thrombolyt | 2004 |
Stroke prevention. MATCHing therapy to the patient with TIA.
Topics: Aspirin; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Recurrenc | 2005 |
[Antithrombotic therapy after myocardial infarction: arguments for the use of acetylsalicylic acid and coumarin derivatives].
Topics: Anticoagulants; Aspirin; Clopidogrel; Coumarins; Death, Sudden, Cardiac; Fibrinolytic Agents; Humans | 2005 |
[Stroke and other thromboembolic complications of atrial fibrillation. Part VI. Choice of optimal approach and drugs for prevention of stroke].
Topics: Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Agents; Electri | 2005 |
[Antithrombotic therapy in patients with first-ever stroke and known non-rheumatic atrial fibrillation].
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrilla | 2005 |
Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke.
Topics: Anticoagulants; Aspirin; Clopidogrel; Dipyridamole; Drug Interactions; Drug Therapy, Combination; Hu | 2005 |
Current treatments in neurology: stroke.
Topics: Aspirin; Heparin; Humans; Neurology; Neuroprotective Agents; Neurosurgery; Stents; Stroke; Thromboly | 2005 |
Aspirin resistance in stroke: 2004.
Topics: Aspirin; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Stroke; Treatment Outcome | 2005 |
Efficacy and costs of secondary prevention with antiplatelets after ischaemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Health Care Costs; Humans | 2005 |
Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risks.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Synergism; Drug Therapy, Combination; Humans; Ischemic At | 2005 |
What every emergency nurse needs to know about aspirin.
Topics: Aspirin; Colorectal Neoplasms; Coronary Disease; Delayed-Action Preparations; Drug Administration Sc | 2005 |
Stroke prevention.
Topics: Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Drug Th | 2004 |
Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Brain Ischemia; C-Reactive Prote | 2005 |
Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Chemic | 2005 |
Using aspirin to prevent stroke.
Topics: Anticoagulants; Aspirin; Humans; Primary Prevention; Stroke | 2005 |
[Patent foramen ovale and stroke].
Topics: Adult; Age of Onset; Aspirin; Heart Septal Defects, Atrial; Humans; Middle Aged; Platelet Aggregatio | 2004 |
Atrial fibrillation and anticoagulation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dose-Response Relationship, Drug; Humans; Platelet Agg | 2004 |
Risk of hemorrhagic stroke with aspirin use: an update.
Topics: Adult; Aged; Aged, 80 and over; Angiography; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain | 2005 |
Antiplatelet therapy in ischemic stroke.
Topics: Aspirin; Brain Ischemia; Humans; Platelet Aggregation Inhibitors; Stroke; Thrombolytic Therapy | 2005 |
Triflusal for preventing serious vascular events in people at high risk.
Topics: Aspirin; Humans; Ischemic Attack, Transient; Myocardial Infarction; Platelet Aggregation Inhibitors; | 2005 |
Antiplatelet agents in secondary prevention of stroke: a perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Brain Ischemia; Clinical Trials | 2005 |
Stroke management.
Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Humans; Neuroprotective Agents; Stroke; Stroke Reh | 2005 |
Carotid endarterectomy--an evidence-based review: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Topics: Aspirin; Carotid Stenosis; Causality; Clinical Trials as Topic; Dose-Response Relationship, Drug; En | 2005 |
Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; B | 2006 |
Antiphospholipid antibodies in young adults with stroke.
Topics: Adolescent; Adult; Age Factors; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagu | 2005 |
Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Recurrence; Salicylates | 2005 |
Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.
Topics: Aspirin; Atrial Fibrillation; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; R | 2005 |
What is the role of dipyridamole in long-term secondary prevention after an ischemic stroke or transient ischemic attack?
Topics: Aspirin; Dipyridamole; Evidence-Based Medicine; Humans; Ischemic Attack, Transient; Platelet Aggrega | 2005 |
[Primary prevention of coronary heart disease with aspirin].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Comorbidity; Coronary Di | 2005 |
[Preventing cerebrovascular accidents during atrial fibrillation].
Topics: Administration, Oral; Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conver | 2005 |
[Temporal arteritis and cerebrovascular complications].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemotherapy, Adjuvant; G | 2005 |
[Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; | 2005 |
Low-dose aspirin for the prevention of atherothrombosis.
Topics: Arteriosclerosis; Aspirin; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Interactions; Drug Resi | 2005 |
Low-dose aspirin for the prevention of atherothrombosis.
Topics: Arteriosclerosis; Aspirin; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Interactions; Drug Resi | 2005 |
Low-dose aspirin for the prevention of atherothrombosis.
Topics: Arteriosclerosis; Aspirin; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Interactions; Drug Resi | 2005 |
Low-dose aspirin for the prevention of atherothrombosis.
Topics: Arteriosclerosis; Aspirin; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Interactions; Drug Resi | 2005 |
Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.
Topics: Aspirin; Cardiovascular Diseases; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Platelet | 2006 |
[Patient with antithrombotic medication. Which do bleedings or preoperative?].
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atherosc | 2006 |
Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance.
Topics: Animals; Aspirin; Coronary Disease; Drug Resistance; Heart Failure; Humans; Ischemia; Platelet Aggre | 2006 |
Aspirin to prevent heart attack and stroke: what's the right dose?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Female; H | 2006 |
Primary and secondary stroke prevention with antiplatelet drugs.
Topics: Aspirin; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Stroke; Treatment Failure | 2006 |
[Anti-platelet drugs (aspirin, ticlopidine, etc)].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Humans; Meta-An | 2006 |
[Adding aspirin to clopidogrel in secondary prevention of ischemic stroke: no significant benefits. Results of the Match study].
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage; | 2006 |
Stroke prevention.
Topics: Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; Aspirin; Drug Therapy, Combination; E | 2005 |
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische | 2006 |
[Prevention of thromboembolism in patients with atrial fibrillation].
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disea | 2006 |
MATCH results: implications for the internist.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Controlled Clinical Trials as Topic; Double-Blind Method; Dru | 2006 |
[Atheromatosis of the thoracic aorta and risk of stroke].
Topics: Anticoagulants; Aorta, Thoracic; Aortic Diseases; Aspirin; Atherosclerosis; Clopidogrel; Controlled | 2006 |
Trials in sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Aspirin; Blood Transfusion; Child; Child, Preschool; Clinical Trial | 2006 |
Prevention of vascular events in patients with cerebrovascular disease: efficacy and appropriate duration of antiplatelet therapy.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Pl | 2006 |
Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Drug Therapy, Combination; H | 2006 |
Aortic arch atheroma and the risk of stroke.
Topics: Aorta, Thoracic; Aspirin; Atherosclerosis; Clopidogrel; History, 18th Century; Humans; Risk Factors; | 2006 |
Clinical inquiries. What is the best management for patients who have a TIA while on aspirin therapy?
Topics: Aspirin; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Ischemic Attack, Transient; Pla | 2006 |
Antiplatelet agents, carotid endarterectomy, and perioperative complications.
Topics: Aspirin; Endarterectomy, Carotid; Humans; Intraoperative Complications; Models, Biological; Platelet | 2000 |
[Advanced medical therapy in patients with acute ischemic stroke].
Topics: Administration, Oral; Anticoagulants; Antipyrine; Arginine; Aspirin; Drug Design; Edaravone; Fibrino | 2006 |
Stroke prevention in diabetes and obesity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Fibrillation; Blood Glucose; Cardiovascular | 2006 |
Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pl | 2006 |
Stroke management.
Topics: Anticoagulants; Aspirin; Humans; Neuroprotective Agents; Rehabilitation Centers; Stroke; Stroke Reha | 2006 |
Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. Use of aspirin in acute stroke.
Topics: Aged; Aspirin; Emergencies; Evidence-Based Medicine; Humans; Male; Platelet Aggregation Inhibitors; | 2006 |
How much esprit is in ESPRIT?
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; Randomized Controlled Trials as Topic; Str | 2006 |
Optimising stroke prevention in non-valvular atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Electric Countershock; | 2006 |
Atrial fibrillation and stroke prevention.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Risk Factors; Stroke; Warfarin | 2006 |
Pathophysiology and medical management of systemic hypertension in preeclampsia.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium; Calcium Channel Blockers; Cerebral Hemorrhage; Female | 2006 |
[Platelet-function inhibitors in the secondary prevention of ischemic stroke].
Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Middle Aged; Platelet A | 2006 |
Antithrombotic agents in cerebral ischaemia.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Fibrinolytic Agents; Humans; Risk Assessment; Risk Factors; | 2006 |
Therapy for early reperfusion after stroke.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Diffusion Magnetic Resonance I | 2006 |
[Antiphospholipid syndrome].
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Blood Coagulation | 2006 |
Stroke and the statistics of the aspirin/clopidogrel secondary prevention trials.
Topics: Aspirin; Clinical Protocols; Clinical Trials as Topic; Clopidogrel; Data Interpretation, Statistical | 2007 |
Evolving perspectives on clopidogrel in the treatment of ischemic stroke.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggreg | 2006 |
Confronting atrial fibrillation in the elderly: stroke risk stratification and emerging antithrombotic therapies.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Evaluation; Drug Therapy, Combination; Fema | 2007 |
Current management of transient ischemic attack.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Endarterectomy, Carotid; Humans; Ischemic Attack, T | 2007 |
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr | 2007 |
Antiplatelet therapy in the treatment of atherothrombotic disease: considering the evidence.
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Co | 2007 |
[Aspirin].
Topics: Aspirin; Humans; Recurrence; Stroke | 2006 |
Dipyridamole with aspirin is better than aspirin alone in preventing vascular events after ischaemic stroke or TIA.
Topics: Aspirin; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient | 2007 |
[Antiplatelet therapy for acute ischemic stroke].
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragment | 2006 |
Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial | 2007 |
Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines.
Topics: Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Guidelines as Topic; Humans; Ischemic | 2007 |
Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease.
Topics: Angina, Unstable; Aspirin; Atherosclerosis; Biomarkers; Blood Platelets; Clopidogrel; Humans; Inflam | 2007 |
The discovery of aspirin's antithrombotic effects.
Topics: Animals; Aspirin; Awards and Prizes; California; Fibrinolytic Agents; History, 18th Century; History | 2007 |
Prevention of ischemic stroke: surgery.
Topics: Aspirin; Brain Ischemia; Carotid Artery, External; Carotid Artery, Internal; Carotid Stenosis; Coron | 2007 |
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische | 2007 |
Assessing stroke risk in patients with AF.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cardiac Pacing, Artificial; Electrocardiography; Human | 2007 |
Independent predictors of stroke in patients with atrial fibrillation: a systematic review.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Case-Control Studies; Cohort Stu | 2007 |
Clinical practice. Acute ischemic stroke.
Topics: Acute Disease; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Contraindications; Diag | 2007 |
Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2007 |
[What should be done after the first TIA?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Clopi | 2007 |
Chances and battles in stroke research.
Topics: Aspirin; Biomedical Research; Endarterectomy, Carotid; Europe; Fibrinolytic Agents; History, 20th Ce | 2007 |
Antiplatelet therapy in cerebrovascular disease: implications of Management of Artherothrombosis with Clopidogrel in High-risk Patients and the Clopidogrel for High Artherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance studies' resu
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Embolism, C | 2007 |
The PRoFESS trial: future impact on secondary stroke prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Clopid | 2007 |
Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
Topics: Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Drug Therapy, Combination; Family P | 2007 |
PRO: Should aspirin be used in all women older than 65 years to prevent stroke?
Topics: Age Factors; Aged; Aspirin; Cardiovascular Diseases; Cost of Illness; Evidence-Based Practice; Femal | 2007 |
Atrial fibrillation and stroke prevention.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Platelet Aggregation Inhibitors; Stroke; Warfa | 2007 |
Anticoagulants, aspirin and dipyridamole in the secondary prevention of cerebral ischaemia: which is the best for which patient?
Topics: Anticoagulants; Aspirin; Brain Ischemia; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Stro | 2007 |
Aspirin in the treatment and prevention of cardiovascular disease: current perspectives and future directions.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation | 2007 |
[Brief report: stroke in multiple myeloma patient treated with thalidomide].
Topics: Aged; Anticoagulants; Aspirin; Embolism, Paradoxical; Foramen Ovale, Patent; Humans; Male; Multiple | 2007 |
The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
Topics: Acute Disease; Anticholesteremic Agents; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination | 2008 |
Antiplatelet therapy for stroke prevention.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel | 2007 |
Aspirin: promise and resistance in the new millennium.
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Dr | 2008 |
Secondary stroke prevention: inside the vessels and beyond.
Topics: Animals; Antihypertensive Agents; Aspirin; Blood Vessels; Fibrinolytic Agents; Humans; Hydroxymethyl | 2008 |
Antiplatelet agents and randomized trials.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; P | 2007 |
Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Death, Sudden, Cardiac; Drug Resistance; | 2008 |
Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Death, Sudden, Cardiac; Drug Resistance; | 2008 |
Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Death, Sudden, Cardiac; Drug Resistance; | 2008 |
Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Death, Sudden, Cardiac; Drug Resistance; | 2008 |
Clinical benefit of early anticoagulation in cardioembolic stroke.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Embolism; Heparin; Humans; Risk Factors; Secondary Pre | 2008 |
Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Clopidogrel; Coron | 2008 |
Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis.
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggre | 2008 |
Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls.
Topics: Accidental Falls; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Int | 2008 |
Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke.
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggre | 2008 |
Use of antiplatelet agents to prevent stroke: what is the role for combinations of medications?
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Interactions; Drug Therapy, Combi | 2008 |
Antithrombotic and thrombolytic therapy for ischemic stroke.
Topics: Aspirin; Benzenesulfonates; Cardiomyopathies; Clopidogrel; Comorbidity; Drug Therapy, Combination; F | 2008 |
Safety of clopidogrel and aspirin for stroke prevention: implications of the CHARISMA trial.
Topics: Animals; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Platelet | 2008 |
Aggressive management of ischemic stroke: the case for the hospitalist.
Topics: Aspirin; Clinical Trials as Topic; Hospitalists; Humans; Nutritional Support; Platelet Aggregation I | 2008 |
Antithrombotic and thrombolytic therapy for ischemic stroke.
Topics: Aspirin; Brain Ischemia; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; Platelet Aggregati | 1999 |
Fibromuscular dysplasia of the internal carotid artery. Personal experience with 13 cases and literature review.
Topics: Aged; Aneurysm; Angioplasty, Balloon; Aspirin; Blindness; Brain Ischemia; Carotid Artery Diseases; C | 1999 |
Antithrombotic management of atrial fibrillation for stroke prevention in older people.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebral Hemorrhage; Contraindications; Fibrinol | 1999 |
Platelets and stroke.
Topics: Animals; Aspirin; Blood Platelets; Clinical Trials as Topic; Hemostasis; Humans; Megakaryocytes; Pla | 1999 |
Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery.
Topics: Administration, Oral; Amputation, Surgical; Anticoagulants; Aspirin; Graft Occlusion, Vascular; Huma | 1999 |
Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations.
Topics: Aspirin; Cost-Benefit Analysis; Hospital Units; Humans; Risk Factors; Stroke; Thrombolytic Therapy; | 1999 |
Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Female; Humans; Male; Risk Factors; Stroke; Thromboemb | 1999 |
Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis.
Topics: Administration, Oral; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combination; Humans; | 1999 |
Clinical implication of antiembolic trials in atrial fibrillation and role of transesophageal echocardiography in atrial fibrillation.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Echocardi | 2000 |
Long-term management--the way forward?
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Artery Disease; Dalteparin; Drug Therapy, Combin | 2000 |
Acute ischaemic stroke.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Evidence-Based Medicine; Hematoma, Subdural; Human | 2000 |
Stroke. Preemptive strikes.
Topics: Alcohol Drinking; Aspirin; Female; Hormone Replacement Therapy; Humans; Hypercholesterolemia; Hypert | 2000 |
Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses.
Topics: Adult; Aged; Arteriosclerosis; Aspirin; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; | 2000 |
[Aspirin and cerebral ischemic accidents].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Cerebral Infarction; Clinica | 2000 |
Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Fibrinolytic Agents; Humans; Platelet Aggregation Inh | 2000 |
Thrombolysis and percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Antithrombins; Aspirin; Cerebral Hemorrhage; Clinical Trials, Phase | 2000 |
Update on antiplatelet therapy for stroke prevention.
Topics: Aspirin; Clinical Trials as Topic; Delayed-Action Preparations; Dipyridamole; Dose-Response Relation | 2000 |
Anticoagulation therapy for atrial fibrillation and coronary disease.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Coronary Disease; Drug Thera | 2000 |
[Antithrombotic therapy for stroke prevention in patients with atrial fibrillation].
Topics: Age Factors; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Diabetes Compli | 2000 |
Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhib | 2000 |
The role of C-reactive protein in cardiovascular disease risk.
Topics: Arteriosclerosis; Aspirin; Biomarkers; C-Reactive Protein; Coronary Disease; Female; Humans; Male; P | 1999 |
Antiplatelet agents for stroke prevention.
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein G | 2000 |
Aspirin or heparin in acute stroke.
Topics: Acute Disease; Aspirin; Fibrinolytic Agents; Heparin; Humans; Platelet Aggregation Inhibitors; Rando | 2000 |
Prevention of ischaemic stroke--antiplatelets.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Humans; Ischemic Attack, Transient; Pl | 2000 |
Antiplatelet agents in stroke prevention. combination therapy: present and future.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Clopidogrel; Dipyridamole; Humans; Immunoglobulin Fab Fr | 2000 |
Aggrenox: a fixed-dose combination of aspirin and dipyridamole.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Aspirin, Dipyridamole Drug Combination; Clinical T | 2000 |
[Acetylsalicylic acid versus coumarin derivatives in atrial fibrillation].
Topics: Adult; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Coumarins; Dose-Respo | 2000 |
Antithrombotic therapy in atrial fibrillation.
Topics: Administration, Oral; Aged; Aspirin; Atrial Fibrillation; Electric Countershock; Fibrinolytic Agents | 2001 |
Antithrombotic agents in coronary artery disease.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Embolism; Fibrinolytic Agents; Humans; Platelet | 2001 |
Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Coronary Disease; Female; Hemorrhage; Humans; Male; Mortality; Myo | 2001 |
Aspirin in the treatment and prevention of cardiovascular disease.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Case-Control Studie | 2000 |
Stroke prevention: antiplatelet and antithrombolytic therapy.
Topics: Anticoagulants; Aspirin; Brain Damage, Chronic; Carotid Stenosis; Clinical Trials as Topic; Clopidog | 2000 |
[The development of new drugs for acute stroke].
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Antioxidants; Antipyrine; Aspirin; Clinical Trial | 2000 |
Atrial fibrillation and stroke : concepts and controversies.
Topics: Aged; Aspirin; Atrial Appendage; Atrial Fibrillation; Humans; Intracranial Embolism; Prevalence; Ran | 2001 |
[Pharma-clinics. The drug of the month. Dipyridamole-acetylsalicylic acid combination (Aggrenox)].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Humans; Ischemic A | 2000 |
[Atrial fibrillation and thromboembolic events prevention. State of the art].
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Controlled Clini | 2001 |
Antithrombotic drugs for secondary stroke prophylaxis.
Topics: Adult; Aspirin; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Platelet Aggre | 2001 |
Regular or "super-aspirins"? A review of thienopyridines or aspirin to prevent stroke.
Topics: Aspirin; Clopidogrel; Drug Combinations; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitor | 2001 |
Aspirin in cardiovascular disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans; Myocardial Infarc | 2001 |
Aspirin in patients with coronary artery disease: is it simply irresistible?
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Benzamidines; Clinical Trials as Topic; Clopidogrel; Cor | 2001 |
Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Heparin; | 2001 |
Vascular biology of thrombosis: platelet-vessel wall interactions and aspirin effects.
Topics: Aspirin; Blood Platelets; Cell Communication; Cerebral Arteries; Humans; Intracranial Thrombosis; Pl | 2001 |
Inhibition of thrombus formation by low-dose acetylsalicylic acid, dipyridamole, and their combination in a model of platelet-vessel wall interaction.
Topics: Aspirin; Blood Platelets; Cell Communication; Cerebral Arteries; Clinical Trials, Phase I as Topic; | 2001 |
Antiplatelet agents for secondary prevention of ischemic stroke.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Humans; Myocard | 2001 |
Combination therapy with clopidogrel and aspirin: can the CURE results be extrapolated to cerebrovascula patients?
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; | 2001 |
Reducing the risk: heart disease, stroke and aspirin.
Topics: Acute Disease; Aspirin; Blood Platelets; Chronic Disease; Cost-Benefit Analysis; Drug Costs; Heart D | 2001 |
[Thromboembolism in non-rheumatic atrial fibrillation].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical | 2001 |
An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2; Cycloox | 2001 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force.
Topics: Adult; Aged; Aspirin; Chemoprevention; Coronary Disease; Evidence-Based Medicine; Female; Fibrinolyt | 2002 |
[Advances and perspectives in the prevention of venous thromboembolic disease].
Topics: Anesthesia, Conduction; Anticoagulants; Aspirin; Heparin, Low-Molecular-Weight; Humans; Myocardial I | 2001 |
From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Heparin; Humans; Intracranial Art | 2002 |
[Acetylsalicylic acid in primary prevention of cardiovascular events; literature study].
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Aspirin; Diabetes Mellitus; Humans; Hyperlipidemias; Hype | 2002 |
Antiplatelet therapy in secondary stroke prevention.
Topics: Aspirin; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Com | 2001 |
The use of antithrombotic drugs in older people.
Topics: Aged; Aspirin; Clopidogrel; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Myo | 2002 |
Antithrombotic drugs for prevention of recurrent stroke.
Topics: Adult; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Fibrinolytic Agents; F | 2002 |
Warfarin versus aspirin in the secondary prevention of stroke: the WARSS study.
Topics: Anticoagulants; Aspirin; Double-Blind Method; Humans; International Normalized Ratio; Odds Ratio; Pl | 2002 |
[Management of atherosclerotic renal artery stenoses].
Topics: Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Aspirin; Cardiovascular Agents; Combined | 2002 |
522 trials available for aspirin and Stroke
| Article | Year |
|---|---|
Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Infarction; Cohort Studies; Double-Bli | 2022 |
Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study.
Topics: Anticoagulants; Aspirin; Child; Factor Xa Inhibitors; Hemorrhage; Humans; Rivaroxaban; Stroke; Throm | 2021 |
Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial.
Topics: Aged; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Age | 2021 |
Literature Commentary.
Topics: Aged; Aspirin; Humans; Ophthalmology; Piperidines; Pyridines; Pyrroles; Retrospective Studies; Spiro | 2021 |
Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy.
Topics: Aged; Aspirin; Brain Infarction; Cerebral Hemorrhage; Double-Blind Method; Embolic Stroke; Factor Xa | 2022 |
Validation of Cardiovascular End Points Ascertainment Leveraging Multisource Electronic Health Records Harmonized Into a Common Data Model in the ADAPTABLE Randomized Clinical Trial.
Topics: Aspirin; Electronic Health Records; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation | 2021 |
Effects of Dose Titration on Dipyridamole-Induced Headache: A Randomized, Double-Blind Clinical Trial.
Topics: Aspirin; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; Headache; Humans; Ischemic At | 2022 |
Infarct on Brain Imaging, Subsequent Ischemic Stroke, and Clopidogrel-Aspirin Efficacy: A Post Hoc Analysis of a Randomized Clinical Trial.
Topics: Aged; Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Female; Humans; Ischemic | 2022 |
Functional Abilities of an International Post-Stroke Population: Standard Assessment of Global Everyday Activities (SAGEA) Scale.
Topics: Activities of Daily Living; Aged; Aspirin; Female; Humans; Male; Rivaroxaban; Stroke | 2022 |
Dabigatran versus aspirin for stroke prevention after cryptogenic stroke with patent foramen ovale: A prospective study.
Topics: Aspirin; Dabigatran; Foramen Ovale, Patent; Humans; Ischemic Stroke; Prospective Studies; Recurrence | 2022 |
Safety and efficacy of aspirin, unfractionated heparin, both, or neither during endovascular stroke treatment (MR CLEAN-MED): an open-label, multicentre, randomised controlled trial.
Topics: Adult; Aspirin; Brain Ischemia; Heparin; Humans; Magnetic Resonance Imaging; Stroke; Treatment Outco | 2022 |
Tachycardia Changes Increase Neurological Deterioration in Patients with Acute Non-Cardioembolic Stroke: An ADS Post-Hoc Analysis.
Topics: Aspirin; Cilostazol; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Prospective | 2023 |
Rivaroxaban versus aspirin on functional and cognitive outcomes after embolic stroke of undetermined source: NAVIGATE ESUS trial.
Topics: Activities of Daily Living; Aspirin; Cognition; Double-Blind Method; Embolic Stroke; Factor Xa Inhib | 2022 |
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD.
Topics: Aspirin; Diabetes Mellitus; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Pe | 2022 |
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial.
Topics: Aspirin; Drug Therapy, Combination; Humans; Infant; Myocardial Infarction; Peripheral Arterial Disea | 2022 |
Indobufen versus aspirin in acute ischaemic stroke (INSURE): rationale and design of a multicentre randomised trial.
Topics: Aspirin; Brain Ischemia; Hemorrhage; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; Strok | 2022 |
Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiov
Topics: Adolescent; Adult; Aspirin; Cardiovascular Diseases; Female; Hemorrhage; Humans; Male; Multicenter S | 2022 |
Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarcti | 2022 |
Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemorrha | 2022 |
Effect of Hypertension on Efficacy and Safety of Ticagrelor-Aspirin Versus Clopidogrel-Aspirin in Minor Stroke or Transient Ischemic Attack.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Hypertension; Ischemic Attack, Transient; P | 2022 |
Predictors of Recurrent Stroke After Embolic Stroke of Undetermined Source in the RE-SPECT ESUS Trial.
Topics: Aspirin; Cerebral Infarction; Dabigatran; Embolic Stroke; Humans; Intracranial Embolism; Male; Risk | 2022 |
Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial.
Topics: Aged; Alleles; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; He | 2022 |
Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial.
Topics: Aspirin; Cerebral Infarction; Cilostazol; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combi | 2023 |
Aspirin platelet reactivity on platelet function and clinical outcome in minor stroke or transient ischemic attack.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggreg | 2022 |
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study.
Topics: Aspirin; Coronary Artery Bypass; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarctio | 2022 |
RESCUE BT 2, a multicenter, randomized, double-blind, double-dummy trial of intravenous tirofiban in acute ischemic stroke: Study rationale and design.
Topics: Aspirin; Double-Blind Method; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; Prospective | 2023 |
Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Factor XIa; Fibrinolytic Agent | 2022 |
External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Hea
Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Myocardial Infarction; Outcome | 2023 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarcti | 2022 |
A randomized pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke.
Topics: Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Ischemic Stroke; Pilot Proje | 2023 |
A randomized pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke.
Topics: Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Ischemic Stroke; Pilot Proje | 2023 |
A randomized pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke.
Topics: Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Ischemic Stroke; Pilot Proje | 2023 |
A randomized pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke.
Topics: Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Ischemic Stroke; Pilot Proje | 2023 |
Aminotransferase Level and the Effects of Dual Antiplatelet in Minor Stroke or Transient Ischemic Attack: A post hoc Analysis of a Randomized Control Trial.
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Fema | 2023 |
Aminotransferase Level and the Effects of Dual Antiplatelet in Minor Stroke or Transient Ischemic Attack: A post hoc Analysis of a Randomized Control Trial.
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Fema | 2023 |
Aminotransferase Level and the Effects of Dual Antiplatelet in Minor Stroke or Transient Ischemic Attack: A post hoc Analysis of a Randomized Control Trial.
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Fema | 2023 |
Aminotransferase Level and the Effects of Dual Antiplatelet in Minor Stroke or Transient Ischemic Attack: A post hoc Analysis of a Randomized Control Trial.
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Fema | 2023 |
To study the mechanism of panax notoginseng in the treatment of aspirin resistance in the secondary prevention of stroke based on TLR4/MyD88/NF-κB signaling pathway: A study protocol.
Topics: Aged; Aspirin; Humans; Middle Aged; Myeloid Differentiation Factor 88; NF-kappa B; Panax notoginseng | 2022 |
Genotype-Guided Dual Antiplatelet Use for Transient Ischemic Attack and Minor Stroke by Imaging Status: Subgroup Analysis of the CHANCE-2 Trial.
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Genotype; Hemorrhage; Humans; | 2023 |
Antiplatelet effect of ginkgo diterpene lactone meglumine injection in acute ischemic stroke: A randomized, double-blind, placebo-controlled clinical trial.
Topics: Aspirin; Ginkgo biloba; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; Stroke | 2023 |
Rationale and design of a randomised double-blind 2×2 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial atherosclero
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Atorvastatin; Brain Ischemia; Clopidogrel; | 2023 |
Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; | 2023 |
Rationale and design of the TUXEDO-2 India study: Ultra-Thin strUt Supraflex Cruz versus XiencE in a Diabetic pOpulation with multi-vessel disease-2.
Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus; Everolimus; Humans; Myocardial Infarction; Perc | 2023 |
Stroke Recurrence and Antiplatelets in Posterior Versus Anterior Circulation Minor Stroke or Transient Ischemic Attack.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Infarction; Ischemic Attack, Tr | 2023 |
Dual antiplatelet Use for extended period taRgeted to AcuTe ischemic stroke with presumed atherosclerotic OrigiN (DURATION) trial: Rationale and design.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Strok | 2023 |
Subsequent ischemic stroke and tobacco smoking: A secondary analysis of the POINT trial.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Neoplasm Recu | 2023 |
The predictive value of interarm systolic blood pressure differences in patients with vascular disease: Sub-analysis of the COMPASS trial.
Topics: Aspirin; Blood Pressure; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Peripheral Arteria | 2023 |
Outcomes among patients with peripheral artery disease in the Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) study.
Topics: Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Patient-Centered Care; Peripheral | 2023 |
Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial.
Topics: Aspirin; Brain Ischemia; Double-Blind Method; Female; Humans; Ischemic Stroke; Male; Middle Aged; St | 2023 |
Sex Differences in Outcomes After Transcatheter Aortic Valve Replacement: A POPular TAVI Subanalysis.
Topics: Anticoagulants; Aortic Valve; Aortic Valve Stenosis; Aspirin; Female; Hemorrhage; Humans; Male; Myoc | 2023 |
Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; East Asian People; Female; Hemorrhage; Humans; | 2023 |
Rationale and design of a randomized study comparing the Watchman FLX device to DOACs in patients with atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Embolism; Female; Follow-Up Studies; | 2023 |
Internet Versus Noninternet Participation in a Decentralized Clinical Trial: Lessons From the ADAPTABLE Study.
Topics: Aged; Aspirin; Female; Humans; Internet; Male; Myocardial Infarction; Stroke | 2023 |
Dual Antiplatelet Therapy vs Alteplase for Patients With Minor Nondisabling Acute Ischemic Stroke: The ARAMIS Randomized Clinical Trial.
Topics: Administration, Intravenous; Aged; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combinat | 2023 |
Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack.
Topics: Aspirin; Body Mass Index; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attac | 2023 |
Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia.
Topics: Acute Disease; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female | 2023 |
Low-Dose Aspirin and the Risk of Stroke and Intracerebral Bleeding in Healthy Older People: Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Aspirin; Cerebral Hemorrhage; Female; Humans; Intracranial Hemorrhages; Ischemic Stroke; Plate | 2023 |
Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Gastrointestinal Hemorrhage; Humans; Ma | 2023 |
Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial.
Topics: Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutaneous Coronary Interventio | 2023 |
Comparison of Antiplatelet Monotherapies After Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Pe | 2023 |
Vulnerable and Stabilized States After Cerebral Ischemic Events: Implications of Kinetic Modeling in the SOCRATES, POINT, and THALES Trials.
Topics: Aspirin; Cerebral Infarction; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platele | 2023 |
Ticagrelor Versus Clopidogrel in Minor Stroke or Transient Ischemic Attack With Intracranial Artery Stenosis: A Post Hoc Analysis of CHANCE-2.
Topics: Arteries; Aspirin; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combination; Female; Humans; | 2023 |
In healthy older adults, low-dose aspirin did not differ from placebo for ischemic stroke but increased intracranial bleeding.
Topics: Aged; Aspirin; Cerebral Hemorrhage; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; Stroke | 2023 |
Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Case-Control Studies; Cause of Death; Drug Therapy, Combinat | 2019 |
Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carotid Artery Diseases; | 2019 |
Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
Topics: Aged; Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy | 2019 |
Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Hemo | 2019 |
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis.
Topics: Aged; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug Therapy, Combination; Female; Gastroin | 2019 |
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis.
Topics: Aged; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug Therapy, Combination; Female; Gastroin | 2019 |
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis.
Topics: Aged; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug Therapy, Combination; Female; Gastroin | 2019 |
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis.
Topics: Aged; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug Therapy, Combination; Female; Gastroin | 2019 |
Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial.
Topics: Aspirin; Atherosclerosis; Atrial Fibrillation; Carotid Stenosis; Double-Blind Method; Drug Therapy, | 2020 |
Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial.
Topics: Aged; Aorta, Thoracic; Aspirin; Atherosclerosis; Double-Blind Method; Echocardiography, Transesophag | 2019 |
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
Topics: Aged; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; | 2019 |
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
Topics: Aged; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; | 2019 |
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
Topics: Aged; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; | 2019 |
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
Topics: Aged; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; | 2019 |
Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI.
Topics: Aged; Aspirin; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reva | 2019 |
Post-stroke cognitive impairment as an independent predictor of ischemic stroke recurrence: PICASSO sub-study.
Topics: Aged; Aspirin; Cilostazol; Cognitive Dysfunction; Female; Fibrinolytic Agents; Humans; Male; Middle | 2020 |
Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Female; Follow-Up Studies; Humans; M | 2020 |
Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Female; Follow-Up Studies; Humans; M | 2020 |
Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Female; Follow-Up Studies; Humans; M | 2020 |
Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Female; Follow-Up Studies; Humans; M | 2020 |
Homocysteine Level Predicts Response to Dual Antiplatelet in Women With Minor Stroke or Transient Ischemic Attack: Subanalysis of the CHANCE Trial.
Topics: Aged; Aspirin; Biomarkers; China; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Femal | 2020 |
Higher early recurrence risk and potential benefit of dual antiplatelet therapy for minor stroke with watershed infarction: subgroup analysis of CHANCE.
Topics: Aspirin; Drug Therapy, Combination; Female; Humans; Infarction; Male; Middle Aged; Platelet Aggregat | 2020 |
Comparison of Antiplatelet Therapies for Prevention of Patent Foramen Ovale-Associated Stroke.
Topics: Adolescent; Adult; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Foramen Ov | 2020 |
Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial.
Topics: Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; | 2020 |
Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.
Topics: Aged; Aged, 80 and over; Aspirin; Comorbidity; Coronary Artery Disease; Double-Blind Method; Drug Ad | 2021 |
Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Disease-Free Survival; Double-Blind Method; Female | 2020 |
Practice advisory update summary: Patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology.
Topics: Adult; Aspirin; Atrial Fibrillation; Foramen Ovale, Patent; Humans; Platelet Aggregation Inhibitors; | 2020 |
Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups.
Topics: Aged; Aged, 80 and over; Aspirin; Dabigatran; Double-Blind Method; Female; Fibrinolytic Agents; Huma | 2020 |
An investigation into the impact of enteric coated of aspirin in patients with newly diagnosed ischemic stroke (ECASIS).
Topics: Adolescent; Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; Female; Gastrointestinal Hemorrha | 2020 |
A comparison of three platelet function tests in ischemic stroke patients with antiplatelet therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Clopidogrel; Drug Therapy, Combin | 2020 |
High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Double-Blind Method; Factor Xa Inhibitors; Female; Fol | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Platelet function in stroke/transient ischemic attack patients treated with tocotrienol.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy.
Topics: Aged; Aspirin; Double-Blind Method; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Intra | 2020 |
Incidence of Cardiovascular Events and Safety Profile of Prasugrel in Korean Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting | 2020 |
Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the O
Topics: Acute Coronary Syndrome; Adult; Aspirin; Clopidogrel; Double-Blind Method; Drug-Eluting Stents; Dual | 2020 |
Dual Antiplatelet Therapy Beyond 90 days in Symptomatic Intracranial Stenosis in the SAMMPRIS Trial.
Topics: Aged; Angioplasty; Aspirin; Clopidogrel; Drug Administration Schedule; Dual Anti-Platelet Therapy; F | 2020 |
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Double | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial.
Topics: Administration, Oral; Aspirin; Atrial Fibrillation; Atrial Flutter; Bioprosthesis; Brazil; Cause of | 2021 |
Ipsilateral Nonstenotic Carotid Disease in Minor Ischemic Stroke: an Exploratory Analysis of The POINT Randomized Clinical Trial.
Topics: Aged; Aspirin; Carotid Artery Diseases; Clopidogrel; Comorbidity; Double-Blind Method; Dual Anti-Pla | 2020 |
Association between aspirin use and cardiovascular outcomes in ALLHAT participants with and without chronic kidney disease: A post hoc analysis.
Topics: Aspirin; Cardiovascular Diseases; Humans; Hypertension; Myocardial Infarction; Renal Insufficiency, | 2021 |
Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Factor Xa Inhibitors; Fema | 2021 |
Double-blind, placebo-controlled randomised clinical trial to evaluate the effect of ASPIRIN discontinuation after left atrial appendage occlusion in atrial fibrillation: protocol of the ASPIRIN LAAO trial.
Topics: Aspirin; Atrial Appendage; Atrial Fibrillation; China; Humans; Multicenter Studies as Topic; Prospec | 2021 |
Aspirin versus anticoagulation in cervical artery dissection (TREAT-CAD): an open-label, randomised, non-inferiority trial.
Topics: Acenocoumarol; Adult; Anticoagulants; Aspirin; Carotid Artery, Internal, Dissection; Denmark; Female | 2021 |
Ticagrelor or Aspirin After Coronary Artery Bypass in Patients With Chronic Kidney Disease.
Topics: Aged; Aged, 80 and over; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Meth | 2022 |
Carotid Stenosis and Recurrent Ischemic Stroke: A Post-Hoc Analysis of the POINT Trial.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Carotid Stenosis; Clopidogrel; Dual Anti-Platelet | 2021 |
Clopidogrel with aspirin in High-risk patients with Acute Non-disabling Cerebrovascular Events II (CHANCE-2): rationale and design of a multicentre randomised trial.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibi | 2021 |
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Female; Hemorrhage; Hospitalization; Humans | 2021 |
Personalized antiplatelet therapy based on clopidogrel/aspirin resistance tests in acute ischemic stroke and transient ischemic attack: Study protocol of a multi-center, single-blinded and randomized controlled trial.
Topics: Aftercare; Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Ischemic Stroke | 2021 |
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial.
Topics: Aged; Aspirin; Brain Ischemia; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Peripheral A | 2021 |
Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: Time course analysis of CHANCE.
Topics: Aspirin; Brain Ischemia; China; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Fibrino | 2017 |
Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Drug | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Dual Therapy with Aspirin and Cilostazol May Improve Platelet Aggregation in Noncardioembolic Stroke Patients: A Pilot Study.
Topics: Aged; Aged, 80 and over; Aspirin; Cilostazol; Drug Therapy, Combination; Female; Humans; Male; Middl | 2017 |
Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; D | 2017 |
Rationale and Design for a Randomized Comparison of Efficacy and Safety between Aspirin and Clopidogrel in Atrial Fibrillation Patients with Low Stroke Risk: CESAC-AF trial.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Endoscopy, Digestive System; G | 2017 |
High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study.
Topics: Aspirin; Atorvastatin; Coronary Artery Disease; Drug-Eluting Stents; Female; Graft Occlusion, Vascul | 2018 |
Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source.
Topics: Adenosine; Aged; Aortic Diseases; Aspirin; Atherosclerosis; Carotid Stenosis; Female; Humans; Intrac | 2017 |
Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial.
Topics: Administration, Oral; Aged; Aspirin; Atrial Fibrillation; Disease-Free Survival; Double-Blind Method | 2017 |
Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents.
Topics: Aged; Aspirin; Clinical Decision-Making; Clopidogrel; Coronary Disease; Coronary Thrombosis; Decisio | 2017 |
The aspirin in reducing events in the elderly trial: Statistical analysis plan.
Topics: Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Double-Blind Method; Female; F | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Comparison of 1-Year Outcomes of Triple (Aspirin + Clopidogrel + Cilostazol) Versus Dual Antiplatelet Therapy (Aspirin + Clopidogrel + Placebo) After Implantation of Second-Generation Drug-Eluting Stents into One or More Coronary Arteries: from the DECREA
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Double-Blind Method | 2018 |
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Clopidogrel; Denmark; Dipyridamole; Drug Therapy, Comb | 2018 |
Enoxaparin vs Aspirin in Patients With Cancer and Ischemic Stroke: The TEACH Pilot Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Enoxaparin; Female; Fibrinolyti | 2018 |
Rationale and Study Design for a Single-Arm Phase IIa Study Investigating Feasibility of Preventing Ischemic Cerebrovascular Events in High-Risk Patients with Acute Non-disabling Ischemic Cerebrovascular Events Using Remote Ischemic Conditioning.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Ther | 2018 |
The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Catheter Ablation; Dose-Response Relationship, D | 2018 |
Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Drug Monitoring; Female | 2018 |
Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; China; Drug Therapy, Combination; | 2018 |
Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Comorbidity; Double-Blind Method; Factor Xa Inhibitor | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
Topics: Aged; Aspirin; Brain Ischemia; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Emboli | 2018 |
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
Topics: Aged; Aspirin; Brain Ischemia; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Emboli | 2018 |
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
Topics: Aged; Aspirin; Brain Ischemia; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Emboli | 2018 |
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
Topics: Aged; Aspirin; Brain Ischemia; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Emboli | 2018 |
Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial.
Topics: Aged; Antioxidants; Asian People; Aspirin; Brain Ischemia; Cardiovascular Diseases; Cerebral Hemorrh | 2018 |
Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial.
Topics: Aged; Aspirin; Brain Ischemia; Coronary Artery Disease; Cyclooxygenase Inhibitors; Female; Greece; H | 2019 |
An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rat
Topics: Acute Coronary Syndrome; Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Hemorrha | 2018 |
Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aspirin; Bayes Theorem; Brain Ischemia; Dou | 2018 |
Oxidized low-density lipoprotein predicts recurrent stroke in patients with minor stroke or TIA.
Topics: Aged; Aspirin; Blood Pressure; Body Mass Index; Clopidogrel; Double-Blind Method; Female; Follow-Up | 2018 |
Dual antiplatelet therapy pretreatment in IV thrombolysis for acute ischemic stroke.
Topics: Administration, Intravenous; Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; | 2018 |
Aspirin plus clopidogrel may reduce the risk of early neurologic deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Fem | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat | 2018 |
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.
Topics: Aged; Aspirin; Cohort Studies; Double-Blind Method; Factor Xa Inhibitors; Female; Foramen Ovale, Pat | 2018 |
Effects of policosanol in the functional recovery of non-cardioembolic ischemic stroke hypertensive patients.
Topics: Aged; Aspirin; Brain Ischemia; Double-Blind Method; Drug Therapy, Combination; Fatty Alcohols; Femal | 2018 |
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70).
Topics: Aged; Asian People; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus; Dyslipidem | 2019 |
Stroke Outcomes in the COMPASS Trial.
Topics: Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Female; Follow | 2019 |
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Chronic Disease; Corona | 2019 |
The Acute S
Topics: Aged; Aged, 80 and over; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Is | 2019 |
Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial.
Topics: Aged; Aged, 80 and over; Aspirin; Endpoint Determination; Female; Hemorrhage; Humans; Ischemic Attac | 2019 |
Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study.
Topics: Aged; Aspirin; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Diabetes Mellitus, Type | 2019 |
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fib | 2019 |
Antiplatelet Therapy vs Anticoagulation Therapy in Cervical Artery Dissection: The Cervical Artery Dissection in Stroke Study (CADISS) Randomized Clinical Trial Final Results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Carotid Artery, Internal, Disse | 2019 |
Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY).
Topics: Aspirin; Coronary Artery Disease; Drug Administration Routes; Drug Therapy, Combination; Endpoint De | 2019 |
Antiplatelet vs. R-tPA for acute mild ischemic stroke: A prospective, random, and open label multi-center study.
Topics: Adolescent; Adult; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hum | 2019 |
Use of a Geographic Information System to create treatment groups for group-randomized community trials: The Minnesota Heart Health Program.
Topics: Aged; Aspirin; Cardiovascular Agents; Community Health Services; Cross-Over Studies; Female; Geograp | 2019 |
The influence of mean arterial pressure on the efficacy and safety of dual antiplatelet therapy in minor stroke or transient ischemic attack patients.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arterial Pressure; Aspirin; Blood Pressure; Case-Cont | 2019 |
Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Intracr | 2019 |
Effect of dual versus mono antiplatelet therapy on recurrent stroke modulated by activated partial thromboplastin time.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2019 |
Effect of warfarin versus aspirin on blood viscosity in cardioembolic stroke with atrial fibrillation: a prospective clinical trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Viscosity; Female; Huma | 2019 |
Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Ther | 2019 |
Disparities and Temporal Trends in the Use of Anticoagulation in Patients With Ischemic Stroke and Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Flori | 2019 |
Permanent Percutaneous Carotid Artery Filter to Prevent Stroke in Atrial Fibrillation Patients: The CAPTURE Trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Carotid Artery, Common; Clopidogrel; Embolic Pro | 2019 |
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
Topics: Aged; Antithrombins; Aspirin; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Incidence | 2019 |
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
Topics: Aged; Antithrombins; Aspirin; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Incidence | 2019 |
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
Topics: Aged; Antithrombins; Aspirin; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Incidence | 2019 |
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
Topics: Aged; Antithrombins; Aspirin; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Incidence | 2019 |
Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial.
Topics: Aspirin; Hemorrhage; Humans; Ischemic Attack, Transient; Mortality; Myocardial Infarction; Observer | 2019 |
Low dose concomitant treatment with chlorpromazine and promethazine is safe in acute ischemic stroke.
Topics: Adult; Aged; Aspirin; Atorvastatin; Chlorpromazine; Double-Blind Method; Drug Therapy, Combination; | 2019 |
Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Constriction, Pathologic; | 2019 |
Personalised antiplatelet therapy based on pharmacogenomics in acute ischaemic minor stroke and transient ischaemic attack: study protocol for a randomised controlled trial.
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Hemorrhage; Humans; Ische | 2019 |
Combination therapy with beraprost sodium and aspirin for acute ischemic stroke: a single-center retrospective study.
Topics: Aged; Aspirin; Brain Ischemia; Drug Therapy, Combination; Epoprostenol; Female; Follow-Up Studies; H | 2019 |
Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind Method; Factor Xa Inhibitors; Female; Hu | 2019 |
Efficacy of clopidogrel for stroke depends on CYP2C19 genotype and risk profile.
Topics: Aged; Alleles; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Therapy, Co | 2019 |
Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient Ischemic Attack and Minor Ischemic Stroke.
Topics: Acute Disease; Aspirin; Clinical Protocols; Clopidogrel; Drug Therapy, Combination; Drug-Related Sid | 2019 |
Acute Aspirin Plus Cilostazol Dual Therapy for Noncardioembolic Stroke Patients Within 48 Hours of Symptom Onset.
Topics: Aged; Aspirin; Cilostazol; Drug Combinations; Female; Humans; Male; Middle Aged; Platelet Aggregatio | 2019 |
Frequency of silent brain lesions and aspirin protection evaluation over 3 years follow-up in beta thalassemia patients.
Topics: Adolescent; Adult; Aspirin; beta-Thalassemia; Child; Female; Follow-Up Studies; Humans; Magnetic Res | 2019 |
Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial.
Topics: Aspirin; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; D | 2013 |
Dual antiplatelets reduce microembolic signals in patients with transient ischemic attack and minor stroke: subgroup analysis of CLAIR study.
Topics: Adult; Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Humans; I | 2014 |
Optimal medical treatment versus carotid endarterectomy: the rationale and design of the Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis (AMTEC) study.
Topics: Amlodipine; Antihypertensive Agents; Aspirin; Carotid Stenosis; Combined Modality Therapy; Endartere | 2015 |
Effectiveness of antiplatelet therapy in atherosclerotic disease: comparing the ASA low-response prevalence in CVD, CAD and PAD.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Female; Humans; Male; Middle Aged; | 2014 |
Aspirin possibly reduces cerebrovascular events in type 2 diabetic patients with higher C-reactive protein level: subanalysis from the JPAD trial.
Topics: Aged; Aspirin; Atherosclerosis; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Discontinuation of antiplatelet study medication and risk of recurrent stroke and cardiovascular events: results from the PRoFESS study.
Topics: Aged; Aged, 80 and over; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dipyridamole; | 2013 |
Long-term effect of carotid surgery in asymptomatic stenosis.
Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Carotid Stenosis; Endarterectomy, Carotid; Female; | 2012 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpr | 2013 |
Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Double-Blind Method; Drug The | 2013 |
Benefit of warfarin compared with aspirin in patients with heart failure in sinus rhythm: a subgroup analysis of WARCEF, a randomized controlled trial.
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind | 2013 |
Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-plate
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, | 2013 |
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
Topics: Age Factors; Aged; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Diabetes | 2014 |
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
Topics: Age Factors; Aged; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Diabetes | 2014 |
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
Topics: Age Factors; Aged; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Diabetes | 2014 |
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
Topics: Age Factors; Aged; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Diabetes | 2014 |
Results of the PERFORM magnetic resonance imaging study.
Topics: Aged; Aged, 80 and over; Aspirin; Brain; Brain Ischemia; Female; Fibrinolytic Agents; Humans; Magnet | 2013 |
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Embolism; Fema | 2014 |
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Double-Blind Method; Drug | 2014 |
Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia).
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Restenosis; Female; Humans; Italy; Male; Mid | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
[Acetylsalicylic acid non-responders after ischemic insult in geriatric patients].
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Female; Humans; Male; Platelet Aggregation Inhibit | 2014 |
Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke.
Topics: Aged; Aspirin; Biomarkers; Brain Ischemia; C-Reactive Protein; Cilostazol; Disease Progression; Doub | 2014 |
Aspirin versus vitamin K antagonist treatment guided by transoesophageal echocardiography in patients with atrial fibrillation: a pilot study.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Echocardiography, Transesophageal; Female; Fibri | 2014 |
Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial.
Topics: Aged; Aspirin; Atrial Fibrillation; Double-Blind Method; Drug Administration Schedule; Factor Xa Inh | 2014 |
Low-molecular-weight heparin is more effective than aspirin in preventing early neurologic deterioration and improving six-month outcome.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Enoxaparin; Female; Humans; Male; | 2014 |
Thrombolysis ImPlementation in Stroke (TIPS): evaluating the effectiveness of a strategy to increase the adoption of best evidence practice--protocol for a cluster randomised controlled trial in acute stroke care.
Topics: Aspirin; Australia; Cooperative Behavior; Diffusion of Innovation; Emergency Medical Services; Evide | 2014 |
Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aorta, Thoracic; Aortic Diseases; Aspirin; Brain Ischemia; | 2014 |
A comparative study of dual versus monoantiplatelet therapy in patients with acute large-artery atherosclerosis stroke.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Endpoint Determination; Female; Humans; Intra | 2014 |
Warfarin compared with aspirin for older Chinese patients with stable coronary heart diseases and atrial fibrillation complications.
Topics: Age Factors; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Coagulation; Chi | 2014 |
The effect of a slower than standard dose escalation scheme for dipyridamole on headaches in secondary prevention therapy of strokes: a randomized, open-label trial (DOSE).
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Female; Headache; Humans; Ischemic Attack, Transie | 2014 |
Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study.
Topics: Age Factors; Aged; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Comorbidity; D | 2014 |
Impacts of COX-1 gene polymorphisms on vascular outcomes in patients with ischemic stroke and treated with aspirin.
Topics: Aged; Alleles; Aspirin; Brain Ischemia; Cohort Studies; Cyclooxygenase 1; Female; Gene Frequency; Ge | 2014 |
Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
Topics: Aged; Angina, Stable; Aspirin; Belgium; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coron | 2014 |
An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Ad | 2014 |
Early deterioration after thrombolysis plus aspirin in acute stroke: a post hoc analysis of the Antiplatelet Therapy in Combination with Recombinant t-PA Thrombolysis in Ischemic Stroke trial.
Topics: Aged; Aspirin; Female; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; Male; Middle Aged; Pla | 2014 |
An open-label evaluator-blinded clinical study of minocycline neuroprotection in ischemic stroke: gender-dependent effect.
Topics: Aged; Aspirin; Female; Humans; Male; Middle Aged; Minocycline; Neuroprotective Agents; Platelet Aggr | 2015 |
Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES.
Topics: Aged; Aspirin; Atrial Fibrillation; Brain Ischemia; Double-Blind Method; Embolism; Female; Fibrinoly | 2015 |
Initial 3-weeks' Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) followed by Clopidogrel alone in high-risk patients with Acute Non-Disabling Cerebrovascular Events (ADANCE): study protocol for a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aspirin; Clopidogrel; Double-Blind Method; Drug Administrat | 2014 |
Clopidogrel plus aspirin versus aspirin alone for preventing early neurological deterioration in patients with acute ischemic stroke.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; M | 2015 |
Predictors of contemporary coronary artery bypass grafting outcomes.
Topics: Age Factors; Aminoimidazole Carboxamide; Aspirin; Cardiopulmonary Bypass; Cardiovascular Agents; Chi | 2014 |
Clopidogrel plus aspirin prevents early neurologic deterioration and improves 6-month outcome in patients with acute large artery atherosclerosis stroke.
Topics: Acute Disease; Aged; Aspirin; Atherosclerosis; Clopidogrel; Female; Humans; Male; Nervous System Dis | 2015 |
Dual antiplatelet therapy in patients with stable coronary artery disease in modern practice: prevalence, correlates, and impact on prognosis (from the Suivi d'une cohorte de patients COROnariens stables en region NORd-Pas-de-Calais study).
Topics: Aged; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Female; Follow-Up Studies; France | 2014 |
Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial.
Topics: Aged; Anticoagulants; Aspirin; Female; Fibrinolytic Agents; Heart Failure; Humans; Male; Middle Aged | 2014 |
The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double-blind, placebo-controlled multicenter trial.
Topics: Aspirin; Cilostazol; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hu | 2015 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopid | 2015 |
Statistical analysis plan for the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Double-Blind Method; Female; Humans; Internation | 2015 |
Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combinat | 2015 |
Glycated albumin predicts the effect of dual and single antiplatelet therapy on recurrent stroke.
Topics: Aged; Aspirin; Biomarkers; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Glyc | 2015 |
Aspirin resistance in the acute stages of acute ischemic stroke is associated with the development of new ischemic lesions.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Drug Resistan | 2015 |
Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Chi-Square Distribution; Double- | 2015 |
Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studie | 2015 |
Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studie | 2015 |
Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studie | 2015 |
Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studie | 2015 |
Rationale and design of the PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage (PICASSO) study: A randomized controlled trial.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Double-Blind Method; Female; | 2015 |
Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin.
Topics: Aged; Anticoagulants; Aspirin; Female; Heart Failure; Hemorrhage; Humans; Male; Middle Aged; Platele | 2015 |
Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: CHANCE substudy.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Ischemic | 2015 |
Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients.
Topics: Aged; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Factor Xa Inhibitors; Female; Hemorrhage; | 2015 |
Dual antiplatelet therapy in stroke and ICAS: Subgroup analysis of CHANCE.
Topics: Aged; Aspirin; Clopidogrel; Constriction, Pathologic; Double-Blind Method; Drug Therapy, Combination | 2015 |
Does the Stenting Versus Aggressive Medical Therapy Trial Support Stenting for Subgroups With Intracranial Stenosis?
Topics: Angioplasty; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Clopidogrel; Constriction, Patholo | 2015 |
Combined clopidogrel-aspirin treatment for high risk TIA or minor stroke does not increase cerebral microbleeds.
Topics: Aged; Aspirin; Cerebral Cortex; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Female; | 2015 |
Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT E
Topics: Administration, Oral; Antithrombins; Aspirin; Dabigatran; Double-Blind Method; Fibrinolytic Agents; | 2015 |
Treatment of Rivaroxaban versus Aspirin for Non-disabling Cerebrovascular Events (TRACE): study protocol for a randomized controlled trial.
Topics: Adult; Aspirin; Clinical Protocols; Factor Xa Inhibitors; Female; Humans; Ischemic Attack, Transient | 2015 |
The first prognostic model for stroke and death in patients with systolic heart failure.
Topics: Aged; Algorithms; Anticoagulants; Area Under Curve; Aspirin; Cause of Death; Double-Blind Method; Fe | 2016 |
Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Factor Xa Inhibi | 2016 |
Antiplatelet Therapy in Carotid Artery Stenting and Carotid Endarterectomy in the Asymptomatic Carotid Surgery Trial-2.
Topics: Aspirin; Carotid Artery, Common; Carotid Stenosis; Clopidogrel; Dose-Response Relationship, Drug; En | 2016 |
Comparing Cerebralcare Granule and aspirin for neurological dysfunction in acute stroke in real-life practice.
Topics: Aged; Aspirin; China; Cognition; Drugs, Chinese Herbal; Female; Humans; Life Change Events; Male; Mi | 2017 |
Clinical Significance of Laboratory-determined Aspirin Poor Responsiveness After Primary Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Blood Platelets; Blood Pressure; Creatine Kinase; Female; Heart Rate; Hemorrhage; Hum | 2016 |
[Argatroban, Aspirin, and Clopidogrel Combination Therapy for Acute Penetrating Artery Infarction: A Pilot Study].
Topics: Acute Disease; Aged; Arginine; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Infa | 2016 |
Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Aspirin; Chi-Square Distribution; China; Clopidogrel; Disease Progression; Double-Blind Method | 2016 |
Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.
Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyspepsia; | 2016 |
Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Administration Schedu | 2016 |
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease.
Topics: Adenosine; Aged; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemor | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Adenosine; Aged; Aspirin; Double-Blind Method; Female; Hemorrhage; Humans; Ischemic Attack, Transien | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Adenosine; Aged; Aspirin; Double-Blind Method; Female; Hemorrhage; Humans; Ischemic Attack, Transien | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Adenosine; Aged; Aspirin; Double-Blind Method; Female; Hemorrhage; Humans; Ischemic Attack, Transien | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Adenosine; Aged; Aspirin; Double-Blind Method; Female; Hemorrhage; Humans; Ischemic Attack, Transien | 2016 |
Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Comorbidity; Diabetes Mellitus; Dyslipidemias; Fem | 2016 |
Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Biomarkers; Cholesterol, HDL; Clopidogrel; | 2016 |
6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial.
Topics: Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug | 2016 |
Risks and Benefits of Dual Antiplatelet Therapy Beyond 12 Months After Coronary Stenting: A Prospective Randomized Cohort Study.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; | 2016 |
Efficacy and Safety of Vinpocetine as Part of Treatment for Acute Cerebral Infarction: A Randomized, Open-Label, Controlled, Multicenter CAVIN (Chinese Assessment for Vinpocetine in Neurology) Trial.
Topics: Aged; Anticoagulants; Aspirin; Cerebral Infarction; Cerebrovascular Circulation; China; Clopidogrel; | 2016 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone.
Topics: Aged; Aspirin; Atherosclerosis; Brain; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therap | 2016 |
The curative effect comparison of two kinds of therapeutic regimens on decreasing the relative intensity of microembolic signal in CLAIR trial.
Topics: Aspirin; Brain Ischemia; Carotid Stenosis; Cerebral Arterial Diseases; Clopidogrel; Drug Therapy, Co | 2016 |
Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
Topics: Aspirin; Atrial Fibrillation; Blood Transfusion; Clopidogrel; Drug Therapy, Combination; Drug-Elutin | 2017 |
Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; D | 2016 |
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; D | 2016 |
Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; C | 2016 |
Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm
Topics: Adenosine; Aged; Aspirin; Coronary Artery Disease; Female; Hemorrhage; Humans; Intracranial Hemorrha | 2016 |
A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Investig
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Bypass; Coronary Artery Disease; | 2016 |
Abnormal glucose regulation increases stroke risk in minor ischemic stroke or TIA.
Topics: Aged; Aspirin; Blood Glucose; Brain Ischemia; Clopidogrel; Diabetes Complications; Double-Blind Meth | 2016 |
ASPREE-NEURO study protocol: A randomized controlled trial to determine the effect of low-dose aspirin on cerebral microbleeds, white matter hyperintensities, cognition, and stroke in the healthy elderly.
Topics: Aged; Aspirin; Brain; Cerebral Hemorrhage; Cognition; Double-Blind Method; Fibrinolytic Agents; Huma | 2017 |
Effect of Estimated Glomerular Filtration Rate Decline on the Efficacy and Safety of Clopidogrel With Aspirin in Minor Stroke or Transient Ischemic Attack: CHANCE Substudy (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events).
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Comorbidity; Drug Therapy, Combi | 2016 |
Baseline characteristics of the 3096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischemic Stroke' trial.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Humans; | 2017 |
A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy | 2016 |
Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design.
Topics: Aspirin; Brain; Embolism; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Pyrazoles; Pyridones; R | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes).
Topics: Adenosine; Aged; Anti-Inflammatory Agents, Non-Steroidal; Asian People; Aspirin; Cohort Studies; Dou | 2017 |
The effectiveness and safety of dual antiplatelet therapy in ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis in Chinese patients: A randomized and controlled trail.
Topics: Arterial Occlusive Diseases; Aspirin; China; Clopidogrel; Dose-Response Relationship, Drug; Drug The | 2017 |
Association of multiple infarctions and ICAS with outcomes of minor stroke and TIA.
Topics: Aged; Aspirin; Brain; Brain Infarction; Brain Ischemia; Clopidogrel; Female; Humans; Image Processin | 2017 |
Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial.
Topics: Adenosine; Adult; Aged; Aspirin; Atherosclerosis; Dose-Response Relationship, Drug; Double-Blind Met | 2017 |
Impact of Glycemic Control on Efficacy of Clopidogrel in Transient Ischemic Attack or Minor Stroke Patients With
Topics: Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind Method; Female; Glycated Serum Al | 2017 |
Efficacy of cilostazol-based dual antiplatelet treatment in patients undergoing carotid artery stenting.
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Stenosis; Cilostazol; Clopidogrel; Drug Therapy, Combinati | 2017 |
Antiplatelet cilostazol, an inhibitor of type III phosphodiesterase, improves swallowing function in patients with a history of stroke.
Topics: Aged; Aspirin; Cilostazol; Cross-Over Studies; Deglutition Disorders; Double-Blind Method; Humans; M | 2008 |
Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Coronary Vessels; Drug Therapy, Combination; Drug-Elutin | 2008 |
Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Drug Resistance; Female; Humans; Hypertr | 2008 |
A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility.
Topics: Aged; Aspirin; Blood Pressure; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Drug Tolerance; | 2008 |
Antiplatelet therapy vs. anticoagulation in cervical artery dissection: rationale and design of the Cervical Artery Dissection in Stroke Study (CADISS).
Topics: Anticoagulants; Aortic Dissection; Aspirin; Clinical Protocols; Clopidogrel; Diagnostic Imaging; Dip | 2007 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFE
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Cogn | 2008 |
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFE
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Cogn | 2008 |
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFE
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Cogn | 2008 |
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFE
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Cogn | 2008 |
Serum urate predicts long-term risk of acute coronary events in women after a transient ischaemic attack and stroke.
Topics: Acute Disease; Aged; Aspirin; Biomarkers; Coronary Disease; Female; Humans; Ischemic Attack, Transie | 2008 |
Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Death, Sudden, Cardiac; Double-Blind Method; F | 2009 |
A pilot study of resistance to aspirin in stroke patients.
Topics: Aged; Aged, 80 and over; Aspirin; Australia; Drug Resistance; Female; Humans; Longitudinal Studies; | 2008 |
Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; Middle A | 2008 |
The relationship between baseline blood pressure and computed tomography findings in acute stroke: data from the tinzaparin in acute ischaemic stroke trial (TAIST).
Topics: Acute Disease; Aspirin; Blood Pressure; Brain; Brain Ischemia; Causality; Cerebral Hemorrhage; Comor | 2009 |
Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopi | 2008 |
Failure of antithrombotic therapy and risk of stroke in patients with symptomatic intracranial stenosis.
Topics: Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Constriction, Pathologic; Double-Blind Met | 2009 |
Frequency of microemboli signal in stroke patients treated with low molecular weight heparin or aspirin.
Topics: Anticoagulants; Aspirin; Comorbidity; Female; Heparin, Low-Molecular-Weight; Hong Kong; Humans; Inci | 2010 |
Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chronic Disease; Clopidogrel; Death; Double-Blind Method; F | 2009 |
Low molecular weight heparin significantly reduces embolisation after carotid endarterectomy--a randomised controlled trial.
Topics: Adenosine Diphosphate; Aged; Anticoagulants; Arachidonic Acid; Aspirin; Carotid Artery Diseases; Dal | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double- | 2009 |
Aortic arch plaques and risk of recurrent stroke and death.
Topics: Adult; Aged; Aged, 80 and over; Aorta, Thoracic; Aortic Diseases; Aspirin; Atherosclerosis; Death; D | 2009 |
Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Arteries; Cerebrovascular Disorde | 2009 |
Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Arteries; Cerebrovascular Disorde | 2009 |
Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Arteries; Cerebrovascular Disorde | 2009 |
Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Arteries; Cerebrovascular Disorde | 2009 |
The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population.
Topics: Activities of Daily Living; Aged; Aspirin; Cognition; Diabetes Complications; Dose-Response Relation | 2009 |
[Clopidogrel in the treatment of atrial fibrillation: benefit from addition to aspirin. The results of ACTIVE A trial].
Topics: Age Factors; Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Follow-Up S | 2009 |
Dipyridamole-associated headache in stroke patients--interindividual differences?
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Dipyridamole; Drug Therapy, Combination; Femal | 2009 |
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Chest Pain; Dose-Response Relationship, Drug | 2009 |
Reproducibility of measures of visit-to-visit variability in blood pressure after transient ischaemic attack or minor stroke.
Topics: Aged; Aspirin; Blood Pressure; Blood Pressure Determination; Endarterectomy, Carotid; Female; Follow | 2009 |
Triflusal and aspirin have different effects on inflammatory biomarkers measured in patients with acute ischemic stroke.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Aspirin; Biomarkers; Brain Ischemia; Female; Huma | 2009 |
Distribution of dipyridamole in blood components among post-stroke patients treated with extended release formulation.
Topics: Aged; Aspirin; Aspirin, Dipyridamole Drug Combination; Blood Platelets; Delayed-Action Preparations; | 2009 |
Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug | 2009 |
Stroke and aspirin non-responder patients: relation with hypertension and platelet response to adenosine diphosphate.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Female; Humans; Hypertension; Male; Middle Ag | 2009 |
Antiplatelet therapy in combination with rt-PA thrombolysis in ischemic stroke (ARTIS): rationale and design of a randomized controlled trial.
Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Intracranial Hemorr | 2010 |
Alcohol consumption and functional outcome after stroke in men.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Aspirin; Cohort Studies; Follow-Up Studies; Humans | 2010 |
Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial.
Topics: Aspirin; Bleeding Time; Brain Ischemia; Cilostazol; Double-Blind Method; Drug Resistance; Drug Thera | 2010 |
Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke.
Topics: Aspirin; Blood Flow Velocity; Brain; Brain Ischemia; Cerebral Angiography; Cerebral Arteries; Cerebr | 2009 |
Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Humans; Kapla | 2009 |
Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Chi-Square Distribution; Disability Evaluation; Do | 2010 |
Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Embolism; Feasibility Studies | 2010 |
Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Female; Fibrinolytic Agents; Humans; Kapla | 2010 |
Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes.
Topics: Aged; Antibodies; Aspirin; Atorvastatin; Cause of Death; Chi-Square Distribution; Death, Sudden; Dia | 2010 |
Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial.
Topics: Aged; Ankle; Aspirin; Atherosclerosis; Blood Pressure; Brachial Artery; Cardiovascular Diseases; Dou | 2010 |
Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Drug Administration Sche | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial.
Topics: Adult; Aged; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Clopidogrel; Drug Therapy, Combina | 2010 |
Warfarin and aspirin use in atrial fibrillation among practicing cardiologist (from the AFFECTS Registry).
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiology; Decision Making; Follow-Up Studies; | 2010 |
Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Double-Blind Method; Female; Fo | 2010 |
Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Double-Blind Method; Female; Fo | 2010 |
Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Double-Blind Method; Female; Fo | 2010 |
Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Double-Blind Method; Female; Fo | 2010 |
A randomised controlled trial of antiplatelet therapy in combination with Rt-PA thrombolysis in ischemic stroke: rationale and design of the ARTIS-Trial.
Topics: Aspirin; Brain Ischemia; Drug Administration Schedule; Drug Therapy, Combination; Fibrinolytic Agent | 2010 |
Rationale, design and population baseline characteristics of the PERFORM vascular project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke o
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Carotid Arteries; Carotid Stenosis; Data Interpre | 2010 |
Platelet function and spontaneous thrombolytic activity of patients with cerebral infarction assessed by the global thrombosis test.
Topics: Adult; Aged; Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Cerebral Infarction; Femal | 2010 |
Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Incidence; Intention to Treat Analy | 2010 |
Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W.
Topics: Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, Combination; Fibrinolyt | 2010 |
[Changes of plasma fibrinogen level among acute ischemic stroke subtypes according to TOAST criteria and effects of Songling Xuemaikang].
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Drugs, Chinese Herbal; Female; Fibrinogen; Humans; | 2010 |
Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vas
Topics: Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Cilostazol; Clinical Protocols; Clopidogrel | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Humans; Intention to Treat Ana | 2010 |
Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Humans; Intention to Treat Ana | 2010 |
Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Humans; Intention to Treat Ana | 2010 |
Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Humans; Intention to Treat Ana | 2010 |
Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial.
Topics: Adult; Aged; Aspirin; Cerebral Infarction; Cilostazol; Double-Blind Method; Female; Follow-Up Studie | 2010 |
Prevention with low-dose aspirin plus dipyridamole in patients with disabling stroke.
Topics: Aspirin; Dipyridamole; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combinat | 2010 |
Effects of Aggrenox and aspirin on plasma endothelial nitric oxide synthase and oxidised low-density lipoproteins in patients after ischaemic stroke. The AGgrenox versus aspirin therapy evaluation (AGATE) biomarker substudy.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Atherosclerosis; Biomarkers; Case-Control Studies; | 2011 |
Asymptomatic hemorrhagic transformation of infarction and its relationship with functional outcome and stroke subtype: assessment from the Tinzaparin in Acute Ischaemic Stroke Trial.
Topics: Aged; Anticoagulants; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Dose-Response Relationship, | 2010 |
Radix/rhizoma notoginseng extract (sanchitongtshu) for ischemic stroke: a randomized controlled study.
Topics: Activities of Daily Living; Aged; Aspirin; Brain Ischemia; Cognition Disorders; Double-Blind Method; | 2011 |
Predictors of adherence to secondary preventive medication in stroke patients.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Attitude to Health; Brain Ische | 2011 |
Non-invasive alternating current stimulation induces recovery from stroke.
Topics: Aged; Aphasia; Aspirin; Brain Ischemia; Clopidogrel; Combined Modality Therapy; Electric Stimulation | 2010 |
Enhanced ex vivo inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: first results from the TRinity AntiPlatelet responsiveness (TrAP) study.
Topics: Adult; Aged; Aspirin; Blood Platelets; Blood Specimen Collection; Dipyridamole; Drug Therapy, Combin | 2011 |
Clopidogrel versus dipyridamole in addition to aspirin in reducing embolization detected with ambulatory transcranial Doppler: a randomized trial.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Aspirin; Clopidogrel; Dipyridamole; Double-Blind Method; D | 2011 |
Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Creatinine; Diabetes Mellit | 2011 |
Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study.
Topics: Acute Coronary Syndrome; Administration, Cutaneous; Age Factors; Aged; Angioplasty, Balloon, Coronar | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
The Secondary Prevention of Small Subcortical Strokes (SPS3) study.
Topics: Antihypertensive Agents; Aspirin; Clopidogrel; Cognition Disorders; Humans; Hypertension; Magnetic R | 2011 |
The Secondary Prevention of Small Subcortical Strokes (SPS3) study.
Topics: Antihypertensive Agents; Aspirin; Clopidogrel; Cognition Disorders; Humans; Hypertension; Magnetic R | 2011 |
The Secondary Prevention of Small Subcortical Strokes (SPS3) study.
Topics: Antihypertensive Agents; Aspirin; Clopidogrel; Cognition Disorders; Humans; Hypertension; Magnetic R | 2011 |
The Secondary Prevention of Small Subcortical Strokes (SPS3) study.
Topics: Antihypertensive Agents; Aspirin; Clopidogrel; Cognition Disorders; Humans; Hypertension; Magnetic R | 2011 |
Quality of life after ischemic stroke varies in western countries: data from the tinzaparin in Acute Ischaemic Stroke Trial (TAIST).
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Chi-Square Distribution; Emotions; Europe; Female; | 2012 |
High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combinati | 2011 |
The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
Topics: Aged; Asian People; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action | 2011 |
The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
Topics: Aged; Asian People; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action | 2011 |
The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
Topics: Aged; Asian People; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action | 2011 |
The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
Topics: Aged; Asian People; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action | 2011 |
The International Stroke Trial database.
Topics: Access to Information; Activities of Daily Living; Aged, 80 and over; Anticoagulants; Asia; Aspirin; | 2011 |
Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Humans; International Nor | 2011 |
Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial.
Topics: Aged; Aspirin; Cilostazol; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemorrhage | 2011 |
Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; N | 2011 |
The role of aspirin in childhood tuberculous meningitis.
Topics: Anti-Inflammatory Agents; Aspirin; Child, Preschool; Dose-Response Relationship, Drug; Female; Follo | 2011 |
The role of aspirin in childhood tuberculous meningitis.
Topics: Anti-Inflammatory Agents; Aspirin; Child, Preschool; Dose-Response Relationship, Drug; Female; Follo | 2011 |
The role of aspirin in childhood tuberculous meningitis.
Topics: Anti-Inflammatory Agents; Aspirin; Child, Preschool; Dose-Response Relationship, Drug; Female; Follo | 2011 |
The role of aspirin in childhood tuberculous meningitis.
Topics: Anti-Inflammatory Agents; Aspirin; Child, Preschool; Dose-Response Relationship, Drug; Female; Follo | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Mal | 2011 |
Apixaban with antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combina | 2011 |
Apixaban with antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combina | 2011 |
Apixaban with antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combina | 2011 |
Apixaban with antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combina | 2011 |
Aspirin treatment influences platelet-related inflammatory biomarkers in healthy individuals but not in acute stroke patients.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies; CD40 Ligand; Cyclooxygenase 1; Fem | 2011 |
Aspirin resistance in cerebrovascular patients.
Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Female; Follow-Up Studies; Humans; Male; Middle Aged | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Warfarin in atrial fibrillation patients with moderate chronic kidney disease.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Coagulation; Canada; Chi-Square Distributi | 2011 |
Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Drug Therapy, Combination; Female; Humans; Male; Middle A | 2012 |
Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial | 2011 |
Low-molecular-weight heparin versus aspirin for acute ischemic stroke with large artery occlusive disease: subgroup analyses from the Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arterial Occlusive Diseases; As | 2012 |
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind | 2011 |
Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects.
Topics: Aged; Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Female; Hemorrhage; Humans; Mi | 2011 |
The influence of fluid intake on stroke recurrence--a prospective study.
Topics: Aged; Aspirin; Beverages; Double-Blind Method; Drinking; Female; Follow-Up Studies; Humans; Male; Me | 2012 |
Pilot study of the safety of starting administration of low-dose aspirin and cilostazol in acute ischemic stroke.
Topics: Acute Disease; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cilostazol; Drug Therapy, Combinati | 2011 |
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C | 2012 |
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C | 2012 |
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C | 2012 |
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C | 2012 |
[Branch atheromatous disease: prognosis and management. The SPS3 experience].
Topics: Aspirin; Basilar Artery; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stroke; Stroke, Lacun | 2011 |
Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Female; Fibrinolytic Agents; Humans; Ischemic | 2012 |
Cilostazol versus aspirin therapy in patients with chronic dizziness after ischemic stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Brain Stem; Cerebellum; Cerebrovascular Circulatio | 2012 |
Closure or medical therapy for cryptogenic stroke with patent foramen ovale.
Topics: Adolescent; Adult; Anticoagulants; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Therapy, Co | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score.
Topics: Age Factors; Aged; Aspirin; Body Weight; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Female; F | 2012 |
Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial.
Topics: Aged; Antihypertensive Agents; Aspirin; Black or African American; Blood Pressure; Chi-Square Distri | 2013 |
Risk of intracerebral hemorrhage in patients with cerebral microbleeds undergoing endovascular intervention.
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Telmisartan on top of antihypertensive treatment does not prevent progression of cerebral white matter lesions in the prevention regimen for effectively avoiding second strokes (PRoFESS) MRI substudy.
Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agen | 2012 |
Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial.
Topics: Aged; Aged, 80 and over; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Early Ter | 2012 |
Association of COX-2 rs20417 with aspirin resistance.
Topics: Adult; Aged; Alleles; Aspirin; Brain Ischemia; Cyclooxygenase 2; Drug Resistance; Female; Follow-Up | 2013 |
Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease.
Topics: Aged; Aspirin; Atrial Fibrillation; Biomarkers; Chi-Square Distribution; Creatinine; Double-Blind Me | 2012 |
Comparative evaluation of treatment with low-dose aspirin plus dipyridamole versus aspirin only in patients with acute ischaemic stroke.
Topics: Aged; Aspirin; Brain Ischemia; Comorbidity; Dipyridamole; Drug Therapy, Combination; Female; Humans; | 2012 |
The effectiveness of dual antiplatelet treatment in acute ischemic stroke patients with intracranial arterial stenosis: a subgroup analysis of CLAIR study.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combination | 2013 |
Low-molecular-weight heparin and early neurologic deterioration in acute stroke caused by large artery occlusive disease.
Topics: Aged; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Chi-Square Distribution; Drug Administra | 2012 |
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Doub | 2012 |
Effects of clopidogrel added to aspirin in patients with recent lacunar stroke.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hem | 2012 |
Monocyte chemotactic protein-1 as a potential biomarker for early anti-thrombotic therapy after ischemic stroke.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Brain Ischemia; Chemokine CCL2; Dipyridamole; D | 2012 |
Different impacts of blood pressure variability on the progression of cerebral microbleeds and white matter lesions.
Topics: Aspirin; Blood Pressure; Brain; Brain Diseases; Cerebral Hemorrhage; Cilostazol; Disease Progression | 2012 |
High on-treatment platelet reactivity on commonly prescribed antiplatelet agents following transient ischaemic attack or ischaemic stroke: results from the Trinity Antiplatelet Responsiveness (TRAP) study.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cross-Over Studies; Female; Humans; Ischemic Attack, Tr | 2013 |
The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogre | 2013 |
Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Contraindic | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
What is better antiplatelet agent to prevent recurrent stroke?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Clopid | 2012 |
Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin.
Topics: Administration, Oral; Adolescent; Adult; Aspirin; Clopidogrel; Cross-Over Studies; Cyclooxygenase 1; | 2013 |
Aspirin resistance in Chinese stroke patients increased the rate of recurrent stroke and other vascular events.
Topics: Aged; Asian People; Aspirin; Cardiovascular Diseases; Drug Resistance; Female; Humans; Male; Myocard | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel | 2013 |
Amino terminal pro-B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy.
Topics: Aged; Anticoagulants; Aspirin; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Humans; M | 2013 |
Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study.
Topics: Aged; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Fibrinolytic Agents; Health Status Indic | 2013 |
Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Netherlands; | 2002 |
Unfractionated heparin is associated with a lower rise of serum vascular cell adhesion molecule-1 in acute ischemic stroke patients.
Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Brain Ischemia; Female; Forecasting; Heparin; Humans; | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Platelet serotonin transporter in stroke patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Binding, Competitive; Biomarkers; Blood Plat | 2003 |
Early and late effects of clopidogrel in patients with acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combinatio | 2003 |
Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study.
Topics: Antigens, CD; Aspirin; Blood Platelets; Brain Ischemia; Case-Control Studies; Clopidogrel; Cross-Ove | 2003 |
Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial.
Topics: Aspirin; Cardiovascular Diseases; Cerebral Infarction; Double-Blind Method; Female; Hemorrhage; Huma | 2003 |
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Female; Fibrinolyti | 2003 |
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Female; Fibrinolyti | 2003 |
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Female; Fibrinolyti | 2003 |
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Female; Fibrinolyti | 2003 |
Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension.
Topics: Aged; Antihypertensive Agents; Aspirin; Blood Pressure; Calcium Channel Blockers; Cost-Benefit Analy | 2003 |
Rapid platelet inhibition after a single capsule of Aggrenox: challenging a conventional full-dose aspirin antiplatelet advantage?
Topics: Adenosine Diphosphate; Adult; Aspirin; Aspirin, Dipyridamole Drug Combination; Blood Platelets; Caps | 2003 |
The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Heart Failure | 2003 |
Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel.
Topics: Aged; Arteriosclerosis; Aspirin; Blood Platelets; Brain Ischemia; C-Reactive Protein; Clopidogrel; D | 2002 |
A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin.
Topics: Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Decision Support Techniques; Fibrinolytic Ag | 2003 |
Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Biomarkers; Drug Therapy, Combination; Endothelium, Vascular; Enzyme-L | 2003 |
Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial.
Topics: Aged; Aspirin; Black or African American; Double-Blind Method; Female; Humans; Male; Middle Aged; Pl | 2003 |
Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Double-Blind Method; Female; | 2003 |
Thrombosis prevention trial: compliance with warfarin treatment and investigation of a retained effect.
Topics: Anticoagulants; Aspirin; Coronary Disease; Double-Blind Method; Follow-Up Studies; Humans; Male; Mid | 2003 |
Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke.
Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Drug Administration | 2003 |
Danish multicenter randomized study on fibrinolytic therapy versus acute coronary angioplasty in acute myocardial infarction: rationale and design of the DANish trial in Acute Myocardial Infarction-2 (DANAMI-2).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Drug Therapy, Combination; Electrocardiography; Fibrinolyti | 2003 |
Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN89345269]
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Incidence; International Normalized Rati | 2003 |
Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure.
Topics: Aspirin; Blood Pressure; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Female; Follow-Up | 2003 |
Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blin | 2003 |
Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke.
Topics: Adult; Aged; Aspirin; Cerebral Infarction; Drug Therapy, Combination; Female; Humans; Ischemic Attac | 2003 |
Nadroparin plus aspirin versus aspirin alone in the treatment of acute ischemic stroke.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Drug Therapy, Combination; Female; Humans; Injections, Subc | 2003 |
Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Ambulances; Angioplasty, Balloon, Coronary; Aspirin; Emergency Medic | 2003 |
Aspirin in the prevention of progressing stroke: a randomized controlled study.
Topics: Acute Disease; Aged; Aspirin; Disease Progression; Double-Blind Method; Female; Fibrinolytic Agents; | 2003 |
Antiplatelet effect of aspirin in patients with cerebrovascular disease.
Topics: Age Factors; Aspirin; Blood Platelets; Cerebrovascular Disorders; Cohort Studies; Dose-Response Rela | 2004 |
Acetylsalicylic acid and acetaminophen to combat elevated body temperature in acute ischemic stroke.
Topics: Acetaminophen; Acute Disease; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroida | 2004 |
Stroke prevention in hospitalized patients with atrial fibrillation: a population-based study.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Utilization; Female; Fibrinolytic Agents; H | 2003 |
Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke.
Topics: Aged; Antibodies, Antiphospholipid; Anticoagulants; Aspirin; Cohort Studies; Female; Humans; Male; M | 2004 |
Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study.
Topics: Aged; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; | 2004 |
Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inh | 2004 |
Transient ischemic attacks in patients with atrial fibrillation: implications for secondary prevention: the European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III trial.
Topics: Aged; Aspirin; Atrial Fibrillation; Female; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; | 2004 |
Leukocyte count as an independent predictor of recurrent ischemic events.
Topics: Aspirin; Biomarkers; Brain Ischemia; Cause of Death; Clopidogrel; Female; Humans; Inflammation; Leuk | 2004 |
What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke?
Topics: Adult; Aged; Aspirin; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Ischemi | 2004 |
An outreach intervention to implement evidence based practice in residential care: a randomized controlled trial [ISRCTN67855475].
Topics: Accidental Falls; Aged; Aged, 80 and over; Aspirin; Blood Pressure Determination; Chemoprevention; C | 2004 |
Effect of aspirin and warfarin therapy in stroke patients with valvular strands.
Topics: Adult; Aged; Aortic Valve; Aspirin; Echocardiography, Transesophageal; Endpoint Determination; Fibri | 2004 |
Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study.
Topics: Aged; Aspirin; Cerebral Infarction; Double-Blind Method; Female; Follow-Up Studies; Humans; Ischemic | 2004 |
Aspirin attenuates the incidence of silent brain lesions in patients with nonvalvular atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Brain; Brain Ischemia; Female; Humans; Incidence; Magnetic Reson | 2004 |
Predictors of stroke in patients paced for sick sinus syndrome.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cardiac Pacing, Artificial; Female; F | 2004 |
The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure.
Topics: Aged; Anticoagulants; Aspirin; Cardiomyopathy, Dilated; Feasibility Studies; Female; Hospitalization | 2004 |
Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
Topics: Acute Disease; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2004 |
Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Topics: Abciximab; Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Angioplasty, Ba | 2004 |
Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial.
Topics: Aged; Antigens, CD; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; CD40 Ligand; Di | 2004 |
Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome.
Topics: Acute Disease; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypa | 2004 |
Emboli rate during and early after carotid endarterectomy after a single preoperative dose of 120 mg acetylsalicylic acid--a prospective double-blind placebo controlled randomised trial.
Topics: Aged; Aged, 80 and over; Aspirin; Dose-Response Relationship, Drug; Double-Blind Method; Endarterect | 2005 |
Factors associated with development of stroke long-term after myocardial infarction: experiences from the LoWASA trial.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Female; Follow- | 2005 |
Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke.
Topics: Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; Case-Control Studies; Cell Adhesion; Clopidog | 2005 |
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cycloo | 2005 |
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cycloo | 2005 |
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cycloo | 2005 |
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cycloo | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Embolism; | 2005 |
Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Embolism; | 2005 |
Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Embolism; | 2005 |
Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Embolism; | 2005 |
Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Enzyme-Linked Immunosorbent Assay; Female; Heart | 2005 |
The rapid anticoagulation prevents ischemic damage study in acute stroke--final results from the writing committee.
Topics: Aged; Anticoagulants; Aspirin; Brain; Brain Ischemia; Clinical Trials as Topic; Endpoint Determinati | 2005 |
Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Combined Mod | 2005 |
The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cost-Benefit Analysis; Diabetes Complications; Fe | 2005 |
Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) tria
Topics: Aspirin; Cardiac Catheterization; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Fem | 2005 |
Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial.
Topics: Aged; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Blood Platelets; Bra | 2005 |
Complement factor H Y402H gene polymorphism, C-reactive protein, and risk of incident myocardial infarction, ischaemic stroke, and venous thromboembolism: a nested case-control study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta Carotene; Brain Ischemia; C-Reactive Protein; Cardiova | 2006 |
Antiplatelets in stroke prevention: the MATCH trial. Some answers, many questions and countless perspectives.
Topics: Age Factors; Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Drug Therapy, Combination; Femal | 2005 |
Aspirin resistance in secondary stroke prevention.
Topics: Aged; Aspirin; Drug Resistance; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Select | 2006 |
Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting.
Topics: Aprotinin; Aspirin; Biomarkers; Blood Coagulation Tests; Blood Loss, Surgical; Coronary Artery Bypas | 2006 |
Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Humans; Japan | 2006 |
Effects of vitamin C and aspirin in ischemic stroke-related lipid peroxidation: results of the AVASAS (Aspirin Versus Ascorbic acid plus Aspirin in Stroke) Study.
Topics: Ascorbic Acid; Aspirin; Carotenoids; Dinoprost; Humans; Kinetics; Lipid Peroxidation; Oxidative Stre | 2005 |
Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke.
Topics: Adult; Arteriosclerosis; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; C-Reactive Protein; C | 2006 |
Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Constriction, Pathologic | 2006 |
Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Constriction, Pathologic | 2006 |
Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Constriction, Pathologic | 2006 |
Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Constriction, Pathologic | 2006 |
Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.
Topics: Aged; Alanine; Angina, Unstable; Aspirin; Cerebral Hemorrhage; Female; Fibrinolytic Agents; Follow-U | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death: subgroup analyses from the Warfarin-Aspirin Recurrent Stroke Study.
Topics: Aged; Anticoagulants; Aspirin; Cerebral Hemorrhage; Cohort Studies; Double-Blind Method; Female; Hum | 2006 |
Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug Therapy, Combination; Fem | 2006 |
Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug Therapy, Combination; Fem | 2006 |
Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug Therapy, Combination; Fem | 2006 |
Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug Therapy, Combination; Fem | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C | 2006 |
Dose titration to reduce dipyridamole-related headache.
Topics: Aged; Aspirin; Dipyridamole; Drug Administration Schedule; Drug Therapy, Combination; Female; Headac | 2006 |
Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study.
Topics: Aged; Aspirin; Brain Ischemia; Dipyridamole; Drug Administration Schedule; Drug Therapy, Combination | 2005 |
A cross-sectional study of hypertension in an elderly population (75 years and over) with atrial fibrillation: secondary analysis of data from the Birmingham Atrial Fibrillation in the Aged (BAFTA) randomised controlled trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Bloo | 2007 |
Dipyridamole/aspirin combination in secondary stroke prevention: effects on absolute myocardial blood flow and coronary vascular resistance.
Topics: Aged; Aged, 80 and over; Aspirin; Coronary Circulation; Coronary Vessels; Dipyridamole; Drug Therapy | 2006 |
Aspirin prevents stroke but not MI in women; vitamin E has no effect on CV disease or cancer.
Topics: Aged; Aspirin; Cardiovascular Diseases; Chemoprevention; Female; Humans; Middle Aged; Myocardial Inf | 2006 |
Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Confidence Intervals; Dose-Response Relationship, Drug; Drug Therapy, | 2007 |
Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR).
Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Artery Disease; Death; Drug Resistance; Female | 2007 |
ESPRIT study design and outcomes--a critical appraisal.
Topics: Aspirin; Biomarkers; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; H | 2007 |
Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Be | 2007 |
Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arterial Occlusive Diseases; A | 2007 |
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studie | 2007 |
Variable platelet response to aspirin in patients with ischemic stroke.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Biological Availabi | 2007 |
Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring.
Topics: Aged; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dextrans; Dipyri | 2007 |
Gender differences in outcomes among patients with symptomatic intracranial arterial stenosis.
Topics: Aged; Anticoagulants; Aspirin; Constriction, Pathologic; Female; Humans; Intracranial Arterial Disea | 2007 |
Leukocyte count and vascular risk in symptomatic intracranial atherosclerosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Constriction, Pathologic; Female; Humans; Intracranial Arterio | 2007 |
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Disease-Free Survival; Drug Th | 2007 |
Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Fibrillation; Fema | 2007 |
Impact of valvular thickness on stroke recurrence in medically treated patients with stroke.
Topics: Adult; Aged; Aortic Valve; Aspirin; Brain Ischemia; Double-Blind Method; Echocardiography, Transesop | 2007 |
Sex differences in quality of life in stroke survivors: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST).
Topics: Activities of Daily Living; Age Factors; Aged; Aspirin; Brain Ischemia; Double-Blind Method; Female; | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Co | 2007 |
Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis.
Topics: Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Cross-Over S | 2008 |
Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events.
Topics: Age Factors; Aged; Anti-Inflammatory Agents; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel | 2008 |
[Randomized multicenter control clinical study on acute ischemic stroke treatment with traditional Chinese medicine].
Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Drug Therapy, Combination; Drugs, Chinese Herbal; Fibr | 2007 |
Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Ele | 2008 |
Aspirin responsiveness in acute brain ischaemia: association with stroke severity and clinical outcome.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Female; Fol | 2008 |
Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Bipheny | 2008 |
Platelet aggregation and recruitment with aspirin-clopidogrel therapy.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Humans; Platelet Ag | 2008 |
Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study.
Topics: Aged; Aged, 80 and over; Aspirin; Cohort Studies; Coronary Artery Disease; Drug Resistance; Female; | 2008 |
Danqi Piantan Jiaonang does not modify hemostasis, hematology, and biochemistry in normal subjects and stroke patients.
Topics: Administration, Oral; Adult; Aged; Aspirin; Capsules; Cohort Studies; Dose-Response Relationship, Dr | 2008 |
Less benefit from warfarin in diabetics after myocardial infarction?
Topics: Aged; Anticoagulants; Aspirin; Confounding Factors, Epidemiologic; Diabetes Complications; Drug Ther | 2008 |
Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; China; Cilostazol; Double-Blind Method; Female; | 2008 |
The effect of aspirin, ticlopidine and their low-dose combination on platelet aggregability in acute ischemic stroke: a short duration follow-up study.
Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Drug Therapy, Combin | 1999 |
Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Gastrointest | 1999 |
The gene encoding atrial natriuretic peptide and the risk of human stroke.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Animals; Aspirin; Atrial Natriuretic Factor; Base Sequence; | 1999 |
Ex vivo response to aspirin differs in stroke patients with single or recurrent events: a pilot study.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Aged; Aspirin; Dose-Response Rel | 1999 |
Clinical efficacy of an automated high-sensitivity C-reactive protein assay.
Topics: Aged; Aged, 80 and over; Antioxidants; Aspirin; beta Carotene; C-Reactive Protein; Case-Control Stud | 1999 |
Is carotid endarterectomy cost-effective in symptomatic patients with moderate (50% to 69%) stenosis?
Topics: Aged; Aspirin; Carotid Stenosis; Cohort Studies; Cost-Benefit Analysis; Decision Support Techniques; | 1999 |
Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study).
Topics: Aged; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Blood Flow Velocity; Drug Ther | 1999 |
Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: II. Dense spontaneous echocardiographic contrast (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study).
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Flow Velocity; Contrast Media; Drug Therap | 1999 |
Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus.
Topics: Adult; Antibodies, Antiphospholipid; Antigens; Aspirin; Cross-Sectional Studies; Dose-Response Relat | 1999 |
Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Fibrillation; Cohort Studies; Dose-Re | 2000 |
Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole.
Topics: Aged; Aged, 80 and over; Aspirin; Cost-Benefit Analysis; Decision Support Techniques; Dipyridamole; | 1999 |
Long-term management--the way forward?
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Artery Disease; Dalteparin; Drug Therapy, Combin | 2000 |
[What dose of acetylsalicylic acid to use after carotid endarterectomy?].
Topics: Aspirin; Carotid Stenosis; Endarterectomy, Carotid; Humans; Myocardial Infarction; Platelet Aggregat | 2000 |
Self-selected posttrial aspirin use and subsequent cardiovascular disease and mortality in the physicians' health study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Confounding Factors, Epidemiologic | 2000 |
Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; | 2000 |
Using anticoagulation or aspirin to prevent stroke. Study does not have the power to show that aspirin is as good as anticoagulation.
Topics: Anticoagulants; Aspirin; Humans; Research Design; Stroke | 2000 |
Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment.
Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Blood Pressure; Cardiovascul | 2000 |
Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial.
Topics: Aged; Aspirin; Blood Pressure; Death, Sudden, Cardiac; Humans; Male; Middle Aged; Myocardial Infarct | 2000 |
Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.
Topics: Administration, Oral; Alanine; Anticoagulants; Aspirin; Coronary Disease; Double-Blind Method; Femal | 2000 |
Symptomatic intracranial atherosclerosis: outcome of patients who fail antithrombotic therapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Female; Fibrinolytic Agents; F | 2000 |
Effect of contralateral occlusion on long-term efficacy of endarterectomy in the asymptomatic carotid atherosclerosis study (ACAS). ACAS Investigators.
Topics: Aged; Arteriosclerosis; Aspirin; Carotid Stenosis; Disease-Free Survival; Endarterectomy, Carotid; F | 2000 |
Piracetam versus acetylsalicylic acid in secondary stroke prophylaxis. A double-blind, randomized, parallel group, 2 year follow-up study.
Topics: Aspirin; Blood Platelets; Demography; Double-Blind Method; Endpoint Determination; Female; Follow-Up | 2000 |
Cardiac safety in the European Stroke Prevention Study 2 (ESPS2).
Topics: Angina Pectoris; Aspirin; Dipyridamole; Humans; Ischemic Attack, Transient; Longitudinal Studies; My | 2001 |
Acetylsalicylic acid and microembolic events detected by transcranial Doppler in symptomatic arterial stenoses.
Topics: Aged; Aspirin; Carotid Stenosis; Cerebrovascular Circulation; Female; Humans; Intracranial Embolism | 2001 |
Variations between countries in outcome after stroke in the International Stroke Trial (IST).
Topics: Aged; Argentina; Aspirin; Australia; Europe; Female; Follow-Up Studies; Heparin; Humans; Logistic Mo | 2001 |
Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS).
Topics: Aged; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electroc | 2001 |
Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial.
Topics: Aged; Aged, 80 and over; Aspirin; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fib | 2001 |
Inhibition of thrombus formation by low-dose acetylsalicylic acid, dipyridamole, and their combination in a model of platelet-vessel wall interaction.
Topics: Aspirin; Blood Platelets; Cell Communication; Cerebral Arteries; Clinical Trials, Phase I as Topic; | 2001 |
Urinary 11-dehydro-thromboxane B(2) and coagulation activation markers measured within 24 h of human acute ischemic stroke.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Coagulation; Brain Ischemi | 2001 |
Aspirin versus low-dose low-molecular-weight heparin: antithrombotic therapy in pediatric ischemic stroke patients: a prospective follow-up study.
Topics: Adolescent; Aspirin; Brain Ischemia; Child; Child, Preschool; Fibrinolytic Agents; Follow-Up Studies | 2001 |
Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation?
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fi | 2001 |
Effect of prior aspirin use on stroke severity in the trial of Org 10172 in acute stroke treatment (TOAST).
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Chondroitin Sulfates; Confou | 2001 |
Aspirin and urinary 11-dehydrothromboxane B(2) in African American stroke patients.
Topics: Adult; Aged; Aspirin; Black People; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Stroke; | 2002 |
A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind Method; Female | 2001 |
Efficacy of n-3 polyunsaturated fatty acids after myocardial infarction: results of GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2001 |
Clopidogrel: a CURE in acute coronary syndromes?
Topics: Acute Disease; Aged; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Hemorrhage | 2002 |
Blood pressure and clinical outcomes in the International Stroke Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Blood Pressure; Brain Ischemia; Cohort Studies; Fe | 2002 |
Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; De | 2002 |
1427 other studies available for aspirin and Stroke
| Article | Year |
|---|---|
Antioxidative and thrombolytic TMP nitrone for treatment of ischemic stroke.
Topics: Animals; Antioxidants; Brain Ischemia; Fibrinolytic Agents; Nitrogen Oxides; Pyrazines; Rats; Stroke | 2008 |
Novel multi-functional nitrones for treatment of ischemic stroke.
Topics: Animals; Dose-Response Relationship, Drug; Drug Design; Free Radical Scavengers; Male; Molecular Str | 2012 |
Discovery of a potential anti-ischemic stroke agent: 3-pentylbenzo[c]thiophen-1(3H)-one.
Topics: Animals; Antioxidants; Brain; Brain Edema; Brain Infarction; Brain Ischemia; Fibrinolytic Agents; Fr | 2012 |
Novel hybrids of optically active ring-opened 3-n-butylphthalide derivative and isosorbide as potential anti-ischemic stroke agents.
Topics: Animals; Benzofurans; Blood-Brain Barrier; Isosorbide; Platelet Aggregation Inhibitors; Rats; Stereo | 2013 |
Novel hybrids of 3-n-butylphthalide and edaravone: Design, synthesis and evaluations as potential anti-ischemic stroke agents.
Topics: Animals; Antipyrine; Benzofurans; Cell Line; Drug Design; Edaravone; Free Radical Scavengers; Humans | 2015 |
Novel potent antiplatelet thrombotic agent derived from biguanide for ischemic stroke.
Topics: Administration, Oral; Animals; Biguanides; Brain Ischemia; Dose-Response Relationship, Drug; Male; M | 2020 |
[Anti-Platelet and Anti-Coagulant Drugs].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Pharmaceutical Preparations; Platelet Aggregat | 2021 |
Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.
Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Hemor | 2022 |
Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis.
Topics: Aspirin; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Female; Gastrointestina | 2021 |
[Current opportunities for secondary prevention of atherothrombotic stroke].
Topics: Aspirin; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Rivaroxaban; Secondary | 2021 |
Relation of Pre-Stroke Aspirin Use With Cerebral Infarct Volume and Functional Outcomes.
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Infarction; Female; Fibr | 2021 |
Letter to the Editor. Aspirin versus anticoagulation for stroke prophylaxis: a dispute not yet closed.
Topics: Anticoagulants; Aspirin; Dissent and Disputes; Humans; Stroke; Warfarin | 2021 |
High On-Treatment Platelet Reactivity as Predictor of Long-term Clinical Outcomes in Stroke Patients with Antiplatelet Agents.
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Platelet Aggregation Inhibitors; Stroke; Tre | 2022 |
Biochemical aspirin resistance in acute stroke patients and its association with clinical factors: a prospective pilot study.
Topics: Aged; Aspirin; Humans; Ischemic Attack, Transient; Peptide Fragments; Pilot Projects; Prospective St | 2021 |
Efficacy and safety of perioperative dual antiplatelet therapy with ticagrelor versus clopidogrel in carotid artery stenting.
Topics: Aspirin; Carotid Arteries; Carotid Stenosis; Clopidogrel; Endovascular Procedures; Femoral Artery; H | 2022 |
Left atrial appendage closure: a new strategy for cardioembolic events despite oral anticoagulation.
Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Hemorrhage; Humans; Retrospective St | 2023 |
Application of Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping Score for Efficacy of Clopidogrel: Secondary Analysis of the CHANCE Trial.
Topics: Age Factors; Aged; Aspirin; Body Mass Index; Cerebrovascular Disorders; Clopidogrel; Cytochrome P-45 | 2022 |
Antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation and chronic coronary syndrome.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Fibrinolytic Agents; He | 2022 |
Dual Antiplatelet Therapy Is Superior to Aspirin in Preventing Short-Term Recurrent Stroke at the Cost of More Major Bleeding.
Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggrega | 2021 |
Dual Antiplatelet Therapy Plus Argatroban Prevents Early Neurological Deterioration in Branch Atherosclerosis Disease.
Topics: Arginine; Aspirin; Atherosclerosis; Brain Ischemia; Clopidogrel; Humans; Pipecolic Acids; Platelet A | 2022 |
Concurrent Cerebral, Splenic, and Renal Infarction in a Patient With COVID-19 Infection.
Topics: Anticoagulants; Aspirin; COVID-19; Humans; Infarction; Male; Middle Aged; Stroke; Thrombosis | 2022 |
Associations of CYP2C19 and F2R genetic polymorphisms with platelet reactivity in Chinese ischemic stroke patients receiving clopidogrel therapy.
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Ischemic Stroke; Platelet Aggregation Inhibi | 2022 |
Stroke: Long-Term Poststroke Management.
Topics: Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Recovery of Function; Secondary Preve | 2022 |
Hyperglycemia, Risk of Subsequent Stroke, and Efficacy of Dual Antiplatelet Therapy: A Post Hoc Analysis of the POINT Trial.
Topics: Aspirin; Blood Glucose; Clopidogrel; Humans; Hyperglycemia; Ischemic Attack, Transient; Ischemic Str | 2022 |
Imaging analysis of ischemic strokes due to blunt cerebrovascular injury.
Topics: Aspirin; Cerebrovascular Trauma; Humans; Ischemic Stroke; Retrospective Studies; Stroke; Wounds, Non | 2022 |
Conservative versus aggressive antiplatelet strategy for emergent carotid stenting during stroke thrombectomy.
Topics: Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Stroke; | 2023 |
[Modern strategies of antithrombotic therapy in patients with multifocal atherosclerosis].
Topics: Aspirin; Atherosclerosis; Fibrinolytic Agents; Humans; Stroke | 2022 |
Dual versus mono antiplatelet therapy in mild-to-moderate stroke during hospitalization.
Topics: Aspirin; Clopidogrel; Cohort Studies; Hemorrhage; Hospitalization; Humans; Hydroxymethylglutaryl-CoA | 2022 |
Evaluation of the association between admission systolic blood pressure and the choice of initial antiplatelet therapy for minor ischemic stroke in real-world.
Topics: Aged; Aspirin; Blood Pressure; Clopidogrel; Drug Therapy, Combination; Humans; Hypertension; Ischemi | 2022 |
Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory: Report of the AAN Guideline Subcommittee.
Topics: Arteries; Aspirin; Clopidogrel; Humans; Intracranial Arteriosclerosis; Stroke | 2022 |
Evaluation of Evidence-Based Dual Antiplatelet Therapy for Secondary Prevention in US Patients With Acute Ischemic Stroke.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Ischemic Stroke | 2022 |
Cinnamon and Aspirin for Mild Ischemic Stroke or Transient Ischemic Attack: A Pilot Trial.
Topics: Aspirin; Cinnamomum zeylanicum; Clopidogrel; Constriction, Pathologic; Double-Blind Method; Drug The | 2022 |
Antithrombotic therapies for neurointerventional surgery: a 2021 French comprehensive national survey.
Topics: Aspirin; Cross-Sectional Studies; Fibrinolytic Agents; Heparin; Humans; Platelet Aggregation Inhibit | 2023 |
Egg consumption and risk of cardiovascular events among Iranians: results from Isfahan Cohort Study (ICS).
Topics: Adult; Aspirin; Cardiovascular Diseases; Cohort Studies; Eggs; Follow-Up Studies; Humans; Iran; Myoc | 2022 |
Dual versus triple antithrombotic therapy after percutaneous coronary intervention: the prospective multicentre WOEST 2 Study.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Drug Therapy, Combination; Fibrinolyti | 2022 |
Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack.
Topics: Aged; Aspirin; Drug Therapy, Combination; Female; Hemorrhage; Humans; Ischemia; Ischemic Attack, Tra | 2022 |
Antiplatelets and Anticoagulants in Ischemic Stroke,Transient Ischaemic Attack: A Practice Survey Among Singapore Neurologists.
Topics: Adult; Anticoagulants; Aspirin; Cerebrovascular Disorders; Female; Heparin; Humans; Ischemic Attack, | 2022 |
[COMPASS study results as a foundation for new treatment approach for neurological patients. Opinion of the expert council of december 18, 2021].
Topics: Aspirin; Drug Therapy, Combination; Humans; Rivaroxaban; Stroke | 2022 |
Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Fibrinolytic Agents; Frailty; Humans | 2022 |
Dual antiplatelet use in the management of COVID-19 associated acute ischemic stroke reocclusion.
Topics: Aspirin; Brain Ischemia; COVID-19; Humans; Ischemic Stroke; Middle Aged; Retrospective Studies; SARS | 2023 |
Dual Antiplatelet Therapy With Aspirin Plus Clopidogrel for 30 Days Is the Best Option After Minor Stroke or TIA.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggreg | 2022 |
Cost-Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke.
Topics: Aspirin; Cilostazol; Clopidogrel; Cost-Benefit Analysis; Humans; Markov Chains; Platelet Aggregation | 2022 |
Incidence of nonvalvular atrial fibrillation and oral anticoagulant prescribing in England, 2009 to 2019: A cohort study.
Topics: Administration, Oral; Adolescent; Adult; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemi | 2022 |
No rebound effect after a course of clopidogrel in patients with acute TIA or minor stroke.
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Humans; Ischemic Attack, | 2022 |
Synergistic Neuroprotection by a PAF Antagonist Plus a Docosanoid in Experimental Ischemic Stroke: Dose-Response and Therapeutic Window.
Topics: Animals; Aspirin; Infarction, Middle Cerebral Artery; Ischemic Stroke; Male; Neuroprotection; Neurop | 2022 |
Optimizing the Time Course of Risks and Benefits of Acute Dual Antiplatelet Therapy for Stroke Prevention.
Topics: Aspirin; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Humans; Platelet Aggregation Inhibit | 2022 |
Cost-effectiveness of testing for CYP2C19 loss-of-function carriers following transient ischemic attack/minor stroke: A Canadian perspective.
Topics: Aspirin; Canada; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Humans; Ischemic Atta | 2023 |
Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients.
Topics: Aspirin; Body Weight; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, T | 2022 |
Non-vitamin K oral anticoagulant compared with aspirin may not significantly reduce the rate of ischaemic stroke in patients with mixed cardiovascular disease in sinus rhythm.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cardiovascular D | 2022 |
Association between body mass index and bleeding events associated with the use of aspirin in ischemic stroke or transient ischemic attack patients.
Topics: Aspirin; Body Mass Index; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; | 2022 |
Analysis of Prescriptions for Dual Antiplatelet Therapy After Acute Ischemic Stroke.
Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Humans; Ischemic Stroke; Male; Platelet Aggregation Inhi | 2022 |
Long term survival after a first transient ischaemic attack in England: A retrospective matched cohort study.
Topics: Aspirin; Cohort Studies; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Retros | 2022 |
Dual Antiplatelet Therapy Is Associated with Increased Risk of Bleeding and Decreased Risk of Stroke Following Carotid Endarterectomy.
Topics: Aspirin; Carotid Stenosis; Coronary Artery Disease; Endarterectomy, Carotid; Humans; Platelet Aggreg | 2023 |
Effectiveness and Safety of Clopidogrel vs Aspirin in Elderly Patients With Ischemic Stroke.
Topics: Aged; Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Gastrointestinal Hemorrh | 2022 |
Isolated hand weakness due to brain lesion.
Topics: Aspirin; Brain; Carpal Tunnel Syndrome; Humans; Median Nerve; Stroke | 2022 |
Consensus Recommendations for Managing Childhood Cancer Survivors at Risk for Stroke After Cranial Irradiation: A Delphi Study.
Topics: Aspirin; Cancer Survivors; Child; Consensus; Cranial Irradiation; Delphi Technique; Humans; Hydroxym | 2022 |
Work-up and Management of Asymptomatic Extracranial Traumatic Vertebral Artery Injury.
Topics: Aspirin; Canada; Craniocerebral Trauma; Cross-Sectional Studies; Humans; Stroke; Vertebral Artery | 2023 |
Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Brain Ischemia; Dipyridamole; Humans; Ischemic Atta | 2022 |
Effect of Chronic Antiplatelet and Anticoagulant Medication in Neck Hematoma and Perioperative Outcomes after Carotid Endarterectomy.
Topics: Anticoagulants; Aspirin; Endarterectomy, Carotid; Hematoma; Hemorrhage; Humans; Retrospective Studie | 2023 |
Are Factor Xa Inhibitors Efficacious for Ischemic Stroke Prevention in Patients Without Atrial Fibrillation? Evidence From Randomized Clinical Trials.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemic Str | 2023 |
Low Body Mass Index without Malnutrition Is an Independent Risk Factor for Major Cardiovascular Events in Patients with Hemodialysis.
Topics: Albumins; Aspirin; Blood Proteins; Body Mass Index; Cardiovascular Diseases; Cholesterol; Heart Fail | 2022 |
A descriptive cross-sectional study of self-management in patients with nonvalvular atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cross-Sectional Studies; Humans; Self-Management | 2022 |
Insurance status is associated with urgent carotid endarterectomy and worse postoperative outcomes.
Topics: Aged; Aspirin; Carotid Stenosis; Endarterectomy, Carotid; Humans; Hydroxymethylglutaryl-CoA Reductas | 2023 |
Concordance Between Patient-Reported Health Data and Electronic Health Data in the ADAPTABLE Trial.
Topics: Aged; Aspirin; Electronic Health Records; Female; Hemorrhage; Humans; Male; Myocardial Infarction; P | 2022 |
Comparison of Cilostazol versus Clopidogrel in Addition to Aspirin in Patients with Ischemic Stroke who Underwent Intracranial or Extracranial Artery Stent Implantation.
Topics: Arteries; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic | 2023 |
Aspirin versus aggressive antiplatelet therapy for acute carotid stenting plus thrombectomy in tandem occlusions: ETIS Registry results.
Topics: Aspirin; Carotid Stenosis; Endovascular Procedures; Humans; Ischemic Stroke; Platelet Aggregation In | 2023 |
In CV disease, clopidogrel reduces nonfatal MI and MACE vs. aspirin but not stroke or mortality.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stroke | 2022 |
In CV disease, clopidogrel reduces nonfatal MI and MACE vs. aspirin but not stroke or mortality.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stroke | 2022 |
In CV disease, clopidogrel reduces nonfatal MI and MACE vs. aspirin but not stroke or mortality.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stroke | 2022 |
In CV disease, clopidogrel reduces nonfatal MI and MACE vs. aspirin but not stroke or mortality.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stroke | 2022 |
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemorrhage; Humans; Platele | 2023 |
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemorrhage; Humans; Platele | 2023 |
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemorrhage; Humans; Platele | 2023 |
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemorrhage; Humans; Platele | 2023 |
Association of Aspirin Use with Reduced Risk of Developing Alzheimer's Disease in Elderly Ischemic Stroke Patients: A Retrospective Cohort Study.
Topics: Aged; Alzheimer Disease; Aspirin; Humans; Ischemic Stroke; Retrospective Studies; Risk Factors; Stro | 2023 |
Association of Aspirin Use with Reduced Risk of Developing Alzheimer's Disease in Elderly Ischemic Stroke Patients: A Retrospective Cohort Study.
Topics: Aged; Alzheimer Disease; Aspirin; Humans; Ischemic Stroke; Retrospective Studies; Risk Factors; Stro | 2023 |
Association of Aspirin Use with Reduced Risk of Developing Alzheimer's Disease in Elderly Ischemic Stroke Patients: A Retrospective Cohort Study.
Topics: Aged; Alzheimer Disease; Aspirin; Humans; Ischemic Stroke; Retrospective Studies; Risk Factors; Stro | 2023 |
Association of Aspirin Use with Reduced Risk of Developing Alzheimer's Disease in Elderly Ischemic Stroke Patients: A Retrospective Cohort Study.
Topics: Aged; Alzheimer Disease; Aspirin; Humans; Ischemic Stroke; Retrospective Studies; Risk Factors; Stro | 2023 |
Family history of premature myocardial infarction and the effect of aspirin.
Topics: Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; | 2023 |
Family history of premature myocardial infarction and the effect of aspirin.
Topics: Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; | 2023 |
Family history of premature myocardial infarction and the effect of aspirin.
Topics: Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; | 2023 |
Family history of premature myocardial infarction and the effect of aspirin.
Topics: Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; | 2023 |
Ticagrelor Aspirin vs Clopidogrel Aspirin in
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Huma | 2023 |
Efficacy and safety of single versus dual antiplatelet therapy in carotid artery stenting.
Topics: Aspirin; Carotid Arteries; Carotid Stenosis; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Re | 2023 |
Monitoring antiplatelet therapy: where are we now?
Topics: Anticoagulants; Aspirin; Atherosclerosis; Drug Therapy, Combination; Hemorrhage; Humans; Percutaneou | 2023 |
A hybrid automated event adjudication system for clinical trials.
Topics: Aspirin; Double-Blind Method; Embolic Stroke; Embolism; Factor Xa; Factor Xa Inhibitors; Humans; Myo | 2023 |
Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneou
Topics: Aspirin; Cardiology; Clopidogrel; Coronary Artery Disease; Fibrinolytic Agents; Hemorrhage; Humans; | 2023 |
Intravenous thrombolysis versus antiplatelet therapy in minor stroke patients with large vessel occlusion.
Topics: Aspirin; Brain Ischemia; Cerebral Hemorrhage; Fibrinolytic Agents; Humans; Platelet Aggregation Inhi | 2023 |
Cryo-Shocked Platelet Coupled with ROS-Responsive Nanomedicine for Targeted Treatment of Thromboembolic Disease.
Topics: Aspirin; Fibrinolytic Agents; Humans; Liposomes; Nanomedicine; Reactive Oxygen Species; Stroke; Thro | 2023 |
In-Hospital Aspirin Dose as a Risk Factor for Hemorrhagic Transformation in Patients Not Treated With Thrombolysis.
Topics: Aspirin; Brain Ischemia; Cerebral Hemorrhage; Hospitals; Humans; Ischemic Stroke; Retrospective Stud | 2023 |
Comparative effectiveness of clopidogrel versus aspirin as a maintenance monotherapy 1 year after coronary artery bypass grafting.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Pla | 2023 |
Analysis of antiplatelet therapy adherence in patients with ischemic cerebral stroke.
Topics: Aspirin; Humans; Ischemic Stroke; Medication Adherence; Nervous System Diseases; Platelet Aggregatio | 2023 |
Impact of continued clopidogrel use on outcomes of patients undergoing carotid endarterectomy.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Endarterectomy, Carotid; Female; Humans; Male; Myocard | 2023 |
Efficacy and Prognosis of Adjuvant Argatroban Treatment in Acute Ischemic Stroke Patients with Early Neurological Deterioration.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Stroke; Prognosis; Stroke; Treatment Outcome | 2023 |
Tirofiban in the treatment of cancer-associated ischemic stroke.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Stroke; Neoplasms; Retrospective Studies; Stroke; Tirofiba | 2023 |
Safety and Efficacy of Baseline Antiplatelet Treatment in Patients Undergoing Mechanical Thrombectomy for Ischemic Stroke: Antiplatelets Before Mechanical Thrombectomy.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Intracranial Hemorrhages; Ischemic Stroke; Mechanical | 2023 |
Risk of secondary stroke subsequent to restarting aspirin in chronic stroke patients suffering from traumatic brain injury in Taiwan.
Topics: Adult; Aspirin; Brain Damage, Chronic; Brain Injuries, Traumatic; Drug Therapy, Combination; Female; | 2023 |
Heterogeneity after harmonisation: A retrospective cohort study of bleeding and stroke risk after the introduction of direct oral anticoagulants in four Western European countries.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Hemorrhage; Humans; Retrospectiv | 2023 |
Monitoring the Antiplatelet Therapy Efficacy in Patients with Acute Ischemic Stroke.
Topics: Arteries; Aspirin; Clopidogrel; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; Stroke | 2023 |
Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Hemorrhagi | 2023 |
The Budget Impact Analysis of Adopting Direct Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation Patients in Malawi.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Malawi; Stroke; Warfarin | 2023 |
Pre-aspirin use has no benefit on the neurological disability and mortality after cardiovascular events: A nation-wide population-based cohort study.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cohort Studies; Hemorrhagic Stroke; Humans; Platelet Aggrega | 2023 |
Antithrombotic Medication and Major Complications After Mechanical Aortic Valve Replacement.
Topics: Anticoagulants; Aortic Valve; Aspirin; Fibrinolytic Agents; Heart Valve Prosthesis; Heart Valve Pros | 2023 |
Dual Antiplatelet Therapies and Causes in Minor Stroke or Transient Ischemic Attack: A Prespecified Analysis in the CHANCE-2 Trial.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attac | 2023 |
Determinants and Temporal Trends of Dual Antiplatelet Therapy After Mild Noncardioembolic Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Cross-Sectional Studies; Drug Therapy | 2023 |
Comparative effectiveness of dual antiplatelet therapy versus monotherapy in patients with ischemic stroke.
Topics: Aspirin; Clopidogrel; Cross-Sectional Studies; Drug Therapy, Combination; Humans; Ischemic Stroke; P | 2023 |
DAPT Is Comparable to OAC Following LAAC With WATCHMAN FLX: A National Registry Analysis.
Topics: Aged; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Female; Hemorrhage; Humans; Ma | 2023 |
Pharmacological Effects of a New Soluble Guanylate Cyclase Stimulator in Experimental Ischemic Stroke.
Topics: Animals; Aspirin; Brain Ischemia; Cerebral Infarction; Ischemic Stroke; Platelet Aggregation; Platel | 2023 |
The impact of long-term aspirin use on the patients undergoing shoulder arthroplasty.
Topics: Adult; Aged; Arthroplasty, Replacement, Shoulder; Aspirin; Comorbidity; Female; Humans; Medicare; Po | 2023 |
Formulation of aspirin nanoparticles using solvent evaporation method and in vivo evaluation of its antithrombotic effect.
Topics: Animals; Antioxidants; Aspirin; Brain Ischemia; Drug Carriers; Fibrinolytic Agents; Nanoparticles; P | 2023 |
[Embolic stroke of undetermined source - ESUS: a new challenge for the cardiologist].
Topics: Aspirin; Atrial Fibrillation; Cardiologists; Embolic Stroke; Heart Failure; Humans; Risk Factors; St | 2023 |
Is Embolic Stroke of Undetermined Source Shrinking?
Topics: Aspirin; Carotid Artery Diseases; Embolism; Humans; Rivaroxaban; Stroke | 2019 |
Review: After stroke or TIA, adding clopidogrel to aspirin for ≤ 1 month reduces recurrence and MACE.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhib | 2019 |
Effect of concomitant antiplatelet therapy in patients with nonvalvular atrial fibrillation initiating non-vitamin K antagonists.
Topics: Aged; Aged, 80 and over; Antithrombins; Aspirin; Atrial Fibrillation; Dabigatran; Drug Therapy, Comb | 2019 |
Aspirin better than clopidogrel on major adverse cardiovascular events reduction after ischemic stroke: A retrospective nationwide cohort study.
Topics: Aged; Aspirin; Brain Ischemia; Cardiovascular Diseases; Cerebral Hemorrhage; Clopidogrel; Female; Ga | 2019 |
Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary Analysis.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; | 2019 |
MRI-based thrombolytic therapy in patients with acute ischemic stroke presenting with a low NIHSS.
Topics: Aged; Aspirin; Brain Ischemia; Female; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; Magnet | 2019 |
Management of Extracranial Blunt Cerebrovascular Injuries: Experience with an Aspirin-Based Approach.
Topics: Adolescent; Adult; Aged; Anticoagulants; Aortic Dissection; Aspirin; Carotid Artery Injuries; Caroti | 2020 |
Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With High Bleeding Risk: Insight From the STOPDAPT-2 Trial.
Topics: Aged; Aspirin; Chromium Alloys; Clopidogrel; Coronary Restenosis; Drug Administration Schedule; Drug | 2019 |
Comparative Effectiveness of Dual Antiplatelet Therapy With Aspirin and Clopidogrel Versus Aspirin Monotherapy in Acute, Nonminor Stroke: A Nationwide, Multicenter Registry-Based Study.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Disease-Free Survival; Drug Therapy, Combination; Fem | 2019 |
Dual Antiplatelet Therapy Increases Hemorrhagic Transformation Following Thrombolytic Treatment in Experimental Stroke.
Topics: Animals; Aspirin; Clopidogrel; Coronary Thrombosis; Disease Models, Animal; Drug Therapy, Combinatio | 2019 |
Mortality risk in atrial fibrillation: the role of aspirin, vitamin K and non-vitamin K antagonists.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort | 2019 |
Relationship between 'on-treatment platelet reactivity', shear stress, and micro-embolic signals in asymptomatic and symptomatic carotid stenosis.
Topics: Aged; Aspirin; Blood Platelets; Brain Ischemia; Carotid Stenosis; Female; Humans; Intracranial Embol | 2020 |
Cases in Precision Medicine: A Personalized Approach to Stroke and Cardiovascular Risk Assessment in Women.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Evidence-Bas | 2019 |
Enhanced Platelet Reactivity under Aspirin Medication and Major Adverse Cardiac and Cerebrovascular Events in Patients with Coronary Artery Disease.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Coronary Artery Disease; Female; Humans; Male; My | 2020 |
Effectiveness of Only Aspirin or Clopidogrel Following Percutaneous Left Atrial Appendage Closure.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Cathe | 2019 |
Bilateral paramedian pontine infarcts: a rare cause of bilateral horizontal gaze palsy.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Flutter; Brain; Cerebral Infarction; | 2019 |
Left Atrial Enlargement Could Be Detected on Extended Computed Tomography Angiography Within Initial Stroke Assessment.
Topics: Aspirin; Atrial Fibrillation; Computed Tomography Angiography; Humans; Rivaroxaban; Stroke | 2020 |
Left Atrial Enlargement Could Be Detected on Extended Computed Tomography Angiography Within Initial Stroke Assessment-Reply.
Topics: Aspirin; Atrial Fibrillation; Computed Tomography Angiography; Humans; Rivaroxaban; Stroke | 2020 |
Intensive antiplatelet therapy with three agents does not reduce risk of another stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Stroke | 2020 |
Ticagrelor monotherapy versus aspirin in patients undergoing multiple arterial or single arterial coronary artery bypass grafting: insights from the TiCAB trial.
Topics: Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Humans; Myocardial Infarction; Stroke; Tic | 2020 |
Lp-PLA
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Aspirin; Cerebrovascular Disorders; Clopidogre | 2020 |
CSPS.com Trial of Adding Cilostazol to Antiplatelet Therapy to Reduce Recurrent Stroke.
Topics: Aspirin; Cerebral Infarction; Cilostazol; Drug Therapy, Combination; Female; Humans; Male; Middle Ag | 2020 |
Confusion vs Broca Aphasia: A Case Report.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aphasia, Broca; Aspirin; Confusion; Diagnosis, Differ | 2020 |
Impact of aspirin on takotsubo syndrome: a propensity score-based analysis of the InterTAK Registry.
Topics: Aspirin; Heart Failure; Humans; Ischemic Attack, Transient; Myocardial Infarction; Platelet Aggregat | 2020 |
Assessment of Cardiovascular Risk by the Combination of Clinical Risk Scores Plus Platelet Expression of FcγRIIa.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cohort Studies; Drug Therapy, Combination; Flow C | 2020 |
Dual Antiplatelet Therapy after Intravenous Thrombolysis for Acute Minor Ischemic Stroke.
Topics: Administration, Intravenous; Aged; Aspirin; Brain Ischemia; Clopidogrel; Dual Anti-Platelet Therapy; | 2019 |
Patent foramen ovale closure by using transesophageal echocardiography for cryptogenic stroke: single center experience in 132 consecutive patients.
Topics: Adolescent; Adult; Aged; Aspirin; Cardiac Catheterization; Cardiac Surgical Procedures; Child; Contr | 2020 |
Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percut
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cor | 2020 |
Aspirin plus clopidogrel versus aspirin Mono-Therapy for ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2020 |
Association of platelet-derived microvesicles with high on-treatment platelet reactivity in convalescent ischemic stroke patients treated with acetylsalicylic acid
Topics: Aspirin; Blood Platelets; Brain Ischemia; Cell-Derived Microparticles; Humans; Stroke | 2019 |
Response by Chen et al to Letter Regarding Article, "Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in CYP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity".
Topics: Alleles; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Obesity; Overweight; Stroke | 2020 |
Letter by L. Schlemm and E. Schlemm Regarding Article, "Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in CYP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity".
Topics: Alleles; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Obesity; Overweight; Stroke | 2020 |
Aspirin in Primary Prevention: Needs Individual Clinical Judgments.
Topics: Aspirin; Clinical Decision-Making; Evidence-Based Medicine; Humans; Myocardial Infarction; Patient S | 2020 |
Low density lipoprotein cholesterol values and outcome of stroke patients: influence of previous aspirin therapy.
Topics: Aged; Aspirin; Cholesterol, LDL; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospecti | 2020 |
Disability After Minor Stroke and Transient Ischemic Attack in the POINT Trial.
Topics: Aged; Aspirin; Clopidogrel; Disability Evaluation; Double-Blind Method; Female; Humans; Intracranial | 2020 |
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P | 2020 |
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P | 2020 |
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P | 2020 |
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P | 2020 |
Failure of platelet function analyser 200 to demonstrate clinical clopidogrel resistance in a patient undergoing intracranial vascular stenting.
Topics: Aged; Aspirin; Clopidogrel; Diagnosis, Differential; Drug Resistance; Humans; Intracranial Aneurysm; | 2020 |
Derivation and Application of a Tool to Estimate Benefits From Multiple Therapies That Reduce Recurrent Stroke Risk.
Topics: Aged; Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Aspirin; Diet Therapy; Exer | 2020 |
Haemorrhagic transformation following ischaemic stroke: A retrospective study.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Hemorrhage; Humans; Intr | 2020 |
Focal Cerebral Arteriopathy in Young Adult Patients With Stroke.
Topics: Acyclovir; Adult; Antibodies, Viral; Antiviral Agents; Aspirin; Carotid Artery, Internal; Carotid St | 2020 |
Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Thrombosis; Fa | 2020 |
Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The MESA Study (Multi-Ethnic Study of Atherosclerosis).
Topics: Aged; Aged, 80 and over; Aspirin; Clinical Decision-Making; Computed Tomography Angiography; Coronar | 2020 |
Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Clo | 2020 |
Risk Versus Benefit of Combined Aspirin and Warfarin Therapy in Patients With Atrial Fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Humans; Platelet Aggregation Inhibitor | 2021 |
Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial.
Topics: Aged; Aspirin; Bacteria; Case-Control Studies; Dual Anti-Platelet Therapy; Female; Gastrointestinal | 2020 |
Canadian Stroke Best Practice Recommendations, seventh edition: acetylsalicylic acid for prevention of vascular events.
Topics: Aspirin; Canada; Cardiovascular Diseases; Decision Making, Shared; Humans; Primary Prevention; Risk | 2020 |
Preventive Effects of Neuroprotective Agents in a Neonatal Rat of Photothrombotic Stroke Model.
Topics: Animals; Animals, Newborn; Aspirin; Brain Ischemia; Clopidogrel; Disease Models, Animal; Inflammatio | 2020 |
Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Cardiovascular Dise | 2020 |
Should aspirin be used for prophylaxis of COVID-19-induced coagulopathy?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Autopsy; Blood Coagulation Disorde | 2020 |
New Canadian guideline is wrong to say acetylsalicylic acid is only for patients with symptomatic vascular disease.
Topics: Aspirin; Canada; Fibrinolytic Agents; Humans; Stroke | 2020 |
Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study.
Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Coronary Artery Disease; Dual An | 2020 |
Nonusefulness of Antithrombotic Therapy After Surgical Bioprosthetic Aortic Valve Replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aortic Valve; Aortic Valve Insufficiency; Aortic Val | 2020 |
Prevalence and Outcome of Potential Candidates for Left Atrial Appendage Closure After Stroke With Atrial Fibrillation: WATCH-AF Registry.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Female; Fol | 2020 |
Cost-utility of ticagrelor plus aspirin in diabetic patients with stable coronary artery disease.
Topics: Aspirin; Brain Ischemia; Coronary Artery Disease; Diabetes Mellitus; Humans; Percutaneous Coronary I | 2021 |
Postimplant Phosphodiesterase Type 5 Inhibitors Use Is Associated With Lower Rates of Thrombotic Events After Left Ventricular Assist Device Implantation.
Topics: Adult; Aged; Aspirin; Cohort Studies; Female; Heart-Assist Devices; Humans; Male; Middle Aged; Phosp | 2020 |
Anticoagulation and Antiplatelet Therapy in Atrial Fibrillation: A Teachable Moment.
Topics: Accidental Falls; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Com | 2020 |
Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial.
Topics: Adult; Aspirin; Humans; Ischemic Attack, Transient; Odds Ratio; Platelet Aggregation Inhibitors; Pra | 2020 |
[Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation].
Topics: Acute Coronary Syndrome; Acute Disease; Aspirin; Atrial Fibrillation; Clopidogrel; Combined Modality | 2020 |
Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events.
Topics: Aspirin; Data Interpretation, Statistical; Dual Anti-Platelet Therapy; Endpoint Determination; Equiv | 2020 |
Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry.
Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug | 2020 |
Caught in a Flare.
Topics: Arthralgia; Aspirin; Atorvastatin; Brain; Diagnosis, Differential; Exanthema; Fatigue; Female; Hemat | 2020 |
News coverage and online advertising effects on patient-led search for aspirin, heart health, and stroke information and educational tool use.
Topics: Advertising; Aspirin; Humans; Minnesota; Stroke; Tool Use Behavior | 2021 |
[In patient with symptomatic peripheral arterial disease who had undergone lower-extremity revascularization, does rivaroxaban 2.5 mg twice daily plus aspirin reduce the composite risk of acute limb ischemia, major amputation for vascular causes, myocardi
Topics: Amputation, Surgical; Aspirin; Brain Ischemia; Chocolate; Cysts; Humans; Ischemia; Ischemic Stroke; | 2020 |
Safety and efficacy of low-dose aspirin in ischemic stroke patients with different G6PD conditions.
Topics: Aspirin; Brain Ischemia; Cohort Studies; Drug Therapy, Combination; Glucosephosphate Dehydrogenase; | 2021 |
Predictors of hemorrhagic stroke in older persons taking nonsteroidal anti-inflammatory drugs: Results from the Food and Drug Administration Adverse Event Reporting System.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Hemorrhagic Stroke; Human | 2020 |
Safety and Efficacy of Single Versus Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiovascular Diseases; Cl | 2020 |
Acute Stroke as the Presenting Symptom of SARS-CoV-2 Infection in a Young Patient with Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy.
Topics: Adult; Aspirin; Betacoronavirus; CADASIL; Coronavirus Infections; COVID-19; Female; Host-Pathogen In | 2020 |
In established atherosclerosis, P2Y12 inhibitor vs. aspirin monotherapy reduces MI but not stroke or mortality.
Topics: Aspirin; Atherosclerosis; Hemorrhage; Humans; Patients; Percutaneous Coronary Intervention; Platelet | 2020 |
Gastrointestinal bleeding risk with rivaroxaban vs aspirin in atrial fibrillation: A multinational study.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Gastrointestinal Hemorrhage; Humans; R | 2020 |
Comparison of Antithrombotic Strategies in Chinese Patients in Sinus Rhythm after Bioprosthetic Mitral Valve Replacement: Early Outcomes from a Multicenter Registry in China.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Bioprosthesis; China; Comorbidity; Drug Therapy, Combina | 2021 |
Aspirin reduces cardiovascular events in patients with pneumonia: a prior event rate ratio analysis in a large primary care database.
Topics: Aged; Aspirin; Brain Ischemia; Humans; Platelet Aggregation Inhibitors; Pneumonia; Primary Health Ca | 2021 |
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy.
Topics: Aged; Aspirin; Brain; Brain Infarction; Cognitive Dysfunction; Drug Therapy, Combination; Factor Xa | 2020 |
Not all aspirin products have equivalent antiplatelet efficacy-Aspirin formulated with magnesium stearate is less effective in preventing ischemic stroke.
Topics: Aged; Aspirin; Brain Ischemia; Drug Therapy, Combination; Female; Humans; Ischemic Stroke; Male; Pla | 2020 |
Clopidogrel increases risk of pneumonia compared with aspirin in acute ischemic minor stroke patients.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; | 2021 |
Safety of Aspirin Use in Patients With Stroke and Small Unruptured Aneurysms.
Topics: Aged; Aneurysm, Ruptured; Aspirin; Cohort Studies; Female; Humans; Intracranial Aneurysm; Male; Midd | 2021 |
Safety of Aspirin Use in Patients With Stroke and Small Unruptured Aneurysms.
Topics: Aged; Aneurysm, Ruptured; Aspirin; Cohort Studies; Female; Humans; Intracranial Aneurysm; Male; Midd | 2021 |
Safety of Aspirin Use in Patients With Stroke and Small Unruptured Aneurysms.
Topics: Aged; Aneurysm, Ruptured; Aspirin; Cohort Studies; Female; Humans; Intracranial Aneurysm; Male; Midd | 2021 |
Safety of Aspirin Use in Patients With Stroke and Small Unruptured Aneurysms.
Topics: Aged; Aneurysm, Ruptured; Aspirin; Cohort Studies; Female; Humans; Intracranial Aneurysm; Male; Midd | 2021 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Stroke; Ticagrelor | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. Reply.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Stroke; Ticagrelor | 2020 |
Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Algorithms; Aspirin; Case-Control Studies; | 2020 |
Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease.
Topics: Adult; Aspirin; Atherosclerosis; Cohort Studies; Coronary Artery Disease; Coronary Disease; Eye Hemo | 2021 |
Complex intracranial vascular complications caused by essential thrombocythemia: a critical case report.
Topics: Adult; Aspirin; Blood Platelets; Female; Hemorrhage; Humans; Magnetic Resonance Imaging; Mutation; M | 2020 |
1-Year Safety of 3-Month Dual Antiplatelet Therapy Followed by Aspirin or P2Y
Topics: Absorbable Implants; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; My | 2020 |
Understanding the barriers to using oral anticoagulants among long-term aspirin users with atrial fibrillation - a qualitative study.
Topics: Administration, Oral; Anticoagulants; Asia; Aspirin; Atrial Fibrillation; Humans; Stroke | 2020 |
Cilostazol Addition to Aspirin could not Reduce the Neurological Deterioration in TOAST Subtypes: ADS Post-Hoc Analysis.
Topics: Aged; Aspirin; Cilostazol; Disease Progression; Dual Anti-Platelet Therapy; Female; Humans; Japan; M | 2021 |
Benefits and Risks of Prolonged Duration Dual Antiplatelet Therapy (Clopidogrel and Aspirin) After Percutaneous Coronary Intervention in High-Risk Patients With Diabetes Mellitus.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Dual | 2021 |
Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutio
Topics: Academic Medical Centers; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Computer Security; Dat | 2021 |
In acute ischemic stroke or TIA, adding ticagrelor to aspirin reduced stroke or death and increased severe bleeding.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Ischemic Stroke; Stroke; Ticagrelor | 2020 |
Effects of atorvastatin and aspirin on post-stroke epilepsy and usage of levetiracetam.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Aspirin; Atorvastatin; Cerebral Infarction; Drug Therapy, | 2020 |
Efficacy of aspirin, clopidogrel, and ticlopidine in stroke prevention: A population-based case-cohort study in Taiwan.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged | 2020 |
A trial of antithrombotic therapy in patients with refractory migraine and antiphospholipid antibodies: A retrospective study of 75 patients.
Topics: Adolescent; Adult; Aged; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Child; Cl | 2021 |
Adjunctive treatment with low dose intra-arterial eptifibatide and intravenous aspirin during carotid stenting: A case series.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Endovascular Procedures; Eptifibatide; Female; Humans; | 2021 |
Pretreatment of Indobufen and Aspirin and their Combinations with Clopidogrel or Ticagrelor Alleviates Inflammasome Mediated Pyroptosis Via Inhibiting NF-κB/NLRP3 Pathway in Ischemic Stroke.
Topics: Animals; Aspirin; Brain Ischemia; Clopidogrel; Inflammasomes; Ischemic Stroke; Isoindoles; NF-kappa | 2021 |
The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients.
Topics: Aged; Aptamers, Peptide; Aspirin; Blood Platelets; Collagen; Female; Humans; Intracranial Arterioscl | 2021 |
Assessment of The High risk and unmEt Need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource use, cost, and burden of illness in a commercially insured population.
Topics: Aspirin; Coronary Artery Disease; Cost of Illness; Delivery of Health Care; Diabetes Mellitus, Type | 2021 |
Non-persistence with anti-platelet therapy and long-term mortality after ischemic stroke: A nationwide study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Cardiovascular Diseases; C | 2021 |
Two cases of rt-PA with dual antiplatelet therapies with capsular warning syndrome.
Topics: Aspirin; Clopidogrel; Diffusion Magnetic Resonance Imaging; Dual Anti-Platelet Therapy; Fibrinolytic | 2021 |
Comparison of Aspirin Monotherapy versus Dual Antiplatelet Therapy Following Coronary Artery Bypass Grafting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Dual Anti-Platelet Therapy; Female; Humans; Male | 2021 |
Risk of Early Bleeding with Dual Antiplatelet Therapy in Acute Stroke and Transient Ischemic Attack Regardless of NIHSS Admission.
Topics: Aged; Aspirin; Brazil; Clopidogrel; Databases, Factual; Disability Evaluation; Drug Administration S | 2021 |
Antiplatelet therapy in secondary prevention of non-embolic ischaemic stroke.
Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Humans; Ischemic Stroke; Platelet Aggregation In | 2020 |
Should Senior Citizens Take Aspirin Daily to Prevent Heart Attacks or Strokes?
Topics: Aged; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibi | 2021 |
Clopidogrel underactivity is a common in patients with acute symptomatic severe carotid stenosis.
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Stenosis; Clopidogrel; Female; Humans; Male; Middle Aged; | 2021 |
Statin but not aspirin treatment is associated with reduced cardiovascular risk in patients with diabetes without obstructive coronary artery disease: a cohort study from the Western Denmark Heart Registry.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Cohort Studies; Coronary Artery Disease; Denmark; | 2022 |
Evaluation of Systolic Blood Pressure, Use of Aspirin and Clopidogrel, and Stroke Recurrence in the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial.
Topics: Aged; Aspirin; Blood Pressure; Clopidogrel; Cohort Studies; Dual Anti-Platelet Therapy; Female; Huma | 2021 |
Microbleeds and clinical outcome in acute mild stroke patients treated with antiplatelet therapy: ADS post-hoc analysis.
Topics: Aged; Aspirin; Cerebral Hemorrhage; Cilostazol; Dual Anti-Platelet Therapy; Female; Humans; Magnetic | 2021 |
Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events.
Topics: Acute Coronary Syndrome; Aspirin; Cerebrovascular Disorders; Coronary Artery Disease; Humans; Intrac | 2021 |
Aspirin withdrawal: A risk factor for ischemic stroke severity.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Stroke; Risk Factors; Stroke | 2021 |
Prehemorrhage antiplatelet use in aneurysmal subarachnoid hemorrhage and impact on clinical outcome.
Topics: Aspirin; Glasgow Outcome Scale; Humans; Stroke; Subarachnoid Hemorrhage; Treatment Outcome | 2022 |
Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Intracranial Hemorrhages; Isc | 2021 |
Effect of aspirin in takotsubo syndrome: protocol of a systematic review and meta-analysis.
Topics: Aspirin; Humans; Ischemic Attack, Transient; Meta-Analysis as Topic; Research Design; Retrospective | 2021 |
Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Female; Fibrin | 2017 |
Malignant stroke in a ticagrelor non-responder as a complication following aneurysm treatment with the Pipeline Embolization Device™.
Topics: Adenosine; Aged; Aspirin; Carotid Artery, Internal; Cerebral Angiography; Clopidogrel; Embolization, | 2017 |
The association between high on-treatment platelet reactivity and early recurrence of ischemic events after minor stroke or TIA.
Topics: Adult; Aged; Aspirin; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Ischem | 2017 |
Association between PTGS1 polymorphisms and functional outcomes in Chinese patients with stroke during aspirin therapy: Interaction with smoking.
Topics: Asian People; Aspirin; Brain Ischemia; China; Cyclooxygenase 1; Female; Fibrinolytic Agents; Follow- | 2017 |
Prevention of Cardiovascular Events in Patients With Diabetes: How Beneficial Is Dual Antiplatelet Therapy?
Topics: Aspirin; Belgium; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combination; Humans; Myocardial Infa | 2017 |
Numerous Fusiform and Saccular Cerebral Aneurysms in Central Nervous System Lupus Presenting with Ischemic Stroke.
Topics: Adult; Antihypertensive Agents; Aspirin; Brain Ischemia; Cerebral Angiography; Diffusion Magnetic Re | 2017 |
Aspirin and the risk of cardiovascular events in atherosclerosis patients with and without prior ischemic events.
Topics: Aged; Aspirin; Chi-Square Distribution; Coronary Artery Disease; Female; Humans; Male; Middle Aged; | 2017 |
Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; Coronary A | 2017 |
Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Chi-Square Distribution; Clopidog | 2017 |
Ischemic stroke complicating thrombolytic therapy with tenecteplase for ST elevation myocardial infarction: two case reports.
Topics: Aged; Aspirin; Clopidogrel; Electrocardiography; Fibrinolytic Agents; Heparin; Humans; Ischemic Atta | 2017 |
Internal carotid artery occlusion and stroke as a complication of cisplatin-based chemotherapy for metastatic testicular germ cell tumour.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Aspi | 2017 |
Anti-inflammatory treatment and risk for depression after first-time stroke in a cohort of 147 487 Danish patients.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Aspirin; Denmark; Depressive D | 2017 |
Different levels of blood pressure, different benefit from dual antiplatelet therapy in minor stroke or TIA patients.
Topics: Adult; Aged; Aspirin; Blood Pressure; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Kapla | 2017 |
Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcome
Topics: Adenosine; Aged; Aspirin; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Purinergic P | 2017 |
Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Computer Simulation; Coronary Thrombosis; Cost-Benefi | 2017 |
Stroke: Secondary prevention of ischemic events.
Topics: Aspirin; Family Practice; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Secon | 2017 |
A comparison between vitamin K antagonists and new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials, Phase III as To | 2017 |
I Do Not Have Heart Disease-Should I Be Taking Aspirin?
Topics: Aspirin; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidel | 2017 |
High On-Treatment Platelet Reactivity to Adenosine Diphosphate Predicts Ischemic Events of Minor Stroke and Transient Ischemic Attack.
Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; Clopidogrel; Drug Resi | 2017 |
Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Diabetes Mel | 2017 |
Association between platelet function and recurrent ischemic vascular events after TIA and minor stroke
.
Topics: Alleles; Aspirin; Blood Coagulation Tests; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; F | 2017 |
Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease.
Topics: Aged; Aspirin; Brain Ischemia; Coronary Artery Disease; Coronary Thrombosis; Drug Resistance; Female | 2017 |
A Case of Lenticulostriate Stroke Due to Minor Closed Head Injury in a 2-Year-Old Child: Role of Mineralizing Angiopathy.
Topics: Accidental Falls; Aspirin; Basal Ganglia Cerebrovascular Disease; Brain; Calcinosis; Child, Preschoo | 2018 |
Emergent loading dose of antiplatelets for stenting after IV rt-PA in acute ischemic stroke: a feasibility study.
Topics: Administration, Intravenous; Aged; Aspirin; Brain Ischemia; Clopidogrel; Computed Tomography Angiogr | 2018 |
Aspirin resistance are associated with long-term recurrent stroke events after ischaemic stroke.
Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Female; Follow-Up Studies; Humans; Logistic Models; | 2017 |
Aspirin Use and Mortality in Two Contemporary US Cohorts.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cause of Death; Cohort Studies; Female; Humans; Male; Middle | 2018 |
Which is the best antiaggregant or anticoagulant therapy after TAVI? A propensity-matched analysis from the ITER registry. The management of DAPT after TAVI.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Female; Hemorrhage; Humans; Male; Pla | 2017 |
Response by Lee and Ovbiagele to Letter Regarding Article, "Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis".
Topics: Aspirin; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2017 |
Letter by Spence Regarding Article, "Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis".
Topics: Aspirin; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2017 |
Beneficial Effect of Beraprost Sodium Plus Aspirin in the Treatment of Acute Ischemic Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Infarction; Drug Therapy, Combination; Ep | 2017 |
Lights Out: An Unusual Case of Amaurosis Fugax.
Topics: Amaurosis Fugax; Angiography, Digital Subtraction; Anticholesteremic Agents; Arterial Occlusive Dise | 2018 |
Dual Antiplatelet Therapy Is Associated With Coagulopathy Detectable by Thrombelastography in Acute Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Coagulation; Clopidogrel; Dual Anti-Platelet Therapy; Female | 2020 |
Thrombosis on a left atrial appendage occluder device: the double-edged sword of stroke prevention strategies in atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Dabigatran; Echocardiography, | 2017 |
Association of GPIa and COX-2 gene polymorphism with aspirin resistance.
Topics: Aged; Aspirin; Cyclooxygenase 2; Drug Tolerance; Female; Humans; Integrin alpha2; Male; Middle Aged; | 2018 |
Isolated left ventricular non-compaction (LVNC) and recurrent strokes: to anticoagulate or not to anticoagulate, that is the question.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Diagnosis, Differential; Humans; Isolated Noncompaction | 2017 |
PFA-100-measured aspirin resistance is the predominant risk factor for hospitalized cardiovascular events in aspirin-treated patients: A 5-year cohort study.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cardiovascular System; Cohort Studies; Drug Resistance; Fema | 2018 |
Assessing Bleeding Risk in Patients Taking Anticoagulants.
Topics: Age Factors; Alcohol Drinking; Anemia; Anticoagulants; Aspirin; Atrial Fibrillation; Decision Suppor | 2017 |
Extensive cerebrovascular disease and stroke with prolonged prodromal symptoms as first presentation of perinatally-acquired human immunodeficiency virus infection in a young adult.
Topics: Adult; Aspirin; Basilar Artery; Cerebrovascular Disorders; Computed Tomography Angiography; Delayed | 2018 |
Letter re: Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: Time course analysis of CHANCE.
Topics: Aspirin; Clopidogrel; Humans; Ischemic Attack, Transient; Risk Assessment; Stroke | 2017 |
Author response: Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: Time course analysis of CHANCE.
Topics: Aspirin; Clopidogrel; Humans; Ischemic Attack, Transient; Risk Assessment; Stroke | 2017 |
Anticoagulation strategies in patients with atrial fibrillation after PCI or with ACS : The end of triple therapy?
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido | 2018 |
Low-Dose Aspirin after an Episode of Haemorrhagic Stroke Is Associated with Improved Survival.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cohort Studies; Female; Fibrinolytic Agents; Follow-Up Stud | 2017 |
Expression of tissue inhibitor of metalloproteinases and matrix metalloproteinases in the ischemic brain of photothrombosis model mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain; Disease Models, Animal; Endothelia | 2018 |
STARTING-SICH Nomogram to Predict Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis for Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Female; Fibrinol | 2018 |
Internal Carotid Artery Web as the Cause of Recurrent Cryptogenic Ischemic Stroke.
Topics: Adult; Aspirin; Atorvastatin; Biopsy; Brain Ischemia; Cardiovascular Agents; Carotid Artery Diseases | 2018 |
Dual antiplatelet therapy is safe and efficient after left atrial appendage closure.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Drug Therapy, | 2018 |
[Takotsubo Cardiomyopathy and Neurogenic Pulmonary Edema Following Fibrinolytic Therapy for Embolic Stroke:A Case Report].
Topics: Aged; Aspirin; Fibrinolytic Agents; Humans; Male; Pulmonary Edema; Stroke; Takotsubo Cardiomyopathy; | 2018 |
Short-term dual antiplatelet therapy after interventional left atrial appendage closure with different devices.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Cathet | 2018 |
Aspirin and clopidogrel high on-treatment platelet reactivity and genetic predictors in peripheral arterial disease.
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Angiography; Aryldialkylphosphatase; Aspirin; | 2018 |
Low-Dose Aspirin in Heart Failure Not Complicated by Atrial Fibrillation: A Nationwide Propensity-Matched Study.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cause of Death; Denmark; Dose-Response Relati | 2018 |
Basilar artery fenestration: an unusual possible cause of ischaemic stroke?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Ataxia; Basilar Artery; Cerebral Angiograph | 2018 |
Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; England; Fe | 2018 |
Charting the Course: Risk Scores for Major Bleeding in Transient Ischemic Attack and Ischemic Stroke.
Topics: Aspirin; Brain Ischemia; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibi | 2018 |
Antithrombotic Therapy Underutilization in Patients With Atrial Flutter.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial | 2018 |
A 57-year-old man with a spontaneous carotid artery dissection.
Topics: Aspirin; Carotid Artery, Internal, Dissection; Dyspnea; Fibrinolytic Agents; Humans; Male; Medical H | 2018 |
Monoacylglycerol lipase inhibitor, JZL-184, confers neuroprotection in the mice middle cerebral artery occlusion model of stroke.
Topics: Animals; Aspirin; Behavior, Animal; Benzodioxoles; Brain; Brain Edema; Brain Ischemia; Disease Model | 2018 |
Pre-admission use of platelet inhibitors and short-term stroke mortality: a population-based cohort study.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Denmark; Drug Th | 2018 |
Third-Generation P2Y12 Inhibitors in East Asian Acute Myocardial Infarction Patients: A Nationwide Prospective Multicentre Study.
Topics: Aged; Asia; Aspirin; Clopidogrel; Drug Administration Schedule; Female; Humans; Incidence; Inpatient | 2018 |
Can aspirin help?
Topics: Adult; Aspirin; Double-Blind Method; HIV; Humans; Stroke; Tuberculosis, Meningeal | 2018 |
Artery of Percheron: an unusual stroke presentation.
Topics: Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Atorv | 2018 |
Dual antithrombotic plus adjunctive antiinflammatory therapy to improve cardiovascular outcome in atrial fibrillation patients with concurrent acute coronary syndrome: A triple-pathway strategy.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents; Anticoagulants; Arrhythmias, Cardiac; Aspirin; At | 2018 |
Impact of Depressive Disorder on Access and Quality of Care in Veterans With Prevalent Cardiovascular Disease.
Topics: Age Distribution; Aged; Angina Pectoris; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; | 2018 |
Over-the-counter analgesic powder use in patients presenting with intracerebral hemorrhage: A case series.
Topics: Acetaminophen; Adult; Aged; Analgesics; Aspirin; Black or African American; Cerebral Hemorrhage; Dos | 2018 |
Cerebrovascular Accidents During Mechanical Circulatory Support: New Predictors of Ischemic and Hemorrhagic Strokes and Outcome.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Female; Heart Failure; Heart-Ass | 2018 |
Bilateral visual loss and cerebral infarction after spleen embolization in a trauma patient with idiopathic thrombocytopenic purpura: A case report.
Topics: Adult; Aspirin; Blindness, Cortical; Brain Ischemia; Embolization, Therapeutic; Female; Humans; Magn | 2018 |
Monotherapy of acetylsalicylic acid or warfarin for prevention of ischemic stroke in low-risk atrial fibrillation: A Easter Asian population-based study.
Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Comparative Effectiveness | 2019 |
Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic Obstructive Pulmonary Disease.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Disease Progression; Female; Humans; Male; Myocard | 2018 |
Management of acute tandem occlusions: Stent-retriever thrombectomy with emergency stenting or angioplasty.
Topics: Aged; Angioplasty; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cl | 2018 |
Anterior spinal cord infarct: a rare yet disabling stroke.
Topics: Aged, 80 and over; Aspirin; Atorvastatin; Clopidogrel; Diagnosis, Differential; Humans; Hydroxymethy | 2018 |
Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; China; Clinical Decision-Making; Clopidogrel; Cyto | 2018 |
Are Patients Getting Their Aspirin's Worth in Ischemic Stroke?
Topics: Aspirin; Brain Ischemia; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Stroke | 2018 |
Positive trials in ischaemic stroke reported at ESOC 2018.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Stroke | 2018 |
Efficacy and safety of CYP2C19 genotype in stroke or transient ischemic attack patients treated with clopidogrel monotherapy or clopidogrel plus aspirin: Protocol for a systemic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Genotype; Humans; Ischemi | 2018 |
Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Dr | 2018 |
Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?
Topics: Aspirin; Atherosclerosis; Chronic Disease; Clinical Trials as Topic; Death; Drug Therapy, Combinatio | 2019 |
Aspirin in Primary Prevention of Myocardial Infarction/Angina and Stroke in Hypertensive Patients.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Cardiovascular Diseases; Cross-Sectional S | 2018 |
Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction.
Topics: Aged; Aspirin; Drug Therapy, Combination; Female; Germany; Hemorrhage; Humans; Male; Middle Aged; Pe | 2018 |
What now for embolic stroke of undetermined source?
Topics: Anticoagulants; Aspirin; Brain Ischemia; Clinical Trials as Topic; Humans; Intracranial Embolism; Ri | 2018 |
Aspirin resistance predicts unfavorable functional outcome in acute ischemic stroke patients.
Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Female; Follow-Up Studies; Humans; Male; Middle Aged | 2018 |
Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials.
Topics: Age Factors; Aged; Aspirin; Body Height; Body Weight; Cardiovascular Diseases; Colorectal Neoplasms; | 2018 |
Novel oral anticoagulants in primary care in patients with atrial fibrillation: a cross-sectional comparison before and after their introduction.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cross-Sect | 2018 |
Cessation of dual antiplatelet therapy and cardiovascular events following acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Female; | 2019 |
Argatroban plus aspirin versus aspirin in acute ischemic stroke.
Topics: Arginine; Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fema | 2018 |
Vessel wall enhancement by gadolinium-enhanced MRI in a patient with delayed stenosis after mechanical thrombectomy.
Topics: Angiography, Digital Subtraction; Aspirin; Coronary Stenosis; Female; Gadolinium; Humans; Image Proc | 2018 |
Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocar | 2018 |
Effect of Antiplatelet Therapy (Aspirin + Dipyridamole Versus Clopidogrel) on Mortality Outcome in Ischemic Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combinati | 2018 |
The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhag | 2019 |
[Ten key messages regarding embolic stroke of undetermined source and cryptogenic stroke].
Topics: Anticoagulants; Aspirin; Embolism; Humans; Secondary Prevention; Stroke | 2018 |
Effects of high- and low-dose aspirin on adaptive immunity and hypertension in the stroke-prone spontaneously hypertensive rat.
Topics: Adaptive Immunity; Angiotensin II; Animals; Aspirin; Biomarkers; Blood Pressure; Blood Vessels; Card | 2019 |
External Validation of the DAPT Score in a Nationwide Population.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Decision Support Techniques; Drug Therapy, Combinat | 2018 |
Opportunities for intervention: stroke treatments, disability and mortality in urban Tanzania.
Topics: Aged; Antihypertensive Agents; Aspirin; Brain Ischemia; Cohort Studies; Deglutition Disorders; Disab | 2019 |
Aspirin-still the GLOBAL LEADER in antiplatelet therapy.
Topics: Aspirin; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2018 |
Pharmacogenetic and clinical predictors of response to clopidogrel plus aspirin after acute coronary syndrome in Egyptians.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combina | 2018 |
Antiplatelet Therapy for Long-Term Management of Patients with Mechanical Aortic Prostheses.
Topics: Adult; Aged; Aged, 80 and over; Aortic Valve; Aspirin; Clopidogrel; Female; Follow-Up Studies; Heart | 2017 |
In embolic stroke of undetermined source, rivaroxaban vs aspirin did not reduce recurrence and increased bleeding.
Topics: Aspirin; Hemorrhage; Humans; Rivaroxaban; Stroke | 2018 |
Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease.
Topics: Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Coronar | 2018 |
Ischemic stroke following a wasp sting - a rare complication: a case report.
Topics: Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Atorvasta | 2018 |
Prevalence of high on-treatment platelet reactivity in patients with chronic kidney disease treated with acetylsalicylic acid for stroke prevention.
Topics: Adult; Age Factors; Aspirin; Blood Platelets; Case-Control Studies; Female; Humans; Male; Middle Age | 2018 |
Optimal stroke prevention in patients with patent foramen ovale.
Topics: Aspirin; Foramen Ovale, Patent; Humans; Rivaroxaban; Secondary Prevention; Stroke | 2018 |
Letter by Tong et al Regarding Article, "Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials".
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Randomized Controlled Trials as Topic; Stroke | 2018 |
Response by de Veer et al to Letter Regarding Article, "Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials".
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Randomized Controlled Trials as Topic; Stroke | 2018 |
Antiplatelet Agents in Acute Stroke and TIA.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke | 2018 |
Dual Antiplatelet Therapy for Minor Stroke and High-Risk Transient Ischemic Attack.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggreg | 2018 |
Antiplatelet Agents in Acute Stroke and TIA.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke | 2018 |
Antiplatelet Agents in Acute Stroke and TIA.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke | 2018 |
Comparison Between Aspirin and Clopidogrel in Secondary Stroke Prevention Based on Real-World Data.
Topics: Aged; Aspirin; Clopidogrel; Female; Follow-Up Studies; Humans; Incidence; Male; Platelet Aggregation | 2018 |
Acute administration of tirofiban versus aspirin in emergent carotid artery stenting.
Topics: Aged; Aspirin; Carotid Stenosis; Cerebral Angiography; Female; Fibrinolytic Agents; Humans; Male; Mi | 2019 |
Management of a pregnancy with underlying fibromuscular dysplasia with a history of stroke and carotid artery dissection.
Topics: Adult; Aortic Dissection; Aspirin; Carotid Artery Diseases; Female; Fibromuscular Dysplasia; Humans; | 2019 |
Prestroke Aspirin Use is Associated with Clinical Outcomes in Ischemic Stroke Patients with Atherothrombosis, Small Artery Disease, and Cardioembolic Stroke.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Biomarkers; Brain Ischemia; | 2019 |
Antiplatelet effects of aspirin and clopidogrel after left atrial appendage (LAA) occluder implantation.
Topics: Aged; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Dose-Response Relationship, Drug; | 2019 |
Primary stroke centers: are they worthy of an upgrade?
Topics: Aspirin; Brain Ischemia; Cardiac Resynchronization Therapy; Humans; Stroke; Tissue Plasminogen Activ | 2019 |
Safety and efficacy of cangrelor in acute stenting for the treatment of cerebrovascular pathology: preliminary experience in a single-center pilot study.
Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Drug Therapy, Comb | 2019 |
Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhib | 2018 |
Oral anticoagulation and left atrial appendage closure: a new strategy for recurrent cardioembolic stroke.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Cardiac Surgical Procedures; Ech | 2019 |
Aspirin reduces long-term stroke risk in women with prior hypertensive disorders of pregnancy.
Topics: Adult; Age Factors; Aspirin; Female; Fibrinolytic Agents; Follow-Up Studies; Hospitalists; Humans; H | 2019 |
Stroke prevention: How low can you go?
Topics: Aspirin; Female; Humans; Hypertension, Pregnancy-Induced; Pregnancy; Stroke | 2019 |
Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.
Topics: Aged; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Cohort Studies; Diabetes Complicati | 2019 |
Anticoagulation in patients with Embolic Stroke of Unknown Source.
Topics: Anticoagulants; Aspirin; Embolism, Paradoxical; Foramen Ovale, Patent; Humans; Monitoring, Physiolog | 2019 |
New opportunities to optimize antithrombotic therapy for secondary stroke prevention.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Ischemic Attack, Trans | 2019 |
Evaluating the Effect of a Patient Decision Aid for Atrial Fibrillation Stroke Prevention Therapy.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; British Columbia; Decision Making; Decision Supp | 2019 |
Stroke prevention in atrial fibrillation: Closing the gap.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Health Services Misu | 2019 |
Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Aspirin; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Cytochrome P-450 CYP2C19; | 2019 |
Stroke prevention in patients with acute ischemic stroke and atrial fibrillation in Germany - a cross sectional survey.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cross-Sectional Studies; Female; Germany; Humans | 2019 |
Twenty-and-a-half syndrome: a case report.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atorvast | 2019 |
Preparing of aspirin sustained-release granules by hot-melt granulation and micro-crystal coating.
Topics: Aspirin; Cellulose; Delayed-Action Preparations; Drug Compounding; Drug Liberation; Drug Stability; | 2019 |
Optimal stroke prevention in patients with PFO.
Topics: Aspirin; Foramen Ovale, Patent; Humans; Recurrence; Rivaroxaban; Stroke | 2019 |
Platelet Surface CD62p and Serum Vitamin D Levels are Associated with Clopidogrel Resistance in Chinese Patients with Ischemic Stroke.
Topics: Aged; Asian People; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; China; Clopidogrel; Drug R | 2019 |
Stroke in a young man: a late complication of radiation therapy.
Topics: Adult; Anticholesteremic Agents; Aortic Valve; Aspirin; Echocardiography, Transesophageal; Factor Xa | 2019 |
Uptake of Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in a Single Clinical Commissioning Group in England Without Restrictions to Their Use.
Topics: Administration, Oral; Advisory Committees; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial | 2019 |
Aspirin use in central retinal arterial occlusion to prevent ischaemic stroke: a retrospective cohort study in Taiwan.
Topics: Aged; Aspirin; Cause of Death; Databases, Factual; Female; Fibrinolytic Agents; Humans; Incidence; M | 2019 |
Association of Aspirin Resistance with Increased Mortality in Ischemic Stroke.
Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Female; Humans; Male; Middle Aged; Mortality; Outcom | 2019 |
Sex Differences in Care and Long-Term Mortality After Stroke: Australian Stroke Clinical Registry.
Topics: Aged; Aged, 80 and over; Aspirin; Australia; Cohort Studies; Evidence-Based Practice; Female; Fibrin | 2019 |
Dual Versus Mono Antiplatelet Therapy in Large Atherosclerotic Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clopidogrel; Dual Anti-Platelet T | 2019 |
Dual Versus Mono Antiplatelet Therapy in Large Atherosclerotic Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clopidogrel; Dual Anti-Platelet T | 2019 |
Dual Versus Mono Antiplatelet Therapy in Large Atherosclerotic Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clopidogrel; Dual Anti-Platelet T | 2019 |
Dual Versus Mono Antiplatelet Therapy in Large Atherosclerotic Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clopidogrel; Dual Anti-Platelet T | 2019 |
Guideline: Starting dual antiplatelet therapy ≤ 24 h after high-risk TIA or minor ischemic stroke is recommended.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; | 2019 |
Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocar | 2019 |
Influence of blood pressure on the effects of low-dose asprin in elderly patients with multiple atherosclerotic risks.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Pressure; Diabetes Mellitus; Dyslipidemias; Female; Hemorrha | 2019 |
Clopidogrel use and smoking cessation result in lower coated-platelet levels after stroke.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Cross-Sectional Studies; Drug | 2020 |
Efficacy of Antiplatelet Agent Usage for Primary and Secondary Prevention in Dialysis Patients: a Nationwide Data Survey and Propensity Analysis.
Topics: Aspirin; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Myocardial Infarction; Plat | 2019 |
Administrative claims data to support pragmatic clinical trial outcome ascertainment on cardiovascular health.
Topics: Administrative Claims, Healthcare; Aged; Aspirin; Cardiovascular Diseases; Electronic Health Records | 2019 |
Association between High Platelet Reactivity Following Dual Antiplatelet Therapy and Ischemic Events in Japanese Patients with Coronary Artery Disease Undergoing Stent Implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Japan; Male; Middle Aged; Myoca | 2020 |
Navigating the treacherous waters of antithrombotic therapies in patients with atrial fibrillation and coronary artery disease: Lessons from AUGUSTUS.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Drug Therapy, Combination; Fi | 2019 |
Ischemic stroke in the combined territories of the septum pellucidum and the cingulate gyrus: A case report and literature review.
Topics: Anticoagulants; Aspirin; Brain Infarction; Clopidogrel; Gyrus Cinguli; Humans; Male; Middle Aged; Se | 2019 |
Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
Topics: Adrenergic beta-Antagonists; Aspirin; Atenolol; Budgets; Cardiovascular Diseases; Cost Savings; Cost | 2019 |
Collagen-Induced Platelet Aggregates, Diabetes, and Aspirin Therapy Predict Clinical Outcomes in Acute Ischemic Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Comorbidity; Cross-Se | 2019 |
Response by Berberich et al to Letters Regarding Article, "Dual Antiplatelet Therapy Improves Functional Outcome in Patients With Progressive Lacunar Strokes".
Topics: Aspirin; Dual Anti-Platelet Therapy; Humans; Platelet Aggregation Inhibitors; Stroke; Stroke, Lacuna | 2019 |
Letter by Gutierrez Regarding Article, "Dual Antiplatelet Therapy Improves Functional Outcome in Patients With Progressive Lacunar Strokes".
Topics: Aspirin; Dual Anti-Platelet Therapy; Humans; Platelet Aggregation Inhibitors; Stroke; Stroke, Lacuna | 2019 |
Aspirin in stroke patients modifies the immunomodulatory interactions of marrow stromal cells and monocytes.
Topics: Aged; Aspirin; Bone Marrow; Chemokine CCL2; Coculture Techniques; Cytokines; Female; Humans; Immunom | 2019 |
Impact of platelet turnover on long-term adverse cardiovascular outcomes in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Diseas | 2019 |
Posterior reversible encephalopathy syndrome, preeclampsia or stroke? A diagnostic dilemma.
Topics: Abdominal Pain; Adrenergic beta-Antagonists; Aspirin; Diagnosis, Differential; Factor V; Female; Hea | 2019 |
Delusional parasitosis as presenting symptom of occipital lobe cerebrovascular accident.
Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Delusional Parasitosis; Female; Humans; Middle Aged | 2019 |
Stroke and transient ischemic attacks related to antiplatelet or warfarin interruption.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brazil; Clopidogrel; Cross-Sectional Studies; Fe | 2019 |
Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Female; Humans; | 2013 |
Amplatzer left atrial appendage occlusion: single center 10-year experience.
Topics: Aged; Aged, 80 and over; Anesthesia, Local; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac | 2013 |
Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
Topics: Aged; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; | 2013 |
Aspirin nonresponders in patients with ischaemic stroke.
Topics: Aspirin; Brain Ischemia; Female; Humans; Male; Middle Aged; Multivariate Analysis; Platelet Aggregat | 2013 |
Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Cohort Studies; Female; Humans; Longitudinal Studies; Male; | 2013 |
Aspirin not effective in some people. Failure to take the drug may be the most common reason.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Drug Administrat | 2012 |
Bo Norrving: putting stroke on the world map.
Topics: Aspirin; Clinical Trials as Topic; Global Health; History, 20th Century; History, 21st Century; Huma | 2013 |
64-MDCT can depict the thrombi expanded from the left lower pulmonary vein to the left atrium in the patient with angina pectoris.
Topics: Aged; Angina Pectoris; Aspirin; Coronary Thrombosis; Diagnosis, Differential; Echocardiography; Hear | 2013 |
Therapy for triggered acute risk prevention in subjects at increased cardiovascular risk.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Death, Sudden, Cardiac; Drug Therapy, | 2013 |
Primary prophylactic aspirin use and incident stroke: reasons for geographic and racial differences in stroke study.
Topics: Aged; Aged, 80 and over; Aspirin; Black or African American; Cardiovascular Agents; Chi-Square Distr | 2013 |
The use, misuse and abuse of dabigatran.
Topics: Advertising; Anticoagulants; Antithrombins; Aspirin; Australia; Benzimidazoles; beta-Alanine; Cardio | 2013 |
JAMA patient page. Aspirin therapy.
Topics: Aspirin; Contraindications; Humans; Myocardial Infarction; Peripheral Arterial Disease; Platelet Agg | 2013 |
Catheter ablation of atrial fibrillation in patients at low thrombo-embolic risk: efficacy and safety of a simplified periprocedural anticoagulation strategy.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Catheter Ablation; Echocardiography, Transesophageal; | 2013 |
[Atrial fibrillation. Apixaban reduces stroke risk].
Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Drug | 2013 |
Epidemiology of atrial fibrillation in Turkey: preliminary results of the multicenter AFTER study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Electrocardiography; F | 2013 |
Major bleeding events and risk stratification of antithrombotic agents in hemodialysis: results from the DOPPS.
Topics: Aged; Anticoagulants; Aspirin; Cohort Studies; Female; Fibrinolytic Agents; Gastrointestinal Hemorrh | 2013 |
Aspirin non-responder in Thai ischemic stroke patients.
Topics: Age Factors; Aged; Aspirin; Dose-Response Relationship, Drug; Drug Resistance; Female; Humans; Male; | 2013 |
Association of ALOX5AP1 SG13S114T/A variant with ischemic stroke, stroke subtypes and aspirin resistance.
Topics: 5-Lipoxygenase-Activating Proteins; Adult; Aged; Aspirin; Case-Control Studies; Chi-Square Distribut | 2013 |
Carotid artery stenting outcomes: do they correlate with antiplatelet response assays?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Carotid Stenosis; Cerebral Revascularizatio | 2014 |
Contra: "New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation".
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; | 2013 |
Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.".
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabet | 2013 |
Progression of asymptomatic carotid stenosis despite optimal medical therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Asymptomatic Diseases; Biomarkers; Cardiovascular Agents; Carotid | 2013 |
Early dual therapy for Chinese adults with TIA.
Topics: Aspirin; China; Clopidogrel; Drug Therapy, Combination; Female; Humans; Intracranial Hemorrhages; Is | 2013 |
TXA2 synthesis and COX1-independent platelet reactivity in aspirin-treated patients soon after acute cerebral stroke or transient ischaemic attack.
Topics: Acute Disease; Aged; Aspirin; Case-Control Studies; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Fem | 2013 |
Early and late mortality of spontaneous hemorrhagic transformation of ischemic stroke.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Cohort Studies; Disease Progressio | 2014 |
"Aspirin resistance" in ischemic stroke: insights using short thrombelastography.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Brain Ischemia; Cytokines; Drug Resistance; Female; Hu | 2013 |
Antithrombotic drugs and risk of hemorrhagic stroke in the general population.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Cohort Studies; Female; Fibrinolytic | 2013 |
The place of newer oral anticoagulants in the treatment of patients with non-valvular atrial fibrillation and coronary artery disease.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Dis | 2013 |
Aspirin after heart attack or stroke.
Topics: Aftercare; Aspirin; Dose-Response Relationship, Drug; Health Promotion; Humans; Myocardial Infarctio | 2013 |
Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial.
Topics: Anticoagulants; Aspirin; Brain Damage, Chronic; Brain Ischemia; Cerebral Hemorrhage; Heart Failure; | 2013 |
Long-term effects of secondary prevention on cognitive function in stroke patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Cognition Disorders; Dipyridamole; Female | 2013 |
Risks and benefits of early antithrombotic therapy after thrombolytic treatment in patients with acute stroke.
Topics: Administration, Oral; Aged; Aspirin; Brain; Clopidogrel; Female; Fibrinolytic Agents; Heparin; Human | 2013 |
[Your patient needs antithrombotic drugs, 7. Averting the risk of stroke: with whom and how?].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Drug Therapy, Combination; F | 2013 |
Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Asian People; Aspirin; Atrial Fibrillation; Blood Coagulation; Clopidogrel; Co | 2014 |
Cervical rib resulting in amaurosis fugax and stroke.
Topics: Adolescent; Amaurosis Fugax; Aspirin; Cerebral Angiography; Cervical Rib; Humans; Male; Shoulder Joi | 2013 |
Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; China; Clopidogrel; Cost-Benefit Analysis; Drug Therap | 2014 |
The clinical outcomes of percutaneous coronary intervention performed without pre-procedural aspirin.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Artery Disease; Drug Utilization; F | 2013 |
Factors influencing multiplate whole blood impedance platelet aggregometry measurements, during aspirin treatment in acute ischemic stroke: a pilot study.
Topics: Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; C-Reactive Protein; Cholesterol, HDL; Clopido | 2013 |
Neuroprotective effect of a new synthetic aspirin-decursinol adduct in experimental animal models of ischemic stroke.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Benzopyrans; Butyrates; Disease Models, A | 2013 |
Predictors of 1-year outcomes in the Taiwan Acute Coronary Syndrome Full Spectrum Registry.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up Studies; | 2014 |
Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; | 2014 |
Implications of aspirin biochemistry in the pathobiology of ischemic cerebrovascular disease.
Topics: Aspirin; Dipyridamole; Female; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; Male; Random | 2014 |
Atrial fibrillation patients do not benefit from acetylsalicylic acid.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Female; Gastr | 2014 |
Efficacy of contemporary medical management for asymptomatic carotid artery stenosis.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2013 |
Aspirin resistant patients with recent ischemic stroke.
Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Female; Humans; Platelet Aggregation Inhibitors; Rec | 2014 |
Acetylsalicylic acid for stroke prevention in atrial fibrillation: a conspiracy that needs to end?
Topics: Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Humans; Male; Platelet Aggregation Inhibitors; | 2014 |
Aspirin protects some hearts better than others. It's in the genes. A biomarker can predict a person's response to this potentially lifesaving medication.
Topics: Aspirin; Blood Platelets; Genetic Markers; Genetic Predisposition to Disease; Heart Diseases; Humans | 2013 |
Interaction between vWF levels and aspirin resistance in ischemic stroke patients.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Female; Humans; Male; | 2013 |
Progressive hemorrhagic transformation following dual antiplatelet therapy.
Topics: Angiography, Digital Subtraction; Aspirin; Brain; Cerebral Angiography; Cerebral Hemorrhage; Clopido | 2014 |
Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Thera | 2014 |
Neurovascular protection of cilostazol in stroke-prone spontaneous hypertensive rats associated with angiogenesis and pericyte proliferation.
Topics: Animals; Antigens; Aspirin; Cerebrovascular Circulation; Cilostazol; Clopidogrel; Disease Models, An | 2014 |
Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Dipyridamole | 2014 |
Is enteric aspirin safer than regular aspirin?
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, | 2013 |
Risk of ischemic stroke after an acute myocardial infarction in patients with diabetes mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Diabetes Complications; Female; Follow-Up Studies; Humans; Hydroxy | 2014 |
Antithrombotic drugs and ischaemic stroke.
Topics: Aspirin; Brain Ischemia; Fibrinolytic Agents; Humans; Stroke | 2013 |
Secondary prevention of atherothrombotic or cryptogenic stroke.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Clopidogrel; Drug Th | 2014 |
Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies; | 2014 |
Switching from aspirin to clopidogrel in patients with aspirin resistance after an ischemic stroke. Is it a good solution?
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Drug Resistance; Drug Substitution; F | 2014 |
Dual antiplatelet therapy (clopidogrel and aspirin) is associated with increased all-cause mortality after carotid revascularization for asymptomatic carotid disease.
Topics: Aged; Alabama; Angioplasty; Aspirin; Asymptomatic Diseases; Carotid Stenosis; Clopidogrel; Drug Ther | 2014 |
Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Drug Costs; Factor Xa Inh | 2014 |
Intracranial stenosis: impact of randomized trials on treatment preferences of US neurologists and neurointerventionists.
Topics: Angioplasty; Aspirin; Cerebral Arteries; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combin | 2014 |
Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the American Academy of Neurology.
Topics: Academies and Institutes; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Practice Guidelines | 2014 |
Modern clinical research: guidelines for the practicing clinician or source of confusion?
Topics: Aspirin; Biomedical Research; Cardiovascular Agents; Evidence-Based Medicine; Family Practice; Guide | 2013 |
Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate | 2014 |
Outcome of overt stroke in sickle cell anaemia, a single institution's experience.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Aspirin; Child; Erythrocyte Transfusion; Female; Humans; Mal | 2014 |
The clinical dilemma of treating transient ischaemic attack-like symptoms in patients with coexisting arteriovenous malformation.
Topics: Aged; Aspirin; Female; Humans; Intracranial Arteriovenous Malformations; Intracranial Hemorrhages; I | 2014 |
Prevalence of stroke and the need for thromboprophylaxis in young patients with atrial fibrillation: a cohort study.
Topics: Adolescent; Adult; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Utilization; Female; Follow-Up | 2014 |
Triple versus dual antiplatelet therapy after percutaneous coronary intervention for coronary bifurcation lesions: results from the COBIS (COronary BIfurcation Stent) II Registry.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2015 |
Aortic arch atheroma: a plaque of a different color or more of the same?
Topics: Anticoagulants; Aortic Diseases; Aspirin; Clopidogrel; Female; Humans; Male; Platelet Aggregation In | 2014 |
Extracranial traumatic aneurysms due to blunt cerebrovascular injury.
Topics: Adolescent; Adult; Aneurysm; Aspirin; Cerebral Angiography; Cerebrovascular Trauma; Cohort Studies; | 2014 |
Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease.
Topics: Aged; Amputation, Surgical; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Female; Guideline Adh | 2014 |
Longitudinal assessment of von Willebrand factor antigen and von Willebrand factor propeptide in response to alteration of antiplatelet therapy after TIA or ischaemic stroke.
Topics: Adult; Aged; Aspirin; Clopidogrel; Dipyridamole; Enzyme-Linked Immunosorbent Assay; Female; Humans; | 2014 |
Association of cyclooxygenase-2 genetic variant with cardiovascular disease.
Topics: 6-Ketoprostaglandin F1 alpha; Aged; Aspirin; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Female; He | 2014 |
FDA questions use of aspirin for primary prevention of stroke and heart attack.
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Primary Prevention; Stroke; | 2014 |
Values and preferences for oral antithrombotic therapy in patients with atrial fibrillation: physician and patient perspectives.
Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Attitude of Health Personnel; Female; Fib | 2015 |
Relative importance of benefits and risks associated with antithrombotic therapies for acute coronary syndrome: patient and physician perspectives.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Attitude of Health Personnel; Card | 2014 |
Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comparati | 2014 |
Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey.
Topics: Age Distribution; Aged; Alcohol Drinking; Anticoagulants; Aspirin; Atrial Fibrillation; Diabetes Com | 2014 |
Million hearts: prevalence of leading cardiovascular disease risk factors--United States, 2005-2012.
Topics: Adolescent; Adult; Aged; Aspirin; Cardiovascular Diseases; Female; Health Promotion; Humans; Hyperch | 2014 |
Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke.
Topics: Aspirin; China; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; H | 2014 |
Delayed ischemic stroke after stent-assisted coil placement in cerebral aneurysm: characteristics and optimal duration of preventative dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Embolization, Therapeutic; Female; Humans; Intracranial Aneurysm; Male; Middle | 2014 |
Delayed ischemic stroke after stent-assisted coil placement in cerebral aneurysm: characteristics and optimal duration of preventative dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Embolization, Therapeutic; Female; Humans; Intracranial Aneurysm; Male; Middle | 2014 |
Delayed ischemic stroke after stent-assisted coil placement in cerebral aneurysm: characteristics and optimal duration of preventative dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Embolization, Therapeutic; Female; Humans; Intracranial Aneurysm; Male; Middle | 2014 |
Delayed ischemic stroke after stent-assisted coil placement in cerebral aneurysm: characteristics and optimal duration of preventative dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Embolization, Therapeutic; Female; Humans; Intracranial Aneurysm; Male; Middle | 2014 |
Stroke prevention in women: synopsis of the 2014 American Heart Association/American Stroke Association guideline.
Topics: American Heart Association; Aspirin; Female; Humans; Platelet Aggregation Inhibitors; Practice Guide | 2014 |
Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Female | 2014 |
Aspirin still overprescribed for stroke prevention in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Stroke; Unnecessary Procedures | 2014 |
Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis.
Topics: Aged; Aspirin; Brain Ischemia; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combination; | 2014 |
The natural history of asymptomatic severe carotid artery stenosis.
Topics: Aged; Aspirin; Asymptomatic Diseases; Blood Flow Velocity; Cardiovascular Agents; Carotid Stenosis; | 2014 |
Expanding antiplatelet use for patients with stroke: the case for stroke of unknown type.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Decision Support Techniques; Female; Humans; Male; | 2014 |
Aspirin for acute stroke of unknown etiology in resource-limited settings: a decision analysis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Decision Support Techniques; Female; Humans | 2014 |
Antithrombotic therapy for secondary stroke prevention in bacterial meningitis in children.
Topics: Adolescent; Aspirin; Brain; Child; Child, Preschool; Diagnostic Imaging; Female; Fibrinolytic Agents | 2014 |
Daily aspirin reduces risk of developing and dying from cancer, researchers find.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Neoplasms; Stroke | 2014 |
Acute Carotid Artery Stent Thrombosis Due to Dual Antiplatelet Resistance.
Topics: Acute Disease; Aged; Aspirin; Carotid Artery Thrombosis; Carotid Artery, Internal; Clopidogrel; Drug | 2015 |
Aspirin for secondary prevention after stroke of unknown etiology in resource-limited settings.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cost-Benefit Analysis; | 2014 |
Extract of Antrodia camphorata exerts neuroprotection against embolic stroke in rats without causing the risk of hemorrhagic incidence.
Topics: Animals; Antrodia; Aspirin; Brain; Drug Therapy, Combination; Hemoglobins; Hemorrhage; Male; Neuropr | 2014 |
[The clinical analysis of atrial fibrillation of 1 310 in patients in Urumqi of China].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; China; Comor | 2014 |
New advice to help women lower their stroke risk.
Topics: Adult; Aged; Aspirin; Female; Health Education; Humans; Risk Assessment; Risk Reduction Behavior; St | 2014 |
Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in Belgium.
Topics: Aged; Aspirin; Atrial Fibrillation; Belgium; Cost-Benefit Analysis; Factor Xa Inhibitors; Female; He | 2014 |
New ways to assess stroke risk and tame an abnormal heartbeat. Cardiology groups update guidelines to treat atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Middle Aged; Practi | 2014 |
New guidelines update treatment of atrial fibrillation. Changes include adding new clot-preventing drugs and using less aspirin.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Platelet Aggregation Inhibitors; Practice Guid | 2014 |
Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Female; Hemor | 2014 |
Analysis of periinterventional complications of intracranial angioplasty and stenting: a single center experience.
Topics: Aged; Angioplasty; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Diabetes Complication | 2014 |
Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Disease Progression; Health Res | 2014 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2014 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2014 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2014 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2014 |
Aspirin: still a wonder drug? Sorting out aspirin's role in heart attack and stroke prevention.
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Primary Prevention; Stroke; | 2014 |
Does atrial fibrillation pattern affect stroke risk? Data dredging to help the clinician.
Topics: Aspirin; Atrial Fibrillation; Female; Fibrinolytic Agents; Humans; Male; Stroke | 2015 |
Involvement of Arg306 mutation in factor V gene in two young men with ischemic stroke.
Topics: Anticholesteremic Agents; Arginine; Aspirin; Brain Ischemia; DNA Mutational Analysis; Factor V; Fibr | 2014 |
Preadmission use of nonaspirin nonsteroidal anti-inflammatory drugs and 30-day stroke mortality.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Female; Humans; Male; Middle | 2014 |
Reply to the letter to the editor 'the harms of low-dose aspirin prophylaxis are overstated' by P. Elwood and G. Morgan.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Neoplasms; Stroke | 2015 |
Intensity and quality of warfarin anticoagulation in Chinese patients: setting the record straight.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Huma | 2015 |
Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; | 2015 |
The harms of low-dose aspirin prophylaxis are overstated.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Neoplasms; Stroke | 2015 |
Reviewing a clinical decision aid for the selection of anticoagulation treatment in patients with nonvalvular atrial fibrillation: applications in a US managed care health plan database.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Databases, Factual; Decision Support | 2014 |
Impact of aspirin according to type of stable coronary artery disease: insights from a large international cohort.
Topics: Aged; Aspirin; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction; My | 2015 |
A stroke of bad luck.
Topics: Aspirin; Female; Giant Cell Arteritis; Headache; Humans; Middle Aged; Steroids; Stroke | 2014 |
Aspirin use in women for primary prevention.
Topics: Aspirin; Female; Gastrointestinal Hemorrhage; Humans; Myocardial Infarction; Neoplasms; Platelet Agg | 2015 |
Aspirin for first-line heart attack prevention. These is still no consensus; the benefits must be weighed against the risks.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Primary Preve | 2014 |
Prospective evaluation of blood coagulability and effect of treatment in patients with stroke using rotational thromboelastometry.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Coagulation; Brain Ischemia; Female; Fibrinolytic Agents; Hu | 2015 |
Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Denmark; Female; Follow-Up Studi | 2014 |
Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; China; Cohort St | 2015 |
Patterns of Antiplatelet Therapy in Patients Who Have Experienced an Acute Coronary Event: A Descriptive Study in UK Primary Care.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Female; Foll | 2015 |
The effect of different doses and different routes of acetylsalicylic acid administration on platelet aggregation in healthy volunteers and ischemic stroke patients.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Drug Administration Routes; | 2015 |
[Analysis about characteristics of drug used in clinical for ischemic stroke patients based on hospital electronic medical database].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Drug Combinations; Drugs, Chinese Herbal; Female; Fibrinoly | 2014 |
[Chinese subgroup analysis of the global anticoagulant registry in the FIELD (GARFIELD) registry in the patients with non-valvular atrial fibrillation].
Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; China; Female; H | 2014 |
A short-term risk-benefit analysis of occasional and regular use of low-dose aspirin in primary prevention of vascular diseases: a nationwide population-based study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Databases, | 2015 |
Comparison of statistical and operational properties of subject randomization procedures for large multicenter clinical trial treating medical emergencies.
Topics: Algorithms; Aspirin; Computer Simulation; Double-Blind Method; Emergencies; Fibrinolytic Agents; Hum | 2015 |
Letter by Feng et al regarding article, "Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control".
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Intracra | 2015 |
Response to letter regarding article, "Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control".
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Intracra | 2015 |
Pathophysiologic, rather than laboratory-defined resistance drives aspirin failure in ischemic stroke.
Topics: Aged; Aspirin; Blood Platelets; Brain Ischemia; Cohort Studies; Drug Resistance; Female; Humans; In | 2015 |
Regular aspirin use does not reduce risk of cognitive decline.
Topics: Aged; Aspirin; Cognition Disorders; Cohort Studies; Female; Humans; Incidence; Male; Middle Aged; St | 2015 |
Effect of preoperatively continued aspirin use on early and mid-term outcomes in off-pump coronary bypass surgery: a propensity score-matched study of 1418 patients.
Topics: Aged; Aspirin; Coronary Artery Bypass, Off-Pump; Coronary Artery Disease; Female; Humans; Male; Midd | 2015 |
Do Glycoprotein IIb/IIIa Inhibitors Improve Outcomes in Acute Ischemic Stroke?
Topics: Antibodies, Monoclonal; Aspirin; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation Inhibito | 2015 |
Comment: TIA response to antiplatelets stratified by glycated albumin.
Topics: Aspirin; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Male; Stroke; Ticlopidine | 2015 |
Recurrent ischaemic stroke unveils polycythaemia vera.
Topics: Aspirin; Atorvastatin; Bloodletting; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutar | 2015 |
Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Coagulation; Cohort | 2015 |
Patients with atrial fibrillation and a CHA2DS2-VASc score of 1: are they at low or high stroke risk?
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Female; Humans; Male; Stroke | 2015 |
Relationship between Troponin Elevation, Cardiovascular History and Adverse Events in Patients with acute exacerbation of COPD.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Cause of Death; Creatinine; Disease Progression; Fema | 2015 |
Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy.
Topics: Aged; Aspirin; Atrial Fibrillation; Cilostazol; Clopidogrel; Databases, Factual; Female; Fibrinolyti | 2015 |
Acute stroke unit improves stroke management-four years on from INASC.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Deglutition; Female; Hospital Units; Humans | 2015 |
Effect of Active Smoking on Comparative Efficacy of Antithrombotic Therapy in Patients With Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Case-Control Studies; Clopido | 2015 |
Neurologic symptom severity after a recent noncardioembolic stroke and recurrent vascular risk.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Double-Blind Method; Female; Fibri | 2015 |
Antiplatelet therapy discontinuation and the risk of serious cardiovascular events after coronary stenting: observations from the CREDO-Kyoto Registry Cohort-2.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Restenosis; Drug-Eluting Stents; Female; Hum | 2015 |
Can the previous therapeutic control of the main risk factors of cerebrovascular disease influence the acetylsalicylic Acid-nonresponsive status in acute ischemic stroke patients? Results from a portuguese prospective cohort study.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Cohort Studies; Female; | 2015 |
Neighborhood deprivation and warfarin, aspirin and statin prescription - A cohort study of men and women treated for atrial fibrillation in Swedish primary care.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Drug Prescrip | 2015 |
Account should also have been taken of the harm versus benefit of aspirin use.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Gastrointestinal Hemorrhage; Humans; Platelet | 2015 |
Stroke mimicking relapse in a patient with CLIPPERS syndrome.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Brain Stem; Encephalomye | 2015 |
The changes in clot microstructure in patients with ischaemic stroke and the effects of therapeutic intervention: a prospective observational study.
Topics: Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Cohort Studies; Elasticity; Female; Fibrinog | 2015 |
Use of aspirin and statins for the primary prevention of myocardial infarction and stroke in patients with human immunodeficiency virus infection.
Topics: Aged; Aspirin; Cross-Sectional Studies; Female; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Re | 2016 |
Antiplatelets Versus Anticoagulation for Cervical Arterial Dissection.
Topics: Anticoagulants; Aortic Dissection; Aspirin; Carotid Artery, Internal, Dissection; Cervical Vertebrae | 2015 |
Clopidogrel versus aspirin in patients with recent ischemic stroke and established peripheral artery disease: an economic evaluation in a Chinese setting.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cost-Benefit Analysis; Humans; Middle Aged; Pe | 2015 |
Cost-Effectiveness of Proton Pump Inhibitor Co-Therapy in Patients Taking Aspirin for Secondary Prevention of Ischemic Stroke.
Topics: Aspirin; Cost-Benefit Analysis; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Inci | 2015 |
Impact of bridging with perioperative low-molecular-weight heparin on cardiac and bleeding outcomes of stented patients undergoing non-cardiac surgery.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Comorbidity; Coronary Disease; Coronary Restenosis; Drug Sub | 2015 |
INR optimization based on stroke risk factors in patients with non-valvular atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Asian People; Aspirin; Atrial Fibrillation; Fe | 2015 |
Pediatric Acute Ischemic Cerebral Vascular Accidents: A Case Report.
Topics: Aspirin; Brain Ischemia; Child; Diffusion Magnetic Resonance Imaging; Female; Heparin; Humans; Strok | 2017 |
Impact of Antithrombotic Therapy in Atrial Fibrillation on the Presentation of Coronary Artery Disease.
Topics: Aged; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Female; Fibrinolytic Agents; Hong Kong; | 2015 |
Clinical outcomes of multiple chronic total occlusions in coronary arteries according to three therapeutic strategies: Bypass surgery, percutaneous intervention and medication.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Bypass; | 2015 |
Dual antiplatelet therapy for TIA reduces subsequent disability: A CHANCE to improve outcomes?
Topics: Aspirin; Female; Humans; Ischemic Attack, Transient; Male; Outcome Assessment, Health Care; Platelet | 2015 |
Stroke and Bleeding Risk Associated With Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation in Clinical Practice.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Blood Coagulation; California; Comorbidity; D | 2015 |
Incidence and Predictors of Hemorrhagic Stroke in Users of Low-Dose Acetylsalicylic Acid.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Cohort Studies; Female; Fibrinolytic Agents; Humans; | 2015 |
Net Clinical Benefit for Oral Anticoagulation, Aspirin, or No Therapy in Nonvalvular Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex).
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Denmark; Female; | 2015 |
Clinical Implications of Changes in Individual Platelet Reactivity to Aspirin Over Time in Acute Ischemic Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Female; Follow-Up Studies; Humans | 2015 |
Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Decision Support Techni | 2015 |
Optimizing the Safe Use of Direct Oral Anticoagulants in Older Patients: A Teachable Moment.
Topics: Acenocoumarol; Administration, Oral; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation | 2015 |
Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Female; Fibrinolytic Agents; Humans; | 2015 |
Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Fe | 2015 |
Adequacy of preadmission oral anticoagulation with vitamin K antagonists and ischemic stroke severity and outcome in patients with atrial fibrillation.
Topics: Acenocoumarol; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibril | 2016 |
Evaluating resistance to acetyl salicylic acid using platelet function test in patients with ischemic stroke at Cipto Mangunkusumo Hospital.
Topics: Aged; Aspirin; Comorbidity; Cross-Sectional Studies; Drug Resistance; Female; Humans; Hypertension; | 2015 |
Antiplatelet therapy in Takotsubo cardiomyopathy: does it improve cardiovascular outcomes during index event?
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Heart Failure; Hospital Mortality; Hu | 2016 |
Peter Rothwell: aspirin(g) physician with a little stroke of genius.
Topics: Aspirin; History, 20th Century; History, 21st Century; Humans; Physicians; Stroke | 2015 |
Failure of the Platelet Function Assay (PFA)-100 to detect antiplatelet agents.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelet Disorders; Brain Injuries; Clopidogrel; False Negat | 2015 |
Isolated brachiocephalic artery dissection presenting as acute stroke.
Topics: Adult; Anticoagulants; Antihypertensive Agents; Aortic Dissection; Aspirin; Ataxia; Brachiocephalic | 2015 |
[Anticoagulants to more people can prevent many cases of stroke].
Topics: Age Factors; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Disease; Humans; Medication Adhe | 2015 |
Interest of Antiplatelet Drug Testing after an Acute Ischemic Stroke.
Topics: Aged; Aspirin; Clopidogrel; Drug Resistance; Female; Humans; Male; Middle Aged; Platelet Aggregation | 2015 |
Underutilisation of Guideline-based Therapy Primary Prevention among Patients Presenting with AF-related Ischaemic Stroke.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; | 2015 |
Is Extended Duration of Dual Antiplatelet Therapy After Carotid Stenting Beneficial?
Topics: Aged; Aspirin; Carotid Arteries; Carotid Stenosis; Clopidogrel; Female; Follow-Up Studies; Humans; M | 2015 |
Ask about aspirin.
Topics: Aspirin; beta Carotene; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Healt | 2015 |
Thromboembolic stroke in patients with a HeartMate-II left ventricular assist device - the role of anticoagulation.
Topics: Adult; Anticoagulants; Aspirin; Female; Heart Failure; Heart-Assist Devices; Heparin; Humans; Intern | 2015 |
Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Hong Kong; Hospitaliz | 2016 |
Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Cohort Studies; | 2015 |
The Interplay between Stroke Severity, Antiplatelet Use, and Aspirin Resistance in Ischemic Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Female; Humans; Magnetic Resonance Imaging; Male; | 2016 |
Relationship between Inflammation and Aspirin and Clopidogrel Antiplatelet Responses in Acute Ischemic Stroke.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Brain Ischemia; CD40 Ligand; Clopidogrel; Femal | 2016 |
CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
Topics: Aged; Aspirin; Carboxylic Ester Hydrolases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Gene Freq | 2016 |
Different Antiplatelet Strategies in Patients With New Ischemic Stroke While Taking Aspirin.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Drug Therapy, Combination; Female; Follow-Up Studi | 2016 |
A long-term risk-benefit analysis of low-dose aspirin in primary prevention.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Databases, Factual; Female; Gastro | 2016 |
Comparative Effectiveness of Prestroke Aspirin on Stroke Severity and Outcome.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Female; Humans; Intracranial Hemorrhages; Male; Mi | 2016 |
Durlaza--a 24-hour extended-release aspirin.
Topics: Aspirin; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Costs; Humans; Myocardial Infa | 2016 |
Risk of early recurrent stroke in symptomatic carotid stenosis after best medical therapy and before endarterectomy.
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Arteries; Carotid Stenosis; Clopidogrel; Endarterectomy, C | 2016 |
Treatment with Clopidogrel Prior to Acute Non-Cardioembolic Ischemic Stroke Attenuates Stroke Severity.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Disability E | 2016 |
Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study).
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Endovascular Procedures; F | 2016 |
Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; | 2016 |
Aspirin resistance in cerebrovascular disease and the role of glycoprotein IIIa polymorphism in Turkish stroke patients.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Asymptomatic Diseases; Blood Platelets; Drug Resistan | 2016 |
Continuation and adherence rates on initially-prescribed intensive secondary prevention therapy after Rapid Access Stroke Prevention (RASP) service assessment.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Brain Ischemia; Clopidogrel; Dipyr | 2016 |
Likelihood ratio meta-analysis: New motivation and approach for an old method.
Topics: Aspirin; Bayes Theorem; Clopidogrel; Data Interpretation, Statistical; Humans; Hydroxymethylglutaryl | 2016 |
Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin.
Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Surgical Procedures; Clopido | 2016 |
Stroke prevention in atrial fibrillation and 'real world' adherence to guidelines in the Balkan Region: The BALKAN-AF Survey.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Balkan Peni | 2016 |
The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Cardiography, Impedance; Clopidogrel; Cytochrome | 2017 |
Web Exclusives. The Consult Guys--CHADS, SHMADS: What's All This About Anticoagulation?
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Female; Fibrinolytic Agents; Humans; Middle Aged; Prac | 2016 |
Antithrombotic therapy in patients with non-valvular atrial fibrillation in Southern Sweden: A population-based cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Female; Human | 2016 |
Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.
Topics: Aged; Aged, 80 and over; Amlodipine; Aspirin; Cardiovascular Agents; Case-Control Studies; Cohort St | 2016 |
Dual antiplatelet therapy reduces stroke but increases bleeding at the time of carotid endarterectomy.
Topics: Aged; Aspirin; Asymptomatic Diseases; Carotid Artery Diseases; Chi-Square Distribution; Clopidogrel; | 2016 |
Hsp70 protects from stroke in atrial fibrillation patients by preventing thrombosis without increased bleeding risk.
Topics: Animals; Aspirin; Atrial Fibrillation; Bleeding Time; Carotid Artery Diseases; Case-Control Studies; | 2016 |
Does clopidogrel plus aspirin really significantly increase the risk of subdural hematoma?
Topics: Aspirin; Clopidogrel; Hematoma, Subdural; Humans; Randomized Controlled Trials as Topic; Stroke | 2016 |
Adoption of direct oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutte | 2016 |
Net clinical benefit of adding aspirin to warfarin in patients with atrial fibrillation: Insights from the J-RHYTHM Registry.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Humans; | 2016 |
Aspirin resistance is associated with increased stroke severity and infarct volume.
Topics: Aged; Aspirin; Brain; Brain Ischemia; Diffusion Magnetic Resonance Imaging; Drug Resistance; Female; | 2016 |
Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force.
Topics: Adult; Aged; Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Decisi | 2016 |
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: Recommendations From the U.S. Preventive Services Task Force.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Aspirin; Cardiovascular Diseases; Cerebral Hemorrha | 2016 |
The contemporary management of intracranial atherosclerotic disease.
Topics: Angioplasty; Aspirin; Clopidogrel; Fibrinolytic Agents; Humans; Intracranial Arteriosclerosis; Strok | 2016 |
Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: The case study of Japan.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovas | 2016 |
[After the first stroke, acetylsalicylic acid is no longer enough].
Topics: Aged; Aspirin; Clopidogrel; Drug Substitution; Drug Therapy, Combination; Humans; Recurrence; Stroke | 2016 |
Extended use of clopidogrel and aspirin after ischemic stroke.
Topics: Aspirin; Clopidogrel; Drug Administration Schedule; Humans; Platelet Aggregation Inhibitors; Post-Ex | 2016 |
Extended use of clopidogrel and aspirin after ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Administration Schedule; Humans; Platelet Aggregation Inh | 2016 |
The benefits of aspirin in early secondary stroke prevention.
Topics: Aspirin; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke | 2016 |
Chronic Kidney Disease and Health Status Outcomes Following Acute Myocardial Infarction.
Topics: Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Case-Control Studies; Coho | 2016 |
Medical research: Time to think differently about diabetes.
Topics: Adipose Tissue; Animals; Aspirin; Bariatric Surgery; Bile Acids and Salts; Biomedical Research; Bloo | 2016 |
Failure of old and new anticoagulants to prevent ischemic stroke in high-risk atrial fibrillation: a case report.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Humans; Rivaroxaban; Str | 2016 |
Assessment of Vascular Disease Prevention Practices in Urban Women.
Topics: Aged; Aspirin; Female; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; | 2016 |
Antiplatelet drug resistance is associated with early neurological deterioration in acute minor ischemic stroke in the Chinese population.
Topics: Aged; Aged, 80 and over; Asian People; Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; M | 2016 |
A rabbit model of cerebral microembolic signals for translational research: preclinical validation for aspirin and clopidogrel.
Topics: Animals; Aspirin; Carotid Artery Thrombosis; Chlorides; Clopidogrel; Disease Models, Animal; Drug Ev | 2016 |
A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction.
Topics: Aspirin; Cardiovascular System; Clopidogrel; Hemorrhage; Humans; Lactones; Myocardial Infarction; Pl | 2016 |
Dipyrone comedication in aspirin treated stroke patients impairs outcome.
Topics: Aged; Aged, 80 and over; Analgesics; Arachidonic Acid; Aspirin; Cohort Studies; Dipyrone; Drug Inter | 2016 |
Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2).
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Early Diagnosis; Female; Humans; Isr | 2016 |
Interaction between COX-1 and COX-2 Variants Associated with Aspirin Resistance in Chinese Stroke Patients.
Topics: Aged; Aged, 80 and over; Asian People; Aspirin; Cyclooxygenase 1; Cyclooxygenase 2; Drug Resistance; | 2016 |
[Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy].
Topics: Aspirin; Beijing; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; | 2016 |
High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome: Subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial.
Topics: Aged; Aspirin; C-Reactive Protein; Clopidogrel; Drug Therapy, Combination; Female; Humans; Incidence | 2016 |
Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations.
Topics: Adenosine; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cause of Death; Clinical Trial | 2016 |
Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Prescriptions; Female | 2016 |
Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.
Topics: Aged; Aged, 80 and over; Antithrombins; Aspirin; Atrial Fibrillation; Comorbidity; Creatinine; Dabig | 2016 |
Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cerebral Hemorrhage; Female; Heart Failure; Humans; Incidenc | 2016 |
To Load or Not to Load? Aspirin Loading in Acute Ischemic Stroke: A Study of Clinical Outcomes.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cardiovascular Agents; Disability Evaluation; Dise | 2016 |
miR-145 mediated the role of aspirin in resisting VSMCs proliferation and anti-inflammation through CD40.
Topics: Aspirin; Atherosclerosis; Brain Ischemia; CD40 Antigens; Cell Proliferation; Female; Flow Cytometry; | 2016 |
Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Patients With Contraindications to Anticoagulation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Contraindic | 2016 |
Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Hemorrhage; Humans; I | 2016 |
Antecedent Aspirin Use Is Associated with Less Severe Symptoms on Admission for Ischemic Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Biomarkers; Blood Glucose; Blood Pressure; Br | 2016 |
Stroke: So much to do, still so poorly resourced!
Topics: Aspirin; Clinical Trials as Topic; Developing Countries; Hemorrhage; Humans; Stroke | 2016 |
Atrial fibrillation: Stroke prevention in atrial fibrillation: can we do better?
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Stroke | 2016 |
Antithrombotic Medication Use and Misuse Among Patients with Intracranial Hemorrhage: A 16-Year, Lebanese, Single-Center Experience.
Topics: Acenocoumarol; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebra | 2016 |
Philip Majerus.
Topics: Aspirin; Blood Coagulation; Faculty, Medical; Fibrinolytic Agents; Hematology; History, 20th Century | 2016 |
Review: Aspirin for CVD primary prevention increases gastrointestinal bleeding and hemorrhagic stroke.
Topics: Aspirin; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Platelet Aggregation Inhibit | 2016 |
In acute stroke or TIA, ticagrelor did not differ from aspirin for a composite of stroke, MI, or death at 90 days.
Topics: Adenosine; Aspirin; Humans; Platelet Aggregation Inhibitors; Stroke; Ticagrelor | 2016 |
Repeated Thrombosis After Synthetic Cannabinoid Use.
Topics: Adult; Anticoagulants; Aspirin; Cannabinoids; Enoxaparin; Female; Humans; Infarction; Platelet Aggre | 2016 |
Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Drug Therapy, Combination; Embolism | 2016 |
Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Asian People; Aspirin; ATP Binding Cassette Tr | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibit | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibit | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibit | 2016 |
High-Sensitivity C-Reactive Protein and Risk of Stroke in Atrial Fibrillation (from the Reasons for Geographic and Racial Differences in Stroke Study).
Topics: Aged; Animals; Anticoagulants; Aspirin; Atrial Fibrillation; Black or African American; C-Reactive P | 2016 |
Using Large-Scale Linkage Data to Evaluate the Effectiveness of a National Educational Program on Antithrombotic Prescribing and Associated Stroke Prevention in Primary Care.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; General Practitioners; Humans; Information Storage a | 2016 |
Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2016 |
[Prevalence and prognosis of aspirin resistance in critical limb ischemia patients].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; Drug Resistance; Ex | 2016 |
Aspirin is Key to Reducing Risk of Early Stroke Recurrence.
Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Recurrence; Risk Reduction Behavior; Stroke | 2016 |
Letter by Moris and Avgerinos Regarding Article, "Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone".
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Stroke; Ti | 2016 |
Statin and Aspirin Pretreatment Are Associated with Lower Neurological Deterioration and Platelet Activity in Patients with Acute Ischemic Stroke.
Topics: Aged; Aspirin; Brain Ischemia; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Hyd | 2017 |
Letter by Chen et al Regarding Article, "Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial".
Topics: Aspirin; Heart Failure; Humans; Stroke; Stroke Volume; Warfarin | 2016 |
Response by Di Tullio et al to Letter Regarding Article, "Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial".
Topics: Aspirin; Heart Failure; Humans; Stroke; Stroke Volume; Ventricular Function, Left; Warfarin | 2016 |
Association between antithrombotic treatment and hemorrhagic stroke in patients with atrial fibrillation-a cohort study in primary care.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies; | 2017 |
Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Creatinine; Drug Therapy, Co | 2017 |
Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Computer Simulation; Cost-Benefit Analysis; Drug Costs | 2017 |
Different impact of aspirin on renal progression in patients with predialysis advanced chronic kidney disease with or without previous stroke.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cause of Death; Comorbidity; Female; Hematinics; Hemorrhage; | 2017 |
Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials.
Topics: Aspirin; Clopidogrel; Data Interpretation, Statistical; Humans; Models, Statistical; Myocardial Infa | 2017 |
Assessment of platelet function in patients with stroke using multiple electrode platelet aggregometry: a prospective observational study.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Electrodes; Female; Humans; Male; Middle Aged; Pl | 2016 |
Anticoagulation After Biological Aortic Valve Replacement: Is There An Optimal Regimen?
Topics: Aged; Anticoagulants; Aortic Valve; Aspirin; Bioprosthesis; Blood Coagulation; Brain Ischemia; Femal | 2016 |
Antiplatelet Strategies and Outcomes in Patients with Noncardioembolic Ischemic Stroke from a Real-World Study with a Five-Year Follow-Up.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; China; Clopidogrel; Drug Therapy, Combination; Female; Foll | 2017 |
[Aspirin use in patients with atherosclerotic cardiovascular disease: the 2016 Chinese expert consensus statement].
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Case-Control Studies; China; Consensus; Coronary | 2017 |
Percutaneous left atrial appendage closure followed by single antiplatelet therapy: Short- and mid-term outcomes.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Catheterization; Cl | 2017 |
Interaction among COX-2, P2Y1 and GPIIIa gene variants is associated with aspirin resistance and early neurological deterioration in Chinese stroke patients.
Topics: Aged; Asian People; Aspirin; China; Cyclooxygenase 1; Cyclooxygenase 2; Drug Resistance; Female; Gen | 2017 |
Dual Antiplatelet Therapy Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG: FREEDOM Insights.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cause of Death; Clopidogrel; Diabetic Angiopathies; Drug The | 2017 |
Effect of Clopidogrel by Smoking Status on Secondary Stroke Prevention.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Datasets as Topic; Drug Therapy, Combination; Humans | 2017 |
Aspirin Resistance Predicts Adverse Cardiovascular Events in Patients with Symptomatic Peripheral Artery Disease.
Topics: Aged; Aspirin; Brain Ischemia; Chi-Square Distribution; Disease-Free Survival; Drug Resistance; Fema | 2016 |
Secondary Prevention of Childhood Arterial Ischemic Stroke.
Topics: Aspirin; Belgium; Brain Ischemia; Child; France; Guideline Adherence; Health Care Surveys; Humans; P | 2017 |
Efficacy of aspirin and statins in primary prevention of cardiovascular mortality in uncomplicated hypertensive participants: a Korean national cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cause of Death; Co | 2017 |
Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox?
Topics: Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Plat | 2017 |
Towards best practice in acute stroke care in Ghana: a survey of hospital services.
Topics: Acute Disease; Aspirin; Female; Fibrinolytic Agents; Ghana; Health Policy; Health Services Accessibi | 2017 |
Dual Antiplatelet Therapy Does Not Increase the Risk of Bleeding After Carotid Endarterectomy: Results of a Prospective Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Asymptomatic Diseases; Carotid Stenosis; Clopidogr | 2017 |
Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis.
Topics: Aged; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Drug Ther | 2017 |
Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; | 2017 |
Letter by Moris et al Regarding Article, "Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes)".
Topics: Adenosine; Aspirin; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Tic | 2017 |
Response by Wang and Johnston to Letter Regarding Article, "Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcom
Topics: Adenosine; Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregat | 2017 |
Analgesic medication with dipyrone in patients with coronary artery disease: Relation to MACCE.
Topics: Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Aspirin; Chest Pain; Coronary Artery Disease; Dip | 2017 |
A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery s
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Clopidogrel; Coronary Stenosis; Drug Therapy, Comb | 2017 |
State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease.
Topics: Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Lactones; Male; Middle Aged; Myocardial Infarction | 2017 |
Association of genetic variant and platelet function in patients undergoing neuroendovascular stenting.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Aspirin; Brain Ischemia; Clopidogrel; Female; Genetic Varia | 2017 |
In the news: ISC 2017 - getting the heads-up on stroke.
Topics: Aspirin; Double-Blind Method; Humans; Ischemic Attack, Transient; Stroke; Ticagrelor | 2017 |
Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study.
Topics: Aged; Aspirin; Brain Ischemia; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combinati | 2017 |
Current practice of antithrombotic treatment in ischemic stroke: a survey among Hungarian neurologists.
Topics: Adult; Aged; Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Prescriptions; | 2008 |
Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Femal | 2008 |
Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Evidence-Based Medici | 2008 |
Subgaleal hematoma in a child with Sturge-Weber syndrome: to prevent stroke-like episodes, is treatment with aspirin advisable?
Topics: Aspirin; Child, Preschool; Craniocerebral Trauma; Hematoma; Humans; Male; Platelet Aggregation Inhib | 2008 |
[Secondary stroke prevention according to the PRoFESS Study. What are the sequelae for practical therapy?].
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Germany; Humans; Multicenter Studies | 2008 |
Stroke in pregnancy associated with syphilis.
Topics: Adult; Anti-Bacterial Agents; Aspirin; Female; Gestational Age; Humans; Magnetic Resonance Imaging; | 2008 |
Does differential prophylactic aspirin use contribute to racial and geographic disparities in stroke and coronary heart disease (CHD)?
Topics: Aged; Aged, 80 and over; Aspirin; Black or African American; Coronary Disease; Cross-Sectional Studi | 2008 |
[The importance of oral anticoagulation in patients with atrial fibrillation for stroke prevention].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Platelet Aggregation Inhibitors; Stroke; Warfa | 2008 |
Spontaneous left atrial thrombus during patent foramen ovale closure.
Topics: Anticoagulants; Aspirin; Atrial Septum; Balloon Occlusion; Drug Therapy, Combination; Echocardiograp | 2008 |
Diagnosis and initial management of acute stroke and transient ischaemic attack: summary of NICE guidance.
Topics: Anticoagulants; Aspirin; Deglutition Disorders; Dietary Supplements; Endarterectomy, Carotid; Humans | 2008 |
Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; An | 2008 |
Does Aggrenox (aspirin/dipyridamole) reduce the risk of recurrent stroke to a greater degree than aspirin alone?
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Humans; Platelet A | 2008 |
Use of statistical process control charts in stroke medicine to determine if clinical evidence and changes in service delivery were associated with improvements in the quality of care.
Topics: Aspirin; Brain; Delivery of Health Care; Evidence-Based Medicine; Fibrinolytic Agents; Forms and Rec | 2008 |
Aspirin non-responders in Thai ischemic stroke/TIA patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Female; Humans; Ischemic At | 2008 |
The PRoFESS trial results: what went wrong?
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Randomized Controlled T | 2008 |
CHARISMA revisited: is the glass half full or just empty?
Topics: Aspirin; Clopidogrel; Coronary Disease; Disease Progression; Humans; Platelet Aggregation Inhibitors | 2008 |
Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?
Topics: Age Factors; Aged; Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combi | 2006 |
Complete resolution of a mitral valve vegetation with anticoagulation in seronegative antiphospholipid syndrome.
Topics: Abortion, Habitual; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Cesarean Section; Fem | 2008 |
Stroke prevention--insights from incoherence.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Dipyridam | 2008 |
Epidemiology, risk factors for stroke, and management of atrial fibrillation in China.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; China; Humans; Incidence; Platelet Aggregation Inhibit | 2008 |
[Secondary prevention with clopidogrel or acetylsalicylic acid after acute cerebrovascular event. Health services research study of private primary care specialists].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Comorbidity; Cross-Sectional Studies; Female; | 2008 |
The exact distribution of Cochran's heterogeneity statistic in one-way random effects meta-analysis.
Topics: Aspirin; Biometry; Confidence Intervals; Diuretics; Esophageal and Gastric Varices; Female; Glycerol | 2008 |
Is the finding of the PROFESS study consistent with predictions of network meta-analysis?
Topics: Aspirin; Bayes Theorem; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; | 2008 |
[Inhibition of platelet aggregation and angiotensin II-receptor blockade following TIA; the unexpected results of the Prevention Regimen For Effectively Avoiding Second Strokes (PROFESS) trial].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Aspirin; Benzimida | 2008 |
[Anticoagulation in atrial fibrillation].
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Blood Coagulation; Blood Coagula | 2008 |
Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation--a nationwide descriptive study in Taiwan.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Prescriptions; Female; Fibrinolytic Agents; | 2008 |
Low incidence of neurologic events during long-term support with the HeartMate XVE left ventricular assist device.
Topics: Adult; Aged; Aspirin; Brain Diseases, Metabolic; Cardiomyopathy, Dilated; Cause of Death; Cognition | 2008 |
Values and preferences in oral anticoagulation in patients with atrial fibrillation, physicians' and patients' perspectives: protocol for a two-phase study.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Focus Groups; Humans; Male; Middle Aged; | 2008 |
Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial).
Topics: Aged; Aspirin; Cause of Death; Coronary Disease; Female; Fibrinolytic Agents; Hemorrhage; Humans; Ma | 2008 |
Low thromboembolic risk for patients with the Heartmate II left ventricular assist device.
Topics: Adult; Aged; Anticoagulants; Aspirin; Female; Heart-Assist Devices; Hemorrhage; Humans; Male; Middle | 2008 |
Antiplatelets for stroke prevention: implications of the PRoFESS trial.
Topics: Aspirin; Cerebral Hemorrhage; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Drug Therapy, | 2009 |
Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke.
Topics: Adult; Aged; Arachidonate Lipoxygenases; Aspirin; Brain Ischemia; Case-Control Studies; Cyclooxygena | 2009 |
ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Aspirin; Brain Ischemia; Clopidogrel; Drug Synergism; Dr | 2008 |
[The BAFTA study].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Randomized Controlled Trials as Topic; Stroke; | 2008 |
Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease-Free Survival; D | 2008 |
Challenges of designing trials for the primary prevention of stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Humans; National Institute of Neurologica | 2009 |
Aspirin resistance determined with PFA-100 does not predict new thrombotic events in patients with stable ischemic cerebrovascular disease.
Topics: Aged; Aspirin; Cognition Disorders; Drug Resistance; Female; Follow-Up Studies; Hematologic Tests; H | 2009 |
[Brain hypoperfusion revealed by an ocular ischemic syndrome].
Topics: Antihypertensive Agents; Aspirin; Atorvastatin; Brain Ischemia; Carotid Artery Thrombosis; Ciliary B | 2008 |
High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Cell Size; Female; Giant Cell Art | 2009 |
[The impact of acute cerebral blood flow disturbances on platelet aggregation].
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Data Interpretation, Statistical; Female; Hu | 2008 |
Prevention strategies of cardioembolic ischemic stroke in Chagas' disease.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Chagas Cardiomyopathy; Epidemiologic Methods; Female; Hemor | 2008 |
[Celiac disease and ischemic stroke].
Topics: Adult; Aspirin; Brain Ischemia; Celiac Disease; Female; Humans; Platelet Aggregation Inhibitors; Str | 2009 |
Recurrent stroke in a child with incontinentia pigmenti.
Topics: Aspirin; Brain; Female; Humans; Incontinentia Pigmenti; Infant, Newborn; Magnetic Resonance Imaging; | 2009 |
The choice of aspirin dose for primary prevention of embolic complications of nonvalvular atrial fibrillation in elderly people.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Dose-Response Relationship, Drug; Embolism; H | 2009 |
Indirect comparison: relative risk fallacies and odds solution.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Aspirin; Atrial Fibrillat | 2009 |
Safety and effectiveness of combining carotid artery stenting with cardiac surgery: preliminary results of a single-center experience.
Topics: Aged; Aged, 80 and over; Angioplasty; Anticoagulants; Aspirin; Carotid Artery Diseases; Coronary Art | 2009 |
Would self-expanding stent occlude middle cerebral artery perforators?
Topics: Adult; Aged; Angioplasty; Aspirin; Clopidogrel; Female; Follow-Up Studies; Humans; Infarction, Middl | 2009 |
The utilization status of aspirin for the secondary prevention of ischemic stroke.
Topics: Aged; Aspirin; Female; Humans; Male; Middle Aged; Patient Compliance; Retrospective Studies; Seconda | 2009 |
Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study.
Topics: Aged; Aged, 80 and over; Arterial Occlusive Diseases; Aspirin; Case-Control Studies; Female; Humans; | 2009 |
Resistance to acetylsalicylic acid in patients after ischemic stroke.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Drug Resistance; Female; H | 2008 |
First trimester stroke prophylaxis in pregnant women with a history of stroke.
Topics: Anticoagulants; Aspirin; Female; Fibrinolytic Agents; Health Care Surveys; Heparin, Low-Molecular-We | 2009 |
Combined effect of health behaviours and risk of first ever stroke in 20,040 men and women over 11 years' follow-up in Norfolk cohort of European Prospective Investigation of Cancer (EPIC Norfolk): prospective population study.
Topics: Adult; Aged; Alcohol Drinking; Aspirin; England; Exercise; Female; Fruit; Health Behavior; Humans; I | 2009 |
Use of stroke secondary prevention services: are there disparities in care?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cross-Sectional Studies; Data Interpretation, S | 2009 |
Atrial fibrillation and stroke risk prevention in real-life clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Clini | 2009 |
How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Drug | 2009 |
[Guidelines for the general management of patients with acute ischemic stroke].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Fibrinolytic Agents; Humans; Inpatients; Stroke; Taiwan; Ti | 2008 |
Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Arteries; Dipyridamole; Drug Therapy, Combination; Female; H | 2009 |
Using icon arrays to communicate medical risks: overcoming low numeracy.
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Aspirin; Attitude to Health; Computer Graph | 2009 |
Combined aspirin plus warfarin: recent evidence and residual questions.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Randomi | 2009 |
Does the combination of warfarin and aspirin have a place in secondary stroke prevention? No.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibit | 2009 |
Does the combination of warfarin and aspirin have a place in secondary stroke prevention? Yes.
Topics: Anticoagulants; Aspirin; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combi | 2009 |
Clopidogrel for preventing cardiovascular events.
Topics: Aspirin; Clopidogrel; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Evidence-Based Medicine; | 2009 |
Aspirin vs anticoagulation in carotid artery dissection: a study of 298 patients.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Artery, Internal, Dissection; Female; Follow-Up Stu | 2009 |
Role of the primary care physician in stroke prevention. Introduction.
Topics: Aspirin; Humans; Physicians, Family; Platelet Aggregation Inhibitors; Risk Factors; Stroke | 2009 |
Reduced valve replacement surgery and complication rate in Staphylococcus aureus endocarditis patients receiving acetyl-salicylic acid.
Topics: Aged; Aspirin; Cohort Studies; Embolism; Endocarditis, Bacterial; Female; Heart Failure; Heart Valve | 2009 |
Pretreatment with aspirin and etiology of first-ever ischemic stroke in young and middle-aged patients.
Topics: Adolescent; Adult; Aged; Aspirin; Brain Ischemia; Female; Humans; Logistic Models; Male; Middle Aged | 2009 |
[Atrial fibrillation].
Topics: Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Electric Countershock; Electrocardiography | 2009 |
Influence of cyclooxygenase-1 genotype on ex vivo aspirin response in patients at risk for stroke.
Topics: Aged; Alleles; Aspirin; Black or African American; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Fema | 2009 |
The preventive and therapeutic impact of antiplatelet agents: past and present.
Topics: Adult; Aged; Aspirin; Coronary Artery Disease; Female; Fibrinolytic Agents; History, 19th Century; H | 2009 |
The use of aspirin and dipyridamole in the treatment of acute ischaemic stroke/transient ischaemic attack: an audit-based discussion.
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Medical Audit; | 2009 |
The ACTIVE pursuit of stroke prevention in patients with atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation I | 2009 |
ACTIVE A: balancing the benefits and risks of clopidogrel and aspirin.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Female; Humans; Intracra | 2009 |
Aspirin for prevention of myocardial infarction and stroke: is the right dose 81 or 160 mg/day?
Topics: Aspirin; Dose-Response Relationship, Drug; Female; Humans; Male; Myocardial Infarction; Platelet Agg | 2009 |
Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Heart Diseases; Humans; M | 2009 |
Prevention of stroke in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; | 2009 |
Achieved anticoagulation vs prosthesis selection for mitral mechanical valve replacement: a population-based outcome study.
Topics: Adult; Aged; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Female; Follow-Up Studies; H | 2009 |
Oral anticoagulation with antiplatelet therapy after drug-eluting stent placement: adequate INR control must be demonstrated.
Topics: Anticoagulants; Aspirin; Drug-Eluting Stents; Humans; International Normalized Ratio; Stroke | 2009 |
Time of taking aspirin can have an effect on the frequency of occurrence of stroke.
Topics: Aspirin; Drug Administration Schedule; Humans; Platelet Aggregation Inhibitors; Stroke; Time Factors | 2009 |
Does anticoagulation benefit patients with congestive heart failure (CHF) who have reduced left ventricular ejection fraction (LVEF) and are in normal sinus rhythm?
Topics: Anticoagulants; Aspirin; Evidence-Based Medicine; Female; Heart Failure; Humans; Male; Meta-Analysis | 2009 |
[Oral anticoagulant use in patients with atrial fibrillation].
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Humans; Hypertension; International Norm | 2009 |
Experts recommend low-dose aspirin to prevent stroke in women. Lower doses are as effective as higher doses and are likely to be safer.
Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Health Knowledge, Atti | 2009 |
Anosognosia for right hemiplegia from dominant anterior cerebral artery stroke.
Topics: Aged, 80 and over; Agnosia; Aspirin; Awareness; Female; Fibrinolytic Agents; Hemiplegia; Humans; Mag | 2009 |
Aspirin for heart attack, stroke prevention. When benefits outweigh risks: four new studies help clarify who should--and who shouldn't--take the drug.
Topics: Aspirin; Clopidogrel; Contraindications; Drug Interactions; Drug Therapy, Combination; Female; Gastr | 2009 |
Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
Topics: Accidental Falls; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Dementia; F | 2009 |
The prescribing patterns of antithrombotic agents for prevention of recurrent ischemic stroke.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Drug Utilization; Female; Fibrinolytic Agents; Humans; Male; M | 2009 |
Who is ineligible for warfarin in atrial fibrillation?
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; | 2009 |
Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Contraindications; Drug Therapy, Combinat | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Embolism; Humans; Myocardial I | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Costs; Drug Therapy, Combination; Humans; Platelet A | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hu | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hu | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Humans; Pla | 2009 |
Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atri | 2009 |
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2009 |
Antiplatelet agents in stroke prevention: acute and long-term treatment strategies.
Topics: Aged; Aspirin; Female; Humans; Ischemic Attack, Transient; Male; Platelet Aggregation Inhibitors; Pr | 2009 |
P2Y12 inhibitors: thienopyridines and direct oral inhibitors.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Corona | 2009 |
Letter by Kan et al regarding Article, "randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart failure (WATCH) trial".
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chronic Disease; Clopidogrel; Death; Double-Blind Method; F | 2009 |
ProFESS trial: any lessons to learn for future anti-platelet trials?
Topics: Aged; Aspirin; Brain; Cerebral Arteries; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Femal | 2009 |
Aspirin gets a backup against atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation I | 2009 |
[Warning signs of transient ischemic attacks. A stroke threatens every 10th person].
Topics: Aspirin; Cross-Sectional Studies; Family Practice; Fibrinolytic Agents; Germany; Humans; Ischemic At | 2009 |
The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Fibrinolytic Agents; Fol | 2010 |
Impact of chronic antithrombotic therapy on hospital course of patients with acute myocardial infarction.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Bundle-Branch Block; Coumarins; Diabetes Mellitus; Femal | 2009 |
Antiplatelet drugs for patients at high cardiovascular risk. Aspirin generally remains the best choice.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Brain Ischemia; Clini | 2009 |
Clopidogrel for the hot patient.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; C-Reactive Protein; Clopidogrel; Drug Therapy, | 2009 |
Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; C-Reactive Protein; Clopidogrel; Double-B | 2009 |
Aspirin use, dose, and clinical outcomes in postmenopausal women with stable cardiovascular disease: the Women's Health Initiative Observational Study.
Topics: Aged; Angina Pectoris; Aspirin; Cardiovascular Diseases; Death, Sudden, Cardiac; Dose-Response Relat | 2009 |
Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrh | 2010 |
Platelet activation and reactivity in the convalescent phase of ischaemic stroke.
Topics: Aged; Aspirin; Case-Control Studies; Cell-Derived Microparticles; Convalescence; Humans; Middle Aged | 2010 |
Anticoagulation intensity for elderly atrial fibrillation patients: should we use a conventional INR target (2.0 to 3.0) or a lower range?
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; International Normalized Ratio; Stroke; | 2010 |
Letter by Bhindi and Ormerod regarding article, "Aortic arch plaques and risk of recurrent stroke and death".
Topics: Anticoagulants; Aortic Diseases; Aspirin; Atherosclerosis; Fibrinolytic Agents; Humans; Hydroxymethy | 2010 |
[A rare disease with varied manifestations. Here threaten blindness, stroke, myocardial infarction].
Topics: Aged; Aspirin; Biopsy; Blindness; Female; Humans; Myocardial Infarction; Platelet Aggregation Inhibi | 2009 |
Warfarin versus aspirin: using CHADS2 to guide therapy for stroke prevention in nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Monitoring; Female; Fibr | 2009 |
Aspirin for the primary prevention of stroke and myocardial infarction: ineffective or wrong dose?
Topics: Aspirin; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Myocardial Infarction; Strok | 2010 |
Safety of carotid endarterectomy while on clopidogrel (Plavix). Clinical article.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Clopidogrel; Cohort Studies; Edema; E | 2010 |
Stroke in heart failure: atrial fibrillation revisited?
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Heart Failure; Hemorrhage; Humans; Patient Selection; | 2010 |
Antithrombotic treatment in neonatal cerebral sinovenous thrombosis: results of the International Pediatric Stroke Study.
Topics: Aspirin; Brain; Female; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Infant, | 2010 |
Prevention and treatment of cardioembolic stroke: a case study.
Topics: Aged; Aspirin; Atrial Fibrillation; Embolism; Female; Fibrinolytic Agents; Humans; Risk Factors; Str | 2009 |
Aspirin and primary prevention. BHS reaffirms its guidance.
Topics: Aspirin; Fibrinolytic Agents; Humans; Myocardial Infarction; Stroke | 2010 |
Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Fema | 2010 |
Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Dis | 2010 |
Preliminary evidence of a high risk of bleeding on aspirin plus clopidogrel in aspirin-naïve patients in the acute phase after TIA or minor ischaemic stroke.
Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fol | 2010 |
Stroke recurrence in an elderly CADASIL patient on aspirin discontinuation due to severe auto-immune thrombocytopenia.
Topics: Aged, 80 and over; Aspirin; Autoimmune Diseases; CADASIL; Exons; Humans; Male; Receptor, Notch3; Rec | 2010 |
Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, increases survival in stroke-prone rats by preventing systemic inflammation and endothelial dysfunction: comparison with aspirin and rosuvastatin.
Topics: Animals; Aspirin; Biomarkers; Blood Pressure; Brain; Endothelium, Vascular; Fluorobenzenes; Hyperten | 2010 |
Time matters for reducing risk of stroke.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Risk; Stroke; T | 2010 |
Do healthy people need an aspirin a day? The healthier your heart and arteries, the less you need aspirin.
Topics: Aspirin; Drug Administration Schedule; Health Knowledge, Attitudes, Practice; Health Status; Humans; | 2010 |
[Stroke: women have a different risk profile].
Topics: Aspirin; Contraceptive Agents, Female; Diabetes Complications; Education; Exercise; Female; Hormones | 2010 |
Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy.
Topics: Anticoagulants; Aspirin; Drug Administration Schedule; Female; Heart Failure; Heart Transplantation; | 2010 |
Determining patient characteristics for decision analysis support systems using anonymized electronic patient records.
Topics: Aged; Aged, 80 and over; Aspirin; Cohort Studies; Databases, Factual; Decision Making, Computer-Assi | 2010 |
Missed opportunities to prevent stroke recurrence.
Topics: Aspirin; China; Fibrinolytic Agents; Humans; Meta-Analysis as Topic; Platelet Aggregation Inhibitors | 2010 |
Is higher serum total cholesterol level associated with better long-term functional outcomes after noncardioembolic ischemic stroke?
Topics: Aged; Aspirin; Brain Ischemia; Cholesterol; Cohort Studies; Female; Fibrinolytic Agents; Follow-Up S | 2010 |
Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Ischemic A | 2010 |
USPSTF recommendations you may have missed amid the breast cancer controversy.
Topics: Adolescent; Age Factors; Aspirin; Breast Neoplasms; Breast Self-Examination; Child; Depression; Depr | 2010 |
Aspirin resistance and compliance with therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Case-Control Studies; | 2011 |
Biochemical aspirin resistance and recurrent lesions in patients with acute ischemic stroke.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diffusion Magnetic Resonance Imaging; | 2010 |
Aspirin use in elderly women receiving medication therapy management services.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Comorbidity; Contraindications; Diabetes | 2010 |
Treatment of acute ischemic stroke in patients with cerebral microbleeds: a decision analysis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Cerebral | 2011 |
Rapid change in prescribing behavior in hospitals participating in get with the guidelines-stroke after release of the management of atherothrombosis with clopidogrel in high-risk patients (MATCH) clinical trial results.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; P | 2010 |
Duration of clopidogrel therapy with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule | 2010 |
Facts versus theories: an everlasting struggle. The Johann Jakob Wepfer Award 2010.
Topics: Aspirin; Awards and Prizes; Dose-Response Relationship, Drug; Europe; History, 17th Century; History | 2010 |
Platelet function testing for aspirin resistance is reasonable to do: yes!
Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Recurrence; Stroke | 2010 |
The use of platelet function assays may help to determine appropriate antiplatelet treatment options in a patient with recurrent stroke on baby aspirin: against.
Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Recurrence; Stroke | 2010 |
Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism: procedural and follow-up results after implantation of the Amplatzer®-occluder device.
Topics: Aspirin; Cardiac Catheterization; Clopidogrel; Echocardiography, Transesophageal; Embolism, Paradoxi | 2011 |
Increasing aspirin use among persons at risk for cardiovascular events in Oklahoma.
Topics: Aged; Aged, 80 and over; Aspirin; Behavioral Risk Factor Surveillance System; Coronary Disease; Fema | 2010 |
Duration of clopidogrel therapy with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule | 2010 |
Duration of clopidogrel therapy with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Asian People; Aspirin; Clopidogrel; Coronary Disease; Drug Administr | 2010 |
Secondary prevention of stroke: can we do better than aspirin?
Topics: Aspirin; Humans; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Anticoagulation can reduce nonfatal myocardial infarction.
Topics: Anticoagulants; Aspirin; Humans; Myocardial Infarction; Stroke | 2010 |
I've read that some people are aspirin resistant and do not benefit from the daily use of aspirin to prevent a heart attack or stroke. Should I be tested for aspirin resistance?
Topics: Aged; Aspirin; Coronary Disease; Drug Resistance; Female; Health Knowledge, Attitudes, Practice; Hum | 2010 |
Concise guidance: diagnosis and management of giant cell arteritis.
Topics: Aspirin; Blindness; Diagnosis, Differential; Diagnostic Imaging; Early Diagnosis; Giant Cell Arterit | 2010 |
Does current oral antiplatelet agent or subtherapeutic anticoagulation use have an effect on tissue-plasminogen-activator-mediated recanalization rate in patients with acute ischemic stroke?
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, C | 2010 |
From bench to bedside: report of the Sixth International Stroke Summit, Nanjing, China, July 9-11, 2010.
Topics: Asia; Aspirin; China; Cilostazol; Endarterectomy; Humans; Platelet Aggregation Inhibitors; Stents; S | 2010 |
Outcomes related to antiplatelet or anticoagulation use in patients undergoing carotid endarterectomy.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Endar | 2011 |
Platelet function analysis with two different doses of aspirin.
Topics: Analysis of Variance; Aspirin; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Female; Hea | 2010 |
Hemichorea: a rare neurological deficit in the emergency department.
Topics: Aged, 80 and over; Anti-Dyskinesia Agents; Aspirin; Chorea; Emergency Service, Hospital; Haloperidol | 2011 |
[Reducing blood pressure, giving aspirin... What must (never) be done in V.a. stroke].
Topics: Antihypertensive Agents; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Heparin; Humans; Platelet Agg | 2010 |
Paradoxical embolism.
Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Dyspnea; Echocardiography, Transesophageal; Embolism, Para | 2010 |
[New options in the therapeutic management of acute ischaemic stroke. Good results with combined i. v. and i. a. lysis and mechanical thrombectomy].
Topics: Acute Disease; Adult; Aged; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebral Angiography; | 2010 |
[Aggregation activity of platelets in various periods of ischemic stroke].
Topics: Aged; Aspirin; Blood Coagulation Disorders; Blood Coagulation Tests; Brain Ischemia; Female; Humans; | 2010 |
Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Female; Fibrinolytic Agents; Guideline Adhere | 2010 |
Antiplatelet therapy effectively reduces plasma plasminogen activator inhibitor-1 levels.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Down-Reg | 2011 |
Ischaemic stroke--prevention is better than cure.
Topics: Adult; Age Factors; Aged; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Blo | 2010 |
[Resistance to aspirin in secondary stroke prevention. A pilot study].
Topics: Aged; Aspirin; Drug Monitoring; Drug Resistance; Female; Humans; Male; Pilot Projects; Platelet Aggr | 2010 |
Design, data management, and population baseline characteristics of the PERFORM magnetic resonance imaging project.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Image Interpretation, Computer-Ass | 2011 |
Aspirin non-responder status and early neurological deterioration: a prospective study.
Topics: Aged; Aspirin; Brain Ischemia; Cohort Studies; Drug Resistance; Female; Humans; Male; Middle Aged; N | 2011 |
Ask the doctor. I am a 79-year-old man with atrial fibrillation that is well controlled by Pacerone. I also take warfarin and aspirin to prevent stroke. I plan to have a tooth pulled next month and wonder if is is safe to go off the blood thinners. Ho
Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Prescriptions; Heal | 2010 |
Do you need aspirin therapy? Your risks of heart attack and stroke based upon your current and past medical history must be weighed against the chances of internal bleeding.
Topics: Aspirin; Coronary Artery Disease; Health Knowledge, Attitudes, Practice; Hemorrhage; Humans; Platele | 2009 |
Aspirin and your heart: many questions, some answers.
Topics: Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Health Knowledge, Attitudes, Practice; | 2010 |
Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Cohort Studies | 2011 |
Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Cohort Studies | 2011 |
Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Cohort Studies | 2011 |
Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Cohort Studies | 2011 |
Prevalence of aspirin resistance in stroke patients in Phramongkutklao Hospital.
Topics: Adolescent; Adult; Aspirin; Drug Resistance; Female; Hospitals, Teaching; Humans; Male; Platelet Agg | 2010 |
Effect of timing of chronic preoperative aspirin discontinuation on morbidity and mortality in coronary artery bypass surgery.
Topics: Aged; Aspirin; Blood Loss, Surgical; Blood Transfusion; Coronary Artery Bypass; Female; Hospital Mor | 2011 |
Optimal antithrombotic therapy in patients receiving long-term oral anticoagulation requiring percutaneous coronary intervention: "triple therapy" or "triple threat".
Topics: Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Heart Disease | 2011 |
Effects of extended-release dipyridamole in vitro on thrombin indices measured by calibrated automated thrombography in poststroke survivors.
Topics: Aged; Aspirin; Brain Ischemia; Delayed-Action Preparations; Dipyridamole; Dose-Response Relationship | 2012 |
Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan.
Topics: Aspirin; Brain Ischemia; Cross-Sectional Studies; Databases, Factual; Drug Prescriptions; Humans; In | 2011 |
What are the therapeutic options for strokes secondary to intracranial large artery stenosis?
Topics: Anticoagulants; Aspirin; Cilostazol; Evidence-Based Medicine; Humans; Intracranial Arteriosclerosis; | 2011 |
What is the best antiplatelet agent for prevention of recurrent stroke in Pakistani patients? Do combinations offer significant advantages in the South Asian context?
Topics: Asian People; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Evidence-Based Medicine | 2010 |
What is the best first agent to give to a patient with acute ischaemic stroke? Aspirin, heparin, clopidogrel, cilostazol or dipyridamole?
Topics: Aspirin; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Evidence-B | 2010 |
Relapsed spontaneous spinal epidural hematoma associated with aspirin and clopidogrel.
Topics: Aspirin; Clopidogrel; Hematoma, Epidural, Spinal; Humans; Magnetic Resonance Imaging; Male; Middle A | 2011 |
Significance of cardiocoronary pathology in acute stroke.
Topics: Aspirin; Clopidogrel; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2011 |
Ischaemic stroke management by emergency care physicians at public sector hospitals of Karachi, Pakistan.
Topics: Aspirin; Cross-Sectional Studies; Electrocardiography; Emergency Medical Services; Female; Fibrinoly | 2011 |
Atrial fibrillation, is warfarin the only option for stroke prevention?
Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Comp | 2011 |
Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM Registry.
Topics: Aged; Aged, 80 and over; Anticoagulants; Asian People; Aspirin; Atrial Fibrillation; Blood Coagulati | 2011 |
Delphi-consensus weights for ischemic and bleeding events to be included in a composite outcome for RCTs in thrombosis prevention.
Topics: Aspirin; Hemorrhage; Humans; Ischemia; Randomized Controlled Trials as Topic; Stroke; Thrombosis; Tr | 2011 |
Aspirin resistance in patients with acute ischemic stroke.
Topics: Aged; Aspirin; Drug Resistance; Female; Heparin; Humans; Male; Middle Aged; Platelet Aggregation Inh | 2011 |
Finding a balance in long-term anticoagulation therapy.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Practice Guidelines as Topic; Stroke; Time Fac | 2010 |
A pharmacoeconomic perspective on stroke prevention in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Drug Monitoring; Fibrinolytic Agents; Humans; Practice Guidelines as T | 2010 |
Letter by Borja and Garcia-Rafanell regarding article, "Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association"
Topics: Aspirin; Carotid Arteries; Clinical Trials as Topic; Endarterectomy, Carotid; Guidelines as Topic; H | 2011 |
The unmet need of patients with atrial fibrillation: AVERROES and the novel oral anticoagulants.
Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Comp | 2011 |
Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Denmark; Drug Interactions; Humans; Kaplan-Meier Esti | 2011 |
Dissection of the posterior inferior cerebellar artery in the hypereosinophilic syndrome.
Topics: Adolescent; Anti-Inflammatory Agents; Aortic Dissection; Arteries; Aspirin; Cerebellum; Female; Huma | 2011 |
Peter Rothwell: a dedicated flouter of fashion.
Topics: Aspirin; Blood Pressure; Cardiovascular Agents; Endarterectomy, Carotid; Fibrinolytic Agents; Histor | 2011 |
Aspirin in the prevention of cancer.
Topics: Age Factors; Anticarcinogenic Agents; Aspirin; Clinical Trials as Topic; Gastrointestinal Hemorrhage | 2011 |
Fabry disease and Factor V Leiden: a potent vascular risk combination.
Topics: Activated Protein C Resistance; alpha-Galactosidase; Aspirin; Atorvastatin; Coronary Stenosis; Defib | 2011 |
Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Cause of Death; Female; Follow-Up Studies; Health Personnel; Heart Fai | 2011 |
Stroke- and pregnancy-induced hypertensive syndromes.
Topics: Adult; Antihypertensive Agents; Aspirin; Female; Fibrinolytic Agents; Humans; Hypertension, Pregnanc | 2011 |
Vascular events after stroke: terutroban fails to PERFORM.
Topics: Aspirin; Early Termination of Clinical Trials; Humans; Naphthalenes; Platelet Aggregation Inhibitors | 2011 |
Stroke in Malawi--what do we know about it and how should we manage it? Manage it?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Blood Pressure; Fe | 2010 |
Calculation of numbers-needed-to-treat in parallel group trials assessing ordinal outcomes: case examples from acute stroke and stroke prevention.
Topics: Aged; Algorithms; Aspirin; Aspirin, Dipyridamole Drug Combination; Clinical Trials as Topic; Confide | 2011 |
Recurrent ischemic stroke in a patient with ulcerative colitis and high levels of lipoprotein (a).
Topics: Anticholesteremic Agents; Anticoagulants; Aspirin; Atorvastatin; Blood Coagulation Tests; Carotid St | 2011 |
Aspirin for the prevention of cardiovascular disease: recommendation statement.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Gastrointestinal Hemorrhag | 2011 |
Aspirin for the prevention of cardiovascular disease.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Decision Making; Evidence-Based Medicine; | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Pyrazoles; Pyridones; Stroke; Warfarin | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemi | 2011 |
[Intracerebral hemorrhage in anticoagulated patients: what do we do afterwards?].
Topics: Aged; Anticoagulants; Aspirin; Cerebral Hemorrhage; Clopidogrel; Female; Follow-Up Studies; Humans; | 2012 |
Ischemic stroke in patients receiving aspirin.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Argentina; Aspirin; Brain Ischemia; Chi-Square Dis | 2012 |
Have medical therapy and stenting been fairly compared? A repercussion upon termination of recruitment in the SAMMPRIS trial.
Topics: Angioplasty; Aspirin; Carotid Stenosis; Clinical Trials as Topic; Clopidogrel; Humans; National Inst | 2011 |
Novel platelet antiaggregants and the changing landscape of stroke prevention.
Topics: Aspirin; Controlled Clinical Trials as Topic; Humans; Platelet Aggregation Inhibitors; Stroke | 2011 |
Cilostazol, not aspirin, reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats.
Topics: Animals; Aspirin; Brain Ischemia; Cerebral Cortex; Cerebrovascular Circulation; Cilostazol; Endothel | 2011 |
Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.
Topics: Aspirin; Atherosclerosis; Drug Delivery Systems; Drug Design; Hemorrhage; Humans; Myocardial Infarct | 2011 |
Patent foramen ovale may be causal for the first stroke but unrelated to subsequent ischemic events.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Clopidogrel; Female; Follow-Up Studies; Foramen Ovale, Patent; | 2011 |
Aspirin treatment failure and the risk of recurrent stroke and death among patients with ischemic stroke.
Topics: Aged; Aspirin; Brain Ischemia; Female; Humans; Male; Middle Aged; Multivariate Analysis; Odds Ratio; | 2013 |
Preoperative aspirin resistance does not increase myocardial injury during off-pump coronary artery bypass surgery.
Topics: Aged; Aspirin; Cohort Studies; Coronary Artery Bypass, Off-Pump; Coronary Disease; Drug Resistance; | 2011 |
Comparison of characteristics, management practices, and outcomes of patients between the global registry and the gulf registry of acute coronary events.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Aspiri | 2011 |
Microembolic signals and aspirin resistance in patients with carotid stenosis.
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Drug Monitoring; Drug | 2012 |
[The AVERROES study].
Topics: Aspirin; Atrial Fibrillation; Follow-Up Studies; Humans; Italy; Platelet Aggregation Inhibitors; Pyr | 2011 |
Stopping anticoagulation before TURP does not appear to increase perioperative cardiovascular complications.
Topics: Aged; Angina Pectoris; Anticoagulants; Arrhythmias, Cardiac; Aspirin; Blood Transfusion; Humans; Isc | 2011 |
Antithrombotic therapy use at discharge and 1 year in patients with atrial fibrillation and acute stroke: results from the AVAIL Registry.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Femal | 2011 |
Residual platelet reactivity after aspirin and clopidogrel treatment predicts 2-year major cardiovascular events in patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug T | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
Development of a tool to improve the quality of decision making in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Decision Support Techniques; Hemorrhage; Humans; Patie | 2011 |
Long-term risk of recurrent stroke in young cryptogenic stroke patients with and without patent foramen ovale.
Topics: Adolescent; Adult; Aspirin; Female; Fibrinolytic Agents; Foramen Ovale, Patent; Humans; Male; Middle | 2012 |
Small unruptured partially thrombosed aneurysms and stroke: report of three cases and review of the literature.
Topics: Aspirin; Atorvastatin; Craniotomy; Echocardiography, Transesophageal; Fibrinolytic Agents; Heptanoic | 2012 |
Clinician-trialist rounds: 6. Testing for blindness at the end of your trial is a mug's game.
Topics: Aspirin; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Randomized Controlled | 2011 |
Aspirin treatment increases the risk of cerebral microbleeds.
Topics: Aged; Aspirin; Cerebral Hemorrhage; Female; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; | 2011 |
Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model.
Topics: Animals; Aspirin; Brain; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Immunohistochemistry; | 2012 |
Selecting the optimal stroke prevention therapy in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhib | 2011 |
Long-term incidence of myocardial infarct, stroke, and mortality in patients operated on for abdominal aortic aneurysms.
Topics: Aged; Aortic Aneurysm, Abdominal; Aspirin; Chi-Square Distribution; Denmark; Female; Fibrinolytic Ag | 2012 |
Low-molecular-weight heparin in atherosclerotic stroke: a surprising resurrection of anticoagulants?
Topics: Antifibrinolytic Agents; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Female; Humans; Intra | 2012 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Medical management trumps stenting for intracranial arterial stenosis.
Topics: Angioplasty; Aspirin; Cerebral Arteries; Clopidogrel; Combined Modality Therapy; Constriction, Patho | 2011 |
Clinical outcomes following coronary stenting in Japanese patients treated with and without proton pump inhibitor.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Asian People; Aspirin; Clopidogrel; Coronar | 2012 |
Aspirin versus warfarin in atrial fibrillation: decision analysis may help patients' choice.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Decision Support Techniques; Decision Trees; Hemorrhag | 2012 |
Dose-dependent effect of early antiplatelet therapy in acute ischaemic stroke.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Body Mass Index; Brain Ischemia; Clopidogrel; Dose-Response | 2012 |
Association of C3435T multi drug resistance gene-1 polymorphism with aspirin resistance in ischemic stroke and its subtypes.
Topics: Adult; Aged; Aspirin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporte | 2012 |
Utilisation of antithrombotic therapy for stroke prevention in atrial fibrillation in a Sydney hospital: then and now.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Femal | 2012 |
Editorial - do not throw the baby out with the bathwater….
Topics: Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Humans; Multicenter Studies as Topic; National | 2011 |
My patient just had a transient ischaemic attack. Can I predict his risk for stroke? Is stroke inevitable or preventable?
Topics: Aspirin; Clopidogrel; Evidence-Based Medicine; Humans; Ischemic Attack, Transient; Middle Aged; Plat | 2011 |
Clopidogrel responsiveness in stroke patients on a chronic aspirin regimen.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Drug Administration Schedule; Drug Re | 2013 |
Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel; Cohort St | 2012 |
Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cause of Death; Coronary Artery Disease; Co | 2012 |
Advances in stroke: population studies.
Topics: Aspirin; Birth Weight; Circadian Rhythm; Diet; Humans; Life Style; Motor Activity; Population Survei | 2012 |
Advances in prevention and health services delivery 2010-2011.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Delivery of Health Care; Humans; Platelet Aggregation | 2012 |
Systematic reporting bias in meta-analyses of trials of aspirin for the primary prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Agents; Cause of Death; Female; Humans; Male; Myocardial Infarction; Primary | 2012 |
Antiplatelet therapy for transient ischemic attack.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Clopidogrel; Cognition Disorders; | 2012 |
Clinical, neuroradiological and molecular features of a patient affected by pseudoxhantoma elasticum associated to carotid rete mirabile: case report.
Topics: Adult; Angiography, Digital Subtraction; Aspirin; Brain Ischemia; Carotid Arteries; Carotid Artery D | 2012 |
What the million hearts initiative means for stroke: a presidential advisory from the American Heart Association/American Stroke Association.
Topics: American Heart Association; Aspirin; Blood Pressure; Cardiovascular Diseases; Centers for Disease Co | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Aspirin; Catheterization; Combined Modality Therapy; Ductus Arteriosus, Patent; Evidence-Based Medic | 2012 |
Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Aspirin; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Therapy, Combination; Evi | 2012 |
Effects of preoperative aspirin on cardiocerebral and renal complications in non-emergent cardiac surgery patients: a sub-group and cohort study.
Topics: Aged; Aspirin; Cardiac Surgical Procedures; Cardiovascular Diseases; Case-Control Studies; Cohort St | 2012 |
Prevention of stroke in atrial fibrillation: cautious optimism.
Topics: Aspirin; Atrial Fibrillation; Female; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; Male; | 2012 |
Recurrent cerebral infarction in Klippel-Trenaunay-Weber syndrome.
Topics: Aspirin; Cerebral Angiography; Cerebral Infarction; Dysarthria; Female; Fibromuscular Dysplasia; Gai | 2012 |
[Management of acute ischemic stroke].
Topics: Aspirin; Brain Ischemia; Decompressive Craniectomy; Humans; Stroke; Thrombolytic Therapy | 2012 |
A new antiplatelet agent cilostazol--what is the evidence for its use and tolerability?
Topics: Aspirin; Cilostazol; Evidence-Based Medicine; Humans; Platelet Aggregation Inhibitors; Randomized Co | 2012 |
Trans fat, aspirin, and ischemic stroke in postmenopausal women.
Topics: Aged; Aspirin; Brain Ischemia; Cohort Studies; Confidence Intervals; Dietary Fats, Unsaturated; Fema | 2012 |
High antiphospholipid antibody levels are associated with statin use and may reflect chronic endothelial damage in non-autoimmune thrombosis: cross-sectional study.
Topics: Aged; Antibodies, Antiphospholipid; Aspirin; Biomarkers; Chronic Disease; Cross-Sectional Studies; E | 2012 |
Daily aspirin prevents dangerous clots. Yet only half the people who should take it, do.
Topics: Aspirin; Drug Administration Schedule; Health Behavior; Humans; Myocardial Infarction; Platelet Aggr | 2012 |
Low stroke rate and few thrombo-embolic events after HeartMate II implantation under mild anticoagulation.
Topics: Anticoagulants; Aspirin; Female; Heart Failure; Heart-Assist Devices; Heparin; Humans; Male; Middle | 2012 |
Cardiology patient page: Aspirin.
Topics: Aspirin; Blood Coagulation; Cardiovascular Diseases; Coronary Artery Disease; Drug Therapy, Combinat | 2012 |
Aspirin's effect on platelet inhibition in migraineurs.
Topics: Adult; Aspirin; Blood Platelets; Female; Humans; Male; Middle Aged; Migraine Disorders; Myocardial I | 2012 |
What is the most effective and safest delivery of thromboprophylaxis in atrial fibrillation?
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemor | 2012 |
Blood loss and complications following carotid endarterectomy in patients treated with clopidogrel.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Carotid Artery Diseases; Clopidogrel; Drug T | 2012 |
The Million Hearts™ initiative: why psychosocial nurses should care.
Topics: Aspirin; Cholesterol; Comorbidity; Health Promotion; Humans; Hypertension; Mental Disorders; Myocard | 2012 |
Massive pulmonary thromboembolism after intravenous stroke thrombolysis.
Topics: Aged; Aspirin; Echocardiography; Female; Heparin, Low-Molecular-Weight; Humans; Infusions, Intraveno | 2012 |
Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Cohort Studies; | 2012 |
[Ulcerated plaques of the aorta as a cause of ischaemic stroke].
Topics: Acenocoumarol; Aspirin; Echocardiography; Foramen Ovale, Patent; Humans; Hydroxymethylglutaryl-CoA R | 2012 |
Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study.
Topics: Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Brain Ische | 2012 |
Recommended use of aspirin and other antiplatelet medications among adults--National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, United States, 2005-2008.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Guideline Adhe | 2012 |
Clopidogrel in atrial fibrillation: is there any justification now in the era of new anticoagulants?
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Practice Guideli | 2012 |
Follow-up of aspirin-resistant patients with end-stage kidney disease.
Topics: Aged; Angina, Unstable; Area Under Curve; Aspirin; Cause of Death; Cohort Studies; Drug Resistance; | 2013 |
A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Databases, F | 2012 |
Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Contraindications; Cost-Benefit Analysis; Drug C | 2012 |
Reperfusion trials for acute ischaemic stroke.
Topics: Aspirin; Female; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; Male; Platelet Aggregation I | 2012 |
Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inh | 2012 |
Effects of heparin on synaptic activity in the hemorrhagic stroke model in vitro.
Topics: Action Potentials; Animals; Aspirin; Blood Coagulation; Brain; Disease Models, Animal; Fibrinolytic | 2012 |
Perioperative use of aspirin for patients undergoing carotid endarterectomy.
Topics: Administration, Oral; Aged; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Drug Administration | 2012 |
[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazo | 2012 |
One-year follow-up healthcare costs of patients hospitalized for transient ischemic attack or ischemic stroke and discharged with aspirin plus extended-release dipyridamole or clopidogrel.
Topics: Adolescent; Adult; Age Factors; Aged; Aspirin; Clopidogrel; Delayed-Action Preparations; Drug Therap | 2012 |
Obesity and intracranial in-stent thrombosis.
Topics: Abciximab; Angioplasty, Balloon; Antibodies, Monoclonal; Aspirin; Body Mass Index; Brain Ischemia; C | 2013 |
Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fi | 2012 |
Long-term risk of vascular events after peripheral bypass surgery. A cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amputation, Surgical; Anticoagulants; Aspirin; Blood | 2012 |
Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Decision Making; Female; Fibrinolytic Agents; He | 2012 |
Stroke and bleeding in atrial fibrillation with chronic kidney disease.
Topics: Aged; Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Kidney Failure, | 2012 |
Stroke and bleeding in atrial fibrillation with chronic kidney disease.
Topics: Aged; Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Kidney Failure, | 2012 |
Stroke and bleeding in atrial fibrillation with chronic kidney disease.
Topics: Aged; Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Kidney Failure, | 2012 |
Stroke and bleeding in atrial fibrillation with chronic kidney disease.
Topics: Aged; Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Kidney Failure, | 2012 |
Prevention of cardiovascular diseases in developing countries.
Topics: Antihypertensive Agents; Aspirin; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase I | 2012 |
Sudden bilateral anterior cerebral infarction: unusual stroke associated with unusual vascular anomalies.
Topics: Adult; Aspirin; Atorvastatin; Carotid Artery Diseases; Carotid Artery, Internal; Drug Therapy, Combi | 2013 |
Incidence of cerebral ischemic events after discontinuation of clopidogrel in patients with intracranial aneurysms treated with stent-assisted techniques.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Drug Therapy, Combina | 2012 |
Platelet response to aspirin in Chinese stroke patients is independent of genetic polymorphisms of COX-1 C50T and COX-2 G765C.
Topics: Aged; Aspirin; Base Sequence; Blood Platelets; China; Cyclooxygenase 1; Cyclooxygenase 2; DNA Primer | 2013 |
Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Aspirin, Dipyridamole Drug Combination; Blood Platelets; Br | 2013 |
Secondary stroke prevention: misguided by guidelines?
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Pla | 2012 |
African-Americans and strokes: minutes and hours make the difference.
Topics: Aspirin; Black or African American; Female; Fibrinolytic Agents; Foramen Ovale, Patent; Health Statu | 2011 |
Symptomatic patients with intraluminal carotid artery thrombus: outcome with a strategy of initial anticoagulation.
Topics: Adult; Aged; Anticoagulants; Aspirin; Brain Ischemia; Carotid Arteries; Carotid Artery Thrombosis; C | 2013 |
Longitudinal assessment of thrombin generation potential in response to alteration of antiplatelet therapy after TIA or ischaemic stroke.
Topics: Adult; Aged; Aspirin; Clopidogrel; Dipyridamole; Female; Humans; Ischemic Attack, Transient; Longitu | 2013 |
Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cor | 2012 |
Relationship between acute stroke outcome, aspirin resistance, and humoral factors.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; C-Reactive Protein; Drug Resistance; Female; | 2012 |
Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis.
Topics: Anticoagulants; Aspirin; Case-Control Studies; Coronary Thrombosis; Europe; Fibrinolytic Agents; Hea | 2012 |
Know the benefits and risks of daily aspirin therapy. A small dose can have big benefits for many patients with heart disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Dose-Response Relationshi | 2011 |
Aspirin resistance and ischemic stroke outcome: fact or fiction?
Topics: Aspirin; Blood Platelets; Drug Resistance; Humans; Stroke | 2012 |
The role of aspirin in primary prevention of vascular events.
Topics: Aspirin; Cardiovascular Agents; Cause of Death; Female; Humans; Male; Myocardial Infarction; Primary | 2012 |
Association of aspirin resistance with increased stroke severity and infarct size.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Infarction; Drug Resistance; Female; Humans; Male; Prospe | 2013 |
Guidelines for acute ischemic stroke treatment: part II: stroke treatment.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Fibrinolytic Agents; Heparin; Humans; Platelet Aggregation | 2012 |
Polypill: the path from concept to “near” reality in preventing cardiovascular disease.
Topics: Antihypertensive Agents; Aspirin; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase I | 2012 |
Atrial fibrillation and chronic kidney disease.
Topics: Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Male; Renal Insufficie | 2012 |
Atrial fibrillation and chronic kidney disease.
Topics: Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Male; Renal Insufficie | 2012 |
Atrial fibrillation and chronic kidney disease.
Topics: Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Male; Renal Insufficie | 2012 |
Timing and mechanism of ischemic stroke due to extracranial blunt traumatic cerebrovascular injury.
Topics: Adult; Angiography, Digital Subtraction; Aspirin; Brain Ischemia; Cerebral Angiography; Cerebral Art | 2013 |
Dual antiplatelet therapy in peripheral arterial disease and after peripheral percutaneous revascularization.
Topics: Aspirin; Clopidogrel; Endovascular Procedures; Hemorrhage; Humans; Peripheral Arterial Disease; Plat | 2012 |
Antiplatelet therapy in ischemic stroke: does one size fit all?
Topics: Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2012 |
Clopidogrel has no effect on mortality from hip fracture.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Aspirin; Bl | 2013 |
Quality of acute ischemic stroke care in Thailand: a prospective multicenter countrywide cohort study.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Chi-Square Distribution; Combined Modality Therapy; D | 2014 |
Basilar artery strokes in children: good outcomes with conservative medical treatment.
Topics: Adolescent; Anticoagulants; Aspirin; Child; Child, Preschool; Female; Humans; Infant; Infant, Newbor | 2013 |
Should paediatric stroke be treated as adult stroke?
Topics: Anticoagulants; Aspirin; Female; Humans; Male; Outcome Assessment, Health Care; Stroke; Vertebrobasi | 2013 |
Asymptomatic carotid stenosis.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Aspirin; Asymptomatic Diseases; Atorvastatin; Azetidines | 2013 |
How should meta-regression analyses be undertaken and interpreted?
Topics: Adrenergic beta-Antagonists; Aminoglycosides; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-S | 2002 |
How much daily aspirin should I take to prevent a heart attack or stroke?
Topics: Aspirin; Fibrinolytic Agents; Humans; Myocardial Infarction; Stroke | 2002 |
VHA heart attack initiative increases aspirin and beta blocker usage.
Topics: Adrenergic beta-Antagonists; Aspirin; Community-Institutional Relations; Evidence-Based Medicine; Ho | 2001 |
Aspirin versus low-molecular-weight heparin for ischemic stroke in children: an unanswered question.
Topics: Aspirin; Brain Ischemia; Child; Clinical Trials as Topic; Dose-Response Relationship, Drug; Feasibil | 2002 |
Aspirin should be first-line antiplatelet therapy in the secondary prevention of stroke.
Topics: Aspirin; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Humans; Platelet Aggregation I | 2002 |
Aspirin therapy should be first-line treatment in secondary prevention of stroke--against.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Drug | 2002 |
Aspirin therapy should be first line: probably, but watch this space.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Synergism; Humans; Myocardial Isc | 2002 |
Stroke prevention in elderly patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Humans; Male; Platele | 2002 |
Antithrombotic prescribing in atrial fibrillation: application of a prescribing indicator and multidisciplinary feedback to improve prescribing.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Australia; Clinical Audit; Cr | 2002 |
Rx for stroke: aspirin, within 48 hours.
Topics: Aspirin; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Patient Education as Topic; | 2002 |
Aspirin with bypass surgery--from taboo to new standard of care.
Topics: Aspirin; Coronary Artery Bypass; Coronary Disease; Drug Administration Schedule; Humans; Inflammatio | 2002 |
Effect of increasing doses of aspirin on platelet aggregation among stroke patients.
Topics: Adenosine Diphosphate; Adult; Aspirin; Blood Platelets; Collagen; Dose-Response Relationship, Drug; | 2002 |
Differences in treatment preferences between persons who enrol and do not enrol in a clinical trial.
Topics: Aspirin; Attitude to Health; Humans; Myocardial Infarction; Patient Participation; Patient Selection | 2001 |
Clopidogrel plus aspirin for stroke prevention.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Follow- | 2002 |
Time lag to diagnosis of stroke in children.
Topics: Adolescent; Age Factors; Aspirin; Brain Ischemia; Child; Emergency Medical Services; Episode of Care | 2002 |
[Acetylsalicylic acid--is everything clear? Probably not].
Topics: Aspirin; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Stroke | 2002 |
[Anticoagulation in permanent atrial fibrillation after 75 years of age].
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Hu | 2002 |
Mitral valve prolapse: old beliefs yield to new knowledge.
Topics: Adrenergic beta-Antagonists; Antibiotic Prophylaxis; Anticoagulants; Arrhythmias, Cardiac; Aspirin; | 2002 |
Staying alive after heart bypass.
Topics: Aspirin; Coronary Artery Bypass; Humans; Myocardial Infarction; Renal Insufficiency; Stroke; Surviva | 2002 |
Stroke prevention in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Prescriptions; Female; F | 2003 |
Ischaemic stroke in young people: a prospective and long-term follow-up study.
Topics: Acenocoumarol; Adolescent; Adult; Anticoagulants; Aspirin; Brain Ischemia; Disability Evaluation; Ec | 2003 |
Aspirin or warfarin: what's best after a heart attack? Risk of bleeding counters warfarin's edge in efficacy.
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; | 2002 |
Warfarin, aspirin, or both after myocardial infarction.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregat | 2003 |
Warfarin, aspirin, or both after myocardial infarction.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Humans; | 2003 |
Heart attack and stroke prevention guidelines emphasize lifestyle factors.
Topics: Adult; Age Factors; American Heart Association; Aspirin; Diabetes Mellitus, Type 2; Diet; Exercise; | 2002 |
Thrombotic complications related to discontinuation of warfarin and aspirin therapy perioperatively for cutaneous operation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Female; Humans; Ischemic Attack, Transient; Male; | 2003 |
Atrial fibrillation, stroke, and acute antithrombotic therapy.
Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Randomized | 2003 |
I'm a 65-year-old man with high blood pressure and a family history of stroke. Which stroke-prevention medication would be better for me--aspirin or clopidogrel (Plavix)?
Topics: Aged; Aspirin; Clopidogrel; Family Health; Humans; Hypertension; Life Style; Male; Platelet Aggregat | 2003 |
Bedside calculation of stroke risk in patients with atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Computers, Handheld; Hemorrh | 2003 |
[Anticoagulation and antiaggregation in cardiac patients].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Clo | 2003 |
[Anticoagulation and antiaggregation in neurological patients].
Topics: Acute Disease; Administration, Oral; Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopid | 2003 |
[Anticoagulation and antiaggregation in patients with peripheral arterial occlusive diseases].
Topics: Administration, Oral; Angioplasty, Balloon; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Bl | 2003 |
Visible infarction on computed tomography is an independent predictor of poor functional outcome after stroke, and not of haemorrhagic transformation.
Topics: Aged; Aspirin; Brain Infarction; Female; Fibrinolytic Agents; Follow-Up Studies; Heparin; Humans; In | 2003 |
Smoking and the risk of hemorrhagic stroke in men.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alcohol Drinking; Aspirin; beta Carotene; Body Mass Ind | 2003 |
Can aspirin ever be surpassed for stroke prevention?
Topics: Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Fibrinolytic Agents; Forecasting; Huma | 2003 |
Synergistic antiplatelet effects of clopidogrel and aspirin detected with the PFA-100 in stroke patients.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Activation; Platelet Aggregation I | 2003 |
Adherence to secondary stroke prevention strategies--results from the German Stroke Data Bank.
Topics: Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Databases as Topic; Female; Follow-Up St | 2003 |
[Clearly superior in acute coronary syndrome. Helps aggressive platelet inhibition even after stroke?].
Topics: Acute Disease; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; My | 2003 |
Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage.
Topics: Anticoagulants; Arterial Occlusive Diseases; Asia, Southeastern; Aspirin; Brain Ischemia; Dipyridamo | 2003 |
Editorial comment: Low-dose or moderate-dose anticoagulation: dream or hope for stroke prevention?
Topics: Administration, Oral; Anticoagulants; Aspirin; Brain Ischemia; Clinical Trials as Topic; Dose-Respon | 2003 |
Antiplatelet agents. European perspective.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Europe; Hum | 2003 |
Antithrombotic treatment of atrial fibrillation in a regional hospital in Hong Kong.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Chronic Disease; Contraindications; Fe | 2003 |
[Secondary prevention of stroke].
Topics: Anticoagulants; Aspirin; Endarterectomy, Carotid; Humans; Secondary Prevention; Stroke; Warfarin | 2003 |
"Silent" strokes and dementia.
Topics: Aspirin; Brain Infarction; Dementia; Humans; Platelet Aggregation Inhibitors; Stroke | 2003 |
Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Brain Ischemia; Female; Follow-Up Studies | 2003 |
Bleeding time, stroke and myocardial infarction: the Caerphilly prospective study.
Topics: Aged; Aspirin; Bleeding Time; Follow-Up Studies; Hemostasis; Humans; Male; Middle Aged; Myocardial I | 2003 |
Why are eligible patients not prescribed aspirin in primary care? A qualitative study indicating measures for improvement.
Topics: Aspirin; Attitude of Health Personnel; Drug Prescriptions; Humans; Patient Compliance; Physicians, F | 2003 |
Aspirin for cardiovascular disease prevention.
Topics: Aspirin; Atrial Fibrillation; Coronary Disease; Heart Valve Prosthesis; Humans; Myocardial Infarctio | 2003 |
Management and short-term outcome of diabetic patients hospitalized for acute myocardial infarction: results of a nationwide French survey.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Body Mass Index; Diabetic Angiopathies; Female; France; | 2003 |
[Long-term therapy with clopidogrel in combination with ASA significantly reduces risk of death, myocardial infarct or stroke].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; H | 2003 |
Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke.
Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; China; Cohort Stu | 2003 |
[Recurrence prophylaxis for stroke patients. Which platelet inhibitor combination protects best?].
Topics: Angiotensin II Type 1 Receptor Blockers; Aspirin; Aspirin, Dipyridamole Drug Combination; Benzimidaz | 2003 |
[Stroke is not equal to stroke. Keep track of the causes].
Topics: Adult; Antihypertensive Agents; Aspirin; Carotid Artery, Common; Carotid Artery, External; Carotid S | 2003 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic | 2003 |
Atrial fibrillation and stroke prevention.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Stroke; Thromboembolism; Warfarin | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Atrial anatomy in non-cardioembolic stroke patients: effect of medical therapy.
Topics: Anticoagulants; Aspirin; Double-Blind Method; Female; Heart Aneurysm; Heart Atria; Heart Septal Defe | 2003 |
Cardiology Patient Page. C-reactive protein: a simple test to help predict risk of heart attack and stroke.
Topics: Age Factors; Aspirin; C-Reactive Protein; Cholesterol; Diabetes Mellitus; Female; Heart Diseases; Hu | 2003 |
Stop those anti-platelet drugs before surgery!
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Myocardial Infarction; Platelet Aggregatio | 2003 |
Racial disparities in receipt of secondary stroke prevention agents among US nursing home residents.
Topics: Aged; Anticoagulants; Aspirin; Databases, Factual; Dipyridamole; Drug Therapy, Combination; Drug Uti | 2003 |
[PRoFESS study presented. Change in secondary prevention].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Aspirin, Dipyridamole Drug Combination; Benzimida | 2003 |
[ASS and dipyridamole combination. A decisive contribution to secondary prevention after stroke].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clinical Trials as Topic; Delayed-Action Preparatio | 2003 |
[Secondary prevention of ischemic insult and transient cerebral ischemia. Is ASS alone enough?].
Topics: Aspirin; Controlled Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; Ische | 2003 |
[Dual platelet inhibition with clopidogrel and ASS. Who profits from the combination?].
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclooxygenase Inhi | 2003 |
Introduction to monitoring. What is what you prescribed actually doing?
Topics: Acetaminophen; Aged; Aspirin; Australia; Celecoxib; Drug Interactions; Drug Therapy, Combination; Fa | 2003 |
Increased sensitivity to ADP-aggregation in aspirin treated patients with recurrent ischemic stroke?
Topics: Adenosine Diphosphate; Aspirin; Female; Humans; Male; Pilot Projects; Platelet Aggregation; Platelet | 2003 |
Regression dilution of systolic and diastolic blood pressure in patients with established cerebrovascular disease.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atenolol; Blood Press | 2003 |
Should I start all my ischaemic stroke and TIA patients on a statin, an ACE inhibitor, a diuretic, and aspirin today?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Brain Ischemia; Humans; Hydroxymethylglutaryl-CoA | 2003 |
Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study.
Topics: Antigens, CD; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Clopidogrel; Cross-Over Studies; | 2003 |
Aspirin therapy in diabetes.
Topics: Aspirin; Diabetes Mellitus; Diabetic Angiopathies; Female; Humans; Male; Platelet Aggregation Inhibi | 2004 |
[Secondary prevention after stroke. Doubled performs better].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Controlled Clinical Trials as Topic; Dipyridamole; | 2003 |
A feasibility study of the safety and efficacy of a combined clopidogrel and aspirin regimen following off-pump coronary artery bypass grafting.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Feasibility | 2003 |
Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events.
Topics: Aged; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Databases, Factual; Female; Hospitaliz | 2004 |
Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Echocardiography; Female; Fibrinoly | 2004 |
Stroke prophylaxis in institutionalized elderly patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Female; Fibrinolytic Agents; Humans; Long-Ter | 2004 |
[After stroke or TIA. Double protection by second platelet inhibitor].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clinical Trials as Topic; Delayed-Action Preparatio | 2003 |
The specificity of prescription patterns in secondary stroke prevention.
Topics: Accidental Falls; Anticoagulants; Aspirin; Cognition Disorders; Geriatric Assessment; Humans; Patien | 2004 |
[Migraine, inflammation, genes. New risk factors for stroke].
Topics: Adult; Arteriosclerosis; Aspirin; C-Reactive Protein; Case-Control Studies; Contraceptives, Oral; Fe | 2003 |
The development and evaluation of a computerised decision support system for primary care based upon 'patient profile decision analysis'.
Topics: Aspirin; Attitude of Health Personnel; Attitude to Computers; Chemoprevention; Decision Support Syst | 2003 |
By the way, doctor. My husband takes an aspirin every day to reduce his risk of another heart attack. I'm 60 and healthy. Is there any reason I shouldn't do the same to avoid a heart attack or stroke?
Topics: Aspirin; Female; Fibrinolytic Agents; Humans; Middle Aged; Myocardial Infarction; Stroke | 2004 |
Increased platelet CD63 and P-selectin expression persist in atherosclerotic ischemic stroke.
Topics: Adenosine Diphosphate; Aged; Anticoagulants; Antigens, CD; Aspirin; Blood Platelets; Brain Ischemia; | 2004 |
Ximelagatran or warfarin in atrial fibrillation?
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Drug Therapy, Combination; H | 2004 |
Ximelagatran or warfarin in atrial fibrillation?
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Humans; Randomized Controlle | 2004 |
[Efficacy and safety of treatment of acute ischemic stroke with glycoprotein IIb/IIIa receptor blocker in routine clinical practice].
Topics: Adult; Aged; Anticoagulants; Aspirin; Brain; Brain Ischemia; Carotid Arteries; Clopidogrel; Drug The | 2004 |
Aspirin dose and six-month outcome after an acute coronary syndrome.
Topics: Aged; Anticoagulants; Aspirin; Drug Administration Schedule; Female; Humans; Ireland; Male; Middle A | 2004 |
Trial application of a Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS) to assist priority setting in stroke.
Topics: Acute Disease; Aspirin; Cost-Benefit Analysis; Fibrinolytic Agents; Health Care Costs; Health Priori | 2004 |
Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke.
Topics: Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Case-Control Studies; Cyclooxygenase 1; DNA Muta | 2003 |
The Polypill: a simple "cure" for heart disease and stroke?
Topics: Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Drug Combinations; Folic Acid; Heart Dis | 2004 |
Is the endovascular treatment of carotid stenosis in high-risk patients really safer than carotid endarterectomy?
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Aspirin; Carotid Stenosis; Endarterectomy, Car | 2004 |
Community-based study of atrial fibrillation and stroke prevention.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Attitude of Health Personnel; | 2004 |
Therapeutic failure or resistance to aspirin.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Fibrinolytic Agents; Humans; Myocardial Infarctio | 2004 |
Aspirin: it's hard to beat.
Topics: Aspirin; Cerebral Infarction; Humans; Pilot Projects; Platelet Aggregation Inhibitors; Randomized Co | 2004 |
Secondary prevention of stroke: more than just aspirin or warfarin.
Topics: Aged; Anticoagulants; Aspirin; Fibrinolytic Agents; Humans; Hypertension; Secondary Prevention; Stro | 2004 |
Noncompliance in antiplatelet trials: the AGATE trial perspective.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Controlled Clinical Trials as Topic; Dipyridamole; | 2004 |
Changes in stroke care at Auckland Hospital between 1996 and 2001.
Topics: Aged; Anticoagulants; Antihypertensive Agents; Aspirin; Female; Hospitalization; Hospitals, Urban; H | 2004 |
"Super aspirin" cuts risks after multiple cardiac events.
Topics: Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Secondary Prev | 2004 |
Hemorrhagic transformation of ischemic stroke associated with enoxaparin and aspirin concomitant therapy.
Topics: Acute Disease; Anticoagulants; Aspirin; Cerebral Hemorrhage; Drug Therapy, Combination; Enoxaparin; | 2004 |
Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy.
Topics: Aged; Antigens, CD; Aspirin; Blood Platelets; CD40 Antigens; Cohort Studies; Epinephrine; Female; Hu | 2004 |
[Management of stroke in a ward of internal medicine. Limits and prospects].
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; | 2004 |
Clinical and radiological predictors of recanalisation and outcome of 40 patients with acute basilar artery occlusion treated with intra-arterial thrombolysis.
Topics: Acute Disease; Adult; Aged; Aspirin; Basilar Artery; Cerebral Angiography; Female; Fibrinolytic Agen | 2004 |
Serial changes in platelet activation in patients after ischemic stroke: role of pharmacodynamic modulation.
Topics: Aged; Anticoagulants; Aspirin; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; P-Se | 2004 |
Anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Electric Countershock; Fibri | 2004 |
Aspirin bias in SPORTIF III trial.
Topics: Anticoagulants; Aspirin; Azetidines; Benzylamines; Humans; Platelet Aggregation Inhibitors; Prodrugs | 2004 |
[Stroke and Other Thromboembolic Complications of Atrial Fibrillation. Part III. Prevention With Aspirin].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Stroke; Warfarin | 2004 |
Platelet inhibition by aspirin is diminished in patients during carotid surgery: a form of transient aspirin resistance?
Topics: Aged; Aged, 80 and over; Angioplasty; Arachidonic Acid; Aspirin; Blood Platelets; Case-Control Studi | 2004 |
Late incidence and determinants of stroke after aortic and mitral valve replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aortic Valve; Aspirin; Atrial Fibrillation; Cerebral | 2004 |
Risk factors and in-hospital outcomes in stroke and myocardial infarction patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Croa | 2004 |
Economic assessment of the secondary prevention of ischaemic stroke with dipyridamole plus aspirin (Aggrenox/Asasantin) in France.
Topics: Adolescent; Adult; Aged; Aspirin; Aspirin, Dipyridamole Drug Combination; Confidence Intervals; Cost | 2004 |
[Asasantin Retard or Persantin Retard+ASA?].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Delayed-Action Preparations; Dipyridamole; Drug Com | 2004 |
The Willis Lecture 2003: evaluating treatments for stroke patients too slowly: time to get out of second gear.
Topics: Angioplasty; Anticoagulants; Antihypertensive Agents; Aspirin; Carotid Stenosis; Clinical Trials as | 2004 |
A critical appraisal of the CURE trial: role of clopidogrel in non-ST-segment elevation acute coronary syndromes.
Topics: Aspirin; Clopidogrel; Confidence Intervals; Humans; Myocardial Infarction; Randomized Controlled Tri | 2004 |
Venous thromboembolism after acute ischemic stroke: a prospective study using magnetic resonance direct thrombus imaging.
Topics: Aged; Aspirin; Bandages; Female; Fibrinolytic Agents; Humans; Magnetic Resonance Imaging; Male; Pulm | 2004 |
Physicians' attitudes toward anticoagulant therapy in patients with chronic atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Attitude of Health Personnel; | 2004 |
Circulating reticulated platelets in the early and late phases after ischaemic stroke and transient ischaemic attack.
Topics: Aged; Aspirin; Blood Platelets; Brain Ischemia; Cell Size; Dose-Response Relationship, Drug; Female; | 2004 |
Thrombin generation in non-cardioembolic stroke subtypes: the Hemostatic System Activation Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Biomarkers; Brain Infarction; Brain Ischemia; Coho | 2004 |
A community-based educational intervention to improve antithrombotic drug use in atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Attitude to Health; Case-Control Studies; Female | 2004 |
Typical versus atypical antipsychotics.
Topics: Antipsychotic Agents; Aspirin; Drug Costs; Humans; Myocardial Infarction; Prevalence; Schizophrenia; | 2004 |
[Clopidogrel protection is not increased further by ASS!].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ische | 2004 |
[Clopidogrel as basic therapy in high-risk stroke patients].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Hemo | 2004 |
Should the MATCH results be extrapolated to all stroke patients and affect ongoing trials evaluating clopidogrel plus aspirin?
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stroke; Tic | 2004 |
[Secondary prevention of stroke with antiplatelet drugs].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, | 2004 |
[Stroke and other tromboembolic complications in atrial fibrillation. Part I. Prevalence and risk factors].
Topics: Age Factors; Aged; Aspirin; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Chronic Disease; Cros | 2004 |
[Patients with arterial occlusive disease die of myocardial infarct or stroke. The dangerous sisters: arterial occlusive disease and coronary heart disease].
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Cause of Death; Clinical Trials as Topic; Clopidogrel; C | 2004 |
Aspirin. A look at an old drug's new uses.
Topics: Aspirin; Coronary Disease; Humans; Neoplasms; Stroke | 2004 |
Anticoagulation to prevent strokes in older people with atrial fibrillation: assembling individualized risk and benefit information.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Long-Term Care; | 2004 |
Aspirin for stroke prevention taken in the evening?
Topics: Aspirin; Chronotherapy; Humans; Platelet Aggregation Inhibitors; Stroke | 2004 |
Reduction of body temperature with paracetamol in patients with acute stroke: randomised clinical trials are needed.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Fever; Hu | 2004 |
Antiplatelet drug discontinuation is a risk factor for ischemic stroke.
Topics: Aspirin; Brain Ischemia; Humans; Platelet Aggregation Inhibitors; Risk Factors; Stroke | 2004 |
Association of aspirin with eosinophilia in peripheral blood.
Topics: Aged; Antiparkinson Agents; Aspirin; Eosinophilia; Humans; Levodopa; Male; Parkinson Disease; Platel | 2004 |
Aspirin resistance in vitro and hypertension in stroke patients.
Topics: Aged; Aspirin; Blood Coagulation Tests; Drug Resistance; Female; Humans; Hypertension; Male; Middle | 2004 |
Antiplatelet therapy.
Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Drug Interactions; Humans; Myocardial Infarction; Patient | 2004 |
Declining incidence and mortality of stroke in persons aged > or = 75 years in Finland; the FINSTROKE study.
Topics: Aged; Anticoagulants; Aspirin; Drug Utilization; Female; Finland; Humans; Incidence; Male; Platelet | 2004 |
Anti-thrombotic therapy for atrial fibrillation and patients' preferences for treatment.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Monitoring; Humans; Internatio | 2005 |
Efficacy of anticoagulation for secondary stroke prevention in older people with non-valvular atrial fibrillation: a prospective case series study.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cause of Death; | 2005 |
[Secondary prevention of stroke].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Diabetes Complications; Guideline Adherence; Humans; H | 2004 |
[Stroke prevention in atrial fibrillation -- transfer of study results to the practice].
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrilla | 2004 |
Aspirin resistance: a worry?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Drug Resistance; Fibrinolytic Age | 2005 |
Primary angioplasty in acute myocardial infarction: Hypothetical estimate of superiority over aspirin or untreated controls.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Forecasting; Humans; Mo | 2005 |
Creative cost-effectiveness analysis of CAPRIE data- dust in our eyes.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Humans; Peripheral Vascular | 2005 |
Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Chr | 2005 |
Screening for proximal deep vein thrombosis after acute ischemic stroke: a prospective study using clinical factors and plasma D-dimers.
Topics: Age Factors; Aged; Aspirin; Bandages; Female; Fibrin Fibrinogen Degradation Products; Humans; Ischem | 2004 |
Summaries for patients. Is it cost-effective to treat high-risk cardiac patients with clopidogrel plus aspirin as opposed to aspirin alone?
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit A | 2005 |
A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit A | 2005 |
Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry.
Topics: Adolescent; Adult; Aged; Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; | 2005 |
Endovascular stent-assisted angioplasty in the management of traumatic internal carotid artery dissections.
Topics: Adult; Angiography; Angioplasty; Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis I | 2005 |
The puzzle of aspirin and sex.
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Female; Humans; Male; Myocardial Infarc | 2005 |
Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations.
Topics: Adult; Aged; Aspirin; Delayed-Action Preparations; Dipyridamole; Double-Blind Method; Drug Therapy, | 2005 |
In-hospital patients exposed to clopidogrel before coronary artery bypass graft surgery: a word of caution.
Topics: Aged; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass; Female; Heparin; Hospital | 2005 |
Warfarin, aspirin, and intracranial vascular disease.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Fibrinolytic Agents; Hemorrhage; Humans; | 2005 |
Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; | 2004 |
Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry.
Topics: Adult; Aged; Aspirin; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggreg | 2005 |
Neurological outcome of conservative versus endovascular treatment of patients with asymptomatic high-grade carotid artery stenosis: a propensity score-adjusted analysis.
Topics: Aged; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Disease-Free Survival; Female; Follow-Up | 2005 |
[Female, young, healthy. ASS does not protect from myocardial infarct].
Topics: Adult; Age Factors; Aged; Aspirin; Female; Humans; Male; Myocardial Infarction; Placebos; Platelet A | 2005 |
Strategies for stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Balloon Occlusion; Electric Countershock; Heart Atria; | 2005 |
Atrial septal abnormalities and cryptogenic stroke: a paradoxical science.
Topics: Anticoagulants; Aspirin; Heart Atria; Heart Septal Defects, Atrial; Heart Septum; Humans; Stroke; Un | 2005 |
Counting the true cost of antiplatelet therapy for stroke prevention.
Topics: Aged; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Cost-Benefit Analysis; Dipyridam | 2005 |
Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Dose-Response Relationship, Dr | 2005 |
Guideline recommendations for the management of patients admitted with acute stroke: implications of a local audit.
Topics: Acute Disease; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Cerebral Hemorrhage; Feasi | 2005 |
Aspirin and women--age matters. Aspirin can help healthy women over age 56 prevent both strokes and heart attacks. For younger women, the hazards of aspirin outweigh the benefits.
Topics: Age Factors; Aspirin; Female; Fibrinolytic Agents; Hemorrhage; Humans; Middle Aged; Myocardial Infar | 2005 |
Anticoagulation influences long-term outcome in patients with nonvalvular atrial fibrillation and severe ischemic stroke.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Follow-Up S | 2004 |
Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70.
Topics: Aged; Aged, 80 and over; Aspirin; Female; Fibrinolytic Agents; Gastrointestinal Hemorrhage; Humans; | 2005 |
Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease.
Topics: Aged; Alleles; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Clopidogrel; Cohort Studies; Ex | 2005 |
The (variable) definition of benefit in the case of clopidogrel vs aspirin.
Topics: Aspirin; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Platelet Aggregat | 2005 |
Timing of aspirin and secondary preventative therapies in acute stroke: support for use of stroke units.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Brain Ischemia; Chemopre | 2005 |
[Highlights from the American College of Cardiology Annual Scientific Session 2005: March 5-9, 2005, Orlando, Florida].
Topics: Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Clopidogrel; Humans; Hypercholesterolemia; Obesi | 2005 |
Aspirin in the prevention of cardiovascular disease in women.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Male; Myocardial Infarction; Plate | 2005 |
Choosing between warfarin (Coumadin) and aspirin therapy for patients with atrial fibrillation.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Evidence-Based Medicine; Female; Hu | 2005 |
Link between platelet activity and outcomes after an ischemic stroke.
Topics: Aged; Aspirin; Blood Platelets; Endpoint Determination; Female; Flow Cytometry; Humans; Logistic Mod | 2005 |
Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Blood Platelets; Case-Control Studies; Cyclo | 2005 |
Frequency and effect of optimal anticoagulation before onset of ischaemic stroke in patients with known atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Fibrinolytic Agents; | 2005 |
Preventive aspirin for women?
Topics: Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Middle Aged; Myocardial Infarction; Prevent | 2005 |
A patient with cerebral Whipple's disease and a stroke-like syndrome.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Diseases; Ceftriaxone | 2005 |
[Prevention of stroke with aspirin, vitamin E is ineffective].
Topics: Aged; Antioxidants; Aspirin; Clinical Trials as Topic; Female; Humans; Middle Aged; Platelet Aggrega | 2005 |
[Strokes associated with cervical artery dissection, and systemic mastocytosis: an unfortuitous association? A report of two cases].
Topics: Aspirin; Brain Infarction; Carotid Artery, Internal, Dissection; Carotid Stenosis; Clopidogrel; Fibr | 2005 |
Aspirin study refocuses prevention message for women. Aspirin therapy does less than anticipated in preventing heart attacks in women--but more than we knew in warding off strokes.
Topics: Aspirin; Female; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Treatment O | 2005 |
A doctor talks about aspirin.
Topics: Age Factors; Aged; Aspirin; Female; Humans; Middle Aged; Myocardial Infarction; Platelet Aggregation | 2005 |
Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Coronary Artery Disea | 2005 |
Risk factors for cerebrovascular events following fontan palliation in patients with a functional single ventricle.
Topics: Aspirin; Cardiac Catheterization; Child, Preschool; Echocardiography; Female; Follow-Up Studies; Fon | 2005 |
Progressive symptomatic carotid dissection treated with multiple stents.
Topics: Angiography; Angioplasty; Anticoagulants; Aspirin; Blood Vessel Prosthesis Implantation; Carotid Art | 2005 |
Use of dipyridamole in patients with recent stroke or TIA.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, | 2005 |
Stroke prevention.
Topics: Aspirin; Canada; Ischemic Attack, Transient; Patient Education as Topic; Platelet Aggregation Inhibi | 2005 |
Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparin.
Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemo | 2005 |
Increased platelet count and leucocyte-platelet complex formation in acute symptomatic compared with asymptomatic severe carotid stenosis.
Topics: Acute Disease; Aged; Aspirin; Carotid Stenosis; Female; Fibrinolytic Agents; Flow Cytometry; Humans; | 2005 |
[Prophylaxis of stroke].
Topics: Age Factors; Aged; Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fi | 2005 |
Stroke units, tissue plasminogen activator, aspirin and neuroprotection: which stroke intervention could provide the greatest community benefit?
Topics: Acute Disease; Aged; Aspirin; Australia; Emergency Medical Services; Female; Fibrinolytic Agents; Ho | 2005 |
Stroke Rx: an aspirin a day, forever. Daily aspirin helps prevent a second stroke...and in women, a first.
Topics: Aspirin; Female; Fibrinolytic Agents; Humans; Male; Secondary Prevention; Sex Factors; Stroke | 2005 |
Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Drug Ther | 2005 |
Clearing up mixed messages about aspirin for women.
Topics: Aspirin; Female; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke | 2005 |
Oral clopidogrel load in aspirin-resistant capsular warning syndrome.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female | 2005 |
Preoperative aspirin therapy is associated with improved postoperative outcomes in patients undergoing coronary artery bypass grafting.
Topics: Aged; Aspirin; Cohort Studies; Coronary Artery Bypass; Coronary Disease; Drug Administration Schedul | 2005 |
Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Drug Therapy | 2005 |
Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Drug Therapy | 2005 |
Acute stroke.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain; Cerebrovascular Circul | 2003 |
The lady aspirin for cardiovascular disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pl | 2005 |
Effect of access to anticoagulation management services on warfarin use in patients with atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Aspirin; Atrial Fibrillation; | 2005 |
[Cerebral secondary prevention--clopidogrel alone or in combination with ASS].
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Huma | 2005 |
No one-size-fits-all for aspirin and elders.
Topics: Aged; Aspirin; Cerebral Hemorrhage; Female; Gastrointestinal Hemorrhage; Humans; Male; Myocardial In | 2005 |
Feasibility trial of carotid stenting with and without an embolus protection device.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Vessel Prosthesis Implantation; Carotid Artery, Commo | 2005 |
Procedure-related complications and early neurological adverse events of unprotected and protected carotid stenting: temporal trends in a consecutive patient series.
Topics: Aged; Aspirin; Blood Vessel Prosthesis Implantation; Carotid Artery, Internal; Carotid Stenosis; Clo | 2005 |
Antiplatelet therapy and the vascular tree.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Artery Dis | 2006 |
Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980 to 2000: report of a community-based study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Blood Pressur | 2005 |
Aspirin prevents strokes in middle-aged and older women, heart attacks in older women.
Topics: Age Factors; Aged; Aspirin; Female; Fibrinolytic Agents; Humans; Middle Aged; Myocardial Infarction; | 2005 |
[Radiotherapy of the neck as a risk factor for stroke].
Topics: Aspirin; Humans; Laryngeal Neoplasms; Radiation Injuries; Stroke; Urea | 2005 |
Racial differences in the use of aspirin: an important tool for preventing heart disease and stroke.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Black People; Coronary Disease; Femal | 2005 |
For the patient. Use of aspirin lower among ethnic populations.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Black People; Heart Diseases; Hispanic or Latino; | 2005 |
The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2005 |
Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2.
Topics: Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dipyridamole; Female; Humans; Male; Middle | 2006 |
Dipyridamole decreases protease-activated receptor and annexin-v binding on platelets of post stroke patients with aspirin nonresponsiveness.
Topics: Aged; Aspirin; Cell Culture Techniques; Dipyridamole; Dose-Response Relationship, Drug; Drug Resista | 2006 |
Antiplatelet versus anticoagulant therapies in advanced age: an unfinished task.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Humans; Platelet Aggregation Inh | 2006 |
Streptokinase-induced hypotension has no detrimental effect on patients with thrombolytic treatment for acute myocardial infarction. A substudy of the Romanian Study for Accelerated Streptokinase in Acute Myocardial Infarction (ASK-ROMANIA).
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Female | 2004 |
Aspirin, "super aspirin" use in women for cardioprevention probed.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Platelet Aggregation Inhibitors; Platelet Glycopro | 2006 |
[Peroral antithrombotic treatment].
Topics: Administration, Oral; Antifibrinolytic Agents; Aspirin; Dipyridamole; Drug Therapy, Combination; Hum | 2006 |
Efficacy of dual antiplatelet therapy in cerebrovascular disease as demonstrated by a decline in microembolic signals. A report of eight cases.
Topics: Aged; Aspirin; Cerebrovascular Disorders; China; Clopidogrel; Drug Therapy, Combination; Embolism; F | 2006 |
Rebound inflammation and the risk of ischemic stroke after discontinuation of aspirin therapy.
Topics: Aspirin; Brain Ischemia; C-Reactive Protein; Humans; Inflammation; Platelet Aggregation Inhibitors; | 2006 |
Antiplatelet therapy in stroke prevention: present and future.
Topics: Aspirin; Blood Platelets; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Random | 2006 |
New modalities and aspects of antiplatelet therapy for stroke prevention.
Topics: Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Drug Design; Drug Resistance; Drug Therapy, Combi | 2006 |
Regional differences in incidence and management of stroke - is there any difference between Western and Japanese guidelines on antiplatelet therapy?
Topics: Aspirin; Brain Infarction; Cilostazol; Humans; Incidence; Japan; Myocardial Ischemia; Platelet Aggre | 2006 |
Biological basis and clinical implications of acetylsalicylic acid resistance.
Topics: Acetylation; Acetyltransferases; Arachidonic Acid; Aspirin; Drug Resistance; Fibrinolytic Agents; Hu | 2006 |
Adherence to aspirin in secondary prevention of ischemic stroke.
Topics: Adult; Aged; Ambulatory Care; Aspirin; Brain Ischemia; Female; Follow-Up Studies; Health Care Survey | 2006 |
Oral anticoagulant therapy, endocapsular hematoma, and neodymium:YAG capsulotomy.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; | 2006 |
Summaries for patients. The cost-effectiveness of aspirin, statins, or both drugs in the primary prevention of heart disease.
Topics: Aspirin; Computer Simulation; Coronary Disease; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Com | 2006 |
Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.
Topics: Aspirin; Computer Simulation; Coronary Disease; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Com | 2006 |
The risks and safety of clopidogrel in pediatric arterial ischemic stroke.
Topics: Adolescent; Aspirin; Brain Ischemia; Child; Child, Preschool; Clopidogrel; Cohort Studies; Drug Ther | 2006 |
Moyamoya syndrome in a splenectomized patient with beta-thalassemia intermedia.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; beta-Thalassemia; Carotid Arteries; Di | 2006 |
High prevalence of previous antiplatelet drug use in patients with new or recurrent ischemic stroke: Buffalo metropolitan area and Erie County stroke study.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Cross-Sectional Studies; Drug Therapy, Combination; Hospitaliz | 2006 |
Dipyridamole plus aspirin: the best regimen for stroke prevention after noncardioembolic focal cerebral ischemia.
Topics: Aspirin; Brain Ischemia; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combination; Human | 2006 |
Compatibility of carotid stenting and cardiac surgery.
Topics: Aspirin; Blood Loss, Surgical; Carotid Arteries; Carotid Stenosis; Humans; Platelet Aggregation Inhi | 2006 |
Sex difference in the antiplatelet effect of aspirin in patients with stroke.
Topics: Adult; Aged; Aspirin; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggreg | 2006 |
Aspirin's benefits: fewer heart attacks for him, fewer strokes for her.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Sex Factors; | 2006 |
Low-dose aspirin for stroke prevention.
Topics: Aspirin; Atrial Fibrillation; Dose-Response Relationship, Drug; Humans; Platelet Aggregation Inhibit | 2006 |
Growth in clopidogrel-aspirin combination therapy.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Data Collection; Drug Therapy, Combination; Drug Uti | 2006 |
Dissection of cervical arteries: Long-term follow-up study of 130 consecutive cases.
Topics: Adult; Anticoagulants; Aspirin; Brain Ischemia; Carotid Artery, Internal, Dissection; Female; Humans | 2006 |
Dipyridamole with aspirin for secondary stroke prevention.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; R | 2006 |
Aspirin for prevention of stroke in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Platelet Aggregation Inhibitors; Stroke; Throm | 2006 |
Long-term outcome in patients with cervical-artery dissections: There is still a lot to know.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Artery, Internal, Dissection; Humans; Platelet Aggr | 2006 |
Secondary stroke prevention and antiplatelet therapy.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Humans; Platelet A | 2006 |
Dipyridamole plus aspirin for stroke prevention.
Topics: Aspirin; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Stroke | 2006 |
[Comparative study of warfarin and aspirin for stroke prevention in elderly patients with atrial fibrillation].
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; China; Female; Humans; Male; Retrospective Studi | 2006 |
Antiplatelet therapy prior to carotid endarterectomy--still room for improvement.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Austria; Carotid Artery, Internal; Carotid Stenosis; Clopid | 2006 |
Enhanced platelet activation by prolactin in patients with ischemic stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Ischemic Attack, Tran | 2006 |
A new theory of cryptogenic stroke and its relationship to patent foramen ovale; or, the puzzle of the missing extra risk.
Topics: Adult; Aged; Aspirin; Databases, Factual; Foramen Ovale, Patent; Humans; Middle Aged; Recurrence; Ri | 2006 |
Carotid stenting.
Topics: Aged; Aspirin; Cardiovascular Agents; Carotid Artery, Internal; Carotid Stenosis; Clopidogrel; Endar | 2006 |
Softening the blow.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Car | 2006 |
Clopidogrel for the prevention of atherothrombotic events.
Topics: Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation I | 2006 |
Clopidogrel for the prevention of atherothrombotic events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platel | 2006 |
ESPRIT trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Drug Administrat | 2006 |
New ways to prevent stroke.
Topics: Aspirin; Humans; Hypertension; Platelet Aggregation Inhibitors; Risk Assessment; Smoking Prevention; | 2006 |
Could discontinuation of aspirin therapy be a trigger for stroke?
Topics: Aspirin; Humans; Ischemia; Platelet Aggregation Inhibitors; Risk; Stroke; Substance Withdrawal Syndr | 2006 |
[Physicians and insurance may collaborate on therapy].
Topics: Aspirin; Clopidogrel; Contract Services; Cooperative Behavior; Cost-Benefit Analysis; Drug Costs; Fa | 2006 |
Cryptogenic stroke and patent foramen ovale.
Topics: Aspirin; Heart Septal Defects, Atrial; Humans; Platelet Aggregation Inhibitors; Stroke | 2006 |
Cardiology groups' antithrombotic guidelines challenge ACCP's.
Topics: Aspirin; Atrial Fibrillation; Cardiology; Fibrinolytic Agents; Patient Selection; Platelet Aggregati | 2006 |
Aspirin and stroke severity.
Topics: Aspirin; Humans; Multicenter Studies as Topic; Severity of Illness Index; Stroke | 2006 |
[When ASS, when anticoagulants?].
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Clopidogrel; Female; Heart Disease | 2006 |
[Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark].
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Bypass; Coronary | 2006 |
Does prior aspirin use reduce stroke mortality?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Female; Fibrinolytic A | 2006 |
A case of stroke in pregnancy: the optimum management of such patients remains a challenge.
Topics: Adult; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pregnancy Complications; P | 2006 |
[Prevention of vascular events after transient ischemic attack or cerebral infarct].
Topics: Angioplasty, Balloon; Anticoagulants; Aspirin; Cerebral Infarction; Clopidogrel; Dipyridamole; Drug | 2006 |
Effects of policosanol on patients with ischemic stroke: a pilot open study.
Topics: Aged; Anticholesteremic Agents; Aspirin; Fatty Alcohols; Female; Follow-Up Studies; Humans; Lipids; | 2006 |
Antiplatelet and anticoagulant therapy in patients with giant cell arteritis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Dose- | 2006 |
Endarterectomy for carotid artery stenosis: who qualifies?
Topics: Aspirin; Carotid Stenosis; Endarterectomy, Carotid; Humans; Patient Selection; Platelet Aggregation | 2006 |
[Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome].
Topics: Age Factors; Aged; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Com | 2006 |
[Old patient with atrial fibrillation: do you too hesitate to use anticoagulants?].
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrilla | 2006 |
Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colonic Neoplasms; Databases | 2007 |
Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Drug Therapy, Combinat | 2006 |
Clinical trials and dipyridamole formulation selection.
Topics: Aspirin; Brain Ischemia; Chemistry, Pharmaceutical; Delayed-Action Preparations; Dipyridamole; Drug | 2007 |
Role of antiplatelets in carotid artery stenting.
Topics: Angioplasty, Balloon; Aspirin; Carotid Stenosis; Clinical Trials as Topic; Clopidogrel; Dipyridamole | 2007 |
Antithrombotic therapy and predilection for cerebellar hemorrhage.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arteriosclerosis; Aspirin; Blo | 2007 |
[Combination of acetylsalicylic acid with dipyridamole is better than acetylsalicylic acid monotherapy].
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; Multicenter Studies as Topic; Platelet Agg | 2006 |
Stroke: the dashed hopes of neuroprotection.
Topics: Acute Disease; Aspirin; Benzenesulfonates; Carotid Arteries; Clopidogrel; Dipyridamole; Europe; Huma | 2007 |
Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio | 2006 |
Variation and importance of aspirin resistance in patients with known cardiovascular disease.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Drug Resistance; Female; Follow-Up Studie | 2007 |
Studies show aspirin affects women differently than men.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Secondary Pre | 2006 |
Prevention of vascular events in atrial fibrillation.
Topics: Accidental Falls; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Platelet Aggreg | 2007 |
New guidelines for atrial fibrillation focus on stroke risk.
Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Practice Guidelines as Topic; Risk Factor | 2006 |
Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Drug Therapy, Combinat | 2007 |
Combination antiplatelet therapy with aspirin and clopidogrel: the role of antecedent and concomitant doses of aspirin. An analysis of 711 patients.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug T | 2007 |
Evaluation of a service development to implement the top three process indicators for quality stroke care.
Topics: Aged; Aspirin; Deglutition Disorders; Delivery of Health Care; Guideline Adherence; Humans; Male; Me | 2007 |
CHARISMA: the antiplatelet saga continues.
Topics: Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2007 |
Take aspirin before ibuprofen, not after.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Administration Schedule; Drug Interactions; H | 2006 |
Newly detected atrial fibrillation and compliance with antithrombotic guidelines.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Fibrinolytic Agents; | 2007 |
Emerging therapies: ESPRIT.
Topics: Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clinical Trials as Topic; Dipyridamole; Drug Therapy, | 2007 |
TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents.
Topics: Acute Disease; Adult; Aged; Aspirin; Brain Ischemia; Cells, Cultured; Clopidogrel; Dipyridamole; Fem | 2007 |
Update on the use of antiplatelet agents in secondary stroke prevention.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Embolism, Cholester | 2007 |
Combining aspirin with oral anticoagulant therapy: is this a safe and effective practice in patients with atrial fibrillation?
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Drug T | 2007 |
Dosing frequency of aspirin and prevention of heart attacks and strokes.
Topics: Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Myocardial Infarcti | 2007 |
Enteric coated aspirin.
Topics: Aspirin; Gastrointestinal Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors | 2007 |
[The management of stroke in Phnom Penh, Cambodia].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Calcium Channe | 2007 |
Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis.
Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Drug Administration Sche | 2007 |
Combination treatment with dipyridamole, aspirin, and tPA in an embolic model of stroke in rats.
Topics: Animals; Aspirin; Brain; Cerebral Infarction; Cerebrovascular Circulation; Dipyridamole; Drug Therap | 2007 |
Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study.
Topics: Aspirin; Atherosclerosis; Biomarkers; Black or African American; Case-Control Studies; Coronary Dise | 2008 |
Combination shows no advantage over aspirin alone.
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Stroke | 2007 |
dl-3n-butylphthalide prevents stroke via improvement of cerebral microvessels in RHRSP.
Topics: Animals; Aspirin; Benzofurans; Brain; Brain Ischemia; Cerebral Arteries; Cerebrovascular Circulation | 2007 |
Comparison of relative and attributable risk of myocardial infarction and stroke according to C-reactive protein and low-density lipoprotein cholesterol levels.
Topics: Adult; Aged; Anticholesteremic Agents; Aspirin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Co | 2007 |
Stroke prevention in atrial fibrillation--things can only get better.
Topics: Aged, 80 and over; Aspirin; Atrial Fibrillation; Dose-Response Relationship, Drug; Humans; Platelet | 2007 |
Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring.
Topics: Aged; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dextrans; Dipyri | 2007 |
Effect of combination of endothelin receptor antagonist (TAK-044) and aspirin in middle cerebral artery occlusion model of acute ischemic stroke in rats.
Topics: Animals; Antioxidants; Aspirin; Brain Ischemia; Disease Models, Animal; Drug Therapy, Combination; E | 2007 |
The BC genotype of the VNTR polymorphism of platelet glycoprotein Ibalpha is overrepresented in patients with recurrent stroke regardless of aspirin therapy.
Topics: Aged; Aspirin; Case-Control Studies; Female; Gene Frequency; Genetic Predisposition to Disease; Huma | 2007 |
Who needs to be taking aspirin for cardiovascular protection? Studies conflict about the benefits for women.
Topics: Aspirin; Female; Guidelines as Topic; Humans; Male; Myocardial Infarction; Neoplasms; Platelet Aggre | 2007 |
Comment on the WASPO study.
Topics: Aged; Aged, 80 and over; Aspirin; Humans; Risk Factors; Stroke; Thrombosis; Warfarin | 2007 |
By the way, doctor. Must I take aspirin?
Topics: Aspirin; Attitude of Health Personnel; Colitis, Ulcerative; Diabetic Angiopathies; Female; Humans; M | 2007 |
Benign long-term outcome of conservatively treated cervical aneurysms due to carotid dissection.
Topics: Adult; Aged; Aneurysm, Ruptured; Anticoagulants; Aortic Dissection; Aspirin; Carotid Artery, Interna | 2007 |
I've had atrial fibrillation without associated heart disease for 40 years. I'm unable to take Coumadin, so for many years I've taken one 325 mg aspirin daily for its anticoagulation effect. How do you compare aspirin's benefits with Coumadin's?
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Stroke; Treatment Outcome; Warfarin | 2007 |
Stroke prevention in elderly patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fi | 2007 |
Aspirin: a user's guide to who needs it and how much to take. Just because you can buy aspirin without a prescription (and for pennies a tablet) doesn't mean everyone should be taking it to prevent a heart attack or stroke.
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke | 2007 |
Daily aspirin therapy. Questions and answers about benefits and risks.
Topics: Aspirin; Drug Administration Schedule; Female; Humans; Male; Myocardial Infarction; Platelet Aggrega | 2007 |
Ischemic stroke and peripheral arterial thromboembolism in a patient with Crohn's disease: a case presentation.
Topics: Anticoagulants; Aspirin; Blood Cell Count; Blood Coagulation; Bone Marrow; Brain Ischemia; Crohn Dis | 2008 |
Creating and synthesizing evidence with decision makers in mind: integrating evidence from clinical trials and other study designs.
Topics: Aspirin; Cardiovascular Diseases; Decision Making; Drug Evaluation; Endarterectomy, Carotid; Evidenc | 2007 |
Improving depiction of benefits and harms: analyses of studies of well-known therapeutics and review of high-impact medical journals.
Topics: Antipsychotic Agents; Appetite Depressants; Aspirin; Aspirin, Dipyridamole Drug Combination; Contrac | 2007 |
CON: Should aspirin be used in all women older than 65 years to prevent stroke?
Topics: Age Factors; Aspirin; Cardiovascular Diseases; Female; Humans; Patient Selection; Platelet Aggregati | 2007 |
Does an aspirin a day really keep a stroke away?
Topics: Aspirin; Evidence-Based Practice; Female; Humans; Patient Selection; Platelet Aggregation Inhibitors | 2007 |
Clopidogrel in addition to aspirin reduces one-year major adverse cardiac and cerebrovascular events in unselected patients with non-ST segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Comorbidity; Drug Therapy, Combination; | 2008 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Sweet and sticky: diabetic platelets, enhanced reactivity, and cardiovascular risk.
Topics: Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudden, Car | 2007 |
Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; | 2007 |
[Antithrombotic therapy in ischemic stroke and transient ischemic attack].
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; | 2007 |
Optical platelet aggregometry does not appear useful as a means of assessing the risk of recurrent vascular events in aspirin-treated patients.
Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Electronic Data Processing; Female; Humans; Ischemic | 2008 |
Can aspirin resistance be clinically predicted in stroke patients?
Topics: Adult; Aged; Aspirin; Brain Ischemia; Cohort Studies; Drug Resistance; Female; Humans; Male; Middle | 2008 |
Warfarin versus aspirin for stroke prevention (BAFTA).
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Humans; Risk Factors; Stroke | 2007 |
Neuroprotection by early and delayed treatment of acute stroke with high dose aspirin.
Topics: Acute Disease; Animals; Aspirin; Brain; Brain Damage, Chronic; Dose-Response Relationship, Drug; Dru | 2007 |
[Late-onset hemorrhagic infarction in patients with patent foramen ovale: reports of two cases].
Topics: Acute-Phase Reaction; Aged; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Foramen Ovale, Patent | 2007 |
Methodological considerations for interpretation of rates of major haemorrhage in studies of anticoagulant therapy for atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Bias; Humans; In | 2008 |
Distribution of etiologies in patients above and below age 45 with first-ever ischemic stroke.
Topics: Adult; Age Distribution; Aging; Anticoagulants; Aspirin; Atrial Fibrillation; Embolism; Female; Fora | 2008 |
Aspirin use in the prevention of cardiovascular events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; | 2007 |
Aspirin + clopidogrel therapy: how does your care compare to the evidence?
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; | 2008 |
Oral carriage of yeasts and coliforms in stroke sufferers: a prospective longitudinal study.
Topics: Aged; Aspirin; Candida albicans; Candida glabrata; Candida tropicalis; Dentures; Enterobacteriaceae; | 2008 |
Antiplatelet agents for stroke prevention following transient ischemic attack.
Topics: Angioplasty, Balloon; Aspirin; Carotid Artery Diseases; Clopidogrel; Dipyridamole; Drug Therapy, Com | 2008 |
Prediction and prevention of stroke in patients with symptomatic carotid stenosis: the high-risk period and the high-risk patient.
Topics: Aspirin; Carotid Stenosis; Clopidogrel; Endarterectomy, Carotid; Humans; Ischemic Attack, Transient; | 2008 |
Aspirin-associated intracerebral hemorrhage in a patient with CADASIL.
Topics: Acute Disease; Adult; Aspirin; CADASIL; Cerebral Hemorrhage; Diffusion Magnetic Resonance Imaging; F | 2008 |
Warfarin trumps aspirin for stroke prevention in elderly.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Stroke; Warfarin | 2007 |
Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cerebrovascular Disorders; Clopido | 2008 |
Comment on "hyperresponsiveness of platelets in ischemic stroke" by Fateh-Moghadam et al.
Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Epine | 2008 |
Aspirin dose do's and don'ts.
Topics: Aspirin; Cyclooxygenase Inhibitors; Hemorrhage; Humans; Middle Aged; Neoplasms; Platelet Aggregation | 2007 |
Nonaspirin nonsteroidal anti-inflammatory drugs and hemorrhagic stroke risk: the Acute Brain Bleeding Analysis study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Asian People | 2008 |
Interpretation of ESPRIT in the FASTER trial.
Topics: Aspirin; Clinical Trials as Topic; Data Interpretation, Statistical; Humans; Ischemic Attack, Transi | 2008 |
Which patients receiving warfarin can be treated safely with a drug-eluting stent?
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Restenosis; Cor | 2008 |
Use of dose modification schedules is effective for blinding trials of warfarin: evidence from the WASID study.
Topics: Anticoagulants; Aspirin; Data Interpretation, Statistical; Double-Blind Method; Drug Administration | 2008 |
Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests.
Topics: Aspirin; Drug Resistance; Humans; Ischemic Attack, Transient; Platelet Aggregation; Platelet Aggrega | 2008 |
Vertebral artery dissection: not a rare cause of stroke in the young.
Topics: Adult; Amlodipine; Anticoagulants; Antihypertensive Agents; Aspirin; Craniocerebral Trauma; Female; | 2008 |
Cerebellar hemorrhage provoked by combined use of nattokinase and aspirin in a patient with cerebral microbleeds.
Topics: Aspirin; Diffusion Magnetic Resonance Imaging; Female; Fibrinolytic Agents; Herb-Drug Interactions; | 2008 |
Acetylsalicylic acid provides cerebrovascular protection from oxidant damage in salt-loaded stroke-prone rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Basilar Artery; Blood Pressure; Blood-Bra | 2008 |
Withholding warfarin therapy for atrial fibrillation patients in the perioperative period.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Enoxaparin; Humans; Perioperative Care; Stroke; | 2008 |
Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity.
Topics: Aged; Aspirin; Brain Infarction; Drug Resistance; Embolism; Female; Humans; Interleukin-6; Male; Pla | 2008 |
Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Combinations; Dru | 2008 |
The balance between stroke prevention and bleeding risk in atrial fibrillation: a delicate balance revisited.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Blood Coagulation Factors; Brain Ischemia; Cerebral He | 2008 |
Trends in usage of alternative antiplatelet therapy after stroke and transient ischemic attack.
Topics: Aged; Aged, 80 and over; Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Prescrip | 2008 |
Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Electri | 2008 |
Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Coronary Disease; Disease-Free Survival; Female; | 2008 |
[Stroke due to spontaneous calcified cerebral embolus as presenting feature of calcified aortic stenosis].
Topics: Aged, 80 and over; Anterior Cerebral Artery; Aortic Valve; Aortic Valve Stenosis; Aspirin; Atorvasta | 2008 |
Cilostazol shows promise as an alternative to aspirin for patients with ischaemic stroke.
Topics: Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Data Interpretation, Statistical; Dose-Res | 2008 |
[Emergency treatment of transient cerebral ischemia].
Topics: Aspirin; Clopidogrel; Emergency Treatment; Humans; Ischemic Attack, Transient; Platelet Aggregation | 2008 |
Warfarin in atrial fibrillation: underused in the elderly, often inappropriately used in the young.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Humans; Male; Risk Assessment; Stroke; W | 1999 |
Use of antithrombotic measures for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cross-Sectional Studies; Female; Fibrinolytic | 1999 |
AHA Scientific Statement. Supplement to the guidelines for the management of transient ischemic attacks: A statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association.
Topics: Angioplasty; Anticoagulants; Aspirin; Carotid Artery Diseases; Humans; Ischemic Attack, Transient; P | 1999 |
Stroke risk, cholesterol and statins.
Topics: Aged; Aspirin; Diabetes Complications; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitor | 1999 |
Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; beta-Thromboglobulin; Biomarkers; F | 1999 |
Unfractionated heparin is the heparin of choice in the management of patients with acute coronary syndromes.
Topics: Aspirin; Coronary Disease; Disease Management; Drug Therapy, Combination; Fibrinolytic Agents; Hepar | 2000 |
Secular trends in the management of hypertension and atrial fibrillation in patients presenting with stroke.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillatio | 2000 |
From the Food and Drug Administration.
Topics: Aspirin; Dipyridamole; Drug Combinations; Equipment Reuse; Humans; Platelet Aggregation Inhibitors; | 2000 |
FDA approves new drug to reduce risk of stroke.
Topics: Aspirin; Dipyridamole; Drug Combinations; Humans; Platelet Aggregation Inhibitors; Stroke; United St | 2000 |
Aspirin and dipyridamole for stroke prevention.
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Stroke | 2000 |
Treatment and secondary prevention of stroke.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Stroke; Ti | 2000 |
Treatment and secondary prevention of stroke.
Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Stroke | 2000 |
Preventing stroke in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Evidence-Based Medicine; Female; Humans; Male; P | 2000 |
Aspirin benefit remains elusive in primary stroke prevention.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Platelet Aggregat | 2000 |
Does prior use of aspirin affect outcome in ischemic stroke?
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Female; Humans; Male; Middle | 2000 |
Aggrenox: a combination of antiplatelet drugs for stroke prevention.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clinical Trials as Topic; Dipyridamole; Dose-Respon | 2000 |
Risk stratification in the management of atrial fibrillation in the community.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Family Practice; Female; Fibrinolytic Agents; | 1999 |
ABC of arterial and venous disease. Acute stroke.
Topics: Aspirin; Heparin; Humans; Magnetic Resonance Imaging; Platelet Aggregation Inhibitors; Stroke; Strok | 2000 |
Using anticoagulation or aspirin to prevent stroke. Research was methodologically flawed.
Topics: Aged; Anticoagulants; Aspirin; Humans; Research Design; Stroke | 2000 |
Serum C-reactive protein and self-reported stroke: findings from the Third National Health and Nutrition Examination Survey.
Topics: Adult; Aspirin; Blood Pressure; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Female; Health Su | 2000 |
Stent-assisted angioplasty of intracranial vertebrobasilar atherosclerosis: an initial experience.
Topics: Abciximab; Adult; Aged; Angiography; Angioplasty; Antibodies, Monoclonal; Anticoagulants; Aspirin; B | 2000 |
Using anticoagulation or aspirin to prevent stroke. Aspirin is the logical choice for non-rheumatic atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Humans; Platelet Aggregation Inhibitors; Stroke | 2000 |
Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; | 2000 |
Shaking the world of gene therapy.
Topics: Aspirin; California; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Genetic Therapy; | 2000 |
Aspirin to prevent strokes: fact or fiction?
Topics: Aged; Aspirin; Cerebral Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggre | 2000 |
Anticoagulation for chronic atrial fibrillation.
Topics: Aged; Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Echocardiography, T | 2000 |
Non-rheumatic atrial fibrillation and stroke.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Risk Assessment; Risk Factors; Stroke; Warfari | 1999 |
Outcome in patients with symptomatic occlusion of the internal carotid artery.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Carotid Artery, Internal; Carotid Stenosis; | 2000 |
Beyond willow bark: aspirin in the prevention of chronic disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Humans; Myocardial Infarction; Pr | 2000 |
Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Fibrinolytic Agents; Heart Valve | 2000 |
Dipyridamole plus aspirin in cerebrovascular disease.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Cerebrovascular Disorders; Clinical Trials as Topic | 2000 |
Prescribing patterns for the use of antithrombotics in the management of atrial fibrillation in Zimbabwe.
Topics: Adult; Aspirin; Atrial Fibrillation; Cross-Sectional Studies; Female; Fibrinolytic Agents; Humans; M | 1999 |
Heparin vs aspirin in acute ischaemic stroke.
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Dalteparin; Dose-Response Relationship, Drug; Hum | 2000 |
Does carotid endarterectomy benefit patients with carotid stenosis but no symptoms?
Topics: Aged; Aspirin; Carotid Stenosis; Endarterectomy, Carotid; Female; Fibrinolytic Agents; Follow-Up Stu | 2000 |
Sex differences and similarities in the management and outcome of stroke patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Comorbidity; | 2000 |
PEP trial. Pulmonary Embolism Prevention.
Topics: Aged; Arthroplasty, Replacement, Hip; Aspirin; Hip Fractures; Humans; Male; Myocardial Infarction; P | 2000 |
Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Drug Therapy, Combination; Humans; Platel | 2000 |
Ask the doctor. Recently I read that aspirin can actually increase a person's risk for a stroke by causing bleeding in the brain. I have atrial fibrillation and my doctor wants me to take a blood thinner - if not warfarin, then at least aspirin. I've alre
Topics: Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Humans; Platelet Aggregation Inhi | 2000 |
Paramedics should delay giving aspirin to patients with stroke.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Contraindications; Emergency Treatment; Humans; Pr | 2000 |
The Hypertension Optimal Treatment Study: what did it give us?
Topics: Aged; Aspirin; Blood Pressure; Diabetic Angiopathies; Fibrinolytic Agents; Humans; Hypertension; Mid | 1999 |
Heparin versus aspirin in ischaemic stroke.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Disease Progression; Fibrinolytic Agents; Heparin, Low | 2000 |
Heparin versus aspirin in ischaemic stroke.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Secondary Preve | 2000 |
Aspirin in acute ischemic stroke.
Topics: Ancrod; Aspirin; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Stroke; Tissue Plasmi | 2000 |
Care is required with cost effectiveness approach.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Drug Costs; Humans; Stroke | 2000 |
Antiplatelet drugs in cardiovascular prevention: stroke: acute phase and secondary prevention.
Topics: Anticoagulants; Arrhythmia, Sinus; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Dipyridamole | 2000 |
Antiplatelet drugs in cardiovascular prevention: stroke prevention in patients with thrombogenic heart disease.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Drug Therapy, Combination; E | 2000 |
Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: primary prevention.
Topics: Aspirin; Carotid Stenosis; Cost-Benefit Analysis; Diabetes Mellitus; Digestive System; Female; Human | 2000 |
My doctor recently recommended that I take low-dose aspirin to minimize the risk of a heart attack or stroke. I routinely take ibuprofen for arthritis pain. Do I need both, and is it safe to combine the two?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Interactions; Humans; Ibuprofen; Myocardial I | 2000 |
Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Dipyridamole; Drug Therapy, Combi | 2000 |
[Calculation of costs of stroke, cost effectiveness of stroke units and secondary prevention in patients after a stroke, as recommended by revised CBO practice guideline 'Stroke'].
Topics: Age Factors; Aspirin; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Drug Costs; Health Care Cost | 2000 |
Which acute stroke patients with atrial fibrillation are prescribed warfarin therapy? Results from one-year's experience in Dundee.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Contraindications; Female; Hospitalization; H | 2000 |
Economic assessment of the secondary prevention of ischaemic events with lysine acetylsalicylate.
Topics: Aspirin; Cost-Benefit Analysis; Humans; Lysine; Myocardial Ischemia; Platelet Aggregation Inhibitors | 2000 |
Implementation of antithrombotic management in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Fibrinoly | 2000 |
Development of a decision aid for atrial fibrillation who are considering antithrombotic therapy.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Decision Support Techniques; Humans; Multimedia; Plate | 2000 |
[Old and new platelet aggregation inhibitors: which to choose for prevention of stroke?].
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein G | 2000 |
Transient ischemic attacks after dipyridamole-aspirin therapy.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug The | 2000 |
Images in clinical radiology. Updated MR work-up of hyperacute stroke.
Topics: Aspirin; Echo-Planar Imaging; Fibrinolytic Agents; Humans; Image Enhancement; Infarction, Anterior C | 1999 |
Use of aspirin, epistaxis, and untreated hypertension as risk factors for primary intracerebral hemorrhage in middle-aged and elderly people.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Aspirin; Cerebral Hemorrhage; Comorbidity; Epileps | 2001 |
Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Blood Pressure; Brain Ischemia; Ce | 2001 |
Authors' reply on aspirin for primary prevention.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Disease; Gastrointestinal Hemorrhage; Hum | 2001 |
Aspirin use and risk of stroke in the elderly: the Rotterdam Study.
Topics: Aged; Aspirin; Cohort Studies; Female; Humans; Male; Middle Aged; Netherlands; Prospective Studies; | 2001 |
Stroke can be beaten if you catch the danger signs.
Topics: Aged; Aspirin; Humans; Male; Middle Aged; Primary Prevention; Risk Factors; Stroke; United States | 2000 |
Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey.
Topics: Adult; Albuminuria; Angina Pectoris; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabe | 2001 |
Aggrenox and stress testing.
Topics: Adenosine; Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Humans; | 2001 |
ASA or low-molecular-weight heparin in the initial management of acute ischemic stroke complicating atrial fibrillation?
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2001 |
Newer antiplatelet therapies in stroke prevention.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibito | 2001 |
Atrial fibrillation and anticoagulation.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebral Hemorrhage; Drug Therapy, | 2001 |
Heparin and aspirin in stroke.
Topics: Aspirin; Heparin, Low-Molecular-Weight; Humans; Recurrence; Risk Factors; Stroke | 2001 |
Better stroke prevention.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Humans; Platelet Aggregatio | 2001 |
Second stroke.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Chemoprevention; Dipyridamole; Drug Approval; Drug | 2000 |
[Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Clopidogrel; Coronary Disease; D | 2001 |
Clinical correlates and drug treatment of residents with stroke in long-term care.
Topics: Aged; Aged, 80 and over; Aspirin; Cognition Disorders; Comorbidity; Cross-Sectional Studies; Databas | 2001 |
Venous thromboembolism after acute stroke.
Topics: Acute Disease; Aspirin; Bandages; Humans; Multicenter Studies as Topic; Platelet Aggregation Inhibit | 2001 |
Transient ischaemic attacks: a GP guide.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Carotid Arteries; Diagnosis, Differentia | 2001 |
Moyamoya syndrome with spherocytosis: effect of splenectomy on strokes.
Topics: Aspirin; Brain; Child, Preschool; Dipyridamole; Humans; Magnetic Resonance Angiography; Magnetic Res | 2001 |
Is ticlopidine more effective than aspirin in preventing adverse cardiovascular events after myocardial infarction (MI)?
Topics: Angina Pectoris; Aspirin; Double-Blind Method; Fibrinolytic Agents; Humans; Multicenter Studies as T | 2001 |
Long term anticoagulation or antiplatelet treatment. Only warfarin has been shown to reduce stroke risk in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Meta-Analysis as Topic; Platelet Aggrega | 2001 |
Long term anticoagulation or antiplatelet treatment. Giving warfarin always depends on balancing risks.
Topics: Anticoagulants; Aspirin; Drug Administration Schedule; Hemorrhage; Humans; Platelet Aggregation Inhi | 2001 |
Long term anticoagulation or antiplatelet treatment. How do we decide between warfarin and aspirin?
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Assessment; Strok | 2001 |
Clopidogrel: new preparation. An alternative to aspirin.
Topics: Aspirin; Clinical Trials as Topic; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; S | 1999 |
Ticlopidine: a second look. No further use in routine practice.
Topics: Aspirin; Clinical Trials as Topic; Fibrinolytic Agents; Humans; Stroke; Ticlopidine; Treatment Outco | 1999 |
[Antibodies to phospholipids and ischemic disorders of cerebral circulation in young age].
Topics: Adolescent; Adult; Age Factors; Alcohol Drinking; Antibodies, Antiphospholipid; Anticoagulants; Anti | 1997 |
New drugs, or new trials of current drugs, for the treatment of acute ischaemic stroke?
Topics: Aspirin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Stroke; Tinzaparin | 2001 |
Effect of antiplatelet and anticoagulant agents on risk of hospitalization for bleeding among a population of elderly nursing home stroke survivors.
Topics: Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Black People; Case-Control Studi | 2001 |
[Stroke management in a general internal medicine department: results of a survey regarding practice].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Data Collection; Echocardiography; Ele | 2001 |
Antithrombotic drugs for secondary stroke prophylaxis--a comment.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dipyridamole; Drug Combinations; Fibri | 2001 |
Aspirin and warfarin equally good for stroke patients.
Topics: Anticoagulants; Aspirin; Humans; Platelet Aggregation Inhibitors; Recurrence; Stroke; Warfarin | 2001 |
Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Attitude of Health Personn | 2001 |
Antiplatelet therapy: a neurology perspective.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Humans; Neurology; Platelet Aggregatio | 2000 |
Antiplatelet therapy: a neurology perspective.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Humans; Neurology; Platelet Aggregatio | 2000 |
Dual antiplatelet therapy with clopidogrel and aspirin after carotid artery stenting.
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Stenosis; Clopidogrel; Combined Modality Therapy; Female; | 2001 |
Current strategies of secondary prevention after a cerebrovascular event: the Vienna stroke registry.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; | 2001 |
Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both.
Topics: Adolescent; Adult; Aspirin; Brain Ischemia; Echocardiography, Transesophageal; Female; Follow-Up Stu | 2001 |
[Guidelines for antithrombotic therapy in atrial fibrillation: what the Italian Hemostasis and Thrombosis Society thinks].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Diabetes | 2001 |
Is acetylsalicylic acid plus dipyridamole superior to ASA alone for secondary prevention of stroke?
Topics: Aged; Aspirin; Dipyridamole; Drug Therapy, Combination; Female; Humans; Male; Platelet Aggregation I | 2001 |
Early aspirin use lowers the risk of further stroke and death in acute ischemic stroke patients.
Topics: Aspirin; Humans; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2000 |
Discontinuing chronic aspirin therapy: another risk factor for stroke?
Topics: Aged; Aged, 80 and over; Aspirin; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Prospectiv | 2002 |
Acute stroke management.
Topics: Acute Disease; Aspirin; Databases, Factual; Decision Making; Evidence-Based Medicine; Fibrinolytic A | 2001 |
Gathering intelligence on antiplatelet drugs: the view from 30 000 feet. When combined with other information overviews lead to conviction.
Topics: Aspirin; Coronary Disease; Humans; Meta-Analysis as Topic; Platelet Aggregation Inhibitors; Stroke | 2002 |
Preventing atherosclerotic events with aspirin.
Topics: Arteriosclerosis; Aspirin; Humans; Meta-Analysis as Topic; Myocardial Infarction; Platelet Aggregati | 2002 |
[Primary prevention of cardiovascular events by ASS and vitamin E. PPP--Primary Prevention Project].
Topics: Antioxidants; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Myocardial Infarct | 2001 |
Oral anticoagulant therapy for the prevention of stroke.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Humans; International Normalized Ratio; Platelet Aggregatio | 2001 |
Efficacy and safety of aspirin in the long-term management of atherothrombosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Blood Platelets; Cardiovascular | 2002 |
Aspirin gets a tentative nod.
Topics: Aspirin; Coronary Disease; Gastrointestinal Hemorrhage; Humans; Risk Assessment; Risk Factors; Strok | 2002 |
Transcatheter closure of patent foramen ovale in patients with paradoxical embolism: intermediate-term risk of recurrent neurological events.
Topics: Adolescent; Adult; Aged; Anticoagulants; Aspirin; Catheters, Indwelling; Embolism, Paradoxical; Fema | 2002 |
Early anticoagulation in acute ischaemic stroke.
Topics: Aspirin; Clinical Trials as Topic; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Strok | 2002 |
Early anticoagulation in acute ischaemic stroke.
Topics: Aspirin; Fibrinolytic Agents; Heparin; Humans; Stroke; Venous Thrombosis | 2002 |
Balancing the risks of stroke and upper gastrointestinal tract bleeding in older patients with atrial fibrillation.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Decisio | 2002 |
Antiplatelet aggregating versus anticoagulant agents in preventing early recurrent stroke among patients with atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Dalteparin; Platelet Aggrega | 2001 |
Oral anticoagulation for acute coronary syndromes.
Topics: Administration, Oral; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Clopi | 2002 |
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Canada; Cardiovascular Diseases; Case-Contr | 2002 |
Warfarin or aspirin for recurrent ischemic stroke.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Data Interpretation, Statistical; Hemorrhage; Humans; Plate | 2002 |
Atherosclerosis: the new view.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Arterie | 2002 |
Warfarin or aspirin for recurrent ischemic stroke.
Topics: Anticoagulants; Aspirin; Heart Septal Defects, Atrial; Humans; Middle Aged; Platelet Aggregation Inh | 2002 |
Warfarin or aspirin for recurrent ischemic stroke.
Topics: Anticoagulants; Aorta; Aspirin; Brain Ischemia; Echocardiography, Transesophageal; Humans; Platelet | 2002 |
Warfarin or aspirin for recurrent ischemic stroke.
Topics: Administration, Oral; Anticoagulants; Aspirin; Brain Ischemia; Hemorrhage; Humans; International Nor | 2002 |
Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain.
Topics: Adenosine Triphosphatases; Animals; Antigens, CD; Apyrase; Aspirin; Brain Ischemia; Disease Models, | 2002 |
Who should be taking aspirin?
Topics: Aspirin; Gastrointestinal Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors | 2002 |
Thrombolysis for acute ischemic stroke: still a treatment for the few by the few.
Topics: Aspirin; Fibrinolytic Agents; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as | 2002 |
Patent foramen ovale and recurrent stroke: another paradoxical twist.
Topics: Anticoagulants; Aspirin; Embolism, Paradoxical; Heart Septal Defects, Atrial; Humans; Intracranial E | 2002 |
Use of selective serotonin reuptake inhibitors and the risk of stroke: is there reason for concern?
Topics: Aged; Aspirin; Case-Control Studies; Depression; Drug Interactions; Female; Hemorrhage; Humans; Male | 2002 |
Warfarin-Aspirin Recurrent Stroke Study (WARSS) trial: is warfarin really a reasonable therapeutic alternative to aspirin for preventing recurrent noncardioembolic ischemic stroke?
Topics: Anticoagulants; Aspirin; Brain Ischemia; Data Interpretation, Statistical; Embolism; Endpoint Determ | 2002 |
[Secondary prophylaxis after cerebral infarction without cardiac source of embolism. Anticoagulants are not better than ASA according to a new extensive trial (WARSS)].
Topics: Anticoagulants; Aspirin; Cerebral Infarction; Fibrinolytic Agents; Humans; International Normalized | 2002 |
The morbidity related to atrial fibrillation at a tertiary centre in one year: 9.0% of all strokes are potentially preventable.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Australia; Embolism; Hemorrha | 2002 |